[{
	"source": 37986,
	"target": 32478,
	"type": 2767,
	"label": "Method of making oligonucleotides, oligonucleoside thiophosphates and oligonucleoside phosphotriesters using H-phosphonate intermediates",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 7359,
	"target": 6854,
	"type": 2967,
	"label": "agente para a supressço de dano a uma ilhota transplantada depois do transplante de ilhota e usos de um inibidor de il-6",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37878,
	"type": 3150,
	"label": "CYTOTOXIC T-CELL (CTC) INDUCING PEPTIDE, METHOD OF INDUCING CTC, ANTIBODY BOUND TO SAID PEPTIDE, USE OF SAID PEPTIDE IN PHARMACEUTICAL COMPOSITION AND FOR TREATING OR PREVENTING CANCER, ANTIGEN-PRESENTING CELL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 3150,
	"label": "CYTOTOXIC T-CELL (CTC) INDUCING PEPTIDE, METHOD OF INDUCING CTC, ANTIBODY BOUND TO SAID PEPTIDE, USE OF SAID PEPTIDE IN PHARMACEUTICAL COMPOSITION AND FOR TREATING OR PREVENTING CANCER, ANTIGEN-PRESENTING CELL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37878,
	"target": 7507,
	"type": 3150,
	"label": "CYTOTOXIC T-CELL (CTC) INDUCING PEPTIDE, METHOD OF INDUCING CTC, ANTIBODY BOUND TO SAID PEPTIDE, USE OF SAID PEPTIDE IN PHARMACEUTICAL COMPOSITION AND FOR TREATING OR PREVENTING CANCER, ANTIGEN-PRESENTING CELL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 3150,
	"label": "CYTOTOXIC T-CELL (CTC) INDUCING PEPTIDE, METHOD OF INDUCING CTC, ANTIBODY BOUND TO SAID PEPTIDE, USE OF SAID PEPTIDE IN PHARMACEUTICAL COMPOSITION AND FOR TREATING OR PREVENTING CANCER, ANTIGEN-PRESENTING CELL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37878,
	"target": 6854,
	"type": 3150,
	"label": "CYTOTOXIC T-CELL (CTC) INDUCING PEPTIDE, METHOD OF INDUCING CTC, ANTIBODY BOUND TO SAID PEPTIDE, USE OF SAID PEPTIDE IN PHARMACEUTICAL COMPOSITION AND FOR TREATING OR PREVENTING CANCER, ANTIGEN-PRESENTING CELL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37904,
	"target": 37899,
	"type": 3801,
	"label": "COMPOSITIONS FOR TREATING HEPATIC DISORDERS AND METHODS AND KITS FOR DIAGNOSING AND MONITORING SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56836,
	"target": 37904,
	"type": 3801,
	"label": "COMPOSITIONS FOR TREATING HEPATIC DISORDERS AND METHODS AND KITS FOR DIAGNOSING AND MONITORING SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 3801,
	"label": "COMPOSITIONS FOR TREATING HEPATIC DISORDERS AND METHODS AND KITS FOR DIAGNOSING AND MONITORING SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 3801,
	"label": "COMPOSITIONS FOR TREATING HEPATIC DISORDERS AND METHODS AND KITS FOR DIAGNOSING AND MONITORING SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37904,
	"target": 6795,
	"type": 3801,
	"label": "COMPOSITIONS FOR TREATING HEPATIC DISORDERS AND METHODS AND KITS FOR DIAGNOSING AND MONITORING SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 4320,
	"label": "SELECTION METHOD",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 4320,
	"label": "SELECTION METHOD",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 4320,
	"label": "SELECTION METHOD",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37900,
	"target": 37899,
	"type": 4321,
	"label": "ANTICUERPOS ANTI-RECEPTOR DEL FACTOR DEL CRECIMIENTO SIMILAR A LA INSULINA I (IGF-IR); COMPOSICION FARMACEUTICA QUE LO CONTIENE; Y SU USO PARA TRATAR EL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 4321,
	"label": "ANTICUERPOS ANTI-RECEPTOR DEL FACTOR DEL CRECIMIENTO SIMILAR A LA INSULINA I (IGF-IR); COMPOSICION FARMACEUTICA QUE LO CONTIENE; Y SU USO PARA TRATAR EL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 4321,
	"label": "ANTICUERPOS ANTI-RECEPTOR DEL FACTOR DEL CRECIMIENTO SIMILAR A LA INSULINA I (IGF-IR); COMPOSICION FARMACEUTICA QUE LO CONTIENE; Y SU USO PARA TRATAR EL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 4321,
	"label": "ANTICUERPOS ANTI-RECEPTOR DEL FACTOR DEL CRECIMIENTO SIMILAR A LA INSULINA I (IGF-IR); COMPOSICION FARMACEUTICA QUE LO CONTIENE; Y SU USO PARA TRATAR EL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 4321,
	"label": "ANTICUERPOS ANTI-RECEPTOR DEL FACTOR DEL CRECIMIENTO SIMILAR A LA INSULINA I (IGF-IR); COMPOSICION FARMACEUTICA QUE LO CONTIENE; Y SU USO PARA TRATAR EL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 38065,
	"type": 4322,
	"label": "SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA-1. 6-FUCOSYLTRANSFERASE.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 4322,
	"label": "SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA-1. 6-FUCOSYLTRANSFERASE.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 4322,
	"label": "SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA-1. 6-FUCOSYLTRANSFERASE.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 4696,
	"label": "Pyrido(3,2-d)pyrimidines useful for treating viral infections",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 31965,
	"target": 31912,
	"type": 4697,
	"label": "Pyrido(3,2-d)pyridmidines useful for treating viral infections",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 4697,
	"label": "Pyrido(3,2-d)pyridmidines useful for treating viral infections",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 31965,
	"target": 6376,
	"type": 4697,
	"label": "Pyrido(3,2-d)pyridmidines useful for treating viral infections",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 4698,
	"label": "PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 6303,
	"target": 6301,
	"type": 4742,
	"label": "COMPUESTOS DERIVADOS DE ESPIRO-PIPERIDINA, MODULADORES DEL RECEPTOR DE VASOPRESINA V1A; PROCESO DE OBTENCION; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO DE ENFERMEMDADES TALES COMO DISMENORREA, HIPERTENSION, ANSIEDAD Y TRASTORNOS DEPRESIVOS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6301,
	"target": 6298,
	"type": 4742,
	"label": "COMPUESTOS DERIVADOS DE ESPIRO-PIPERIDINA, MODULADORES DEL RECEPTOR DE VASOPRESINA V1A; PROCESO DE OBTENCION; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO DE ENFERMEMDADES TALES COMO DISMENORREA, HIPERTENSION, ANSIEDAD Y TRASTORNOS DEPRESIVOS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6303,
	"target": 6298,
	"type": 4742,
	"label": "COMPUESTOS DERIVADOS DE ESPIRO-PIPERIDINA, MODULADORES DEL RECEPTOR DE VASOPRESINA V1A; PROCESO DE OBTENCION; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO DE ENFERMEMDADES TALES COMO DISMENORREA, HIPERTENSION, ANSIEDAD Y TRASTORNOS DEPRESIVOS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 5043,
	"label": "Anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptìdeo isolado, formulação lìquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 5936,
	"label": "TRANSGENIC MICE EXPRESSING HUMANIZED VEGF",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 6695,
	"label": "Compositions and methods for detecting methicillin-resistant S. aureus",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32003,
	"target": 6303,
	"type": 6766,
	"label": "COMPUESTOS DERIVADOS DE AZAESPIRO; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA; Y SU USO PARA PREVENIR Y TRATAR ANSIEDAD, TRASTORNOS DEPRESIVOS, ENTRE OTRAS ENFERMEDADES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7560,
	"label": "Substituted pyridines and pyrimidines and their use in treatment of cancer",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7563,
	"label": "Substituted heterocycles and methods of use",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 7869,
	"label": "COMPOSITIONS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7869,
	"label": "COMPOSITIONS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37988,
	"target": 37899,
	"type": 7869,
	"label": "COMPOSITIONS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 6371,
	"type": 7979,
	"label": "PYRIMIDINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7995,
	"label": "IMIDAZOPYRIDINE INHIBITORS OF IAP",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6301,
	"target": 6279,
	"type": 7995,
	"label": "IMIDAZOPYRIDINE INHIBITORS OF IAP",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7995,
	"label": "IMIDAZOPYRIDINE INHIBITORS OF IAP",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 6301,
	"type": 7995,
	"label": "IMIDAZOPYRIDINE INHIBITORS OF IAP",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 7995,
	"label": "IMIDAZOPYRIDINE INHIBITORS OF IAP",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 8105,
	"label": "ANTICUERPO ANTI-RECEPTOR DEL FACTOR DE CRECIMIENTO INSULINICO I (IGF-IR); POLINUCLEOTIDO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37875,
	"target": 32770,
	"type": 8105,
	"label": "ANTICUERPO ANTI-RECEPTOR DEL FACTOR DE CRECIMIENTO INSULINICO I (IGF-IR); POLINUCLEOTIDO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8105,
	"label": "ANTICUERPO ANTI-RECEPTOR DEL FACTOR DE CRECIMIENTO INSULINICO I (IGF-IR); POLINUCLEOTIDO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 8105,
	"label": "ANTICUERPO ANTI-RECEPTOR DEL FACTOR DE CRECIMIENTO INSULINICO I (IGF-IR); POLINUCLEOTIDO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 8105,
	"label": "ANTICUERPO ANTI-RECEPTOR DEL FACTOR DE CRECIMIENTO INSULINICO I (IGF-IR); POLINUCLEOTIDO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 8296,
	"label": "METODO PARA INHIBIR UNION DEL RECEPTOR DE MUERTE 6 (DR6) A LA PROTEINA PRECURSORA AMILOIDE (APP) QUE COMPRENDE UNO O MAS ANTAGONISTAS DEL DR6; USO DE DICHOS ANTAGONISTAS; METODO PARA IDENTIFICAR UNA MOLECULA DE INTERES QUE INHIBE LA UNION DEL DR6 A L",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 9113,
	"label": "PROCEDIMIENTO DE USO Y USO DE UNA COMBINACION DE UN ANTICUERPO ANTI-ERBB2 Y UN AGENTE QUIMICOTERAPEUTICO DISTINTO DE UN DERIVADO DE ANTRACICLINA PARA LA MANUFACTURA DE UN MEDICAMENTO UTIL PARA EL TRATAMIENTO DE CANCER",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 9113,
	"label": "PROCEDIMIENTO DE USO Y USO DE UNA COMBINACION DE UN ANTICUERPO ANTI-ERBB2 Y UN AGENTE QUIMICOTERAPEUTICO DISTINTO DE UN DERIVADO DE ANTRACICLINA PARA LA MANUFACTURA DE UN MEDICAMENTO UTIL PARA EL TRATAMIENTO DE CANCER",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 9113,
	"label": "PROCEDIMIENTO DE USO Y USO DE UNA COMBINACION DE UN ANTICUERPO ANTI-ERBB2 Y UN AGENTE QUIMICOTERAPEUTICO DISTINTO DE UN DERIVADO DE ANTRACICLINA PARA LA MANUFACTURA DE UN MEDICAMENTO UTIL PARA EL TRATAMIENTO DE CANCER",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37875,
	"target": 32694,
	"type": 10644,
	"label": "An antibody against a receptor for human interleukin - 12 and its use",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32694,
	"target": 7510,
	"type": 10644,
	"label": "An antibody against a receptor for human interleukin - 12 and its use",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37875,
	"target": 7510,
	"type": 10644,
	"label": "An antibody against a receptor for human interleukin - 12 and its use",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 7375,
	"type": 10694,
	"label": "VARIANTES DE ANTICUERPOS CON UNA AFINIDAD DE UNION MAYOR EN COMPARACION CON LOS ANTICUERPOS PARENTALES.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 12036,
	"label": "Oligonucleotides for rapidly identifying microbial DNA or RNA",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56765,
	"target": 38164,
	"type": 12036,
	"label": "Oligonucleotides for rapidly identifying microbial DNA or RNA",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56765,
	"target": 32478,
	"type": 12036,
	"label": "Oligonucleotides for rapidly identifying microbial DNA or RNA",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 7358,
	"type": 12791,
	"label": "COMPOSICONES Y PROCEDIMIENTOS PARA EL TRATAMIENTO DE TRASTORNOS FIBROTICOS.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7358,
	"target": 6483,
	"type": 12791,
	"label": "COMPOSICONES Y PROCEDIMIENTOS PARA EL TRATAMIENTO DE TRASTORNOS FIBROTICOS.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6483,
	"type": 12791,
	"label": "COMPOSICONES Y PROCEDIMIENTOS PARA EL TRATAMIENTO DE TRASTORNOS FIBROTICOS.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 12802,
	"label": "DR5 antibodies and articles of manufacture containing same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 12802,
	"label": "DR5 antibodies and articles of manufacture containing same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37875,
	"target": 32770,
	"type": 12802,
	"label": "DR5 antibodies and articles of manufacture containing same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 12802,
	"label": "DR5 antibodies and articles of manufacture containing same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 12802,
	"label": "DR5 antibodies and articles of manufacture containing same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32769,
	"type": 13578,
	"label": "Characterization and identification of unique human adiponectin isoforms and antibodies",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32769,
	"target": 6854,
	"type": 13578,
	"label": "Characterization and identification of unique human adiponectin isoforms and antibodies",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 13578,
	"label": "Characterization and identification of unique human adiponectin isoforms and antibodies",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31995,
	"target": 6303,
	"type": 13580,
	"label": "COMPUESTOS DERIVADOS DE ESPIROPIPERIDINA-GLICINAMIDA; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO DEL COMPUESTO PARA EL TRATAMIENTO DE LA HIPERTENSION, DISMENORREA, FALLO CARDIACO CRONICO, ANSIEDAD, T",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 13968,
	"label": "Methods for inhibiting cell proliferation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 7428,
	"type": 13968,
	"label": "Methods for inhibiting cell proliferation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7509,
	"target": 7428,
	"type": 13968,
	"label": "Methods for inhibiting cell proliferation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6299,
	"target": 6298,
	"type": 14554,
	"label": "CICLETANINE AND PKC INHIBITORS IN THE TREATMENT OF PULMONARY AND CARDIAC DISORDERS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7409,
	"target": 6299,
	"type": 14554,
	"label": "CICLETANINE AND PKC INHIBITORS IN THE TREATMENT OF PULMONARY AND CARDIAC DISORDERS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7409,
	"target": 6298,
	"type": 14554,
	"label": "CICLETANINE AND PKC INHIBITORS IN THE TREATMENT OF PULMONARY AND CARDIAC DISORDERS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 14694,
	"label": "Bis-aryl amide derivatives useful for the treatment of cancer",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 14694,
	"label": "Bis-aryl amide derivatives useful for the treatment of cancer",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 14694,
	"label": "Bis-aryl amide derivatives useful for the treatment of cancer",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 17254,
	"label": "Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 6795,
	"target": 6582,
	"type": 18924,
	"label": "DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 6795,
	"type": 18924,
	"label": "DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 6582,
	"type": 18924,
	"label": "DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 19278,
	"label": "Genetic variations of tyrosine kinase 2 resulting in an activated catalytic domain are associated with colon and stomach cancer",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 19835,
	"label": "Fremgangsmåte for rensing av et polypeptid med en del av den strukturelle oppbygning til blodplate-avledet vekstfaktor, samt monoklonalt antistoff som er spesifikt for en epitop derav",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 21020,
	"label": "AGENTES DE UNION SELECTIVOS A ANTIGENOS DE LA PROTEINA DE UNION A OSTEOPROTEGERINA.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 21020,
	"label": "AGENTES DE UNION SELECTIVOS A ANTIGENOS DE LA PROTEINA DE UNION A OSTEOPROTEGERINA.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 21020,
	"label": "AGENTES DE UNION SELECTIVOS A ANTIGENOS DE LA PROTEINA DE UNION A OSTEOPROTEGERINA.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 7450,
	"type": 21020,
	"label": "AGENTES DE UNION SELECTIVOS A ANTIGENOS DE LA PROTEINA DE UNION A OSTEOPROTEGERINA.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 7450,
	"type": 21020,
	"label": "AGENTES DE UNION SELECTIVOS A ANTIGENOS DE LA PROTEINA DE UNION A OSTEOPROTEGERINA.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 21562,
	"label": "Genetically engineered antibody analogues and fusion proteins thereof",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 21562,
	"label": "Genetically engineered antibody analogues and fusion proteins thereof",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 21562,
	"label": "Genetically engineered antibody analogues and fusion proteins thereof",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 38042,
	"type": 21562,
	"label": "Genetically engineered antibody analogues and fusion proteins thereof",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 21562,
	"label": "Genetically engineered antibody analogues and fusion proteins thereof",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 21648,
	"label": "MODIFICATIONS OF PEPTIDE COMPOSITIONS TO INCREASE STABILITY AND DELIVERY EFFICIENCY",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 22046,
	"label": "MARCADORES BIOLOGICOS PREDICTIVOS DE RESPUESTA ANTI-CANCERIGENA A INHIBIDORES DE QUINASA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38237,
	"target": 7507,
	"type": 22046,
	"label": "MARCADORES BIOLOGICOS PREDICTIVOS DE RESPUESTA ANTI-CANCERIGENA A INHIBIDORES DE QUINASA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 22046,
	"label": "MARCADORES BIOLOGICOS PREDICTIVOS DE RESPUESTA ANTI-CANCERIGENA A INHIBIDORES DE QUINASA DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7360,
	"target": 6213,
	"type": 22058,
	"label": "composto, processo para a sua manufatura, utilização do mesmo, método para o tratamento de obesidade, diabetes do tipo ii ou sìndrome metabólica e composição farmacêutica que compreende o composto",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 23317,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 23317,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 23317,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 23317,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32788,
	"type": 23317,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 23318,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 23318,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 23318,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 23318,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 23318,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 23319,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 23319,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 32771,
	"type": 23319,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 23319,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 23319,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 24000,
	"label": "Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 24000,
	"label": "Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 24000,
	"label": "Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 24057,
	"label": "DERIVATIVE OF [3{BETA}, 5Z, 7E]-9,10-SECOCHOLESTA-5,7,10[19],16-TETRAEN-23-INE-3,25-DIOL, PROCESS OF ITS PREPARATION, INTERMEDIATE FOR PRODUCING SUCH DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND ITS USE IN THERAPY",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 24226,
	"label": "Protein-free G-CSF formulations",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 25078,
	"label": "TAAR1 TRANSGENIC ANIMALS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 25078,
	"label": "TAAR1 TRANSGENIC ANIMALS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 25078,
	"label": "TAAR1 TRANSGENIC ANIMALS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32734,
	"type": 25078,
	"label": "TAAR1 TRANSGENIC ANIMALS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32734,
	"type": 25078,
	"label": "TAAR1 TRANSGENIC ANIMALS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 32527,
	"type": 26363,
	"label": "PRECIPITACION CON POLIELECTROLITO Y PURIFICACION DE ANTICUERPOS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 26507,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 26507,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7450,
	"type": 26507,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 26507,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 26507,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 26919,
	"label": "POLYPEPTID MED EGENSKABER SOM HUMAN BETA-NERVEVAEKSTFAKTOR OG FREMGANGSMAADE TIL FREMSTILLING DERAF, DNA-ISOLAT OMFATTENDE EN SEKVENS SOM KODER FOR POLYPEPTIDET, REPLICERBAR UDTRYKKELSESVEKTOR FOR DNA-SEKVENSEN, REKOMBINANT VAERTSCELLE TRANSFORMERET MED VEKTOREN, FARMACEUTISK PRAEPARAT INDEHOLDENDE POLYPEPTIDET OG FREMG. DER OMFATTER ANVENDELSEN AF POLYPEPTIDET TIL FREMST. AF ET FARMACEUTISK PRAEPARAT",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 26919,
	"label": "POLYPEPTID MED EGENSKABER SOM HUMAN BETA-NERVEVAEKSTFAKTOR OG FREMGANGSMAADE TIL FREMSTILLING DERAF, DNA-ISOLAT OMFATTENDE EN SEKVENS SOM KODER FOR POLYPEPTIDET, REPLICERBAR UDTRYKKELSESVEKTOR FOR DNA-SEKVENSEN, REKOMBINANT VAERTSCELLE TRANSFORMERET MED VEKTOREN, FARMACEUTISK PRAEPARAT INDEHOLDENDE POLYPEPTIDET OG FREMG. DER OMFATTER ANVENDELSEN AF POLYPEPTIDET TIL FREMST. AF ET FARMACEUTISK PRAEPARAT",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 26919,
	"label": "POLYPEPTID MED EGENSKABER SOM HUMAN BETA-NERVEVAEKSTFAKTOR OG FREMGANGSMAADE TIL FREMSTILLING DERAF, DNA-ISOLAT OMFATTENDE EN SEKVENS SOM KODER FOR POLYPEPTIDET, REPLICERBAR UDTRYKKELSESVEKTOR FOR DNA-SEKVENSEN, REKOMBINANT VAERTSCELLE TRANSFORMERET MED VEKTOREN, FARMACEUTISK PRAEPARAT INDEHOLDENDE POLYPEPTIDET OG FREMG. DER OMFATTER ANVENDELSEN AF POLYPEPTIDET TIL FREMST. AF ET FARMACEUTISK PRAEPARAT",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 27029,
	"label": "ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37904,
	"type": 27029,
	"label": "ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 27029,
	"label": "ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 27029,
	"label": "ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37904,
	"target": 32779,
	"type": 27029,
	"label": "ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 27945,
	"label": "Inhibitorer av IAP",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 28935,
	"label": "Substitutional variants of APO-2 ligand",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 28935,
	"label": "Substitutional variants of APO-2 ligand",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 28935,
	"label": "Substitutional variants of APO-2 ligand",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 32694,
	"type": 28935,
	"label": "Substitutional variants of APO-2 ligand",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 28935,
	"label": "Substitutional variants of APO-2 ligand",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 29003,
	"label": "Gene disruptions, compositions and methods relating thereto",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 29864,
	"label": "KCNB: a novel potassium channel protein and methods for treating cancer",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 29864,
	"label": "KCNB: a novel potassium channel protein and methods for treating cancer",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 37862,
	"type": 29864,
	"label": "KCNB: a novel potassium channel protein and methods for treating cancer",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 37859,
	"type": 29864,
	"label": "KCNB: a novel potassium channel protein and methods for treating cancer",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 29864,
	"label": "KCNB: a novel potassium channel protein and methods for treating cancer",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 29902,
	"label": "KONDENSIERTE HETEROZYKLISCHE VERBINDUNGEN",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 30168,
	"label": "FACTORES ASOCIADOS CON EL FACTOR DE NECROSIS DEL TUMOR RECEPTOR DE TIPO 2 (TNF-R2).",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 30692,
	"label": "PROCESSO PARA PRODUCAO DE UMA CULTURA DE CELULAS DE VERTEBRADOS TRANSFORMANTES A DITA CULTURA USO DO ANTIGENO DE SUPERFICIE DA HEPATITE B PRODUTO DO DITO PROCESSO VETOR DE EXPRESSAO DE DNA E PARTICULA COMPREENDENDO TAL ANTIGENO",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37875,
	"target": 6854,
	"type": 30692,
	"label": "PROCESSO PARA PRODUCAO DE UMA CULTURA DE CELULAS DE VERTEBRADOS TRANSFORMANTES A DITA CULTURA USO DO ANTIGENO DE SUPERFICIE DA HEPATITE B PRODUTO DO DITO PROCESSO VETOR DE EXPRESSAO DE DNA E PARTICULA COMPREENDENDO TAL ANTIGENO",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 30692,
	"label": "PROCESSO PARA PRODUCAO DE UMA CULTURA DE CELULAS DE VERTEBRADOS TRANSFORMANTES A DITA CULTURA USO DO ANTIGENO DE SUPERFICIE DA HEPATITE B PRODUTO DO DITO PROCESSO VETOR DE EXPRESSAO DE DNA E PARTICULA COMPREENDENDO TAL ANTIGENO",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 30859,
	"label": "ENHANCER FOR BIOLOGICAL RESPONSE MODIFIER FOR THE TREATMENT OF LYMPHOID TUMOR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 30859,
	"label": "ENHANCER FOR BIOLOGICAL RESPONSE MODIFIER FOR THE TREATMENT OF LYMPHOID TUMOR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 6816,
	"type": 30859,
	"label": "ENHANCER FOR BIOLOGICAL RESPONSE MODIFIER FOR THE TREATMENT OF LYMPHOID TUMOR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 31732,
	"label": "Methods for generating monovalent IgG",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 7425,
	"type": 31732,
	"label": "Methods for generating monovalent IgG",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 7425,
	"type": 31732,
	"label": "Methods for generating monovalent IgG",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 34179,
	"label": "Osteoprotegerin, multimer thereof, antibody, binding said polypeptide, pharmaceutical composition containing this polypeptide, process for preparing the polypeptide and nucleic acid, expression vector, host cell and transgenic mammal usable in this preparation process",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 34179,
	"label": "Osteoprotegerin, multimer thereof, antibody, binding said polypeptide, pharmaceutical composition containing this polypeptide, process for preparing the polypeptide and nucleic acid, expression vector, host cell and transgenic mammal usable in this preparation process",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 34179,
	"label": "Osteoprotegerin, multimer thereof, antibody, binding said polypeptide, pharmaceutical composition containing this polypeptide, process for preparing the polypeptide and nucleic acid, expression vector, host cell and transgenic mammal usable in this preparation process",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 34179,
	"label": "Osteoprotegerin, multimer thereof, antibody, binding said polypeptide, pharmaceutical composition containing this polypeptide, process for preparing the polypeptide and nucleic acid, expression vector, host cell and transgenic mammal usable in this preparation process",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 34179,
	"label": "Osteoprotegerin, multimer thereof, antibody, binding said polypeptide, pharmaceutical composition containing this polypeptide, process for preparing the polypeptide and nucleic acid, expression vector, host cell and transgenic mammal usable in this preparation process",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 34349,
	"label": "Methods of identification of methylation of CpG",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 34349,
	"label": "Methods of identification of methylation of CpG",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 34349,
	"label": "Methods of identification of methylation of CpG",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 34867,
	"label": "FUSION PROTEINS CONSISTING OF A LIGAND BINDING PROTEIN AND ASTABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 34867,
	"label": "FUSION PROTEINS CONSISTING OF A LIGAND BINDING PROTEIN AND ASTABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 34867,
	"label": "FUSION PROTEINS CONSISTING OF A LIGAND BINDING PROTEIN AND ASTABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 34867,
	"label": "FUSION PROTEINS CONSISTING OF A LIGAND BINDING PROTEIN AND ASTABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 34867,
	"label": "FUSION PROTEINS CONSISTING OF A LIGAND BINDING PROTEIN AND ASTABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 30972,
	"target": 7507,
	"type": 35234,
	"label": "Derivados de bencimidazol utilizados como agonistas del FXR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6295,
	"type": 35424,
	"label": "THIADIAZOLE MODULATORS OF PKB",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 6376,
	"target": 6332,
	"type": 35428,
	"label": "COMBINATION OF A DE NOVO PURINE BIOSYNTHESIS INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR FOR THE TREATMENT OF CANCER",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 35428,
	"label": "COMBINATION OF A DE NOVO PURINE BIOSYNTHESIS INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR FOR THE TREATMENT OF CANCER",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6332,
	"type": 35428,
	"label": "COMBINATION OF A DE NOVO PURINE BIOSYNTHESIS INHIBITOR AND A CYCLIN DEPENDENT KINASE INHIBITOR FOR THE TREATMENT OF CANCER",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 35735,
	"label": "THERAPEUTIC AGENT FOR PROSTATE CANCER",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 36261,
	"label": "A METHOD FOR GENERATING HIGH AFFINITY ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32777,
	"target": 6854,
	"type": 36261,
	"label": "A METHOD FOR GENERATING HIGH AFFINITY ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 36261,
	"label": "A METHOD FOR GENERATING HIGH AFFINITY ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6840,
	"target": 6795,
	"type": 36522,
	"label": "ENZIMAS DE ACILTRANFERASA DE LECITINA-COLESTEROL, MODIFICADAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 6840,
	"type": 36522,
	"label": "ENZIMAS DE ACILTRANFERASA DE LECITINA-COLESTEROL, MODIFICADAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 36522,
	"label": "ENZIMAS DE ACILTRANFERASA DE LECITINA-COLESTEROL, MODIFICADAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37999,
	"target": 37986,
	"type": 36772,
	"label": "APO-3 LIGAND POLYPEPTIDE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38042,
	"target": 37999,
	"type": 36772,
	"label": "APO-3 LIGAND POLYPEPTIDE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 36772,
	"label": "APO-3 LIGAND POLYPEPTIDE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 36772,
	"label": "APO-3 LIGAND POLYPEPTIDE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37999,
	"target": 6795,
	"type": 36772,
	"label": "APO-3 LIGAND POLYPEPTIDE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 37561,
	"label": "HUMANIZED ANTI-FGF19 ANTAGONISTS AND METHODS USING SAME",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37878,
	"target": 7509,
	"type": 37561,
	"label": "HUMANIZED ANTI-FGF19 ANTAGONISTS AND METHODS USING SAME",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37878,
	"target": 7507,
	"type": 37561,
	"label": "HUMANIZED ANTI-FGF19 ANTAGONISTS AND METHODS USING SAME",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 37582,
	"label": "Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 7509,
	"type": 37582,
	"label": "Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 37582,
	"label": "Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 38652,
	"label": "CONJUGADO QUE CONSTA DE UN ANTICUERPO ANTI-CCR5 Y UNO O MAS PEPTIDOS ANTIFUSOGENICOS; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; METODO DE PREPARACION; Y SU USO PARA TRATAR INFECCIONES VIRALES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 38652,
	"label": "CONJUGADO QUE CONSTA DE UN ANTICUERPO ANTI-CCR5 Y UNO O MAS PEPTIDOS ANTIFUSOGENICOS; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; METODO DE PREPARACION; Y SU USO PARA TRATAR INFECCIONES VIRALES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32779,
	"target": 6854,
	"type": 38652,
	"label": "CONJUGADO QUE CONSTA DE UN ANTICUERPO ANTI-CCR5 Y UNO O MAS PEPTIDOS ANTIFUSOGENICOS; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; METODO DE PREPARACION; Y SU USO PARA TRATAR INFECCIONES VIRALES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7422,
	"target": 7409,
	"type": 38713,
	"label": "SUBSTITUIERTE HYDANTOINE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 38713,
	"label": "SUBSTITUIERTE HYDANTOINE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 38713,
	"label": "SUBSTITUIERTE HYDANTOINE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 39400,
	"label": "Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5&prime;-3&prime; nuclease activity",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 39400,
	"label": "Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5&prime;-3&prime; nuclease activity",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38237,
	"target": 32478,
	"type": 39400,
	"label": "Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5&prime;-3&prime; nuclease activity",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7360,
	"target": 6302,
	"type": 39411,
	"label": "Process for the preparation of pyrido [2, 1-alpha] isoquinoline derivatives and polymorphic froms thereof",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 39411,
	"label": "Process for the preparation of pyrido [2, 1-alpha] isoquinoline derivatives and polymorphic froms thereof",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 39411,
	"label": "Process for the preparation of pyrido [2, 1-alpha] isoquinoline derivatives and polymorphic froms thereof",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 40008,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 40008,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38065,
	"target": 37875,
	"type": 40008,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 40008,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 40008,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6447,
	"target": 6272,
	"type": 40121,
	"label": "USO DE ERLOTINIB Y DE UN INHIBIDOR DE MEK PARA INHIBIR LA PROLIFERACION DE CELULAS TUMORALES.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6447,
	"type": 40121,
	"label": "USO DE ERLOTINIB Y DE UN INHIBIDOR DE MEK PARA INHIBIR LA PROLIFERACION DE CELULAS TUMORALES.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6272,
	"type": 40121,
	"label": "USO DE ERLOTINIB Y DE UN INHIBIDOR DE MEK PARA INHIBIR LA PROLIFERACION DE CELULAS TUMORALES.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 40121,
	"label": "USO DE ERLOTINIB Y DE UN INHIBIDOR DE MEK PARA INHIBIR LA PROLIFERACION DE CELULAS TUMORALES.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37875,
	"target": 6447,
	"type": 40121,
	"label": "USO DE ERLOTINIB Y DE UN INHIBIDOR DE MEK PARA INHIBIR LA PROLIFERACION DE CELULAS TUMORALES.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31307,
	"target": 6290,
	"type": 40948,
	"label": "Derivatives of urea and related diamines, methods for their manufacture, and uses therefor.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 42108,
	"label": "PHARMACEUTICAL COMPOSITIONS COMPRISING FC FUSION PROTEINS",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 37900,
	"type": 42780,
	"label": "REGIONES DE CADENA PESADA VARIABLE Y LIVIANA VARIABLE; ACIDOS NUCLEICOS QUE LAS CODIFICAN; METODO DE PRODUCCION; ANTICUERPOS ANTI-NOTCH3 QUE LAS COMPRENDEN; Y USO DE LOS ANTICUERPOS PARA TRATAR ENFERMEDADES RELACIONADAS CON EL RECEPTOR NOTCH3.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 42780,
	"label": "REGIONES DE CADENA PESADA VARIABLE Y LIVIANA VARIABLE; ACIDOS NUCLEICOS QUE LAS CODIFICAN; METODO DE PRODUCCION; ANTICUERPOS ANTI-NOTCH3 QUE LAS COMPRENDEN; Y USO DE LOS ANTICUERPOS PARA TRATAR ENFERMEDADES RELACIONADAS CON EL RECEPTOR NOTCH3.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 42780,
	"label": "REGIONES DE CADENA PESADA VARIABLE Y LIVIANA VARIABLE; ACIDOS NUCLEICOS QUE LAS CODIFICAN; METODO DE PRODUCCION; ANTICUERPOS ANTI-NOTCH3 QUE LAS COMPRENDEN; Y USO DE LOS ANTICUERPOS PARA TRATAR ENFERMEDADES RELACIONADAS CON EL RECEPTOR NOTCH3.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 42780,
	"label": "REGIONES DE CADENA PESADA VARIABLE Y LIVIANA VARIABLE; ACIDOS NUCLEICOS QUE LAS CODIFICAN; METODO DE PRODUCCION; ANTICUERPOS ANTI-NOTCH3 QUE LAS COMPRENDEN; Y USO DE LOS ANTICUERPOS PARA TRATAR ENFERMEDADES RELACIONADAS CON EL RECEPTOR NOTCH3.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37900,
	"target": 7507,
	"type": 42780,
	"label": "REGIONES DE CADENA PESADA VARIABLE Y LIVIANA VARIABLE; ACIDOS NUCLEICOS QUE LAS CODIFICAN; METODO DE PRODUCCION; ANTICUERPOS ANTI-NOTCH3 QUE LAS COMPRENDEN; Y USO DE LOS ANTICUERPOS PARA TRATAR ENFERMEDADES RELACIONADAS CON EL RECEPTOR NOTCH3.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 46158,
	"label": "2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS P2X ANTAGONISTS OR AS PRODRUGS THEREOF",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7409,
	"target": 6301,
	"type": 46159,
	"label": "PYRAZOLOPYRIIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 46159,
	"label": "PYRAZOLOPYRIIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 46159,
	"label": "PYRAZOLOPYRIIDINE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7423,
	"target": 7409,
	"type": 46160,
	"label": "COMPUESTOS DERIVADOS DE DIAMINOPIRIMIDINA SUSTITUIDA; METODO DE PREPARACION DE DICHOS COMPUESTOS; COMPOSICION FARMACEUTICA; Y USO DEL COMPUESTO PARA EL TRATAMIENTO DE UNA ENFERMEDAD DEL TRACTO URINARIO, UN ESTADO PATOLOGICO DOLOROSO, UN TRASTORNO RES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6347,
	"target": 6298,
	"type": 46588,
	"label": "Use of cicletanine and other furo-pyridines for treatment of systolic predominant hypertension, isolated systolic hypertension, elevated pulse pressure and general hypertension",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 6500,
	"target": 6347,
	"type": 46588,
	"label": "Use of cicletanine and other furo-pyridines for treatment of systolic predominant hypertension, isolated systolic hypertension, elevated pulse pressure and general hypertension",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 6500,
	"target": 6298,
	"type": 46588,
	"label": "Use of cicletanine and other furo-pyridines for treatment of systolic predominant hypertension, isolated systolic hypertension, elevated pulse pressure and general hypertension",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 46641,
	"label": "COMPOSITION AND METHOD FOR TREATMENT OF DISEASE AND DISORDER ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODY THAT BINDS TO IL-22 AND ANTIBODY THAT BINDS TO IL-22R",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 46641,
	"label": "COMPOSITION AND METHOD FOR TREATMENT OF DISEASE AND DISORDER ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODY THAT BINDS TO IL-22 AND ANTIBODY THAT BINDS TO IL-22R",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 46641,
	"label": "COMPOSITION AND METHOD FOR TREATMENT OF DISEASE AND DISORDER ASSOCIATED WITH CYTOKINE SIGNALING INVOLVING ANTIBODY THAT BINDS TO IL-22 AND ANTIBODY THAT BINDS TO IL-22R",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 46962,
	"label": "PSMA ANTIBODIES AND PROTEIN MULTIMERS",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 46962,
	"label": "PSMA ANTIBODIES AND PROTEIN MULTIMERS",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 46962,
	"label": "PSMA ANTIBODIES AND PROTEIN MULTIMERS",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 46962,
	"label": "PSMA ANTIBODIES AND PROTEIN MULTIMERS",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 46962,
	"label": "PSMA ANTIBODIES AND PROTEIN MULTIMERS",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 47006,
	"label": "Transgenic animal model for Glyt1 function",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 47006,
	"label": "Transgenic animal model for Glyt1 function",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 47006,
	"label": "Transgenic animal model for Glyt1 function",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31939,
	"target": 7358,
	"type": 47383,
	"label": "Use of ª‰-2-hydroxymethyl-5-(5-fluctyosine-1-yl)-1,3-oxathialane in preparation of medicine and composition containing same",
	"group": "Gilead",
	"time": 1999,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 47889,
	"label": "Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 47889,
	"label": "Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 6854,
	"type": 47889,
	"label": "Krebsimpfstoff mit einem Krebs-Antigen auf Grundlage des Produkts aus dem Tumorunterdrückungsgen WT1 und einem kationischen Liposom",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 49261,
	"label": "ANTICUERPO ANTAGONISTA AISLADO ANTI-RECEPTOR OX40 HUMANO; MOLECULA DE ACIDO NUCLEICO QUE LO CODIFICA; VECTOR Y CELULA HUESPED; METODO DE PRODUCCION; COMPOSICION QUE LO COMPRENDE; SU USO PARA TRATAR TRASTORNOS MEDIADOS POR OX40; Y METODO PARA DETECTAR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 49261,
	"label": "ANTICUERPO ANTAGONISTA AISLADO ANTI-RECEPTOR OX40 HUMANO; MOLECULA DE ACIDO NUCLEICO QUE LO CODIFICA; VECTOR Y CELULA HUESPED; METODO DE PRODUCCION; COMPOSICION QUE LO COMPRENDE; SU USO PARA TRATAR TRASTORNOS MEDIADOS POR OX40; Y METODO PARA DETECTAR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 7510,
	"type": 49261,
	"label": "ANTICUERPO ANTAGONISTA AISLADO ANTI-RECEPTOR OX40 HUMANO; MOLECULA DE ACIDO NUCLEICO QUE LO CODIFICA; VECTOR Y CELULA HUESPED; METODO DE PRODUCCION; COMPOSICION QUE LO COMPRENDE; SU USO PARA TRATAR TRASTORNOS MEDIADOS POR OX40; Y METODO PARA DETECTAR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 49967,
	"label": "A METHOD FOR CULTURING MAMMALIAN CELLS TO IMPROVE RECOMBINANT PROTEIN PRODUCTION",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56836,
	"target": 32770,
	"type": 49997,
	"label": "IL-17 HETEROMERIC RECEPTOR COMPLEX",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 49997,
	"label": "IL-17 HETEROMERIC RECEPTOR COMPLEX",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56836,
	"target": 7511,
	"type": 49997,
	"label": "IL-17 HETEROMERIC RECEPTOR COMPLEX",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 50499,
	"label": "TRATAMIENTO DE TRASTORNOS ASOCIADOS CON LFA-1 CON DOSIS CRECIENTES DE ANTAGONISTA DE LFA-1.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 50932,
	"label": "PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 51968,
	"label": "TIAZOLIOPIRIMIDINAS Y SU UTILIZACION COMO INHIBIDORES DE LA FOSFATIDILINOSITOL-3-QUINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7360,
	"target": 6376,
	"type": 51968,
	"label": "TIAZOLIOPIRIMIDINAS Y SU UTILIZACION COMO INHIBIDORES DE LA FOSFATIDILINOSITOL-3-QUINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 51968,
	"label": "TIAZOLIOPIRIMIDINAS Y SU UTILIZACION COMO INHIBIDORES DE LA FOSFATIDILINOSITOL-3-QUINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 52237,
	"label": "DNA POLYMERASES AND RELATED METHODS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 52237,
	"label": "DNA POLYMERASES AND RELATED METHODS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 52237,
	"label": "DNA POLYMERASES AND RELATED METHODS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 52237,
	"label": "DNA POLYMERASES AND RELATED METHODS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 52237,
	"label": "DNA POLYMERASES AND RELATED METHODS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 52603,
	"label": "Fetally expressed gene as a human colon cancer marker",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 52728,
	"label": "COMPUESTOS PARA LA INHIBICION DE ENZIMAS",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 53769,
	"label": "TREATMENT OF METASTATIC BREAST CANCER",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 53769,
	"label": "TREATMENT OF METASTATIC BREAST CANCER",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7425,
	"type": 53769,
	"label": "TREATMENT OF METASTATIC BREAST CANCER",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32771,
	"target": 7509,
	"type": 53769,
	"label": "TREATMENT OF METASTATIC BREAST CANCER",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 53769,
	"label": "TREATMENT OF METASTATIC BREAST CANCER",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 6301,
	"target": 6279,
	"type": 54535,
	"label": "IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 54535,
	"label": "IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7360,
	"target": 6301,
	"type": 54535,
	"label": "IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7360,
	"target": 6279,
	"type": 54535,
	"label": "IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 54535,
	"label": "IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 55189,
	"label": "COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 55189,
	"label": "COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 55189,
	"label": "COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 55189,
	"label": "COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 55189,
	"label": "COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 55300,
	"label": "ANTICUERPOS ANTI-NOTCH1 NRR, METODO DE PREPARACION Y COMPOSICION FARMACEUTICA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 6550,
	"type": 55300,
	"label": "ANTICUERPOS ANTI-NOTCH1 NRR, METODO DE PREPARACION Y COMPOSICION FARMACEUTICA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 55300,
	"label": "ANTICUERPOS ANTI-NOTCH1 NRR, METODO DE PREPARACION Y COMPOSICION FARMACEUTICA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 55300,
	"label": "ANTICUERPOS ANTI-NOTCH1 NRR, METODO DE PREPARACION Y COMPOSICION FARMACEUTICA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 55300,
	"label": "ANTICUERPOS ANTI-NOTCH1 NRR, METODO DE PREPARACION Y COMPOSICION FARMACEUTICA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6376,
	"target": 6366,
	"type": 55332,
	"label": "HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 55332,
	"label": "HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 55332,
	"label": "HETEROCYCLIC COMPOUNDS AS RAF KINASE MODULATORS",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 55454,
	"label": "PYRIMIDYLCYCLOPENTANE ALS INHIBITOREN DER AKT- PROTEINKINASE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 55454,
	"label": "PYRIMIDYLCYCLOPENTANE ALS INHIBITOREN DER AKT- PROTEINKINASE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31042,
	"target": 6371,
	"type": 55454,
	"label": "PYRIMIDYLCYCLOPENTANE ALS INHIBITOREN DER AKT- PROTEINKINASE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37875,
	"target": 37864,
	"type": 55478,
	"label": "Prevention of disulfide bond reduction during recombinant production of polypeptides",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 55478,
	"label": "Prevention of disulfide bond reduction during recombinant production of polypeptides",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 55478,
	"label": "Prevention of disulfide bond reduction during recombinant production of polypeptides",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 55557,
	"label": "TREATMENTS AND DIAGNOSTICS FOR CANCER, INFLAMMATORY DISORDERS AND AUTOIMMUNE DISORDERS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 55557,
	"label": "TREATMENTS AND DIAGNOSTICS FOR CANCER, INFLAMMATORY DISORDERS AND AUTOIMMUNE DISORDERS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 55557,
	"label": "TREATMENTS AND DIAGNOSTICS FOR CANCER, INFLAMMATORY DISORDERS AND AUTOIMMUNE DISORDERS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 6962,
	"type": 55588,
	"label": "Humanized anti-cd79b antibodies and immunoconjugates and methods of use.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 55588,
	"label": "Humanized anti-cd79b antibodies and immunoconjugates and methods of use.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 55588,
	"label": "Humanized anti-cd79b antibodies and immunoconjugates and methods of use.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 55588,
	"label": "Humanized anti-cd79b antibodies and immunoconjugates and methods of use.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 7508,
	"type": 55588,
	"label": "Humanized anti-cd79b antibodies and immunoconjugates and methods of use.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 55589,
	"label": "ANTICUERPOS ANTI-CD79B E INMMUNOCONJUGADOS Y METODOS DE USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 55589,
	"label": "ANTICUERPOS ANTI-CD79B E INMMUNOCONJUGADOS Y METODOS DE USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 55589,
	"label": "ANTICUERPOS ANTI-CD79B E INMMUNOCONJUGADOS Y METODOS DE USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 55589,
	"label": "ANTICUERPOS ANTI-CD79B E INMMUNOCONJUGADOS Y METODOS DE USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 55589,
	"label": "ANTICUERPOS ANTI-CD79B E INMMUNOCONJUGADOS Y METODOS DE USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 55740,
	"label": "AGONISTISCHE ANTIKÖRPER GEGEN DEN THROMBOPOIETINREZEPTOR UND DEREN THERAPEUTISCHE VERWENDUNGEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 55740,
	"label": "AGONISTISCHE ANTIKÖRPER GEGEN DEN THROMBOPOIETINREZEPTOR UND DEREN THERAPEUTISCHE VERWENDUNGEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 55740,
	"label": "AGONISTISCHE ANTIKÖRPER GEGEN DEN THROMBOPOIETINREZEPTOR UND DEREN THERAPEUTISCHE VERWENDUNGEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 55778,
	"label": "Antibodies binding to human insulin-like growth factor i receptor (igf-ir) and uses thereof for the manufacture of pharmaceutical compositions",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 55778,
	"label": "Antibodies binding to human insulin-like growth factor i receptor (igf-ir) and uses thereof for the manufacture of pharmaceutical compositions",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 55778,
	"label": "Antibodies binding to human insulin-like growth factor i receptor (igf-ir) and uses thereof for the manufacture of pharmaceutical compositions",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 55778,
	"label": "Antibodies binding to human insulin-like growth factor i receptor (igf-ir) and uses thereof for the manufacture of pharmaceutical compositions",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 55778,
	"label": "Antibodies binding to human insulin-like growth factor i receptor (igf-ir) and uses thereof for the manufacture of pharmaceutical compositions",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 39999,
	"target": 38237,
	"type": 56317,
	"label": "Gene expression markers of tumor resistance to HER2 inhibitor treatment",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 7510,
	"type": 56320,
	"label": "ANTICUERPOS CONTRA C3b Y METODOS PARA LA PREVENCION Y EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON EL COMPLEMENTO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 57410,
	"label": "N-SUBSTITUTED AZAINDOLES AND METHODS OF USE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 57410,
	"label": "N-SUBSTITUTED AZAINDOLES AND METHODS OF USE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 6301,
	"type": 57410,
	"label": "N-SUBSTITUTED AZAINDOLES AND METHODS OF USE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 57410,
	"label": "N-SUBSTITUTED AZAINDOLES AND METHODS OF USE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 57410,
	"label": "N-SUBSTITUTED AZAINDOLES AND METHODS OF USE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6301,
	"target": 6272,
	"type": 58657,
	"label": "UREA AND CARBAMATE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 58657,
	"label": "UREA AND CARBAMATE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6272,
	"type": 58657,
	"label": "UREA AND CARBAMATE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 58911,
	"label": "System and method for detection of HIV drug resistant variants",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 59854,
	"label": "PROTEINAS DE UNION A ANTIGENO QUE SE UNEN AL RECEPTOR ACTIVADO POR PROTEASAS 2 (PAR-2); ACIDO NUCLEICO QUE LAS CODIFICA; VECTOR Y CELULA HUESPED; METODO DE PRODUCCION; Y COMPOSICION QUE LAS COMPRENDE.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 59854,
	"label": "PROTEINAS DE UNION A ANTIGENO QUE SE UNEN AL RECEPTOR ACTIVADO POR PROTEASAS 2 (PAR-2); ACIDO NUCLEICO QUE LAS CODIFICA; VECTOR Y CELULA HUESPED; METODO DE PRODUCCION; Y COMPOSICION QUE LAS COMPRENDE.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 59854,
	"label": "PROTEINAS DE UNION A ANTIGENO QUE SE UNEN AL RECEPTOR ACTIVADO POR PROTEASAS 2 (PAR-2); ACIDO NUCLEICO QUE LAS CODIFICA; VECTOR Y CELULA HUESPED; METODO DE PRODUCCION; Y COMPOSICION QUE LAS COMPRENDE.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 61723,
	"label": "Prevention and the treatment of complement-associated eye conditions",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37947,
	"target": 7510,
	"type": 61723,
	"label": "Prevention and the treatment of complement-associated eye conditions",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 7510,
	"type": 61723,
	"label": "Prevention and the treatment of complement-associated eye conditions",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 62066,
	"label": "DERIVADOS DE PIRAZOLOL(3,4-d)-PIRIMIDINA COMO AGENTE ANTIPROLIFERATIVOS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31965,
	"target": 7507,
	"type": 62066,
	"label": "DERIVADOS DE PIRAZOLOL(3,4-d)-PIRIMIDINA COMO AGENTE ANTIPROLIFERATIVOS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31965,
	"target": 6376,
	"type": 62066,
	"label": "DERIVADOS DE PIRAZOLOL(3,4-d)-PIRIMIDINA COMO AGENTE ANTIPROLIFERATIVOS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 64501,
	"label": "OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 64501,
	"label": "OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 64501,
	"label": "OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 6229,
	"target": 6215,
	"type": 64778,
	"label": "METODO PARA TRATAR UN TUMOR QUE COMPRENDE UN ANTAGONISTA VEGF Y UN INHIBIDOR DE PROTEINA QUINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6795,
	"target": 6229,
	"type": 64778,
	"label": "METODO PARA TRATAR UN TUMOR QUE COMPRENDE UN ANTAGONISTA VEGF Y UN INHIBIDOR DE PROTEINA QUINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6795,
	"target": 6215,
	"type": 64778,
	"label": "METODO PARA TRATAR UN TUMOR QUE COMPRENDE UN ANTAGONISTA VEGF Y UN INHIBIDOR DE PROTEINA QUINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 64778,
	"label": "METODO PARA TRATAR UN TUMOR QUE COMPRENDE UN ANTAGONISTA VEGF Y UN INHIBIDOR DE PROTEINA QUINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 64778,
	"label": "METODO PARA TRATAR UN TUMOR QUE COMPRENDE UN ANTAGONISTA VEGF Y UN INHIBIDOR DE PROTEINA QUINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32022,
	"target": 31995,
	"type": 65357,
	"label": "SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31995,
	"target": 6303,
	"type": 65357,
	"label": "SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32022,
	"target": 6303,
	"type": 65357,
	"label": "SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 65402,
	"label": "HUMANIZED ANTIBODY IGG1",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7437,
	"target": 6795,
	"type": 65864,
	"label": "NUCLEAR FACTOR OF ACTIVATED T CELLS RECEPTOR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37878,
	"target": 37875,
	"type": 66323,
	"label": "Fremgangsmåder til behandling af et cellekulturmedium til anvendelse i en bioreaktor",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 37878,
	"type": 66323,
	"label": "Fremgangsmåder til behandling af et cellekulturmedium til anvendelse i en bioreaktor",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 37875,
	"type": 66323,
	"label": "Fremgangsmåder til behandling af et cellekulturmedium til anvendelse i en bioreaktor",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 66468,
	"label": "CHO CELL.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 66468,
	"label": "CHO CELL.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 66468,
	"label": "CHO CELL.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 66469,
	"label": "PROMOTER.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38065,
	"target": 37988,
	"type": 66469,
	"label": "PROMOTER.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 66469,
	"label": "PROMOTER.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38237,
	"target": 38065,
	"type": 66469,
	"label": "PROMOTER.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38237,
	"target": 37988,
	"type": 66469,
	"label": "PROMOTER.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 66470,
	"label": "HEAVY CHAIN MUTANT LEADING TO IMPROVED IMMUNOGLOBULIN PRODUCTION.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 66470,
	"label": "HEAVY CHAIN MUTANT LEADING TO IMPROVED IMMUNOGLOBULIN PRODUCTION.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 66470,
	"label": "HEAVY CHAIN MUTANT LEADING TO IMPROVED IMMUNOGLOBULIN PRODUCTION.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 67806,
	"label": "TRICYCLISCHE AZOLDERIVATE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS PHARMAZEUTISCHE MITTEL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 30606,
	"target": 7507,
	"type": 67806,
	"label": "TRICYCLISCHE AZOLDERIVATE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS PHARMAZEUTISCHE MITTEL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 30606,
	"target": 6279,
	"type": 67806,
	"label": "TRICYCLISCHE AZOLDERIVATE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS PHARMAZEUTISCHE MITTEL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 67807,
	"label": "derivados de aminopirazol, sua fabricação, composição farmacêutica e uso como agentes farmacêuticos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 67807,
	"label": "derivados de aminopirazol, sua fabricação, composição farmacêutica e uso como agentes farmacêuticos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6279,
	"type": 67807,
	"label": "derivados de aminopirazol, sua fabricação, composição farmacêutica e uso como agentes farmacêuticos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 67921,
	"label": "ANTICUERPOS ANTI-CCR5 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 67921,
	"label": "ANTICUERPOS ANTI-CCR5 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 67921,
	"label": "ANTICUERPOS ANTI-CCR5 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 67921,
	"label": "ANTICUERPOS ANTI-CCR5 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 67921,
	"label": "ANTICUERPOS ANTI-CCR5 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 68029,
	"label": "DETERMINATION OF RESPONDERS TO CHEMOTHERAPY.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 68029,
	"label": "DETERMINATION OF RESPONDERS TO CHEMOTHERAPY.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38237,
	"target": 7507,
	"type": 68029,
	"label": "DETERMINATION OF RESPONDERS TO CHEMOTHERAPY.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38237,
	"target": 6539,
	"type": 68029,
	"label": "DETERMINATION OF RESPONDERS TO CHEMOTHERAPY.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 68029,
	"label": "DETERMINATION OF RESPONDERS TO CHEMOTHERAPY.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 68032,
	"label": "Method for predicting the response to a treatment with a HER dimerization inhibitor by assessing the level of expression of a marker protein encoded by the transforming growth factor (TGF) alpha marker gene",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 68094,
	"label": "VERFAHREN ZUR MODIFIZIERUNG DER STABILITÄT VON ANTIKÖRPERN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 68094,
	"label": "VERFAHREN ZUR MODIFIZIERUNG DER STABILITÄT VON ANTIKÖRPERN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 68094,
	"label": "VERFAHREN ZUR MODIFIZIERUNG DER STABILITÄT VON ANTIKÖRPERN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 68204,
	"label": "HERSTELLUNG VON ANTIKÖRPERN MITTELS CRE- VERMITTELTER ORTSSPEZIFISCHER REKOMBINATION",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 68204,
	"label": "HERSTELLUNG VON ANTIKÖRPERN MITTELS CRE- VERMITTELTER ORTSSPEZIFISCHER REKOMBINATION",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 68204,
	"label": "HERSTELLUNG VON ANTIKÖRPERN MITTELS CRE- VERMITTELTER ORTSSPEZIFISCHER REKOMBINATION",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37875,
	"type": 68204,
	"label": "HERSTELLUNG VON ANTIKÖRPERN MITTELS CRE- VERMITTELTER ORTSSPEZIFISCHER REKOMBINATION",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 68204,
	"label": "HERSTELLUNG VON ANTIKÖRPERN MITTELS CRE- VERMITTELTER ORTSSPEZIFISCHER REKOMBINATION",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 68278,
	"label": "PROTEIN HAVING CYTOTOXIC LYMPHOCYTE MATURATION FACTOR (CLMF) ACTIVITY; DNA ENCODING IT; RECOMBINANT VECTOR: MICROORGANISM TRANSFORMED WITH THE VECTOR: ANTIBODIES TO CLMF: AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37999,
	"target": 37899,
	"type": 68278,
	"label": "PROTEIN HAVING CYTOTOXIC LYMPHOCYTE MATURATION FACTOR (CLMF) ACTIVITY; DNA ENCODING IT; RECOMBINANT VECTOR: MICROORGANISM TRANSFORMED WITH THE VECTOR: ANTIBODIES TO CLMF: AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38184,
	"target": 37999,
	"type": 68278,
	"label": "PROTEIN HAVING CYTOTOXIC LYMPHOCYTE MATURATION FACTOR (CLMF) ACTIVITY; DNA ENCODING IT; RECOMBINANT VECTOR: MICROORGANISM TRANSFORMED WITH THE VECTOR: ANTIBODIES TO CLMF: AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 68278,
	"label": "PROTEIN HAVING CYTOTOXIC LYMPHOCYTE MATURATION FACTOR (CLMF) ACTIVITY; DNA ENCODING IT; RECOMBINANT VECTOR: MICROORGANISM TRANSFORMED WITH THE VECTOR: ANTIBODIES TO CLMF: AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 32698,
	"type": 68278,
	"label": "PROTEIN HAVING CYTOTOXIC LYMPHOCYTE MATURATION FACTOR (CLMF) ACTIVITY; DNA ENCODING IT; RECOMBINANT VECTOR: MICROORGANISM TRANSFORMED WITH THE VECTOR: ANTIBODIES TO CLMF: AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56834,
	"target": 56804,
	"type": 68982,
	"label": "Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 69047,
	"label": "AZABENZIMIDALZOLDERIVATE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS ANTIKREBSMITTEL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 69047,
	"label": "AZABENZIMIDALZOLDERIVATE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS ANTIKREBSMITTEL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 69047,
	"label": "AZABENZIMIDALZOLDERIVATE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS ANTIKREBSMITTEL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 69158,
	"label": "HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 69158,
	"label": "HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 6301,
	"type": 69158,
	"label": "HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 69158,
	"label": "HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 69158,
	"label": "HETEROCYCLIC BENZYLAMINO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 69162,
	"label": "PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 70294,
	"label": "Chimeric serine proteases",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37947,
	"target": 37864,
	"type": 70294,
	"label": "Chimeric serine proteases",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 70294,
	"label": "Chimeric serine proteases",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6812,
	"type": 70470,
	"label": "Fanconi-gene II",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 70667,
	"label": "CONJUGATES OF THE C DOMAIN OF HUMAN GELATINASE A AND POLYETHYLENE GLYCOL, METHODS OF PURIFICATION AND USES THEREOF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 70667,
	"label": "CONJUGATES OF THE C DOMAIN OF HUMAN GELATINASE A AND POLYETHYLENE GLYCOL, METHODS OF PURIFICATION AND USES THEREOF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37947,
	"target": 7507,
	"type": 70667,
	"label": "CONJUGATES OF THE C DOMAIN OF HUMAN GELATINASE A AND POLYETHYLENE GLYCOL, METHODS OF PURIFICATION AND USES THEREOF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 70667,
	"label": "CONJUGATES OF THE C DOMAIN OF HUMAN GELATINASE A AND POLYETHYLENE GLYCOL, METHODS OF PURIFICATION AND USES THEREOF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 70667,
	"label": "CONJUGATES OF THE C DOMAIN OF HUMAN GELATINASE A AND POLYETHYLENE GLYCOL, METHODS OF PURIFICATION AND USES THEREOF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32022,
	"target": 6303,
	"type": 70806,
	"label": "PIPERIDINE DERIVATIVES.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 6913,
	"target": 6892,
	"type": 70828,
	"label": "Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 71227,
	"label": "DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 71227,
	"label": "DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 6371,
	"type": 71227,
	"label": "DIAZINE AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 71237,
	"label": "A PEPTIDE-IMMUNOGLOBULIN-CONJUGATE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 71237,
	"label": "A PEPTIDE-IMMUNOGLOBULIN-CONJUGATE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 32779,
	"type": 71237,
	"label": "A PEPTIDE-IMMUNOGLOBULIN-CONJUGATE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 6913,
	"type": 71237,
	"label": "A PEPTIDE-IMMUNOGLOBULIN-CONJUGATE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32788,
	"target": 6913,
	"type": 71237,
	"label": "A PEPTIDE-IMMUNOGLOBULIN-CONJUGATE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 71238,
	"label": "METODO PARA LA EXPRESION RECOMBINANTE DE UN POLIPEPTIDO.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 71238,
	"label": "METODO PARA LA EXPRESION RECOMBINANTE DE UN POLIPEPTIDO.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 71238,
	"label": "METODO PARA LA EXPRESION RECOMBINANTE DE UN POLIPEPTIDO.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 71238,
	"label": "METODO PARA LA EXPRESION RECOMBINANTE DE UN POLIPEPTIDO.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 71238,
	"label": "METODO PARA LA EXPRESION RECOMBINANTE DE UN POLIPEPTIDO.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 71244,
	"label": "Protein expression in rodent cells",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38065,
	"target": 38042,
	"type": 71562,
	"label": "UNA CELULA HUMANA PARA LA FABRICACION DE ERITROPOYETINA POR ACTIVACION GENICA ENDOGENA, UN PROCEDIMIENTO PARA LA FABRICACION DE LA MISMA Y UNA CONSTRUCCIONDE ADN A SER USADA EN EL MISMO, UN PROCEDIMIENTO PARA LA FABRICACION DE EPO HUMANA, EPO HUMANA AISLADA OBTENIDA POR EL MISMO Y UN PREPARADO FARMA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 71562,
	"label": "UNA CELULA HUMANA PARA LA FABRICACION DE ERITROPOYETINA POR ACTIVACION GENICA ENDOGENA, UN PROCEDIMIENTO PARA LA FABRICACION DE LA MISMA Y UNA CONSTRUCCIONDE ADN A SER USADA EN EL MISMO, UN PROCEDIMIENTO PARA LA FABRICACION DE EPO HUMANA, EPO HUMANA AISLADA OBTENIDA POR EL MISMO Y UN PREPARADO FARMA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 71562,
	"label": "UNA CELULA HUMANA PARA LA FABRICACION DE ERITROPOYETINA POR ACTIVACION GENICA ENDOGENA, UN PROCEDIMIENTO PARA LA FABRICACION DE LA MISMA Y UNA CONSTRUCCIONDE ADN A SER USADA EN EL MISMO, UN PROCEDIMIENTO PARA LA FABRICACION DE EPO HUMANA, EPO HUMANA AISLADA OBTENIDA POR EL MISMO Y UN PREPARADO FARMA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 71562,
	"label": "UNA CELULA HUMANA PARA LA FABRICACION DE ERITROPOYETINA POR ACTIVACION GENICA ENDOGENA, UN PROCEDIMIENTO PARA LA FABRICACION DE LA MISMA Y UNA CONSTRUCCIONDE ADN A SER USADA EN EL MISMO, UN PROCEDIMIENTO PARA LA FABRICACION DE EPO HUMANA, EPO HUMANA AISLADA OBTENIDA POR EL MISMO Y UN PREPARADO FARMA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 71562,
	"label": "UNA CELULA HUMANA PARA LA FABRICACION DE ERITROPOYETINA POR ACTIVACION GENICA ENDOGENA, UN PROCEDIMIENTO PARA LA FABRICACION DE LA MISMA Y UNA CONSTRUCCIONDE ADN A SER USADA EN EL MISMO, UN PROCEDIMIENTO PARA LA FABRICACION DE EPO HUMANA, EPO HUMANA AISLADA OBTENIDA POR EL MISMO Y UN PREPARADO FARMA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 71565,
	"label": "UN ANTIGENO POLIPEPTIDICO ESPECIFICO DE TUMORES, SU USO, UN METODO PARA PRODUCIRLO, METODOS PARA EL AISLAMIENTO DE mRNA DE UN ANTIGENO ESPECIFICO DETUMORES Y PARA LA MEDICION DE LA PROLIFERACION DE CELULAS T CITOTOXICAS ESPECIFICAS DE TUMORES Y USO DE UN ACIDO NUCLEICO CODIFICADOR DE UN ANTIGENOPOLI",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 71587,
	"label": "TUMOR-SUPPRESSORGEN DEL-27 UND DAS DADURCH KODIERTE PROTEIN, VERFAHREN ZU DEREN HERSTELLUNG UND NUTZUNG",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32754,
	"type": 71587,
	"label": "TUMOR-SUPPRESSORGEN DEL-27 UND DAS DADURCH KODIERTE PROTEIN, VERFAHREN ZU DEREN HERSTELLUNG UND NUTZUNG",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 32754,
	"type": 71587,
	"label": "TUMOR-SUPPRESSORGEN DEL-27 UND DAS DADURCH KODIERTE PROTEIN, VERFAHREN ZU DEREN HERSTELLUNG UND NUTZUNG",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 71622,
	"label": "Water-soluble pharmaceutical composition comprising an ionic complex of a polypeptide and an amphiphilic compound and a method for increasing the activity of a polypeptide by forming the aforementioned complex",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 71856,
	"label": "PROCEDIMIENTO PARA EL CULTIVO DE CELULAS PARA LA PRODUCCION DE SUBSTANCIAS.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37878,
	"target": 37875,
	"type": 71856,
	"label": "PROCEDIMIENTO PARA EL CULTIVO DE CELULAS PARA LA PRODUCCION DE SUBSTANCIAS.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 71856,
	"label": "PROCEDIMIENTO PARA EL CULTIVO DE CELULAS PARA LA PRODUCCION DE SUBSTANCIAS.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 71856,
	"label": "PROCEDIMIENTO PARA EL CULTIVO DE CELULAS PARA LA PRODUCCION DE SUBSTANCIAS.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 71856,
	"label": "PROCEDIMIENTO PARA EL CULTIVO DE CELULAS PARA LA PRODUCCION DE SUBSTANCIAS.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 72403,
	"label": "derivados tricìclicos da lactama, sua produção e seus usos como agentes farmacêuticos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 72405,
	"label": "DOMAIN-GRAFTED ANTIBODIES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 72405,
	"label": "DOMAIN-GRAFTED ANTIBODIES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37859,
	"target": 32788,
	"type": 72405,
	"label": "DOMAIN-GRAFTED ANTIBODIES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 32788,
	"type": 72405,
	"label": "DOMAIN-GRAFTED ANTIBODIES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37859,
	"target": 32779,
	"type": 72405,
	"label": "DOMAIN-GRAFTED ANTIBODIES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 72534,
	"label": "compostos de estirilsulfonamidas, processo para sua preparacão, composicão farmacêutica, bem como seu uso",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 30201,
	"target": 7508,
	"type": 72534,
	"label": "compostos de estirilsulfonamidas, processo para sua preparacão, composicão farmacêutica, bem como seu uso",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 30201,
	"target": 7507,
	"type": 72534,
	"label": "compostos de estirilsulfonamidas, processo para sua preparacão, composicão farmacêutica, bem como seu uso",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6301,
	"target": 6279,
	"type": 72554,
	"label": "DERIVADOS DE ARIL-ISOXAZOL-4-IL-IMIDAZO[1,5-A]PIRIDINA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 72554,
	"label": "DERIVADOS DE ARIL-ISOXAZOL-4-IL-IMIDAZO[1,5-A]PIRIDINA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6279,
	"type": 72554,
	"label": "DERIVADOS DE ARIL-ISOXAZOL-4-IL-IMIDAZO[1,5-A]PIRIDINA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 72814,
	"label": "Pharmaceutical composition for treatment of thromboembolic disorder or atherosclerosis or to inhibit blood coagulation",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38071,
	"target": 37986,
	"type": 72831,
	"label": "LíNEA CELULAR DE EMPAQUETAMIENTO DE RETROVIRUS ANFOTRoPICO, PROCESO PARA SU PRODUCCIoN, Y PROCESO PARA LA PRODUCCIoN DE UN VECTOR RETROVIRAL MEDIANTE LA MISMA.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 72831,
	"label": "LíNEA CELULAR DE EMPAQUETAMIENTO DE RETROVIRUS ANFOTRoPICO, PROCESO PARA SU PRODUCCIoN, Y PROCESO PARA LA PRODUCCIoN DE UN VECTOR RETROVIRAL MEDIANTE LA MISMA.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38071,
	"target": 37899,
	"type": 72831,
	"label": "LíNEA CELULAR DE EMPAQUETAMIENTO DE RETROVIRUS ANFOTRoPICO, PROCESO PARA SU PRODUCCIoN, Y PROCESO PARA LA PRODUCCIoN DE UN VECTOR RETROVIRAL MEDIANTE LA MISMA.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 72870,
	"label": "NUEVOS DERIVADOS DE DIHIDROPIRIMIDO [4,5-D] PIRIMIDINONA SUSTITUIDA POR AMIINO, FABRICACION Y USO DE LOS MISMOS COMO AGENTES FARMACEUTICOS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 73487,
	"label": "Phosphorylated COP1 molecules and uses thereof",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 73689,
	"label": "IRAK-4 ZUSAMMENSETZUNGEN UND DEREN VERWENDUNGEN",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 73819,
	"label": "INHIBIDORES ANTI-C2/C2A DE LA ACTIVACION DEL COMPLEMENTO.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 73819,
	"label": "INHIBIDORES ANTI-C2/C2A DE LA ACTIVACION DEL COMPLEMENTO.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 73819,
	"label": "INHIBIDORES ANTI-C2/C2A DE LA ACTIVACION DEL COMPLEMENTO.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 75251,
	"label": "METODOS PARA EL DIAGNOSTICO Y EL TRATAMIENTO DE METASTASIS Y UNA COMPOSICION UTIL PARA ESE FIN.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 75251,
	"label": "METODOS PARA EL DIAGNOSTICO Y EL TRATAMIENTO DE METASTASIS Y UNA COMPOSICION UTIL PARA ESE FIN.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 75251,
	"label": "METODOS PARA EL DIAGNOSTICO Y EL TRATAMIENTO DE METASTASIS Y UNA COMPOSICION UTIL PARA ESE FIN.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 75512,
	"label": "Method for the purification of an N-terminal fragment of hepatocyte growth factor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 75512,
	"label": "Method for the purification of an N-terminal fragment of hepatocyte growth factor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 75512,
	"label": "Method for the purification of an N-terminal fragment of hepatocyte growth factor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 75514,
	"label": "OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 75593,
	"label": "METHOD FOR RECOMBINANT EXPRESSION OF N-TERMINAL FRAGMENT OF HEPATOCYTE GROWTH FACTOR",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 75601,
	"label": "NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 75601,
	"label": "NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 75601,
	"label": "NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37900,
	"target": 6854,
	"type": 76078,
	"label": "INHIBICION DE LA ACTIVACION DEL COMPLEMENTO C5 PARA EL TRATAMIENTO Y LA PREVENCION DE RECHAZO DE XENOINJERTO RETRASADO O RECHAZO VASCULAR AGUDO.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 76332,
	"label": "IMPROVED METHOD FOR THE RECOMBINANT PRODUCTION AND PURIFICATION OF PROTEIN KINASES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6500,
	"target": 6371,
	"type": 76619,
	"label": "VERWENDUNG VON TRIOXOPYRIMIDIN ZUR BEHANDLUNG UND PRÄVENTION VON ENTZÜNDLICHEN ERKRANKUNGEN DER BRONCHIEN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6939,
	"target": 6500,
	"type": 76619,
	"label": "VERWENDUNG VON TRIOXOPYRIMIDIN ZUR BEHANDLUNG UND PRÄVENTION VON ENTZÜNDLICHEN ERKRANKUNGEN DER BRONCHIEN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7409,
	"target": 6939,
	"type": 76619,
	"label": "VERWENDUNG VON TRIOXOPYRIMIDIN ZUR BEHANDLUNG UND PRÄVENTION VON ENTZÜNDLICHEN ERKRANKUNGEN DER BRONCHIEN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6939,
	"target": 6371,
	"type": 76619,
	"label": "VERWENDUNG VON TRIOXOPYRIMIDIN ZUR BEHANDLUNG UND PRÄVENTION VON ENTZÜNDLICHEN ERKRANKUNGEN DER BRONCHIEN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7409,
	"target": 6500,
	"type": 76619,
	"label": "VERWENDUNG VON TRIOXOPYRIMIDIN ZUR BEHANDLUNG UND PRÄVENTION VON ENTZÜNDLICHEN ERKRANKUNGEN DER BRONCHIEN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 76842,
	"label": "derivados de tioéter, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 76872,
	"label": "PYRAZOLO PYRIMIDINES.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 76872,
	"label": "PYRAZOLO PYRIMIDINES.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31042,
	"target": 6376,
	"type": 76872,
	"label": "PYRAZOLO PYRIMIDINES.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 77196,
	"label": "DERIVADOS DE TETRAHIDROPIRIDINA, PROCESO PARA PREPARARLOS, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31912,
	"target": 30815,
	"type": 77196,
	"label": "DERIVADOS DE TETRAHIDROPIRIDINA, PROCESO PARA PREPARARLOS, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 77196,
	"label": "DERIVADOS DE TETRAHIDROPIRIDINA, PROCESO PARA PREPARARLOS, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7508,
	"target": 6301,
	"type": 77196,
	"label": "DERIVADOS DE TETRAHIDROPIRIDINA, PROCESO PARA PREPARARLOS, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 30815,
	"target": 7508,
	"type": 77196,
	"label": "DERIVADOS DE TETRAHIDROPIRIDINA, PROCESO PARA PREPARARLOS, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, Y USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 77247,
	"label": "HIDROXIAMIDAS DE ACIDO (1-OXO-1,2,3,4-TETRAHIDRO-NAFTALEN-2-IL)-ALCANOICO, PROCESO PARA LA MANUFACTURA DE ESTOS COMPUESTOS, COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS Y LOS USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 77424,
	"label": "METODO PARA UNA BIOTINILACION ESPECIFICA DE SECUENCIA DE POLIPEPTIDOS IN VITRO.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 78038,
	"label": "THIOPHENE HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HDAC INHIBITORS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6484,
	"target": 6483,
	"type": 78712,
	"label": "Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6489,
	"target": 6484,
	"type": 78712,
	"label": "Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6489,
	"target": 6483,
	"type": 78712,
	"label": "Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6795,
	"target": 6489,
	"type": 78712,
	"label": "Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6795,
	"target": 6484,
	"type": 78712,
	"label": "Oligoribonucleotide or peptide nucleic acid which inhibits action of hepatitis C virus",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 78793,
	"label": "USE OF A LECTIN PATHWAY-SPECIFIC COMPLEMENT INHIBITORS IN MANUFACTURE OF MEDICAMENTS FOR PREVENTING OR INHIBITING TISSUE DAMAGE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 78903,
	"label": "COMPUESTOS DERIVADOS DEL ACIDO 6-(2-BROMOFENIL)-PIRIDO[2,3-DIPIRIMIDIN-7-CARBOXILICO; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION; Y USO PARA TRATAR EL CANCER Y PARA PREPARAR MEDICAMENTOS PARA INHIBIR EL CRECIMIENTO TUMORAL.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 78903,
	"label": "COMPUESTOS DERIVADOS DEL ACIDO 6-(2-BROMOFENIL)-PIRIDO[2,3-DIPIRIMIDIN-7-CARBOXILICO; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION; Y USO PARA TRATAR EL CANCER Y PARA PREPARAR MEDICAMENTOS PARA INHIBIR EL CRECIMIENTO TUMORAL.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 78903,
	"label": "COMPUESTOS DERIVADOS DEL ACIDO 6-(2-BROMOFENIL)-PIRIDO[2,3-DIPIRIMIDIN-7-CARBOXILICO; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION; Y USO PARA TRATAR EL CANCER Y PARA PREPARAR MEDICAMENTOS PARA INHIBIR EL CRECIMIENTO TUMORAL.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6280,
	"type": 78904,
	"label": "COMPUESTOS DERIVADOS DE OXAZOL; SALES DE DICHOS COMPUESTOS; PROCEDIMIENTO DE PREPARACION DE DICHOS COMPUESTOS; COMPOSICION FARMACEUTICA QUE CONTIENE DICHOS COMPUESTOS; Y SU USO PARA INHIBIR EL CRECIMIENTO TUMORAL.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 78934,
	"label": "AMIDDERIVATE VON 3-PHENYLDIHYDROPYRIMIDOÄ4,5- DÜPYRIMIDINONEN, DEREN HERSTELLUNG UND VERWENDUNG ALS PHARMAZEUTISCHE MITTEL",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 78994,
	"label": "1,2,3 -TRIAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 79006,
	"label": "derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 79025,
	"label": "TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 79025,
	"label": "TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6279,
	"type": 79025,
	"label": "TRICYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6280,
	"type": 79044,
	"label": "INDOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 79055,
	"label": "Amide derivatives of 7-amino-3-phenyl-dihydropyrimido [4,5-d]pyrimidinones, their manufacture and use as protein kinase ingibitor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 79084,
	"label": "Anticuerpos anti-OX40L",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 79084,
	"label": "Anticuerpos anti-OX40L",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 79084,
	"label": "Anticuerpos anti-OX40L",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 79084,
	"label": "Anticuerpos anti-OX40L",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 79084,
	"label": "Anticuerpos anti-OX40L",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 79085,
	"label": "6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 79085,
	"label": "6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 79085,
	"label": "6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 79086,
	"label": "azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7422,
	"target": 6302,
	"type": 79086,
	"label": "azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 79086,
	"label": "azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 79086,
	"label": "azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7422,
	"type": 79086,
	"label": "azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 79096,
	"label": "METHOD FOR PREVENTING AND TREATING MAST CELL MEDIATED DISEASES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 79463,
	"label": "7H-PYRIDOÄ3,4-DÜPYRIMIDIN-8-ONE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS PROTEINKINASEINHIBITOREN",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 79463,
	"label": "7H-PYRIDOÄ3,4-DÜPYRIMIDIN-8-ONE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS PROTEINKINASEINHIBITOREN",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 79463,
	"label": "7H-PYRIDOÄ3,4-DÜPYRIMIDIN-8-ONE, IHRE HERSTELLUNG UND IHRE VERWENDUNG ALS PROTEINKINASEINHIBITOREN",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 79557,
	"label": "PEG-CONJUGATES OF HEPATOCYTE GROWTH FACTOR HGT-NK4",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 79686,
	"label": "DERIVADOS TRICICLICOS DE LACTAMA Y SULTAMA, PROCESOS PARA SU ELABORACION, MEDICAMENTOS QUE LOS CONTIENEN, Y EL USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37904,
	"target": 37899,
	"type": 79806,
	"label": "ANTIKÖRPER GEGEN DEN INSULINÄHNLICHEN WACHSTUMSFAKTOR I-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38065,
	"target": 37993,
	"type": 79806,
	"label": "ANTIKÖRPER GEGEN DEN INSULINÄHNLICHEN WACHSTUMSFAKTOR I-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37904,
	"type": 79806,
	"label": "ANTIKÖRPER GEGEN DEN INSULINÄHNLICHEN WACHSTUMSFAKTOR I-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 79806,
	"label": "ANTIKÖRPER GEGEN DEN INSULINÄHNLICHEN WACHSTUMSFAKTOR I-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38065,
	"target": 37904,
	"type": 79806,
	"label": "ANTIKÖRPER GEGEN DEN INSULINÄHNLICHEN WACHSTUMSFAKTOR I-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6295,
	"target": 6290,
	"type": 80215,
	"label": "AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6295,
	"type": 80215,
	"label": "AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 80215,
	"label": "AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 80228,
	"label": "Method for Improved Selection of Rnai Transfectants",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 80236,
	"label": "TRYCYCLIC HETEROCYCLES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 80254,
	"label": "Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 80254,
	"label": "Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 80254,
	"label": "Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 80261,
	"label": "Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 80261,
	"label": "Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 80261,
	"label": "Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56765,
	"target": 32777,
	"type": 80292,
	"label": "DETECTION OF A THERAPEUTIC ANTIBODY IN AN EXPERIMENTAL ANIMAL.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 80662,
	"label": "PIRIMIDIN-2,4,6-TRIONAS 5,5-DISUSTITUIDAS, COMPOSICIONES FARMACEUTICAS QUE LAS COMPRENDEN, Y EL USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6290,
	"target": 6191,
	"type": 80663,
	"label": "THIAZOLIDINEDIONES ALONE OR IN CONBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 80663,
	"label": "THIAZOLIDINEDIONES ALONE OR IN CONBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6191,
	"type": 80663,
	"label": "THIAZOLIDINEDIONES ALONE OR IN CONBINATION WITH OTHER THERAPEUTIC AGENTS FOR INHIBITING OR REDUCING TUMOUR GROWTH",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32788,
	"target": 32527,
	"type": 80669,
	"label": "MUTANTS OF IGF BINDING PROTEINS AND METHODS OF PRODUCTION OF ANTAGONISTS THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 80669,
	"label": "MUTANTS OF IGF BINDING PROTEINS AND METHODS OF PRODUCTION OF ANTAGONISTS THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 32527,
	"type": 80669,
	"label": "MUTANTS OF IGF BINDING PROTEINS AND METHODS OF PRODUCTION OF ANTAGONISTS THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32527,
	"target": 6795,
	"type": 80669,
	"label": "MUTANTS OF IGF BINDING PROTEINS AND METHODS OF PRODUCTION OF ANTAGONISTS THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 80669,
	"label": "MUTANTS OF IGF BINDING PROTEINS AND METHODS OF PRODUCTION OF ANTAGONISTS THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7509,
	"target": 6539,
	"type": 80758,
	"label": "COMBINACION DE UN INHIBIDOR DE GELATINA CON UN AGENTE ANTITUMORAL Y USOS DE LA MISMA.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7358,
	"target": 6795,
	"type": 80853,
	"label": "PIPERIDINAS SUSTITUIDAS COMO MODULADORES DEL RECEPTOR DE MELANOCORTINA.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 80948,
	"label": "Imidazolidine derivatives",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37900,
	"target": 37899,
	"type": 81193,
	"label": "ANTICUERPOS CONTRA EL RECEPCTOR DE LA INTERLEUQUINA- 1 Y LOS USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37900,
	"type": 81193,
	"label": "ANTICUERPOS CONTRA EL RECEPCTOR DE LA INTERLEUQUINA- 1 Y LOS USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 81193,
	"label": "ANTICUERPOS CONTRA EL RECEPCTOR DE LA INTERLEUQUINA- 1 Y LOS USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 81193,
	"label": "ANTICUERPOS CONTRA EL RECEPCTOR DE LA INTERLEUQUINA- 1 Y LOS USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 81193,
	"label": "ANTICUERPOS CONTRA EL RECEPCTOR DE LA INTERLEUQUINA- 1 Y LOS USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38232,
	"target": 38164,
	"type": 81298,
	"label": "High-throughput prion assays",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 81505,
	"label": "Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7508,
	"type": 81505,
	"label": "Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 81505,
	"label": "Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 81505,
	"label": "Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 6854,
	"type": 81505,
	"label": "Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6371,
	"target": 6290,
	"type": 81567,
	"label": "Derivado de cumarina novedoso que tiene actividad antitumoral",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 81630,
	"label": "composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 81630,
	"label": "composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6290,
	"type": 81630,
	"label": "composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 81662,
	"label": "2, 3-phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6281,
	"target": 6279,
	"type": 81663,
	"label": "SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6371,
	"target": 6281,
	"type": 81663,
	"label": "SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6371,
	"target": 6279,
	"type": 81663,
	"label": "SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 81663,
	"label": "SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6281,
	"type": 81663,
	"label": "SUBSTITUTED INDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 81665,
	"label": "Antibody of human IgG1 or IgG3 type being glycosylated with a sugar chain at Asn297",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 81665,
	"label": "Antibody of human IgG1 or IgG3 type being glycosylated with a sugar chain at Asn297",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7487,
	"type": 81665,
	"label": "Antibody of human IgG1 or IgG3 type being glycosylated with a sugar chain at Asn297",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 81665,
	"label": "Antibody of human IgG1 or IgG3 type being glycosylated with a sugar chain at Asn297",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 81665,
	"label": "Antibody of human IgG1 or IgG3 type being glycosylated with a sugar chain at Asn297",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 81666,
	"label": "Anticuerpos contra el receptor del factor l de crecimiento similar a la insulina y usos de los mismos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 81666,
	"label": "Anticuerpos contra el receptor del factor l de crecimiento similar a la insulina y usos de los mismos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 81666,
	"label": "Anticuerpos contra el receptor del factor l de crecimiento similar a la insulina y usos de los mismos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 81666,
	"label": "Anticuerpos contra el receptor del factor l de crecimiento similar a la insulina y usos de los mismos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 81666,
	"label": "Anticuerpos contra el receptor del factor l de crecimiento similar a la insulina y usos de los mismos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6303,
	"type": 81673,
	"label": "Synergistic compositions for treating HIV-1",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38004,
	"target": 32698,
	"type": 82551,
	"label": "Monoklonale antistoffer mot interleukin-15, farmasoytisk sammensetning inneholdende slike og anvendelse av antistoffene for fremstilling av et medikament for behandling av sykdommer forbundet med IL-15.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 82551,
	"label": "Monoklonale antistoffer mot interleukin-15, farmasoytisk sammensetning inneholdende slike og anvendelse av antistoffene for fremstilling av et medikament for behandling av sykdommer forbundet med IL-15.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38004,
	"target": 6795,
	"type": 82551,
	"label": "Monoklonale antistoffer mot interleukin-15, farmasoytisk sammensetning inneholdende slike og anvendelse av antistoffene for fremstilling av et medikament for behandling av sykdommer forbundet med IL-15.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 7409,
	"type": 82679,
	"label": "ANTIBODIES THAT BIND PAR-2.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 38164,
	"type": 82776,
	"label": "PLASMIDEO,PROCESSO PARA PRODUCAO DE UM POLIPEPTIDO ESPECIFICO VEICULO CLONAL,CULTURA BACTERIANA TRANSFORMANTE,PROCESSO PARA PRODUZIR UMA SUBSTANCIA IMUNOGENICA PROCESSO PARA PREPARAR UM GENE ESTRUTURAL,E POLIDESOXIRRIBONUCLEOTIDO DE FAIXA DUPLA",
	"group": "Roche",
	"time": 1978,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 82776,
	"label": "PLASMIDEO,PROCESSO PARA PRODUCAO DE UM POLIPEPTIDO ESPECIFICO VEICULO CLONAL,CULTURA BACTERIANA TRANSFORMANTE,PROCESSO PARA PRODUZIR UMA SUBSTANCIA IMUNOGENICA PROCESSO PARA PREPARAR UM GENE ESTRUTURAL,E POLIDESOXIRRIBONUCLEOTIDO DE FAIXA DUPLA",
	"group": "Roche",
	"time": 1978,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 82776,
	"label": "PLASMIDEO,PROCESSO PARA PRODUCAO DE UM POLIPEPTIDO ESPECIFICO VEICULO CLONAL,CULTURA BACTERIANA TRANSFORMANTE,PROCESSO PARA PRODUZIR UMA SUBSTANCIA IMUNOGENICA PROCESSO PARA PREPARAR UM GENE ESTRUTURAL,E POLIDESOXIRRIBONUCLEOTIDO DE FAIXA DUPLA",
	"group": "Roche",
	"time": 1978,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 83261,
	"label": "NOVEL TRIARYLIMIDAZOLES.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6280,
	"type": 83273,
	"label": "1-.PRIME.(E)-2-(PHENYL) ETHENYL-4-(ARYLALKOXY)-OXAZOLE OR - THIAZOLE COMPOUNDS AS HER-2 TYROSINE KINASES INHIBITORS AND THEIR USE IN THETREATMENT OF CANCER",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 83593,
	"label": "IN VIVO MODEL FOR IMMUNOCOMPARABILITY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 83826,
	"label": "METHODS OF PURIFICATION AND REACTIVATION OF PRECIPITATED HETEROLOGOUS PROTEINS",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 83908,
	"label": "Fremgangsmåde til fremstilling af et immunoglobulin omfattende tung og let kæde og med specificitet for et bestemt identificeret antigen,  replicerbare udtrykkelsesvektorer omfattende DNA-sekvenser, der koder for henholdsvis den tunge og den lette kæde, og rekombinante værtsceller transformeret med vektorerne",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 83908,
	"label": "Fremgangsmåde til fremstilling af et immunoglobulin omfattende tung og let kæde og med specificitet for et bestemt identificeret antigen,  replicerbare udtrykkelsesvektorer omfattende DNA-sekvenser, der koder for henholdsvis den tunge og den lette kæde, og rekombinante værtsceller transformeret med vektorerne",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 83908,
	"label": "Fremgangsmåde til fremstilling af et immunoglobulin omfattende tung og let kæde og med specificitet for et bestemt identificeret antigen,  replicerbare udtrykkelsesvektorer omfattende DNA-sekvenser, der koder for henholdsvis den tunge og den lette kæde, og rekombinante værtsceller transformeret med vektorerne",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 37897,
	"type": 84273,
	"label": "METODOS MEJORADOS PARA EL CULTIVO DE CELULAS DE MAMIFEROS IN VITRO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 84273,
	"label": "METODOS MEJORADOS PARA EL CULTIVO DE CELULAS DE MAMIFEROS IN VITRO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37897,
	"target": 37875,
	"type": 84273,
	"label": "METODOS MEJORADOS PARA EL CULTIVO DE CELULAS DE MAMIFEROS IN VITRO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 84273,
	"label": "METODOS MEJORADOS PARA EL CULTIVO DE CELULAS DE MAMIFEROS IN VITRO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 84273,
	"label": "METODOS MEJORADOS PARA EL CULTIVO DE CELULAS DE MAMIFEROS IN VITRO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 84951,
	"label": "METODO DE IDENTIFICACION DE UN ACIDO NUCLEICO QUE CODIFICA UNA ESTRUCTURA TIPO HEMOPEXINA QUE SE UNE DE FORMA ESPECIFICA A UNA MOLECULA DIANA PREDETERMINADA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 84951,
	"label": "METODO DE IDENTIFICACION DE UN ACIDO NUCLEICO QUE CODIFICA UNA ESTRUCTURA TIPO HEMOPEXINA QUE SE UNE DE FORMA ESPECIFICA A UNA MOLECULA DIANA PREDETERMINADA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37947,
	"type": 84951,
	"label": "METODO DE IDENTIFICACION DE UN ACIDO NUCLEICO QUE CODIFICA UNA ESTRUCTURA TIPO HEMOPEXINA QUE SE UNE DE FORMA ESPECIFICA A UNA MOLECULA DIANA PREDETERMINADA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 84987,
	"label": "anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de  hibridoma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 84987,
	"label": "anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de  hibridoma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 84987,
	"label": "anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de  hibridoma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 84987,
	"label": "anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de  hibridoma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 84987,
	"label": "anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de  hibridoma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 85076,
	"label": "ACTIVATION OF RECOMBINANT PROTEINS BY SOLUBILISATION OR RENATURATION WHEREIN THE N- OR C-TERMINAL HELPER SEQUENCE IS PROVIDED (EXEMPLIFIED USING G-CSF)",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32696,
	"target": 32694,
	"type": 85076,
	"label": "ACTIVATION OF RECOMBINANT PROTEINS BY SOLUBILISATION OR RENATURATION WHEREIN THE N- OR C-TERMINAL HELPER SEQUENCE IS PROVIDED (EXEMPLIFIED USING G-CSF)",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 85076,
	"label": "ACTIVATION OF RECOMBINANT PROTEINS BY SOLUBILISATION OR RENATURATION WHEREIN THE N- OR C-TERMINAL HELPER SEQUENCE IS PROVIDED (EXEMPLIFIED USING G-CSF)",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 85076,
	"label": "ACTIVATION OF RECOMBINANT PROTEINS BY SOLUBILISATION OR RENATURATION WHEREIN THE N- OR C-TERMINAL HELPER SEQUENCE IS PROVIDED (EXEMPLIFIED USING G-CSF)",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 32696,
	"type": 85076,
	"label": "ACTIVATION OF RECOMBINANT PROTEINS BY SOLUBILISATION OR RENATURATION WHEREIN THE N- OR C-TERMINAL HELPER SEQUENCE IS PROVIDED (EXEMPLIFIED USING G-CSF)",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 85120,
	"label": "Gj¶rmutanter med N-glykosyleringsdefekter, fremgangsmåte for fremstilling av gj¶rmutanter, og anvendelse av disse, samtfremgangsmåte for fremstilling av et rekombinant protein",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32788,
	"target": 32694,
	"type": 85162,
	"label": "P40 HOMODIMER (TWO ASSOCIATED P40 SUBUNITS) OF INTERLEUKIN 12, ITS PREPARATION AND COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 85162,
	"label": "P40 HOMODIMER (TWO ASSOCIATED P40 SUBUNITS) OF INTERLEUKIN 12, ITS PREPARATION AND COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 85162,
	"label": "P40 HOMODIMER (TWO ASSOCIATED P40 SUBUNITS) OF INTERLEUKIN 12, ITS PREPARATION AND COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 85162,
	"label": "P40 HOMODIMER (TWO ASSOCIATED P40 SUBUNITS) OF INTERLEUKIN 12, ITS PREPARATION AND COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 85162,
	"label": "P40 HOMODIMER (TWO ASSOCIATED P40 SUBUNITS) OF INTERLEUKIN 12, ITS PREPARATION AND COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 85430,
	"label": "METHOD FOR DIAGNOSIS AND TREATMENT OF PANCREATIC CARCINOMA AND COMPOSITION USEFUL FOR THE SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 85430,
	"label": "METHOD FOR DIAGNOSIS AND TREATMENT OF PANCREATIC CARCINOMA AND COMPOSITION USEFUL FOR THE SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 85430,
	"label": "METHOD FOR DIAGNOSIS AND TREATMENT OF PANCREATIC CARCINOMA AND COMPOSITION USEFUL FOR THE SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 85473,
	"label": "Fremgangsmåder til rekombinant frembringelse af antifusogene peptider",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 85473,
	"label": "Fremgangsmåder til rekombinant frembringelse af antifusogene peptider",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 85473,
	"label": "Fremgangsmåder til rekombinant frembringelse af antifusogene peptider",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 85473,
	"label": "Fremgangsmåder til rekombinant frembringelse af antifusogene peptider",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 85473,
	"label": "Fremgangsmåder til rekombinant frembringelse af antifusogene peptider",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 85511,
	"label": "HITZELABILE DESOXYRIBONUKLEASE I-VARIANTEN",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 85844,
	"label": "PROCEDIMIENTO PARA LA DETERMINACION DE CTP11 Y PARA LA DETERMINACION DEL POTENCIAL METASTASICO DE UNA MUESTRA DE TUMOR.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7424,
	"target": 7358,
	"type": 86081,
	"label": "Heterocykliske sulfonamider, farmasoytiske preparater omfattende slike, anvendelse av disse for fremstilling av medikamenter for behandling eller forebygging av lidelser, fremstilling av disse samt anvendelse av disse for behandling av sykdommer.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6795,
	"target": 6483,
	"type": 87032,
	"label": "Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 87032,
	"label": "Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 87032,
	"label": "Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32788,
	"target": 6483,
	"type": 87032,
	"label": "Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 87032,
	"label": "Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 87172,
	"label": "Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 87172,
	"label": "Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 87172,
	"label": "Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32779,
	"target": 6854,
	"type": 87172,
	"label": "Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32788,
	"target": 6854,
	"type": 87172,
	"label": "Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 87896,
	"label": "IDENTIFICATION OF CELLULAR POLYPEPTIDES DIFFERENTIALLY EXPRESSED BY TUMOR CELLS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 88492,
	"label": "METHODS AND COMPOSITIONS FOR TREATING TUMOR DISEASES.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 88492,
	"label": "METHODS AND COMPOSITIONS FOR TREATING TUMOR DISEASES.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 88492,
	"label": "METHODS AND COMPOSITIONS FOR TREATING TUMOR DISEASES.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 88634,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, métodos para o tratamento e/ou prevenção de enfermidades que estão associados com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal  e usos dos compostos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 88750,
	"label": "EPHA2 BITE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 88750,
	"label": "EPHA2 BITE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7487,
	"target": 6854,
	"type": 88750,
	"label": "EPHA2 BITE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 88750,
	"label": "EPHA2 BITE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 88750,
	"label": "EPHA2 BITE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 32754,
	"type": 89217,
	"label": "UN ACIDO NUCLEICO REGULADO POSITIVAMENTE EN CELULAS CANCEROSAS HUMANAS, UNA PROTEINA CODIFICADA DE ESTE MODO Y UN PROCEDIMIENTO PARA EL DIAGNOSTICO DEL TUMOR.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32754,
	"target": 6483,
	"type": 89217,
	"label": "UN ACIDO NUCLEICO REGULADO POSITIVAMENTE EN CELULAS CANCEROSAS HUMANAS, UNA PROTEINA CODIFICADA DE ESTE MODO Y UN PROCEDIMIENTO PARA EL DIAGNOSTICO DEL TUMOR.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 6483,
	"type": 89217,
	"label": "UN ACIDO NUCLEICO REGULADO POSITIVAMENTE EN CELULAS CANCEROSAS HUMANAS, UNA PROTEINA CODIFICADA DE ESTE MODO Y UN PROCEDIMIENTO PARA EL DIAGNOSTICO DEL TUMOR.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38067,
	"target": 37899,
	"type": 89482,
	"label": "PROTEINA AISLADA QUE COMPRENDE UN POLIPEPTIDO DEL RECEPTOR IIB DE UNA VARIANTE DE ACTIVINA; ACIDO NUCLEICO AISLADO; VECTOR RECOMBINANTE QUE COMPRENDE DICHO ACIDO NUCLEICO; CELULA HUESPED; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA PROTEINA; USO DE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 89482,
	"label": "PROTEINA AISLADA QUE COMPRENDE UN POLIPEPTIDO DEL RECEPTOR IIB DE UNA VARIANTE DE ACTIVINA; ACIDO NUCLEICO AISLADO; VECTOR RECOMBINANTE QUE COMPRENDE DICHO ACIDO NUCLEICO; CELULA HUESPED; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA PROTEINA; USO DE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 89482,
	"label": "PROTEINA AISLADA QUE COMPRENDE UN POLIPEPTIDO DEL RECEPTOR IIB DE UNA VARIANTE DE ACTIVINA; ACIDO NUCLEICO AISLADO; VECTOR RECOMBINANTE QUE COMPRENDE DICHO ACIDO NUCLEICO; CELULA HUESPED; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA PROTEINA; USO DE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38067,
	"target": 7507,
	"type": 89482,
	"label": "PROTEINA AISLADA QUE COMPRENDE UN POLIPEPTIDO DEL RECEPTOR IIB DE UNA VARIANTE DE ACTIVINA; ACIDO NUCLEICO AISLADO; VECTOR RECOMBINANTE QUE COMPRENDE DICHO ACIDO NUCLEICO; CELULA HUESPED; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA PROTEINA; USO DE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 6812,
	"type": 89482,
	"label": "PROTEINA AISLADA QUE COMPRENDE UN POLIPEPTIDO DEL RECEPTOR IIB DE UNA VARIANTE DE ACTIVINA; ACIDO NUCLEICO AISLADO; VECTOR RECOMBINANTE QUE COMPRENDE DICHO ACIDO NUCLEICO; CELULA HUESPED; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHA PROTEINA; USO DE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 89978,
	"label": "ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS IN PPAR GAMMA WITH OSTEOPOROSIS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6478,
	"target": 6215,
	"type": 90611,
	"label": "METODO PARA TRATAR UN PACIENTE CON UN TIPO DE CANCER QUE EXPRESA EL RECEPTOR HER3 A UN NIVEL BAJO MEDIANTE LA ADMINISTRACION DE UN INHIBIDOR DE LA DIMERIZACION DE HER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 90611,
	"label": "METODO PARA TRATAR UN PACIENTE CON UN TIPO DE CANCER QUE EXPRESA EL RECEPTOR HER3 A UN NIVEL BAJO MEDIANTE LA ADMINISTRACION DE UN INHIBIDOR DE LA DIMERIZACION DE HER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6215,
	"type": 90611,
	"label": "METODO PARA TRATAR UN PACIENTE CON UN TIPO DE CANCER QUE EXPRESA EL RECEPTOR HER3 A UN NIVEL BAJO MEDIANTE LA ADMINISTRACION DE UN INHIBIDOR DE LA DIMERIZACION DE HER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 90611,
	"label": "METODO PARA TRATAR UN PACIENTE CON UN TIPO DE CANCER QUE EXPRESA EL RECEPTOR HER3 A UN NIVEL BAJO MEDIANTE LA ADMINISTRACION DE UN INHIBIDOR DE LA DIMERIZACION DE HER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 6478,
	"type": 90611,
	"label": "METODO PARA TRATAR UN PACIENTE CON UN TIPO DE CANCER QUE EXPRESA EL RECEPTOR HER3 A UN NIVEL BAJO MEDIANTE LA ADMINISTRACION DE UN INHIBIDOR DE LA DIMERIZACION DE HER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 91236,
	"label": "METHOD FOR PROMOTION OF ACTIVE CONFORMATION OF GLYCOSYLATED RECOMBINANT PROTEIN, METHOD FOR PREPARING ACTIVE GLYCOSYLATED PROTEIN AND METHOD FOR PREPARING COMPOSITION OF THIS PROTEIN FOR ADMINISTRATION TO USER AND/OR PATIENT OR FOR USING BY USER AND/OR PATIENT",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 91236,
	"label": "METHOD FOR PROMOTION OF ACTIVE CONFORMATION OF GLYCOSYLATED RECOMBINANT PROTEIN, METHOD FOR PREPARING ACTIVE GLYCOSYLATED PROTEIN AND METHOD FOR PREPARING COMPOSITION OF THIS PROTEIN FOR ADMINISTRATION TO USER AND/OR PATIENT OR FOR USING BY USER AND/OR PATIENT",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 91236,
	"label": "METHOD FOR PROMOTION OF ACTIVE CONFORMATION OF GLYCOSYLATED RECOMBINANT PROTEIN, METHOD FOR PREPARING ACTIVE GLYCOSYLATED PROTEIN AND METHOD FOR PREPARING COMPOSITION OF THIS PROTEIN FOR ADMINISTRATION TO USER AND/OR PATIENT OR FOR USING BY USER AND/OR PATIENT",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 91450,
	"label": "ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligaçã",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6812,
	"type": 91450,
	"label": "ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligaçã",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 56836,
	"target": 6812,
	"type": 91450,
	"label": "ácido nucleico isolado, vetor de expressão, célula hospedeira, processos para produzir uma proteìna de ligação da osteoprotegerina, para detectar a presença de uma proteìna de ligação à osteoprotegerina em uma amostra biológica, para avaliar a capacidade de um composto candidato de ligar-se a uma proteìna de ligação da osteoprotegerina e de um composto de teste para aumentar ou reduzir a ligação da proteìna de ligação da osteoprotegerina a odar, para regular a expressão de uma proteìna de ligaçã",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 91526,
	"label": "AMELIORATION OF CELLULAR STRESS RESPONSE.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 92339,
	"label": "3-AMINO-2-ARILPROPIL AZAINDOLES Y USOS DE LOS MISMOS.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 92874,
	"label": "anticorpos anti-efrina b2 isolado, vetor, célula hospedeira, método de elaboração de anticorpo anti-efrina b2, método de elaboração de imunoconjugado anti-efrina b2, método de detecção de efrina b2, método de diagnóstico de disfunção, composição, método de inibição da angiogênese e uso de anticorpo anti-efrina b2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 92874,
	"label": "anticorpos anti-efrina b2 isolado, vetor, célula hospedeira, método de elaboração de anticorpo anti-efrina b2, método de elaboração de imunoconjugado anti-efrina b2, método de detecção de efrina b2, método de diagnóstico de disfunção, composição, método de inibição da angiogênese e uso de anticorpo anti-efrina b2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 32771,
	"type": 92874,
	"label": "anticorpos anti-efrina b2 isolado, vetor, célula hospedeira, método de elaboração de anticorpo anti-efrina b2, método de elaboração de imunoconjugado anti-efrina b2, método de detecção de efrina b2, método de diagnóstico de disfunção, composição, método de inibição da angiogênese e uso de anticorpo anti-efrina b2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 92874,
	"label": "anticorpos anti-efrina b2 isolado, vetor, célula hospedeira, método de elaboração de anticorpo anti-efrina b2, método de elaboração de imunoconjugado anti-efrina b2, método de detecção de efrina b2, método de diagnóstico de disfunção, composição, método de inibição da angiogênese e uso de anticorpo anti-efrina b2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 92874,
	"label": "anticorpos anti-efrina b2 isolado, vetor, célula hospedeira, método de elaboração de anticorpo anti-efrina b2, método de elaboração de imunoconjugado anti-efrina b2, método de detecção de efrina b2, método de diagnóstico de disfunção, composição, método de inibição da angiogênese e uso de anticorpo anti-efrina b2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56833,
	"target": 32770,
	"type": 92919,
	"label": "anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 92919,
	"label": "anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56833,
	"target": 7507,
	"type": 92919,
	"label": "anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 93260,
	"label": "ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 93260,
	"label": "ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 93260,
	"label": "ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 93260,
	"label": "ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 93260,
	"label": "ANTI-EPHB2 ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 96738,
	"label": "METHOD FOR QUICK DETERMINATION OF CYTOKERATIN 19 (CK19) AND PRIMERS AND PROBES THEREFORE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37988,
	"type": 96738,
	"label": "METHOD FOR QUICK DETERMINATION OF CYTOKERATIN 19 (CK19) AND PRIMERS AND PROBES THEREFORE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 96738,
	"label": "METHOD FOR QUICK DETERMINATION OF CYTOKERATIN 19 (CK19) AND PRIMERS AND PROBES THEREFORE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 38164,
	"type": 96738,
	"label": "METHOD FOR QUICK DETERMINATION OF CYTOKERATIN 19 (CK19) AND PRIMERS AND PROBES THEREFORE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 37988,
	"type": 96738,
	"label": "METHOD FOR QUICK DETERMINATION OF CYTOKERATIN 19 (CK19) AND PRIMERS AND PROBES THEREFORE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 39999,
	"target": 7507,
	"type": 98318,
	"label": "PREDICTIVE MARKERS FOR EGFR INHIBITORS TREATMENT",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 98321,
	"label": "PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 98321,
	"label": "PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 98321,
	"label": "PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 98324,
	"label": "PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 98484,
	"label": "2,2-DI-SUBSTITUTED 1Alpha,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 98484,
	"label": "2,2-DI-SUBSTITUTED 1Alpha,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7511,
	"target": 6429,
	"type": 98484,
	"label": "2,2-DI-SUBSTITUTED 1Alpha,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 30485,
	"target": 7511,
	"type": 98484,
	"label": "2,2-DI-SUBSTITUTED 1Alpha,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 98484,
	"label": "2,2-DI-SUBSTITUTED 1Alpha,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 98485,
	"label": "ZELLTOD-INDUZIERENDER WIRKSTOFF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 32738,
	"type": 98485,
	"label": "ZELLTOD-INDUZIERENDER WIRKSTOFF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 98485,
	"label": "ZELLTOD-INDUZIERENDER WIRKSTOFF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32738,
	"type": 98485,
	"label": "ZELLTOD-INDUZIERENDER WIRKSTOFF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32738,
	"target": 7511,
	"type": 98485,
	"label": "ZELLTOD-INDUZIERENDER WIRKSTOFF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 99585,
	"label": "VIRAL INHIBITORS",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 102403,
	"label": "COMPLEMENT PATHWAY INHIBITORS BINDING TO C5 AND C5A WITHOUT PREVENTING THE FORMATION OF C5B.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 102428,
	"label": "Apo-2dcr polypeptides",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 102428,
	"label": "Apo-2dcr polypeptides",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 102428,
	"label": "Apo-2dcr polypeptides",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37862,
	"target": 32788,
	"type": 102428,
	"label": "Apo-2dcr polypeptides",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 102428,
	"label": "Apo-2dcr polypeptides",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 104477,
	"label": "anticorpo produzido por hibridoma, anticorpos isolados, composição farmacêutica polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo, método para reduzir ou inibir a angiogênese e método pata aumentar a eficácia de um agente anti-angiogênico",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 104477,
	"label": "anticorpo produzido por hibridoma, anticorpos isolados, composição farmacêutica polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo, método para reduzir ou inibir a angiogênese e método pata aumentar a eficácia de um agente anti-angiogênico",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 104477,
	"label": "anticorpo produzido por hibridoma, anticorpos isolados, composição farmacêutica polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo, método para reduzir ou inibir a angiogênese e método pata aumentar a eficácia de um agente anti-angiogênico",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 104660,
	"label": "Reagents and methods for detecting Neisseria gonorrhoeae",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37988,
	"type": 104660,
	"label": "Reagents and methods for detecting Neisseria gonorrhoeae",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 104660,
	"label": "Reagents and methods for detecting Neisseria gonorrhoeae",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 104660,
	"label": "Reagents and methods for detecting Neisseria gonorrhoeae",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37988,
	"target": 32478,
	"type": 104660,
	"label": "Reagents and methods for detecting Neisseria gonorrhoeae",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 105659,
	"label": "EMPLEO DE UN MATERIAL DE SILICE EN UNA REACCION DE AMPLIFICACION.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 105684,
	"label": "Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 106786,
	"label": "IMPROVED METHOD FOR TREATMENT OF BISULFITE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 106786,
	"label": "IMPROVED METHOD FOR TREATMENT OF BISULFITE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 106786,
	"label": "IMPROVED METHOD FOR TREATMENT OF BISULFITE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 106904,
	"label": "VERFAHREN ZUR HERSTELLUNG VON SCDB-BIBLIOTHEKEN",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 38059,
	"type": 107119,
	"label": "UN PROCEDIMIENTO PARA PROVEER UNA CÉLULA EUCARIoTICA DHFR NEGATIVA, UN PROCEDIMIENTO PARA INTRODUCIR DE UN GEN DHFR HETERoLOGO EN UNA CÉLULA EUCARIoTICA, UN VECTOR PARA RECOMBINACIoN HOMoLOGA Y UNA CÉLULA EUCARIoTICA, PREFERENTEMENTE UNA CÉLULA HUMANA QUE NO PUEDE DAR LUGAR A UN ORGANISMO ENTERO.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38059,
	"target": 37899,
	"type": 107119,
	"label": "UN PROCEDIMIENTO PARA PROVEER UNA CÉLULA EUCARIoTICA DHFR NEGATIVA, UN PROCEDIMIENTO PARA INTRODUCIR DE UN GEN DHFR HETERoLOGO EN UNA CÉLULA EUCARIoTICA, UN VECTOR PARA RECOMBINACIoN HOMoLOGA Y UNA CÉLULA EUCARIoTICA, PREFERENTEMENTE UNA CÉLULA HUMANA QUE NO PUEDE DAR LUGAR A UN ORGANISMO ENTERO.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 107119,
	"label": "UN PROCEDIMIENTO PARA PROVEER UNA CÉLULA EUCARIoTICA DHFR NEGATIVA, UN PROCEDIMIENTO PARA INTRODUCIR DE UN GEN DHFR HETERoLOGO EN UNA CÉLULA EUCARIoTICA, UN VECTOR PARA RECOMBINACIoN HOMoLOGA Y UNA CÉLULA EUCARIoTICA, PREFERENTEMENTE UNA CÉLULA HUMANA QUE NO PUEDE DAR LUGAR A UN ORGANISMO ENTERO.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 109617,
	"label": "MACROCYCLIC DEPSIPEPTIDE ANTIBODY-DRUG CONJUGATES AND METHODS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 110318,
	"label": "método de ensaio imunossorvente ligado por enzimas, anticorpos, hibridoma e kit de imunoensaio",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6295,
	"target": 6290,
	"type": 111380,
	"label": "DERIVADOS DE (4-(HETEROARIL)PIPERACIN-1-IL)-(FENIL 2,5-SUSTITUIDO)METANONA COMO INHIBIDORES DEL TRANSPORTADOR DE GLICINA 1 (GLYT-1) PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS E NEUROPSIQUIATRICOS.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 111403,
	"label": "SELECTING PATIENTS FOR THERAPY WITH A HER INHIBITOR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 111767,
	"label": "proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 111884,
	"label": "agente de ligação marcado, molécula de ácido nucleico, vetor, célula hospedeira, métodos de tratar um tumor maligno em um animal, de tratar adesão e/ou invasão celular induzidas por upar relacionadas com a doença, e de tratar uma doença não neoplástica, conjugado, e, uso do agente de ligação marcado",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 111884,
	"label": "agente de ligação marcado, molécula de ácido nucleico, vetor, célula hospedeira, métodos de tratar um tumor maligno em um animal, de tratar adesão e/ou invasão celular induzidas por upar relacionadas com a doença, e de tratar uma doença não neoplástica, conjugado, e, uso do agente de ligação marcado",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7509,
	"type": 111884,
	"label": "agente de ligação marcado, molécula de ácido nucleico, vetor, célula hospedeira, métodos de tratar um tumor maligno em um animal, de tratar adesão e/ou invasão celular induzidas por upar relacionadas com a doença, e de tratar uma doença não neoplástica, conjugado, e, uso do agente de ligação marcado",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 111884,
	"label": "agente de ligação marcado, molécula de ácido nucleico, vetor, célula hospedeira, métodos de tratar um tumor maligno em um animal, de tratar adesão e/ou invasão celular induzidas por upar relacionadas com a doença, e de tratar uma doença não neoplástica, conjugado, e, uso do agente de ligação marcado",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 7509,
	"type": 111884,
	"label": "agente de ligação marcado, molécula de ácido nucleico, vetor, célula hospedeira, métodos de tratar um tumor maligno em um animal, de tratar adesão e/ou invasão celular induzidas por upar relacionadas com a doença, e de tratar uma doença não neoplástica, conjugado, e, uso do agente de ligação marcado",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 112358,
	"label": "GUINEA PIG CHYMASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 112358,
	"label": "GUINEA PIG CHYMASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37947,
	"target": 37864,
	"type": 112358,
	"label": "GUINEA PIG CHYMASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38232,
	"target": 37947,
	"type": 112358,
	"label": "GUINEA PIG CHYMASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38232,
	"target": 37899,
	"type": 112358,
	"label": "GUINEA PIG CHYMASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 112649,
	"label": "anticorpo monoclonal, polinucleotìdeo, região variável de cadeia leve, região variável de cadeia pesada, composição, mistura, métodos para produzir um anticorpo , para preparar uma composição farmacêutica ou uma mistura, de diagnóstico de uma doença ou condição associada a amilóide, para determinar o grau de carga de placa amiloidogênica em um tecido, para diagnosticar uma  predisposição para uma doença ou condição, para monitorar doença residual mìnima e para prever responsabilidade de um pacie",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 112979,
	"label": "A chimeric chain L, chimeric chain H, chimeric monoclonal antibody, polypeptide, chain L of humanized antibody, chain H of humanized antibody, humanized antibody, DNA, recombined vector, host cell, method of producing chimeric antibody, method of producing humanized antibody, pharmaceutical mixture, agent.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38042,
	"target": 37993,
	"type": 112979,
	"label": "A chimeric chain L, chimeric chain H, chimeric monoclonal antibody, polypeptide, chain L of humanized antibody, chain H of humanized antibody, humanized antibody, DNA, recombined vector, host cell, method of producing chimeric antibody, method of producing humanized antibody, pharmaceutical mixture, agent.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 112979,
	"label": "A chimeric chain L, chimeric chain H, chimeric monoclonal antibody, polypeptide, chain L of humanized antibody, chain H of humanized antibody, humanized antibody, DNA, recombined vector, host cell, method of producing chimeric antibody, method of producing humanized antibody, pharmaceutical mixture, agent.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38042,
	"type": 112979,
	"label": "A chimeric chain L, chimeric chain H, chimeric monoclonal antibody, polypeptide, chain L of humanized antibody, chain H of humanized antibody, humanized antibody, DNA, recombined vector, host cell, method of producing chimeric antibody, method of producing humanized antibody, pharmaceutical mixture, agent.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 112979,
	"label": "A chimeric chain L, chimeric chain H, chimeric monoclonal antibody, polypeptide, chain L of humanized antibody, chain H of humanized antibody, humanized antibody, DNA, recombined vector, host cell, method of producing chimeric antibody, method of producing humanized antibody, pharmaceutical mixture, agent.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 113703,
	"label": "USE OF A WISP POLYPEPTIDE FOR THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT OF MAMMALIAN CARTILAGE CELLS OR MAMMALIAN CARTILAGE TISSUE DAMAGED FROM A DEGENERATIVE CARTILAGENOUS DISORDER OR INJURY",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37904,
	"target": 37875,
	"type": 114336,
	"label": "MONOCLONAL ANTIBODY AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND MEDICINAL USES THEREOF",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 114336,
	"label": "MONOCLONAL ANTIBODY AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND MEDICINAL USES THEREOF",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37875,
	"type": 114336,
	"label": "MONOCLONAL ANTIBODY AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND MEDICINAL USES THEREOF",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 6321,
	"target": 6301,
	"type": 114506,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os contém, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos, tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6321,
	"type": 114506,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os contém, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos, tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 114506,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os contém, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos, tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 115162,
	"label": "COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 115162,
	"label": "COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 115162,
	"label": "COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7487,
	"type": 115162,
	"label": "COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 115162,
	"label": "COMBINATION THERAPY WITH TYPE I AND TYPE II ANTI-CD20 ANTIBODIES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 115568,
	"label": "Hyperglycosylated analogs of human erythropoietin and pharmaceutical composition thereof, DNA sequences encoding said analogs, and host cells comprising said sequences",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 6816,
	"target": 6398,
	"type": 116726,
	"label": "compostos antivirais heterocìclicos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 117019,
	"label": "SHOTGUN SCANNING, A COMBINATORIAL METHOD FOR MAPPING FUNCTIONAL PROTEIN EPITOPES",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37859,
	"target": 32772,
	"type": 117019,
	"label": "SHOTGUN SCANNING, A COMBINATORIAL METHOD FOR MAPPING FUNCTIONAL PROTEIN EPITOPES",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 32772,
	"type": 117019,
	"label": "SHOTGUN SCANNING, A COMBINATORIAL METHOD FOR MAPPING FUNCTIONAL PROTEIN EPITOPES",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 117341,
	"label": "PROTEINAS ENLAZADAS AL ANTIGENO DE CELULA DE CEPA MCDONOUGH DE FELINO HUMANAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 117341,
	"label": "PROTEINAS ENLAZADAS AL ANTIGENO DE CELULA DE CEPA MCDONOUGH DE FELINO HUMANAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 117341,
	"label": "PROTEINAS ENLAZADAS AL ANTIGENO DE CELULA DE CEPA MCDONOUGH DE FELINO HUMANAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 117494,
	"label": "Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 117494,
	"label": "Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 117494,
	"label": "Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 117494,
	"label": "Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 117494,
	"label": "Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 118073,
	"label": "Human monoclonal antibody or antigen-binding portion thereof that specifically binds to IGF-IR, pharmaceutical composition comprising the antibody or antigen-binding portion thereof, isolated cell line producing the antibody, isolated nucleic acid molecule, vector, host cell, transgenic animal, method of making of antibody or antigen-binding portion thereof and use of the antibody and the isolated nucleic acid molecule",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 118073,
	"label": "Human monoclonal antibody or antigen-binding portion thereof that specifically binds to IGF-IR, pharmaceutical composition comprising the antibody or antigen-binding portion thereof, isolated cell line producing the antibody, isolated nucleic acid molecule, vector, host cell, transgenic animal, method of making of antibody or antigen-binding portion thereof and use of the antibody and the isolated nucleic acid molecule",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 118073,
	"label": "Human monoclonal antibody or antigen-binding portion thereof that specifically binds to IGF-IR, pharmaceutical composition comprising the antibody or antigen-binding portion thereof, isolated cell line producing the antibody, isolated nucleic acid molecule, vector, host cell, transgenic animal, method of making of antibody or antigen-binding portion thereof and use of the antibody and the isolated nucleic acid molecule",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 118073,
	"label": "Human monoclonal antibody or antigen-binding portion thereof that specifically binds to IGF-IR, pharmaceutical composition comprising the antibody or antigen-binding portion thereof, isolated cell line producing the antibody, isolated nucleic acid molecule, vector, host cell, transgenic animal, method of making of antibody or antigen-binding portion thereof and use of the antibody and the isolated nucleic acid molecule",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 118073,
	"label": "Human monoclonal antibody or antigen-binding portion thereof that specifically binds to IGF-IR, pharmaceutical composition comprising the antibody or antigen-binding portion thereof, isolated cell line producing the antibody, isolated nucleic acid molecule, vector, host cell, transgenic animal, method of making of antibody or antigen-binding portion thereof and use of the antibody and the isolated nucleic acid molecule",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 119080,
	"label": "MULTIZYKLISCHE VERBINDUNG UND VERWENDUNGSVERFAHREN",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 119372,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 119372,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 119372,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 32771,
	"type": 119372,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 38065,
	"type": 119372,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32772,
	"target": 7409,
	"type": 120095,
	"label": "THERAPY OF NON-MALIGNANT DISEASES OR DISORDERS WITH ANTI-ERBB2 ANTIBODIES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 121477,
	"label": "Methods and compositions for detecting autoimmune disorders",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 60265,
	"target": 39999,
	"type": 121477,
	"label": "Methods and compositions for detecting autoimmune disorders",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 60265,
	"target": 37986,
	"type": 121477,
	"label": "Methods and compositions for detecting autoimmune disorders",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7511,
	"target": 6795,
	"type": 121587,
	"label": "AGENTES PREVENTIVOS Y/O REMEDIOS QUE CONTIENEN ANTICUERPOS NEUTRALIZANTES ANTIRECEPTORES DE IL-6 PARA REDUCIR LA EXCRECION DE LA PROTEINA URINARIA EN EL LUPUS ERITEMATOSO SISTEMICO.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 121587,
	"label": "AGENTES PREVENTIVOS Y/O REMEDIOS QUE CONTIENEN ANTICUERPOS NEUTRALIZANTES ANTIRECEPTORES DE IL-6 PARA REDUCIR LA EXCRECION DE LA PROTEINA URINARIA EN EL LUPUS ERITEMATOSO SISTEMICO.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 121587,
	"label": "AGENTES PREVENTIVOS Y/O REMEDIOS QUE CONTIENEN ANTICUERPOS NEUTRALIZANTES ANTIRECEPTORES DE IL-6 PARA REDUCIR LA EXCRECION DE LA PROTEINA URINARIA EN EL LUPUS ERITEMATOSO SISTEMICO.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6812,
	"type": 121637,
	"label": "Methods of using WISP antagonists",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 121733,
	"label": "Compositions and methods for the screening pro-apoptotic compounds",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37947,
	"target": 37864,
	"type": 121733,
	"label": "Compositions and methods for the screening pro-apoptotic compounds",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 121733,
	"label": "Compositions and methods for the screening pro-apoptotic compounds",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 121733,
	"label": "Compositions and methods for the screening pro-apoptotic compounds",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38232,
	"target": 37947,
	"type": 121733,
	"label": "Compositions and methods for the screening pro-apoptotic compounds",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7497,
	"target": 7487,
	"type": 121747,
	"label": "PHOSPHATE- CONTAINING PURIN DERIVATIVES (VARIANTS), MEDICAMENT BASED THEREON FOR EFFECTING UPON HUMAN PAPILLOMA VIRUS AND UPON TUMOR CELLS (VARIANTS)",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 32291,
	"target": 7497,
	"type": 121747,
	"label": "PHOSPHATE- CONTAINING PURIN DERIVATIVES (VARIANTS), MEDICAMENT BASED THEREON FOR EFFECTING UPON HUMAN PAPILLOMA VIRUS AND UPON TUMOR CELLS (VARIANTS)",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 32291,
	"target": 7487,
	"type": 121747,
	"label": "PHOSPHATE- CONTAINING PURIN DERIVATIVES (VARIANTS), MEDICAMENT BASED THEREON FOR EFFECTING UPON HUMAN PAPILLOMA VIRUS AND UPON TUMOR CELLS (VARIANTS)",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 37864,
	"type": 121754,
	"label": "IGF BINDING PROTEINS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 121776,
	"label": "ácido nucléico isolado, vetor, célula hospedeira, processo para produção, polipeptìdeo isolado, molécula quimérica, anticorpo, anticorpo isolado, composição de interesse, artigo de fabricação, método de alìvio de uma disfunção imune relacionada, método para determinar a presença de um polipeptìdeo em uma amostra suspeita de conter dito polipeptìdeo, método de diagnóstico de uma doença imune relacionada em um mamìfero, método de alìvio de linfoma em um mamìfero em necessidade deste, método de alì",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 122434,
	"label": "PROCEDIMIENTOS DE FABRICACION DE PROTEINAS RECOMBINANTES UTILIZANDO INHIBIDORES DE LA APOPTOSIS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 122434,
	"label": "PROCEDIMIENTOS DE FABRICACION DE PROTEINAS RECOMBINANTES UTILIZANDO INHIBIDORES DE LA APOPTOSIS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 122434,
	"label": "PROCEDIMIENTOS DE FABRICACION DE PROTEINAS RECOMBINANTES UTILIZANDO INHIBIDORES DE LA APOPTOSIS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 122822,
	"label": "POLYCATIONIC CALCIUM MODULATOR PEPTIDES FOR THE TREATMENT OF HYPERPARATHYROIDISM AND HYPERCALCEMIC DISORDERS",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 6816,
	"target": 6301,
	"type": 122941,
	"label": "IMIDAZO[4,5-C]PYRIDINFORBINDELSER OG FREMGANGSMÅDER TIL ANTIVIRAL BEHANDLING",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 6816,
	"type": 122941,
	"label": "IMIDAZO[4,5-C]PYRIDINFORBINDELSER OG FREMGANGSMÅDER TIL ANTIVIRAL BEHANDLING",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 122941,
	"label": "IMIDAZO[4,5-C]PYRIDINFORBINDELSER OG FREMGANGSMÅDER TIL ANTIVIRAL BEHANDLING",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 124625,
	"label": "Analyser og fremgangsmåder, der anvender biomarkører",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56833,
	"target": 56765,
	"type": 124625,
	"label": "Analyser og fremgangsmåder, der anvender biomarkører",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 56765,
	"type": 124625,
	"label": "Analyser og fremgangsmåder, der anvender biomarkører",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56765,
	"target": 7507,
	"type": 124625,
	"label": "Analyser og fremgangsmåder, der anvender biomarkører",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56833,
	"target": 7507,
	"type": 124625,
	"label": "Analyser og fremgangsmåder, der anvender biomarkører",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 124712,
	"label": "Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7511,
	"target": 7508,
	"type": 124712,
	"label": "Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 124712,
	"label": "Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 124712,
	"label": "Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 124712,
	"label": "Fremgangsmater for anvendelse av dodsreseptorligander og CD20-antistoffer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 124730,
	"label": "método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 124730,
	"label": "método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 124730,
	"label": "método para o tratamento de células de cáncer e método de tratamento de uma doença imune relacionada",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 124788,
	"label": "CONJUGADO DE POLIPEPTIDOS ANTIFUSOGENICOS Y POLIPEPTIDOS DERIVADOS DE LA CABEZA GLOBULAR DEL FACTOR DEL COMPLEMENTO C1Q; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; SU USO PARA TRATAR INFECCIONES VIRICAS; Y METODO DE PRODUCCION.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 124788,
	"label": "CONJUGADO DE POLIPEPTIDOS ANTIFUSOGENICOS Y POLIPEPTIDOS DERIVADOS DE LA CABEZA GLOBULAR DEL FACTOR DEL COMPLEMENTO C1Q; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; SU USO PARA TRATAR INFECCIONES VIRICAS; Y METODO DE PRODUCCION.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38042,
	"target": 6795,
	"type": 124788,
	"label": "CONJUGADO DE POLIPEPTIDOS ANTIFUSOGENICOS Y POLIPEPTIDOS DERIVADOS DE LA CABEZA GLOBULAR DEL FACTOR DEL COMPLEMENTO C1Q; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; SU USO PARA TRATAR INFECCIONES VIRICAS; Y METODO DE PRODUCCION.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 38065,
	"type": 125613,
	"label": "Transgenic mammals having human ig loci including plural v<sub>h</sub> and v g(k) regions and antibodies produced therefrom",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38065,
	"target": 32770,
	"type": 125613,
	"label": "Transgenic mammals having human ig loci including plural v<sub>h</sub> and v g(k) regions and antibodies produced therefrom",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 125613,
	"label": "Transgenic mammals having human ig loci including plural v<sub>h</sub> and v g(k) regions and antibodies produced therefrom",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 125789,
	"label": "agentes terapêuticos com toxicidade diminuìda",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 125789,
	"label": "agentes terapêuticos com toxicidade diminuìda",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 6854,
	"type": 125789,
	"label": "agentes terapêuticos com toxicidade diminuìda",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 7510,
	"type": 125789,
	"label": "agentes terapêuticos com toxicidade diminuìda",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 125789,
	"label": "agentes terapêuticos com toxicidade diminuìda",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 125791,
	"label": "métodos de tratamento de vasculite e artigos de fabricação",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 125792,
	"label": "polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 125796,
	"label": "anticorpo ou polipeptìdeo de ligação anti-beta7, anticorpo anti-beta7 humanizado ou seu fragmento de ligação a beta7, método de inibição da interação de subunidade de integrina beta7 humana, método de modulação do recrutamento e/ou adesão celular, composição e artigo industrializado",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 125798,
	"label": "Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain     a free cysteine amino acid in the heavy chain",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 125798,
	"label": "Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain     a free cysteine amino acid in the heavy chain",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 6962,
	"type": 125798,
	"label": "Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain     a free cysteine amino acid in the heavy chain",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 125951,
	"label": "AGENTE TERAPEUTICO PARA CANCER RESISTENTE A AGENTES QUIMIOTERAPEUTICOS QUE COMPRENDE UN ANTICUERPO QUE RECONOCE HLA DE CLASE I COMO INGREDIENTE ACTIVO; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO; Y METODO PARA TRATAR CANCER RESISTENTE A",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 125951,
	"label": "AGENTE TERAPEUTICO PARA CANCER RESISTENTE A AGENTES QUIMIOTERAPEUTICOS QUE COMPRENDE UN ANTICUERPO QUE RECONOCE HLA DE CLASE I COMO INGREDIENTE ACTIVO; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO; Y METODO PARA TRATAR CANCER RESISTENTE A",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 125951,
	"label": "AGENTE TERAPEUTICO PARA CANCER RESISTENTE A AGENTES QUIMIOTERAPEUTICOS QUE COMPRENDE UN ANTICUERPO QUE RECONOCE HLA DE CLASE I COMO INGREDIENTE ACTIVO; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO; Y METODO PARA TRATAR CANCER RESISTENTE A",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 126848,
	"label": "DETECTION OF BIOLOGICAL DNA",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 128121,
	"label": "K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 128121,
	"label": "K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56833,
	"target": 37986,
	"type": 128121,
	"label": "K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 128121,
	"label": "K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56833,
	"target": 32770,
	"type": 128121,
	"label": "K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY THERAPY",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 128122,
	"label": "K-ras and B-raf mutations and anti-EGFr antibody therapy",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 128540,
	"label": "PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 6476,
	"target": 6133,
	"type": 128540,
	"label": "PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7487,
	"target": 6476,
	"type": 128540,
	"label": "PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6476,
	"type": 128540,
	"label": "PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7487,
	"target": 6133,
	"type": 128540,
	"label": "PROCESS FOR THE MANUFACTURE OF A PULVEROUS PREPARATION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32769,
	"type": 128613,
	"label": "Ameliorative agent for low vasopressin concentration",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38065,
	"target": 32770,
	"type": 128665,
	"label": "AN ANTIBODY TO HUMAN TISSUE FACTOR AND EXPERIMENTAL ANIMALS HAVING INSERTED CELLS WITH THE GENE ENCODING HUMAN TISSUE FACTOR",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 129273,
	"label": "EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 129273,
	"label": "EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 129273,
	"label": "EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 129273,
	"label": "EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 129273,
	"label": "EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 129866,
	"label": "Forma constitutivamente activa del receptor Notch1 o un anticuerpo anti-receptor Notch1 para el tratamiento de cáncer de próstata",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 129866,
	"label": "Forma constitutivamente activa del receptor Notch1 o un anticuerpo anti-receptor Notch1 para el tratamiento de cáncer de próstata",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6812,
	"type": 129866,
	"label": "Forma constitutivamente activa del receptor Notch1 o un anticuerpo anti-receptor Notch1 para el tratamiento de cáncer de próstata",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 129866,
	"label": "Forma constitutivamente activa del receptor Notch1 o un anticuerpo anti-receptor Notch1 para el tratamiento de cáncer de próstata",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 6812,
	"type": 129866,
	"label": "Forma constitutivamente activa del receptor Notch1 o un anticuerpo anti-receptor Notch1 para el tratamiento de cáncer de próstata",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 130211,
	"label": "Polypeptide that does not contain a Fc region of an IgG but comprises a salvage receptor binding epitope of an Fc region of an IgG",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 130211,
	"label": "Polypeptide that does not contain a Fc region of an IgG but comprises a salvage receptor binding epitope of an Fc region of an IgG",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 130211,
	"label": "Polypeptide that does not contain a Fc region of an IgG but comprises a salvage receptor binding epitope of an Fc region of an IgG",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37993,
	"target": 7511,
	"type": 130211,
	"label": "Polypeptide that does not contain a Fc region of an IgG but comprises a salvage receptor binding epitope of an Fc region of an IgG",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 7511,
	"type": 130211,
	"label": "Polypeptide that does not contain a Fc region of an IgG but comprises a salvage receptor binding epitope of an Fc region of an IgG",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 130310,
	"label": "Nucleic acid detection by the 5'-3'exonuclease activity of polymerases acting on adjacently hybridized oligonucleotides",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 130389,
	"label": "METODO DE IDENTIFICACION DE DOMINIOS DE SITIOS DE UNION QUE CONSERVAN LA CAPACIDAD DE UNIRSE A UN EPITOPO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 130389,
	"label": "METODO DE IDENTIFICACION DE DOMINIOS DE SITIOS DE UNION QUE CONSERVAN LA CAPACIDAD DE UNIRSE A UN EPITOPO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 130389,
	"label": "METODO DE IDENTIFICACION DE DOMINIOS DE SITIOS DE UNION QUE CONSERVAN LA CAPACIDAD DE UNIRSE A UN EPITOPO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 130389,
	"label": "METODO DE IDENTIFICACION DE DOMINIOS DE SITIOS DE UNION QUE CONSERVAN LA CAPACIDAD DE UNIRSE A UN EPITOPO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 130389,
	"label": "METODO DE IDENTIFICACION DE DOMINIOS DE SITIOS DE UNION QUE CONSERVAN LA CAPACIDAD DE UNIRSE A UN EPITOPO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 131798,
	"label": "Célula bacteriana, método para a produção de um polipeptìdeo heterólogo, método para a prevenção de clivagem, métodos para a clivagem e métodos para a produção de um polipeptìdeo clivado",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 131798,
	"label": "Célula bacteriana, método para a produção de um polipeptìdeo heterólogo, método para a prevenção de clivagem, métodos para a clivagem e métodos para a produção de um polipeptìdeo clivado",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 131798,
	"label": "Célula bacteriana, método para a produção de um polipeptìdeo heterólogo, método para a prevenção de clivagem, métodos para a clivagem e métodos para a produção de um polipeptìdeo clivado",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6840,
	"type": 132214,
	"label": "PROTEIN KINASE C PEPTIDE MODULATORS OF ANGIOGENESIS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 132619,
	"label": "Cancerous disease modifying antibody 141205-02",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 132619,
	"label": "Cancerous disease modifying antibody 141205-02",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 132619,
	"label": "Cancerous disease modifying antibody 141205-02",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 132619,
	"label": "Cancerous disease modifying antibody 141205-02",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 6962,
	"type": 132619,
	"label": "Cancerous disease modifying antibody 141205-02",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 39999,
	"target": 32772,
	"type": 133295,
	"label": "Binding polypeptides with diversified and consensus VH/VL hypervariable sequences",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37878,
	"target": 37875,
	"type": 133546,
	"label": "Pharmaceutical for prevention and treatment of demyelinating disease",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 133966,
	"label": "COMPOSICIONES Y METODOS PARA EL DIAGNOSTICO Y EL TRATAMIENTO DE TUMORES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 133966,
	"label": "COMPOSICIONES Y METODOS PARA EL DIAGNOSTICO Y EL TRATAMIENTO DE TUMORES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 133966,
	"label": "COMPOSICIONES Y METODOS PARA EL DIAGNOSTICO Y EL TRATAMIENTO DE TUMORES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 6484,
	"type": 133966,
	"label": "COMPOSICIONES Y METODOS PARA EL DIAGNOSTICO Y EL TRATAMIENTO DE TUMORES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 6484,
	"type": 133966,
	"label": "COMPOSICIONES Y METODOS PARA EL DIAGNOSTICO Y EL TRATAMIENTO DE TUMORES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 133970,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 133970,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 133970,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 6854,
	"type": 133997,
	"label": "Composition and methods for the diagnosis of immune related diseases involving the PRO52254 polypeptide",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 134104,
	"label": "Novel compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 134104,
	"label": "Novel compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 6812,
	"type": 134104,
	"label": "Novel compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 134363,
	"label": "Anvendelse av et antistoff mot interleukin-6-reseptor som blokkerer IL-6 signal-transduksjon ved a inhibere bindingen av IL-6 til IL-6-reseptoren for fremstilling av et farmasoytisk preparat.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 134363,
	"label": "Anvendelse av et antistoff mot interleukin-6-reseptor som blokkerer IL-6 signal-transduksjon ved a inhibere bindingen av IL-6 til IL-6-reseptoren for fremstilling av et farmasoytisk preparat.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 134363,
	"label": "Anvendelse av et antistoff mot interleukin-6-reseptor som blokkerer IL-6 signal-transduksjon ved a inhibere bindingen av IL-6 til IL-6-reseptoren for fremstilling av et farmasoytisk preparat.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 134953,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 134953,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 134953,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 37864,
	"type": 134953,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 37862,
	"type": 134953,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6371,
	"target": 6263,
	"type": 135502,
	"label": "compostos heterocìclicos antivirais",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6371,
	"target": 6263,
	"type": 135505,
	"label": "compostos antivirais hetero  bicìclicos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6272,
	"type": 135927,
	"label": "INHIBIDORES DE QUINASA BASADOS EN LA HIDANTOINA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 32698,
	"type": 136983,
	"label": "Antagonistas de il-15",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 136983,
	"label": "Antagonistas de il-15",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38042,
	"target": 32698,
	"type": 136983,
	"label": "Antagonistas de il-15",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 136983,
	"label": "Antagonistas de il-15",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 136983,
	"label": "Antagonistas de il-15",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 139783,
	"label": "COMPOSITION, METHOD FOR PRODUCING ARTIFICIAL ORDERED AND REPETITIONS-CONTAINING ANTIGEN MATRIX, METHOD FOR CARRYING OUT THERAPY AND IMMUNIZATION",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 139783,
	"label": "COMPOSITION, METHOD FOR PRODUCING ARTIFICIAL ORDERED AND REPETITIONS-CONTAINING ANTIGEN MATRIX, METHOD FOR CARRYING OUT THERAPY AND IMMUNIZATION",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7511,
	"target": 7487,
	"type": 139783,
	"label": "COMPOSITION, METHOD FOR PRODUCING ARTIFICIAL ORDERED AND REPETITIONS-CONTAINING ANTIGEN MATRIX, METHOD FOR CARRYING OUT THERAPY AND IMMUNIZATION",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7487,
	"target": 6854,
	"type": 139783,
	"label": "COMPOSITION, METHOD FOR PRODUCING ARTIFICIAL ORDERED AND REPETITIONS-CONTAINING ANTIGEN MATRIX, METHOD FOR CARRYING OUT THERAPY AND IMMUNIZATION",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 139783,
	"label": "COMPOSITION, METHOD FOR PRODUCING ARTIFICIAL ORDERED AND REPETITIONS-CONTAINING ANTIGEN MATRIX, METHOD FOR CARRYING OUT THERAPY AND IMMUNIZATION",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 140382,
	"label": "COMPOSITION FOR THE ELIMINATION OF AUTOREACTIVE B-CELLS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 140382,
	"label": "COMPOSITION FOR THE ELIMINATION OF AUTOREACTIVE B-CELLS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 140382,
	"label": "COMPOSITION FOR THE ELIMINATION OF AUTOREACTIVE B-CELLS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 140382,
	"label": "COMPOSITION FOR THE ELIMINATION OF AUTOREACTIVE B-CELLS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32779,
	"target": 6854,
	"type": 140382,
	"label": "COMPOSITION FOR THE ELIMINATION OF AUTOREACTIVE B-CELLS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 140444,
	"label": "METHOD FOR INCREASING PRODUCT YIELD OF A MAMMALIAN POLYPEPTIDE PRODUCED BY RECOMBINANT BACTERIAL HOST CELLS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 140444,
	"label": "METHOD FOR INCREASING PRODUCT YIELD OF A MAMMALIAN POLYPEPTIDE PRODUCED BY RECOMBINANT BACTERIAL HOST CELLS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 140444,
	"label": "METHOD FOR INCREASING PRODUCT YIELD OF A MAMMALIAN POLYPEPTIDE PRODUCED BY RECOMBINANT BACTERIAL HOST CELLS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 142092,
	"label": "ácidos 4-fenil-tiazol-5-carboxìlicos e amidas de ácido 4-fenil-tiazol-5-carboxìlico como inibidores de plk1",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 142914,
	"label": "Mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 142914,
	"label": "Mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 142914,
	"label": "Mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 142914,
	"label": "Mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 142914,
	"label": "Mutants of pyrroloquinoline quinone dependent soluble glucose dehydrogenase",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7360,
	"target": 6821,
	"type": 144886,
	"label": "GLP-1 COMPOUNDS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 144966,
	"label": "Polynucleotide encoding an anti-FGF19 antibody",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 144966,
	"label": "Polynucleotide encoding an anti-FGF19 antibody",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 144966,
	"label": "Polynucleotide encoding an anti-FGF19 antibody",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 145300,
	"label": "DIAZINOPYRIMIDINE UND IHRE VERWENDUNG ALS PROTEINKINASEINHIBITOREN",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 146283,
	"label": "PEPTIDOS DE WT1 DE TIPO SUSTITUIDO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 146283,
	"label": "PEPTIDOS DE WT1 DE TIPO SUSTITUIDO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 146283,
	"label": "PEPTIDOS DE WT1 DE TIPO SUSTITUIDO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 146283,
	"label": "PEPTIDOS DE WT1 DE TIPO SUSTITUIDO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 146283,
	"label": "PEPTIDOS DE WT1 DE TIPO SUSTITUIDO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 146302,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSORIASIS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 146302,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSORIASIS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 146302,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF PSORIASIS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37875,
	"target": 37864,
	"type": 146437,
	"label": "COMPOSICION DE INHIBIDOR DE METALOPROTEINASA DE TEJIDO QUIMICAMENTE MODIFICADO DE TIPO TRES (TIMP-3) Y PROCEDIMIENTOS.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 146437,
	"label": "COMPOSICION DE INHIBIDOR DE METALOPROTEINASA DE TEJIDO QUIMICAMENTE MODIFICADO DE TIPO TRES (TIMP-3) Y PROCEDIMIENTOS.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 146437,
	"label": "COMPOSICION DE INHIBIDOR DE METALOPROTEINASA DE TEJIDO QUIMICAMENTE MODIFICADO DE TIPO TRES (TIMP-3) Y PROCEDIMIENTOS.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 147471,
	"label": "PROCEDIMIENTO PARA LA DETECCION TEMPRANA DE LA SEROCONVERSION DE UN ANTICUERPO CONTRA EL VIRUS DE LA HEPATITIS C.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 147471,
	"label": "PROCEDIMIENTO PARA LA DETECCION TEMPRANA DE LA SEROCONVERSION DE UN ANTICUERPO CONTRA EL VIRUS DE LA HEPATITIS C.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 147471,
	"label": "PROCEDIMIENTO PARA LA DETECCION TEMPRANA DE LA SEROCONVERSION DE UN ANTICUERPO CONTRA EL VIRUS DE LA HEPATITIS C.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 148646,
	"label": "ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6957,
	"type": 148646,
	"label": "ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 148646,
	"label": "ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 148646,
	"label": "ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 6957,
	"type": 148646,
	"label": "ANTIBODIES AGAINST T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 1 (TIM-1) ANTIGEN AND USES THEREOF",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 7424,
	"target": 6371,
	"type": 149461,
	"label": "DERIVADOS DE SULFONAMIDA COMO INHIBIDORES DE LA RESORCION OSEA Y COMO INHIBIDORES DE LA ADHESION CELULAR, UN PROCESO PARA SU PREPARACION YCOMPOSICION FARMACEUTICA QUE LOS CONTIENEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 149787,
	"label": "Human monoclonal antibodies which bind c-Met",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 149787,
	"label": "Human monoclonal antibodies which bind c-Met",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 149787,
	"label": "Human monoclonal antibodies which bind c-Met",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 149787,
	"label": "Human monoclonal antibodies which bind c-Met",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 149787,
	"label": "Human monoclonal antibodies which bind c-Met",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 149988,
	"label": "NEW KINASE BEARING INFORMATION TRANSMISSION SYSTEM OF TGF-BETA FAMILY",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 149988,
	"label": "NEW KINASE BEARING INFORMATION TRANSMISSION SYSTEM OF TGF-BETA FAMILY",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 149988,
	"label": "NEW KINASE BEARING INFORMATION TRANSMISSION SYSTEM OF TGF-BETA FAMILY",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30251,
	"target": 7360,
	"type": 151514,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e utilização desses compostos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32769,
	"type": 151551,
	"label": "proteìna de ligação especìfica, molécula de ácido nucleico, vetor, célula hospedeira, anticorpo monoclonal humano, método para determinar o nìvel de fator de crescimento tipo insulina-ii (igf-1i) e fator de crescimento tipo insulina i (igf-1) em uma amostra de paciente, uso da proteìna de ligação especìfica, e, conjugado",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32769,
	"target": 7507,
	"type": 151551,
	"label": "proteìna de ligação especìfica, molécula de ácido nucleico, vetor, célula hospedeira, anticorpo monoclonal humano, método para determinar o nìvel de fator de crescimento tipo insulina-ii (igf-1i) e fator de crescimento tipo insulina i (igf-1) em uma amostra de paciente, uso da proteìna de ligação especìfica, e, conjugado",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 151551,
	"label": "proteìna de ligação especìfica, molécula de ácido nucleico, vetor, célula hospedeira, anticorpo monoclonal humano, método para determinar o nìvel de fator de crescimento tipo insulina-ii (igf-1i) e fator de crescimento tipo insulina i (igf-1) em uma amostra de paciente, uso da proteìna de ligação especìfica, e, conjugado",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 151633,
	"label": "anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 151633,
	"label": "anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 151633,
	"label": "anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 151633,
	"label": "anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 151633,
	"label": "anticorpos anti- ephb4 isolado polinucleotìdeo, vetor, célula hospedeira, método para produção de um anticorpo anti ephb4, método para produção de um imunoconjugado anti ephb4, método para a detecção de ephb4, método para diagnosticar um distúrbio composição, método para inibir a angiogênese, método para tratar um cáncer, tumor e/ou distúrbio da proliferação celular e uso de um anticorpo",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 6812,
	"type": 151641,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6795,
	"target": 6376,
	"type": 151701,
	"label": "TERAPIA COMBINADA QUE UTILIZA UN INHIBIDOR DEL IL-1 PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL IL-1.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 152419,
	"label": "anticorpos de anti-mpl",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37988,
	"target": 37859,
	"type": 152419,
	"label": "anticorpos de anti-mpl",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37988,
	"type": 152419,
	"label": "anticorpos de anti-mpl",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37859,
	"type": 152419,
	"label": "anticorpos de anti-mpl",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37859,
	"target": 32779,
	"type": 152419,
	"label": "anticorpos de anti-mpl",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 7510,
	"type": 153027,
	"label": "Methods of monitoring a human anti-human antibody response and inhibitors thereof",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 153120,
	"label": "Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 153665,
	"label": "ISOLATED BINDING PROTEIN THAT BINDS TO HER-3, AND USE THEREOF",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 153665,
	"label": "ISOLATED BINDING PROTEIN THAT BINDS TO HER-3, AND USE THEREOF",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 153665,
	"label": "ISOLATED BINDING PROTEIN THAT BINDS TO HER-3, AND USE THEREOF",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 153665,
	"label": "ISOLATED BINDING PROTEIN THAT BINDS TO HER-3, AND USE THEREOF",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 32772,
	"type": 153665,
	"label": "ISOLATED BINDING PROTEIN THAT BINDS TO HER-3, AND USE THEREOF",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 154626,
	"label": "Polipeptìdeo fibrinoliticamente ativo, molécula de ácido nucléico, vetor de expressão, célula hospedeira, célula procariótica transformada ou transfectada, célula de levedura transformada ou transfectada, métodos para a produção de nat, para a produção de um agente fibrinolìtico de metaloproteinase, e para o tratamento de trombose em um mamìfero, e , anticorpo",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 6838,
	"type": 154626,
	"label": "Polipeptìdeo fibrinoliticamente ativo, molécula de ácido nucléico, vetor de expressão, célula hospedeira, célula procariótica transformada ou transfectada, célula de levedura transformada ou transfectada, métodos para a produção de nat, para a produção de um agente fibrinolìtico de metaloproteinase, e para o tratamento de trombose em um mamìfero, e , anticorpo",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37947,
	"target": 6838,
	"type": 154626,
	"label": "Polipeptìdeo fibrinoliticamente ativo, molécula de ácido nucléico, vetor de expressão, célula hospedeira, célula procariótica transformada ou transfectada, célula de levedura transformada ou transfectada, métodos para a produção de nat, para a produção de um agente fibrinolìtico de metaloproteinase, e para o tratamento de trombose em um mamìfero, e , anticorpo",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 154982,
	"label": "USE OF AN Apo-2 LIGAND FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CANCER AND IN-VITRO OR EX-VIVO METHODS OF INDUCING APOPTOSIS IN MAMMALIAN CANCER CELLS USING SUCH Apo-2 LIGAND",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 154982,
	"label": "USE OF AN Apo-2 LIGAND FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CANCER AND IN-VITRO OR EX-VIVO METHODS OF INDUCING APOPTOSIS IN MAMMALIAN CANCER CELLS USING SUCH Apo-2 LIGAND",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 154982,
	"label": "USE OF AN Apo-2 LIGAND FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CANCER AND IN-VITRO OR EX-VIVO METHODS OF INDUCING APOPTOSIS IN MAMMALIAN CANCER CELLS USING SUCH Apo-2 LIGAND",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 155345,
	"label": "COMPOSITION COMPRISING AN ISOLATED AGONISTIC ANTIBODY WHICH SPECIFICALLY CROSS REACTS WITH DIFFERENT APO - 2L RECEPTORS FOR USE IN INDUCING APOPTOSIS IN MAMMALIAN CANCER CELLS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 155345,
	"label": "COMPOSITION COMPRISING AN ISOLATED AGONISTIC ANTIBODY WHICH SPECIFICALLY CROSS REACTS WITH DIFFERENT APO - 2L RECEPTORS FOR USE IN INDUCING APOPTOSIS IN MAMMALIAN CANCER CELLS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37862,
	"type": 155345,
	"label": "COMPOSITION COMPRISING AN ISOLATED AGONISTIC ANTIBODY WHICH SPECIFICALLY CROSS REACTS WITH DIFFERENT APO - 2L RECEPTORS FOR USE IN INDUCING APOPTOSIS IN MAMMALIAN CANCER CELLS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 155345,
	"label": "COMPOSITION COMPRISING AN ISOLATED AGONISTIC ANTIBODY WHICH SPECIFICALLY CROSS REACTS WITH DIFFERENT APO - 2L RECEPTORS FOR USE IN INDUCING APOPTOSIS IN MAMMALIAN CANCER CELLS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 155345,
	"label": "COMPOSITION COMPRISING AN ISOLATED AGONISTIC ANTIBODY WHICH SPECIFICALLY CROSS REACTS WITH DIFFERENT APO - 2L RECEPTORS FOR USE IN INDUCING APOPTOSIS IN MAMMALIAN CANCER CELLS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 155346,
	"label": "RECUPERACION DE PROTEINAS MEDIANTE CROMATOGRAFIA SEGUIDA DE FILTRACION SOBRE UNA CAPA CARGADA.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 155346,
	"label": "RECUPERACION DE PROTEINAS MEDIANTE CROMATOGRAFIA SEGUIDA DE FILTRACION SOBRE UNA CAPA CARGADA.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 155346,
	"label": "RECUPERACION DE PROTEINAS MEDIANTE CROMATOGRAFIA SEGUIDA DE FILTRACION SOBRE UNA CAPA CARGADA.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 157322,
	"label": "derivados de amida heterobicìclica",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 157692,
	"label": "Uso de fusiones de proteína/péptido de transtiretina para aumentar la semivida sérica de péptidos/proteínas farmacológicamente activos",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 6376,
	"target": 6371,
	"type": 158224,
	"label": "COMPUESTOS HETEROCICLICOS SUSTITUIDOS Y SUS METODOS DE UTILIZACION.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7450,
	"target": 6376,
	"type": 158224,
	"label": "COMPUESTOS HETEROCICLICOS SUSTITUIDOS Y SUS METODOS DE UTILIZACION.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7450,
	"target": 6371,
	"type": 158224,
	"label": "COMPUESTOS HETEROCICLICOS SUSTITUIDOS Y SUS METODOS DE UTILIZACION.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7450,
	"type": 158224,
	"label": "COMPUESTOS HETEROCICLICOS SUSTITUIDOS Y SUS METODOS DE UTILIZACION.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 158224,
	"label": "COMPUESTOS HETEROCICLICOS SUSTITUIDOS Y SUS METODOS DE UTILIZACION.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 158290,
	"label": "composto, medicamento, uso do medicamento, e, processo para preparar um composto",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 158290,
	"label": "composto, medicamento, uso do medicamento, e, processo para preparar um composto",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6366,
	"type": 158290,
	"label": "composto, medicamento, uso do medicamento, e, processo para preparar um composto",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 158468,
	"label": "anticorpo isolado, molécula de ácido nucléico, vetor, célula hospedeira, linhagem celular, método para a produção de anticorpo, composição, método para determinar a presença de um polipeptìdeo relt, método para tratar uma doença ou condição  patológica causada agravada ou prolongada pelo ifn-alfa, método para tratar uma doença ou condição patológica associada com o ifn-alfa, métodos para aumentar a proporção de células dendrìticas plasmocitóides (pdc), métodos para diminuir a proporção de célula",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 159059,
	"label": "COMPUESTOS DERIVADOS -3,4-DIHIDRO-1H-PIRIMIDO[4,5-D]PIRIMIDIN-2-ONA OPTICAMENTE ACTIVOS Y SU USO COMO AGENTES ANTITUMORALES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 159059,
	"label": "COMPUESTOS DERIVADOS -3,4-DIHIDRO-1H-PIRIMIDO[4,5-D]PIRIMIDIN-2-ONA OPTICAMENTE ACTIVOS Y SU USO COMO AGENTES ANTITUMORALES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7509,
	"target": 6376,
	"type": 159059,
	"label": "COMPUESTOS DERIVADOS -3,4-DIHIDRO-1H-PIRIMIDO[4,5-D]PIRIMIDIN-2-ONA OPTICAMENTE ACTIVOS Y SU USO COMO AGENTES ANTITUMORALES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 160149,
	"label": "Monoclonal antibodies specific for human OX40L (CD 134L)",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 161177,
	"label": "DERIVADOS DE PIRIDINO-2,3-DIPIRIMIDINA COMO INHIBIDORES SELECTIVOS DE KDR Y FGFR.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 161177,
	"label": "DERIVADOS DE PIRIDINO-2,3-DIPIRIMIDINA COMO INHIBIDORES SELECTIVOS DE KDR Y FGFR.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 161177,
	"label": "DERIVADOS DE PIRIDINO-2,3-DIPIRIMIDINA COMO INHIBIDORES SELECTIVOS DE KDR Y FGFR.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 161614,
	"label": "USO DE CYFRA 21-1 Y OSTEOPONTINA, COMO MARCADORES PARA EL CANCER COLORRECTAL.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 161614,
	"label": "USO DE CYFRA 21-1 Y OSTEOPONTINA, COMO MARCADORES PARA EL CANCER COLORRECTAL.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 161614,
	"label": "USO DE CYFRA 21-1 Y OSTEOPONTINA, COMO MARCADORES PARA EL CANCER COLORRECTAL.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7487,
	"target": 7358,
	"type": 161657,
	"label": "5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 7358,
	"target": 6301,
	"type": 161657,
	"label": "5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 7487,
	"target": 6301,
	"type": 161657,
	"label": "5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7487,
	"type": 161657,
	"label": "5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7358,
	"type": 161657,
	"label": "5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 56740,
	"target": 6854,
	"type": 161816,
	"label": "METHOD FOR THE IDENTIFICATION OF EPITOPES RELATED TO IMMUNOGENICITY IN BIOPHARMACEUTICALS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 162484,
	"label": "NUEVAS AZAINDOL-TIAZOLINONAS COMO AGENTES ANTI-CANCEROSOS.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 162484,
	"label": "NUEVAS AZAINDOL-TIAZOLINONAS COMO AGENTES ANTI-CANCEROSOS.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 162484,
	"label": "NUEVAS AZAINDOL-TIAZOLINONAS COMO AGENTES ANTI-CANCEROSOS.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 162875,
	"label": "Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 162875,
	"label": "Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 162875,
	"label": "Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 162875,
	"label": "Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 162875,
	"label": "Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 163027,
	"label": "INTEGRIN ADHESION ANTAGONISTS.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 163027,
	"label": "INTEGRIN ADHESION ANTAGONISTS.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 163027,
	"label": "INTEGRIN ADHESION ANTAGONISTS.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 31851,
	"target": 31307,
	"type": 163582,
	"label": "HETEROARILACETAMIDAS COMO INHIBIDORES DEL FACTOR XA.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 164476,
	"label": "Detection of group B streptococcus",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 164496,
	"label": "OLIGONUCLEOTIDOS QUE CONTIENEN BASTONES MOLECULARES.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 164496,
	"label": "OLIGONUCLEOTIDOS QUE CONTIENEN BASTONES MOLECULARES.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 164496,
	"label": "OLIGONUCLEOTIDOS QUE CONTIENEN BASTONES MOLECULARES.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 164558,
	"label": "METHODS OF GENOTYPING USING DIFFERENCES IN MELTING TEMPERATURE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 164774,
	"label": "4-AMINOPYRIMIDINE-5-THIONE-DERIVATIVES FOR THE TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 164872,
	"label": "polipeptìdeos, anticorpo, polipeptìdeo de fusão, composição, polinucleotìdeo, vetor, célula hospedeira, método de produção de um polipeptìdeo, biblioteca de polipeptìdeos, métodos para gerar uma composição, método para a seleção de um domìnio variável ligante ao antìgeno, método para selecionar polipeptìdeos, método para isolar um ou mais polipeptìdeos, método para o tratamento  de cáncer e método para tratar",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 164872,
	"label": "polipeptìdeos, anticorpo, polipeptìdeo de fusão, composição, polinucleotìdeo, vetor, célula hospedeira, método de produção de um polipeptìdeo, biblioteca de polipeptìdeos, métodos para gerar uma composição, método para a seleção de um domìnio variável ligante ao antìgeno, método para selecionar polipeptìdeos, método para isolar um ou mais polipeptìdeos, método para o tratamento  de cáncer e método para tratar",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 164872,
	"label": "polipeptìdeos, anticorpo, polipeptìdeo de fusão, composição, polinucleotìdeo, vetor, célula hospedeira, método de produção de um polipeptìdeo, biblioteca de polipeptìdeos, métodos para gerar uma composição, método para a seleção de um domìnio variável ligante ao antìgeno, método para selecionar polipeptìdeos, método para isolar um ou mais polipeptìdeos, método para o tratamento  de cáncer e método para tratar",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 39999,
	"target": 32779,
	"type": 164872,
	"label": "polipeptìdeos, anticorpo, polipeptìdeo de fusão, composição, polinucleotìdeo, vetor, célula hospedeira, método de produção de um polipeptìdeo, biblioteca de polipeptìdeos, métodos para gerar uma composição, método para a seleção de um domìnio variável ligante ao antìgeno, método para selecionar polipeptìdeos, método para isolar um ou mais polipeptìdeos, método para o tratamento  de cáncer e método para tratar",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 39999,
	"target": 32772,
	"type": 164872,
	"label": "polipeptìdeos, anticorpo, polipeptìdeo de fusão, composição, polinucleotìdeo, vetor, célula hospedeira, método de produção de um polipeptìdeo, biblioteca de polipeptìdeos, métodos para gerar uma composição, método para a seleção de um domìnio variável ligante ao antìgeno, método para selecionar polipeptìdeos, método para isolar um ou mais polipeptìdeos, método para o tratamento  de cáncer e método para tratar",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32777,
	"type": 165222,
	"label": "VARIANTES DE INMUNOGLOBULINAS PARA RECEPTORES FC-EPSILON ESPECIFICOS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 165222,
	"label": "VARIANTES DE INMUNOGLOBULINAS PARA RECEPTORES FC-EPSILON ESPECIFICOS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 165222,
	"label": "VARIANTES DE INMUNOGLOBULINAS PARA RECEPTORES FC-EPSILON ESPECIFICOS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 165222,
	"label": "VARIANTES DE INMUNOGLOBULINAS PARA RECEPTORES FC-EPSILON ESPECIFICOS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 165222,
	"label": "VARIANTES DE INMUNOGLOBULINAS PARA RECEPTORES FC-EPSILON ESPECIFICOS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 165797,
	"label": "Composto que se liga a um receptor mp1, dìmero, métodos para aumentar megacariócitos ou plaquetas em um paciente com necessidade disto, e para produzir um composto, composição farmacêutica, polinucleotìdeo, vetor, e, célula hospedeira.",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 165797,
	"label": "Composto que se liga a um receptor mp1, dìmero, métodos para aumentar megacariócitos ou plaquetas em um paciente com necessidade disto, e para produzir um composto, composição farmacêutica, polinucleotìdeo, vetor, e, célula hospedeira.",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 165797,
	"label": "Composto que se liga a um receptor mp1, dìmero, métodos para aumentar megacariócitos ou plaquetas em um paciente com necessidade disto, e para produzir um composto, composição farmacêutica, polinucleotìdeo, vetor, e, célula hospedeira.",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 165797,
	"label": "Composto que se liga a um receptor mp1, dìmero, métodos para aumentar megacariócitos ou plaquetas em um paciente com necessidade disto, e para produzir um composto, composição farmacêutica, polinucleotìdeo, vetor, e, célula hospedeira.",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 165797,
	"label": "Composto que se liga a um receptor mp1, dìmero, métodos para aumentar megacariócitos ou plaquetas em um paciente com necessidade disto, e para produzir um composto, composição farmacêutica, polinucleotìdeo, vetor, e, célula hospedeira.",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 165830,
	"label": "Chemical modification of granulocyte colony stimulating factor (G-CSF) to improve biocompatibility and bioactivity",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32696,
	"target": 6795,
	"type": 165830,
	"label": "Chemical modification of granulocyte colony stimulating factor (G-CSF) to improve biocompatibility and bioactivity",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 165830,
	"label": "Chemical modification of granulocyte colony stimulating factor (G-CSF) to improve biocompatibility and bioactivity",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 167228,
	"label": "HUMANIZED C-KIT ANTIBODY AND USE THEREOF",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 167228,
	"label": "HUMANIZED C-KIT ANTIBODY AND USE THEREOF",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32772,
	"type": 167228,
	"label": "HUMANIZED C-KIT ANTIBODY AND USE THEREOF",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 167228,
	"label": "HUMANIZED C-KIT ANTIBODY AND USE THEREOF",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 167228,
	"label": "HUMANIZED C-KIT ANTIBODY AND USE THEREOF",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7360,
	"target": 6376,
	"type": 167764,
	"label": "compostos, processo para a preparação desses compostos, composições farmacêuticas que comprendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que são moduladas por inibidores de ptp1b e sua utilização",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7450,
	"target": 6213,
	"type": 167809,
	"label": "derivados de nitrila de benzamida",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 168516,
	"label": "PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 168516,
	"label": "PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 168516,
	"label": "PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37859,
	"target": 32694,
	"type": 168516,
	"label": "PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 32694,
	"type": 168516,
	"label": "PEPTIDES AND RELATED COMPOUNDS HAVING THROMBOPOIETIC ACTIVITY.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 168843,
	"label": "EPIDERMAL GROWTH FACTOR RECEPTOR GENE COPY NUMBER",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 168843,
	"label": "EPIDERMAL GROWTH FACTOR RECEPTOR GENE COPY NUMBER",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 168843,
	"label": "EPIDERMAL GROWTH FACTOR RECEPTOR GENE COPY NUMBER",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 6962,
	"target": 6957,
	"type": 169485,
	"label": "VERWENDUNG VON ANTIKÖRPERN GEGEN DAS MUC18- ANTIGEN",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7509,
	"target": 6962,
	"type": 169485,
	"label": "VERWENDUNG VON ANTIKÖRPERN GEGEN DAS MUC18- ANTIGEN",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7509,
	"target": 6957,
	"type": 169485,
	"label": "VERWENDUNG VON ANTIKÖRPERN GEGEN DAS MUC18- ANTIGEN",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 7509,
	"type": 169485,
	"label": "VERWENDUNG VON ANTIKÖRPERN GEGEN DAS MUC18- ANTIGEN",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 169485,
	"label": "VERWENDUNG VON ANTIKÖRPERN GEGEN DAS MUC18- ANTIGEN",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 32738,
	"type": 169788,
	"label": "polipeptìdios, agentes de ligação especìficos, moléculas de ácido nucleico e linhas de células isoladas, células hospedeiras, composições e anticorpo ou domìnio de ligação de antìgeno e métodos de tratamento de cáncer e de tumor sólido num paciente, de detecção do nìvel do fator de crescimento hepatócito (hgf) numa amostra, de obtenção de anticorpo e de inibição da ligação de hgf a met e de diminuição ou prevenção da ligação de qualquer um dos agentes de ligação especìficos ao fator de crescimen",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 173089,
	"label": "Guanosine triphosphate binding protein-coupled receptors, genes thereof and production and use of the same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 173089,
	"label": "Guanosine triphosphate binding protein-coupled receptors, genes thereof and production and use of the same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 173089,
	"label": "Guanosine triphosphate binding protein-coupled receptors, genes thereof and production and use of the same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 173089,
	"label": "Guanosine triphosphate binding protein-coupled receptors, genes thereof and production and use of the same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 37862,
	"type": 173089,
	"label": "Guanosine triphosphate binding protein-coupled receptors, genes thereof and production and use of the same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 173188,
	"label": "OPG Fusion protein compositions and methods.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 173188,
	"label": "OPG Fusion protein compositions and methods.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37859,
	"target": 32788,
	"type": 173188,
	"label": "OPG Fusion protein compositions and methods.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 32788,
	"type": 173188,
	"label": "OPG Fusion protein compositions and methods.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37859,
	"target": 32779,
	"type": 173188,
	"label": "OPG Fusion protein compositions and methods.",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 6471,
	"target": 6166,
	"type": 173189,
	"label": "COMPOSICIONES Y METODOS PARA LA PREVENCION O EL TRATAMIENTO DE CANCER Y DE LA PERDIDA OSEA ASOCIADA CON EL CANCER.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 6795,
	"target": 6471,
	"type": 173189,
	"label": "COMPOSICIONES Y METODOS PARA LA PREVENCION O EL TRATAMIENTO DE CANCER Y DE LA PERDIDA OSEA ASOCIADA CON EL CANCER.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 6795,
	"target": 6166,
	"type": 173189,
	"label": "COMPOSICIONES Y METODOS PARA LA PREVENCION O EL TRATAMIENTO DE CANCER Y DE LA PERDIDA OSEA ASOCIADA CON EL CANCER.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7509,
	"target": 6795,
	"type": 173189,
	"label": "COMPOSICIONES Y METODOS PARA LA PREVENCION O EL TRATAMIENTO DE CANCER Y DE LA PERDIDA OSEA ASOCIADA CON EL CANCER.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7509,
	"target": 6471,
	"type": 173189,
	"label": "COMPOSICIONES Y METODOS PARA LA PREVENCION O EL TRATAMIENTO DE CANCER Y DE LA PERDIDA OSEA ASOCIADA CON EL CANCER.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 174120,
	"label": "Vectors and recombinant host cells comprising nucleic acid molecules encoding Fibroblast Growth Factor-like polypeptides",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 174120,
	"label": "Vectors and recombinant host cells comprising nucleic acid molecules encoding Fibroblast Growth Factor-like polypeptides",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 174120,
	"label": "Vectors and recombinant host cells comprising nucleic acid molecules encoding Fibroblast Growth Factor-like polypeptides",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37862,
	"target": 32698,
	"type": 175223,
	"label": "MOLECULAS AFINES A ANTAGONISTAS DEL RECEPTOR DE INTERLEUQUINA-1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 175258,
	"label": "SECRETED EPITHELIAL COLON STROMAL-1 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 175258,
	"label": "SECRETED EPITHELIAL COLON STROMAL-1 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 175258,
	"label": "SECRETED EPITHELIAL COLON STROMAL-1 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 175258,
	"label": "SECRETED EPITHELIAL COLON STROMAL-1 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 175258,
	"label": "SECRETED EPITHELIAL COLON STROMAL-1 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 175261,
	"label": "MOLECULAS SIMILARES A ANTAGONISTAS DE RECEPTORES DE INTERLEUKIN-1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32777,
	"target": 32698,
	"type": 175261,
	"label": "MOLECULAS SIMILARES A ANTAGONISTAS DE RECEPTORES DE INTERLEUKIN-1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32698,
	"target": 7511,
	"type": 175261,
	"label": "MOLECULAS SIMILARES A ANTAGONISTAS DE RECEPTORES DE INTERLEUKIN-1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32698,
	"target": 7507,
	"type": 175261,
	"label": "MOLECULAS SIMILARES A ANTAGONISTAS DE RECEPTORES DE INTERLEUKIN-1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32777,
	"target": 7511,
	"type": 175261,
	"label": "MOLECULAS SIMILARES A ANTAGONISTAS DE RECEPTORES DE INTERLEUKIN-1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 31912,
	"target": 7450,
	"type": 175787,
	"label": "Agentes moduladores de receptores de calcio",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 175945,
	"label": "Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7450,
	"type": 175945,
	"label": "Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 7450,
	"type": 175945,
	"label": "Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 38237,
	"target": 38184,
	"type": 175947,
	"label": "HER-2 RECEPTOR TYROSINE KINASE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 6483,
	"type": 175947,
	"label": "HER-2 RECEPTOR TYROSINE KINASE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38237,
	"target": 6483,
	"type": 175947,
	"label": "HER-2 RECEPTOR TYROSINE KINASE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 176673,
	"label": "Palifermin et ses dérivés pharmaceutiquement acceptables (KEPIVANCE)",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7511,
	"target": 7424,
	"type": 177961,
	"label": "METHODS FOR TREATING KIDNEY DISORDERS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 178074,
	"label": "BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 178074,
	"label": "BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 178074,
	"label": "BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 32772,
	"type": 178074,
	"label": "BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32772,
	"type": 178074,
	"label": "BINDING POLYPEPTIDES WITH OPTIMIZED SCAFFOLDS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32779,
	"target": 32777,
	"type": 178722,
	"label": "Downregulation of immune response by administering B7RP-2 fusion protein",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 178722,
	"label": "Downregulation of immune response by administering B7RP-2 fusion protein",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32777,
	"target": 7487,
	"type": 178722,
	"label": "Downregulation of immune response by administering B7RP-2 fusion protein",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 7487,
	"type": 178722,
	"label": "Downregulation of immune response by administering B7RP-2 fusion protein",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32777,
	"target": 6795,
	"type": 178722,
	"label": "Downregulation of immune response by administering B7RP-2 fusion protein",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7424,
	"target": 7409,
	"type": 178776,
	"label": "G-PROTEIN COUPLED RECEPTOR MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7409,
	"target": 7358,
	"type": 178776,
	"label": "G-PROTEIN COUPLED RECEPTOR MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7424,
	"target": 7358,
	"type": 178776,
	"label": "G-PROTEIN COUPLED RECEPTOR MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 178776,
	"label": "G-PROTEIN COUPLED RECEPTOR MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 178776,
	"label": "G-PROTEIN COUPLED RECEPTOR MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 178792,
	"label": "TUMOR ENDOTHELIAL MARKER 7 ALPHA MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 178792,
	"label": "TUMOR ENDOTHELIAL MARKER 7 ALPHA MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 178792,
	"label": "TUMOR ENDOTHELIAL MARKER 7 ALPHA MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 32698,
	"target": 6854,
	"type": 180114,
	"label": "IL-1 FAMILY VARIANTS",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 180237,
	"label": "ANTICORPO, COMPOSIÇÃO FARMACÊUTICA, POLIPEPTÍDEO, POLINUCLEOTÍDEO ISOLADO, PLASMÍDEO, CÉLULA ISOLADA, E, MÉTODOS PARA FABRICAR UM POLIPEPTÍDEO QUE SE LIGA ESPECIFICAMENTE AO  RECEPTOR IL-17 A, PARA TRATAR UM ESTADO DE DOENÇA ASSOCIADO COM A ATIVAÇÃO DE IL-17RA EM UM PACIENTE, PARA INIBIR A PRODUÇÃO DE PELO MENOS UMA CITOCINA, QUIMIOCINA, METALOPROTEINASE DE MATRIZ OU CONTRA MOLÉCULA ASSOCIADA COM A ATIVAÇÃO DE IL-17RA E PARA TRATAR INFLAMAÇÃO E DONEÇA AUTOIMUNE EM UM PACIENTE.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 180776,
	"label": "APO-2 ligand variants and uses thereof",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 180776,
	"label": "APO-2 ligand variants and uses thereof",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 180776,
	"label": "APO-2 ligand variants and uses thereof",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 180776,
	"label": "APO-2 ligand variants and uses thereof",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 7510,
	"type": 180776,
	"label": "APO-2 ligand variants and uses thereof",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7511,
	"target": 7508,
	"type": 181449,
	"label": "ATP - Binding Cassette Transporter - Like Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 181449,
	"label": "ATP - Binding Cassette Transporter - Like Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 181449,
	"label": "ATP - Binding Cassette Transporter - Like Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 181449,
	"label": "ATP - Binding Cassette Transporter - Like Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37859,
	"target": 32788,
	"type": 181449,
	"label": "ATP - Binding Cassette Transporter - Like Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 181645,
	"label": "Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 181645,
	"label": "Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 181645,
	"label": "Substituerede indolizinlignende forbindelser og fremgangsmåder til anvendelse",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6407,
	"type": 181934,
	"label": "PIRIMIDODIAZEPINAS SUSTITUIDAS UTILES COMO INHIBIDORES DE PLK1.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32777,
	"type": 182326,
	"label": "PEPTIDO RELACIONADO A CONDROMODULINA-I",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 182326,
	"label": "PEPTIDO RELACIONADO A CONDROMODULINA-I",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 182326,
	"label": "PEPTIDO RELACIONADO A CONDROMODULINA-I",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 32777,
	"type": 182326,
	"label": "PEPTIDO RELACIONADO A CONDROMODULINA-I",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 182326,
	"label": "PEPTIDO RELACIONADO A CONDROMODULINA-I",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32779,
	"target": 32698,
	"type": 182329,
	"label": "MOLCCULAS SEMEJANTES A IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 6795,
	"target": 6483,
	"type": 182329,
	"label": "MOLCCULAS SEMEJANTES A IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 182329,
	"label": "MOLCCULAS SEMEJANTES A IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 182329,
	"label": "MOLCCULAS SEMEJANTES A IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32698,
	"target": 6483,
	"type": 182329,
	"label": "MOLCCULAS SEMEJANTES A IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7511,
	"target": 7508,
	"type": 182333,
	"label": "IMIDAZOLE DERIVATIVES KINASE INHIBITORS, THEIR USE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7508,
	"target": 7360,
	"type": 182333,
	"label": "IMIDAZOLE DERIVATIVES KINASE INHIBITORS, THEIR USE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7511,
	"target": 7360,
	"type": 182333,
	"label": "IMIDAZOLE DERIVATIVES KINASE INHIBITORS, THEIR USE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 183216,
	"label": "MOLECULAS SIMILARES A RECEPTORES IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 183216,
	"label": "MOLECULAS SIMILARES A RECEPTORES IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 183216,
	"label": "MOLECULAS SIMILARES A RECEPTORES IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 183216,
	"label": "MOLECULAS SIMILARES A RECEPTORES IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 183216,
	"label": "MOLECULAS SIMILARES A RECEPTORES IL-17 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7511,
	"target": 7487,
	"type": 183221,
	"label": "Antibodies that specifically bind beta-like glycoprotein hormone polypeptides and heterodimers thereof",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 183272,
	"label": "CD20 IgE RECEPTOR LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 183272,
	"label": "CD20 IgE RECEPTOR LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 183272,
	"label": "CD20 IgE RECEPTOR LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7428,
	"type": 183272,
	"label": "CD20 IgE RECEPTOR LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 183272,
	"label": "CD20 IgE RECEPTOR LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 7409,
	"type": 183282,
	"label": "Anticuerpo que enlaza con la integrina alfa4beta7 y su uso para tratar la enfermedad intestinal inflamatoria",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 183303,
	"label": "Nucleic acids encoding fibroblast growth factor receptor-like proteins and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 183377,
	"label": "IL-17 like molecules and uses thereoflike molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 183377,
	"label": "IL-17 like molecules and uses thereoflike molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 183377,
	"label": "IL-17 like molecules and uses thereoflike molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 183377,
	"label": "IL-17 like molecules and uses thereoflike molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 183377,
	"label": "IL-17 like molecules and uses thereoflike molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 184152,
	"label": "CYSTINE-KNOT POLYPEPTIDES: CLOAKED-2 MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 184257,
	"label": "Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 184257,
	"label": "Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 184257,
	"label": "Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37859,
	"target": 32788,
	"type": 184257,
	"label": "Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 32788,
	"type": 184257,
	"label": "Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 184298,
	"label": "B7-LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 184298,
	"label": "B7-LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 184298,
	"label": "B7-LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 184502,
	"label": "NEURITINA, UN NEUROGENO.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 184502,
	"label": "NEURITINA, UN NEUROGENO.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 184502,
	"label": "NEURITINA, UN NEUROGENO.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 184817,
	"label": "METHOD FOR PRODUCTION OF POLYPEPTIDE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 184817,
	"label": "METHOD FOR PRODUCTION OF POLYPEPTIDE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 184817,
	"label": "METHOD FOR PRODUCTION OF POLYPEPTIDE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 184817,
	"label": "METHOD FOR PRODUCTION OF POLYPEPTIDE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 184817,
	"label": "METHOD FOR PRODUCTION OF POLYPEPTIDE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 185054,
	"label": "C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7425,
	"target": 6795,
	"type": 185054,
	"label": "C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37859,
	"target": 32779,
	"type": 185054,
	"label": "C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 185054,
	"label": "C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 32779,
	"target": 7425,
	"type": 185054,
	"label": "C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 185116,
	"label": "LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR-8 MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 185116,
	"label": "LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR-8 MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 185116,
	"label": "LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR-8 MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 185116,
	"label": "LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR-8 MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37859,
	"target": 32770,
	"type": 185116,
	"label": "LEUCINE-RICH REPEAT-CONTAINING G-PROTEIN COUPLED RECEPTOR-8 MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 185209,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN MIT ANALOGEN VON G-CSF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37887,
	"target": 37864,
	"type": 185209,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN MIT ANALOGEN VON G-CSF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37887,
	"target": 37862,
	"type": 185209,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN MIT ANALOGEN VON G-CSF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37887,
	"type": 185209,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN MIT ANALOGEN VON G-CSF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 185209,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN MIT ANALOGEN VON G-CSF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 6812,
	"target": 6376,
	"type": 185444,
	"label": "TERAPIA DE COMBINACION QUE UTILIZA UNA PROTEINA DE UNION DEL FACTOR DE NECROSIS TUMORAL (TNF) EN EL TRATAMIENTO DE ENFERMEDADES INDUCIDAS POR EL TNF.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 32777,
	"type": 185646,
	"label": "ANTICUERPO ANTI-IGE/M1'; ACIDO NUCLEICO QUE LO CODIFICA; VECTOR Y CELULA HUESPED; PROCESO DE PRODUCCION; COMPOSICION QUE COMPRENDE AL ANTICUERPO; Y SU USO PARA TRATAR TRASTORNOS MEDIADOS POR IGE.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31042,
	"target": 7409,
	"type": 185793,
	"label": "KINASE INHIBITORS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 185817,
	"label": "Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 185817,
	"label": "Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 185817,
	"label": "Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 185817,
	"label": "Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 7511,
	"type": 185817,
	"label": "Novel polypeptide B7RP-1 T cell ligand-receptor pair involved in immune response modulation",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 186212,
	"label": "TRANSFORMING GROWTH FACTOR-BETA-RELATED MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 186212,
	"label": "TRANSFORMING GROWTH FACTOR-BETA-RELATED MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 186212,
	"label": "TRANSFORMING GROWTH FACTOR-BETA-RELATED MOLECULES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37904,
	"target": 37899,
	"type": 186272,
	"label": "APOPTOSIS PROVOCADA POR EL ANTICUERPO MONOCLONAL ANTI-HER2.",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 186272,
	"label": "APOPTOSIS PROVOCADA POR EL ANTICUERPO MONOCLONAL ANTI-HER2.",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 32772,
	"target": 32754,
	"type": 186272,
	"label": "APOPTOSIS PROVOCADA POR EL ANTICUERPO MONOCLONAL ANTI-HER2.",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 32779,
	"target": 32754,
	"type": 186272,
	"label": "APOPTOSIS PROVOCADA POR EL ANTICUERPO MONOCLONAL ANTI-HER2.",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 186272,
	"label": "APOPTOSIS PROVOCADA POR EL ANTICUERPO MONOCLONAL ANTI-HER2.",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 186305,
	"label": "METODO MEJORADO PARA TRATAMIENTO POR BISULFITO.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 188883,
	"label": "AGONISTEN FÜR DEN REZEPTOR DES HEPATOZYTEN- WACHSTUMSFAKTORS UND DEREN ANWENDUNGEN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 32772,
	"type": 188883,
	"label": "AGONISTEN FÜR DEN REZEPTOR DES HEPATOZYTEN- WACHSTUMSFAKTORS UND DEREN ANWENDUNGEN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 188883,
	"label": "AGONISTEN FÜR DEN REZEPTOR DES HEPATOZYTEN- WACHSTUMSFAKTORS UND DEREN ANWENDUNGEN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 7424,
	"type": 188883,
	"label": "AGONISTEN FÜR DEN REZEPTOR DES HEPATOZYTEN- WACHSTUMSFAKTORS UND DEREN ANWENDUNGEN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32772,
	"target": 7424,
	"type": 188883,
	"label": "AGONISTEN FÜR DEN REZEPTOR DES HEPATOZYTEN- WACHSTUMSFAKTORS UND DEREN ANWENDUNGEN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 37900,
	"type": 189415,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS PARA LA ACTIVINA DEL RECEPTOR TIPO QUINASA-1",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 189415,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS PARA LA ACTIVINA DEL RECEPTOR TIPO QUINASA-1",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 189415,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS PARA LA ACTIVINA DEL RECEPTOR TIPO QUINASA-1",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 189415,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS PARA LA ACTIVINA DEL RECEPTOR TIPO QUINASA-1",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37900,
	"target": 7507,
	"type": 189415,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS PARA LA ACTIVINA DEL RECEPTOR TIPO QUINASA-1",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 189691,
	"label": "VEGF-MODULATED GENES AND METHODS EMPLOYING THEM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 189691,
	"label": "VEGF-MODULATED GENES AND METHODS EMPLOYING THEM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 189691,
	"label": "VEGF-MODULATED GENES AND METHODS EMPLOYING THEM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 189791,
	"label": "(2S)-2-(ADAMANTAN-1-YLMETHOXYCARBONYLAMINO)-3-( - (2-(1,4,5,6-TETRAHYDROPYRIMIDIN-2- YLCARBAMOYL)ETHYL)BENZOYLAMINO)PROPION SÄUREISOPROPYLESTER, DESSEN HERSTELLUNG UND DESSEN VERWENDUNG",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56833,
	"target": 38237,
	"type": 189926,
	"label": "ENSAYO GENERICO DE DETECCION DE ACTIVIDAD QUINASA/FOSFATASA CON UNA UNICA LECTURA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6371,
	"target": 6303,
	"type": 189958,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 189958,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7409,
	"target": 6303,
	"type": 189958,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6447,
	"target": 6382,
	"type": 189959,
	"label": "PRODRUGS TO THYROID HORMONE ANALOGS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6447,
	"type": 189959,
	"label": "PRODRUGS TO THYROID HORMONE ANALOGS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 189959,
	"label": "PRODRUGS TO THYROID HORMONE ANALOGS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 190036,
	"label": "Fixed single injection dosage for ocrelizumab (2H7)",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37960,
	"target": 6854,
	"type": 190798,
	"label": "Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6382,
	"target": 6376,
	"type": 191202,
	"label": "AZACHINOLINOLPHOSPHONATVERBINDUNGEN ALS INTEGRASEINHIBITOREN",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 6382,
	"type": 191202,
	"label": "AZACHINOLINOLPHOSPHONATVERBINDUNGEN ALS INTEGRASEINHIBITOREN",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 191202,
	"label": "AZACHINOLINOLPHOSPHONATVERBINDUNGEN ALS INTEGRASEINHIBITOREN",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 191892,
	"label": "De-immunized MOG (poly)peptide constructs",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 191892,
	"label": "De-immunized MOG (poly)peptide constructs",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 191892,
	"label": "De-immunized MOG (poly)peptide constructs",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 7510,
	"type": 191892,
	"label": "De-immunized MOG (poly)peptide constructs",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 191892,
	"label": "De-immunized MOG (poly)peptide constructs",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 192299,
	"label": "Utilización de la proteína ASC como marcador para cáncer de seno",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 56804,
	"type": 192299,
	"label": "Utilización de la proteína ASC como marcador para cáncer de seno",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56836,
	"target": 56804,
	"type": 192299,
	"label": "Utilización de la proteína ASC como marcador para cáncer de seno",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56804,
	"target": 32754,
	"type": 192299,
	"label": "Utilización de la proteína ASC como marcador para cáncer de seno",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 32754,
	"type": 192299,
	"label": "Utilización de la proteína ASC como marcador para cáncer de seno",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 32772,
	"type": 192813,
	"label": "método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 192813,
	"label": "método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 192813,
	"label": "método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 193157,
	"label": "APARATO Y PROCEDIMIENTO PARA LA SECUENCIACION DE ACIDOS NUCLEICOS.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 193257,
	"label": "Interleukin-1 receptor antagonist-related polypeptide, nucleic acid molecules encoding the same and uses thereof",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32698,
	"target": 6854,
	"type": 193257,
	"label": "Interleukin-1 receptor antagonist-related polypeptide, nucleic acid molecules encoding the same and uses thereof",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 193257,
	"label": "Interleukin-1 receptor antagonist-related polypeptide, nucleic acid molecules encoding the same and uses thereof",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 193959,
	"label": "DIMERISIERTES PEPTID",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32754,
	"target": 7507,
	"type": 193959,
	"label": "DIMERISIERTES PEPTID",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32754,
	"target": 6854,
	"type": 193959,
	"label": "DIMERISIERTES PEPTID",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 193973,
	"label": "Trimerisk polypeptidkonstrukt for induksjon av vedvarende T-cellerespons",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 193973,
	"label": "Trimerisk polypeptidkonstrukt for induksjon av vedvarende T-cellerespons",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 193973,
	"label": "Trimerisk polypeptidkonstrukt for induksjon av vedvarende T-cellerespons",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 7487,
	"type": 193973,
	"label": "Trimerisk polypeptidkonstrukt for induksjon av vedvarende T-cellerespons",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 193973,
	"label": "Trimerisk polypeptidkonstrukt for induksjon av vedvarende T-cellerespons",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 38042,
	"target": 37960,
	"type": 195974,
	"label": "Fusion protein comprising an Escherichia coli chaperone protein and a human chaperone protein",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37960,
	"target": 32788,
	"type": 195974,
	"label": "Fusion protein comprising an Escherichia coli chaperone protein and a human chaperone protein",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 195974,
	"label": "Fusion protein comprising an Escherichia coli chaperone protein and a human chaperone protein",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 195974,
	"label": "Fusion protein comprising an Escherichia coli chaperone protein and a human chaperone protein",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37960,
	"target": 6795,
	"type": 195974,
	"label": "Fusion protein comprising an Escherichia coli chaperone protein and a human chaperone protein",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 199229,
	"label": "Inhibidores de IAP derivados de pirrolidina",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 199483,
	"label": "USO DE UN ANTAGONISTA DEL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF) EN COMBINACION CON UN SEGUNDO AGENTE QUE COMPRENDE UN AGENTE REDUCTOR DE CELULA MIELOIDE PARA TRATAR UN TUMOR RESISTENTE EN UN SUJETO; Y METODO DE DIAGNOSTICO DEL TUMOR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 199483,
	"label": "USO DE UN ANTAGONISTA DEL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF) EN COMBINACION CON UN SEGUNDO AGENTE QUE COMPRENDE UN AGENTE REDUCTOR DE CELULA MIELOIDE PARA TRATAR UN TUMOR RESISTENTE EN UN SUJETO; Y METODO DE DIAGNOSTICO DEL TUMOR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 199483,
	"label": "USO DE UN ANTAGONISTA DEL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF) EN COMBINACION CON UN SEGUNDO AGENTE QUE COMPRENDE UN AGENTE REDUCTOR DE CELULA MIELOIDE PARA TRATAR UN TUMOR RESISTENTE EN UN SUJETO; Y METODO DE DIAGNOSTICO DEL TUMOR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6478,
	"type": 199483,
	"label": "USO DE UN ANTAGONISTA DEL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF) EN COMBINACION CON UN SEGUNDO AGENTE QUE COMPRENDE UN AGENTE REDUCTOR DE CELULA MIELOIDE PARA TRATAR UN TUMOR RESISTENTE EN UN SUJETO; Y METODO DE DIAGNOSTICO DEL TUMOR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 199483,
	"label": "USO DE UN ANTAGONISTA DEL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF) EN COMBINACION CON UN SEGUNDO AGENTE QUE COMPRENDE UN AGENTE REDUCTOR DE CELULA MIELOIDE PARA TRATAR UN TUMOR RESISTENTE EN UN SUJETO; Y METODO DE DIAGNOSTICO DEL TUMOR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 199754,
	"label": "PRETRATAMIENTO DE UNA MUESTRA BIOLOGICA DE UN SUJETO QUE SUFRE UNA ENFERMEDAD AUTOINMUNE.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 200190,
	"label": "processo para preparação de uma enzima heteróloga através do cultivo de uma célula eucariótica transformada.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 201477,
	"label": "SCINTILLATION PROXIMITY ASSAY FOR THE ACTIVITY OF A DNA OR RNA POLYMERASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 201904,
	"label": "METHOD OF ASSESSING COLORECTAL CANCER BY MEASURING HEMOGLOBIN AND M2-PK IN A STOOL SAMPLE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 201959,
	"label": "Improved production of glycoproteins using manganese",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 201959,
	"label": "Improved production of glycoproteins using manganese",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 201959,
	"label": "Improved production of glycoproteins using manganese",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6292,
	"type": 201986,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND ALLEVIATION OF TUMOR",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 37897,
	"type": 201986,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND ALLEVIATION OF TUMOR",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37897,
	"target": 7507,
	"type": 201986,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND ALLEVIATION OF TUMOR",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37897,
	"target": 6292,
	"type": 201986,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND ALLEVIATION OF TUMOR",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 201986,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND ALLEVIATION OF TUMOR",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 7508,
	"type": 201987,
	"label": "anticorpos isolados, molécula de ácido nucléico, vetor, célula hopedeira, linhagem celular, método para a produção de um anticorpo, composição, métodos para identificar a presença de poliubiquitina, para tratar uma doença, para determinar a presença de uma poliubiquitina, para separar as proteìnas poliubiquitinadas, para determinar a função e/ou atividade da poliubiquitina em uma célula e para determinar a função e/ou atividade da poliubiquitina em uma amostra e fragmento de ligação ao antìgeno",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 39999,
	"target": 38184,
	"type": 202211,
	"label": "VERFAHREN ZUM SCREENING AUF AGONISTISCHE ANTIKÖRPER",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 7510,
	"type": 202211,
	"label": "VERFAHREN ZUM SCREENING AUF AGONISTISCHE ANTIKÖRPER",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 39999,
	"target": 7510,
	"type": 202211,
	"label": "VERFAHREN ZUM SCREENING AUF AGONISTISCHE ANTIKÖRPER",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 203959,
	"label": "POLIPEPTIDO DNA19355, UN HOMOLOGO DEL FACTOR DE NECROSIS TUMORAL.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 203959,
	"label": "POLIPEPTIDO DNA19355, UN HOMOLOGO DEL FACTOR DE NECROSIS TUMORAL.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 203959,
	"label": "POLIPEPTIDO DNA19355, UN HOMOLOGO DEL FACTOR DE NECROSIS TUMORAL.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 203959,
	"label": "POLIPEPTIDO DNA19355, UN HOMOLOGO DEL FACTOR DE NECROSIS TUMORAL.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 203959,
	"label": "POLIPEPTIDO DNA19355, UN HOMOLOGO DEL FACTOR DE NECROSIS TUMORAL.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 204184,
	"label": "SUBSTRATE FOR NUCLEIC ACID AMPLIFICATION",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 206405,
	"label": "FremgangsmÕte til fremstilling av rekombinant human interleukin-1-inhibitor",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 206405,
	"label": "FremgangsmÕte til fremstilling av rekombinant human interleukin-1-inhibitor",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 206405,
	"label": "FremgangsmÕte til fremstilling av rekombinant human interleukin-1-inhibitor",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37864,
	"target": 32698,
	"type": 206405,
	"label": "FremgangsmÕte til fremstilling av rekombinant human interleukin-1-inhibitor",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 206405,
	"label": "FremgangsmÕte til fremstilling av rekombinant human interleukin-1-inhibitor",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 207778,
	"label": "Polypeptidanalog til nativ keratinocyttvekstfaktor kalt KGF, farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitel",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 207778,
	"label": "Polypeptidanalog til nativ keratinocyttvekstfaktor kalt KGF, farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitel",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 207778,
	"label": "Polypeptidanalog til nativ keratinocyttvekstfaktor kalt KGF, farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitel",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 207856,
	"label": "ANTI-INFLAMMATORY CD14 POLYPEPTIDES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 7487,
	"type": 207856,
	"label": "ANTI-INFLAMMATORY CD14 POLYPEPTIDES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 207856,
	"label": "ANTI-INFLAMMATORY CD14 POLYPEPTIDES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 208809,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL RECEPTOR DFL FACTOR DE CRECIMIENTO EPIDERMICO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 208809,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL RECEPTOR DFL FACTOR DE CRECIMIENTO EPIDERMICO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 208809,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL RECEPTOR DFL FACTOR DE CRECIMIENTO EPIDERMICO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 208809,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL RECEPTOR DFL FACTOR DE CRECIMIENTO EPIDERMICO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 208809,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL RECEPTOR DFL FACTOR DE CRECIMIENTO EPIDERMICO.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 212010,
	"label": "DNA WHICH CORDS HOMINAL GROWTH HORMONE VARIATION PROTEIN",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 212684,
	"label": "Avkortet gliacellelinjeavledet neurotrof faktor (GDNF)-proteinprodukt, plynukleotid som koder for dette, vektor omfattende polynukleotidet, anvendelse av GDNF-proteinproduktet for fremstilling av medikament, anvendelse av nebnte polynukleotid for fremstilling av medikament, anvendelse av celle som er transformert med polynukleotidet for fremstilling av medikament, prokaryot eller eukaryot vertscelle som er transfektert med polynukleotidet, fremgangsmate for fremstilling av avkortet GDNF-protein,",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 212684,
	"label": "Avkortet gliacellelinjeavledet neurotrof faktor (GDNF)-proteinprodukt, plynukleotid som koder for dette, vektor omfattende polynukleotidet, anvendelse av GDNF-proteinproduktet for fremstilling av medikament, anvendelse av nebnte polynukleotid for fremstilling av medikament, anvendelse av celle som er transformert med polynukleotidet for fremstilling av medikament, prokaryot eller eukaryot vertscelle som er transfektert med polynukleotidet, fremgangsmate for fremstilling av avkortet GDNF-protein,",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 212684,
	"label": "Avkortet gliacellelinjeavledet neurotrof faktor (GDNF)-proteinprodukt, plynukleotid som koder for dette, vektor omfattende polynukleotidet, anvendelse av GDNF-proteinproduktet for fremstilling av medikament, anvendelse av nebnte polynukleotid for fremstilling av medikament, anvendelse av celle som er transformert med polynukleotidet for fremstilling av medikament, prokaryot eller eukaryot vertscelle som er transfektert med polynukleotidet, fremgangsmate for fremstilling av avkortet GDNF-protein,",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 212691,
	"label": "METODO DE TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER POR MEDIO DE UN PRODUCTO PROTEINICO: EL FACTOR NEUROTROFICO DERIVADO DE LINEAS CELULARES GLIALES (GDNF).",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 212691,
	"label": "METODO DE TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER POR MEDIO DE UN PRODUCTO PROTEINICO: EL FACTOR NEUROTROFICO DERIVADO DE LINEAS CELULARES GLIALES (GDNF).",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 212691,
	"label": "METODO DE TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER POR MEDIO DE UN PRODUCTO PROTEINICO: EL FACTOR NEUROTROFICO DERIVADO DE LINEAS CELULARES GLIALES (GDNF).",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 213669,
	"label": "DNA-sekvens som koder for interleukin-1-inhibitorer, rekombinant vektor sominneholder og kan kode DNA-sekvensen, vertcelle som inneholder ogkan uttrykkevektorer, og fremgangsmåte til fremstilling av interleukin-1-inhibitorer, og rekombinant vertcelle s",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 56834,
	"target": 38181,
	"type": 214355,
	"label": "Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 214355,
	"label": "Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 6795,
	"type": 214355,
	"label": "Method of ameliorating the harmful effects of TNF using a polypeptide having the ability to bind to TNF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 214566,
	"label": "METODOS DE TRATAMIENTO DE LAS ENFERMEDADES INDUCIDAS POR LA INTERLEUQUINA-1 Y EL FACTOR DE NECROSIS TUMORAL.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 215378,
	"label": "METHOD OF INHIBITION OF RETROVIRAL INFECTION (VARIANTS), PROTEASE INHIBITOR, NUCLEIC ACID ENCODING AN INHIBITOR AND A METHOD OF RECOMBINANT SERINE PROTEASE INHIBITOR PRODUCING",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 215551,
	"label": "Keratinocyte growth factor for treatment of conditions requiring stimulation of epithelial cells, composition and use",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 215551,
	"label": "Keratinocyte growth factor for treatment of conditions requiring stimulation of epithelial cells, composition and use",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 215551,
	"label": "Keratinocyte growth factor for treatment of conditions requiring stimulation of epithelial cells, composition and use",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 217555,
	"label": "PRODUCTO A BASE DEL FACTOR DE CRECIMIENTO DE QUERATINOCITOS-2 (KGGF-2)",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 217555,
	"label": "PRODUCTO A BASE DEL FACTOR DE CRECIMIENTO DE QUERATINOCITOS-2 (KGGF-2)",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 217555,
	"label": "PRODUCTO A BASE DEL FACTOR DE CRECIMIENTO DE QUERATINOCITOS-2 (KGGF-2)",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 217555,
	"label": "PRODUCTO A BASE DEL FACTOR DE CRECIMIENTO DE QUERATINOCITOS-2 (KGGF-2)",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 217555,
	"label": "PRODUCTO A BASE DEL FACTOR DE CRECIMIENTO DE QUERATINOCITOS-2 (KGGF-2)",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 217625,
	"label": "Análago de scf molécular de DNA N11D DNA viral ou vetor de plasmídeo célula hospedeira processo para produzir análogo de SCF N10D N11D para tratar um distúrbio hematopoiético para sensibilizar células a quimioterapia para tratar dano ao nervo infertilidade ou dano intestinal para cultivar células hematopoiéticas in vitro e para transfectar células hematopoiéticas com dna exógeno e kit",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 217625,
	"label": "Análago de scf molécular de DNA N11D DNA viral ou vetor de plasmídeo célula hospedeira processo para produzir análogo de SCF N10D N11D para tratar um distúrbio hematopoiético para sensibilizar células a quimioterapia para tratar dano ao nervo infertilidade ou dano intestinal para cultivar células hematopoiéticas in vitro e para transfectar células hematopoiéticas com dna exógeno e kit",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 217625,
	"label": "Análago de scf molécular de DNA N11D DNA viral ou vetor de plasmídeo célula hospedeira processo para produzir análogo de SCF N10D N11D para tratar um distúrbio hematopoiético para sensibilizar células a quimioterapia para tratar dano ao nervo infertilidade ou dano intestinal para cultivar células hematopoiéticas in vitro e para transfectar células hematopoiéticas com dna exógeno e kit",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 217625,
	"label": "Análago de scf molécular de DNA N11D DNA viral ou vetor de plasmídeo célula hospedeira processo para produzir análogo de SCF N10D N11D para tratar um distúrbio hematopoiético para sensibilizar células a quimioterapia para tratar dano ao nervo infertilidade ou dano intestinal para cultivar células hematopoiéticas in vitro e para transfectar células hematopoiéticas com dna exógeno e kit",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 217625,
	"label": "Análago de scf molécular de DNA N11D DNA viral ou vetor de plasmídeo célula hospedeira processo para produzir análogo de SCF N10D N11D para tratar um distúrbio hematopoiético para sensibilizar células a quimioterapia para tratar dano ao nervo infertilidade ou dano intestinal para cultivar células hematopoiéticas in vitro e para transfectar células hematopoiéticas com dna exógeno e kit",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 217649,
	"label": "Proteina composição farmacêutica sequencia de acido nucleico isolado vetor celula hospedeira utilização da proteina processos para produção da proteina para tratamento adequado de celulas nervosas dopaminergicas tratamento das doenças de parkinson de alzheimer e esclerose lateral amiotrofica e para analise anticorpo hebridoma e dispositivos para tratamento de danos aos nervos e para analise",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 217649,
	"label": "Proteina composição farmacêutica sequencia de acido nucleico isolado vetor celula hospedeira utilização da proteina processos para produção da proteina para tratamento adequado de celulas nervosas dopaminergicas tratamento das doenças de parkinson de alzheimer e esclerose lateral amiotrofica e para analise anticorpo hebridoma e dispositivos para tratamento de danos aos nervos e para analise",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 217649,
	"label": "Proteina composição farmacêutica sequencia de acido nucleico isolado vetor celula hospedeira utilização da proteina processos para produção da proteina para tratamento adequado de celulas nervosas dopaminergicas tratamento das doenças de parkinson de alzheimer e esclerose lateral amiotrofica e para analise anticorpo hebridoma e dispositivos para tratamento de danos aos nervos e para analise",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 217649,
	"label": "Proteina composição farmacêutica sequencia de acido nucleico isolado vetor celula hospedeira utilização da proteina processos para produção da proteina para tratamento adequado de celulas nervosas dopaminergicas tratamento das doenças de parkinson de alzheimer e esclerose lateral amiotrofica e para analise anticorpo hebridoma e dispositivos para tratamento de danos aos nervos e para analise",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 217649,
	"label": "Proteina composição farmacêutica sequencia de acido nucleico isolado vetor celula hospedeira utilização da proteina processos para produção da proteina para tratamento adequado de celulas nervosas dopaminergicas tratamento das doenças de parkinson de alzheimer e esclerose lateral amiotrofica e para analise anticorpo hebridoma e dispositivos para tratamento de danos aos nervos e para analise",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 217733,
	"label": "TUMOR NECROSIS FACTOR-RELATED POLYPEPTIDE",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 218131,
	"label": "RECOMBINANT MEMBERS OF THE NERVE GROWTH FACTOR/BRAIN DERIVED NEUROTROPHIC FACTOR (NGF/BDNF) FAMILY OF NEUROTROPHIC PROTEINS AND THEIR PRODUCTION",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 218589,
	"label": "INTERLEUKIN-1'beta' CONVERTING ENZYME LIKE CYSTEINE PROTEASE.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 218589,
	"label": "INTERLEUKIN-1'beta' CONVERTING ENZYME LIKE CYSTEINE PROTEASE.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38232,
	"target": 38184,
	"type": 218589,
	"label": "INTERLEUKIN-1'beta' CONVERTING ENZYME LIKE CYSTEINE PROTEASE.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38232,
	"target": 38181,
	"type": 218589,
	"label": "INTERLEUKIN-1'beta' CONVERTING ENZYME LIKE CYSTEINE PROTEASE.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 218589,
	"label": "INTERLEUKIN-1'beta' CONVERTING ENZYME LIKE CYSTEINE PROTEASE.",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6821,
	"type": 218670,
	"label": "UTILIZACION DE PRODUCTO(S) PROTEICO(S) KGF Y DE PRODUCTO(S) PROTEICO(S) GLP-2 PARA LA PREPARACION DE UN MEDICAMENTO.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 219792,
	"label": "DECAY-ACCELERATING FACTOR (DAF) POLYPEPTIDE DNA FUSIONS TO DNA ENCODING HETEROLOGOUS POLYPEPTIDES, HOST CELLS TRANSFORMED WITH DAF FUSION DNA, AND DAF FUSION PROTEINS",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 32769,
	"type": 219792,
	"label": "DECAY-ACCELERATING FACTOR (DAF) POLYPEPTIDE DNA FUSIONS TO DNA ENCODING HETEROLOGOUS POLYPEPTIDES, HOST CELLS TRANSFORMED WITH DAF FUSION DNA, AND DAF FUSION PROTEINS",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 32769,
	"type": 219792,
	"label": "DECAY-ACCELERATING FACTOR (DAF) POLYPEPTIDE DNA FUSIONS TO DNA ENCODING HETEROLOGOUS POLYPEPTIDES, HOST CELLS TRANSFORMED WITH DAF FUSION DNA, AND DAF FUSION PROTEINS",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32769,
	"target": 6795,
	"type": 219792,
	"label": "DECAY-ACCELERATING FACTOR (DAF) POLYPEPTIDE DNA FUSIONS TO DNA ENCODING HETEROLOGOUS POLYPEPTIDES, HOST CELLS TRANSFORMED WITH DAF FUSION DNA, AND DAF FUSION PROTEINS",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 219792,
	"label": "DECAY-ACCELERATING FACTOR (DAF) POLYPEPTIDE DNA FUSIONS TO DNA ENCODING HETEROLOGOUS POLYPEPTIDES, HOST CELLS TRANSFORMED WITH DAF FUSION DNA, AND DAF FUSION PROTEINS",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 222996,
	"label": "VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 224018,
	"label": "anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 224018,
	"label": "anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 224018,
	"label": "anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 224454,
	"label": "ERYTHROPOIETIN RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 224454,
	"label": "ERYTHROPOIETIN RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 224454,
	"label": "ERYTHROPOIETIN RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37859,
	"target": 32770,
	"type": 224454,
	"label": "ERYTHROPOIETIN RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 224454,
	"label": "ERYTHROPOIETIN RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7511,
	"target": 7508,
	"type": 224645,
	"label": "método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7508,
	"target": 7424,
	"type": 224645,
	"label": "método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7511,
	"target": 7424,
	"type": 224645,
	"label": "método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 7511,
	"type": 224645,
	"label": "método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 7508,
	"type": 224645,
	"label": "método de avaliação da eficácia de anticorpo, métodos de imunoterapia, método de detecção de anticorpos neutralizantes a anticorpo terapêutico e método de avaliação da eficácia de antagonista",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 224684,
	"label": "FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 224914,
	"label": "MUTACIONES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 224914,
	"label": "MUTACIONES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 224914,
	"label": "MUTACIONES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 224914,
	"label": "MUTACIONES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 224914,
	"label": "MUTACIONES DEL RECEPTOR DEL FACTOR DE CRECIMIENTO EPIDERMICO",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 225194,
	"label": "Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 225319,
	"label": "Péptidos que modulan la actividad del factor de crecimiento nervioso (NGF), sus composiciones y uso",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 38164,
	"type": 225547,
	"label": "GENE AMPLIFICATION AND OVEREXPRESSION IN CANCER",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 225562,
	"label": "Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 225587,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN, DIE MULTIMERE UND OLIGOMERE LÖSLICHE FRAGMENTE DES TWEAK- REZEPTORS BETREFFEN",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 225587,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN, DIE MULTIMERE UND OLIGOMERE LÖSLICHE FRAGMENTE DES TWEAK- REZEPTORS BETREFFEN",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 225587,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN, DIE MULTIMERE UND OLIGOMERE LÖSLICHE FRAGMENTE DES TWEAK- REZEPTORS BETREFFEN",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32788,
	"target": 6854,
	"type": 225587,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN, DIE MULTIMERE UND OLIGOMERE LÖSLICHE FRAGMENTE DES TWEAK- REZEPTORS BETREFFEN",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 225587,
	"label": "ZUSAMMENSETZUNGEN UND VERFAHREN, DIE MULTIMERE UND OLIGOMERE LÖSLICHE FRAGMENTE DES TWEAK- REZEPTORS BETREFFEN",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 225854,
	"label": "COMBINACIONES PARA EL TRATAMIENTO DE CANCER QUE COMPRENDEN UN ANTICUERPO ANTI-EGFR E INHIBIDORES DE VEGFR.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 226032,
	"label": "composições de matéria, e farmacêutica, dna, vetor de expressão, célula hospedeira, e, uso de uma composição de matéria",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 226245,
	"label": "Methods for treating IFN-gamma mediated diseases using human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 226245,
	"label": "Methods for treating IFN-gamma mediated diseases using human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 226245,
	"label": "Methods for treating IFN-gamma mediated diseases using human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 226343,
	"label": "Substituted pyrimdinone derivatives and methods of use",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 6390,
	"target": 6376,
	"type": 226772,
	"label": "Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 6795,
	"type": 227012,
	"label": "AMPLIFIED GENES INVOLVED IN CANCER",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 227164,
	"label": "2-OXOPYRIDIN-3-YL THIA (DI) AZOLE DERIVATES FOR USE IN THE TREATMENT OF CELL PROLIFERATION AND APOPTOSIS RELATED DISEASES",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 227240,
	"label": "SHORT INTERFERING RNA AS AN ANTIVIRAL AGENT FOR HEPATITIS C",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 6795,
	"target": 6484,
	"type": 227240,
	"label": "SHORT INTERFERING RNA AS AN ANTIVIRAL AGENT FOR HEPATITIS C",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 227240,
	"label": "SHORT INTERFERING RNA AS AN ANTIVIRAL AGENT FOR HEPATITIS C",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 227240,
	"label": "SHORT INTERFERING RNA AS AN ANTIVIRAL AGENT FOR HEPATITIS C",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 6484,
	"type": 227240,
	"label": "SHORT INTERFERING RNA AS AN ANTIVIRAL AGENT FOR HEPATITIS C",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7450,
	"type": 227381,
	"label": "HEH4 MOLECULES AND USES THEREOF",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 6281,
	"target": 6279,
	"type": 227597,
	"label": "CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6382,
	"target": 6281,
	"type": 227597,
	"label": "CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6382,
	"target": 6279,
	"type": 227597,
	"label": "CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6382,
	"type": 227597,
	"label": "CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6281,
	"type": 227597,
	"label": "CONDENSED TRIAZOLES AND INDAZOLES USEFUL IN TREATING CITOKINES MEDIATED DISEASES AND OTHER DISEASES.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 227881,
	"label": "ANTICUERPOS NEUTRALIZADORES HUMANOS ANTI-B7RP1",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 227881,
	"label": "ANTICUERPOS NEUTRALIZADORES HUMANOS ANTI-B7RP1",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 227881,
	"label": "ANTICUERPOS NEUTRALIZADORES HUMANOS ANTI-B7RP1",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56836,
	"target": 37993,
	"type": 227881,
	"label": "ANTICUERPOS NEUTRALIZADORES HUMANOS ANTI-B7RP1",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 227881,
	"label": "ANTICUERPOS NEUTRALIZADORES HUMANOS ANTI-B7RP1",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 227910,
	"label": "Modified Fc molecules",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 227910,
	"label": "Modified Fc molecules",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 227910,
	"label": "Modified Fc molecules",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 227913,
	"label": "PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 228734,
	"label": "NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6382,
	"type": 228734,
	"label": "NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 228734,
	"label": "NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 228892,
	"label": "TRAIL recipient 2 Polypeptides and antibodies",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 228892,
	"label": "TRAIL recipient 2 Polypeptides and antibodies",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 228892,
	"label": "TRAIL recipient 2 Polypeptides and antibodies",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 228892,
	"label": "TRAIL recipient 2 Polypeptides and antibodies",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 228892,
	"label": "TRAIL recipient 2 Polypeptides and antibodies",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 6341,
	"type": 229628,
	"label": "método de tratamento de lúpus e artigo industrializado",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6281,
	"target": 6280,
	"type": 229882,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1, e seu uso",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 230841,
	"label": "MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7450,
	"type": 230841,
	"label": "MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 7450,
	"type": 230841,
	"label": "MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6295,
	"type": 231559,
	"label": "composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 231559,
	"label": "composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6295,
	"type": 231559,
	"label": "composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 32694,
	"type": 231586,
	"label": "MODIFIED FC MOLECULES HAVING PEPTIDES INSERTED IN INTERNAL LOOP REGIONS",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 231586,
	"label": "MODIFIED FC MOLECULES HAVING PEPTIDES INSERTED IN INTERNAL LOOP REGIONS",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 231586,
	"label": "MODIFIED FC MOLECULES HAVING PEPTIDES INSERTED IN INTERNAL LOOP REGIONS",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 231586,
	"label": "MODIFIED FC MOLECULES HAVING PEPTIDES INSERTED IN INTERNAL LOOP REGIONS",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 231586,
	"label": "MODIFIED FC MOLECULES HAVING PEPTIDES INSERTED IN INTERNAL LOOP REGIONS",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 231728,
	"label": "anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 231728,
	"label": "anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 231728,
	"label": "anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 231728,
	"label": "anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 231728,
	"label": "anticorpo anti-ox40l, anticorpos isolados, polinucleotìdeo, vetor, célula hospedeira, método para fabricar um anticorpo anti-ox40l, método para tratar ou previnir uma disfunção imune, composição e uso de um anticorpo anti-ox40l",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 232489,
	"label": "QUINOLINES AND QUINAZOLINE ANALOGS AND THEIR USE AS MEDICAMENTS FOR TREATING CANCER.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7358,
	"target": 6795,
	"type": 232532,
	"label": "THERAPEUTIC FORMULATIONS OF KERATINOCYTE GROWTH FACTOR.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 232535,
	"label": "Aminopyrimidine compounds and methods of use",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 232541,
	"label": "SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 6301,
	"target": 6298,
	"type": 232565,
	"label": "FURANOPYRIDINE DERIVATIVES AS ACK1 AND LCK MODULATORS",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37960,
	"target": 7507,
	"type": 235916,
	"label": "CRYSTALLINE STRUCTURE OF OXIDOSQUALENE SYNTHASE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32698,
	"target": 32697,
	"type": 236722,
	"label": "Fremgangsmåde til isolering og rensning af granulocyt kolonistimulerende faktor (G-CSF) fra en mikroorganisme, der producerer rekombinant G-CSF",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 32697,
	"target": 6816,
	"type": 236722,
	"label": "Fremgangsmåde til isolering og rensning af granulocyt kolonistimulerende faktor (G-CSF) fra en mikroorganisme, der producerer rekombinant G-CSF",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 32698,
	"target": 6816,
	"type": 236722,
	"label": "Fremgangsmåde til isolering og rensning af granulocyt kolonistimulerende faktor (G-CSF) fra en mikroorganisme, der producerer rekombinant G-CSF",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 238093,
	"label": "TLR2-ANTAGONISTISCHER ANTIKÖRPER UND DESSEN VERWENDUNG",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 239195,
	"label": "Pharmaceutical composition for treating fatty liver or hepatic disease",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 239958,
	"label": "VARIANTS OF AN ERWINIA-TYPE CREATINASE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6382,
	"target": 6376,
	"type": 241702,
	"label": "Pyrimidine, quinazoline, pteridine and triazine derivatives",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 241922,
	"label": "METHOD FOR PRODUCING A PLURALITY OF MONOCLONAL ANTIBODIES AND METHOD FOR IDENTIFYING A PLURALITY OF MONOCLONAL ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37904,
	"target": 32777,
	"type": 241922,
	"label": "METHOD FOR PRODUCING A PLURALITY OF MONOCLONAL ANTIBODIES AND METHOD FOR IDENTIFYING A PLURALITY OF MONOCLONAL ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 241922,
	"label": "METHOD FOR PRODUCING A PLURALITY OF MONOCLONAL ANTIBODIES AND METHOD FOR IDENTIFYING A PLURALITY OF MONOCLONAL ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 242108,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING T CELLS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7409,
	"target": 6854,
	"type": 242108,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING T CELLS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 6854,
	"type": 242108,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING T CELLS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37875,
	"target": 32770,
	"type": 242108,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING T CELLS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 242108,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING T CELLS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 242207,
	"label": "PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 242207,
	"label": "PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 242207,
	"label": "PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 242707,
	"label": "HETEROBICYCLIC PYRAZOLE COMPOUNDS AS INHIBITORS OF MET TYROSINE KINASE FOR THE TREATMENT OF CANCER DISEASES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 242707,
	"label": "HETEROBICYCLIC PYRAZOLE COMPOUNDS AS INHIBITORS OF MET TYROSINE KINASE FOR THE TREATMENT OF CANCER DISEASES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 242707,
	"label": "HETEROBICYCLIC PYRAZOLE COMPOUNDS AS INHIBITORS OF MET TYROSINE KINASE FOR THE TREATMENT OF CANCER DISEASES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 243524,
	"label": "Rapid one-step reverse transcriptase PCR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 244203,
	"label": "Cytokine design",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32694,
	"target": 7507,
	"type": 244203,
	"label": "Cytokine design",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 244203,
	"label": "Cytokine design",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7511,
	"target": 7424,
	"type": 246557,
	"label": "Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 246746,
	"label": "PROTEINA DE FUSION OB, SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA DICHA PROTEINA, VECTOR QUE CONTIENE DICHA SECUENCIA, PROCESO PARA PRODUCIR DICHA PROTEINA, COMPOSICION FARMACEUTICA QUE CONTIENE DICHA PROTEINA Y USO DE DICHA PROTEINA PARA FABRICAR UN MEDICAMENTO",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 246746,
	"label": "PROTEINA DE FUSION OB, SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA DICHA PROTEINA, VECTOR QUE CONTIENE DICHA SECUENCIA, PROCESO PARA PRODUCIR DICHA PROTEINA, COMPOSICION FARMACEUTICA QUE CONTIENE DICHA PROTEINA Y USO DE DICHA PROTEINA PARA FABRICAR UN MEDICAMENTO",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 246746,
	"label": "PROTEINA DE FUSION OB, SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA DICHA PROTEINA, VECTOR QUE CONTIENE DICHA SECUENCIA, PROCESO PARA PRODUCIR DICHA PROTEINA, COMPOSICION FARMACEUTICA QUE CONTIENE DICHA PROTEINA Y USO DE DICHA PROTEINA PARA FABRICAR UN MEDICAMENTO",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 247789,
	"label": "Methods of prevention and treatment using apolipoprotein analogues",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 247789,
	"label": "Methods of prevention and treatment using apolipoprotein analogues",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 247789,
	"label": "Methods of prevention and treatment using apolipoprotein analogues",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 247830,
	"label": "Transgenic animals bearing human Ig lambda light chain genes",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 247830,
	"label": "Transgenic animals bearing human Ig lambda light chain genes",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 247830,
	"label": "Transgenic animals bearing human Ig lambda light chain genes",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 248295,
	"label": "CANCER DISEASE MODIFYING ANTIBODY 010207-01 PRODUCED BY HYBRIDOMA CELL LINE AR51A630.3.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 248295,
	"label": "CANCER DISEASE MODIFYING ANTIBODY 010207-01 PRODUCED BY HYBRIDOMA CELL LINE AR51A630.3.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 32771,
	"type": 248295,
	"label": "CANCER DISEASE MODIFYING ANTIBODY 010207-01 PRODUCED BY HYBRIDOMA CELL LINE AR51A630.3.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32788,
	"type": 248295,
	"label": "CANCER DISEASE MODIFYING ANTIBODY 010207-01 PRODUCED BY HYBRIDOMA CELL LINE AR51A630.3.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 248295,
	"label": "CANCER DISEASE MODIFYING ANTIBODY 010207-01 PRODUCED BY HYBRIDOMA CELL LINE AR51A630.3.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 248356,
	"label": "Apex como marcador de cáncer de pulmón",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31965,
	"target": 6376,
	"type": 248405,
	"label": "DERIVADOS DE AZA-PIRIDOPIRIMIDINONA COMO AGONISTAS DE HM74A",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7450,
	"target": 6795,
	"type": 248983,
	"label": "Therapeutic agents for osteopenia",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 250293,
	"label": "Therapeutic agents for solid tumors",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7509,
	"type": 250293,
	"label": "Therapeutic agents for solid tumors",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 250293,
	"label": "Therapeutic agents for solid tumors",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 251447,
	"label": "New antibody to Mucosal Adressin Cell Adhesion Molecule, useful for diagnosing and treating an inflammatory disease, e.g. inflammatory bowel disease, ulcerative colitis, gastritis, insulin-dependent diabetes or graft versus host disease",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 251447,
	"label": "New antibody to Mucosal Adressin Cell Adhesion Molecule, useful for diagnosing and treating an inflammatory disease, e.g. inflammatory bowel disease, ulcerative colitis, gastritis, insulin-dependent diabetes or graft versus host disease",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 7511,
	"type": 251447,
	"label": "New antibody to Mucosal Adressin Cell Adhesion Molecule, useful for diagnosing and treating an inflammatory disease, e.g. inflammatory bowel disease, ulcerative colitis, gastritis, insulin-dependent diabetes or graft versus host disease",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 251738,
	"label": "DERIVATIVES OF QUINOLINE OR BENZOPYRAZINE AND THEIR USES FOR THE TREATMENT OF (INTER ALIA) INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES OR VARIOUS KINDS OF CANCER.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 251738,
	"label": "DERIVATIVES OF QUINOLINE OR BENZOPYRAZINE AND THEIR USES FOR THE TREATMENT OF (INTER ALIA) INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES OR VARIOUS KINDS OF CANCER.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 251738,
	"label": "DERIVATIVES OF QUINOLINE OR BENZOPYRAZINE AND THEIR USES FOR THE TREATMENT OF (INTER ALIA) INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES OR VARIOUS KINDS OF CANCER.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31939,
	"target": 31937,
	"type": 251749,
	"label": "Heterocyclic compounds as selective inhibitors of PI3K activity",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 251749,
	"label": "Heterocyclic compounds as selective inhibitors of PI3K activity",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31937,
	"target": 7507,
	"type": 251749,
	"label": "Heterocyclic compounds as selective inhibitors of PI3K activity",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 251749,
	"label": "Heterocyclic compounds as selective inhibitors of PI3K activity",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31937,
	"target": 6376,
	"type": 251749,
	"label": "Heterocyclic compounds as selective inhibitors of PI3K activity",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 6795,
	"target": 6371,
	"type": 251989,
	"label": "composição, uso de 2xcon4(c), e amg 706 ou 4tbppapc, e seus sais farmaceuticamente aceitáveis, e, kit",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 251989,
	"label": "composição, uso de 2xcon4(c), e amg 706 ou 4tbppapc, e seus sais farmaceuticamente aceitáveis, e, kit",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 251989,
	"label": "composição, uso de 2xcon4(c), e amg 706 ou 4tbppapc, e seus sais farmaceuticamente aceitáveis, e, kit",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 252576,
	"label": "método de redução ou inibição da angiogênese e método de aumento da eficácia de tratamento com agente antiangiogênico",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 253138,
	"label": "anticorpos dirigidos aos mutantes de deleção de receptor de fator de crescimento epidérmico e seus usos",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 31965,
	"target": 6795,
	"type": 253244,
	"label": "(1S, 4R, 6S, 14S, 18R)-4-FLUORO-1,3-DIHYDRO-ISOINDOLE-2-CARBOXYLIC ACID 14-TERT-BUTOXYCARBONYLAMINO-4-CYCLOPROPANESULFONYLAMINOCARBONYL-2,15-DIOXO-3,16-DIAZATRICYCLONONADEC-7-EN-18-YL ESTER AND ITS USE FOR THE MANUFACTURE OF AN ANTI-HCV INFECTION MEDICAMENT",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 254680,
	"label": "IDENTIFICACION Y MODIFICACION DE EPITOPOS INMUNODOMINANTES EN POLIPEPTIDOS.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 254729,
	"label": "TUMOUR NECROSIS FACTOR ASSOCIATED FACTOR (TRAF) INHIBITORS INCLUDING TRAF POLYPEPTIDE, MURINE NUCLEOTIDE SEQUENCE AND ASSOCIATED ASSAYS",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 254729,
	"label": "TUMOUR NECROSIS FACTOR ASSOCIATED FACTOR (TRAF) INHIBITORS INCLUDING TRAF POLYPEPTIDE, MURINE NUCLEOTIDE SEQUENCE AND ASSOCIATED ASSAYS",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 254729,
	"label": "TUMOUR NECROSIS FACTOR ASSOCIATED FACTOR (TRAF) INHIBITORS INCLUDING TRAF POLYPEPTIDE, MURINE NUCLEOTIDE SEQUENCE AND ASSOCIATED ASSAYS",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 254729,
	"label": "TUMOUR NECROSIS FACTOR ASSOCIATED FACTOR (TRAF) INHIBITORS INCLUDING TRAF POLYPEPTIDE, MURINE NUCLEOTIDE SEQUENCE AND ASSOCIATED ASSAYS",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 254729,
	"label": "TUMOUR NECROSIS FACTOR ASSOCIATED FACTOR (TRAF) INHIBITORS INCLUDING TRAF POLYPEPTIDE, MURINE NUCLEOTIDE SEQUENCE AND ASSOCIATED ASSAYS",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 255004,
	"label": "P300 TRANSGENIC ANIMAL",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 257470,
	"label": "NON-HUMAN MAMMALS LACKING EXPRESSION OF OSTEOPROTEGERIN",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 257470,
	"label": "NON-HUMAN MAMMALS LACKING EXPRESSION OF OSTEOPROTEGERIN",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 257470,
	"label": "NON-HUMAN MAMMALS LACKING EXPRESSION OF OSTEOPROTEGERIN",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 257595,
	"label": "Cell surface glycoproteins associated with human BCell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides       cell lymphomas - ULBP, DNA and polypeptides",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 257595,
	"label": "Cell surface glycoproteins associated with human BCell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides       cell lymphomas - ULBP, DNA and polypeptides",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 257595,
	"label": "Cell surface glycoproteins associated with human BCell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides       cell lymphomas - ULBP, DNA and polypeptides",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6812,
	"type": 257595,
	"label": "Cell surface glycoproteins associated with human BCell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides       cell lymphomas - ULBP, DNA and polypeptides",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6812,
	"type": 257595,
	"label": "Cell surface glycoproteins associated with human BCell surface glycoproteins associated with human B cell lymphomas - ULBP, DNA and polypeptides       cell lymphomas - ULBP, DNA and polypeptides",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 258042,
	"label": "ANTICUERPOS MONOCLONALES COMPLETAMENTE HUMANOS PARA IL-13.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6360,
	"type": 258109,
	"label": "Inhibidores de quinoxalina de la vía de señalización hedgehog",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 258247,
	"label": "Antibody fragment comprising a linear heavy chain associated with two light chain fragments",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32772,
	"type": 258247,
	"label": "Antibody fragment comprising a linear heavy chain associated with two light chain fragments",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 32772,
	"type": 258247,
	"label": "Antibody fragment comprising a linear heavy chain associated with two light chain fragments",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 258960,
	"label": "PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SECONDARY HYPERPARATHYROIDISM AND THERAPEUTIC AGENTS FOR CARDIOVASCULAR COMPLICATIONS RESULTING FROM THE TREATMENT FOR SECONDARY HYPERPARATHYROIDISM.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7450,
	"target": 6854,
	"type": 259300,
	"label": "Antibodies against interleukin-1 &bgr;",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 7450,
	"type": 259300,
	"label": "Antibodies against interleukin-1 &bgr;",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 259300,
	"label": "Antibodies against interleukin-1 &bgr;",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 260333,
	"label": "Method for bisulfite treatment",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 262244,
	"label": "Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 262244,
	"label": "Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 262244,
	"label": "Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 262244,
	"label": "Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 262244,
	"label": "Methods and compositions for recombinantly producing functional antibodies or antibody fragments in prokaryotic and eukaryotic host cells",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 262757,
	"label": "CYCLIN-E2 PROTEINE UND DAFÜR KODIERENDE GENE",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38237,
	"target": 37862,
	"type": 262757,
	"label": "CYCLIN-E2 PROTEINE UND DAFÜR KODIERENDE GENE",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38237,
	"target": 37859,
	"type": 262757,
	"label": "CYCLIN-E2 PROTEINE UND DAFÜR KODIERENDE GENE",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 262757,
	"label": "CYCLIN-E2 PROTEINE UND DAFÜR KODIERENDE GENE",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 56834,
	"target": 37862,
	"type": 262757,
	"label": "CYCLIN-E2 PROTEINE UND DAFÜR KODIERENDE GENE",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 6812,
	"target": 6550,
	"type": 262824,
	"label": "Inhibiting vascularization using antibodies to CXCR4 and SDF-1",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 262824,
	"label": "Inhibiting vascularization using antibodies to CXCR4 and SDF-1",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6550,
	"type": 262824,
	"label": "Inhibiting vascularization using antibodies to CXCR4 and SDF-1",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38065,
	"target": 37875,
	"type": 263576,
	"label": "NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 263604,
	"label": "Antibodies to SARS coronavirus",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7409,
	"type": 263604,
	"label": "Antibodies to SARS coronavirus",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 7409,
	"type": 263604,
	"label": "Antibodies to SARS coronavirus",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 263872,
	"label": "CELL GROWTH REGULATOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 265589,
	"label": "DERIVADOS DE LA CLASE DEL EXTASIS, INMUNOGENOS Y ANTICUERPOS Y SU UTILIZACION PARA DETECTAR FARMACOS DE LA CLASE DEL EXTASIS.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 265625,
	"label": "THERMALLY STABLE Taq POLYMERASE FRAGMENT",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 265625,
	"label": "THERMALLY STABLE Taq POLYMERASE FRAGMENT",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37988,
	"target": 32788,
	"type": 265625,
	"label": "THERMALLY STABLE Taq POLYMERASE FRAGMENT",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 268210,
	"label": "SEQUENTIELLE VERABREICHUNG VON CPT-11 UND APO-2L POLYPEPTID",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 268210,
	"label": "SEQUENTIELLE VERABREICHUNG VON CPT-11 UND APO-2L POLYPEPTID",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 268210,
	"label": "SEQUENTIELLE VERABREICHUNG VON CPT-11 UND APO-2L POLYPEPTID",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 268210,
	"label": "SEQUENTIELLE VERABREICHUNG VON CPT-11 UND APO-2L POLYPEPTID",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6812,
	"type": 268210,
	"label": "SEQUENTIELLE VERABREICHUNG VON CPT-11 UND APO-2L POLYPEPTID",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 272288,
	"label": "RECOMBINANT EXPRESSION OF RUBELLA E1 ENVELOPE PROTEIN VARIANTS AS CHAPERONE FUSION-PROTEINS, THEIR REFOLDING INTO SOLUBLE, NATIVE-LIKE AND IMMUNOREACTIVE ANTIGENIC CONFORMATION AND THEIR USE IN DETECTION OF ANTI-RUBELLA ANTIBODIES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 272288,
	"label": "RECOMBINANT EXPRESSION OF RUBELLA E1 ENVELOPE PROTEIN VARIANTS AS CHAPERONE FUSION-PROTEINS, THEIR REFOLDING INTO SOLUBLE, NATIVE-LIKE AND IMMUNOREACTIVE ANTIGENIC CONFORMATION AND THEIR USE IN DETECTION OF ANTI-RUBELLA ANTIBODIES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 272288,
	"label": "RECOMBINANT EXPRESSION OF RUBELLA E1 ENVELOPE PROTEIN VARIANTS AS CHAPERONE FUSION-PROTEINS, THEIR REFOLDING INTO SOLUBLE, NATIVE-LIKE AND IMMUNOREACTIVE ANTIGENIC CONFORMATION AND THEIR USE IN DETECTION OF ANTI-RUBELLA ANTIBODIES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6407,
	"type": 272612,
	"label": "REGIMEN OF ADMINISTRATION FOR 5-(2-CHLOROPHENYL)-1 ,2-DIHYDRO-7-FLUORO-8-METHOXY-3-METHYL-PYRAZOLO [3, 4.-B] [1, 4] BENZODIAZEPINE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6371,
	"target": 6301,
	"type": 272623,
	"label": "Derivados de tiazolo[4,5-c]piridina como antagonistas de receptor MGLU5",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 272746,
	"label": "MEANS AND METHODS FOR THE TREATMENT OF TUMOROUS DISEASES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 272746,
	"label": "MEANS AND METHODS FOR THE TREATMENT OF TUMOROUS DISEASES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 272746,
	"label": "MEANS AND METHODS FOR THE TREATMENT OF TUMOROUS DISEASES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 6854,
	"type": 272746,
	"label": "MEANS AND METHODS FOR THE TREATMENT OF TUMOROUS DISEASES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 272746,
	"label": "MEANS AND METHODS FOR THE TREATMENT OF TUMOROUS DISEASES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 272962,
	"label": "COMPUESTOS DE 2 AMIDO-4-ISOXANOLYL THIAZOLE MOSTRANDO ATP- UTILIZANDO ACTIVIDAD DE UNA ENZIMA INHIBITORIA, COMPOSICIONES Y USOS DE ESO",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 272962,
	"label": "COMPUESTOS DE 2 AMIDO-4-ISOXANOLYL THIAZOLE MOSTRANDO ATP- UTILIZANDO ACTIVIDAD DE UNA ENZIMA INHIBITORIA, COMPOSICIONES Y USOS DE ESO",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 6290,
	"type": 272962,
	"label": "COMPUESTOS DE 2 AMIDO-4-ISOXANOLYL THIAZOLE MOSTRANDO ATP- UTILIZANDO ACTIVIDAD DE UNA ENZIMA INHIBITORIA, COMPOSICIONES Y USOS DE ESO",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7508,
	"type": 272962,
	"label": "COMPUESTOS DE 2 AMIDO-4-ISOXANOLYL THIAZOLE MOSTRANDO ATP- UTILIZANDO ACTIVIDAD DE UNA ENZIMA INHIBITORIA, COMPOSICIONES Y USOS DE ESO",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 272962,
	"label": "COMPUESTOS DE 2 AMIDO-4-ISOXANOLYL THIAZOLE MOSTRANDO ATP- UTILIZANDO ACTIVIDAD DE UNA ENZIMA INHIBITORIA, COMPOSICIONES Y USOS DE ESO",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 37947,
	"type": 273235,
	"label": "método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37947,
	"target": 7507,
	"type": 273235,
	"label": "método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 273235,
	"label": "método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 273576,
	"label": "DERIVADOS DE VITAMINA D QUE POSEEN UN ATOMO 22-OXA O 22-TIA, UNA CADENA LATERAL C17 SUSTITUIDA CON UN GRUPO ACIDO, ESTER O AMIDA Y UN ENLACE DOBLE 16(17).",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 273767,
	"label": "Agonistas del receptor del neuropéptido-2",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 273990,
	"label": "STABLE AQUEOUS PROTEIN OR ANTIBODY PHARMACEUTICAL FORMULATIONS AND THEIR PREPARATION",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 274571,
	"label": "THERAPEUTIC ANTI-HER2 ANTIBODY FUSION POLYPEPTIDES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32772,
	"type": 274571,
	"label": "THERAPEUTIC ANTI-HER2 ANTIBODY FUSION POLYPEPTIDES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32771,
	"type": 274571,
	"label": "THERAPEUTIC ANTI-HER2 ANTIBODY FUSION POLYPEPTIDES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 274571,
	"label": "THERAPEUTIC ANTI-HER2 ANTIBODY FUSION POLYPEPTIDES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32772,
	"type": 274571,
	"label": "THERAPEUTIC ANTI-HER2 ANTIBODY FUSION POLYPEPTIDES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 6539,
	"type": 274572,
	"label": "Method for Diagnosing, Prognosing and Treating Glioma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 275177,
	"label": "DERIVADOS DE ESPIROINDOLINONA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 275177,
	"label": "DERIVADOS DE ESPIROINDOLINONA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 6303,
	"type": 275177,
	"label": "DERIVADOS DE ESPIROINDOLINONA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 276097,
	"label": "compostos, processo para a sua manufatura, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de hm74a e usos dos compostos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 277031,
	"label": "Alkyl amines improve detection of components of formaldehyde-fixed biological samples",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 277034,
	"label": "COMPOSITION OF LABELED AND NON-LABELED MONOCLONAL ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 277074,
	"label": "Agentes de unión biespecíficos específicos de especies cruzadas",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 277074,
	"label": "Agentes de unión biespecíficos específicos de especies cruzadas",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 277074,
	"label": "Agentes de unión biespecíficos específicos de especies cruzadas",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32777,
	"type": 277074,
	"label": "Agentes de unión biespecíficos específicos de especies cruzadas",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 277074,
	"label": "Agentes de unión biespecíficos específicos de especies cruzadas",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 277506,
	"label": "PROCEDIMIENTO PARA LA RECUPERACION FACILITADA DE PROTEINAS HETEROLOGAS A PARTIR DE CELULAS BACTERIANAS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 277506,
	"label": "PROCEDIMIENTO PARA LA RECUPERACION FACILITADA DE PROTEINAS HETEROLOGAS A PARTIR DE CELULAS BACTERIANAS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 277506,
	"label": "PROCEDIMIENTO PARA LA RECUPERACION FACILITADA DE PROTEINAS HETEROLOGAS A PARTIR DE CELULAS BACTERIANAS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 277506,
	"label": "PROCEDIMIENTO PARA LA RECUPERACION FACILITADA DE PROTEINAS HETEROLOGAS A PARTIR DE CELULAS BACTERIANAS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 277506,
	"label": "PROCEDIMIENTO PARA LA RECUPERACION FACILITADA DE PROTEINAS HETEROLOGAS A PARTIR DE CELULAS BACTERIANAS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 278970,
	"label": "22-THIAVITAMIN D<SB>3</SB> DERIVATIVES, METHOD OF PREPARATION THEREOF, METHOD FOR PREPARATION OF COMPOUNDS, AND COMPOUNDS",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 278970,
	"label": "22-THIAVITAMIN D<SB>3</SB> DERIVATIVES, METHOD OF PREPARATION THEREOF, METHOD FOR PREPARATION OF COMPOUNDS, AND COMPOUNDS",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 278970,
	"label": "22-THIAVITAMIN D<SB>3</SB> DERIVATIVES, METHOD OF PREPARATION THEREOF, METHOD FOR PREPARATION OF COMPOUNDS, AND COMPOUNDS",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 278971,
	"label": "A HEPATOMA TRANSMEMBRANE KINASE (Htk) LIGAND, COMPOSITIONS COMPRISING THE SAME, NUCLEIC ACID MOLECULES ENCODING SUCH LIGANDS, VECTORS COMPRISING SUCH NUCLEIC ACID MOLECULES, HOST CELLS COMPRISING SUCH VECTORS, A METHOD FOR PREPARATION OF SUCH LIGAND AND USE THEREOF IN PREPARATION OF A MEDICAMENT AND AS A MEDICAMENT FOR ACTIVATING Htk RECEPTOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 56836,
	"target": 38181,
	"type": 278971,
	"label": "A HEPATOMA TRANSMEMBRANE KINASE (Htk) LIGAND, COMPOSITIONS COMPRISING THE SAME, NUCLEIC ACID MOLECULES ENCODING SUCH LIGANDS, VECTORS COMPRISING SUCH NUCLEIC ACID MOLECULES, HOST CELLS COMPRISING SUCH VECTORS, A METHOD FOR PREPARATION OF SUCH LIGAND AND USE THEREOF IN PREPARATION OF A MEDICAMENT AND AS A MEDICAMENT FOR ACTIVATING Htk RECEPTOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 278971,
	"label": "A HEPATOMA TRANSMEMBRANE KINASE (Htk) LIGAND, COMPOSITIONS COMPRISING THE SAME, NUCLEIC ACID MOLECULES ENCODING SUCH LIGANDS, VECTORS COMPRISING SUCH NUCLEIC ACID MOLECULES, HOST CELLS COMPRISING SUCH VECTORS, A METHOD FOR PREPARATION OF SUCH LIGAND AND USE THEREOF IN PREPARATION OF A MEDICAMENT AND AS A MEDICAMENT FOR ACTIVATING Htk RECEPTOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 278971,
	"label": "A HEPATOMA TRANSMEMBRANE KINASE (Htk) LIGAND, COMPOSITIONS COMPRISING THE SAME, NUCLEIC ACID MOLECULES ENCODING SUCH LIGANDS, VECTORS COMPRISING SUCH NUCLEIC ACID MOLECULES, HOST CELLS COMPRISING SUCH VECTORS, A METHOD FOR PREPARATION OF SUCH LIGAND AND USE THEREOF IN PREPARATION OF A MEDICAMENT AND AS A MEDICAMENT FOR ACTIVATING Htk RECEPTOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 278971,
	"label": "A HEPATOMA TRANSMEMBRANE KINASE (Htk) LIGAND, COMPOSITIONS COMPRISING THE SAME, NUCLEIC ACID MOLECULES ENCODING SUCH LIGANDS, VECTORS COMPRISING SUCH NUCLEIC ACID MOLECULES, HOST CELLS COMPRISING SUCH VECTORS, A METHOD FOR PREPARATION OF SUCH LIGAND AND USE THEREOF IN PREPARATION OF A MEDICAMENT AND AS A MEDICAMENT FOR ACTIVATING Htk RECEPTOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 278978,
	"label": "PROTEINA ACCESORIA HUMANA PARA RECEPTORES DE LA INTERLEUCINA 1",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 278978,
	"label": "PROTEINA ACCESORIA HUMANA PARA RECEPTORES DE LA INTERLEUCINA 1",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 278978,
	"label": "PROTEINA ACCESORIA HUMANA PARA RECEPTORES DE LA INTERLEUCINA 1",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 279051,
	"label": "Nucleic acids encoding cytokine-like proteins that promote cell proliferation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37999,
	"type": 279051,
	"label": "Nucleic acids encoding cytokine-like proteins that promote cell proliferation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37999,
	"target": 32698,
	"type": 279051,
	"label": "Nucleic acids encoding cytokine-like proteins that promote cell proliferation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37999,
	"target": 32694,
	"type": 279051,
	"label": "Nucleic acids encoding cytokine-like proteins that promote cell proliferation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 32698,
	"type": 279051,
	"label": "Nucleic acids encoding cytokine-like proteins that promote cell proliferation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 279988,
	"label": "Methods of treating inflammatory diseases",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 280169,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32694,
	"target": 6812,
	"type": 280169,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 6812,
	"type": 280169,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 280540,
	"label": "DIAGNOSTIC TEST FOR SUSCEPTIBILITY TO B-RAF KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38237,
	"target": 7507,
	"type": 280540,
	"label": "DIAGNOSTIC TEST FOR SUSCEPTIBILITY TO B-RAF KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 280540,
	"label": "DIAGNOSTIC TEST FOR SUSCEPTIBILITY TO B-RAF KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 281866,
	"label": "Péptidos que contienen arginina C-terminal biológicamente activos",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 6913,
	"type": 281923,
	"label": "COMPOSITIONS AND METHODS FOR TREATING COAGULATION RELATED DISORDERS.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 32694,
	"type": 282457,
	"label": "PROCEDIMIENTO PARA LA CORRECCION DE UNA FALTA DE ENLACES DISULFURO EN MOLECULAS FC.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 282457,
	"label": "PROCEDIMIENTO PARA LA CORRECCION DE UNA FALTA DE ENLACES DISULFURO EN MOLECULAS FC.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 282457,
	"label": "PROCEDIMIENTO PARA LA CORRECCION DE UNA FALTA DE ENLACES DISULFURO EN MOLECULAS FC.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32694,
	"target": 7450,
	"type": 282457,
	"label": "PROCEDIMIENTO PARA LA CORRECCION DE UNA FALTA DE ENLACES DISULFURO EN MOLECULAS FC.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32788,
	"target": 7450,
	"type": 282457,
	"label": "PROCEDIMIENTO PARA LA CORRECCION DE UNA FALTA DE ENLACES DISULFURO EN MOLECULAS FC.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 283096,
	"label": "PRODUKTION VON IGM DURCH TRANSFORMIERTE ZELLEN UND VERFAHREN ZUR QUANTIFIZIERUNG DIESER IGM- PRODUKTION",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 283319,
	"label": "SPECIFIC AND SENSITIVE METHOD FOR DETECTING NUCLEIC ACIDS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 39999,
	"target": 38164,
	"type": 283319,
	"label": "SPECIFIC AND SENSITIVE METHOD FOR DETECTING NUCLEIC ACIDS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 283319,
	"label": "SPECIFIC AND SENSITIVE METHOD FOR DETECTING NUCLEIC ACIDS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 283319,
	"label": "SPECIFIC AND SENSITIVE METHOD FOR DETECTING NUCLEIC ACIDS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 283319,
	"label": "SPECIFIC AND SENSITIVE METHOD FOR DETECTING NUCLEIC ACIDS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 283326,
	"label": "An isolated DNA sequence coding for an enzyme involved in the mevalonate pathway or the pathway from isopentenyl pyrophosphate to farnesyl pyrophosphate",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 283368,
	"label": "Methods for detecting expression of human protease molecules",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37947,
	"target": 37864,
	"type": 283368,
	"label": "Methods for detecting expression of human protease molecules",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 283368,
	"label": "Methods for detecting expression of human protease molecules",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 283368,
	"label": "Methods for detecting expression of human protease molecules",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 283368,
	"label": "Methods for detecting expression of human protease molecules",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38065,
	"target": 37988,
	"type": 284124,
	"label": "EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN .BETA.-ACTIN PROMOTER",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 284124,
	"label": "EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN .BETA.-ACTIN PROMOTER",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37988,
	"type": 284124,
	"label": "EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN .BETA.-ACTIN PROMOTER",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37988,
	"target": 32754,
	"type": 284124,
	"label": "EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN .BETA.-ACTIN PROMOTER",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38065,
	"target": 32754,
	"type": 284124,
	"label": "EXPRESSION SYSTEM WITH THE USE OF MAMMALIAN .BETA.-ACTIN PROMOTER",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 284125,
	"label": "MODIFIED ANTIBODIES RECOGNISING RECEPTOR TRIMERS OR HIGHER MULTIMERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37875,
	"target": 37859,
	"type": 284125,
	"label": "MODIFIED ANTIBODIES RECOGNISING RECEPTOR TRIMERS OR HIGHER MULTIMERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37875,
	"type": 284125,
	"label": "MODIFIED ANTIBODIES RECOGNISING RECEPTOR TRIMERS OR HIGHER MULTIMERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37859,
	"type": 284125,
	"label": "MODIFIED ANTIBODIES RECOGNISING RECEPTOR TRIMERS OR HIGHER MULTIMERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37859,
	"target": 32771,
	"type": 284125,
	"label": "MODIFIED ANTIBODIES RECOGNISING RECEPTOR TRIMERS OR HIGHER MULTIMERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37900,
	"target": 32771,
	"type": 284236,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 37900,
	"type": 284236,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 284236,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 284707,
	"label": "VERWENDUNGEN ZUR BEHANDLUNG VON FSH-VERBUNDENEN ZUSTÄNDEN MIT GNRH ANTAGONISTEN",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6421,
	"type": 284707,
	"label": "VERWENDUNGEN ZUR BEHANDLUNG VON FSH-VERBUNDENEN ZUSTÄNDEN MIT GNRH ANTAGONISTEN",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7508,
	"target": 6421,
	"type": 284707,
	"label": "VERWENDUNGEN ZUR BEHANDLUNG VON FSH-VERBUNDENEN ZUSTÄNDEN MIT GNRH ANTAGONISTEN",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 284783,
	"label": "POLIPEPTIDOS RELACIONADOS CON WNT-1, Y ACIDOS NUCLEICOS QUE LOS CODIFICAN.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 284783,
	"label": "POLIPEPTIDOS RELACIONADOS CON WNT-1, Y ACIDOS NUCLEICOS QUE LOS CODIFICAN.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 284783,
	"label": "POLIPEPTIDOS RELACIONADOS CON WNT-1, Y ACIDOS NUCLEICOS QUE LOS CODIFICAN.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 284783,
	"label": "POLIPEPTIDOS RELACIONADOS CON WNT-1, Y ACIDOS NUCLEICOS QUE LOS CODIFICAN.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 284783,
	"label": "POLIPEPTIDOS RELACIONADOS CON WNT-1, Y ACIDOS NUCLEICOS QUE LOS CODIFICAN.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 56804,
	"type": 285639,
	"label": "METHOD OF QUANTIFYING ANTIGEN EXPRESSION",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6301,
	"target": 6290,
	"type": 285719,
	"label": "N - SUBSTITUTED PYRROLIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF IN THE PREPARATION OF MEDICAMENTS FOR THE TREATMENT AND PROPHYLAXIS OF DIPEPTIDYL PEPTIDASE IV -ASSOCIATED DISEASES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37900,
	"type": 286151,
	"label": "FÜR HUMANE MATRIPTASE SPEZIFISCHE BINDUNGSPROTEINE",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7509,
	"target": 6957,
	"type": 286151,
	"label": "FÜR HUMANE MATRIPTASE SPEZIFISCHE BINDUNGSPROTEINE",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37900,
	"target": 7509,
	"type": 286151,
	"label": "FÜR HUMANE MATRIPTASE SPEZIFISCHE BINDUNGSPROTEINE",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 7509,
	"type": 286151,
	"label": "FÜR HUMANE MATRIPTASE SPEZIFISCHE BINDUNGSPROTEINE",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37900,
	"target": 6957,
	"type": 286151,
	"label": "FÜR HUMANE MATRIPTASE SPEZIFISCHE BINDUNGSPROTEINE",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 6795,
	"target": 6483,
	"type": 286573,
	"label": "METHODS OF USING HEDGEHOG KINASE ANTAGONISTS TO INHIBIT HEDGEHOG SIGNALING AND TO TREAT HEDGEHOG MEDIATED DISORDERS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 286573,
	"label": "METHODS OF USING HEDGEHOG KINASE ANTAGONISTS TO INHIBIT HEDGEHOG SIGNALING AND TO TREAT HEDGEHOG MEDIATED DISORDERS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 286573,
	"label": "METHODS OF USING HEDGEHOG KINASE ANTAGONISTS TO INHIBIT HEDGEHOG SIGNALING AND TO TREAT HEDGEHOG MEDIATED DISORDERS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 286573,
	"label": "METHODS OF USING HEDGEHOG KINASE ANTAGONISTS TO INHIBIT HEDGEHOG SIGNALING AND TO TREAT HEDGEHOG MEDIATED DISORDERS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 286573,
	"label": "METHODS OF USING HEDGEHOG KINASE ANTAGONISTS TO INHIBIT HEDGEHOG SIGNALING AND TO TREAT HEDGEHOG MEDIATED DISORDERS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38042,
	"target": 32772,
	"type": 288073,
	"label": "anticorpos, método de seleção de um anticorpo de hvegf, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de um anticorpo, método de uso do anticorpo e método de tratamento de um mamìfero",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 289649,
	"label": "NEUE SERINPROTEASEN DER TRYPSIN-FAMILIE",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38232,
	"target": 38184,
	"type": 289649,
	"label": "NEUE SERINPROTEASEN DER TRYPSIN-FAMILIE",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37947,
	"type": 289649,
	"label": "NEUE SERINPROTEASEN DER TRYPSIN-FAMILIE",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 289649,
	"label": "NEUE SERINPROTEASEN DER TRYPSIN-FAMILIE",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38232,
	"target": 37947,
	"type": 289649,
	"label": "NEUE SERINPROTEASEN DER TRYPSIN-FAMILIE",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 289990,
	"label": "Detection, identification and differentiation of Serratia species using the spacer region",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 290350,
	"label": "Oligonucleotides for genotyping thymidylate synthase gene",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 290406,
	"label": "Verfahren zur Erhöhung der Löslichkeit, der Expressionsrate und der Aktivität von Proteinen während der rekombinanten Herstellung",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 290406,
	"label": "Verfahren zur Erhöhung der Löslichkeit, der Expressionsrate und der Aktivität von Proteinen während der rekombinanten Herstellung",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 290406,
	"label": "Verfahren zur Erhöhung der Löslichkeit, der Expressionsrate und der Aktivität von Proteinen während der rekombinanten Herstellung",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7423,
	"target": 7409,
	"type": 290495,
	"label": "COMPUESTOS DERIVADOS DE AMINO-TETRALINA, SU USO, UN PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 290812,
	"label": "derivados de aril-isoxazol-4-il-imidazo [1,2-a] piridina úteis para o tratamento de doença de alzheimer por intermédio de receptores gaba",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 30816,
	"type": 291332,
	"label": "derivados de fenil metanona e o uso dos mesmos como inibidores do transportador de glicina 1",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 30816,
	"target": 6376,
	"type": 291332,
	"label": "derivados de fenil metanona e o uso dos mesmos como inibidores do transportador de glicina 1",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 291332,
	"label": "derivados de fenil metanona e o uso dos mesmos como inibidores do transportador de glicina 1",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 292253,
	"label": "COMPUESTOS Y METODOS PARA LA INHIBICION DE LA PROTEIN-CINASA RAF",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6854,
	"target": 6812,
	"type": 292302,
	"label": "anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 6854,
	"type": 292302,
	"label": "anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 6812,
	"type": 292302,
	"label": "anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 293144,
	"label": "N-terminally chemically modified G-CSF and analogs process for their preparation and pharmaceutical compositions containing them",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 293621,
	"label": "PYRIMIDINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 293622,
	"label": "Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 293622,
	"label": "Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 293622,
	"label": "Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 294329,
	"label": "EGFR AND KRAS MUTATIONS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 294788,
	"label": "FORMULACION DE UN ANTICUERPO MONOCLONAL HUMANO ANTI-IGF-1R",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 294942,
	"label": "GEGEN DEN TUMOR NEKROSE FAKTOR GERICHTETE ANTIKÖRPER UND DEREN VERWENDUNGEN",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 294980,
	"label": "Optimised protein synthesis",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 294980,
	"label": "Optimised protein synthesis",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 294980,
	"label": "Optimised protein synthesis",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 295165,
	"label": "INHIBITOREN FÜR DEN UROKINASEREZEPTOR",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7450,
	"target": 6795,
	"type": 295165,
	"label": "INHIBITOREN FÜR DEN UROKINASEREZEPTOR",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 295165,
	"label": "INHIBITOREN FÜR DEN UROKINASEREZEPTOR",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 295204,
	"label": "PROCEDIMIENTO PARA LA PRODUCCION DE MUTEíNAS DE POLIPÉPTIDOS EUCARIoTICOS, PROCEDIMIENTO PARA LA PRODUCCIoN DE UNA CÉLULA HUMANA, QUE NO DE LUGAR A UN INIDIVIDUO COMPLETO, QUE EXPRESA UNA MUTEíNA DE UN POLIPÉPTIDO BLANCO HUMANO, CÉLULA HUMANA OBTENIBLE MEDIANTE DICHO PROCESO Y USO DE DICHA CÉLULA HU",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 295204,
	"label": "PROCEDIMIENTO PARA LA PRODUCCION DE MUTEíNAS DE POLIPÉPTIDOS EUCARIoTICOS, PROCEDIMIENTO PARA LA PRODUCCIoN DE UNA CÉLULA HUMANA, QUE NO DE LUGAR A UN INIDIVIDUO COMPLETO, QUE EXPRESA UNA MUTEíNA DE UN POLIPÉPTIDO BLANCO HUMANO, CÉLULA HUMANA OBTENIBLE MEDIANTE DICHO PROCESO Y USO DE DICHA CÉLULA HU",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 295204,
	"label": "PROCEDIMIENTO PARA LA PRODUCCION DE MUTEíNAS DE POLIPÉPTIDOS EUCARIoTICOS, PROCEDIMIENTO PARA LA PRODUCCIoN DE UNA CÉLULA HUMANA, QUE NO DE LUGAR A UN INIDIVIDUO COMPLETO, QUE EXPRESA UNA MUTEíNA DE UN POLIPÉPTIDO BLANCO HUMANO, CÉLULA HUMANA OBTENIBLE MEDIANTE DICHO PROCESO Y USO DE DICHA CÉLULA HU",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 295288,
	"label": "Bacterial strains which overproduce riboflavin and methods of use thereof",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 295856,
	"label": "anticorpos monoclonal, imuniconjugados e composição farmacêutica",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 295856,
	"label": "anticorpos monoclonal, imuniconjugados e composição farmacêutica",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 295856,
	"label": "anticorpos monoclonal, imuniconjugados e composição farmacêutica",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 296281,
	"label": "PROPHYLAKTISCHE ODER THERAPEUTISCHE MITTEL GEGEN ENTZÜNDLICHE ERKRANKUNGEN DES VERDAUUNGSTRAKTES ENTHALTEND ANTAGONISTISCHE IL-6 REZEPTOR ANTIKÖRPER",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 297182,
	"label": "ANTI-PCI NEUTRALIZING ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 7487,
	"type": 297182,
	"label": "ANTI-PCI NEUTRALIZING ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 7487,
	"type": 297182,
	"label": "ANTI-PCI NEUTRALIZING ANTIBODIES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 299588,
	"label": "ADSORCION DE ACIDOS NUCLEICOS EN UNA FASE SOLIDA.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 299652,
	"label": "IMPROVED FRET METHOD",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 300118,
	"label": "ENZIMA TERMOESTAVEL PURIFICADA,CODIFICACAO DE GENE DE ENZIMA,PLASMIDIO SELECIONADO,BACTEREOFOGO,COMPOSICAO DE ENZIMA ESTAVEL,PROCESSO PARA AMPLIFICAR PELO MENOS UMA SEQUENCIA ESPECIFICA DE ACIDO NUCLEICO,PROCESSO PARA DETECTAR PRESENCA OU AUSENCIA DE PELO MENOS UMA SEQUENCIA ESPECIFICA DE ACIDO NUCLEICO,PROCESSO PARA DETECTAR PRESENCA OU AUSENCIA DE PELO MENOS UMA VARIACAO DE NUCLEOTIDEOS EM SEQUENCIA EM UM OU MAIS ACIDOS NUCLEICOS,PROCESSO PARA CLONAGEM EM VETOR DE CLONAGEM DE UMA OU MAIS SEQUE",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32501,
	"target": 6417,
	"type": 304290,
	"label": "3-OXO-D-HOMO-21,24-DINOR-17AALPHA-CHOL-4-ENE-23,17A LACTONE DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1974,
	"strength": 1
}, {
	"source": 7510,
	"target": 7358,
	"type": 306757,
	"label": "VERFAHREN ZUR BEHANDLUNG VON PARASITÄREN INFEKTIONEN UNTER VERWENDUNG VON IGE-ANTAGONISTEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7358,
	"target": 6795,
	"type": 306757,
	"label": "VERFAHREN ZUR BEHANDLUNG VON PARASITÄREN INFEKTIONEN UNTER VERWENDUNG VON IGE-ANTAGONISTEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 306757,
	"label": "VERFAHREN ZUR BEHANDLUNG VON PARASITÄREN INFEKTIONEN UNTER VERWENDUNG VON IGE-ANTAGONISTEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32777,
	"target": 7510,
	"type": 306757,
	"label": "VERFAHREN ZUR BEHANDLUNG VON PARASITÄREN INFEKTIONEN UNTER VERWENDUNG VON IGE-ANTAGONISTEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32777,
	"target": 7358,
	"type": 306757,
	"label": "VERFAHREN ZUR BEHANDLUNG VON PARASITÄREN INFEKTIONEN UNTER VERWENDUNG VON IGE-ANTAGONISTEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 31912,
	"target": 6352,
	"type": 307101,
	"label": "VERFAHREN ZUR HERSTELLUNG VON NEUEN INDOLO(2,3-C)CHINOLINEN, DEREN N-OXIDEN UND SALZEN SOWIE VON OPTISCHEN ISOMEREN DAVON",
	"group": "Roche",
	"time": 1973,
	"strength": 1
}, {
	"source": 28540,
	"target": 28268,
	"type": 307303,
	"label": "1,2,3,4,5,6-HEXAHYDRO-8-HYDROXY-3-BENZAZOCINE DERIVATIVES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1973,
	"strength": 1
}, {
	"source": 32501,
	"target": 6582,
	"type": 307420,
	"label": "STEROIDS OF THE D-HOMO-PREGNANE SERIES,THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1975,
	"strength": 1
}, {
	"source": 6892,
	"target": 6854,
	"type": 308843,
	"label": "Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6892,
	"type": 308843,
	"label": "Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 308843,
	"label": "Vaccines comprising HIV gp120 envelope polypeptides from vaccinees vaccinated with an earlier HIV gp120 vaccine and subsequently infected with HIV",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32501,
	"target": 6417,
	"type": 310652,
	"label": "D-HOMOANDROSTA-17A -CARBOXYLIC ACIDS ESTERS THEREOF THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 312043,
	"label": "Monoklonalt antistoff som binder til cytotoksisk T-lymfocytt antigen 4 (CTLA-4) eller et antigen-bindende fragment derav, fremgangsmate for fremstilling derav, farmasoytisk sammensetning inneholdende slike, cellelinje som danner antistoffet eller fragmentet, isolert nukleinsyre som koder for dette, vertscelle omfattende den isolerte nukleinsyre samt anvendelse derav",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 312043,
	"label": "Monoklonalt antistoff som binder til cytotoksisk T-lymfocytt antigen 4 (CTLA-4) eller et antigen-bindende fragment derav, fremgangsmate for fremstilling derav, farmasoytisk sammensetning inneholdende slike, cellelinje som danner antistoffet eller fragmentet, isolert nukleinsyre som koder for dette, vertscelle omfattende den isolerte nukleinsyre samt anvendelse derav",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 312043,
	"label": "Monoklonalt antistoff som binder til cytotoksisk T-lymfocytt antigen 4 (CTLA-4) eller et antigen-bindende fragment derav, fremgangsmate for fremstilling derav, farmasoytisk sammensetning inneholdende slike, cellelinje som danner antistoffet eller fragmentet, isolert nukleinsyre som koder for dette, vertscelle omfattende den isolerte nukleinsyre samt anvendelse derav",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 312043,
	"label": "Monoklonalt antistoff som binder til cytotoksisk T-lymfocytt antigen 4 (CTLA-4) eller et antigen-bindende fragment derav, fremgangsmate for fremstilling derav, farmasoytisk sammensetning inneholdende slike, cellelinje som danner antistoffet eller fragmentet, isolert nukleinsyre som koder for dette, vertscelle omfattende den isolerte nukleinsyre samt anvendelse derav",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 312043,
	"label": "Monoklonalt antistoff som binder til cytotoksisk T-lymfocytt antigen 4 (CTLA-4) eller et antigen-bindende fragment derav, fremgangsmate for fremstilling derav, farmasoytisk sammensetning inneholdende slike, cellelinje som danner antistoffet eller fragmentet, isolert nukleinsyre som koder for dette, vertscelle omfattende den isolerte nukleinsyre samt anvendelse derav",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 31995,
	"target": 6427,
	"type": 313173,
	"label": "New 2,4-diamino-3,6-dihydro-1,3,5-triazine derivatives, useful for treating disorders associated with insulin resistance syndrome, e.g. diabetes, dislipidemia, obesity or arterial hypertension",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 314245,
	"label": "PROTEINAS DE LA ENVOLTURA DE HCV GLICOSILADAS EN LA ESTRUCTURA CENTRAL, UN METODO PARA PRODUCIR LA PROTEINA DE ENVOLTURA DE HCV AISLADA, UNA COMPOSICION QUE LA COMPRENDE, METODO PARA DETECTAR LA PRESENCIA DE ANTICUERPOS ANTI-HCV EN UNA MUESTRA, UN KIT DE DIAGNOSTICO PARA DETECTAR LA PRESENCIA DE ANT",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 314245,
	"label": "PROTEINAS DE LA ENVOLTURA DE HCV GLICOSILADAS EN LA ESTRUCTURA CENTRAL, UN METODO PARA PRODUCIR LA PROTEINA DE ENVOLTURA DE HCV AISLADA, UNA COMPOSICION QUE LA COMPRENDE, METODO PARA DETECTAR LA PRESENCIA DE ANTICUERPOS ANTI-HCV EN UNA MUESTRA, UN KIT DE DIAGNOSTICO PARA DETECTAR LA PRESENCIA DE ANT",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 314245,
	"label": "PROTEINAS DE LA ENVOLTURA DE HCV GLICOSILADAS EN LA ESTRUCTURA CENTRAL, UN METODO PARA PRODUCIR LA PROTEINA DE ENVOLTURA DE HCV AISLADA, UNA COMPOSICION QUE LA COMPRENDE, METODO PARA DETECTAR LA PRESENCIA DE ANTICUERPOS ANTI-HCV EN UNA MUESTRA, UN KIT DE DIAGNOSTICO PARA DETECTAR LA PRESENCIA DE ANT",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 315174,
	"label": "Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 315174,
	"label": "Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 315174,
	"label": "Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 315174,
	"label": "Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 315174,
	"label": "Anticorpos para o cd40, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento, linhagem, de célula isolada, molécula de ácido nucléico isolada, vetor compreendendo a mesma, célula hospedeira e método de fabricação dos referidos anticorpos",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 317337,
	"label": "anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 317337,
	"label": "anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 317337,
	"label": "anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 317337,
	"label": "anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 317337,
	"label": "anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 317430,
	"label": "Methods of treating arthritic conditions with antibodies to M-CSF",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 318086,
	"label": "A WALK-THROUGH TECHNIQUE FOR i IN VITRO /i RECOMBINATION OF POLYNUCLEOTIDE SEQUENCES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 318948,
	"label": "COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 37947,
	"type": 320808,
	"label": "método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32004,
	"target": 7507,
	"type": 321275,
	"label": "DERIVATIVES OF CAMPTOTHECIN, PROCESS OF THEIR PREPARATION INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS IN WHICH THEY ARE COMPRISED",
	"group": "Gilead",
	"time": 1992,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 321864,
	"label": "método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 321864,
	"label": "método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7511,
	"target": 6812,
	"type": 321864,
	"label": "método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 321864,
	"label": "método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 321864,
	"label": "método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7425,
	"target": 7358,
	"type": 322772,
	"label": "derivados de indol-3-il-carbonil-espiro-piperidina",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7358,
	"target": 6303,
	"type": 322772,
	"label": "derivados de indol-3-il-carbonil-espiro-piperidina",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7425,
	"target": 6303,
	"type": 322772,
	"label": "derivados de indol-3-il-carbonil-espiro-piperidina",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 322785,
	"label": "Host cells comprising alpha 1,2 mannosidase and culture methods thereof",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 324325,
	"label": "Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 325388,
	"label": "UN COMPUESTO DERIVADO DE 5'-DESOXICITIDINA, SU USO, UN PROCESO PARA FABRICARLO, COMPOSICIONES FARMACEUTICAS QUE LO COMPRENDE, Y UN KIT QUE COMPRENDE DICHA COMPOSICION.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 326146,
	"label": "PROCESS FOR FLUOROCYTIDINE DERIVATIVE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7360,
	"target": 6345,
	"type": 326333,
	"label": "Pyrido[2,1-a]isokinolinderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse i medikamenter samt slike forbindelser for anvendelse i behandling av sykdom",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 326333,
	"label": "Pyrido[2,1-a]isokinolinderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse i medikamenter samt slike forbindelser for anvendelse i behandling av sykdom",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6345,
	"type": 326333,
	"label": "Pyrido[2,1-a]isokinolinderivater, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse i medikamenter samt slike forbindelser for anvendelse i behandling av sykdom",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 327021,
	"label": "DETECTION OF PRIMARY INFECTIONS WITH PATHOGENS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 327021,
	"label": "DETECTION OF PRIMARY INFECTIONS WITH PATHOGENS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 327021,
	"label": "DETECTION OF PRIMARY INFECTIONS WITH PATHOGENS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37862,
	"target": 32788,
	"type": 327021,
	"label": "DETECTION OF PRIMARY INFECTIONS WITH PATHOGENS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 327021,
	"label": "DETECTION OF PRIMARY INFECTIONS WITH PATHOGENS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6489,
	"target": 6483,
	"type": 328023,
	"label": "ANTAGONISTAS ESPECIFICOS DE VEGF PARA TERAPIA ADYUVANTE Y NEOADYUVANTE Y EL TRAMIENTO DE TUMORES NEOADYUVANTE Y EL TRATAMIENTO DE TUMORES EN ESTADIOS TEMPRANOS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6838,
	"target": 6812,
	"type": 328023,
	"label": "ANTAGONISTAS ESPECIFICOS DE VEGF PARA TERAPIA ADYUVANTE Y NEOADYUVANTE Y EL TRAMIENTO DE TUMORES NEOADYUVANTE Y EL TRATAMIENTO DE TUMORES EN ESTADIOS TEMPRANOS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6812,
	"target": 6489,
	"type": 328023,
	"label": "ANTAGONISTAS ESPECIFICOS DE VEGF PARA TERAPIA ADYUVANTE Y NEOADYUVANTE Y EL TRAMIENTO DE TUMORES NEOADYUVANTE Y EL TRATAMIENTO DE TUMORES EN ESTADIOS TEMPRANOS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6812,
	"target": 6483,
	"type": 328023,
	"label": "ANTAGONISTAS ESPECIFICOS DE VEGF PARA TERAPIA ADYUVANTE Y NEOADYUVANTE Y EL TRAMIENTO DE TUMORES NEOADYUVANTE Y EL TRATAMIENTO DE TUMORES EN ESTADIOS TEMPRANOS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6838,
	"target": 6489,
	"type": 328023,
	"label": "ANTAGONISTAS ESPECIFICOS DE VEGF PARA TERAPIA ADYUVANTE Y NEOADYUVANTE Y EL TRAMIENTO DE TUMORES NEOADYUVANTE Y EL TRATAMIENTO DE TUMORES EN ESTADIOS TEMPRANOS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37947,
	"target": 6489,
	"type": 329200,
	"label": "MODULATION OF CYTOKINE PRODUCTION",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 330095,
	"label": "SUBSTITUIERTE PYRIDONVERBINDUNGEN UND ANWENDUNGSVERFAHREN",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7509,
	"type": 330095,
	"label": "SUBSTITUIERTE PYRIDONVERBINDUNGEN UND ANWENDUNGSVERFAHREN",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 330095,
	"label": "SUBSTITUIERTE PYRIDONVERBINDUNGEN UND ANWENDUNGSVERFAHREN",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 330102,
	"label": "Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6360,
	"type": 330103,
	"label": "DERIVADOS DEL ACIDO 1-(1-BENCILPIPERIDIN-4-IL)BENCIMIDAZ0L-5-CARBOXILICO, PARA EL TRATAMIENTO DE LA DIABETES MELLITUS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7479,
	"target": 6280,
	"type": 330105,
	"label": "Novel B1 bradykinin receptor antagonists",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 6302,
	"target": 6301,
	"type": 330118,
	"label": "Heterofused piperidines as orexin antagonists",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 330118,
	"label": "Heterofused piperidines as orexin antagonists",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 330118,
	"label": "Heterofused piperidines as orexin antagonists",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 330594,
	"label": "TSG-LIKE GENE",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 330594,
	"label": "TSG-LIKE GENE",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 330594,
	"label": "TSG-LIKE GENE",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37859,
	"target": 6795,
	"type": 330594,
	"label": "TSG-LIKE GENE",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 330594,
	"label": "TSG-LIKE GENE",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 330876,
	"label": "anticorpo antiglipicano-3, agente anticÂncer compreendendo o mesmo, bem como seu uso e seu processo de produÇço",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 330876,
	"label": "anticorpo antiglipicano-3, agente anticÂncer compreendendo o mesmo, bem como seu uso e seu processo de produÇço",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 330876,
	"label": "anticorpo antiglipicano-3, agente anticÂncer compreendendo o mesmo, bem como seu uso e seu processo de produÇço",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 330876,
	"label": "anticorpo antiglipicano-3, agente anticÂncer compreendendo o mesmo, bem como seu uso e seu processo de produÇço",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 330876,
	"label": "anticorpo antiglipicano-3, agente anticÂncer compreendendo o mesmo, bem como seu uso e seu processo de produÇço",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 330907,
	"label": "anticorpo anti-neuropilina-1 e uso do anticorpo anti-neuropilina-1",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 330907,
	"label": "anticorpo anti-neuropilina-1 e uso do anticorpo anti-neuropilina-1",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 330907,
	"label": "anticorpo anti-neuropilina-1 e uso do anticorpo anti-neuropilina-1",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 331775,
	"label": "polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil)amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 331776,
	"label": "polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende ",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 332477,
	"label": "DERIVADOS DE PIRAZOLO-PIRIMIDINA COMO ANTAGONISTAS DE MGLUR2.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 332484,
	"label": "anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 332484,
	"label": "anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 332484,
	"label": "anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 332484,
	"label": "anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 332484,
	"label": "anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 332496,
	"label": "polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 332496,
	"label": "polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 332496,
	"label": "polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 332496,
	"label": "polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 332496,
	"label": "polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 332631,
	"label": "métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6478,
	"type": 332631,
	"label": "métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 332631,
	"label": "métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7450,
	"type": 332674,
	"label": "tratamento de distúrbios ósseos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6290,
	"type": 333192,
	"label": "DERIVADOS DE HETEROARIL FENILUREA",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 333212,
	"label": "Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7409,
	"target": 6301,
	"type": 333236,
	"label": "DERIVADOS DE PIRAZOLO-PIRIMIDINA, DE PIRAZOLO-PIRIMIDINONA, DE PIRAZOLO-PIRIDINA Y DE PIRAZOLO-PIRAZINA FUSIONADOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA PREPARACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA CINASA P38",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 333236,
	"label": "DERIVADOS DE PIRAZOLO-PIRIMIDINA, DE PIRAZOLO-PIRIMIDINONA, DE PIRAZOLO-PIRIDINA Y DE PIRAZOLO-PIRAZINA FUSIONADOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA PREPARACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA CINASA P38",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 333236,
	"label": "DERIVADOS DE PIRAZOLO-PIRIMIDINA, DE PIRAZOLO-PIRIMIDINONA, DE PIRAZOLO-PIRIDINA Y DE PIRAZOLO-PIRAZINA FUSIONADOS, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA PREPARACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA CINASA P38",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6376,
	"target": 6367,
	"type": 333572,
	"label": "derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2, bem como processo para a preparação, composição farmacêutica e emprego dos mesmos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 333572,
	"label": "derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2, bem como processo para a preparação, composição farmacêutica e emprego dos mesmos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 333572,
	"label": "derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2, bem como processo para a preparação, composição farmacêutica e emprego dos mesmos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32771,
	"type": 334244,
	"label": "moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38042,
	"target": 37993,
	"type": 334244,
	"label": "moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 334244,
	"label": "moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 334244,
	"label": "moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 334244,
	"label": "moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 334287,
	"label": "Method for administration of capecitabine",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37900,
	"target": 37899,
	"type": 334904,
	"label": "UN ANTICUERPO QUE SE FIJA SOBRE LA P-SELECTINA, SU USO, UN METODO PARA SU OBTENCION, UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE, UNA MOLECULA DE ACIDO NUCLEICO, UN VECTOR, Y UNA CELULA HOSPEDANTE Y UN KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 334904,
	"label": "UN ANTICUERPO QUE SE FIJA SOBRE LA P-SELECTINA, SU USO, UN METODO PARA SU OBTENCION, UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE, UNA MOLECULA DE ACIDO NUCLEICO, UN VECTOR, Y UNA CELULA HOSPEDANTE Y UN KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 334904,
	"label": "UN ANTICUERPO QUE SE FIJA SOBRE LA P-SELECTINA, SU USO, UN METODO PARA SU OBTENCION, UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE, UNA MOLECULA DE ACIDO NUCLEICO, UN VECTOR, Y UNA CELULA HOSPEDANTE Y UN KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37900,
	"target": 32779,
	"type": 334904,
	"label": "UN ANTICUERPO QUE SE FIJA SOBRE LA P-SELECTINA, SU USO, UN METODO PARA SU OBTENCION, UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE, UNA MOLECULA DE ACIDO NUCLEICO, UN VECTOR, Y UNA CELULA HOSPEDANTE Y UN KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 334904,
	"label": "UN ANTICUERPO QUE SE FIJA SOBRE LA P-SELECTINA, SU USO, UN METODO PARA SU OBTENCION, UNA COMPOSICION FARMACEUTICA QUE LO COMPRENDE, UNA MOLECULA DE ACIDO NUCLEICO, UN VECTOR, Y UNA CELULA HOSPEDANTE Y UN KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 6957,
	"type": 334944,
	"label": "método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6539,
	"target": 6478,
	"type": 335163,
	"label": "métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6478,
	"target": 6229,
	"type": 335163,
	"label": "métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6539,
	"target": 6229,
	"type": 335163,
	"label": "métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 335343,
	"label": "UN MÉTODO PARA PREPARAR UN POLIPÉPTIDO MODIFICADO QUE ES UN ANTICUERPO ANTI-IGE QUE NO EXHIBE DESACTIVACION DE ISOMERIZACIoN DE ASPARTILO Y QUE TIENE AFINIDAD A LA MOLÉCULA OBJETIVO IGE, UNA MOLÉCULA DE ANTICUERPO, UNA MOLECULA DE ACIDO NUCLEICO, UNA COMPOSICIoN Y USO DE UN ANTICUERPO PARA LA MANUFA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 32777,
	"type": 335343,
	"label": "UN MÉTODO PARA PREPARAR UN POLIPÉPTIDO MODIFICADO QUE ES UN ANTICUERPO ANTI-IGE QUE NO EXHIBE DESACTIVACION DE ISOMERIZACIoN DE ASPARTILO Y QUE TIENE AFINIDAD A LA MOLÉCULA OBJETIVO IGE, UNA MOLÉCULA DE ANTICUERPO, UNA MOLECULA DE ACIDO NUCLEICO, UNA COMPOSICIoN Y USO DE UN ANTICUERPO PARA LA MANUFA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 335343,
	"label": "UN MÉTODO PARA PREPARAR UN POLIPÉPTIDO MODIFICADO QUE ES UN ANTICUERPO ANTI-IGE QUE NO EXHIBE DESACTIVACION DE ISOMERIZACIoN DE ASPARTILO Y QUE TIENE AFINIDAD A LA MOLÉCULA OBJETIVO IGE, UNA MOLÉCULA DE ANTICUERPO, UNA MOLECULA DE ACIDO NUCLEICO, UNA COMPOSICIoN Y USO DE UN ANTICUERPO PARA LA MANUFA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32777,
	"target": 7510,
	"type": 335343,
	"label": "UN MÉTODO PARA PREPARAR UN POLIPÉPTIDO MODIFICADO QUE ES UN ANTICUERPO ANTI-IGE QUE NO EXHIBE DESACTIVACION DE ISOMERIZACIoN DE ASPARTILO Y QUE TIENE AFINIDAD A LA MOLÉCULA OBJETIVO IGE, UNA MOLÉCULA DE ANTICUERPO, UNA MOLECULA DE ACIDO NUCLEICO, UNA COMPOSICIoN Y USO DE UN ANTICUERPO PARA LA MANUFA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 7510,
	"type": 335343,
	"label": "UN MÉTODO PARA PREPARAR UN POLIPÉPTIDO MODIFICADO QUE ES UN ANTICUERPO ANTI-IGE QUE NO EXHIBE DESACTIVACION DE ISOMERIZACIoN DE ASPARTILO Y QUE TIENE AFINIDAD A LA MOLÉCULA OBJETIVO IGE, UNA MOLÉCULA DE ANTICUERPO, UNA MOLECULA DE ACIDO NUCLEICO, UNA COMPOSICIoN Y USO DE UN ANTICUERPO PARA LA MANUFA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7424,
	"target": 6213,
	"type": 335508,
	"label": "Compostos, processo para a manufatura de compostos, sua utilização, composição farmacêutica que compreende os mesmos e processo para o tratamento terapêutico e/ou profilático de osteoporose, angina do peito instável e/ou ruptura de placa",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 335696,
	"label": "4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 335696,
	"label": "4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 335696,
	"label": "4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID AMIDES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7511,
	"target": 7358,
	"type": 335744,
	"label": "métodos de prevenção de doença autoimunológica e artigo industrializado",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 335744,
	"label": "métodos de prevenção de doença autoimunológica e artigo industrializado",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7358,
	"type": 335744,
	"label": "métodos de prevenção de doença autoimunológica e artigo industrializado",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38181,
	"target": 6816,
	"type": 335879,
	"label": "polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 335915,
	"label": "Polynucleotide encoding a sclerostin-binding antibody",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 336011,
	"label": "HIV-INTEGRASE INHIBITOR COMPOUNDS",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 336214,
	"label": "composição de pepticorpo terapêutico liofilizado, métodos para fabricar um papticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico liofilizado e para preparar uma composição farmacêutica aquosa",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6263,
	"type": 336246,
	"label": "COMPUESTOS DERIVADOS DE TIENOPIRROLIDINONA, SU USO, MEDICAMENTOS QUE LOS CONTIENEN, UN PROCEDIMIENTO PARA PREPARAR DICHOS COMPUESTOS Y COMPUESTOS INTERMEDIARIOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7479,
	"target": 7424,
	"type": 336357,
	"label": "Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos,: processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7424,
	"target": 6371,
	"type": 336357,
	"label": "Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos,: processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7479,
	"target": 6371,
	"type": 336357,
	"label": "Compostos, composições farmacêuticas que contêm os mesmos, utilização desses compostos,: processo para tratamento terapêutico e/ou profilático e processo para a preparação desses compostos",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6241,
	"target": 6229,
	"type": 336433,
	"label": "Composição farmacêutica, processo para preparação e utilização da mesma, conjunto e processo para tratamento de obesidade, utilização de um inibidor de lìpase e de um sequestrante de ácido de bìlis e processo de tratamento ou prevencão de efeitos colaterais gastrointestinais",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6376,
	"target": 6360,
	"type": 336534,
	"label": "COMPOSICION,METODO, KIT Y TRATAMIENTO CON OXALIPLATINO Y UN INHIBIDOR DEL EGFR,COMO ERLOTINIB",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6360,
	"target": 6341,
	"type": 336534,
	"label": "COMPOSICION,METODO, KIT Y TRATAMIENTO CON OXALIPLATINO Y UN INHIBIDOR DEL EGFR,COMO ERLOTINIB",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6376,
	"target": 6341,
	"type": 336534,
	"label": "COMPOSICION,METODO, KIT Y TRATAMIENTO CON OXALIPLATINO Y UN INHIBIDOR DEL EGFR,COMO ERLOTINIB",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6539,
	"target": 6376,
	"type": 336534,
	"label": "COMPOSICION,METODO, KIT Y TRATAMIENTO CON OXALIPLATINO Y UN INHIBIDOR DEL EGFR,COMO ERLOTINIB",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6539,
	"target": 6360,
	"type": 336534,
	"label": "COMPOSICION,METODO, KIT Y TRATAMIENTO CON OXALIPLATINO Y UN INHIBIDOR DEL EGFR,COMO ERLOTINIB",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6376,
	"target": 6360,
	"type": 336535,
	"label": "Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6360,
	"target": 6341,
	"type": 336535,
	"label": "Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6376,
	"target": 6341,
	"type": 336535,
	"label": "Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6816,
	"type": 336551,
	"label": "METODO PARA TRATAR ESCLEROSIS MULTIPLE CON UNA COMPOSICION QUE CONTIENE UN ANTICUERPO CD20",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 336575,
	"label": "Nucleosidos de 3-?-D-ribofuranosiltiazolo[4,5-d]pirimidina y usos de los mismos",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31965,
	"target": 6263,
	"type": 336590,
	"label": "OCTAHYDROPYRROLO(3,4-C)PYRROLDERIVATE UND DEREN VERWENDUNG ALS ANTIVIRALE MITTELN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 336659,
	"label": "métodos de tratamento de cáncer, artigo industrializado e uso de um anticorpo her",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 336659,
	"label": "métodos de tratamento de cáncer, artigo industrializado e uso de um anticorpo her",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 336659,
	"label": "métodos de tratamento de cáncer, artigo industrializado e uso de um anticorpo her",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7509,
	"target": 6478,
	"type": 336659,
	"label": "métodos de tratamento de cáncer, artigo industrializado e uso de um anticorpo her",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 7509,
	"type": 336659,
	"label": "métodos de tratamento de cáncer, artigo industrializado e uso de um anticorpo her",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6478,
	"target": 6471,
	"type": 336660,
	"label": "COMBINACION DE UN ANTICUERPO HER2 Y GEMCITABINA PARA EL TRATAMIENTO DE CANCER RESISTENTE AL PLATINO",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6854,
	"target": 6478,
	"type": 336660,
	"label": "COMBINACION DE UN ANTICUERPO HER2 Y GEMCITABINA PARA EL TRATAMIENTO DE CANCER RESISTENTE AL PLATINO",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6854,
	"target": 6471,
	"type": 336660,
	"label": "COMBINACION DE UN ANTICUERPO HER2 Y GEMCITABINA PARA EL TRATAMIENTO DE CANCER RESISTENTE AL PLATINO",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 336660,
	"label": "COMBINACION DE UN ANTICUERPO HER2 Y GEMCITABINA PARA EL TRATAMIENTO DE CANCER RESISTENTE AL PLATINO",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 336660,
	"label": "COMBINACION DE UN ANTICUERPO HER2 Y GEMCITABINA PARA EL TRATAMIENTO DE CANCER RESISTENTE AL PLATINO",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 336775,
	"label": "anticorpos direcionados para cd20 e usos dos mesmos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 336775,
	"label": "anticorpos direcionados para cd20 e usos dos mesmos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 336775,
	"label": "anticorpos direcionados para cd20 e usos dos mesmos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 336775,
	"label": "anticorpos direcionados para cd20 e usos dos mesmos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 336775,
	"label": "anticorpos direcionados para cd20 e usos dos mesmos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 336898,
	"label": "compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 336898,
	"label": "compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 336898,
	"label": "compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 336899,
	"label": "PHOSPHOINOSITIDE-3-KINASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID INHIBITORS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 336900,
	"label": "PHARMACEUTICAL COMPOUNDS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 337044,
	"label": "METHOD FOR THE PRODUCTION OF ANTIBODIES IN IMMUNODEFICIENT ANIMAL INJECTED WITH HUMAN FETAL LIVER STEM CELLS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6241,
	"target": 6229,
	"type": 337155,
	"label": "Utilização de um inibidor de lìpases e processo e medicamento oral para tratamento, redução ou prevenção de dispepsia funcional",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32254,
	"target": 7464,
	"type": 337228,
	"label": "Forlopere til NMDA-reseptor-ligander, preparater inneholdende slike forbindelser, fremgangsmate for fremstilling av slike, slike forbindelser for behandling av sykdommer samt anvendelse av disse for fremstilling av preparater for behandling av sykdommer",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 337293,
	"label": "UN METODO PARA SELECCIONAR PACIENTES PARA DETERMINAR SU CAPACIDAD PARA RESPONDER A UN TRATAMIENTO ANTITUMORAL Y UNA PRUEBA DE DIAGNOSTICO PARA LLEVAR A CABO DICHO METODO",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 337300,
	"label": "DERIVADOS NUCLEOSIDOS DE PURINA Y PIRIMIDINA COMO INHIBIDORES DE LA REPLICACION DEL ARN DEL VIRUS DE LA HEPATITIS C SUBGENOMICA",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7424,
	"target": 6241,
	"type": 337328,
	"label": "Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 337435,
	"label": "composto ou um sal ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para o tratamento de uma condição ou doença inflamatória ou imune em um indivìduo e para a modulação da função cxcr3",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 337435,
	"label": "composto ou um sal ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para o tratamento de uma condição ou doença inflamatória ou imune em um indivìduo e para a modulação da função cxcr3",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 337435,
	"label": "composto ou um sal ou pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para o tratamento de uma condição ou doença inflamatória ou imune em um indivìduo e para a modulação da função cxcr3",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7409,
	"target": 6427,
	"type": 337596,
	"label": "Substituted Phenylphosphates as Mutual Prodrugs of Steroids and ß-Agonists for the Treatment of Title Pulmonary Inflammation and Bronchoconstriction",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 337780,
	"label": "DERIVADOS DE TIAZOLO-PIRIMIDINA/PIRIDINA-UREA COMO ANTAGONISTAS DE RECEPTOR DE ADENOSINA A2B.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 337880,
	"label": "HSP90 INHIBITOR.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 337880,
	"label": "HSP90 INHIBITOR.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7358,
	"target": 6382,
	"type": 337880,
	"label": "HSP90 INHIBITOR.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7358,
	"target": 6371,
	"type": 337880,
	"label": "HSP90 INHIBITOR.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 337880,
	"label": "HSP90 INHIBITOR.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 337898,
	"label": "anticorpos, polinucleotìdeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar cáncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fa",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 337898,
	"label": "anticorpos, polinucleotìdeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar cáncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fa",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 337898,
	"label": "anticorpos, polinucleotìdeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar cáncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fa",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 337898,
	"label": "anticorpos, polinucleotìdeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar cáncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fa",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 337898,
	"label": "anticorpos, polinucleotìdeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar cáncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fa",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 337972,
	"label": "USO DE UN INHIBIDOR DE DIMERIZACION DEL RECEPTOR HER PARA TRATAR CANCER QUE PRODUCE ALTOS NIVELES DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGF) O DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ALFA (TGF-ALFA).",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7425,
	"target": 6854,
	"type": 337972,
	"label": "USO DE UN INHIBIDOR DE DIMERIZACION DEL RECEPTOR HER PARA TRATAR CANCER QUE PRODUCE ALTOS NIVELES DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGF) O DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ALFA (TGF-ALFA).",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 337972,
	"label": "USO DE UN INHIBIDOR DE DIMERIZACION DEL RECEPTOR HER PARA TRATAR CANCER QUE PRODUCE ALTOS NIVELES DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGF) O DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ALFA (TGF-ALFA).",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 337972,
	"label": "USO DE UN INHIBIDOR DE DIMERIZACION DEL RECEPTOR HER PARA TRATAR CANCER QUE PRODUCE ALTOS NIVELES DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGF) O DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ALFA (TGF-ALFA).",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32772,
	"target": 7425,
	"type": 337972,
	"label": "USO DE UN INHIBIDOR DE DIMERIZACION DEL RECEPTOR HER PARA TRATAR CANCER QUE PRODUCE ALTOS NIVELES DEL FACTOR DE CRECIMIENTO EPIDERMICO (EGF) O DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ALFA (TGF-ALFA).",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 37900,
	"type": 337988,
	"label": "métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos  de um antagonista de dll4 e uso de um agonisra de dll4",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 337988,
	"label": "métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos  de um antagonista de dll4 e uso de um agonisra de dll4",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37900,
	"target": 7507,
	"type": 337988,
	"label": "métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos  de um antagonista de dll4 e uso de um agonisra de dll4",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 337988,
	"label": "métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos  de um antagonista de dll4 e uso de um agonisra de dll4",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37900,
	"target": 6812,
	"type": 337988,
	"label": "métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos  de um antagonista de dll4 e uso de um agonisra de dll4",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 338337,
	"label": "composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 338337,
	"label": "composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 338337,
	"label": "composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32772,
	"type": 338337,
	"label": "composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 338337,
	"label": "composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 6341,
	"type": 338338,
	"label": "métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 338338,
	"label": "métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6341,
	"type": 338338,
	"label": "métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31747,
	"target": 29057,
	"type": 338346,
	"label": "NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31995,
	"target": 6303,
	"type": 338584,
	"label": "Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6302,
	"target": 6298,
	"type": 338599,
	"label": "aminas cÍclicas fundidas a heteroarila",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 338599,
	"label": "aminas cÍclicas fundidas a heteroarila",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6298,
	"type": 338599,
	"label": "aminas cÍclicas fundidas a heteroarila",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 338846,
	"label": "COMPUESTO PEPTIDICO QUE SE UNE AL RECEPTOR DE LA TROMBOPOYETINA MPL; METODO PARA AUMENTAR LOS MEGACARIOCITOS O LAS PLAQUETAS EN UN PACIENTE; COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO; POLINUCLEOTIDO QUE CODIFICA EL COMPUESTO; VECTOR Y CELUL",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 338846,
	"label": "COMPUESTO PEPTIDICO QUE SE UNE AL RECEPTOR DE LA TROMBOPOYETINA MPL; METODO PARA AUMENTAR LOS MEGACARIOCITOS O LAS PLAQUETAS EN UN PACIENTE; COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO; POLINUCLEOTIDO QUE CODIFICA EL COMPUESTO; VECTOR Y CELUL",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 338846,
	"label": "COMPUESTO PEPTIDICO QUE SE UNE AL RECEPTOR DE LA TROMBOPOYETINA MPL; METODO PARA AUMENTAR LOS MEGACARIOCITOS O LAS PLAQUETAS EN UN PACIENTE; COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO; POLINUCLEOTIDO QUE CODIFICA EL COMPUESTO; VECTOR Y CELUL",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37862,
	"target": 32694,
	"type": 338846,
	"label": "COMPUESTO PEPTIDICO QUE SE UNE AL RECEPTOR DE LA TROMBOPOYETINA MPL; METODO PARA AUMENTAR LOS MEGACARIOCITOS O LAS PLAQUETAS EN UN PACIENTE; COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO; POLINUCLEOTIDO QUE CODIFICA EL COMPUESTO; VECTOR Y CELUL",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 338846,
	"label": "COMPUESTO PEPTIDICO QUE SE UNE AL RECEPTOR DE LA TROMBOPOYETINA MPL; METODO PARA AUMENTAR LOS MEGACARIOCITOS O LAS PLAQUETAS EN UN PACIENTE; COMPOSICION FARMACEUTICA QUE COMPRENDE EL COMPUESTO; POLINUCLEOTIDO QUE CODIFICA EL COMPUESTO; VECTOR Y CELUL",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 338905,
	"label": "Prodrugs of 5-amino-3-(3&prime;-deoxy-&bgr;-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38004,
	"target": 32698,
	"type": 339266,
	"label": "MUTANT INTERLEUKIN-15-CONTAINING COMPOSITIONS AND SUPPRESSION OF AN IMMUNE RESPONSE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 339298,
	"label": "SUBSTITUIERTE HYDANTOINE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37904,
	"target": 37899,
	"type": 339743,
	"label": "UN ANTICUERPO MONOCLONAL PARA LA IL-12 HUMANA, HIBRIDOMA QUE PRODUCE A DICHO ANTICUERPO, COMPOSICION FARMACEUTICA QUE COMPRENDE AL CITADO ANTICUERPO, Y USO DE DICHO ANTICUERPO PARA LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 7511,
	"type": 339743,
	"label": "UN ANTICUERPO MONOCLONAL PARA LA IL-12 HUMANA, HIBRIDOMA QUE PRODUCE A DICHO ANTICUERPO, COMPOSICION FARMACEUTICA QUE COMPRENDE AL CITADO ANTICUERPO, Y USO DE DICHO ANTICUERPO PARA LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37904,
	"target": 7511,
	"type": 339743,
	"label": "UN ANTICUERPO MONOCLONAL PARA LA IL-12 HUMANA, HIBRIDOMA QUE PRODUCE A DICHO ANTICUERPO, COMPOSICION FARMACEUTICA QUE COMPRENDE AL CITADO ANTICUERPO, Y USO DE DICHO ANTICUERPO PARA LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 339763,
	"label": "ANALOGO CICLICO DEL PEPTIDO INTESTINAL VASOACTIVO (VIP); COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES OBSTRUCTIVAS PULMONARES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7409,
	"target": 6812,
	"type": 339763,
	"label": "ANALOGO CICLICO DEL PEPTIDO INTESTINAL VASOACTIVO (VIP); COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES OBSTRUCTIVAS PULMONARES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 339763,
	"label": "ANALOGO CICLICO DEL PEPTIDO INTESTINAL VASOACTIVO (VIP); COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA EL TRATAMIENTO DE ENFERMEDADES OBSTRUCTIVAS PULMONARES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 339777,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDILCICLOPENTANOS HIDROXILADOS Y METOXILADOS; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA; Y USO DEL COMPUESTO EN EL TRATAMIENTO DE UNA ENFERMEDAD INFLAMATORIA, HIPERPROLIFERANTE, CARDIOVASCULAR, NEURODEGENERAT",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 339778,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDILCICLOPENTANOS; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO DEL COMPUESTO EN EL TRATAMIENTO DE UNA ENFERMEDAD INFLAMATORIA, HIPERPROLIFERANTE, CARDIOVASCULAR, NEURODEGE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7409,
	"target": 6301,
	"type": 339997,
	"label": "Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 340228,
	"label": "HIDANTOINAS SUSTITUIDAS PARA EL TRATAMIENTO DE CANCER.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7497,
	"target": 6816,
	"type": 340293,
	"label": "uso de conjugados de peg-ifn-alfa em associação a ribavirina, bem como kit compreendendo os mesmos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 340365,
	"label": "Substituted pyrazolo[3,4-D]pyrimidines as p38 MAP kinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7411,
	"type": 340366,
	"label": "Substituted pyrazolo[3,4-d]pyrimidines as p38 MAP kinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7411,
	"target": 7409,
	"type": 340367,
	"label": "Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 340367,
	"label": "Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7411,
	"target": 6376,
	"type": 340367,
	"label": "Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 340397,
	"label": "molécula de ligação a antìgeno modificada, polinucleotìdeo isolado que codifica um polipeptìdeo, vetor, método de produção da referida molécula, composição farmacêutica que a contém, bem como uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 340397,
	"label": "molécula de ligação a antìgeno modificada, polinucleotìdeo isolado que codifica um polipeptìdeo, vetor, método de produção da referida molécula, composição farmacêutica que a contém, bem como uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 340397,
	"label": "molécula de ligação a antìgeno modificada, polinucleotìdeo isolado que codifica um polipeptìdeo, vetor, método de produção da referida molécula, composição farmacêutica que a contém, bem como uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 340397,
	"label": "molécula de ligação a antìgeno modificada, polinucleotìdeo isolado que codifica um polipeptìdeo, vetor, método de produção da referida molécula, composição farmacêutica que a contém, bem como uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 340397,
	"label": "molécula de ligação a antìgeno modificada, polinucleotìdeo isolado que codifica um polipeptìdeo, vetor, método de produção da referida molécula, composição farmacêutica que a contém, bem como uso da mesma",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 340445,
	"label": "diaminopirimidinas como moduladores de p2x3 e p3x2/3",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 340446,
	"label": "DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 340448,
	"label": "DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6407,
	"type": 341117,
	"label": "DISUBSTITUTED PYRAZOLOBENZODIAZEPINES USED AS CDK2 AND ANGIOGENESIS INHIBITORS, AS WELL AS FOR TREATING MALIGNANT GROWTHS IN MAMMARY GLANDS, LARGE INTESTINES, LUNGS AND PROSTATE GLANDS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6407,
	"target": 6281,
	"type": 341164,
	"label": "Halogen substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepines",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 341283,
	"label": "derivados de Ácido 4-amino-tieno[3,2-c]piridina-7-carboxÍlico, formulaÇço farmacÊutica contendo os mesmos bem como seus usos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32708,
	"target": 7424,
	"type": 341337,
	"label": "Novel erythropoietin conjugate, compoaition of erythropoietin conjugates, pharmacological agent, application of erythropoietin conjugates and their compositions as well as method of obtaining novel erythropoietin conjugates",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6303,
	"target": 6301,
	"type": 341345,
	"label": "DERIVADOS DE INDOL-3-IL-CARBONIL-AZAESPIRO COMO ANTAGONISTAS RECEPTORES DE LA VASOPRESINA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6301,
	"target": 6298,
	"type": 341345,
	"label": "DERIVADOS DE INDOL-3-IL-CARBONIL-AZAESPIRO COMO ANTAGONISTAS RECEPTORES DE LA VASOPRESINA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6303,
	"target": 6298,
	"type": 341345,
	"label": "DERIVADOS DE INDOL-3-IL-CARBONIL-AZAESPIRO COMO ANTAGONISTAS RECEPTORES DE LA VASOPRESINA.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 342175,
	"label": "compostos derivados de naftiridina, processo para preparação dos mesmos, medicamentos e uso dos mesmos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7360,
	"target": 6302,
	"type": 342866,
	"label": "compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização desses compostos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 342866,
	"label": "compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização desses compostos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 342866,
	"label": "compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e utilização desses compostos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31081,
	"target": 6360,
	"type": 342950,
	"label": "Phenyl-piperazine methanone derivatives, substituted by heterocyclic groups",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6539,
	"target": 6478,
	"type": 343003,
	"label": "Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6478,
	"target": 6215,
	"type": 343003,
	"label": "Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6539,
	"target": 6215,
	"type": 343003,
	"label": "Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 343003,
	"label": "Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 343003,
	"label": "Method for the treatment of cancer using a novel pharmaceutical composition containing at least one dolastatin 10 derivative",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 30816,
	"target": 30815,
	"type": 343419,
	"label": "WERKWIJZE VOOR DE BEREIDING VAN 1,2,3,4-TETRAHYDRO-4-FENYLISOCHINOLINEDERIVATEN, ALSMEDE WERKWIJZE VOOR DE BEREIDING VAN FARMACEUTISCHE PREPARATEN MET ANTIDEPRESSIEVE EIGENSCHAPPEN, DIE DEZE DERIVATEN BEVATTEN.",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 30815,
	"target": 30814,
	"type": 343419,
	"label": "WERKWIJZE VOOR DE BEREIDING VAN 1,2,3,4-TETRAHYDRO-4-FENYLISOCHINOLINEDERIVATEN, ALSMEDE WERKWIJZE VOOR DE BEREIDING VAN FARMACEUTISCHE PREPARATEN MET ANTIDEPRESSIEVE EIGENSCHAPPEN, DIE DEZE DERIVATEN BEVATTEN.",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 30816,
	"target": 30814,
	"type": 343419,
	"label": "WERKWIJZE VOOR DE BEREIDING VAN 1,2,3,4-TETRAHYDRO-4-FENYLISOCHINOLINEDERIVATEN, ALSMEDE WERKWIJZE VOOR DE BEREIDING VAN FARMACEUTISCHE PREPARATEN MET ANTIDEPRESSIEVE EIGENSCHAPPEN, DIE DEZE DERIVATEN BEVATTEN.",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 30820,
	"target": 30816,
	"type": 343419,
	"label": "WERKWIJZE VOOR DE BEREIDING VAN 1,2,3,4-TETRAHYDRO-4-FENYLISOCHINOLINEDERIVATEN, ALSMEDE WERKWIJZE VOOR DE BEREIDING VAN FARMACEUTISCHE PREPARATEN MET ANTIDEPRESSIEVE EIGENSCHAPPEN, DIE DEZE DERIVATEN BEVATTEN.",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 30820,
	"target": 30815,
	"type": 343419,
	"label": "WERKWIJZE VOOR DE BEREIDING VAN 1,2,3,4-TETRAHYDRO-4-FENYLISOCHINOLINEDERIVATEN, ALSMEDE WERKWIJZE VOOR DE BEREIDING VAN FARMACEUTISCHE PREPARATEN MET ANTIDEPRESSIEVE EIGENSCHAPPEN, DIE DEZE DERIVATEN BEVATTEN.",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 343677,
	"label": "Skriningsanalyser og fremgangsmater for tumorbehanding",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 343691,
	"label": "PIRIDO-7-PIRIMIDIN-7-ONAS SUSTITUIDAS CON HIDROXIALQUILO.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7511,
	"target": 6376,
	"type": 343773,
	"label": "3,5-DISUBSTITUIDO Y 3,5,7-TRISUBSTITUIDO-3H-OXAZOLO Y 3H-TIAZOLO[4,5-D]PIRIMIDINA-2,1, COMPUESTOS Y PRODROGAS QUE LAS CONTIENEN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7511,
	"target": 6376,
	"type": 343779,
	"label": "ANTIANGIOGENESIS THERAPY OF AUTOIMMUNE DISEASE IN PATIENTS WHO HAVE FAILED PRIOR THERAPY.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 343779,
	"label": "ANTIANGIOGENESIS THERAPY OF AUTOIMMUNE DISEASE IN PATIENTS WHO HAVE FAILED PRIOR THERAPY.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6376,
	"type": 343779,
	"label": "ANTIANGIOGENESIS THERAPY OF AUTOIMMUNE DISEASE IN PATIENTS WHO HAVE FAILED PRIOR THERAPY.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 344509,
	"label": "COMPOSITIONS COMPRISING AN INTERLEUKIN-6 RECEPTOR ANTIBODY AND USE THEREOF FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF VASCULITIS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 345129,
	"label": "NOVEL OXAMIDE DERIVATIVES, METHOD OF OBTAINING THEM, NOVEL DERIVATIVES OF OXANILIC ACID, NOVEL DERIVATIVES OF OXAZOLYL-OXANILIC ACID, PHARMACOLOGICAL AGENT AND METHOD OF OBTAINING SAME AS WELL AS APPLICATION OF SUCH NOVEL OXAMIDE DERIVATIVES IN PRODUCTION OF A PHARMACOLOGICAL AGENT",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 345129,
	"label": "NOVEL OXAMIDE DERIVATIVES, METHOD OF OBTAINING THEM, NOVEL DERIVATIVES OF OXANILIC ACID, NOVEL DERIVATIVES OF OXAZOLYL-OXANILIC ACID, PHARMACOLOGICAL AGENT AND METHOD OF OBTAINING SAME AS WELL AS APPLICATION OF SUCH NOVEL OXAMIDE DERIVATIVES IN PRODUCTION OF A PHARMACOLOGICAL AGENT",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7510,
	"target": 7487,
	"type": 345129,
	"label": "NOVEL OXAMIDE DERIVATIVES, METHOD OF OBTAINING THEM, NOVEL DERIVATIVES OF OXANILIC ACID, NOVEL DERIVATIVES OF OXAZOLYL-OXANILIC ACID, PHARMACOLOGICAL AGENT AND METHOD OF OBTAINING SAME AS WELL AS APPLICATION OF SUCH NOVEL OXAMIDE DERIVATIVES IN PRODUCTION OF A PHARMACOLOGICAL AGENT",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 345496,
	"label": "Fremgangsmåde til fremstilling af et protein som har human vævsplasminogenaktivatorfunktion, fremgangsmåde til fremstilling af et farmaceutisk præparat indeholdende proteinet, DNA-isolat, som koder for proteinet, rekombinante klonings- og ......",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 345496,
	"label": "Fremgangsmåde til fremstilling af et protein som har human vævsplasminogenaktivatorfunktion, fremgangsmåde til fremstilling af et farmaceutisk præparat indeholdende proteinet, DNA-isolat, som koder for proteinet, rekombinante klonings- og ......",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 345496,
	"label": "Fremgangsmåde til fremstilling af et protein som har human vævsplasminogenaktivatorfunktion, fremgangsmåde til fremstilling af et farmaceutisk præparat indeholdende proteinet, DNA-isolat, som koder for proteinet, rekombinante klonings- og ......",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 345904,
	"label": "MUTEINA DE FACTOR DE NECROSIS TUMORAL HUMANO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA,PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LA CONTIENE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 345904,
	"label": "MUTEINA DE FACTOR DE NECROSIS TUMORAL HUMANO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA,PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LA CONTIENE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 345904,
	"label": "MUTEINA DE FACTOR DE NECROSIS TUMORAL HUMANO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA,PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LA CONTIENE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 345904,
	"label": "MUTEINA DE FACTOR DE NECROSIS TUMORAL HUMANO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA,PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LA CONTIENE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 345904,
	"label": "MUTEINA DE FACTOR DE NECROSIS TUMORAL HUMANO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA,PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LA CONTIENE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 345951,
	"label": "ALPHA CHAIN OR PORTION OF HUMAN INTERLEUKIN-5 ACCEPTOR, PARTICULARLY DNA FOR CODING SHIL5R ALPHA, VECTOR CONTAINING SAID DNA, HOST CELL TRANSFORMED BY SAID VECTOR AND METHOD FOR PRODUCTION AND USE THEREOF",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 7409,
	"type": 345951,
	"label": "ALPHA CHAIN OR PORTION OF HUMAN INTERLEUKIN-5 ACCEPTOR, PARTICULARLY DNA FOR CODING SHIL5R ALPHA, VECTOR CONTAINING SAID DNA, HOST CELL TRANSFORMED BY SAID VECTOR AND METHOD FOR PRODUCTION AND USE THEREOF",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 345951,
	"label": "ALPHA CHAIN OR PORTION OF HUMAN INTERLEUKIN-5 ACCEPTOR, PARTICULARLY DNA FOR CODING SHIL5R ALPHA, VECTOR CONTAINING SAID DNA, HOST CELL TRANSFORMED BY SAID VECTOR AND METHOD FOR PRODUCTION AND USE THEREOF",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 345989,
	"label": "ANTICORPO MONOCLONAL,FRAGMENTO,CELULA DE HIBRIDOMA,PROCESSOS PARA A PREPARACAO DA CELULA E DO ANTICORPO,PROCESSOS PARA A PURIFICACAO E DETECCAO DA PRESENCA DE SUB-UNIDADE ALFA,PROCESSO PARA A DETERMINACAO DA PROPORCAO DE IGE,COMPOSICAO,USO,CELULA E ANTICORPO",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 345989,
	"label": "ANTICORPO MONOCLONAL,FRAGMENTO,CELULA DE HIBRIDOMA,PROCESSOS PARA A PREPARACAO DA CELULA E DO ANTICORPO,PROCESSOS PARA A PURIFICACAO E DETECCAO DA PRESENCA DE SUB-UNIDADE ALFA,PROCESSO PARA A DETERMINACAO DA PROPORCAO DE IGE,COMPOSICAO,USO,CELULA E ANTICORPO",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 345989,
	"label": "ANTICORPO MONOCLONAL,FRAGMENTO,CELULA DE HIBRIDOMA,PROCESSOS PARA A PREPARACAO DA CELULA E DO ANTICORPO,PROCESSOS PARA A PURIFICACAO E DETECCAO DA PRESENCA DE SUB-UNIDADE ALFA,PROCESSO PARA A DETERMINACAO DA PROPORCAO DE IGE,COMPOSICAO,USO,CELULA E ANTICORPO",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 345989,
	"label": "ANTICORPO MONOCLONAL,FRAGMENTO,CELULA DE HIBRIDOMA,PROCESSOS PARA A PREPARACAO DA CELULA E DO ANTICORPO,PROCESSOS PARA A PURIFICACAO E DETECCAO DA PRESENCA DE SUB-UNIDADE ALFA,PROCESSO PARA A DETERMINACAO DA PROPORCAO DE IGE,COMPOSICAO,USO,CELULA E ANTICORPO",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 345989,
	"label": "ANTICORPO MONOCLONAL,FRAGMENTO,CELULA DE HIBRIDOMA,PROCESSOS PARA A PREPARACAO DA CELULA E DO ANTICORPO,PROCESSOS PARA A PURIFICACAO E DETECCAO DA PRESENCA DE SUB-UNIDADE ALFA,PROCESSO PARA A DETERMINACAO DA PROPORCAO DE IGE,COMPOSICAO,USO,CELULA E ANTICORPO",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 346980,
	"label": "ANALOGOS DE SUB-UNIDADES DE TOXINA DEL COLERA DERIVADOS DE ADN RECOMBINANTE.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 349002,
	"label": "PURIFICATION OF HUMAN FIBROBLAST INTERFERON:HOMOGENOUS HUMAN FIBROBLAST INTERFERON;PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 349002,
	"label": "PURIFICATION OF HUMAN FIBROBLAST INTERFERON:HOMOGENOUS HUMAN FIBROBLAST INTERFERON;PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 349002,
	"label": "PURIFICATION OF HUMAN FIBROBLAST INTERFERON:HOMOGENOUS HUMAN FIBROBLAST INTERFERON;PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 32694,
	"target": 7507,
	"type": 349002,
	"label": "PURIFICATION OF HUMAN FIBROBLAST INTERFERON:HOMOGENOUS HUMAN FIBROBLAST INTERFERON;PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 32694,
	"target": 6816,
	"type": 349002,
	"label": "PURIFICATION OF HUMAN FIBROBLAST INTERFERON:HOMOGENOUS HUMAN FIBROBLAST INTERFERON;PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 38065,
	"target": 37875,
	"type": 349136,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ET HUMAN FAKTOR VIII,DNA-SEKVENS, REKOMBINANT UDTRYKKELSESVEKTOR, DNA-SEKVENSEN, CELLELINIE OG REKOMBINANT ORGANISME, ANVENDELSE AF POLYPEPTIDET TIL FREMSTILLING AF ET LAEGEMIDDEL OG FARMACEUTISK PRAEPARAT INDEHOLDENDE SAALEDES FREMSTILLET FAKTOR VIII POLYPEPTID",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 349136,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ET HUMAN FAKTOR VIII,DNA-SEKVENS, REKOMBINANT UDTRYKKELSESVEKTOR, DNA-SEKVENSEN, CELLELINIE OG REKOMBINANT ORGANISME, ANVENDELSE AF POLYPEPTIDET TIL FREMSTILLING AF ET LAEGEMIDDEL OG FARMACEUTISK PRAEPARAT INDEHOLDENDE SAALEDES FREMSTILLET FAKTOR VIII POLYPEPTID",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 349136,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ET HUMAN FAKTOR VIII,DNA-SEKVENS, REKOMBINANT UDTRYKKELSESVEKTOR, DNA-SEKVENSEN, CELLELINIE OG REKOMBINANT ORGANISME, ANVENDELSE AF POLYPEPTIDET TIL FREMSTILLING AF ET LAEGEMIDDEL OG FARMACEUTISK PRAEPARAT INDEHOLDENDE SAALEDES FREMSTILLET FAKTOR VIII POLYPEPTID",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 6471,
	"target": 6469,
	"type": 349214,
	"label": "ANTHRACYCLINE GLYCOSIDES,THEIR MANUFACTURE AND PHARMACEUT-COMPOSITIONS CONTAINING THEM AND SOME INTERMEDIATES THEREFOR",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32440,
	"target": 32437,
	"type": 349214,
	"label": "ANTHRACYCLINE GLYCOSIDES,THEIR MANUFACTURE AND PHARMACEUT-COMPOSITIONS CONTAINING THEM AND SOME INTERMEDIATES THEREFOR",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 7507,
	"target": 6471,
	"type": 349214,
	"label": "ANTHRACYCLINE GLYCOSIDES,THEIR MANUFACTURE AND PHARMACEUT-COMPOSITIONS CONTAINING THEM AND SOME INTERMEDIATES THEREFOR",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 7507,
	"target": 6469,
	"type": 349214,
	"label": "ANTHRACYCLINE GLYCOSIDES,THEIR MANUFACTURE AND PHARMACEUT-COMPOSITIONS CONTAINING THEM AND SOME INTERMEDIATES THEREFOR",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32437,
	"target": 7507,
	"type": 349214,
	"label": "ANTHRACYCLINE GLYCOSIDES,THEIR MANUFACTURE AND PHARMACEUT-COMPOSITIONS CONTAINING THEM AND SOME INTERMEDIATES THEREFOR",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 349262,
	"label": "FREMGANGSMAATE FOR FREMSTILLING AV HOEYRENSET NOEYTROFILDOMINANT CSF (KOLONISTIMULERENDE FAKTOR) VED DYRKING AV EN HUMAN G-CSF-PRODUSERENDE CELLELINJE OG ISOLERING VED HJELP AVKOLONNEKROMATOGRAFERING",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 349262,
	"label": "FREMGANGSMAATE FOR FREMSTILLING AV HOEYRENSET NOEYTROFILDOMINANT CSF (KOLONISTIMULERENDE FAKTOR) VED DYRKING AV EN HUMAN G-CSF-PRODUSERENDE CELLELINJE OG ISOLERING VED HJELP AVKOLONNEKROMATOGRAFERING",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 349262,
	"label": "FREMGANGSMAATE FOR FREMSTILLING AV HOEYRENSET NOEYTROFILDOMINANT CSF (KOLONISTIMULERENDE FAKTOR) VED DYRKING AV EN HUMAN G-CSF-PRODUSERENDE CELLELINJE OG ISOLERING VED HJELP AVKOLONNEKROMATOGRAFERING",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 349364,
	"label": "Fragmentos de anticuerpos monoclonales que tienen actividad inmuno supresora procedimiento para su preparación composición farmacéutica que los contiene y método para la supresion de la respuesta inmune",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 349364,
	"label": "Fragmentos de anticuerpos monoclonales que tienen actividad inmuno supresora procedimiento para su preparación composición farmacéutica que los contiene y método para la supresion de la respuesta inmune",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 349364,
	"label": "Fragmentos de anticuerpos monoclonales que tienen actividad inmuno supresora procedimiento para su preparación composición farmacéutica que los contiene y método para la supresion de la respuesta inmune",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 350261,
	"label": "CHOLECALCIFEROLDERIVATER, DISSE DERIVATER TIL BRUG SOM TERAPEUTISK AKTIVE SUBSTANSER, FREMGANGSMAADE TIL FREMSTILLING DERAF SAMT FARMACEUTISK PRAEPARAT BASERET PAA DISSE CHOLECALCIFEROLDERIVATER",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 350580,
	"label": "POLYUNSATURATED ALIPHATIC FATTY ACID DERIVATIVES CONTAINING A 2,6,6-TRIMETHYLCYCLOHEXENE DERIVATIVES; ETHERIFIED COMBINATION AGENT IS E-3,7-DIMETHYL-9-[(2-METHOXY-4-METHYL-6-OCTYLOXY)PHENYL]-2,4,6, 8-NONATETRAENOIC ACID",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 31912,
	"target": 30815,
	"type": 352547,
	"label": "PROCESS FOR PREPARING OCTAHYDROPYRROLO-(2,3-G)-ISOQUIONOLINES IN THE FORM OF THEIR RACEMIC MIXTURE, CIS- AND TRANS-ISOMERS, IN THREE FORM OR IN THE FORM OF SALT",
	"group": "Roche",
	"time": 1979,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 352559,
	"label": "Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 352559,
	"label": "Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 352559,
	"label": "Isoleret biologisk aktivt humant lymphotoxinderiv at og antistof som neutraliserer den cytolytiske aktivitet af dette, nucleinsyre som koder for lymphotoxinderivatet, replikerbar vektor omfattende nucleinsyren, heterolog celle transformeret med nucleinsyren og fremgangsmåde som omfatter fremstilling af lymphotoxinderivatet.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 353076,
	"label": "RECOMBINANT PROTEINS OF A PAKISTANI STRAIN OF HEPARECOMBINANT PROTEINS OF A PAKISTANI STRAIN OF HEPATITIS E AND THEIR USE IN DIAGNOSTIC METHODS AND VATITIS E AND THEIR USE IN DIAGNOSTIC METHODS AND VACCINES                                            CCINES",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 353803,
	"label": "PROCEDE DE PRODUCTION D'INTERLEUKINE-2 HUMAINE, INTERLEUKINE-2 AINSI OBTENUE, SON UTILISATION A TITRE DE MEDICAMENT ET COMPOSITION PHARMACEUTIQUE LA CONTENANT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 37875,
	"type": 353803,
	"label": "PROCEDE DE PRODUCTION D'INTERLEUKINE-2 HUMAINE, INTERLEUKINE-2 AINSI OBTENUE, SON UTILISATION A TITRE DE MEDICAMENT ET COMPOSITION PHARMACEUTIQUE LA CONTENANT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 353803,
	"label": "PROCEDE DE PRODUCTION D'INTERLEUKINE-2 HUMAINE, INTERLEUKINE-2 AINSI OBTENUE, SON UTILISATION A TITRE DE MEDICAMENT ET COMPOSITION PHARMACEUTIQUE LA CONTENANT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38065,
	"target": 37875,
	"type": 353803,
	"label": "PROCEDE DE PRODUCTION D'INTERLEUKINE-2 HUMAINE, INTERLEUKINE-2 AINSI OBTENUE, SON UTILISATION A TITRE DE MEDICAMENT ET COMPOSITION PHARMACEUTIQUE LA CONTENANT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 353803,
	"label": "PROCEDE DE PRODUCTION D'INTERLEUKINE-2 HUMAINE, INTERLEUKINE-2 AINSI OBTENUE, SON UTILISATION A TITRE DE MEDICAMENT ET COMPOSITION PHARMACEUTIQUE LA CONTENANT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 353985,
	"label": "HOMOGENEOUS RECOMBINANT IMMUNE INTERFERON FRAGMENTS AND ITS PREPARATION,A REPLICABLE MICROBIAL EXPRESSION VEHICLE CONTAINING IT AND ITS PREPARATION,A MICROORGANISM TRANSFORMED BY SAID EXPRESSION VEHICLE,AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID IMMUNE INTERFERON FRAGMENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 353985,
	"label": "HOMOGENEOUS RECOMBINANT IMMUNE INTERFERON FRAGMENTS AND ITS PREPARATION,A REPLICABLE MICROBIAL EXPRESSION VEHICLE CONTAINING IT AND ITS PREPARATION,A MICROORGANISM TRANSFORMED BY SAID EXPRESSION VEHICLE,AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID IMMUNE INTERFERON FRAGMENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 6816,
	"type": 353985,
	"label": "HOMOGENEOUS RECOMBINANT IMMUNE INTERFERON FRAGMENTS AND ITS PREPARATION,A REPLICABLE MICROBIAL EXPRESSION VEHICLE CONTAINING IT AND ITS PREPARATION,A MICROORGANISM TRANSFORMED BY SAID EXPRESSION VEHICLE,AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID IMMUNE INTERFERON FRAGMENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 355462,
	"label": "DERIVADOS DE HIDROXICUMARANONA O-SUSTITUIDOS, USO DE LOS MISMOS Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 355767,
	"label": "POLIPEPTIDEOS,SEQUENCIAS DE DNA,VEICULO DE EXPRESSAO,PLASMIDEO,MICROORGANISMO,BACTERIA,LINHAGEM DE E.COLI,COMPOSICAO CONTENDO POLIPEPTIDEO,EXTRATO,COMPOSICAO FARMACEUTICA,CULTURA DE CELULAS MICROBIAIS,USOS DE ALGUNS DESSES ITENS,E PROCESSOS DE PREPARACAO",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 38237,
	"target": 38232,
	"type": 356118,
	"label": "DETERMINATION OF IONS IN FLUIDS INVOLVING INFLUENCE OF THESE ON ENZYME ACTIVITY AND BINDING AGENT FOR MASKING INTERFERING IONS",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 357333,
	"label": "Nye 5'-deoxy-5-fluorcytidinderivater, en fremgangsmåde til fremstilling deraf, farmaceutiske midler indeholdende sådanne derivater og anvendelse af derivaterne til fremstilling af et antitumormiddel",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 358303,
	"label": "Recombinant human interleukin-1  polypeptides,    their preparation and pharmaceutical compositions containing them",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 358303,
	"label": "Recombinant human interleukin-1  polypeptides,    their preparation and pharmaceutical compositions containing them",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 358303,
	"label": "Recombinant human interleukin-1  polypeptides,    their preparation and pharmaceutical compositions containing them",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 358303,
	"label": "Recombinant human interleukin-1  polypeptides,    their preparation and pharmaceutical compositions containing them",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 32698,
	"type": 358303,
	"label": "Recombinant human interleukin-1  polypeptides,    their preparation and pharmaceutical compositions containing them",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 358313,
	"label": "PROCESSO PARA A PREPARACAO DE DERIVADOS DIDE-HIDRO DE VITAMINA D3 E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 7409,
	"target": 6185,
	"type": 358633,
	"label": "THE USE OF RAR SELECTIVE RETINOID AGONIST FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF EMPHYSEMA",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7437,
	"target": 7409,
	"type": 358650,
	"label": "ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PREPARATIONS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 359448,
	"label": "PROCESSO PARA A PREPARACAO DE UMA PROTEINA POSSUINDO UM OU MAIS DETERMINANTES IMUNO-REACTIVOS E/OU ANTIGENICOS DE UM ANTIGENIO DE SUPERFICIE EIMERIA E DE VACINAS CONTRA A COCCIDIOSE QUE A CONTEM",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 361096,
	"label": "SUBSTITUIERTE BISINDOLYLMALEINIMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE AND PHARMACEUTCIAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 361096,
	"label": "SUBSTITUIERTE BISINDOLYLMALEINIMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE AND PHARMACEUTCIAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7509,
	"target": 6290,
	"type": 361096,
	"label": "SUBSTITUIERTE BISINDOLYLMALEINIMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE AND PHARMACEUTCIAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 362221,
	"label": "AEROTHRICIN ANALOGE, DEREN HERSTELLUNG UND VERWENDUNG",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 362381,
	"label": "PROCESS FOR PURIFYING PROTEINS,PURE AND HOMOGENEOUS INTERFERON SPECIES OBTAINED THEREBY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1979,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 368839,
	"label": "MONOCLONAL ANTIBODIES DIRECTED AGAINST HUMAN LEUCOCYTE INTERFERON(HLI);PURIFICATION OF HLI",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 381462,
	"label": "WERKWIJZE VOOR HET BEREIDEN VAN SLEUTEL-TUSSENPRODUKTEN BIJ DE SYNTHESE VAN 1ALFA,25-DIHYDROXYCHOLECALCIFEROL.",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 6892,
	"target": 6854,
	"type": 398093,
	"label": "PROTEINA,SEQUENCIA DE DNA,VETOR RECOMBINANTE,ORGANISMO CELULAR,PROCESSOS PARA PRODUCAO DE UMA PROTEINA E PARA A PREPARACAO DE UM ORGANISMO UNICELULAR,PROCESSOS PARA A DETECCAO DA PRESENCA DE ANTICORPOS E DE VIRUS DE AIDS,PROCESSOS PARA A PREPARACAO DE UMA VACINA E PARA A PREPARACAO DE ANTICORPOS,FORMULACAO DE VACINA,ANTICORPOS,USO,VACINA,KIT DE TESTE E METODO PARA A PREVENCAO DE AIDS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 398093,
	"label": "PROTEINA,SEQUENCIA DE DNA,VETOR RECOMBINANTE,ORGANISMO CELULAR,PROCESSOS PARA PRODUCAO DE UMA PROTEINA E PARA A PREPARACAO DE UM ORGANISMO UNICELULAR,PROCESSOS PARA A DETECCAO DA PRESENCA DE ANTICORPOS E DE VIRUS DE AIDS,PROCESSOS PARA A PREPARACAO DE UMA VACINA E PARA A PREPARACAO DE ANTICORPOS,FORMULACAO DE VACINA,ANTICORPOS,USO,VACINA,KIT DE TESTE E METODO PARA A PREVENCAO DE AIDS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6892,
	"target": 6795,
	"type": 398093,
	"label": "PROTEINA,SEQUENCIA DE DNA,VETOR RECOMBINANTE,ORGANISMO CELULAR,PROCESSOS PARA PRODUCAO DE UMA PROTEINA E PARA A PREPARACAO DE UM ORGANISMO UNICELULAR,PROCESSOS PARA A DETECCAO DA PRESENCA DE ANTICORPOS E DE VIRUS DE AIDS,PROCESSOS PARA A PREPARACAO DE UMA VACINA E PARA A PREPARACAO DE ANTICORPOS,FORMULACAO DE VACINA,ANTICORPOS,USO,VACINA,KIT DE TESTE E METODO PARA A PREVENCAO DE AIDS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 6892,
	"type": 398093,
	"label": "PROTEINA,SEQUENCIA DE DNA,VETOR RECOMBINANTE,ORGANISMO CELULAR,PROCESSOS PARA PRODUCAO DE UMA PROTEINA E PARA A PREPARACAO DE UM ORGANISMO UNICELULAR,PROCESSOS PARA A DETECCAO DA PRESENCA DE ANTICORPOS E DE VIRUS DE AIDS,PROCESSOS PARA A PREPARACAO DE UMA VACINA E PARA A PREPARACAO DE ANTICORPOS,FORMULACAO DE VACINA,ANTICORPOS,USO,VACINA,KIT DE TESTE E METODO PARA A PREVENCAO DE AIDS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 398093,
	"label": "PROTEINA,SEQUENCIA DE DNA,VETOR RECOMBINANTE,ORGANISMO CELULAR,PROCESSOS PARA PRODUCAO DE UMA PROTEINA E PARA A PREPARACAO DE UM ORGANISMO UNICELULAR,PROCESSOS PARA A DETECCAO DA PRESENCA DE ANTICORPOS E DE VIRUS DE AIDS,PROCESSOS PARA A PREPARACAO DE UMA VACINA E PARA A PREPARACAO DE ANTICORPOS,FORMULACAO DE VACINA,ANTICORPOS,USO,VACINA,KIT DE TESTE E METODO PARA A PREVENCAO DE AIDS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32501,
	"target": 6417,
	"type": 410991,
	"label": "PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE D-HOMO-PREGN -4-EN -3, 20 DIONAS QUE TIENEN UTIL ACTIVIDAD ENDOCRINA, ESPECIALMENTE ANTI-INFLAMATORIA.",
	"group": "Roche",
	"time": 1975,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 417900,
	"label": "PEPTIDYL DERIVATIVES OF PHOSPHONIC ACIDS,THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 31571,
	"target": 28540,
	"type": 423159,
	"label": "A process for the preparation of tetrahydro-indane derivatives and certain novel tetrahydro-indane derivatives perse",
	"group": "Roche",
	"time": 1966,
	"strength": 1
}, {
	"source": 32501,
	"target": 6417,
	"type": 428328,
	"label": "NOUVEAUX D-HOMOSTEROIDES, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION EN TANT QUE MEDICAMENTS",
	"group": "Roche",
	"time": 1975,
	"strength": 1
}, {
	"source": 56836,
	"target": 6854,
	"type": 434746,
	"label": "Procédé d'analyse immunologique.",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 441048,
	"label": "SEQUENZA DI ACIDO NUCLEICO CHE CODIFICA PER UNA PROTEINA DEI CANALIDEL SODIO, PREFERIBILMENTE TTX-RESISTENTE.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 449983,
	"label": "POLIPETIDIO ANTI-VIRAL DNA DE DUPLO CORDAO VEICULO DE EXPRESSAO PLASMIDICO REPLICAVEL MICROORGANISMO TRANSFORMADO PLASMIDIO PROCESSO DE FORMACAO DO DITO DNA E DO DITO POLIPEPTIDIO COMPOSICAO FARMACEUTICA E USO DO DITO POLIPEPTIDIO",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 31580,
	"target": 30485,
	"type": 450122,
	"label": "Keyhole saw has concentric centring borer at front end of hollow boring shaft to be retracted by displacement mechanism into boring shaft for removal of drilled material",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 471434,
	"label": "POLIPEPTIDIO SEQUENCIA DE DNA VEICULO DE EXPRESSAO MICROBIIANA COPIAVEL PLASMIDIO MICROORGANISMO COMPOSICAO EXTRATO BACTERIANO COMPOSICAO FARMACEUTICA CULTURA DE CELULAS MICROBIANAS APLICACAO DE UM INTERFERON E PROCESSOS DE PRODUCAODE ALGUNS DESSES ITENS",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 7409,
	"target": 6427,
	"type": 472374,
	"label": "UN PROCEDIMIENTO PARA PREPARAR UN COMPUESTO CRISTALINO 6 AL-FA, FLUORO-11 BETA, 21-HIHIDROXI-16 ALFA, 17ALFA-ZSOPROPILI-DENDIOXIPREGNA-1,4-DIEN-3,20-DIONA.",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 32501,
	"target": 6157,
	"type": 492510,
	"label": "17  -HYDROXY-      -D-HOMOSTEROID DERIVATIVES,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 497627,
	"label": "Fremgangsmåde til fremstilling af klare og stabile oplosninger af vitamin A-alkohol, vitamin D, vitamin E eller en blanding af mindst to af disse vitaminer.",
	"group": "Roche",
	"time": 1963,
	"strength": 1
}, {
	"source": 30821,
	"target": 30820,
	"type": 502370,
	"label": "Verfahren zur Herstellung von neuen N-substituierten 1,2,3,4-Tetrahydroisochinolinverbindungen",
	"group": "Roche",
	"time": 1964,
	"strength": 1
}, {
	"source": 30820,
	"target": 30815,
	"type": 502370,
	"label": "Verfahren zur Herstellung von neuen N-substituierten 1,2,3,4-Tetrahydroisochinolinverbindungen",
	"group": "Roche",
	"time": 1964,
	"strength": 1
}, {
	"source": 30821,
	"target": 30815,
	"type": 502370,
	"label": "Verfahren zur Herstellung von neuen N-substituierten 1,2,3,4-Tetrahydroisochinolinverbindungen",
	"group": "Roche",
	"time": 1964,
	"strength": 1
}, {
	"source": 32501,
	"target": 6417,
	"type": 537322,
	"label": "D-HOMOSTEROIDS THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 32501,
	"target": 6417,
	"type": 537847,
	"label": "Analogifremgangsmåde til fremstilling af D-homopregna-1,4-dien-3,11,20-trioner.",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 638491,
	"label": "DEVICE FOR CARRYING OUT THE CELL-FREE SYNTHESIS OF PROTEINS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 638593,
	"label": "NUEVOS DERIVADOS DE ESTEROIDES 11,BETA-SUSTITUIDOS, SUS PROCEDIMIENTOS DE PREPARACION Y LOS INTERMEDIOS DE ESTE PROCEDIMIENTO, SU APLICACION COMO MEDICAMENTOS Y COMPOSICIONES QUE LOS CONTIENEN.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7450,
	"target": 7424,
	"type": 638593,
	"label": "NUEVOS DERIVADOS DE ESTEROIDES 11,BETA-SUSTITUIDOS, SUS PROCEDIMIENTOS DE PREPARACION Y LOS INTERMEDIOS DE ESTE PROCEDIMIENTO, SU APLICACION COMO MEDICAMENTOS Y COMPOSICIONES QUE LOS CONTIENEN.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 638593,
	"label": "NUEVOS DERIVADOS DE ESTEROIDES 11,BETA-SUSTITUIDOS, SUS PROCEDIMIENTOS DE PREPARACION Y LOS INTERMEDIOS DE ESTE PROCEDIMIENTO, SU APLICACION COMO MEDICAMENTOS Y COMPOSICIONES QUE LOS CONTIENEN.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7509,
	"target": 7450,
	"type": 638593,
	"label": "NUEVOS DERIVADOS DE ESTEROIDES 11,BETA-SUSTITUIDOS, SUS PROCEDIMIENTOS DE PREPARACION Y LOS INTERMEDIOS DE ESTE PROCEDIMIENTO, SU APLICACION COMO MEDICAMENTOS Y COMPOSICIONES QUE LOS CONTIENEN.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 638593,
	"label": "NUEVOS DERIVADOS DE ESTEROIDES 11,BETA-SUSTITUIDOS, SUS PROCEDIMIENTOS DE PREPARACION Y LOS INTERMEDIOS DE ESTE PROCEDIMIENTO, SU APLICACION COMO MEDICAMENTOS Y COMPOSICIONES QUE LOS CONTIENEN.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 638651,
	"label": "Método de tratamento de uma doença autoimunológica em um mamìfero, compreendendo antagonistas que se ligam aos marcadores de superfìcie de células b e artigo de manufatura",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7422,
	"target": 7409,
	"type": 638730,
	"label": "PYRASOLBENZODIAZEPINES AS CDK2 INHIBITORS, SYNTHESIS INTERMEDIATES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 638730,
	"label": "PYRASOLBENZODIAZEPINES AS CDK2 INHIBITORS, SYNTHESIS INTERMEDIATES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 638730,
	"label": "PYRASOLBENZODIAZEPINES AS CDK2 INHIBITORS, SYNTHESIS INTERMEDIATES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7409,
	"target": 6407,
	"type": 638730,
	"label": "PYRASOLBENZODIAZEPINES AS CDK2 INHIBITORS, SYNTHESIS INTERMEDIATES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7422,
	"target": 6407,
	"type": 638730,
	"label": "PYRASOLBENZODIAZEPINES AS CDK2 INHIBITORS, SYNTHESIS INTERMEDIATES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7479,
	"target": 7424,
	"type": 638748,
	"label": "COMPUESTOS DERIVADOS DE PIPERIDINA, SU USO, UN PROCESO PARA SU PREPARACIoN, COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN, Y COMPUESTOS INTERMEDIARIOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 638980,
	"label": "PROCEDIMIENTO PARA LA PREPARACION DE AGENTES ANTIOSTEOPOROTICOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 638980,
	"label": "PROCEDIMIENTO PARA LA PREPARACION DE AGENTES ANTIOSTEOPOROTICOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 638980,
	"label": "PROCEDIMIENTO PARA LA PREPARACION DE AGENTES ANTIOSTEOPOROTICOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30951,
	"target": 30950,
	"type": 639998,
	"label": "PRODUCTION OF HYDROXAMIC ACID DERIVATIVE FROM CORRESPONDING CARBOXYLIC ACID",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38071,
	"target": 37899,
	"type": 640842,
	"label": "VERPACKUNGSZELLE",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 641590,
	"label": "4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2-pyridyl-pyrimidinderivater, farmasoytisk preparat og mellomprodukter, anvendelse og fremgangsmate for fremstilling av medikamenter",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 641613,
	"label": "DNA POLYMERASE AUS I(PYROBACULUM ISLANDICUM)",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 641613,
	"label": "DNA POLYMERASE AUS I(PYROBACULUM ISLANDICUM)",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38237,
	"target": 37864,
	"type": 641613,
	"label": "DNA POLYMERASE AUS I(PYROBACULUM ISLANDICUM)",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 642865,
	"label": "VERFAHREN ZUM SCREENEN NACH GEGEN KREBS GERICHTETEN MEDIKAMENTEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 642865,
	"label": "VERFAHREN ZUM SCREENEN NACH GEGEN KREBS GERICHTETEN MEDIKAMENTEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 642865,
	"label": "VERFAHREN ZUM SCREENEN NACH GEGEN KREBS GERICHTETEN MEDIKAMENTEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 642921,
	"label": "GLYKOSYLIERTE LEPTINZUSAMMENSETZUNGEN UND ZUGEHÖRIGE VERFAHREN",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 643832,
	"label": "ANTICUERPOS PARA LA TERAPIA Y DIAGNOSTICO DEL CANCER.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 643832,
	"label": "ANTICUERPOS PARA LA TERAPIA Y DIAGNOSTICO DEL CANCER.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 643832,
	"label": "ANTICUERPOS PARA LA TERAPIA Y DIAGNOSTICO DEL CANCER.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 643832,
	"label": "ANTICUERPOS PARA LA TERAPIA Y DIAGNOSTICO DEL CANCER.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32771,
	"target": 6795,
	"type": 643832,
	"label": "ANTICUERPOS PARA LA TERAPIA Y DIAGNOSTICO DEL CANCER.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 643946,
	"label": "METODO DE SINTESIS DE POLIPEPTIDOS EN SISTEMAS LIBRES DE CELULAS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 38065,
	"type": 644025,
	"label": "Fremgangsmåde til fremstilling af et monoklonalt antistof",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 644025,
	"label": "Fremgangsmåde til fremstilling af et monoklonalt antistof",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 644025,
	"label": "Fremgangsmåde til fremstilling af et monoklonalt antistof",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 644406,
	"label": "PROCEDIMIENTO PARA LA PRODUCCION DE PROTEINAS PLEGADAS NATURALMENTE Y SECRETADAS MEDIANTE CO-SECRECION DE CHAPERONES MOLECULARES.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32772,
	"target": 6795,
	"type": 651061,
	"label": "USE OF HEREGULIN IN THE PREPARATION OF A MEDICAMENT FOR TREATING PANCREATIC DYSFUNCTION",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 651080,
	"label": "VARIANTES DEL FACTOR DE CRECIMIENTO CELULAR ENDOTELIAL VASCULAR (VEGF) Y SUS USOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 651080,
	"label": "VARIANTES DEL FACTOR DE CRECIMIENTO CELULAR ENDOTELIAL VASCULAR (VEGF) Y SUS USOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 651080,
	"label": "VARIANTES DEL FACTOR DE CRECIMIENTO CELULAR ENDOTELIAL VASCULAR (VEGF) Y SUS USOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37859,
	"target": 32694,
	"type": 651080,
	"label": "VARIANTES DEL FACTOR DE CRECIMIENTO CELULAR ENDOTELIAL VASCULAR (VEGF) Y SUS USOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 32694,
	"type": 651080,
	"label": "VARIANTES DEL FACTOR DE CRECIMIENTO CELULAR ENDOTELIAL VASCULAR (VEGF) Y SUS USOS.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6447,
	"type": 651730,
	"label": "2-METHYL-3-BUTENYL-1-PYROPHOSPHORSÄURESALZE UND MITTEL ZUR BEHANDLUNG VON LYMPHOZYTEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37889,
	"target": 32254,
	"type": 651730,
	"label": "2-METHYL-3-BUTENYL-1-PYROPHOSPHORSÄURESALZE UND MITTEL ZUR BEHANDLUNG VON LYMPHOZYTEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32254,
	"target": 7507,
	"type": 651730,
	"label": "2-METHYL-3-BUTENYL-1-PYROPHOSPHORSÄURESALZE UND MITTEL ZUR BEHANDLUNG VON LYMPHOZYTEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32254,
	"target": 6447,
	"type": 651730,
	"label": "2-METHYL-3-BUTENYL-1-PYROPHOSPHORSÄURESALZE UND MITTEL ZUR BEHANDLUNG VON LYMPHOZYTEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37889,
	"target": 7507,
	"type": 651730,
	"label": "2-METHYL-3-BUTENYL-1-PYROPHOSPHORSÄURESALZE UND MITTEL ZUR BEHANDLUNG VON LYMPHOZYTEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 652159,
	"label": "Tumor suppressor genes",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 652159,
	"label": "Tumor suppressor genes",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 652159,
	"label": "Tumor suppressor genes",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37859,
	"target": 6795,
	"type": 652159,
	"label": "Tumor suppressor genes",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 652159,
	"label": "Tumor suppressor genes",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 653031,
	"label": "PHARMAZEUTISCHE ZUSAMMENSETZUNG VON HYDROPHOB MODIFIZIERTEN HEDGEHOG-PROTEINEN UND DEREN VERWENDUNG",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 653291,
	"label": "VERFAHREN DER ZELLKULTIVIERUNG",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 653498,
	"label": "Astaxanthin synthetic enzyme",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 654081,
	"label": "Fremgangsmate for pavisning av nativt N-terminalt proBNP i en prove som utfores i sandwich-format ved anvendelse av minst to antistoffer som gjenkjenner forskjellige epitoper i det native N-terminale proBNP, og som samtidig kan bindes til nativt N-terminalt proBNP, anvendelse av fremgangsmaten for differensiering mellom prover, anvendelse av rekombinant N-terminalt proBNP som standard i en fremgangsmate, antistoffer mot N-terminalt proBNP fremstilt ved immunisering av en egnet organisme med reko",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 32769,
	"type": 654081,
	"label": "Fremgangsmate for pavisning av nativt N-terminalt proBNP i en prove som utfores i sandwich-format ved anvendelse av minst to antistoffer som gjenkjenner forskjellige epitoper i det native N-terminale proBNP, og som samtidig kan bindes til nativt N-terminalt proBNP, anvendelse av fremgangsmaten for differensiering mellom prover, anvendelse av rekombinant N-terminalt proBNP som standard i en fremgangsmate, antistoffer mot N-terminalt proBNP fremstilt ved immunisering av en egnet organisme med reko",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 32769,
	"type": 654081,
	"label": "Fremgangsmate for pavisning av nativt N-terminalt proBNP i en prove som utfores i sandwich-format ved anvendelse av minst to antistoffer som gjenkjenner forskjellige epitoper i det native N-terminale proBNP, og som samtidig kan bindes til nativt N-terminalt proBNP, anvendelse av fremgangsmaten for differensiering mellom prover, anvendelse av rekombinant N-terminalt proBNP som standard i en fremgangsmate, antistoffer mot N-terminalt proBNP fremstilt ved immunisering av en egnet organisme med reko",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 654190,
	"label": "PROCESS FOR THE PRODUCTION OF TISSUE PLASMINOGEN ACTIVATOR (t-PA) IN CELL CULTURE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 655063,
	"label": "Fysiologisk aktive PEG-GCSF-konjugater, sammensetning omfattende konjugatene og fremgangsmate for fremstilling av konjugatene",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7450,
	"target": 7424,
	"type": 655194,
	"label": "NUEVOS DERIVADOS DE GUANIDINA COMO INHIBIDORES DE ADHESION CELULAR.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7424,
	"target": 6371,
	"type": 655194,
	"label": "NUEVOS DERIVADOS DE GUANIDINA COMO INHIBIDORES DE ADHESION CELULAR.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7450,
	"target": 6371,
	"type": 655194,
	"label": "NUEVOS DERIVADOS DE GUANIDINA COMO INHIBIDORES DE ADHESION CELULAR.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30815,
	"target": 30814,
	"type": 667487,
	"label": "1-benzyl-1, 2, 3, 4, 5, 6, 7, 8-octahydroiso-quinolines and method for their production",
	"group": "Roche",
	"time": 1950,
	"strength": 1
}, {
	"source": 7487,
	"target": 6371,
	"type": 678847,
	"label": "CHROMENYLMETHYLPYRIMIDINDIAMINE ALS ANTIBAKTERIELLE WIRKSTOFFE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 679086,
	"label": "SISTEMA DE EVALUACION PARA PREDECIR LA RECIDIVA DEL CANCER.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 679200,
	"label": "UNA 7-OXO-PIRIDOPIRIMIDINA, SU USO, UN PROCESO PARA PREPARARLA, UNA COMPOSICION FARMACEUTICA QUE LA COMPRENDE, UN PROCESO PARA PRODUCIR UNA PIRIMIDINA, UN PROCESO PARA PRODUCIR UNA PIRIDOPIRIMIDINA, Y COMPUESTOS PREPARADOS MEDIANTE DICHOS PROCESOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 679200,
	"label": "UNA 7-OXO-PIRIDOPIRIMIDINA, SU USO, UN PROCESO PARA PREPARARLA, UNA COMPOSICION FARMACEUTICA QUE LA COMPRENDE, UN PROCESO PARA PRODUCIR UNA PIRIMIDINA, UN PROCESO PARA PRODUCIR UNA PIRIDOPIRIMIDINA, Y COMPUESTOS PREPARADOS MEDIANTE DICHOS PROCESOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 679200,
	"label": "UNA 7-OXO-PIRIDOPIRIMIDINA, SU USO, UN PROCESO PARA PREPARARLA, UNA COMPOSICION FARMACEUTICA QUE LA COMPRENDE, UN PROCESO PARA PRODUCIR UNA PIRIMIDINA, UN PROCESO PARA PRODUCIR UNA PIRIDOPIRIMIDINA, Y COMPUESTOS PREPARADOS MEDIANTE DICHOS PROCESOS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 679625,
	"label": "IN BRUST- UND BLASENKREBS DIFFERENTIELL EXPRIMIERTES GEN UND DURCH DIESES KODIERTE POLYPEPTIDE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 679625,
	"label": "IN BRUST- UND BLASENKREBS DIFFERENTIELL EXPRIMIERTES GEN UND DURCH DIESES KODIERTE POLYPEPTIDE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 679625,
	"label": "IN BRUST- UND BLASENKREBS DIFFERENTIELL EXPRIMIERTES GEN UND DURCH DIESES KODIERTE POLYPEPTIDE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 679625,
	"label": "IN BRUST- UND BLASENKREBS DIFFERENTIELL EXPRIMIERTES GEN UND DURCH DIESES KODIERTE POLYPEPTIDE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 679625,
	"label": "IN BRUST- UND BLASENKREBS DIFFERENTIELL EXPRIMIERTES GEN UND DURCH DIESES KODIERTE POLYPEPTIDE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7511,
	"target": 6795,
	"type": 680210,
	"label": "IgE receptor antagonists that compete with IgE134 for binding to the receptor",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 681340,
	"label": "MEJORA DE LA GALACTOSILACION DE GLICOPROTEINAS RECOMBINANTES.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 681340,
	"label": "MEJORA DE LA GALACTOSILACION DE GLICOPROTEINAS RECOMBINANTES.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 681340,
	"label": "MEJORA DE LA GALACTOSILACION DE GLICOPROTEINAS RECOMBINANTES.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 681340,
	"label": "MEJORA DE LA GALACTOSILACION DE GLICOPROTEINAS RECOMBINANTES.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 681340,
	"label": "MEJORA DE LA GALACTOSILACION DE GLICOPROTEINAS RECOMBINANTES.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 681430,
	"label": "PEPTIDDERIVATE DES APOLIPOPROTEINS-A1/AII",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 681430,
	"label": "PEPTIDDERIVATE DES APOLIPOPROTEINS-A1/AII",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 681430,
	"label": "PEPTIDDERIVATE DES APOLIPOPROTEINS-A1/AII",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 31912,
	"target": 6403,
	"type": 681825,
	"label": "COMPUESTOS DERIVADOS DE QUINAZOLIN-4-ONA Y BENZO[1,2,4]TIADIAZINA-1,1-DIÓXIDO, SU USO, UN PROCESO PARA SU OBTENCION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 682565,
	"label": "ANTICUERPOS CONTRA FORMAS ESPECIALES DE PROPSA Y SU UTILIZACION EN INMUNOENSAYOS.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 682565,
	"label": "ANTICUERPOS CONTRA FORMAS ESPECIALES DE PROPSA Y SU UTILIZACION EN INMUNOENSAYOS.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 682565,
	"label": "ANTICUERPOS CONTRA FORMAS ESPECIALES DE PROPSA Y SU UTILIZACION EN INMUNOENSAYOS.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 684016,
	"label": "METHODS AND COMPOSITIONS OF MATTER CONCERNING APRIL G70, BCMA, BLYS AGP 3, AND TACI.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 684016,
	"label": "METHODS AND COMPOSITIONS OF MATTER CONCERNING APRIL G70, BCMA, BLYS AGP 3, AND TACI.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 684016,
	"label": "METHODS AND COMPOSITIONS OF MATTER CONCERNING APRIL G70, BCMA, BLYS AGP 3, AND TACI.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32772,
	"target": 32754,
	"type": 686017,
	"label": "USE OF AN ANTAGONIST SPECIFIC FOR A NATIVE ErbB4 RECEPTOR IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF STENOSIS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32754,
	"target": 7423,
	"type": 686017,
	"label": "USE OF AN ANTAGONIST SPECIFIC FOR A NATIVE ErbB4 RECEPTOR IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF STENOSIS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32772,
	"target": 7423,
	"type": 686017,
	"label": "USE OF AN ANTAGONIST SPECIFIC FOR A NATIVE ErbB4 RECEPTOR IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF STENOSIS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 37899,
	"type": 686549,
	"label": "Method for the preparation of an in vitro surrogate for identifying expressed genes in a test sample",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 32734,
	"type": 688387,
	"label": "G-protein coupled receptors amplified in breast cancer",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 688387,
	"label": "G-protein coupled receptors amplified in breast cancer",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 32734,
	"type": 688387,
	"label": "G-protein coupled receptors amplified in breast cancer",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32734,
	"target": 7507,
	"type": 688387,
	"label": "G-protein coupled receptors amplified in breast cancer",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 688387,
	"label": "G-protein coupled receptors amplified in breast cancer",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 690434,
	"label": "ANGIOGENESIS - ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 690434,
	"label": "ANGIOGENESIS - ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 690434,
	"label": "ANGIOGENESIS - ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37859,
	"target": 6795,
	"type": 690434,
	"label": "ANGIOGENESIS - ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 690434,
	"label": "ANGIOGENESIS - ASSOCIATED PROTEINS, AND NUCLEIC ACIDS ENCODING THE SAME",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 691694,
	"label": "Enzymatic synthesis of peptide, its mimic or protein, useful e.g. in drug development, using a modified ligase adapted to a particular ester leaving group",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 691694,
	"label": "Enzymatic synthesis of peptide, its mimic or protein, useful e.g. in drug development, using a modified ligase adapted to a particular ester leaving group",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 691694,
	"label": "Enzymatic synthesis of peptide, its mimic or protein, useful e.g. in drug development, using a modified ligase adapted to a particular ester leaving group",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 691694,
	"label": "Enzymatic synthesis of peptide, its mimic or protein, useful e.g. in drug development, using a modified ligase adapted to a particular ester leaving group",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 691694,
	"label": "Enzymatic synthesis of peptide, its mimic or protein, useful e.g. in drug development, using a modified ligase adapted to a particular ester leaving group",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6816,
	"target": 6812,
	"type": 692742,
	"label": "Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 692742,
	"label": "Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 692742,
	"label": "Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 692742,
	"label": "Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 6816,
	"type": 692742,
	"label": "Method for treating myeloma utilizing an expression enhancer for HM1.24 antigen",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6241,
	"target": 6215,
	"type": 692763,
	"label": "Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 6539,
	"target": 6447,
	"type": 692763,
	"label": "Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 6447,
	"target": 6241,
	"type": 692763,
	"label": "Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 6447,
	"target": 6215,
	"type": 692763,
	"label": "Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 6539,
	"target": 6241,
	"type": 692763,
	"label": "Kombinationsbehandling under anvendelse af pentafluorbenzensulfonamid og platinforbindelse",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 692881,
	"label": "Vitamin D3 (cholcalciferol) derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7450,
	"target": 7422,
	"type": 692881,
	"label": "Vitamin D3 (cholcalciferol) derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7422,
	"target": 6431,
	"type": 692881,
	"label": "Vitamin D3 (cholcalciferol) derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7422,
	"target": 6429,
	"type": 692881,
	"label": "Vitamin D3 (cholcalciferol) derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 692881,
	"label": "Vitamin D3 (cholcalciferol) derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 693308,
	"label": "Determining amplification efficiency of a target nucleic acid comprises measuring real-time amplification of diluted series, setting signal threshold value, and determining cycle number at which threshold is exceeded",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 694273,
	"label": "REVERSE TRANSKRIPTION BEI HOHER TEMPERATUR DURCH DIE VERWENDUNG VON MUTIERTEN DNA POLYMERASEN",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31317,
	"target": 30814,
	"type": 695412,
	"label": "UN COMPUESTO DE PIPERAZINA SUSTITUIDA, COMPOSICIONES FARMACEUTICAS Y EL USO DE LOS MISMOS PARA LA ELABORACION DE MEDICAMENTOS",
	"group": "Gilead",
	"time": 2001,
	"strength": 1
}, {
	"source": 30814,
	"target": 6360,
	"type": 695412,
	"label": "UN COMPUESTO DE PIPERAZINA SUSTITUIDA, COMPOSICIONES FARMACEUTICAS Y EL USO DE LOS MISMOS PARA LA ELABORACION DE MEDICAMENTOS",
	"group": "Gilead",
	"time": 2001,
	"strength": 1
}, {
	"source": 31317,
	"target": 6360,
	"type": 695412,
	"label": "UN COMPUESTO DE PIPERAZINA SUSTITUIDA, COMPOSICIONES FARMACEUTICAS Y EL USO DE LOS MISMOS PARA LA ELABORACION DE MEDICAMENTOS",
	"group": "Gilead",
	"time": 2001,
	"strength": 1
}, {
	"source": 37904,
	"target": 37875,
	"type": 696109,
	"label": "Methods for activating an erythropoietin receptor using antibodies",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37875,
	"target": 32770,
	"type": 696109,
	"label": "Methods for activating an erythropoietin receptor using antibodies",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 696109,
	"label": "Methods for activating an erythropoietin receptor using antibodies",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 56765,
	"target": 37904,
	"type": 696109,
	"label": "Methods for activating an erythropoietin receptor using antibodies",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 56765,
	"target": 37875,
	"type": 696109,
	"label": "Methods for activating an erythropoietin receptor using antibodies",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 696222,
	"label": "IMPROVEMENT OF BIOLOGICAL PRODUCTION OF CAROTENOIDS AND BIOLOGICAL MATERIALS THEREFOR.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 696222,
	"label": "IMPROVEMENT OF BIOLOGICAL PRODUCTION OF CAROTENOIDS AND BIOLOGICAL MATERIALS THEREFOR.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37988,
	"target": 37862,
	"type": 696222,
	"label": "IMPROVEMENT OF BIOLOGICAL PRODUCTION OF CAROTENOIDS AND BIOLOGICAL MATERIALS THEREFOR.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 696277,
	"label": "VERFAHREN ZUR IDENTIFIZIERUNG VON EIN PHYSIOLOGISCH AKTIVES POLYPEPTID KODIERENDER DNA IN EINEM NAGETIER",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 696775,
	"label": "VERFAHREN ZUM AUFFINDEN EINES HEILMITTELS FÜR KREBS MIT HILFE VON INTERAKTIONSDOMÄNEN VON P53 UND MORTALIN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 696775,
	"label": "VERFAHREN ZUM AUFFINDEN EINES HEILMITTELS FÜR KREBS MIT HILFE VON INTERAKTIONSDOMÄNEN VON P53 UND MORTALIN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 696775,
	"label": "VERFAHREN ZUM AUFFINDEN EINES HEILMITTELS FÜR KREBS MIT HILFE VON INTERAKTIONSDOMÄNEN VON P53 UND MORTALIN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 697190,
	"label": "Methods and reagents for the polymerase chain reaction amplification of long DNA sequences",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 697822,
	"label": "Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 697822,
	"label": "Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 697822,
	"label": "Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 697822,
	"label": "Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 697822,
	"label": "Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 698267,
	"label": "Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 698267,
	"label": "Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7487,
	"target": 6229,
	"type": 698267,
	"label": "Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 698267,
	"label": "Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 698267,
	"label": "Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7450,
	"target": 7380,
	"type": 698370,
	"label": "DERIVADOS DE PURINA SUSTITUIDOS COMO INHIBIDORES DE LA ADHESION CELULAR, UN PROCEDIMIENTO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA Y EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 31939,
	"target": 7450,
	"type": 698370,
	"label": "DERIVADOS DE PURINA SUSTITUIDOS COMO INHIBIDORES DE LA ADHESION CELULAR, UN PROCEDIMIENTO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA Y EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 31939,
	"target": 7380,
	"type": 698370,
	"label": "DERIVADOS DE PURINA SUSTITUIDOS COMO INHIBIDORES DE LA ADHESION CELULAR, UN PROCEDIMIENTO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA Y EL USO DE DICHOS COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 699258,
	"label": "SINERGIA DE ANTAGONISTA DE RECEPTORES DEL LIGANDO APO-2L Y DE CPT-11.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 699258,
	"label": "SINERGIA DE ANTAGONISTA DE RECEPTORES DEL LIGANDO APO-2L Y DE CPT-11.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 699258,
	"label": "SINERGIA DE ANTAGONISTA DE RECEPTORES DEL LIGANDO APO-2L Y DE CPT-11.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 699474,
	"label": "NUEVA PROTEINA DEL RECEPTOR DE HEMATOPOYETINA, NR12.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6550,
	"target": 6241,
	"type": 699649,
	"label": "Faste lipid-formuleringer, fremstilling av slike samt anvendelse av slike for fremstilling av medikament for forebygging og behandling av fedme.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7464,
	"target": 7437,
	"type": 699783,
	"label": "ANATAGONISTA DEL TNF-ALFA Y ANTAGONISTA DEL LFA-1 PARA EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7437,
	"target": 6795,
	"type": 699783,
	"label": "ANATAGONISTA DEL TNF-ALFA Y ANTAGONISTA DEL LFA-1 PARA EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7464,
	"target": 6795,
	"type": 699783,
	"label": "ANATAGONISTA DEL TNF-ALFA Y ANTAGONISTA DEL LFA-1 PARA EL TRATAMIENTO DE LA ARTRITIS REUMATOIDE.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 699968,
	"label": "PROCESSES FOR THE PRODUCTION OF EUKARYOTIC ALKALINE PHOSPHATASE IN YEAST CELLS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38065,
	"target": 32777,
	"type": 702090,
	"label": "EXPRESSIONSVEKTOREN UND ANWENDUNGSMETHODEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 31939,
	"target": 7424,
	"type": 702192,
	"label": "Naphthyridine derivatives, process of their preparation, their use and pharmaceutical compositions which the derivatives are comprised",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7509,
	"target": 7424,
	"type": 702458,
	"label": "HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINEASE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32779,
	"target": 6229,
	"type": 702795,
	"label": "Anticorpo anti-antìgeno de célula estaminal prostática (psca) isolado, anticorpo monoclonal anti-psca, ácido nucleico isolado, vetor de expressão, célula, célula hospedeira, método de produção de anticorpo, composição método in vitro para matar uma célula cancerosa que expresse psca, uso de uma anticorpo monoclonal anti-psca e artigo industrializado",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 703119,
	"label": "AN HER2 BINDENDE PEPTIDVERBINDUNGEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38042,
	"target": 7507,
	"type": 703119,
	"label": "AN HER2 BINDENDE PEPTIDVERBINDUNGEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38042,
	"target": 6795,
	"type": 703119,
	"label": "AN HER2 BINDENDE PEPTIDVERBINDUNGEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 7424,
	"type": 703148,
	"label": "COMPOSITION COMPRISING A PRO364 OR PRO175 POLYPEPTIDE IN ADMIXTURE WITH A PHARMACEUTICALLY ACCEPTABLE CARRIER AND CARDIOVASCULAR, ENDOTHELIAL OR ANGIOGENIC AGENT, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR PREPARING MEDICAMENTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 703170,
	"label": "ANTICORPOS MONOCLONAIS SELECTIVOS PARA O FCV E SUA UTILIZACAO PARA O TRATAMENTO DE DOENCAS ASSOCIADAS AO FCV",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32779,
	"target": 7360,
	"type": 703170,
	"label": "ANTICORPOS MONOCLONAIS SELECTIVOS PARA O FCV E SUA UTILIZACAO PARA O TRATAMENTO DE DOENCAS ASSOCIADAS AO FCV",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 703170,
	"label": "ANTICORPOS MONOCLONAIS SELECTIVOS PARA O FCV E SUA UTILIZACAO PARA O TRATAMENTO DE DOENCAS ASSOCIADAS AO FCV",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 703176,
	"label": "VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32788,
	"target": 7360,
	"type": 703176,
	"label": "VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 703176,
	"label": "VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7487,
	"target": 6371,
	"type": 703336,
	"label": "SUBSTITUIERTE 5-BENZYL-2,4-DIAMINOPYRIMIDINE",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6447,
	"type": 703395,
	"label": "SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 703910,
	"label": "AMPLIFIZIERUNG UNTER VERWENDUNG VON MODIFIZIERTEN PRIMERN",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 703958,
	"label": "VERFAHREN ZUR ANALYSE VON NICHT-PROTEIN KOMPONENTEN MITTELS VERWENDUNG EINER PROTEASE AUS EINEM BACILLUS-STAMM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 706085,
	"label": "Conjugado, composição que compreende conjugados, composição farmacêutica, utilização de um conjugado ou uma composição, processo para o tratamento profiládico e/ou terapêutico de distúrbios e  processo para a preparação de um conjugado ou composição",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7424,
	"target": 6795,
	"type": 706085,
	"label": "Conjugado, composição que compreende conjugados, composição farmacêutica, utilização de um conjugado ou uma composição, processo para o tratamento profiládico e/ou terapêutico de distúrbios e  processo para a preparação de um conjugado ou composição",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 706085,
	"label": "Conjugado, composição que compreende conjugados, composição farmacêutica, utilização de um conjugado ou uma composição, processo para o tratamento profiládico e/ou terapêutico de distúrbios e  processo para a preparação de um conjugado ou composição",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38232,
	"target": 6795,
	"type": 707020,
	"label": "PEPTIDANTAGONISTEN DES FAKTORS VIIA",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 708311,
	"label": "REKOMBINANTE TERMINALE DEOXYNUKLEOTIDYLTRANSFERASE MIT VERBESSERTER FUNKTIONALITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56833,
	"target": 38237,
	"type": 708311,
	"label": "REKOMBINANTE TERMINALE DEOXYNUKLEOTIDYLTRANSFERASE MIT VERBESSERTER FUNKTIONALITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56833,
	"target": 37986,
	"type": 708311,
	"label": "REKOMBINANTE TERMINALE DEOXYNUKLEOTIDYLTRANSFERASE MIT VERBESSERTER FUNKTIONALITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31081,
	"target": 30802,
	"type": 709182,
	"label": "Compostos, métodos para a preparação de um composto, composições farmacêuticas que compreendem o mesmo e método para o tratamento e/ou prevenção de enfermidades que estão associadas com protéases de cisteìna e utilização desses compostos",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 711089,
	"label": "METHOD FOR THE PRODUCTION OF INSOLUBLE POLYPEPTIDE EXPRESSED IN MICROBIAL HOST",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 711089,
	"label": "METHOD FOR THE PRODUCTION OF INSOLUBLE POLYPEPTIDE EXPRESSED IN MICROBIAL HOST",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 711089,
	"label": "METHOD FOR THE PRODUCTION OF INSOLUBLE POLYPEPTIDE EXPRESSED IN MICROBIAL HOST",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 712796,
	"label": "EINZELNE UND DUALE ANTI-CD4-RANTES CHEMOKIN/ZYTOKIN KONSTRUKTE",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 32694,
	"type": 712796,
	"label": "EINZELNE UND DUALE ANTI-CD4-RANTES CHEMOKIN/ZYTOKIN KONSTRUKTE",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32788,
	"target": 32694,
	"type": 712796,
	"label": "EINZELNE UND DUALE ANTI-CD4-RANTES CHEMOKIN/ZYTOKIN KONSTRUKTE",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 712796,
	"label": "EINZELNE UND DUALE ANTI-CD4-RANTES CHEMOKIN/ZYTOKIN KONSTRUKTE",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 712796,
	"label": "EINZELNE UND DUALE ANTI-CD4-RANTES CHEMOKIN/ZYTOKIN KONSTRUKTE",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 713569,
	"label": "DETECCION DE SUSCEPTIBILIDAD A LAS ENFERMEDADES AUTOINMUNES, ESPECIALMENTE A LA DIABETES TIPO 1.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 713732,
	"label": "ANTICUERPOS CONTRA EL ANTIGENO MUC-18.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 713732,
	"label": "ANTICUERPOS CONTRA EL ANTIGENO MUC-18.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 713732,
	"label": "ANTICUERPOS CONTRA EL ANTIGENO MUC-18.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 713732,
	"label": "ANTICUERPOS CONTRA EL ANTIGENO MUC-18.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 713732,
	"label": "ANTICUERPOS CONTRA EL ANTIGENO MUC-18.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37960,
	"type": 713835,
	"label": "LÖSLICHE KOMPLEXE VON ZIELPROTEINEN UND PEPTIDYL- PROLYL-ISOMERASE-CHAPERONEN SOWIE DEREN HERSTELLUNG UND VERWENDUNG",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 713835,
	"label": "LÖSLICHE KOMPLEXE VON ZIELPROTEINEN UND PEPTIDYL- PROLYL-ISOMERASE-CHAPERONEN SOWIE DEREN HERSTELLUNG UND VERWENDUNG",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38042,
	"target": 37960,
	"type": 713835,
	"label": "LÖSLICHE KOMPLEXE VON ZIELPROTEINEN UND PEPTIDYL- PROLYL-ISOMERASE-CHAPERONEN SOWIE DEREN HERSTELLUNG UND VERWENDUNG",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37960,
	"target": 32788,
	"type": 713835,
	"label": "LÖSLICHE KOMPLEXE VON ZIELPROTEINEN UND PEPTIDYL- PROLYL-ISOMERASE-CHAPERONEN SOWIE DEREN HERSTELLUNG UND VERWENDUNG",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 713835,
	"label": "LÖSLICHE KOMPLEXE VON ZIELPROTEINEN UND PEPTIDYL- PROLYL-ISOMERASE-CHAPERONEN SOWIE DEREN HERSTELLUNG UND VERWENDUNG",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 714402,
	"label": "A3-adenosinreseptoragonist, fremgangsmate for fremstilling og anvendelse derav, og farmasoytisk preparat omfattende slik",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 714509,
	"label": "DERIVADOS DE LA DOLASTATINA 10, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, EL USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS, PROCESOS PARA LA PREPARACION DE DICHOS COMPUESTOS, E INTERMEDIARIOS UTILES EN LA PREPARACION DE DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 716354,
	"label": "Heksasykliske forbindelser, farmasoytiske preparater som omfatter forbindelsene, anvendelser av forbindelsene til fremstilling av medikamenter samt fremgangsmate for fremstilling av forbindelsene og fremgangsmater for fremstilling av mellomprodukter",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32004,
	"target": 7507,
	"type": 716354,
	"label": "Heksasykliske forbindelser, farmasoytiske preparater som omfatter forbindelsene, anvendelser av forbindelsene til fremstilling av medikamenter samt fremgangsmate for fremstilling av forbindelsene og fremgangsmater for fremstilling av mellomprodukter",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32004,
	"target": 6376,
	"type": 716354,
	"label": "Heksasykliske forbindelser, farmasoytiske preparater som omfatter forbindelsene, anvendelser av forbindelsene til fremstilling av medikamenter samt fremgangsmate for fremstilling av forbindelsene og fremgangsmater for fremstilling av mellomprodukter",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6382,
	"target": 6376,
	"type": 717201,
	"label": "Compostos; processo para a preparação de um composto; composição farmacêutica; e método para o tratamento e/ou profilaxia de doenças que estão relacionadas com o nìvel de glicose no sangue",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 719766,
	"label": "COMPUESTOS POLICICLICOS, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, USO DE TALES COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS Y PROCEDIMIENTO PARA PRODUCIR DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 719766,
	"label": "COMPUESTOS POLICICLICOS, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, USO DE TALES COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS Y PROCEDIMIENTO PARA PRODUCIR DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 719766,
	"label": "COMPUESTOS POLICICLICOS, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, USO DE TALES COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS Y PROCEDIMIENTO PARA PRODUCIR DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 30606,
	"target": 6371,
	"type": 720294,
	"label": "SUBSTITUTED INDOLES AND PHARMACEUTICAL COMPOSITION, POSSESSING AGONISTIC ACTIVITY WITH RESPECT TO ALFA- 1A/L ADRENORECERPTOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7497,
	"target": 7358,
	"type": 721831,
	"label": "POLYMORPH UND ANDERE KRISTALLINISCHE FORMEN VON ZUSAMMEN-FTC",
	"group": "Gilead",
	"time": 2002,
	"strength": 1
}, {
	"source": 7358,
	"target": 6371,
	"type": 721831,
	"label": "POLYMORPH UND ANDERE KRISTALLINISCHE FORMEN VON ZUSAMMEN-FTC",
	"group": "Gilead",
	"time": 2002,
	"strength": 1
}, {
	"source": 7497,
	"target": 6371,
	"type": 721831,
	"label": "POLYMORPH UND ANDERE KRISTALLINISCHE FORMEN VON ZUSAMMEN-FTC",
	"group": "Gilead",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 722498,
	"label": "Fremgangsmåde til fremstilling af rekombinant trypsin",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 722498,
	"label": "Fremgangsmåde til fremstilling af rekombinant trypsin",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 722498,
	"label": "Fremgangsmåde til fremstilling af rekombinant trypsin",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 722498,
	"label": "Fremgangsmåde til fremstilling af rekombinant trypsin",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 722498,
	"label": "Fremgangsmåde til fremstilling af rekombinant trypsin",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 722764,
	"label": "REKOMBINANTE PROTEINASE K",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 722764,
	"label": "REKOMBINANTE PROTEINASE K",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 722764,
	"label": "REKOMBINANTE PROTEINASE K",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 722764,
	"label": "REKOMBINANTE PROTEINASE K",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 722764,
	"label": "REKOMBINANTE PROTEINASE K",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 723878,
	"label": "VERFAHREN ZUR EXPRESSION VON PROTEINEN IN EINEM IN VITRO TRANSLATIONSSYSTEM MIT CO-EXPRESSION VON HELFER PROTEINEN FÜR DIE FALTUNG",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 726388,
	"label": "1-BENZYL-5-PIPERAZIN-1-YL-3,4-DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO (1,2,6) THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO- BENZO(D) (1,3) OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 726388,
	"label": "1-BENZYL-5-PIPERAZIN-1-YL-3,4-DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO (1,2,6) THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO- BENZO(D) (1,3) OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 726388,
	"label": "1-BENZYL-5-PIPERAZIN-1-YL-3,4-DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO (1,2,6) THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO- BENZO(D) (1,3) OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 726544,
	"label": "E. coli strain deficient in degP and prc and having a mutant spr gene and a method for making a polypeptide",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 726544,
	"label": "E. coli strain deficient in degP and prc and having a mutant spr gene and a method for making a polypeptide",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 726544,
	"label": "E. coli strain deficient in degP and prc and having a mutant spr gene and a method for making a polypeptide",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 726544,
	"label": "E. coli strain deficient in degP and prc and having a mutant spr gene and a method for making a polypeptide",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 726544,
	"label": "E. coli strain deficient in degP and prc and having a mutant spr gene and a method for making a polypeptide",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 726561,
	"label": "Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 726771,
	"label": "REINIGUNGSVERFAHREN AUF GRUNDLAGE DER BINDUNG VON ENZYMEN AND MARKIERTE PEPTIDE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 726771,
	"label": "REINIGUNGSVERFAHREN AUF GRUNDLAGE DER BINDUNG VON ENZYMEN AND MARKIERTE PEPTIDE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 726771,
	"label": "REINIGUNGSVERFAHREN AUF GRUNDLAGE DER BINDUNG VON ENZYMEN AND MARKIERTE PEPTIDE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6241,
	"target": 6229,
	"type": 727321,
	"label": "Composição farmacêutica que compreende um inibidor de lìpases, processo para preparar essa composição, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6263,
	"target": 6241,
	"type": 727567,
	"label": "Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 729517,
	"label": "Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 729517,
	"label": "Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 729517,
	"label": "Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 729517,
	"label": "Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 32777,
	"type": 729517,
	"label": "Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 729639,
	"label": "METHOD OF DIAGNOSING AND TREATING CARTILAGINOUS DISORDERS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 729639,
	"label": "METHOD OF DIAGNOSING AND TREATING CARTILAGINOUS DISORDERS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 729639,
	"label": "METHOD OF DIAGNOSING AND TREATING CARTILAGINOUS DISORDERS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38237,
	"target": 38164,
	"type": 732770,
	"label": "PCR MULTIPLEX CUANTITATIVA CON UN INTERVALO DINAMICO ELEVADO.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 732770,
	"label": "PCR MULTIPLEX CUANTITATIVA CON UN INTERVALO DINAMICO ELEVADO.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 732770,
	"label": "PCR MULTIPLEX CUANTITATIVA CON UN INTERVALO DINAMICO ELEVADO.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 733927,
	"label": "Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 733927,
	"label": "Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 733927,
	"label": "Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 733927,
	"label": "Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 733927,
	"label": "Inhibidores de la proliferación celular que contienen anticuerpo anti-glipicano 3",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 734579,
	"label": "Polipeptìdio, composição, método para purificação de polipeptìdio a partir de uma composição e método para purificação de um anticorpo a partir de uma composição",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 734579,
	"label": "Polipeptìdio, composição, método para purificação de polipeptìdio a partir de uma composição e método para purificação de um anticorpo a partir de uma composição",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32772,
	"target": 6795,
	"type": 734579,
	"label": "Polipeptìdio, composição, método para purificação de polipeptìdio a partir de uma composição e método para purificação de um anticorpo a partir de uma composição",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 734608,
	"label": "DIAMINOTIAZOLES, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, INTERMEDIARIOS PARA LA PREPARACION DE DICHOS COMPUESTOS, USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS, Y PROCESOS PARA LA PREPARACION DE DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31851,
	"target": 7507,
	"type": 734608,
	"label": "DIAMINOTIAZOLES, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, INTERMEDIARIOS PARA LA PREPARACION DE DICHOS COMPUESTOS, USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS, Y PROCESOS PARA LA PREPARACION DE DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31851,
	"target": 7422,
	"type": 734608,
	"label": "DIAMINOTIAZOLES, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, INTERMEDIARIOS PARA LA PREPARACION DE DICHOS COMPUESTOS, USO DE DICHOS COMPUESTOS EN LA PREPARACION DE MEDICAMENTOS, Y PROCESOS PARA LA PREPARACION DE DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 735262,
	"label": "VERFAHREN ZUR BESTIMMUNG VON NUKLEINSÄUREN MITTELS EINER KONTROLLE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7409,
	"target": 7360,
	"type": 735480,
	"label": "USE OF TNF-DERIVED PEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING OEDEMA",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 735480,
	"label": "USE OF TNF-DERIVED PEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING OEDEMA",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 735480,
	"label": "USE OF TNF-DERIVED PEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING OEDEMA",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 736533,
	"label": "EXPRESION DE LA PROTEINASA K RECOMBINANTE DE TRITIRACHIUM ALBUM EN LEVADURA.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 736668,
	"label": "Use of a compound and paclitaxel in preparation of medicine for treating cancer",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 739607,
	"label": "NS5A nucleotide sequence variation as a marker for interferon response",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 741245,
	"label": "BIOMARKER FOR RESPONSE MONITORING OF CDK INHIBITORS IN THE CLINIC",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 741245,
	"label": "BIOMARKER FOR RESPONSE MONITORING OF CDK INHIBITORS IN THE CLINIC",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38237,
	"target": 7507,
	"type": 741245,
	"label": "BIOMARKER FOR RESPONSE MONITORING OF CDK INHIBITORS IN THE CLINIC",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38237,
	"target": 6371,
	"type": 741245,
	"label": "BIOMARKER FOR RESPONSE MONITORING OF CDK INHIBITORS IN THE CLINIC",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 741245,
	"label": "BIOMARKER FOR RESPONSE MONITORING OF CDK INHIBITORS IN THE CLINIC",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 744339,
	"label": "compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7360,
	"target": 6382,
	"type": 744339,
	"label": "compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7360,
	"target": 6371,
	"type": 744339,
	"label": "compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 745353,
	"label": "C-TERMINALE MODIFIKATION VON POLYPEPTIDEN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 56804,
	"type": 746530,
	"label": "Use of specificly bound reagent of protein MASP in preparing diagnosis reagent",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 748381,
	"label": "RE-ENROLAMENTO DE POLIPEPTIDOS TAIS COMO O FACTOR DE CRESCIMENTO SEMELHANTE A INSULINA IGF-I RECOMBINANTE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6345,
	"target": 6333,
	"type": 748869,
	"label": "USE OF A COMBINATION OF MGLUR 2 ANTAGONIST AND ACHE INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OR TREATING ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6478,
	"target": 6345,
	"type": 748869,
	"label": "USE OF A COMBINATION OF MGLUR 2 ANTAGONIST AND ACHE INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OR TREATING ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6478,
	"target": 6333,
	"type": 748869,
	"label": "USE OF A COMBINATION OF MGLUR 2 ANTAGONIST AND ACHE INHIBITOR IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTING OR TREATING ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 751735,
	"label": "6-ALCOXYPYRIDOPYRIMIDINES AND PHARMACEUTICAL COMPOUND POSSESSING ACTIVITY OF MAP p38 KINASE INHIBITORS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 751735,
	"label": "6-ALCOXYPYRIDOPYRIMIDINES AND PHARMACEUTICAL COMPOUND POSSESSING ACTIVITY OF MAP p38 KINASE INHIBITORS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 751735,
	"label": "6-ALCOXYPYRIDOPYRIMIDINES AND PHARMACEUTICAL COMPOUND POSSESSING ACTIVITY OF MAP p38 KINASE INHIBITORS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 752618,
	"label": "POSITIONELLE ISOMEREN VON PEGYLIERTEM INTERFERON ALPHA 2A",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 752618,
	"label": "POSITIONELLE ISOMEREN VON PEGYLIERTEM INTERFERON ALPHA 2A",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 752618,
	"label": "POSITIONELLE ISOMEREN VON PEGYLIERTEM INTERFERON ALPHA 2A",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7511,
	"target": 6816,
	"type": 752618,
	"label": "POSITIONELLE ISOMEREN VON PEGYLIERTEM INTERFERON ALPHA 2A",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 752618,
	"label": "POSITIONELLE ISOMEREN VON PEGYLIERTEM INTERFERON ALPHA 2A",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6371,
	"target": 6290,
	"type": 753276,
	"label": "COMPUESTOS DERIVADOS DE CARBOXAMIDA DE TIAZOLILPIRROL; PROCEDIMIENTO PARA SU PREPARACION; COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN; Y SU USO PARA EL TRATAMIENTO Y/O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON LA MODULACION DE RECEPTORES CANABINOID",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 32595,
	"type": 754414,
	"label": "CD40 binding molecules or 4-1BB binding molecules used in a monotherapy for the treatment of a tumour or infectious agent by induction of systemic T-cell immunity against the tumour antigen",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 754414,
	"label": "CD40 binding molecules or 4-1BB binding molecules used in a monotherapy for the treatment of a tumour or infectious agent by induction of systemic T-cell immunity against the tumour antigen",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 754414,
	"label": "CD40 binding molecules or 4-1BB binding molecules used in a monotherapy for the treatment of a tumour or infectious agent by induction of systemic T-cell immunity against the tumour antigen",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 32595,
	"type": 754414,
	"label": "CD40 binding molecules or 4-1BB binding molecules used in a monotherapy for the treatment of a tumour or infectious agent by induction of systemic T-cell immunity against the tumour antigen",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32595,
	"target": 7507,
	"type": 754414,
	"label": "CD40 binding molecules or 4-1BB binding molecules used in a monotherapy for the treatment of a tumour or infectious agent by induction of systemic T-cell immunity against the tumour antigen",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 754635,
	"label": "NEUE, MHC KLASSE II ASSOZIIERTE PEPTIDE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32738,
	"target": 7507,
	"type": 754635,
	"label": "NEUE, MHC KLASSE II ASSOZIIERTE PEPTIDE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32738,
	"target": 6812,
	"type": 754635,
	"label": "NEUE, MHC KLASSE II ASSOZIIERTE PEPTIDE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7360,
	"target": 6290,
	"type": 755168,
	"label": "INDOLE-3-CARBOXAMIDE DERIVATIVES AS ACTIVATORS OF GLUCOKINASE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 756173,
	"label": "Verfahren zur Herstellung von zirkulären mutierten und/oder chimären Polynukleotiden",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 756173,
	"label": "Verfahren zur Herstellung von zirkulären mutierten und/oder chimären Polynukleotiden",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 756173,
	"label": "Verfahren zur Herstellung von zirkulären mutierten und/oder chimären Polynukleotiden",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 756173,
	"label": "Verfahren zur Herstellung von zirkulären mutierten und/oder chimären Polynukleotiden",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 756173,
	"label": "Verfahren zur Herstellung von zirkulären mutierten und/oder chimären Polynukleotiden",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7425,
	"target": 7360,
	"type": 756662,
	"label": "CHIRAL DERIVATIVES OF OXAZOLARYLPROPIONIC ACID AND THEIR USING AS AGONISTS OR RECEPTOR ACTIVATED BY PEROXISOME PROLIFERATOR (PPAR AGONISTS)",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 756774,
	"label": "VERWENDUNG VON NICOTINAMIDE N-METHYLTRANSFERASE ZUR DIAGNOSE VON KOLOREKTALEM KREBS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6550,
	"target": 6376,
	"type": 757937,
	"label": "DERIVATIVES OF 1,3,4-TRIAZAPHENALENE AND 1,3,4,6-TETRAAZAPHENALENE SHOWING INHIBITION EFFECT ON EPIDERMAL GROWTH FACTOR OF TYROSINEKYNASE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6550,
	"type": 757937,
	"label": "DERIVATIVES OF 1,3,4-TRIAZAPHENALENE AND 1,3,4,6-TETRAAZAPHENALENE SHOWING INHIBITION EFFECT ON EPIDERMAL GROWTH FACTOR OF TYROSINEKYNASE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 757937,
	"label": "DERIVATIVES OF 1,3,4-TRIAZAPHENALENE AND 1,3,4,6-TETRAAZAPHENALENE SHOWING INHIBITION EFFECT ON EPIDERMAL GROWTH FACTOR OF TYROSINEKYNASE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31056,
	"target": 7507,
	"type": 757937,
	"label": "DERIVATIVES OF 1,3,4-TRIAZAPHENALENE AND 1,3,4,6-TETRAAZAPHENALENE SHOWING INHIBITION EFFECT ON EPIDERMAL GROWTH FACTOR OF TYROSINEKYNASE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31056,
	"target": 6550,
	"type": 757937,
	"label": "DERIVATIVES OF 1,3,4-TRIAZAPHENALENE AND 1,3,4,6-TETRAAZAPHENALENE SHOWING INHIBITION EFFECT ON EPIDERMAL GROWTH FACTOR OF TYROSINEKYNASE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 38164,
	"type": 758819,
	"label": "Mikrobiel hybrid promotor/operator, vektor og udtrykkelsesvektor indeholdende denne, og E. coli stamme transformeret med udtrykkelsesvektoren, kultur af E. coli stammen og fremgangsmåde til mikrobiel produktion af heterologe polypeptider under anvendelse af kulturen",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 38164,
	"target": 37864,
	"type": 758819,
	"label": "Mikrobiel hybrid promotor/operator, vektor og udtrykkelsesvektor indeholdende denne, og E. coli stamme transformeret med udtrykkelsesvektoren, kultur af E. coli stammen og fremgangsmåde til mikrobiel produktion af heterologe polypeptider under anvendelse af kulturen",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 758819,
	"label": "Mikrobiel hybrid promotor/operator, vektor og udtrykkelsesvektor indeholdende denne, og E. coli stamme transformeret med udtrykkelsesvektoren, kultur af E. coli stammen og fremgangsmåde til mikrobiel produktion af heterologe polypeptider under anvendelse af kulturen",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 760638,
	"label": "RECOMBINANT DNA METHOD FOR PRODUCTION OF HEPATITIS B SURFACE ANTIGEN IN YEAST",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37862,
	"target": 6854,
	"type": 760638,
	"label": "RECOMBINANT DNA METHOD FOR PRODUCTION OF HEPATITIS B SURFACE ANTIGEN IN YEAST",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 760638,
	"label": "RECOMBINANT DNA METHOD FOR PRODUCTION OF HEPATITIS B SURFACE ANTIGEN IN YEAST",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 761301,
	"label": "COMPOSICOES DE MATERIA,POLIPEPTIDEO,SEQUENCIA DE DNA,VEICULO DE EXPRESSAO REPLICAVEL,MICROORGANISMO OU CULTURA CELULAR,PLASMIDEO,EXTRATO DE CULTURA CELULAR,CULTURA DE CELULAS TRANSFORMANTES,USO DE INTERFERON IMUNE HUMANO MADURO,PROCESSO DE EXPRESSAO DE UM GENE,PROCESSO PARA PRODUCAO DE UM POLIPEPTIDEO,PROCESSO PARA PRODUCAO DE UM VEICULO DE EXPRESSAO,E PRODUTO OBTIDO POR TAIS PROCESSOS",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 761301,
	"label": "COMPOSICOES DE MATERIA,POLIPEPTIDEO,SEQUENCIA DE DNA,VEICULO DE EXPRESSAO REPLICAVEL,MICROORGANISMO OU CULTURA CELULAR,PLASMIDEO,EXTRATO DE CULTURA CELULAR,CULTURA DE CELULAS TRANSFORMANTES,USO DE INTERFERON IMUNE HUMANO MADURO,PROCESSO DE EXPRESSAO DE UM GENE,PROCESSO PARA PRODUCAO DE UM POLIPEPTIDEO,PROCESSO PARA PRODUCAO DE UM VEICULO DE EXPRESSAO,E PRODUTO OBTIDO POR TAIS PROCESSOS",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 761301,
	"label": "COMPOSICOES DE MATERIA,POLIPEPTIDEO,SEQUENCIA DE DNA,VEICULO DE EXPRESSAO REPLICAVEL,MICROORGANISMO OU CULTURA CELULAR,PLASMIDEO,EXTRATO DE CULTURA CELULAR,CULTURA DE CELULAS TRANSFORMANTES,USO DE INTERFERON IMUNE HUMANO MADURO,PROCESSO DE EXPRESSAO DE UM GENE,PROCESSO PARA PRODUCAO DE UM POLIPEPTIDEO,PROCESSO PARA PRODUCAO DE UM VEICULO DE EXPRESSAO,E PRODUTO OBTIDO POR TAIS PROCESSOS",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 32694,
	"target": 6816,
	"type": 763725,
	"label": "CRYSTALLINE HUMAN LEUKOCYTE INTERFERON,ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 763749,
	"label": "NOVEL VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 763749,
	"label": "NOVEL VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 763749,
	"label": "NOVEL VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 30950,
	"target": 6272,
	"type": 769164,
	"label": "UN PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE IMIDA- ZOLIDINA",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 32440,
	"target": 32437,
	"type": 770811,
	"label": "ANTHRACYCLINE GLYCOSIDES WITH ANTI-TUMOUR ACITIVITY; PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 32440,
	"target": 32437,
	"type": 772835,
	"label": "Process to produce anthracycline glycosides",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 32440,
	"target": 7507,
	"type": 772836,
	"label": "VERFAHREN ZUR HERSTELLUNG VON ACLACINOMYCINEN UND VERWENDETE MIKROORGANISMEN.",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 6427,
	"target": 6417,
	"type": 772840,
	"label": "NEUE ALKYLDERIVATE VON CARDENOLID-BIS-DIGITOXOSIDEN, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 7425,
	"target": 6417,
	"type": 776009,
	"label": "D-HOMOANDROSTANE-17ALPHA-CARBOXYLIC ACIDS,DERIVATIVES THEREOF AND 17ALPHA-SPIROETHERS,THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 32501,
	"target": 7425,
	"type": 776009,
	"label": "D-HOMOANDROSTANE-17ALPHA-CARBOXYLIC ACIDS,DERIVATIVES THEREOF AND 17ALPHA-SPIROETHERS,THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 32501,
	"target": 6417,
	"type": 776009,
	"label": "D-HOMOANDROSTANE-17ALPHA-CARBOXYLIC ACIDS,DERIVATIVES THEREOF AND 17ALPHA-SPIROETHERS,THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 31571,
	"target": 30485,
	"type": 778827,
	"label": "PROCESS FOR PREPARING CYCLOHEXENE DERIVATIVES AND AN INTERMEDIATE MATERIAL IN THIS PROCESS",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 779682,
	"label": "PURIFICATION OF RECOMBINANT HUMAN INTERLEUKIN - 2; PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 779682,
	"label": "PURIFICATION OF RECOMBINANT HUMAN INTERLEUKIN - 2; PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 779682,
	"label": "PURIFICATION OF RECOMBINANT HUMAN INTERLEUKIN - 2; PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 779682,
	"label": "PURIFICATION OF RECOMBINANT HUMAN INTERLEUKIN - 2; PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 779682,
	"label": "PURIFICATION OF RECOMBINANT HUMAN INTERLEUKIN - 2; PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37875,
	"target": 37864,
	"type": 780449,
	"label": "REKOMBINANTE GAMMA-INTERFERON-POLYPEPTIDER, DNA, SOM KODER FOR DEM, REPLICERBARE UDTRYKKELSESVEKTORER, SOM KAN UDTRYKKE DEM, TRANSFORMANTE CELLER, SOM ER TRANSFORMERET MED UDTRYKKELSESVEKTORERNE, OG FARMACEUTISKE PRAEPARATER INDEHOLDENDE POLYPEPTIDER",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 780449,
	"label": "REKOMBINANTE GAMMA-INTERFERON-POLYPEPTIDER, DNA, SOM KODER FOR DEM, REPLICERBARE UDTRYKKELSESVEKTORER, SOM KAN UDTRYKKE DEM, TRANSFORMANTE CELLER, SOM ER TRANSFORMERET MED UDTRYKKELSESVEKTORERNE, OG FARMACEUTISKE PRAEPARATER INDEHOLDENDE POLYPEPTIDER",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 780449,
	"label": "REKOMBINANTE GAMMA-INTERFERON-POLYPEPTIDER, DNA, SOM KODER FOR DEM, REPLICERBARE UDTRYKKELSESVEKTORER, SOM KAN UDTRYKKE DEM, TRANSFORMANTE CELLER, SOM ER TRANSFORMERET MED UDTRYKKELSESVEKTORERNE, OG FARMACEUTISKE PRAEPARATER INDEHOLDENDE POLYPEPTIDER",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 780449,
	"label": "REKOMBINANTE GAMMA-INTERFERON-POLYPEPTIDER, DNA, SOM KODER FOR DEM, REPLICERBARE UDTRYKKELSESVEKTORER, SOM KAN UDTRYKKE DEM, TRANSFORMANTE CELLER, SOM ER TRANSFORMERET MED UDTRYKKELSESVEKTORERNE, OG FARMACEUTISKE PRAEPARATER INDEHOLDENDE POLYPEPTIDER",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 780449,
	"label": "REKOMBINANTE GAMMA-INTERFERON-POLYPEPTIDER, DNA, SOM KODER FOR DEM, REPLICERBARE UDTRYKKELSESVEKTORER, SOM KAN UDTRYKKE DEM, TRANSFORMANTE CELLER, SOM ER TRANSFORMERET MED UDTRYKKELSESVEKTORERNE, OG FARMACEUTISKE PRAEPARATER INDEHOLDENDE POLYPEPTIDER",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32700,
	"target": 32694,
	"type": 782745,
	"label": "GENE ENCODING AN ANALOG OF HUMAN INTERLEUKIN-II WHICH SUBSTANTIALLY RETAINS THE BIOLOGICAL ACTIVITY OF NATURAL HUMAN INTERLEUKIN-II,MICROORGANISM EXPRESSION VECTOR CONTAINING THE GENE,MICROORGANISMS TRANSFORMED BY THE VECTOR AND THE HUMAN INTERLEUKIN-II ANALOG PRODUCED BY THE MICROORGANISMS",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 32700,
	"type": 782745,
	"label": "GENE ENCODING AN ANALOG OF HUMAN INTERLEUKIN-II WHICH SUBSTANTIALLY RETAINS THE BIOLOGICAL ACTIVITY OF NATURAL HUMAN INTERLEUKIN-II,MICROORGANISM EXPRESSION VECTOR CONTAINING THE GENE,MICROORGANISMS TRANSFORMED BY THE VECTOR AND THE HUMAN INTERLEUKIN-II ANALOG PRODUCED BY THE MICROORGANISMS",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 782745,
	"label": "GENE ENCODING AN ANALOG OF HUMAN INTERLEUKIN-II WHICH SUBSTANTIALLY RETAINS THE BIOLOGICAL ACTIVITY OF NATURAL HUMAN INTERLEUKIN-II,MICROORGANISM EXPRESSION VECTOR CONTAINING THE GENE,MICROORGANISMS TRANSFORMED BY THE VECTOR AND THE HUMAN INTERLEUKIN-II ANALOG PRODUCED BY THE MICROORGANISMS",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38065,
	"target": 37875,
	"type": 782866,
	"label": "Fremgangsmåde til fremstilling af et ønsket modent protein i en hvirveldyrværtscelle, polycistronisk ekspressionsvektor  for det ønskede protein og hvirveldyrcellekultur transformeret med vektoren",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 782867,
	"label": "Fremgangsmåde til fremstilling af human vævsplasminogenaktivator (tPA) i værtsceller, ekspressionsvektorer for tPA og et DHFR-protein, rekombinante celler transformeret med vektoren, fremgangsmåde til amplifikation af DNA sekvensen,......",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 782867,
	"label": "Fremgangsmåde til fremstilling af human vævsplasminogenaktivator (tPA) i værtsceller, ekspressionsvektorer for tPA og et DHFR-protein, rekombinante celler transformeret med vektoren, fremgangsmåde til amplifikation af DNA sekvensen,......",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 782867,
	"label": "Fremgangsmåde til fremstilling af human vævsplasminogenaktivator (tPA) i værtsceller, ekspressionsvektorer for tPA og et DHFR-protein, rekombinante celler transformeret med vektoren, fremgangsmåde til amplifikation af DNA sekvensen,......",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 782867,
	"label": "Fremgangsmåde til fremstilling af human vævsplasminogenaktivator (tPA) i værtsceller, ekspressionsvektorer for tPA og et DHFR-protein, rekombinante celler transformeret med vektoren, fremgangsmåde til amplifikation af DNA sekvensen,......",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38065,
	"target": 6841,
	"type": 782867,
	"label": "Fremgangsmåde til fremstilling af human vævsplasminogenaktivator (tPA) i værtsceller, ekspressionsvektorer for tPA og et DHFR-protein, rekombinante celler transformeret med vektoren, fremgangsmåde til amplifikation af DNA sekvensen,......",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37875,
	"target": 32694,
	"type": 782951,
	"label": "MOUSE-MOUSE HYBRIDOMA CELL LINE ATCC HB8209 AND ITS MONOCLONAL ANTIBODY TO ERYTHROPOIETIN",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 56836,
	"target": 37875,
	"type": 782951,
	"label": "MOUSE-MOUSE HYBRIDOMA CELL LINE ATCC HB8209 AND ITS MONOCLONAL ANTIBODY TO ERYTHROPOIETIN",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 56836,
	"target": 32694,
	"type": 782951,
	"label": "MOUSE-MOUSE HYBRIDOMA CELL LINE ATCC HB8209 AND ITS MONOCLONAL ANTIBODY TO ERYTHROPOIETIN",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 784714,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF HUMANT IMMUNINTERFERON SAMT FARMACEUTISKE PRAEPARATER INDEHOLDENDE IMMUNINTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN OG ANVENDELSE AF HUMANT INTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN TIL FREMSTILLING AF ET TERAPEUTISK MIDDEL",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 784714,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF HUMANT IMMUNINTERFERON SAMT FARMACEUTISKE PRAEPARATER INDEHOLDENDE IMMUNINTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN OG ANVENDELSE AF HUMANT INTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN TIL FREMSTILLING AF ET TERAPEUTISK MIDDEL",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 784714,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF HUMANT IMMUNINTERFERON SAMT FARMACEUTISKE PRAEPARATER INDEHOLDENDE IMMUNINTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN OG ANVENDELSE AF HUMANT INTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN TIL FREMSTILLING AF ET TERAPEUTISK MIDDEL",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 7510,
	"type": 784714,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF HUMANT IMMUNINTERFERON SAMT FARMACEUTISKE PRAEPARATER INDEHOLDENDE IMMUNINTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN OG ANVENDELSE AF HUMANT INTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN TIL FREMSTILLING AF ET TERAPEUTISK MIDDEL",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 784714,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF HUMANT IMMUNINTERFERON SAMT FARMACEUTISKE PRAEPARATER INDEHOLDENDE IMMUNINTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN OG ANVENDELSE AF HUMANT INTERFERON FREMSTILLET VED FREMGANGSMAADEN IFOELGE OPFINDELSEN TIL FREMSTILLING AF ET TERAPEUTISK MIDDEL",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 6816,
	"type": 784715,
	"label": "METHOD OF EXTRACTING HUMAN IMMUNE INTERFERON FROM TRANSFORMED MICROORGANISMS IN THE PRECENCE OF A PROTEASE INHIBITOR",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 784716,
	"label": "PROCESS FOR PRODUCING A HOMOGENEOUS IMUNE INTERFERON FRAGMENT AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 784716,
	"label": "PROCESS FOR PRODUCING A HOMOGENEOUS IMUNE INTERFERON FRAGMENT AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32694,
	"target": 6816,
	"type": 784716,
	"label": "PROCESS FOR PRODUCING A HOMOGENEOUS IMUNE INTERFERON FRAGMENT AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 784716,
	"label": "PROCESS FOR PRODUCING A HOMOGENEOUS IMUNE INTERFERON FRAGMENT AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 6816,
	"type": 784716,
	"label": "PROCESS FOR PRODUCING A HOMOGENEOUS IMUNE INTERFERON FRAGMENT AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 785599,
	"label": "MENSCHLICHER, INSULINAEHNLICHER WACHSTUMSFAKTOR (IGF)HERGESTELLT AUS EINEM REKOMBINANTEN WIRT, VERFAHREN, EXPRESSIONSVEKTOR UND REKOMBINANTER WIRT HIERFUER UND IGF ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG.",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 785599,
	"label": "MENSCHLICHER, INSULINAEHNLICHER WACHSTUMSFAKTOR (IGF)HERGESTELLT AUS EINEM REKOMBINANTEN WIRT, VERFAHREN, EXPRESSIONSVEKTOR UND REKOMBINANTER WIRT HIERFUER UND IGF ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG.",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 785599,
	"label": "MENSCHLICHER, INSULINAEHNLICHER WACHSTUMSFAKTOR (IGF)HERGESTELLT AUS EINEM REKOMBINANTEN WIRT, VERFAHREN, EXPRESSIONSVEKTOR UND REKOMBINANTER WIRT HIERFUER UND IGF ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG.",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 787564,
	"label": "Fremgangsmåde til fremstilling af glycoprotein fra Herpes simplex virus, diagnostisk kit til detektion af Herpes simplex virus type 1 og type 2 samt fremgangsmåde til in vitro detektion af antistof eller antigen.",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 787565,
	"label": "PROCEDIMIENTO PARA PREPARAR UNA VACUNA QUE COMPRENDE UN DERIVADO TRUNCADO, LIBRE DE UNA MEMBRANA DE UN TIPO FIJADO A UNA MEMBRANA QUE TIENE DETERMINANTES ANTIGENICOS EXPUESTOS.",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 787565,
	"label": "PROCEDIMIENTO PARA PREPARAR UNA VACUNA QUE COMPRENDE UN DERIVADO TRUNCADO, LIBRE DE UNA MEMBRANA DE UN TIPO FIJADO A UNA MEMBRANA QUE TIENE DETERMINANTES ANTIGENICOS EXPUESTOS.",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 787565,
	"label": "PROCEDIMIENTO PARA PREPARAR UNA VACUNA QUE COMPRENDE UN DERIVADO TRUNCADO, LIBRE DE UNA MEMBRANA DE UN TIPO FIJADO A UNA MEMBRANA QUE TIENE DETERMINANTES ANTIGENICOS EXPUESTOS.",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32022,
	"target": 30485,
	"type": 790157,
	"label": "Compounds of o-(6-hydroxy-3-oxo-3H-thio(seleno)xanthen-9-yl)benzene sulfonic(benzoic) acid useful as photosensitizers",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32700,
	"target": 32694,
	"type": 790345,
	"label": "HOMOGENEOUS HUMAN INTERLEUKIN 2, PROCESS OF ITS PREPARATION AND APHARMACEUTICAL COMPOSITION BASED THEREON",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 790709,
	"label": "Vetor de expressão, célula hospedeira cultivada e processo para produzir polipeptìdeo de interferon de consenso do leucócito humano",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 791252,
	"label": "MENSCHLICHES LYMPHOTOXIN UND SEINE DERIVATE, VERFAHREN ZU SEINER HERSTELLUNG UND DASSELBE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN.",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 792678,
	"label": "PROCESS FOR THE PREPARATION OF CHOLECALCIFEROL DERIVATIVES",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38164,
	"target": 37864,
	"type": 793000,
	"label": "DUAL CHAIN POLYDEOXYNUCLEOTIDE CONTAINING GROWTH HORMONE DISCHARGE FACTOR GRF CODE STRUCTURED GENE",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32694,
	"target": 32527,
	"type": 793184,
	"label": "VERFAHREN ZUR ENTFERNUNG VON VERUNREINIGUNGEN AUS LEUKOZYTINTERFERON-ZUBEREITUNGEN UND DAS SO HERGESTELLTE GEREINIGTE LEUKOZYTINTERFERON.",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32527,
	"target": 6816,
	"type": 793184,
	"label": "VERFAHREN ZUR ENTFERNUNG VON VERUNREINIGUNGEN AUS LEUKOZYTINTERFERON-ZUBEREITUNGEN UND DAS SO HERGESTELLTE GEREINIGTE LEUKOZYTINTERFERON.",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32694,
	"target": 6816,
	"type": 793184,
	"label": "VERFAHREN ZUR ENTFERNUNG VON VERUNREINIGUNGEN AUS LEUKOZYTINTERFERON-ZUBEREITUNGEN UND DAS SO HERGESTELLTE GEREINIGTE LEUKOZYTINTERFERON.",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 31912,
	"target": 30815,
	"type": 793483,
	"label": "PROCESS FOR THE MANUFACTURE OF ISOQUINOLINE DIONES",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 30815,
	"target": 6352,
	"type": 793483,
	"label": "PROCESS FOR THE MANUFACTURE OF ISOQUINOLINE DIONES",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 31912,
	"target": 6352,
	"type": 793483,
	"label": "PROCESS FOR THE MANUFACTURE OF ISOQUINOLINE DIONES",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32694,
	"target": 6816,
	"type": 794006,
	"label": "PURIFICATION OF RECOMBINED INTERFERON",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 794825,
	"label": "PROTEINA,SEQUENCIA DE DNA,VEICULO DE EXPRESSAO REPLICAVEL,MICROORGANISMO OU CULTURA CELULAR,PLASMIDEO,COMPOSICAO,CULTURA DE CELULAS,UTILIZACAO DE TAL PROTEINA,PROCESSO DE EXPRESSAO,PROCESSO PARA PRODUCAO DE UM VEICULO DE EXPRESSAO E PROCESSO PARA PREPARACAO DE UMA PROTEINA UROQUINASE",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 797275,
	"label": "SECRETION OF EXOGENOUS POLYPEPTIDES FROM YEAST",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 797275,
	"label": "SECRETION OF EXOGENOUS POLYPEPTIDES FROM YEAST",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 797275,
	"label": "SECRETION OF EXOGENOUS POLYPEPTIDES FROM YEAST",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 798686,
	"label": "PROCESS FOR THE PREPARATION OF INTERFERON AND EXPRESSION VEHICLES THEREFOR",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 798940,
	"label": "MENSCHLICHES ANTITHROMBIN III, DNS SEQUENZEN DAFUER, EXPRESSIONS- UND KLONIERUNGSVEKTOREN DIE SOLCHE SEQUENZEN ENTHALTEN UND DAMIT TRANSFORMIERTE ZELLKULTUREN, VERFAHREN ZUR EXPRESSION VON MENSCHLICHEM ANTITHROMBIN III UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN.",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 798957,
	"label": "Fremgangsmåde til identificering af DNA, som koder for et ikke-humant dyreinterferon, og DNA, som kan identificeres ved fremgangsmåden, fremgangsmåde til fremstilling af DNA, som koder for et hybridt interferon, og DNA, som kan opnås ved fremgangsmåden, fremgangsmåde til fremstilling af et ikke-humant dyreinterferon eller hybridt interferon, DNA-isolat, som koder for et sådant interferon,",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 38138,
	"target": 6229,
	"type": 799274,
	"label": "HEXADECADIENOIC AND HEXADECANOIC ACID LACTONE DERIVATIVES,THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS AND FOODSTUFFS CONTAINING THEM",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 799459,
	"label": "Fremgangsmåde til fremstilling af et pattedyrprotein, som er heterologt for en gærorganisme, som produkt af gærudtrykkelse -forarbejdning og -sekretion samt gærorganisme-cellekultur, dyrkningsmedium af cellekulturen og gærudtrykkelsesmedium",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 37996,
	"target": 37864,
	"type": 801035,
	"label": "Die alpha- oder beta-Ketten von Inhibin codierende Nukleinsäure und Verfahren zur Synthese von Polypeptiden unter Verwendung einer solchen Nukleinsäure.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37996,
	"type": 801035,
	"label": "Die alpha- oder beta-Ketten von Inhibin codierende Nukleinsäure und Verfahren zur Synthese von Polypeptiden unter Verwendung einer solchen Nukleinsäure.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 801035,
	"label": "Die alpha- oder beta-Ketten von Inhibin codierende Nukleinsäure und Verfahren zur Synthese von Polypeptiden unter Verwendung einer solchen Nukleinsäure.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 801035,
	"label": "Die alpha- oder beta-Ketten von Inhibin codierende Nukleinsäure und Verfahren zur Synthese von Polypeptiden unter Verwendung einer solchen Nukleinsäure.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37996,
	"target": 6795,
	"type": 801035,
	"label": "Die alpha- oder beta-Ketten von Inhibin codierende Nukleinsäure und Verfahren zur Synthese von Polypeptiden unter Verwendung einer solchen Nukleinsäure.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 801187,
	"label": "DNA-sekvens, som koder for et peptid med granulocytstimulerende virkning, rekombinantvektor og transformant indeholdende denne sekvens, samt fremgangsmåde til fremstilling af polypeptidet",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 801187,
	"label": "DNA-sekvens, som koder for et peptid med granulocytstimulerende virkning, rekombinantvektor og transformant indeholdende denne sekvens, samt fremgangsmåde til fremstilling af polypeptidet",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32696,
	"type": 801187,
	"label": "DNA-sekvens, som koder for et peptid med granulocytstimulerende virkning, rekombinantvektor og transformant indeholdende denne sekvens, samt fremgangsmåde til fremstilling af polypeptidet",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32696,
	"target": 6795,
	"type": 801187,
	"label": "DNA-sekvens, som koder for et peptid med granulocytstimulerende virkning, rekombinantvektor og transformant indeholdende denne sekvens, samt fremgangsmåde til fremstilling af polypeptidet",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 801187,
	"label": "DNA-sekvens, som koder for et peptid med granulocytstimulerende virkning, rekombinantvektor og transformant indeholdende denne sekvens, samt fremgangsmåde til fremstilling af polypeptidet",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37986,
	"target": 37875,
	"type": 802209,
	"label": "PRODUCTION OF LECITHIN CHOLESTEROL ACYLTRANSFERASE AND NUCLEIC ACID FOR PRODUCING THE SAME",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 803036,
	"label": "A METHOD AND A HYBRID PROMOTER FOR CONTROLLING EXOGENOUS GENE TRANSCRIPTION.",
	"group": "Amgen",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 803036,
	"label": "A METHOD AND A HYBRID PROMOTER FOR CONTROLLING EXOGENOUS GENE TRANSCRIPTION.",
	"group": "Amgen",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 803036,
	"label": "A METHOD AND A HYBRID PROMOTER FOR CONTROLLING EXOGENOUS GENE TRANSCRIPTION.",
	"group": "Amgen",
	"time": 1986,
	"strength": 1
}, {
	"source": 37986,
	"target": 37875,
	"type": 804610,
	"label": "INSULIN-RECEPTOR, SEINE REINIGUNG, SEINE HERSTELLUNG IN REKOMBINANTEN ZELLEN, DNA HIERFUER, ANTIKOERPER GEGEN DEN INSULIN-RECEPTOR UND DEREN HERSTELLUNG, SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ANTIKOERPER ENTHALTEN.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 804610,
	"label": "INSULIN-RECEPTOR, SEINE REINIGUNG, SEINE HERSTELLUNG IN REKOMBINANTEN ZELLEN, DNA HIERFUER, ANTIKOERPER GEGEN DEN INSULIN-RECEPTOR UND DEREN HERSTELLUNG, SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ANTIKOERPER ENTHALTEN.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 804610,
	"label": "INSULIN-RECEPTOR, SEINE REINIGUNG, SEINE HERSTELLUNG IN REKOMBINANTEN ZELLEN, DNA HIERFUER, ANTIKOERPER GEGEN DEN INSULIN-RECEPTOR UND DEREN HERSTELLUNG, SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ANTIKOERPER ENTHALTEN.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37875,
	"target": 32734,
	"type": 804610,
	"label": "INSULIN-RECEPTOR, SEINE REINIGUNG, SEINE HERSTELLUNG IN REKOMBINANTEN ZELLEN, DNA HIERFUER, ANTIKOERPER GEGEN DEN INSULIN-RECEPTOR UND DEREN HERSTELLUNG, SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ANTIKOERPER ENTHALTEN.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37986,
	"target": 32734,
	"type": 804610,
	"label": "INSULIN-RECEPTOR, SEINE REINIGUNG, SEINE HERSTELLUNG IN REKOMBINANTEN ZELLEN, DNA HIERFUER, ANTIKOERPER GEGEN DEN INSULIN-RECEPTOR UND DEREN HERSTELLUNG, SOWIE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE DIESE ANTIKOERPER ENTHALTEN.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37875,
	"target": 37864,
	"type": 805859,
	"label": "Fremgangsmåde til fremstilling af TGF-beta, DNA og mRNA, som koder for TGF-beta, samt replicerbare vektorer omfattende DNA'en og værtsceller indeholdende vektorerne",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 805859,
	"label": "Fremgangsmåde til fremstilling af TGF-beta, DNA og mRNA, som koder for TGF-beta, samt replicerbare vektorer omfattende DNA'en og værtsceller indeholdende vektorerne",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 805859,
	"label": "Fremgangsmåde til fremstilling af TGF-beta, DNA og mRNA, som koder for TGF-beta, samt replicerbare vektorer omfattende DNA'en og værtsceller indeholdende vektorerne",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37864,
	"target": 32689,
	"type": 805859,
	"label": "Fremgangsmåde til fremstilling af TGF-beta, DNA og mRNA, som koder for TGF-beta, samt replicerbare vektorer omfattende DNA'en og værtsceller indeholdende vektorerne",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37875,
	"target": 32689,
	"type": 805859,
	"label": "Fremgangsmåde til fremstilling af TGF-beta, DNA og mRNA, som koder for TGF-beta, samt replicerbare vektorer omfattende DNA'en og værtsceller indeholdende vektorerne",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 805889,
	"label": "ZUGEORDNETE RIBOSOMEN UND IHRE VERWENDUNG ZUR HERSTELLUNG VON PROTEINEN AUS ZELLKULTUREN.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 806175,
	"label": "GAERVERFAHREN ZUR HERSTELLUNG VON HEPATITISIMPFSTOFF.",
	"group": "Amgen",
	"time": 1986,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 806466,
	"label": "COMPOSICION FARMACEUTICA QUE CONTIENE UN FACTOR ESTIMULANTE DE COLONIAS DE GRANULOCITOS PARA EL TRATAMIENTO DE LA LEUCOPENIA.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 806466,
	"label": "COMPOSICION FARMACEUTICA QUE CONTIENE UN FACTOR ESTIMULANTE DE COLONIAS DE GRANULOCITOS PARA EL TRATAMIENTO DE LA LEUCOPENIA.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32697,
	"target": 7510,
	"type": 806466,
	"label": "COMPOSICION FARMACEUTICA QUE CONTIENE UN FACTOR ESTIMULANTE DE COLONIAS DE GRANULOCITOS PARA EL TRATAMIENTO DE LA LEUCOPENIA.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 806466,
	"label": "COMPOSICION FARMACEUTICA QUE CONTIENE UN FACTOR ESTIMULANTE DE COLONIAS DE GRANULOCITOS PARA EL TRATAMIENTO DE LA LEUCOPENIA.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 7510,
	"type": 806466,
	"label": "COMPOSICION FARMACEUTICA QUE CONTIENE UN FACTOR ESTIMULANTE DE COLONIAS DE GRANULOCITOS PARA EL TRATAMIENTO DE LA LEUCOPENIA.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 806526,
	"label": "VERFAHREN ZUR REINIGUNG VON INTERFERON UND SO HERGESTELLTE ZUSAMMENSETZUNG.",
	"group": "Amgen",
	"time": 1986,
	"strength": 1
}, {
	"source": 32694,
	"target": 6816,
	"type": 806526,
	"label": "VERFAHREN ZUR REINIGUNG VON INTERFERON UND SO HERGESTELLTE ZUSAMMENSETZUNG.",
	"group": "Amgen",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 6816,
	"type": 806526,
	"label": "VERFAHREN ZUR REINIGUNG VON INTERFERON UND SO HERGESTELLTE ZUSAMMENSETZUNG.",
	"group": "Amgen",
	"time": 1986,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 807055,
	"label": "STABILISERET INTERFERONPRAEPARAT, FREMGANGSMAADE TIL DETS FREMSTILLING OG ANVENDELSE AF PRAEPARATET",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32788,
	"target": 7510,
	"type": 807055,
	"label": "STABILISERET INTERFERONPRAEPARAT, FREMGANGSMAADE TIL DETS FREMSTILLING OG ANVENDELSE AF PRAEPARATET",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 807055,
	"label": "STABILISERET INTERFERONPRAEPARAT, FREMGANGSMAADE TIL DETS FREMSTILLING OG ANVENDELSE AF PRAEPARATET",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 808802,
	"label": "UTILIZACION DE UN FACTOR ESTIMULANTE DE LAS COLONIAS GRANULOCITICAS HUMANO PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA LEUCEMIA MIELOGENA.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32697,
	"target": 7508,
	"type": 808802,
	"label": "UTILIZACION DE UN FACTOR ESTIMULANTE DE LAS COLONIAS GRANULOCITICAS HUMANO PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA LEUCEMIA MIELOGENA.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 808802,
	"label": "UTILIZACION DE UN FACTOR ESTIMULANTE DE LAS COLONIAS GRANULOCITICAS HUMANO PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA LEUCEMIA MIELOGENA.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 808803,
	"label": "PHARMAZEUTISCHER STOFF FUER DIE FOERDERUNG DER WIEDERHERSTELLUNG DER HAEMATOPOIETISCHEN FAEHIGKEIT.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32696,
	"target": 32694,
	"type": 808803,
	"label": "PHARMAZEUTISCHER STOFF FUER DIE FOERDERUNG DER WIEDERHERSTELLUNG DER HAEMATOPOIETISCHEN FAEHIGKEIT.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 808803,
	"label": "PHARMAZEUTISCHER STOFF FUER DIE FOERDERUNG DER WIEDERHERSTELLUNG DER HAEMATOPOIETISCHEN FAEHIGKEIT.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 808803,
	"label": "PHARMAZEUTISCHER STOFF FUER DIE FOERDERUNG DER WIEDERHERSTELLUNG DER HAEMATOPOIETISCHEN FAEHIGKEIT.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32696,
	"target": 6795,
	"type": 808803,
	"label": "PHARMAZEUTISCHER STOFF FUER DIE FOERDERUNG DER WIEDERHERSTELLUNG DER HAEMATOPOIETISCHEN FAEHIGKEIT.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 56836,
	"target": 32620,
	"type": 809455,
	"label": "HIV PEPTIDE CONTAINING EPITOPE OF THE ENV PROTEIN",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7360,
	"target": 6429,
	"type": 811274,
	"label": "PHARMACEUTICAL AND VETERINARY COMPOSITIONS CONTAINING SYNERGISTIC MIXTURES OF VITAMIN D 3 DERIVATIVES",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 811281,
	"label": "GRAM-POSITIVE EXPRESSION CONTROL SEQUENCES OF THE BACILLUS SUBTILIS BACTERIA",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32689,
	"type": 812653,
	"label": "MENSCHLICHER TRANSFORMATIONSWACHSTUMSFAKTOR UND VORLAEUFER ODER FRAGMENT HIERVON, ZELLEN, DNA, VEKTOREN UND VERFAHREN ZU IHRER HERSTELLUNG, ZUSAMMENSETZUNGEN UND PRODUKTE, DIE DIESE ENTHALTEN, SOWIE DAVON ABGELEITETE ANTIKOERPER UND DIAGNOSTIZIERVERFAHREN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 56834,
	"target": 38181,
	"type": 812653,
	"label": "MENSCHLICHER TRANSFORMATIONSWACHSTUMSFAKTOR UND VORLAEUFER ODER FRAGMENT HIERVON, ZELLEN, DNA, VEKTOREN UND VERFAHREN ZU IHRER HERSTELLUNG, ZUSAMMENSETZUNGEN UND PRODUKTE, DIE DIESE ENTHALTEN, SOWIE DAVON ABGELEITETE ANTIKOERPER UND DIAGNOSTIZIERVERFAHREN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 56834,
	"target": 32689,
	"type": 812653,
	"label": "MENSCHLICHER TRANSFORMATIONSWACHSTUMSFAKTOR UND VORLAEUFER ODER FRAGMENT HIERVON, ZELLEN, DNA, VEKTOREN UND VERFAHREN ZU IHRER HERSTELLUNG, ZUSAMMENSETZUNGEN UND PRODUKTE, DIE DIESE ENTHALTEN, SOWIE DAVON ABGELEITETE ANTIKOERPER UND DIAGNOSTIZIERVERFAHREN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32689,
	"target": 6795,
	"type": 812653,
	"label": "MENSCHLICHER TRANSFORMATIONSWACHSTUMSFAKTOR UND VORLAEUFER ODER FRAGMENT HIERVON, ZELLEN, DNA, VEKTOREN UND VERFAHREN ZU IHRER HERSTELLUNG, ZUSAMMENSETZUNGEN UND PRODUKTE, DIE DIESE ENTHALTEN, SOWIE DAVON ABGELEITETE ANTIKOERPER UND DIAGNOSTIZIERVERFAHREN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 812653,
	"label": "MENSCHLICHER TRANSFORMATIONSWACHSTUMSFAKTOR UND VORLAEUFER ODER FRAGMENT HIERVON, ZELLEN, DNA, VEKTOREN UND VERFAHREN ZU IHRER HERSTELLUNG, ZUSAMMENSETZUNGEN UND PRODUKTE, DIE DIESE ENTHALTEN, SOWIE DAVON ABGELEITETE ANTIKOERPER UND DIAGNOSTIZIERVERFAHREN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 56834,
	"target": 31912,
	"type": 813886,
	"label": "METALLKOMPLEXE, AN DIE EIN IMMUNOLOGISCH AKTIVES MATERIAL GEKOPPELT WERDEN KANN BZW. IST, DEREN HERSTELLUNG UND VERWENDUNG.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 31912,
	"target": 6854,
	"type": 813886,
	"label": "METALLKOMPLEXE, AN DIE EIN IMMUNOLOGISCH AKTIVES MATERIAL GEKOPPELT WERDEN KANN BZW. IST, DEREN HERSTELLUNG UND VERWENDUNG.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 813886,
	"label": "METALLKOMPLEXE, AN DIE EIN IMMUNOLOGISCH AKTIVES MATERIAL GEKOPPELT WERDEN KANN BZW. IST, DEREN HERSTELLUNG UND VERWENDUNG.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 813933,
	"label": "OPTICALLY ACTIVE PLATINUM COMPLEX AND PRODUCTION THEREOF",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 815920,
	"label": "Tumornecrosefaktorderivater, DNA som koder derfor, replikerbare udtrykkelsesvektorer indeholdende DNA'en, værtsceller transformeret dermed og en fremgangsmåde til fremstilling af tumornecrosefaktorderivaterne samt præparater omfattende tumornecrosefaktorderivaterne",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 815944,
	"label": "VERFAHREN ZUR REINIGUNG DES HEPATITIS-OBERFLAECHEN-ANTIGENS UND DAS SO ERHALTENE PRODUKT.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 815944,
	"label": "VERFAHREN ZUR REINIGUNG DES HEPATITIS-OBERFLAECHEN-ANTIGENS UND DAS SO ERHALTENE PRODUKT.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 815944,
	"label": "VERFAHREN ZUR REINIGUNG DES HEPATITIS-OBERFLAECHEN-ANTIGENS UND DAS SO ERHALTENE PRODUKT.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 815944,
	"label": "VERFAHREN ZUR REINIGUNG DES HEPATITIS-OBERFLAECHEN-ANTIGENS UND DAS SO ERHALTENE PRODUKT.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 815944,
	"label": "VERFAHREN ZUR REINIGUNG DES HEPATITIS-OBERFLAECHEN-ANTIGENS UND DAS SO ERHALTENE PRODUKT.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 816735,
	"label": "VERSCHIEDENARTIGE FAMILIE VON MENSCHLICHEN LEUKOZYTEN-INTERFERONEN, ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN, VERFAHREN ZU IHRER HERSTELLUNG, SOWIE DNA UND TRANSFEKTIERTE WIRTE HIERFUER.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37875,
	"target": 32694,
	"type": 816735,
	"label": "VERSCHIEDENARTIGE FAMILIE VON MENSCHLICHEN LEUKOZYTEN-INTERFERONEN, ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN, VERFAHREN ZU IHRER HERSTELLUNG, SOWIE DNA UND TRANSFEKTIERTE WIRTE HIERFUER.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 816735,
	"label": "VERSCHIEDENARTIGE FAMILIE VON MENSCHLICHEN LEUKOZYTEN-INTERFERONEN, ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN, VERFAHREN ZU IHRER HERSTELLUNG, SOWIE DNA UND TRANSFEKTIERTE WIRTE HIERFUER.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 816735,
	"label": "VERSCHIEDENARTIGE FAMILIE VON MENSCHLICHEN LEUKOZYTEN-INTERFERONEN, ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN, VERFAHREN ZU IHRER HERSTELLUNG, SOWIE DNA UND TRANSFEKTIERTE WIRTE HIERFUER.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 816735,
	"label": "VERSCHIEDENARTIGE FAMILIE VON MENSCHLICHEN LEUKOZYTEN-INTERFERONEN, ZUSAMMENSETZUNGEN, DIE DIESE ENTHALTEN, VERFAHREN ZU IHRER HERSTELLUNG, SOWIE DNA UND TRANSFEKTIERTE WIRTE HIERFUER.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 56834,
	"target": 6795,
	"type": 817388,
	"label": "POLYPEPTIDES FOR THE DETECTION AND CONTROL OF MAMMALIAN CELL GROWTH",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 817778,
	"label": "Vitamin D derivatives, process for producing the same and their use in the differentiation of tumor cells",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 817778,
	"label": "Vitamin D derivatives, process for producing the same and their use in the differentiation of tumor cells",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 817778,
	"label": "Vitamin D derivatives, process for producing the same and their use in the differentiation of tumor cells",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 817866,
	"label": "DNA, ZELLKULTUREN UND VERFAHREN ZUR SEKRETION VON HETEROLOGEN PROTEINEN UND PERIPLASMISCHE PROTEINRUECKGEWINNUNG.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 817866,
	"label": "DNA, ZELLKULTUREN UND VERFAHREN ZUR SEKRETION VON HETEROLOGEN PROTEINEN UND PERIPLASMISCHE PROTEINRUECKGEWINNUNG.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 817866,
	"label": "DNA, ZELLKULTUREN UND VERFAHREN ZUR SEKRETION VON HETEROLOGEN PROTEINEN UND PERIPLASMISCHE PROTEINRUECKGEWINNUNG.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 817930,
	"label": "HORMONE UND VERFAHREN ZUR HERSTELLUNG, VERWENDUNG UND PRUEFUNG DERSELBEN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32708,
	"target": 32576,
	"type": 817930,
	"label": "HORMONE UND VERFAHREN ZUR HERSTELLUNG, VERWENDUNG UND PRUEFUNG DERSELBEN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37996,
	"target": 32708,
	"type": 817930,
	"label": "HORMONE UND VERFAHREN ZUR HERSTELLUNG, VERWENDUNG UND PRUEFUNG DERSELBEN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37996,
	"target": 32576,
	"type": 817930,
	"label": "HORMONE UND VERFAHREN ZUR HERSTELLUNG, VERWENDUNG UND PRUEFUNG DERSELBEN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32576,
	"target": 6854,
	"type": 817930,
	"label": "HORMONE UND VERFAHREN ZUR HERSTELLUNG, VERWENDUNG UND PRUEFUNG DERSELBEN.",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 6892,
	"target": 6795,
	"type": 818183,
	"label": "AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 6892,
	"type": 818183,
	"label": "AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 818183,
	"label": "AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 818944,
	"label": "Ekspressionskontrol-DNA-sekvenser, ekspressionsvektorer, som indeholder disse DNA-sekvenser, transformanter som bærer disse ekspressionsvektorer, og fremgangsmåder til fremstilling af pro- og eukaryote proteiner under anvendelse af de",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 31580,
	"target": 31571,
	"type": 819002,
	"label": "PROCESS FOR THE PREPARATION OF NOVEL OXETANONES OF NOVEL INTERMEDIATES WHICH ARE USABLE IN THIS PROCESS AND OF PHARMACEUTICAL COMPOSITIONS BASED ON SAID OXETANONES OR BASED ON PRECURSORS THEREOF",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 31580,
	"target": 31571,
	"type": 819003,
	"label": "Fremgangsmåde til fremstilling af oxetanoner",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 31571,
	"target": 6229,
	"type": 819003,
	"label": "Fremgangsmåde til fremstilling af oxetanoner",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 31580,
	"target": 6229,
	"type": 819003,
	"label": "Fremgangsmåde til fremstilling af oxetanoner",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 819004,
	"label": "CHOLECALCIFEROLDERIVATER, DISSE DERIVATER TIL ANVENDELSE SOM TERAPEUTISK AKTIVE SUBSTANSER, FREMGANGSMAADE TIL FREMSTILLING AF DISSE, FARMACEUTISKE PRAEPARAT PAA BASIS AF DISSE, SAMT ANVENDELSE AF DISSE VED FREMSTILLING AF ET FARMACEUTISK PRAEPARAT",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38237,
	"target": 38042,
	"type": 819855,
	"label": "Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38042,
	"target": 6854,
	"type": 819855,
	"label": "Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38237,
	"target": 6854,
	"type": 819855,
	"label": "Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 820782,
	"label": "Fremgangsmåte for isolering av granulocytt/makrofag-kolonistimulerende faktor (GM-CSF) fra en GM-CSF-produserende mikroorganisme",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 32696,
	"target": 32694,
	"type": 820782,
	"label": "Fremgangsmåte for isolering av granulocytt/makrofag-kolonistimulerende faktor (GM-CSF) fra en GM-CSF-produserende mikroorganisme",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 820782,
	"label": "Fremgangsmåte for isolering av granulocytt/makrofag-kolonistimulerende faktor (GM-CSF) fra en GM-CSF-produserende mikroorganisme",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 820782,
	"label": "Fremgangsmåte for isolering av granulocytt/makrofag-kolonistimulerende faktor (GM-CSF) fra en GM-CSF-produserende mikroorganisme",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 32697,
	"type": 820782,
	"label": "Fremgangsmåte for isolering av granulocytt/makrofag-kolonistimulerende faktor (GM-CSF) fra en GM-CSF-produserende mikroorganisme",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 821441,
	"label": "HIV-2 ENV PROTEIN POLYPEPTIDES AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 821441,
	"label": "HIV-2 ENV PROTEIN POLYPEPTIDES AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 821441,
	"label": "HIV-2 ENV PROTEIN POLYPEPTIDES AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 821441,
	"label": "HIV-2 ENV PROTEIN POLYPEPTIDES AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 821441,
	"label": "HIV-2 ENV PROTEIN POLYPEPTIDES AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32700,
	"target": 32698,
	"type": 821785,
	"label": "Purification of chimeric proteins containing an IL-2 moiety by receptor-affinity chromatography",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 821785,
	"label": "Purification of chimeric proteins containing an IL-2 moiety by receptor-affinity chromatography",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32700,
	"target": 32694,
	"type": 821785,
	"label": "Purification of chimeric proteins containing an IL-2 moiety by receptor-affinity chromatography",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 32700,
	"type": 821785,
	"label": "Purification of chimeric proteins containing an IL-2 moiety by receptor-affinity chromatography",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 32698,
	"type": 821785,
	"label": "Purification of chimeric proteins containing an IL-2 moiety by receptor-affinity chromatography",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 822288,
	"label": "PROCESSO PARA A PRODUCAO DE NOVOS POLIPEPTIDOS DE CALICREINA DERIVADOS POR TECNICAS DE RECOMBINACAO",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 824281,
	"label": "Fremgangsmåde til dyrkning af rekombinante celler, værtscelle til anvendelse ved fremgangsmåden og kultur omfattende værtscellen",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 824281,
	"label": "Fremgangsmåde til dyrkning af rekombinante celler, værtscelle til anvendelse ved fremgangsmåden og kultur omfattende værtscellen",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 824281,
	"label": "Fremgangsmåde til dyrkning af rekombinante celler, værtscelle til anvendelse ved fremgangsmåden og kultur omfattende værtscellen",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37899,
	"target": 32708,
	"type": 824281,
	"label": "Fremgangsmåde til dyrkning af rekombinante celler, værtscelle til anvendelse ved fremgangsmåden og kultur omfattende værtscellen",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 32708,
	"type": 824281,
	"label": "Fremgangsmåde til dyrkning af rekombinante celler, værtscelle til anvendelse ved fremgangsmåden og kultur omfattende værtscellen",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 824282,
	"label": "PROCEDIMIENTO PARA AUMENTAR LA EXPRESION DE POLIPEPTIDOS EN UN CULTIVO DE CELULA RECOMBINANTE.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30821,
	"target": 30820,
	"type": 824563,
	"label": "Pentadieneamide compounds which have useful activity of treating a disease characterized by an excess of platelet activating factor",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30820,
	"target": 30814,
	"type": 824563,
	"label": "Pentadieneamide compounds which have useful activity of treating a disease characterized by an excess of platelet activating factor",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30821,
	"target": 30814,
	"type": 824563,
	"label": "Pentadieneamide compounds which have useful activity of treating a disease characterized by an excess of platelet activating factor",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 825290,
	"label": "Process for the production of proteins in soluble form by modulation of an inducible promoter",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 826625,
	"label": "MANIFESTATION CONTROL CONFIGURATION WHICH CAN EFFECT HIGH DEPRESSION",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 827761,
	"label": "Immunogenic polypeptides containing an amino acid sequence derived from plasmodium falciparum p190 merozoite antigen, their preparation and their use",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32788,
	"target": 32694,
	"type": 827801,
	"label": "Fusionsproteiner, gener der koder herfor, ekspressionsvektorer, transformeret bakterie, fremgangsmåde til oprensning af fusionsproteiner, fremgangsmåde til oprensning af et biologisk aktivt polypeptid eller protein, vacciner indeholdende fusionsprotei...",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 828951,
	"label": "TISSUE FACTOR PROTEIN, DNA ENCODING IT, VECTORS, HOST CELLS, PRODUCTION OF THE PROTEIN AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 829542,
	"label": "METODOS Y COMPOSICIONES PARA LA UTILIZACION DE POLIPEPTIDOS ENV Y ANTICUERPOS ANTI-ENV DE HIV.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 7510,
	"target": 6854,
	"type": 829542,
	"label": "METODOS Y COMPOSICIONES PARA LA UTILIZACION DE POLIPEPTIDOS ENV Y ANTICUERPOS ANTI-ENV DE HIV.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 829542,
	"label": "METODOS Y COMPOSICIONES PARA LA UTILIZACION DE POLIPEPTIDOS ENV Y ANTICUERPOS ANTI-ENV DE HIV.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 830209,
	"label": "Methods for promoting growth using porcine growth hormone analogs",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 831853,
	"label": "METHOD FOR THE PROPHYLAXIS AND TREATMENT OF RETROVIRAL INFECTIONS AND PROCESS FOR THE PREPARATION OF COMPOSITIONS THEREFOR CONTAINING TUMOR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6913,
	"target": 6816,
	"type": 831853,
	"label": "METHOD FOR THE PROPHYLAXIS AND TREATMENT OF RETROVIRAL INFECTIONS AND PROCESS FOR THE PREPARATION OF COMPOSITIONS THEREFOR CONTAINING TUMOR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6913,
	"target": 6795,
	"type": 831853,
	"label": "METHOD FOR THE PROPHYLAXIS AND TREATMENT OF RETROVIRAL INFECTIONS AND PROCESS FOR THE PREPARATION OF COMPOSITIONS THEREFOR CONTAINING TUMOR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 56765,
	"target": 38232,
	"type": 833153,
	"label": "ASSAYS FOR THROMBOLYTIC ENZYMES WHEREIN TISSUE-TYPE PLASMINOGEN ACTIVATOR IS INHIBITED",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 833201,
	"label": "Modified human tissue-type plasminogen activator devoid of functional carbohydrate structure at amino acid residue 117 having increased in vivo half-life, its preparation and pharmaceutical composition containing said molecule",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 833201,
	"label": "Modified human tissue-type plasminogen activator devoid of functional carbohydrate structure at amino acid residue 117 having increased in vivo half-life, its preparation and pharmaceutical composition containing said molecule",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37947,
	"target": 6841,
	"type": 833201,
	"label": "Modified human tissue-type plasminogen activator devoid of functional carbohydrate structure at amino acid residue 117 having increased in vivo half-life, its preparation and pharmaceutical composition containing said molecule",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 833201,
	"label": "Modified human tissue-type plasminogen activator devoid of functional carbohydrate structure at amino acid residue 117 having increased in vivo half-life, its preparation and pharmaceutical composition containing said molecule",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 833201,
	"label": "Modified human tissue-type plasminogen activator devoid of functional carbohydrate structure at amino acid residue 117 having increased in vivo half-life, its preparation and pharmaceutical composition containing said molecule",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 32734,
	"type": 834487,
	"label": "Hybrid-Rezeptoren, diese kodierende Nukleinsäure, ihre Herstellung und ihre Verwendung zur Bestimmung von Liganden sowie deren Antagonisten oder Agonisten",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 835202,
	"label": "Process for producing biologically active plasminogen activator in recombinant CHO cells using suspension culture and removing detrimental components from medium",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 837419,
	"label": "Enzymatisk aktive analoger av et Bacillus-subtilisin, nukleinsyre, vertscelle, fremgangsmåte for forbedring av varme- og pH-stabiliteten til et slikt subtilisin, samt vaskemiddelblanding som omfatter en slik analog",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 6838,
	"target": 6795,
	"type": 838590,
	"label": "Methods for the treatment of coagulation disorders with lipoprotein associated coagulation inhibitor (LACI)",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 839180,
	"label": "PHARMACEUTICAL COMPOSITION COMPRISING ERYTHROPOIETIN FOR TREATMENT OF IRON OVERLOAD DISORDERS",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 840351,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ENKEPHALINASE OG DNA-ISOLATER, REKOMBINANTE UDTRYKKELSESVEKTORER OG TRANSFORMEREDE CELLER TIL ANVENDELSE VED FREMGANGSMAADEN SAMT FREMGANGSMAADE TIL PROEVNING AF ENKEPHALINASE-AKTIVITET OG FARMACEUTISKE PRAEPARATER TIL BEHANDLING AF SYGDOMME FORMIDLET AF ENDOGENE PEPTIDER",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 840351,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ENKEPHALINASE OG DNA-ISOLATER, REKOMBINANTE UDTRYKKELSESVEKTORER OG TRANSFORMEREDE CELLER TIL ANVENDELSE VED FREMGANGSMAADEN SAMT FREMGANGSMAADE TIL PROEVNING AF ENKEPHALINASE-AKTIVITET OG FARMACEUTISKE PRAEPARATER TIL BEHANDLING AF SYGDOMME FORMIDLET AF ENDOGENE PEPTIDER",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 840351,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ENKEPHALINASE OG DNA-ISOLATER, REKOMBINANTE UDTRYKKELSESVEKTORER OG TRANSFORMEREDE CELLER TIL ANVENDELSE VED FREMGANGSMAADEN SAMT FREMGANGSMAADE TIL PROEVNING AF ENKEPHALINASE-AKTIVITET OG FARMACEUTISKE PRAEPARATER TIL BEHANDLING AF SYGDOMME FORMIDLET AF ENDOGENE PEPTIDER",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37947,
	"target": 37864,
	"type": 840351,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ENKEPHALINASE OG DNA-ISOLATER, REKOMBINANTE UDTRYKKELSESVEKTORER OG TRANSFORMEREDE CELLER TIL ANVENDELSE VED FREMGANGSMAADEN SAMT FREMGANGSMAADE TIL PROEVNING AF ENKEPHALINASE-AKTIVITET OG FARMACEUTISKE PRAEPARATER TIL BEHANDLING AF SYGDOMME FORMIDLET AF ENDOGENE PEPTIDER",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38232,
	"target": 37947,
	"type": 840351,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ENKEPHALINASE OG DNA-ISOLATER, REKOMBINANTE UDTRYKKELSESVEKTORER OG TRANSFORMEREDE CELLER TIL ANVENDELSE VED FREMGANGSMAADEN SAMT FREMGANGSMAADE TIL PROEVNING AF ENKEPHALINASE-AKTIVITET OG FARMACEUTISKE PRAEPARATER TIL BEHANDLING AF SYGDOMME FORMIDLET AF ENDOGENE PEPTIDER",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 32595,
	"type": 840441,
	"label": "DNA-fragmenter af humant papillomavirus og fremgangsmåde til in vitro diagnosticering af papillomavirusinfektioner",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38184,
	"target": 32595,
	"type": 841037,
	"label": "Bestemte DNA-sekvenser afledt af et papillomavirusgenom, DNA-rekombinant indeholdende sekvensen, DNA-hydridiseringsprobe indeholdende DNA-sekvensen eller rekombinanten, værtscelle transformeret med rekombinanten samt peptid afledt af DNS-sekvensen",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32595,
	"target": 6854,
	"type": 841037,
	"label": "Bestemte DNA-sekvenser afledt af et papillomavirusgenom, DNA-rekombinant indeholdende sekvensen, DNA-hydridiseringsprobe indeholdende DNA-sekvensen eller rekombinanten, værtscelle transformeret med rekombinanten samt peptid afledt af DNS-sekvensen",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 841037,
	"label": "Bestemte DNA-sekvenser afledt af et papillomavirusgenom, DNA-rekombinant indeholdende sekvensen, DNA-hydridiseringsprobe indeholdende DNA-sekvensen eller rekombinanten, værtscelle transformeret med rekombinanten samt peptid afledt af DNS-sekvensen",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 842456,
	"label": "Deoxyribonucleic acid sequence encoding non-A, non-B hepatitis virus - obtd. Hutch C59 subgroup encoding polypeptide(s), useful as vaccines, and immuno reactive ABS for diagnosis of virus",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37864,
	"target": 6854,
	"type": 842456,
	"label": "Deoxyribonucleic acid sequence encoding non-A, non-B hepatitis virus - obtd. Hutch C59 subgroup encoding polypeptide(s), useful as vaccines, and immuno reactive ABS for diagnosis of virus",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 842456,
	"label": "Deoxyribonucleic acid sequence encoding non-A, non-B hepatitis virus - obtd. Hutch C59 subgroup encoding polypeptide(s), useful as vaccines, and immuno reactive ABS for diagnosis of virus",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 843255,
	"label": "DNA SEQUENCES ENCODING HUMAN VASCULAR PERMEABILITY FACTOR HAVING 189 AMINO ACIDS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 843255,
	"label": "DNA SEQUENCES ENCODING HUMAN VASCULAR PERMEABILITY FACTOR HAVING 189 AMINO ACIDS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 843255,
	"label": "DNA SEQUENCES ENCODING HUMAN VASCULAR PERMEABILITY FACTOR HAVING 189 AMINO ACIDS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 843372,
	"label": "METHODE ZUR REINIGUNG REKOMBINANTER T-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38184,
	"target": 37947,
	"type": 843372,
	"label": "METHODE ZUR REINIGUNG REKOMBINANTER T-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 843372,
	"label": "METHODE ZUR REINIGUNG REKOMBINANTER T-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 843372,
	"label": "METHODE ZUR REINIGUNG REKOMBINANTER T-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56836,
	"target": 37947,
	"type": 843372,
	"label": "METHODE ZUR REINIGUNG REKOMBINANTER T-PA VON DEN IHREN ENTSPRECHENDEN WIRTSZELLPROTEINEN",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 845008,
	"label": "Co-enzyme-independent L-sorbosone dehydrogenase of gluconobacter oxydans: isolation, characterization, and cloning and autologus expression of the gene",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56765,
	"target": 6854,
	"type": 845112,
	"label": "VERFAHREN ZUR UNTERSUCHUNG VON ANTIKOERPERN SPEZIFISCH FUER RHEUMAKRANKHEITEN, INSBESONDERE CHRONISCHE POLYARTHRITIS SOWIE REAGENS HIERFUER.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 845462,
	"label": "PROTEINS CONNECTING TUMOR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 845462,
	"label": "PROTEINS CONNECTING TUMOR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 845462,
	"label": "PROTEINS CONNECTING TUMOR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 845462,
	"label": "PROTEINS CONNECTING TUMOR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 845462,
	"label": "PROTEINS CONNECTING TUMOR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 845703,
	"label": "CD4 POLYPEPTIDE DERIVATIVES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 845703,
	"label": "CD4 POLYPEPTIDE DERIVATIVES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 845703,
	"label": "CD4 POLYPEPTIDE DERIVATIVES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 846004,
	"label": "TISSUE ACTIVATOR OF PLASMINOGEN, PROCESS OF ITS PREPARATION, DNA CHAIN BEING A CODE FOR THE TISSUE ACTIVATOR, PROCESS FOR PREPARING PLASMIDS AND PHARMACEUTICAL PREPARATION EXHIBITING FIBRINOLYTIC ACTIVITY",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 846677,
	"label": "DNA encoding and methods of production of insulin-like growth factor binding protein BP53",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 846677,
	"label": "DNA encoding and methods of production of insulin-like growth factor binding protein BP53",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 846677,
	"label": "DNA encoding and methods of production of insulin-like growth factor binding protein BP53",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 846677,
	"label": "DNA encoding and methods of production of insulin-like growth factor binding protein BP53",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 846677,
	"label": "DNA encoding and methods of production of insulin-like growth factor binding protein BP53",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 846974,
	"label": "Förderung der Osteogenese durch Verwendung von Vitamin D-Derivaten.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 847049,
	"label": "PROCESSO PARA DETECTAR UMA SEQUENCIA DE ACIDO NUCLEICO,PROCESSO PARA DETERMINAR QUANTITATIVAMENTE A EXTENSAO DE HIBRIDIZACAO,ENSAIO DE HIBRIDIZACAO,ESTOJO,BASES,SONDAS,PROCESSO PARA DETECTAR CHLAMYDIA TRACHOMATIS E LAMINA DE MICROTITULACAO",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38237,
	"target": 37988,
	"type": 847049,
	"label": "PROCESSO PARA DETECTAR UMA SEQUENCIA DE ACIDO NUCLEICO,PROCESSO PARA DETERMINAR QUANTITATIVAMENTE A EXTENSAO DE HIBRIDIZACAO,ENSAIO DE HIBRIDIZACAO,ESTOJO,BASES,SONDAS,PROCESSO PARA DETECTAR CHLAMYDIA TRACHOMATIS E LAMINA DE MICROTITULACAO",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 847049,
	"label": "PROCESSO PARA DETECTAR UMA SEQUENCIA DE ACIDO NUCLEICO,PROCESSO PARA DETERMINAR QUANTITATIVAMENTE A EXTENSAO DE HIBRIDIZACAO,ENSAIO DE HIBRIDIZACAO,ESTOJO,BASES,SONDAS,PROCESSO PARA DETECTAR CHLAMYDIA TRACHOMATIS E LAMINA DE MICROTITULACAO",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 847566,
	"label": "Human tissue plasminogen activator variants methods for their production and pharmaceutical compositions and preparations containing them",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37947,
	"target": 6841,
	"type": 847566,
	"label": "Human tissue plasminogen activator variants methods for their production and pharmaceutical compositions and preparations containing them",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 847566,
	"label": "Human tissue plasminogen activator variants methods for their production and pharmaceutical compositions and preparations containing them",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 848550,
	"label": "Process for the preparation of a hetero-bispecific antibody.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 848550,
	"label": "Process for the preparation of a hetero-bispecific antibody.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 848550,
	"label": "Process for the preparation of a hetero-bispecific antibody.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 848550,
	"label": "Process for the preparation of a hetero-bispecific antibody.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 848550,
	"label": "Process for the preparation of a hetero-bispecific antibody.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 849231,
	"label": "Plasminogenaktivator-varianter, DNA-sekvenser, vektorer, celler og cellekulturer, der omfatter DNA-sekvenser, der koder for sådanne varianter, samt sammensætninger til behandling af karsygdom eller -tilstand, der omfatter en sådan variant",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37947,
	"target": 37862,
	"type": 849231,
	"label": "Plasminogenaktivator-varianter, DNA-sekvenser, vektorer, celler og cellekulturer, der omfatter DNA-sekvenser, der koder for sådanne varianter, samt sammensætninger til behandling af karsygdom eller -tilstand, der omfatter en sådan variant",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 849231,
	"label": "Plasminogenaktivator-varianter, DNA-sekvenser, vektorer, celler og cellekulturer, der omfatter DNA-sekvenser, der koder for sådanne varianter, samt sammensætninger til behandling af karsygdom eller -tilstand, der omfatter en sådan variant",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37862,
	"target": 6841,
	"type": 849231,
	"label": "Plasminogenaktivator-varianter, DNA-sekvenser, vektorer, celler og cellekulturer, der omfatter DNA-sekvenser, der koder for sådanne varianter, samt sammensætninger til behandling af karsygdom eller -tilstand, der omfatter en sådan variant",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37947,
	"target": 6841,
	"type": 849231,
	"label": "Plasminogenaktivator-varianter, DNA-sekvenser, vektorer, celler og cellekulturer, der omfatter DNA-sekvenser, der koder for sådanne varianter, samt sammensætninger til behandling af karsygdom eller -tilstand, der omfatter en sådan variant",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56765,
	"target": 37986,
	"type": 849987,
	"label": "NUCLEIC ACID HYBRIDIZATION ASSAY REAGENT AND KIT",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38184,
	"target": 32769,
	"type": 850065,
	"label": "Methods for the detection of acid-labile subunit (ALS) of insulin-like growth factor binding protein complex",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32769,
	"target": 6795,
	"type": 850065,
	"label": "Methods for the detection of acid-labile subunit (ALS) of insulin-like growth factor binding protein complex",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 850065,
	"label": "Methods for the detection of acid-labile subunit (ALS) of insulin-like growth factor binding protein complex",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 850162,
	"label": "MODIFIED INTERFERON - #Q# RECEPTORS, DNA ENCODING THEM, CELLS, VIRAL VECTORS AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 32770,
	"target": 6816,
	"type": 850162,
	"label": "MODIFIED INTERFERON - #Q# RECEPTORS, DNA ENCODING THEM, CELLS, VIRAL VECTORS AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 6816,
	"type": 850162,
	"label": "MODIFIED INTERFERON - #Q# RECEPTORS, DNA ENCODING THEM, CELLS, VIRAL VECTORS AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 850258,
	"label": "ANTICUERPOS ESPECIFICOS CONTRA TROPONINA T, SU PRODUCCION Y UTILIZACION EN UN REACTIVO PARA LA DETERMINACION DE LAS NECROSIS DEL MIOCARDIO.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 851830,
	"label": "25-Hydroxy-vitamin-D3-derivater, fremgangsmåde til fremstilling deraf samt lægemiddel indeholdende disse forbindelser",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 851830,
	"label": "25-Hydroxy-vitamin-D3-derivater, fremgangsmåde til fremstilling deraf samt lægemiddel indeholdende disse forbindelser",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 851830,
	"label": "25-Hydroxy-vitamin-D3-derivater, fremgangsmåde til fremstilling deraf samt lægemiddel indeholdende disse forbindelser",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 852532,
	"label": "Vævsplasminoaktivator-(t-PA)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmåde til fremstilling deraf, DNA-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og værtsceller tran",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 852532,
	"label": "Vævsplasminoaktivator-(t-PA)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmåde til fremstilling deraf, DNA-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og værtsceller tran",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37947,
	"target": 37862,
	"type": 852532,
	"label": "Vævsplasminoaktivator-(t-PA)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmåde til fremstilling deraf, DNA-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og værtsceller tran",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 852532,
	"label": "Vævsplasminoaktivator-(t-PA)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmåde til fremstilling deraf, DNA-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og værtsceller tran",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 852532,
	"label": "Vævsplasminoaktivator-(t-PA)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmåde til fremstilling deraf, DNA-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og værtsceller tran",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37947,
	"target": 6841,
	"type": 852712,
	"label": "Unglycosylated derivative of tissue-type plasminogen activator having prolonged half-life improved thrombolytic activity and reduced fibrin binding dna encoding said derivative preparation of said derivative and pharmaceutical composition comprising said derivative",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 854624,
	"label": "COMPOSITIONS AND METHODS FOR THE SYNTHESIS OF GROWTH HORMONE RECEPTOR AND GROWTH HORMONE BINDING PROTEIN",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 854642,
	"label": "METHODS FOR PROVIDING VARIANT T-PA EXHIBITING A STATISTICALLY SIGNIFICANT INCREASED PLASMA HALF-LIFE OR DECREASED CLEARANCE RATE RELATIVE TO NATURAL T-PA",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37947,
	"target": 6841,
	"type": 854642,
	"label": "METHODS FOR PROVIDING VARIANT T-PA EXHIBITING A STATISTICALLY SIGNIFICANT INCREASED PLASMA HALF-LIFE OR DECREASED CLEARANCE RATE RELATIVE TO NATURAL T-PA",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 854642,
	"label": "METHODS FOR PROVIDING VARIANT T-PA EXHIBITING A STATISTICALLY SIGNIFICANT INCREASED PLASMA HALF-LIFE OR DECREASED CLEARANCE RATE RELATIVE TO NATURAL T-PA",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 855028,
	"label": "EXPRESSIONS-ENHANCER UND DESSEN VERWENDUNG ZUR ERHOEHUNG DER AUSBEUTE BEI DER EXPRESSION VON REKOMBINANTEN GENEN",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37988,
	"target": 37947,
	"type": 855029,
	"label": "Expression of recombinant genes in Esherichia coli - promoted by high levels of arginine-incorporating transfer RNA",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 37988,
	"type": 855029,
	"label": "Expression of recombinant genes in Esherichia coli - promoted by high levels of arginine-incorporating transfer RNA",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 37947,
	"type": 855029,
	"label": "Expression of recombinant genes in Esherichia coli - promoted by high levels of arginine-incorporating transfer RNA",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38065,
	"target": 37988,
	"type": 855257,
	"label": "AUSGEGLICHENES, KONSTITUTIVES, INDUZIERBARES TRANSKRIPTIONSSYSTEM.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37988,
	"target": 37864,
	"type": 855257,
	"label": "AUSGEGLICHENES, KONSTITUTIVES, INDUZIERBARES TRANSKRIPTIONSSYSTEM.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38065,
	"target": 37864,
	"type": 855257,
	"label": "AUSGEGLICHENES, KONSTITUTIVES, INDUZIERBARES TRANSKRIPTIONSSYSTEM.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 855285,
	"label": "TREATING LUNG CONDITIONS WITH GAMMA INTERFERON AND/OR TUMOUR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 7409,
	"target": 6816,
	"type": 855285,
	"label": "TREATING LUNG CONDITIONS WITH GAMMA INTERFERON AND/OR TUMOUR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 855285,
	"label": "TREATING LUNG CONDITIONS WITH GAMMA INTERFERON AND/OR TUMOUR NECROSIS FACTOR",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 855545,
	"label": "PLASMODIUM FALCIPARUM CS.T3[ALA384,389]-CS9(378-398) PROTEIN FOR USE AS A UNIVERSALLY RECOGNISED T-CELL EPITOPE, DERIVATIVES AND VACCINES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 855545,
	"label": "PLASMODIUM FALCIPARUM CS.T3[ALA384,389]-CS9(378-398) PROTEIN FOR USE AS A UNIVERSALLY RECOGNISED T-CELL EPITOPE, DERIVATIVES AND VACCINES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32788,
	"target": 6854,
	"type": 855545,
	"label": "PLASMODIUM FALCIPARUM CS.T3[ALA384,389]-CS9(378-398) PROTEIN FOR USE AS A UNIVERSALLY RECOGNISED T-CELL EPITOPE, DERIVATIVES AND VACCINES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 855545,
	"label": "PLASMODIUM FALCIPARUM CS.T3[ALA384,389]-CS9(378-398) PROTEIN FOR USE AS A UNIVERSALLY RECOGNISED T-CELL EPITOPE, DERIVATIVES AND VACCINES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 855545,
	"label": "PLASMODIUM FALCIPARUM CS.T3[ALA384,389]-CS9(378-398) PROTEIN FOR USE AS A UNIVERSALLY RECOGNISED T-CELL EPITOPE, DERIVATIVES AND VACCINES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 856948,
	"label": "FACTOR DE CRISTALINO HUMANO DE ESTIMULACION DE COLONIAS DE GRANULOCITOS Y PROCEDIMIENTO PARA SU PREPARACION.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 856948,
	"label": "FACTOR DE CRISTALINO HUMANO DE ESTIMULACION DE COLONIAS DE GRANULOCITOS Y PROCEDIMIENTO PARA SU PREPARACION.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 856948,
	"label": "FACTOR DE CRISTALINO HUMANO DE ESTIMULACION DE COLONIAS DE GRANULOCITOS Y PROCEDIMIENTO PARA SU PREPARACION.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 856948,
	"label": "FACTOR DE CRISTALINO HUMANO DE ESTIMULACION DE COLONIAS DE GRANULOCITOS Y PROCEDIMIENTO PARA SU PREPARACION.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 856948,
	"label": "FACTOR DE CRISTALINO HUMANO DE ESTIMULACION DE COLONIAS DE GRANULOCITOS Y PROCEDIMIENTO PARA SU PREPARACION.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 857406,
	"label": "CDNA, DIE FÜR PEPTIDYL-GLYCIN ALPHAAMIDIERENDE MONOOXYGENASE (PAM) CODIERT",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 6961,
	"target": 6957,
	"type": 858095,
	"label": "VERFAHREN ZUM DIAGNOSTIZIEREN VON BLUTPFROPFEN MIT FIBRIN-BINDENDEN PROTEINEN.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 858704,
	"label": "NOVEL FIBRINOGEN LYTIC ENZYME",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 6961,
	"target": 6841,
	"type": 858704,
	"label": "NOVEL FIBRINOGEN LYTIC ENZYME",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37899,
	"target": 6961,
	"type": 858704,
	"label": "NOVEL FIBRINOGEN LYTIC ENZYME",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 6961,
	"type": 858704,
	"label": "NOVEL FIBRINOGEN LYTIC ENZYME",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37899,
	"target": 6841,
	"type": 858704,
	"label": "NOVEL FIBRINOGEN LYTIC ENZYME",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38068,
	"target": 6854,
	"type": 858836,
	"label": "RECOMBINANT VACCINIA VIRUS (MVA) CONTAINING A DNA INSERT CODING FOR A FOREIGN ANTIGEN",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 858851,
	"label": "PROCEDIMIENTO PARA LA OBTENCION DE PROTEINAS O PRODUCTOS GENICOS QUE CONTIENEN PROTEINAS.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 860890,
	"label": "IMMUNOGEN UND SEINE VERWENDUNG ZUR GEWINNUNG VON ANTIKOERPERN GEGEN HBA(PFEIL ABWAERTS)1(PFEIL ABWAERTS)(PFEIL ABWAERTS)C(PFEIL ABWAERTS)",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 860890,
	"label": "IMMUNOGEN UND SEINE VERWENDUNG ZUR GEWINNUNG VON ANTIKOERPERN GEGEN HBA(PFEIL ABWAERTS)1(PFEIL ABWAERTS)(PFEIL ABWAERTS)C(PFEIL ABWAERTS)",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56836,
	"target": 6795,
	"type": 860890,
	"label": "IMMUNOGEN UND SEINE VERWENDUNG ZUR GEWINNUNG VON ANTIKOERPERN GEGEN HBA(PFEIL ABWAERTS)1(PFEIL ABWAERTS)(PFEIL ABWAERTS)C(PFEIL ABWAERTS)",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 862295,
	"label": "PROCESSO PARA A PREPARACAO DE TESTES IMUNOLOGICOS CONTENDO DERIVADOS DE IGG POLIMERICOS PARA A COMPENSACAO DE FACTORES PERTURBANTES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 862482,
	"label": "MITTEL ZUR KONTROLLE VON THROMBENBILDUNGEN.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32696,
	"target": 32694,
	"type": 862482,
	"label": "MITTEL ZUR KONTROLLE VON THROMBENBILDUNGEN.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 862482,
	"label": "MITTEL ZUR KONTROLLE VON THROMBENBILDUNGEN.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 862482,
	"label": "MITTEL ZUR KONTROLLE VON THROMBENBILDUNGEN.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 862482,
	"label": "MITTEL ZUR KONTROLLE VON THROMBENBILDUNGEN.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 862952,
	"label": "Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage",
	"group": "Amgen",
	"time": 1989,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 863061,
	"label": "MONOCLONAL ANTIBODY TO HUMAN TUMOUR NECROSIS FACTOR RECEPTOR AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 863061,
	"label": "MONOCLONAL ANTIBODY TO HUMAN TUMOUR NECROSIS FACTOR RECEPTOR AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 56836,
	"target": 6795,
	"type": 863061,
	"label": "MONOCLONAL ANTIBODY TO HUMAN TUMOUR NECROSIS FACTOR RECEPTOR AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 863516,
	"label": "Serinproteaser og preparater som omfatter disse, samt DNA-sekvenser, ekspresjonsvektorer og prokaryote eller eukaryote vertsceller for anvendelse ved fremstillingen av dem",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 863516,
	"label": "Serinproteaser og preparater som omfatter disse, samt DNA-sekvenser, ekspresjonsvektorer og prokaryote eller eukaryote vertsceller for anvendelse ved fremstillingen av dem",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 38232,
	"target": 37864,
	"type": 863516,
	"label": "Serinproteaser og preparater som omfatter disse, samt DNA-sekvenser, ekspresjonsvektorer og prokaryote eller eukaryote vertsceller for anvendelse ved fremstillingen av dem",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 863628,
	"label": "Subtilisinanalog, DNA-sekvens som koder for en analog av Bacillus-subtilisin, samt anvendelse av en subtilisinanalog i en vaskemiddelblanding",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 32022,
	"target": 6795,
	"type": 863862,
	"label": "USE OF ACE-INHIBITOR FOR SUPPRESSING THE FORMATION OF NEOINTIMA AND THE REDUCTION OF THE VASCULAR LUMEN BY VASCULAR WALL THICKENING AFTER VASCULAR DAMAGE",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 864242,
	"label": "EXPRESSION VECTOR FOR ADJUSTABLE EXPRESSION OF EXOGENOUS GENES IN PROKARYOTES.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 32769,
	"type": 865004,
	"label": "METHODE UND VERBINDUNGEN ZUR HERSTELLUNG VON ACSF UND ACSF-ANTAGONISTEN.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56834,
	"target": 38181,
	"type": 865004,
	"label": "METHODE UND VERBINDUNGEN ZUR HERSTELLUNG VON ACSF UND ACSF-ANTAGONISTEN.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56834,
	"target": 32769,
	"type": 865004,
	"label": "METHODE UND VERBINDUNGEN ZUR HERSTELLUNG VON ACSF UND ACSF-ANTAGONISTEN.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32769,
	"target": 6795,
	"type": 865004,
	"label": "METHODE UND VERBINDUNGEN ZUR HERSTELLUNG VON ACSF UND ACSF-ANTAGONISTEN.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 865004,
	"label": "METHODE UND VERBINDUNGEN ZUR HERSTELLUNG VON ACSF UND ACSF-ANTAGONISTEN.",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 865445,
	"label": "PROCESS FOR THE ACTIVATION OF GENE-TECHNOLOGICALLY PRODUCED, BIOLOGICALLY-ACTIVE PROTEINS EXPRESSED IN PROKARYOTES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 865445,
	"label": "PROCESS FOR THE ACTIVATION OF GENE-TECHNOLOGICALLY PRODUCED, BIOLOGICALLY-ACTIVE PROTEINS EXPRESSED IN PROKARYOTES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37993,
	"target": 37947,
	"type": 865445,
	"label": "PROCESS FOR THE ACTIVATION OF GENE-TECHNOLOGICALLY PRODUCED, BIOLOGICALLY-ACTIVE PROTEINS EXPRESSED IN PROKARYOTES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 865957,
	"label": "VARIANTE ESPECIFICA DE ACTIVADOR DE PLASMINOGENO TISULAR.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 6841,
	"type": 865957,
	"label": "VARIANTE ESPECIFICA DE ACTIVADOR DE PLASMINOGENO TISULAR.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 865957,
	"label": "VARIANTE ESPECIFICA DE ACTIVADOR DE PLASMINOGENO TISULAR.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 866119,
	"label": "HIV ENVELOPE (ENV) POLYPEPTIDES, ANTIBODIES AND COMPOSITIONS FOR TREATING AIDS",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 866155,
	"label": "PROCESSO PARA A PREPARACAO DE UMA CALCITONINA HIBRIDA",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32700,
	"target": 6854,
	"type": 866497,
	"label": "DERIVATIVES OF N-ACYL-ALPHA-AMINO ACID OR THEIR PHYSIOLOGICALLY ACCEPTABLE SALTS, SIMPLE ETHERS OR ESTERS, AMIDES OR HYDRATES AND COMPOSITION INHIBITING ADHESIVE PROTEINS BINDING WITH PLATELETS AND PLATELET AGGREGATION",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 866897,
	"label": "Methods of use of serine protease variants having peptide ligase activity",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7510,
	"target": 7417,
	"type": 867032,
	"label": "METHOD FOR TREATING AND PREVENTING DISEASES CAUSED BY INCREASING CONTENTS OF A FACTOR INDUCING TUMOR CELL NECROSIS",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 7417,
	"target": 6795,
	"type": 867032,
	"label": "METHOD FOR TREATING AND PREVENTING DISEASES CAUSED BY INCREASING CONTENTS OF A FACTOR INDUCING TUMOR CELL NECROSIS",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 867032,
	"label": "METHOD FOR TREATING AND PREVENTING DISEASES CAUSED BY INCREASING CONTENTS OF A FACTOR INDUCING TUMOR CELL NECROSIS",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38237,
	"target": 32754,
	"type": 867150,
	"label": "METHODS FOR THE IDENTIFICATION OF FARNESYLTRANSFERMETHODS FOR THE IDENTIFICATION OF FARNESYLTRANSFERASE INHIBITORS                                    ASE INHIBITORS",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32754,
	"target": 6795,
	"type": 867150,
	"label": "METHODS FOR THE IDENTIFICATION OF FARNESYLTRANSFERMETHODS FOR THE IDENTIFICATION OF FARNESYLTRANSFERASE INHIBITORS                                    ASE INHIBITORS",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38237,
	"target": 6795,
	"type": 867150,
	"label": "METHODS FOR THE IDENTIFICATION OF FARNESYLTRANSFERMETHODS FOR THE IDENTIFICATION OF FARNESYLTRANSFERASE INHIBITORS                                    ASE INHIBITORS",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32689,
	"target": 6795,
	"type": 867202,
	"label": "METODO PARA PREDISPONER A LOS MAMIFEROS A UNA REPARACION ACELERADA DE LOS TEJIDOS.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 868174,
	"label": "Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 868208,
	"label": "New conjugates of poly:cation and protein",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37960,
	"type": 868660,
	"label": "PROCESS FOR INCREASING THE IN VIVO YIELD OF NATIVE PROTEIN WHEN DISULFIDE-BONDED PROTEINS ARE SECRETED",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 869144,
	"label": "ENLAZADORES PEPTIDICOS RICOS EN SERINA.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 869144,
	"label": "ENLAZADORES PEPTIDICOS RICOS EN SERINA.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 869144,
	"label": "ENLAZADORES PEPTIDICOS RICOS EN SERINA.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 38042,
	"type": 869144,
	"label": "ENLAZADORES PEPTIDICOS RICOS EN SERINA.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 869144,
	"label": "ENLAZADORES PEPTIDICOS RICOS EN SERINA.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 870273,
	"label": "PROCEDIMIENTOS PARA LA SELECCION DE CELULAS HUESPEDES RECOMBINANTES QUE EXPRESAN ALTOS NIVELES DE UNA PROTEINA DESEADA.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 870273,
	"label": "PROCEDIMIENTOS PARA LA SELECCION DE CELULAS HUESPEDES RECOMBINANTES QUE EXPRESAN ALTOS NIVELES DE UNA PROTEINA DESEADA.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 870273,
	"label": "PROCEDIMIENTOS PARA LA SELECCION DE CELULAS HUESPEDES RECOMBINANTES QUE EXPRESAN ALTOS NIVELES DE UNA PROTEINA DESEADA.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 870391,
	"label": "MAMMALIAN EXPRESSION OF THE BONE MORPHOGENETIC PROTEIN-2B USING BMP2A/BMP2B FUSION",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 870391,
	"label": "MAMMALIAN EXPRESSION OF THE BONE MORPHOGENETIC PROTEIN-2B USING BMP2A/BMP2B FUSION",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 870391,
	"label": "MAMMALIAN EXPRESSION OF THE BONE MORPHOGENETIC PROTEIN-2B USING BMP2A/BMP2B FUSION",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 873664,
	"label": "DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 873664,
	"label": "DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 873664,
	"label": "DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 873664,
	"label": "DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 873664,
	"label": "DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 37889,
	"type": 876155,
	"label": "Fremgangsmåde til produktion af TH-uafhængige cytotoksiske T-lymfocytter",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 876155,
	"label": "Fremgangsmåde til produktion af TH-uafhængige cytotoksiske T-lymfocytter",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37889,
	"type": 876155,
	"label": "Fremgangsmåde til produktion af TH-uafhængige cytotoksiske T-lymfocytter",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 876155,
	"label": "Fremgangsmåde til produktion af TH-uafhængige cytotoksiske T-lymfocytter",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 876155,
	"label": "Fremgangsmåde til produktion af TH-uafhængige cytotoksiske T-lymfocytter",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 877164,
	"label": "ENZYMATISCHE SYNTHESE VON OLIGONUKLEOTIDEN",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 877530,
	"label": "PEPTIDEOS CICLICOS,PROCESSO PARA SUA PREPARACAO,COMPOSICAO FARMACEUTICA,USO E PROCESSO PARA TRATAR DESORDENS CONSTRITIVAS BRONCO-TRAQUEAIS",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37900,
	"target": 37899,
	"type": 877630,
	"label": "Dickkopf 5 gene, protein and antibodies: a role inthe treatment and diagnosis of insulin-resistant  states.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 6812,
	"type": 877630,
	"label": "Dickkopf 5 gene, protein and antibodies: a role inthe treatment and diagnosis of insulin-resistant  states.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37900,
	"target": 6812,
	"type": 877630,
	"label": "Dickkopf 5 gene, protein and antibodies: a role inthe treatment and diagnosis of insulin-resistant  states.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 878317,
	"label": "UTILIZACION DE AGENTES PROTECTORES CONTRA ESPECIES DE OXIGENO REACTIVAS.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 878320,
	"label": "METHODS FOR MODIFYING AND DETECTING THE EFFECTS ON THE INTERACTION OF MODIFIED POLYPEPTIDES AND TARGET SUBSTRATES",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38164,
	"target": 37988,
	"type": 878320,
	"label": "METHODS FOR MODIFYING AND DETECTING THE EFFECTS ON THE INTERACTION OF MODIFIED POLYPEPTIDES AND TARGET SUBSTRATES",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 878320,
	"label": "METHODS FOR MODIFYING AND DETECTING THE EFFECTS ON THE INTERACTION OF MODIFIED POLYPEPTIDES AND TARGET SUBSTRATES",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 879106,
	"label": "PROCEDIMIENTO PARA LA DIAGNOSIS DE ENFERMEDADES TUMORALES.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 879147,
	"label": "NYA, FRAON BLODPLAETTAR HAERLEDDA B -KEDJEANALOGER AV TILLVAEXTFAKTORN OCH FOERFARANDE FOER HOMOGEN FRAMSTAELLNING AV DESSA.",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 879147,
	"label": "NYA, FRAON BLODPLAETTAR HAERLEDDA B -KEDJEANALOGER AV TILLVAEXTFAKTORN OCH FOERFARANDE FOER HOMOGEN FRAMSTAELLNING AV DESSA.",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 879147,
	"label": "NYA, FRAON BLODPLAETTAR HAERLEDDA B -KEDJEANALOGER AV TILLVAEXTFAKTORN OCH FOERFARANDE FOER HOMOGEN FRAMSTAELLNING AV DESSA.",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 7425,
	"target": 6819,
	"type": 879205,
	"label": "Fremgangsmåde til forøgelse af fertiliteten hos hunkønsvæsener",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 879370,
	"label": "MAKING OF RECOMBINANT IGA-PROTEASE AND METHOD OF DECOMPOSING FUSED PROTEIN OBTAINED BY ART OF RECOMBINANT IGA- PROTEASE, RECOMBINANT DNA, RECOMBINANT VECTOR, CELL AND GENE.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 880225,
	"label": "Fremgangsmate for fremstilling av en gjaercelle, en ikke-human pattedyrembryonisk ES celle, et kimaert ikke-humant pattedyr og et transgent ikke-humant pattedyr samt gjaercelle og isolert ikke-humant pattedyr ES celle.",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 880225,
	"label": "Fremgangsmate for fremstilling av en gjaercelle, en ikke-human pattedyrembryonisk ES celle, et kimaert ikke-humant pattedyr og et transgent ikke-humant pattedyr samt gjaercelle og isolert ikke-humant pattedyr ES celle.",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 880225,
	"label": "Fremgangsmate for fremstilling av en gjaercelle, en ikke-human pattedyrembryonisk ES celle, et kimaert ikke-humant pattedyr og et transgent ikke-humant pattedyr samt gjaercelle og isolert ikke-humant pattedyr ES celle.",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 881004,
	"label": "Anvendelse av konsensushumanleukocyttinterferon, eventuelt i kombinasjon med ett eller flere kjemoterapeutiske midler, ved fremstillingen av et medikament for behandling av virussykdommer samtidig som bivirkninger reduseres.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 7508,
	"target": 6816,
	"type": 881004,
	"label": "Anvendelse av konsensushumanleukocyttinterferon, eventuelt i kombinasjon med ett eller flere kjemoterapeutiske midler, ved fremstillingen av et medikament for behandling av virussykdommer samtidig som bivirkninger reduseres.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 881004,
	"label": "Anvendelse av konsensushumanleukocyttinterferon, eventuelt i kombinasjon med ett eller flere kjemoterapeutiske midler, ved fremstillingen av et medikament for behandling av virussykdommer samtidig som bivirkninger reduseres.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 881077,
	"label": "Polypeptides having bone resorption inhibitory activity comprising PTHrP-derived sequences",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 7360,
	"type": 881077,
	"label": "Polypeptides having bone resorption inhibitory activity comprising PTHrP-derived sequences",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 881077,
	"label": "Polypeptides having bone resorption inhibitory activity comprising PTHrP-derived sequences",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 881523,
	"label": "Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 32777,
	"type": 881523,
	"label": "Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 881523,
	"label": "Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 881523,
	"label": "Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 881523,
	"label": "Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32770,
	"target": 32734,
	"type": 882075,
	"label": "COMPOSICION FARMACEUTICA QUE COMPRENDE LA HORMONA DE CRECIMIENTO Y LA PROTEINA UNIDORA DE LA HORMONA DE CRECIMIENTO.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32734,
	"target": 6795,
	"type": 882075,
	"label": "COMPOSICION FARMACEUTICA QUE COMPRENDE LA HORMONA DE CRECIMIENTO Y LA PROTEINA UNIDORA DE LA HORMONA DE CRECIMIENTO.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 882075,
	"label": "COMPOSICION FARMACEUTICA QUE COMPRENDE LA HORMONA DE CRECIMIENTO Y LA PROTEINA UNIDORA DE LA HORMONA DE CRECIMIENTO.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 882251,
	"label": "VON STRUKTURPROTEINEN DES HEPATITIS C-VIRUS ABGELEITETE POLYPEPTIDE, TESTKITS, DIE DIESE POLYPEPTIDE ENTHALTEN UND IMPFSTOFFE GEGEN INFEKTIONEN VON HEPATITIS C-VIREN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 883353,
	"label": "Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 883353,
	"label": "Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32777,
	"target": 6854,
	"type": 883353,
	"label": "Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32777,
	"target": 6795,
	"type": 883353,
	"label": "Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 883353,
	"label": "Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7417,
	"target": 6795,
	"type": 884502,
	"label": "OBERFLÄCHENAKTIVE ZUSAMMENSETZUNGEN UND VERFAHREN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 32696,
	"target": 32694,
	"type": 885588,
	"label": "MEGAKARIOCYTE COLONY STIMULTATING FACTOR PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 885588,
	"label": "MEGAKARIOCYTE COLONY STIMULTATING FACTOR PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 885588,
	"label": "MEGAKARIOCYTE COLONY STIMULTATING FACTOR PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 885588,
	"label": "MEGAKARIOCYTE COLONY STIMULTATING FACTOR PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 32696,
	"type": 885588,
	"label": "MEGAKARIOCYTE COLONY STIMULTATING FACTOR PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 886610,
	"label": "PRODUCCION DE FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA I BIOLOGICAMENTE ACTIVO A PARTIR DE SISTEMAS DE CELULAS HOSPEDANTES DE EXPRESION ELEVADA.",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 886610,
	"label": "PRODUCCION DE FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA I BIOLOGICAMENTE ACTIVO A PARTIR DE SISTEMAS DE CELULAS HOSPEDANTES DE EXPRESION ELEVADA.",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 886610,
	"label": "PRODUCCION DE FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA I BIOLOGICAMENTE ACTIVO A PARTIR DE SISTEMAS DE CELULAS HOSPEDANTES DE EXPRESION ELEVADA.",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 886768,
	"label": "METHOD FOR OBTAINING PROTEIN HAVING RECOMBINANT DNA, RECOMBINANT VECTOR, CELL AND ACTIVITY OF N-CARBAMOYLSARCOSINEAMIDEHYDROLASE, SAID PROTEIN AND METHOD FOR MEASURING CREATININE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 56836,
	"target": 56804,
	"type": 887645,
	"label": "PROCEDIMIENTO INMUNOLOGICO DE PRECIPITACION PARA LA DETERMINACION DE UN ANALITO FIJABLE Y REACTIVO PARA LA EJECUCION DE DICHO PROCEDIMIENTO.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 888114,
	"label": "SUBTILISINAS CON MUTACIONES MULTIPLES.",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 889039,
	"label": "Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 889039,
	"label": "Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 889039,
	"label": "Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 889418,
	"label": "Ihmisen plasminogeenin aminohappovarianttia koodittava nukleiinihapposekvenssi, sitä sisältävä ekspressiovektori ja isäntäsolu sekä menetelmä plasminogeenin aminohappovariantin valmistamiseksi ja menetelmä kaksoiskompleksin muodostamiseksi fibrinolyyttisen entsyymin ja ......",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 6841,
	"type": 889418,
	"label": "Ihmisen plasminogeenin aminohappovarianttia koodittava nukleiinihapposekvenssi, sitä sisältävä ekspressiovektori ja isäntäsolu sekä menetelmä plasminogeenin aminohappovariantin valmistamiseksi ja menetelmä kaksoiskompleksin muodostamiseksi fibrinolyyttisen entsyymin ja ......",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 889418,
	"label": "Ihmisen plasminogeenin aminohappovarianttia koodittava nukleiinihapposekvenssi, sitä sisältävä ekspressiovektori ja isäntäsolu sekä menetelmä plasminogeenin aminohappovariantin valmistamiseksi ja menetelmä kaksoiskompleksin muodostamiseksi fibrinolyyttisen entsyymin ja ......",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 6483,
	"type": 889429,
	"label": "OLIGONUKLEOTIDANALOGA MIT NEUARTIGEN BINDUNGEN",
	"group": "Gilead",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 889507,
	"label": "PEPTIDO ASOCIADO A UNA LATENCIA Y UTILIZACIONES DEL MISMO.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37996,
	"target": 37899,
	"type": 889507,
	"label": "PEPTIDO ASOCIADO A UNA LATENCIA Y UTILIZACIONES DEL MISMO.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37996,
	"target": 37864,
	"type": 889507,
	"label": "PEPTIDO ASOCIADO A UNA LATENCIA Y UTILIZACIONES DEL MISMO.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 889507,
	"label": "PEPTIDO ASOCIADO A UNA LATENCIA Y UTILIZACIONES DEL MISMO.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 889507,
	"label": "PEPTIDO ASOCIADO A UNA LATENCIA Y UTILIZACIONES DEL MISMO.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 889603,
	"label": "Composition comprising tumor cell lines containing GD2 ganglioside, GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 889603,
	"label": "Composition comprising tumor cell lines containing GD2 ganglioside, GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 56836,
	"target": 32771,
	"type": 889603,
	"label": "Composition comprising tumor cell lines containing GD2 ganglioside, GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 32771,
	"target": 6854,
	"type": 889603,
	"label": "Composition comprising tumor cell lines containing GD2 ganglioside, GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 889603,
	"label": "Composition comprising tumor cell lines containing GD2 ganglioside, GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38065,
	"target": 37862,
	"type": 890271,
	"label": "PROCEDIMIENTO PARA LA PREPARACION DE LA ADNASA HUMANA.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 890274,
	"label": "Host cells and method of producing soluble analogues of integrins",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 890274,
	"label": "Host cells and method of producing soluble analogues of integrins",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 890274,
	"label": "Host cells and method of producing soluble analogues of integrins",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 32734,
	"type": 890374,
	"label": "ZUSAMMENSETZUNGEN UND METHODEN ZUR SYNTHESE DES B-REZEPTORS FÜR DAS NATRIURETISCHE PROTEIN UND VERWENDUNGSMETHODEN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 890424,
	"label": "TOPICAL PHARMACEUTICAL COMPOSITION COMPRISING 1ALPHA,25-DIHYDROXYCHOLECALCIFEROL TOGETHER WITH AN AGENT TO CONTROL PH TO 6.5 - 7.5 AND A CARRIER",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 891310,
	"label": "COMPOSITIONS CONTAINING A PROTEIN HAVING IMMUNOMODULATORY ACTIVITY AND MIXED MICELLES FROM A CHOLANIC ACID DERIVATIVE AND A LIPID",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7510,
	"target": 6816,
	"type": 891310,
	"label": "COMPOSITIONS CONTAINING A PROTEIN HAVING IMMUNOMODULATORY ACTIVITY AND MIXED MICELLES FROM A CHOLANIC ACID DERIVATIVE AND A LIPID",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 891310,
	"label": "COMPOSITIONS CONTAINING A PROTEIN HAVING IMMUNOMODULATORY ACTIVITY AND MIXED MICELLES FROM A CHOLANIC ACID DERIVATIVE AND A LIPID",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 6301,
	"target": 6229,
	"type": 891538,
	"label": "Anvendelse av antistoff som binder til ErbB2 og blokkerer ligandaktivering av en ErbB2-reseptor, for fremstilling av et medikament for behandling av kreft hos et menneske, anvendelse av rhuMAb 2C4 for fremstilling av et medikament for behandling av kreft, humanisert antistoff, immunkonjugat, affinitetsmodnet antistoff",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6539,
	"target": 6301,
	"type": 891538,
	"label": "Anvendelse av antistoff som binder til ErbB2 og blokkerer ligandaktivering av en ErbB2-reseptor, for fremstilling av et medikament for behandling av kreft hos et menneske, anvendelse av rhuMAb 2C4 for fremstilling av et medikament for behandling av kreft, humanisert antistoff, immunkonjugat, affinitetsmodnet antistoff",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6539,
	"target": 6229,
	"type": 891538,
	"label": "Anvendelse av antistoff som binder til ErbB2 og blokkerer ligandaktivering av en ErbB2-reseptor, for fremstilling av et medikament for behandling av kreft hos et menneske, anvendelse av rhuMAb 2C4 for fremstilling av et medikament for behandling av kreft, humanisert antistoff, immunkonjugat, affinitetsmodnet antistoff",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 891538,
	"label": "Anvendelse av antistoff som binder til ErbB2 og blokkerer ligandaktivering av en ErbB2-reseptor, for fremstilling av et medikament for behandling av kreft hos et menneske, anvendelse av rhuMAb 2C4 for fremstilling av et medikament for behandling av kreft, humanisert antistoff, immunkonjugat, affinitetsmodnet antistoff",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 891538,
	"label": "Anvendelse av antistoff som binder til ErbB2 og blokkerer ligandaktivering av en ErbB2-reseptor, for fremstilling av et medikament for behandling av kreft hos et menneske, anvendelse av rhuMAb 2C4 for fremstilling av et medikament for behandling av kreft, humanisert antistoff, immunkonjugat, affinitetsmodnet antistoff",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31584,
	"target": 31580,
	"type": 892322,
	"label": "PREPARATION OF SUBSTITUTED OXETANONES FROM BETA-HYDROXY-OMEGA-LACTONES; VARIOUS BETA-HYDROXY AND BETA-KETO-OMEGA-LACTONES",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 892922,
	"label": "POLYPEPTIDE ELICITING HEMOPOIETIC BIOLOGICAL ACTIVITY OF STEM CELL FACTOR (VARIANTS), DNA (VARIANTS), EXPRESSING VECTOR (VARIANTS), PHARMACEUTICAL COMPOSITION FOR HEMOPOIETIC THERAPY, METHOD FOR PREPARING POLYPEPTIDE AND METHOD FOR IT USING (VARIANTS)",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 892922,
	"label": "POLYPEPTIDE ELICITING HEMOPOIETIC BIOLOGICAL ACTIVITY OF STEM CELL FACTOR (VARIANTS), DNA (VARIANTS), EXPRESSING VECTOR (VARIANTS), PHARMACEUTICAL COMPOSITION FOR HEMOPOIETIC THERAPY, METHOD FOR PREPARING POLYPEPTIDE AND METHOD FOR IT USING (VARIANTS)",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 892922,
	"label": "POLYPEPTIDE ELICITING HEMOPOIETIC BIOLOGICAL ACTIVITY OF STEM CELL FACTOR (VARIANTS), DNA (VARIANTS), EXPRESSING VECTOR (VARIANTS), PHARMACEUTICAL COMPOSITION FOR HEMOPOIETIC THERAPY, METHOD FOR PREPARING POLYPEPTIDE AND METHOD FOR IT USING (VARIANTS)",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 892972,
	"label": "Analoger av humant erytropoietin, DNA-sekvenser som koder for disse, eukaryot vertscelle transfektert med DNA-sekvensene, preparat som omfatter analogene, anvendelse av analogene til okning av hematokritt, og fremgangsmate for fremstilling av analogene.",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 892972,
	"label": "Analoger av humant erytropoietin, DNA-sekvenser som koder for disse, eukaryot vertscelle transfektert med DNA-sekvensene, preparat som omfatter analogene, anvendelse av analogene til okning av hematokritt, og fremgangsmate for fremstilling av analogene.",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 892972,
	"label": "Analoger av humant erytropoietin, DNA-sekvenser som koder for disse, eukaryot vertscelle transfektert med DNA-sekvensene, preparat som omfatter analogene, anvendelse av analogene til okning av hematokritt, og fremgangsmate for fremstilling av analogene.",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37996,
	"target": 37864,
	"type": 895170,
	"label": "VERFAHREN UND ZUSAMMENSETZUNGEN ZUR ISOLATION VON MENSCHLICHEM RELAXIN.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37864,
	"target": 7425,
	"type": 895170,
	"label": "VERFAHREN UND ZUSAMMENSETZUNGEN ZUR ISOLATION VON MENSCHLICHEM RELAXIN.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37996,
	"target": 7425,
	"type": 895170,
	"label": "VERFAHREN UND ZUSAMMENSETZUNGEN ZUR ISOLATION VON MENSCHLICHEM RELAXIN.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37996,
	"target": 37864,
	"type": 896141,
	"label": "VASCULAR ENDOTHELIAL CELL GROWTH FACTOR THAT IS UNACCOMPANIED BY ASSOCIATED NATIVE GLYCOSYLATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING TRAUMA AFFECTING THE VASCULAR ENDOTHELIUM",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37996,
	"type": 896141,
	"label": "VASCULAR ENDOTHELIAL CELL GROWTH FACTOR THAT IS UNACCOMPANIED BY ASSOCIATED NATIVE GLYCOSYLATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING TRAUMA AFFECTING THE VASCULAR ENDOTHELIUM",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 896141,
	"label": "VASCULAR ENDOTHELIAL CELL GROWTH FACTOR THAT IS UNACCOMPANIED BY ASSOCIATED NATIVE GLYCOSYLATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING TRAUMA AFFECTING THE VASCULAR ENDOTHELIUM",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 896141,
	"label": "VASCULAR ENDOTHELIAL CELL GROWTH FACTOR THAT IS UNACCOMPANIED BY ASSOCIATED NATIVE GLYCOSYLATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING TRAUMA AFFECTING THE VASCULAR ENDOTHELIUM",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37996,
	"target": 32694,
	"type": 896141,
	"label": "VASCULAR ENDOTHELIAL CELL GROWTH FACTOR THAT IS UNACCOMPANIED BY ASSOCIATED NATIVE GLYCOSYLATION, PHARMACEUTICAL COMPOSITION CONTAINING IT AND USE THEREOF IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING TRAUMA AFFECTING THE VASCULAR ENDOTHELIUM",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 896172,
	"label": "MONOCLONAL ANTIBODIES WHICH NEUTRALIZE HIV-1 INFECTION AND THEIR ANTI-IDIOTYPES",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 32689,
	"target": 6795,
	"type": 896992,
	"label": "POLIPEPTIDOS BIOLOGICAMENTE ACTIVOS BASADOS EN LAS SECUENCIAS DEL FACTOR DE CRECIMIENTO DE TRANSFORMACION BETA.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 32770,
	"target": 32734,
	"type": 897063,
	"label": "Luteinizing hormone/choriogonadotropin (LH/CG) receptor",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 897063,
	"label": "Luteinizing hormone/choriogonadotropin (LH/CG) receptor",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 897063,
	"label": "Luteinizing hormone/choriogonadotropin (LH/CG) receptor",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 32770,
	"type": 897063,
	"label": "Luteinizing hormone/choriogonadotropin (LH/CG) receptor",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 32734,
	"type": 897063,
	"label": "Luteinizing hormone/choriogonadotropin (LH/CG) receptor",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 897170,
	"label": "DOMINIO EXTRACELULAR DE HER2.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37862,
	"target": 6854,
	"type": 897170,
	"label": "DOMINIO EXTRACELULAR DE HER2.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37864,
	"target": 6854,
	"type": 897170,
	"label": "DOMINIO EXTRACELULAR DE HER2.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 898483,
	"label": "VERFAHREN ZUR HERSTELLUNG VON HUMANEN RELAXIN",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 898483,
	"label": "VERFAHREN ZUR HERSTELLUNG VON HUMANEN RELAXIN",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 898483,
	"label": "VERFAHREN ZUR HERSTELLUNG VON HUMANEN RELAXIN",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 898646,
	"label": "REGULIERUNG DER STELLEN-SPEZIFISCHEN REKOMBINATION DURCH STELLEN-SPEZIFISCHE FUSIONSPROTEINE, DIE AUS REKOMBINASE UND NUKLEAREM REZEPTOR BESTEHEN",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 898646,
	"label": "REGULIERUNG DER STELLEN-SPEZIFISCHEN REKOMBINATION DURCH STELLEN-SPEZIFISCHE FUSIONSPROTEINE, DIE AUS REKOMBINASE UND NUKLEAREM REZEPTOR BESTEHEN",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 898646,
	"label": "REGULIERUNG DER STELLEN-SPEZIFISCHEN REKOMBINATION DURCH STELLEN-SPEZIFISCHE FUSIONSPROTEINE, DIE AUS REKOMBINASE UND NUKLEAREM REZEPTOR BESTEHEN",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 898646,
	"label": "REGULIERUNG DER STELLEN-SPEZIFISCHEN REKOMBINATION DURCH STELLEN-SPEZIFISCHE FUSIONSPROTEINE, DIE AUS REKOMBINASE UND NUKLEAREM REZEPTOR BESTEHEN",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 898646,
	"label": "REGULIERUNG DER STELLEN-SPEZIFISCHEN REKOMBINATION DURCH STELLEN-SPEZIFISCHE FUSIONSPROTEINE, DIE AUS REKOMBINASE UND NUKLEAREM REZEPTOR BESTEHEN",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 30606,
	"target": 7507,
	"type": 898974,
	"label": "1,3-Dioxo-6-(3-methylaminopropyl)-1,2,3,6-tetrahydro-4-(thiophen-3-yl)pyrrolo[3,4/c]carbazole, use thereof and pharmaceutical preparation in which it is comprised",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 899208,
	"label": "D<SB>3</SB> VITAMIN ANALOGS, METHOD OF PREPARING THEREOF, AND PHARMACEUTICAL DRUG",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 899208,
	"label": "D<SB>3</SB> VITAMIN ANALOGS, METHOD OF PREPARING THEREOF, AND PHARMACEUTICAL DRUG",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6431,
	"type": 899208,
	"label": "D<SB>3</SB> VITAMIN ANALOGS, METHOD OF PREPARING THEREOF, AND PHARMACEUTICAL DRUG",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7508,
	"target": 6431,
	"type": 899208,
	"label": "D<SB>3</SB> VITAMIN ANALOGS, METHOD OF PREPARING THEREOF, AND PHARMACEUTICAL DRUG",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 899208,
	"label": "D<SB>3</SB> VITAMIN ANALOGS, METHOD OF PREPARING THEREOF, AND PHARMACEUTICAL DRUG",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 899287,
	"label": "Nucleic acid encoding PstS variants method for production and method for controlling polypeptide production in bacteria transformed by said nucleic acid",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 899287,
	"label": "Nucleic acid encoding PstS variants method for production and method for controlling polypeptide production in bacteria transformed by said nucleic acid",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 899287,
	"label": "Nucleic acid encoding PstS variants method for production and method for controlling polypeptide production in bacteria transformed by said nucleic acid",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 899468,
	"label": "ELK-L POLYPEPTIDE, CODING SEQUENCE AND VECTOR THEREFOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 899468,
	"label": "ELK-L POLYPEPTIDE, CODING SEQUENCE AND VECTOR THEREFOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 32694,
	"type": 899468,
	"label": "ELK-L POLYPEPTIDE, CODING SEQUENCE AND VECTOR THEREFOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 899468,
	"label": "ELK-L POLYPEPTIDE, CODING SEQUENCE AND VECTOR THEREFOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 899468,
	"label": "ELK-L POLYPEPTIDE, CODING SEQUENCE AND VECTOR THEREFOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 899925,
	"label": "VERWENDUNG VON INTERFERON-GAMMA ZUR VERMEIDUNG DER PROLIFERATION UND DIFFERENZIERUNG DER PRIMITIVEN HÄMAPOIETISCHEN VORLÄUFERZELLEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37893,
	"target": 7507,
	"type": 899925,
	"label": "VERWENDUNG VON INTERFERON-GAMMA ZUR VERMEIDUNG DER PROLIFERATION UND DIFFERENZIERUNG DER PRIMITIVEN HÄMAPOIETISCHEN VORLÄUFERZELLEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37893,
	"target": 6816,
	"type": 899925,
	"label": "VERWENDUNG VON INTERFERON-GAMMA ZUR VERMEIDUNG DER PROLIFERATION UND DIFFERENZIERUNG DER PRIMITIVEN HÄMAPOIETISCHEN VORLÄUFERZELLEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 900012,
	"label": "PROCEDIMIENTO PARA LA OBTENCION DE DERIVADOS DE N-ACIL-5-FLUOROCITIDINA.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32281,
	"target": 31571,
	"type": 900188,
	"label": "VARIOUS (PHENOXY)ACETIC ACID DERIVATIVES, THE ACID MOIETY HAVING AMINO(METHYLIMINO) AND/OR AZAHETEROCYCLIC AND/OR CARBAMOYL CONTAINING SUBSTITUENTS AMONG OTHERS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7511,
	"target": 6795,
	"type": 900413,
	"label": "STABLE LYOPHILIZED PHARMACEUTICAL PREPARATIONS OF G-CSF AND PROCESS FOR PRODUCING THEM",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 900885,
	"label": "PROCEDIMIENTO PARA LA IDENTIFICACION DE CELULAS HUMANAS Y ANIMALES QUE PRESENTAN LA CAPACIDAD PARA UNA PROLIFERACION ILIMITADA O PARA UNA FORMACION DE TUMORES.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 900910,
	"label": "PROCESSOS PARA A EXTINCAO DA FLUORESCENCIA EM FASE DE SOLUCAO DE SONDAS DE OLIGONUCLEOTIDOS MARCADAS COM UM FLUOROFORO",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 901852,
	"label": "DNA fragments activated in expression of melanoma inhibiting protein (MIA)",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37996,
	"target": 37904,
	"type": 901929,
	"label": "Monoclonal antibody that induces apoptosis in the myelocytic cells, fragment thereof, hybridoma producing thereof and pharmaceutical composition in which the antibody is comprised",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37996,
	"type": 901929,
	"label": "Monoclonal antibody that induces apoptosis in the myelocytic cells, fragment thereof, hybridoma producing thereof and pharmaceutical composition in which the antibody is comprised",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 901929,
	"label": "Monoclonal antibody that induces apoptosis in the myelocytic cells, fragment thereof, hybridoma producing thereof and pharmaceutical composition in which the antibody is comprised",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 901929,
	"label": "Monoclonal antibody that induces apoptosis in the myelocytic cells, fragment thereof, hybridoma producing thereof and pharmaceutical composition in which the antibody is comprised",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37996,
	"target": 32770,
	"type": 901929,
	"label": "Monoclonal antibody that induces apoptosis in the myelocytic cells, fragment thereof, hybridoma producing thereof and pharmaceutical composition in which the antibody is comprised",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 901982,
	"label": "CYTOKINES; HEK LIGAND (HEK-L) POLYPEPTIDES, DNA SEQUENCES, VECTORS AND TRANSFORMED HOST CELLS",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 32779,
	"target": 32478,
	"type": 901982,
	"label": "CYTOKINES; HEK LIGAND (HEK-L) POLYPEPTIDES, DNA SEQUENCES, VECTORS AND TRANSFORMED HOST CELLS",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 32779,
	"type": 901982,
	"label": "CYTOKINES; HEK LIGAND (HEK-L) POLYPEPTIDES, DNA SEQUENCES, VECTORS AND TRANSFORMED HOST CELLS",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 901982,
	"label": "CYTOKINES; HEK LIGAND (HEK-L) POLYPEPTIDES, DNA SEQUENCES, VECTORS AND TRANSFORMED HOST CELLS",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 32478,
	"type": 901982,
	"label": "CYTOKINES; HEK LIGAND (HEK-L) POLYPEPTIDES, DNA SEQUENCES, VECTORS AND TRANSFORMED HOST CELLS",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 902632,
	"label": "A bispecific molecule comprising two amino acid sequences at least one of which is an ifn-gamma inhibitor and pharmaceutical composition containing it",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 902632,
	"label": "A bispecific molecule comprising two amino acid sequences at least one of which is an ifn-gamma inhibitor and pharmaceutical composition containing it",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 902632,
	"label": "A bispecific molecule comprising two amino acid sequences at least one of which is an ifn-gamma inhibitor and pharmaceutical composition containing it",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 902844,
	"label": "METODO PARA A MARCACAO DE CELULAS EUCARIOTICAS POR MEIO DA UTILIZACAO DE UM RECEPTOR DA SUPERFICIE DA CELULA COMO UM MARCADOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 902844,
	"label": "METODO PARA A MARCACAO DE CELULAS EUCARIOTICAS POR MEIO DA UTILIZACAO DE UM RECEPTOR DA SUPERFICIE DA CELULA COMO UM MARCADOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 902844,
	"label": "METODO PARA A MARCACAO DE CELULAS EUCARIOTICAS POR MEIO DA UTILIZACAO DE UM RECEPTOR DA SUPERFICIE DA CELULA COMO UM MARCADOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32779,
	"target": 31912,
	"type": 903736,
	"label": "PRODUCING CORRECTLY FOLDED PROTEINS USING MULTIPLE DENATURATION AND RENATURATION CYCLES",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 903736,
	"label": "PRODUCING CORRECTLY FOLDED PROTEINS USING MULTIPLE DENATURATION AND RENATURATION CYCLES",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 31912,
	"type": 903736,
	"label": "PRODUCING CORRECTLY FOLDED PROTEINS USING MULTIPLE DENATURATION AND RENATURATION CYCLES",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 31620,
	"target": 6332,
	"type": 904789,
	"label": "BENZOPYRAN DERIVATIVE AND BENXOXAZINE DERIVATIVE",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 905913,
	"label": "Process for preparing stabilized polypeptide composition comprising stabilizing polypeptide against denaturation when treated with organic solvents, preparation of the polypeptide and composition for controlled release of polypeptide",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 906113,
	"label": "Pyrimidine derivatives for labeled binding partners",
	"group": "Gilead",
	"time": 2002,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 906139,
	"label": "Pharmaceutical composition containing protein and phospholipid and process for its preparation",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 906199,
	"label": "Human foam cells and methods for preparing them, monoclonal antibodies to said foam cells and their pharmaceutical and diagnostic use",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 906199,
	"label": "Human foam cells and methods for preparing them, monoclonal antibodies to said foam cells and their pharmaceutical and diagnostic use",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 906199,
	"label": "Human foam cells and methods for preparing them, monoclonal antibodies to said foam cells and their pharmaceutical and diagnostic use",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6892,
	"target": 6854,
	"type": 907214,
	"label": "Fremgangsmåde til fremstilling af mikrosfærer med et tørringstrin i fluidiseret leje",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 907597,
	"label": "Purified thermostable nucleic acid polymerase and DNA coding sequences from pyrodictium species",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 907598,
	"label": "3-(Tricyclic indolyl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione derivatives their preparation and pharmaceutical compositions containing them",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 908159,
	"label": "LYMPHOCYTE ACTIVATING AGENT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 908159,
	"label": "LYMPHOCYTE ACTIVATING AGENT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37875,
	"target": 6854,
	"type": 908159,
	"label": "LYMPHOCYTE ACTIVATING AGENT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 908361,
	"label": "Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32696,
	"target": 32694,
	"type": 908361,
	"label": "Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 908361,
	"label": "Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32738,
	"target": 6795,
	"type": 908393,
	"label": "Antigen-spezifische, aktivierte T-Lymphozyten, Nachweis und Anwendung",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7487,
	"target": 6371,
	"type": 909711,
	"label": "PHARMACEUTICAL COMPOSITIONS COMPRISING EPIROPRIM (2,4-DIAMINO-5-[3,5-DIETHOXY-4-(PYRROL-1-YL)BENZYL]PYRIMIDINE ) AND DAPSONE (4,4'-DIAMINO-DIPHENYLSULPHONE)",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 909892,
	"label": "Process for producing hydrophobic polypeptides and proteins, and fusion proteins for use in producing same",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 909892,
	"label": "Process for producing hydrophobic polypeptides and proteins, and fusion proteins for use in producing same",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 909892,
	"label": "Process for producing hydrophobic polypeptides and proteins, and fusion proteins for use in producing same",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 910224,
	"label": "INHIBIERUNG VON LEUKOZYTENADHÄSION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 910224,
	"label": "INHIBIERUNG VON LEUKOZYTENADHÄSION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 910224,
	"label": "INHIBIERUNG VON LEUKOZYTENADHÄSION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 7510,
	"type": 910224,
	"label": "INHIBIERUNG VON LEUKOZYTENADHÄSION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 7409,
	"type": 910224,
	"label": "INHIBIERUNG VON LEUKOZYTENADHÄSION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 910514,
	"label": "USE OF FLUORINATED VITAMIN D3 DERIVATIVE FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEBACEOUS GLAND DISEASES",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 910514,
	"label": "USE OF FLUORINATED VITAMIN D3 DERIVATIVE FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEBACEOUS GLAND DISEASES",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 910514,
	"label": "USE OF FLUORINATED VITAMIN D3 DERIVATIVE FOR PRODUCING PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEBACEOUS GLAND DISEASES",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 911422,
	"label": "Brevibacterium Sterolicumista peräisin oleva kolesterolioksidaasi",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 911536,
	"label": "ANTICUERPOS MONOCLONALES CONTRA CK-MB.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56833,
	"target": 38184,
	"type": 911536,
	"label": "ANTICUERPOS MONOCLONALES CONTRA CK-MB.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56833,
	"target": 37899,
	"type": 911536,
	"label": "ANTICUERPOS MONOCLONALES CONTRA CK-MB.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 911663,
	"label": "RECOMBINANT CELL LINE CONTAINING A NON-FUNCTIONAL SIALIDASE GENE AND CODING SEQUENCES THEREFOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 911778,
	"label": "Fremgangsmåde til fremstilling af alfa-interferon",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 911778,
	"label": "Fremgangsmåde til fremstilling af alfa-interferon",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 911778,
	"label": "Fremgangsmåde til fremstilling af alfa-interferon",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37999,
	"target": 37986,
	"type": 911813,
	"label": "Polipeptide poninculeotídeo isolado sequência de Dna e Cdna vetor de Dna célula hospedeira anticorpo composição farmacêutica derivado de Mgdf produto polípeptídeo Mgdf com grupos peg e preparação do mesmo e processo para produzir um polipeptídeo Mgdf humano e uma condição trombocitopênica para aumentar o número de megacarióticos maduroas e de plaquetas em um paciente necessitado dos mesmos e para fixar um polímero solúvel em água a um polipeptídeo Mgdf uma molècula de polietileno glicol a um pol",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 911813,
	"label": "Polipeptide poninculeotídeo isolado sequência de Dna e Cdna vetor de Dna célula hospedeira anticorpo composição farmacêutica derivado de Mgdf produto polípeptídeo Mgdf com grupos peg e preparação do mesmo e processo para produzir um polipeptídeo Mgdf humano e uma condição trombocitopênica para aumentar o número de megacarióticos maduroas e de plaquetas em um paciente necessitado dos mesmos e para fixar um polímero solúvel em água a um polipeptídeo Mgdf uma molècula de polietileno glicol a um pol",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37999,
	"target": 32694,
	"type": 911813,
	"label": "Polipeptide poninculeotídeo isolado sequência de Dna e Cdna vetor de Dna célula hospedeira anticorpo composição farmacêutica derivado de Mgdf produto polípeptídeo Mgdf com grupos peg e preparação do mesmo e processo para produzir um polipeptídeo Mgdf humano e uma condição trombocitopênica para aumentar o número de megacarióticos maduroas e de plaquetas em um paciente necessitado dos mesmos e para fixar um polímero solúvel em água a um polipeptídeo Mgdf uma molècula de polietileno glicol a um pol",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 911813,
	"label": "Polipeptide poninculeotídeo isolado sequência de Dna e Cdna vetor de Dna célula hospedeira anticorpo composição farmacêutica derivado de Mgdf produto polípeptídeo Mgdf com grupos peg e preparação do mesmo e processo para produzir um polipeptídeo Mgdf humano e uma condição trombocitopênica para aumentar o número de megacarióticos maduroas e de plaquetas em um paciente necessitado dos mesmos e para fixar um polímero solúvel em água a um polipeptídeo Mgdf uma molècula de polietileno glicol a um pol",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 911813,
	"label": "Polipeptide poninculeotídeo isolado sequência de Dna e Cdna vetor de Dna célula hospedeira anticorpo composição farmacêutica derivado de Mgdf produto polípeptídeo Mgdf com grupos peg e preparação do mesmo e processo para produzir um polipeptídeo Mgdf humano e uma condição trombocitopênica para aumentar o número de megacarióticos maduroas e de plaquetas em um paciente necessitado dos mesmos e para fixar um polímero solúvel em água a um polipeptídeo Mgdf uma molècula de polietileno glicol a um pol",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 6469,
	"target": 6241,
	"type": 912009,
	"label": "Compound pharmaceutical preparation exhibiting inhibition properties to lipase and use of acarbose for preparing thereof",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 37889,
	"type": 912680,
	"label": "METODO DE INMUNOMODULACION POR MEDIO DE TRANSFERENCIA ADOPTIVA DE LINFOCITOS T-CITOTOXICOS ESPECIFICOS DE ANTIGENOS.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 912680,
	"label": "METODO DE INMUNOMODULACION POR MEDIO DE TRANSFERENCIA ADOPTIVA DE LINFOCITOS T-CITOTOXICOS ESPECIFICOS DE ANTIGENOS.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37889,
	"type": 912680,
	"label": "METODO DE INMUNOMODULACION POR MEDIO DE TRANSFERENCIA ADOPTIVA DE LINFOCITOS T-CITOTOXICOS ESPECIFICOS DE ANTIGENOS.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37889,
	"target": 7510,
	"type": 912680,
	"label": "METODO DE INMUNOMODULACION POR MEDIO DE TRANSFERENCIA ADOPTIVA DE LINFOCITOS T-CITOTOXICOS ESPECIFICOS DE ANTIGENOS.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 912680,
	"label": "METODO DE INMUNOMODULACION POR MEDIO DE TRANSFERENCIA ADOPTIVA DE LINFOCITOS T-CITOTOXICOS ESPECIFICOS DE ANTIGENOS.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 912812,
	"label": "METHOD FOR OBTAINING DNA CAPABLE OF ENCODING THERMOSTABLE PHYTASE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 913185,
	"label": "D-HIDANTOINASA RECOMBINANTE, PROCEDIMIENTO PARA SU PREPARACION Y UTILIZACION.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 913185,
	"label": "D-HIDANTOINASA RECOMBINANTE, PROCEDIMIENTO PARA SU PREPARACION Y UTILIZACION.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 913185,
	"label": "D-HIDANTOINASA RECOMBINANTE, PROCEDIMIENTO PARA SU PREPARACION Y UTILIZACION.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 31851,
	"target": 6290,
	"type": 913701,
	"label": "THIAZOLIDINEDIONES, METHOD FOR PRODUCING THEREOF, THEIR USE FOR P RODUCTION OF MEDICAMENTS FOR TREATMENT OF DIABETES AND PHARMACEUT ICAL PREPARATION CONTAINING THESE THIAZOLIDINEDIONES",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 913934,
	"label": "Methods and reagents for the detection of herpes simplex virus, treponema pallidum, and haemophilus ducreyi",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 914384,
	"label": "1,25-DIHYDROXY-16-ENE-24-OXO-CHOLECALCIFEROL OR 1,24,25- -TRIHYDROXY-16-ENE-CHOLECALCIFEROL",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 914384,
	"label": "1,25-DIHYDROXY-16-ENE-24-OXO-CHOLECALCIFEROL OR 1,24,25- -TRIHYDROXY-16-ENE-CHOLECALCIFEROL",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6431,
	"type": 914384,
	"label": "1,25-DIHYDROXY-16-ENE-24-OXO-CHOLECALCIFEROL OR 1,24,25- -TRIHYDROXY-16-ENE-CHOLECALCIFEROL",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7508,
	"target": 6431,
	"type": 914384,
	"label": "1,25-DIHYDROXY-16-ENE-24-OXO-CHOLECALCIFEROL OR 1,24,25- -TRIHYDROXY-16-ENE-CHOLECALCIFEROL",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 914384,
	"label": "1,25-DIHYDROXY-16-ENE-24-OXO-CHOLECALCIFEROL OR 1,24,25- -TRIHYDROXY-16-ENE-CHOLECALCIFEROL",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 914726,
	"label": "RECEPTOR DE LA QUIMIOQUINA C-C(C-C CKR-1).",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37893,
	"target": 37875,
	"type": 914948,
	"label": "MEDIO PARA LA PROLIFERACION Y EL DESARROLLO DE CELULAS A LARGO PLAZO.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 915524,
	"label": "NEUROBLASTOM-ASSOZIIERTES REGULATOR-GEN",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 915524,
	"label": "NEUROBLASTOM-ASSOZIIERTES REGULATOR-GEN",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37859,
	"type": 915524,
	"label": "NEUROBLASTOM-ASSOZIIERTES REGULATOR-GEN",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 915805,
	"label": "2-Aminoalkyl-5-aminoalkylamino substituted isoquinoindazol-6-(2H)-ones exhibiting antitumor activity, their use, pharmaceutical preparation in which they are comprised and process of their preparation",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 916319,
	"label": "FACTOR DE ESTIMULACION DE PROGENITORES DE CELULAS B, PROCESO PARA SU OBTENCION Y COMPOSICIONES FARMACEUTICAS QUE LO CONTIENEN.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 37999,
	"target": 37875,
	"type": 916319,
	"label": "FACTOR DE ESTIMULACION DE PROGENITORES DE CELULAS B, PROCESO PARA SU OBTENCION Y COMPOSICIONES FARMACEUTICAS QUE LO CONTIENEN.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37999,
	"type": 916319,
	"label": "FACTOR DE ESTIMULACION DE PROGENITORES DE CELULAS B, PROCESO PARA SU OBTENCION Y COMPOSICIONES FARMACEUTICAS QUE LO CONTIENEN.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 37999,
	"type": 916319,
	"label": "FACTOR DE ESTIMULACION DE PROGENITORES DE CELULAS B, PROCESO PARA SU OBTENCION Y COMPOSICIONES FARMACEUTICAS QUE LO CONTIENEN.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 916319,
	"label": "FACTOR DE ESTIMULACION DE PROGENITORES DE CELULAS B, PROCESO PARA SU OBTENCION Y COMPOSICIONES FARMACEUTICAS QUE LO CONTIENEN.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 916462,
	"label": "DERIVATIVES OF N4-(OXYCARBONYL-SUBSTITUTED)-5'-DESOXY-5-FLUOROCYTIDINE, METHOD OF OBTAINING SUCH DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 917166,
	"label": "Isolert DNA som koder for CD40L-mutein, fremgangsmate for fremstilling av dette, rekombinant ekspresjonsvektor, vertscelle, samt CD40L-polypeptid.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 917166,
	"label": "Isolert DNA som koder for CD40L-mutein, fremgangsmate for fremstilling av dette, rekombinant ekspresjonsvektor, vertscelle, samt CD40L-polypeptid.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 917166,
	"label": "Isolert DNA som koder for CD40L-mutein, fremgangsmate for fremstilling av dette, rekombinant ekspresjonsvektor, vertscelle, samt CD40L-polypeptid.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 917166,
	"label": "Isolert DNA som koder for CD40L-mutein, fremgangsmate for fremstilling av dette, rekombinant ekspresjonsvektor, vertscelle, samt CD40L-polypeptid.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 917166,
	"label": "Isolert DNA som koder for CD40L-mutein, fremgangsmate for fremstilling av dette, rekombinant ekspresjonsvektor, vertscelle, samt CD40L-polypeptid.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 919838,
	"label": "NUKLEINSÄURE, EXPRESSIONSVEKTOR UND ZUSAMMENSETZUNGEN ZUR IDENTIFIZIERUNG UND HERSTELLUNG VON REKOMBINANTEN SIALYLTRANSFERASEN",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 919838,
	"label": "NUKLEINSÄURE, EXPRESSIONSVEKTOR UND ZUSAMMENSETZUNGEN ZUR IDENTIFIZIERUNG UND HERSTELLUNG VON REKOMBINANTEN SIALYLTRANSFERASEN",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 919838,
	"label": "NUKLEINSÄURE, EXPRESSIONSVEKTOR UND ZUSAMMENSETZUNGEN ZUR IDENTIFIZIERUNG UND HERSTELLUNG VON REKOMBINANTEN SIALYLTRANSFERASEN",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 32788,
	"target": 32697,
	"type": 920117,
	"label": "G-CSF analogues that do not possess any hematopoietic activity and are useful as antagonists against G-CSF effect, such as overproduction of G-CSF",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 920117,
	"label": "G-CSF analogues that do not possess any hematopoietic activity and are useful as antagonists against G-CSF effect, such as overproduction of G-CSF",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 920117,
	"label": "G-CSF analogues that do not possess any hematopoietic activity and are useful as antagonists against G-CSF effect, such as overproduction of G-CSF",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32697,
	"type": 920117,
	"label": "G-CSF analogues that do not possess any hematopoietic activity and are useful as antagonists against G-CSF effect, such as overproduction of G-CSF",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 920117,
	"label": "G-CSF analogues that do not possess any hematopoietic activity and are useful as antagonists against G-CSF effect, such as overproduction of G-CSF",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 920968,
	"label": "Antibody to osteoclast alphavbeta3 ntegrin",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 921287,
	"label": "H- AND L-CHAINS OF MONOCLONAL ANTIBODY PM-1 (MONAT) TO HUMAN IL-6R RECEPTOR AND THEIR V-REGION, MODIFIED MONAT, ITS H- AND L-CHAINS AND THEIR V-REGIONS, CDR-SEQUENCE, DNA-SEQUENCE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 921287,
	"label": "H- AND L-CHAINS OF MONOCLONAL ANTIBODY PM-1 (MONAT) TO HUMAN IL-6R RECEPTOR AND THEIR V-REGION, MODIFIED MONAT, ITS H- AND L-CHAINS AND THEIR V-REGIONS, CDR-SEQUENCE, DNA-SEQUENCE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 921287,
	"label": "H- AND L-CHAINS OF MONOCLONAL ANTIBODY PM-1 (MONAT) TO HUMAN IL-6R RECEPTOR AND THEIR V-REGION, MODIFIED MONAT, ITS H- AND L-CHAINS AND THEIR V-REGIONS, CDR-SEQUENCE, DNA-SEQUENCE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 921287,
	"label": "H- AND L-CHAINS OF MONOCLONAL ANTIBODY PM-1 (MONAT) TO HUMAN IL-6R RECEPTOR AND THEIR V-REGION, MODIFIED MONAT, ITS H- AND L-CHAINS AND THEIR V-REGIONS, CDR-SEQUENCE, DNA-SEQUENCE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 921287,
	"label": "H- AND L-CHAINS OF MONOCLONAL ANTIBODY PM-1 (MONAT) TO HUMAN IL-6R RECEPTOR AND THEIR V-REGION, MODIFIED MONAT, ITS H- AND L-CHAINS AND THEIR V-REGIONS, CDR-SEQUENCE, DNA-SEQUENCE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 922335,
	"label": "Human PF4A receptors, nucleic acid encoding and antibodies binding thereto",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 922335,
	"label": "Human PF4A receptors, nucleic acid encoding and antibodies binding thereto",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 922335,
	"label": "Human PF4A receptors, nucleic acid encoding and antibodies binding thereto",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 922335,
	"label": "Human PF4A receptors, nucleic acid encoding and antibodies binding thereto",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 922335,
	"label": "Human PF4A receptors, nucleic acid encoding and antibodies binding thereto",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 922340,
	"label": "Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 922340,
	"label": "Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37904,
	"target": 32772,
	"type": 922340,
	"label": "Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 922340,
	"label": "Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 56834,
	"target": 37904,
	"type": 922340,
	"label": "Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6565,
	"type": 922405,
	"label": "Hybridoma and monoclonal antibody specific for human stem cell factor receptor and methods of use of the monoclonal antibody for detection of stem cell factor receptors",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 923084,
	"label": "VARIANTES DEL DOMINIO LECTINA DE LA SELECTINA.",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 923084,
	"label": "VARIANTES DEL DOMINIO LECTINA DE LA SELECTINA.",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 923084,
	"label": "VARIANTES DEL DOMINIO LECTINA DE LA SELECTINA.",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 923173,
	"label": "AKTIVIERUNG VON REZEPTOREN FÄHIG ZUR OLIGOMERISIERUNG DURCH VERWENDUNG VON FUSIONIERTEN REZEPTOR LIGANDEN",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 923173,
	"label": "AKTIVIERUNG VON REZEPTOREN FÄHIG ZUR OLIGOMERISIERUNG DURCH VERWENDUNG VON FUSIONIERTEN REZEPTOR LIGANDEN",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 923173,
	"label": "AKTIVIERUNG VON REZEPTOREN FÄHIG ZUR OLIGOMERISIERUNG DURCH VERWENDUNG VON FUSIONIERTEN REZEPTOR LIGANDEN",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 923173,
	"label": "AKTIVIERUNG VON REZEPTOREN FÄHIG ZUR OLIGOMERISIERUNG DURCH VERWENDUNG VON FUSIONIERTEN REZEPTOR LIGANDEN",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 923173,
	"label": "AKTIVIERUNG VON REZEPTOREN FÄHIG ZUR OLIGOMERISIERUNG DURCH VERWENDUNG VON FUSIONIERTEN REZEPTOR LIGANDEN",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 923470,
	"label": "Method for purification of L-selectin ligands",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 923636,
	"label": "PHARMACEUTICAL COMPOSITIONS CONTAINING A RETINOIC ACID OR A SALT OR ESTER THEREOF AND A VITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 924352,
	"label": "METHOD OF STIMULATING HEPATOCYTE PROLIFERATION BY ADMINISTRATION OF HEPATOCYTE GROWTH FACTOR AND GAMMA-INTERFERON",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 924359,
	"label": "BEHANDLUNG DER HIV-ASSOZIIERTEN IMMUN- THROMBOPENIE PURPURA",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38065,
	"target": 32734,
	"type": 924401,
	"label": "Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32734,
	"target": 6795,
	"type": 924401,
	"label": "Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 924401,
	"label": "Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 925433,
	"label": "AUMENTO DE LA EXPRESION MEDIANTE ORIENTACION GENICA EN SECUENCIAS ENDOGENAS DE TIPO RETROVIRUS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 925433,
	"label": "AUMENTO DE LA EXPRESION MEDIANTE ORIENTACION GENICA EN SECUENCIAS ENDOGENAS DE TIPO RETROVIRUS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 925433,
	"label": "AUMENTO DE LA EXPRESION MEDIANTE ORIENTACION GENICA EN SECUENCIAS ENDOGENAS DE TIPO RETROVIRUS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 925433,
	"label": "AUMENTO DE LA EXPRESION MEDIANTE ORIENTACION GENICA EN SECUENCIAS ENDOGENAS DE TIPO RETROVIRUS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 925433,
	"label": "AUMENTO DE LA EXPRESION MEDIANTE ORIENTACION GENICA EN SECUENCIAS ENDOGENAS DE TIPO RETROVIRUS.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 926275,
	"label": "TISSUE PLASMINOGEN ACTIVATOR GLYCOSYLATION VARIANTS, GLYCOSYLATED AT ANY ONE OF POSITIONS 103 TO 105 AND DEVOID OF GLYCOSYLATION AT POSITION 117, WITH IMPROVED THERAPEUTIC PROPERTIES, METHOD OF PREPARING AND COMPOSITIONS COMPRISING THEM",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 926275,
	"label": "TISSUE PLASMINOGEN ACTIVATOR GLYCOSYLATION VARIANTS, GLYCOSYLATED AT ANY ONE OF POSITIONS 103 TO 105 AND DEVOID OF GLYCOSYLATION AT POSITION 117, WITH IMPROVED THERAPEUTIC PROPERTIES, METHOD OF PREPARING AND COMPOSITIONS COMPRISING THEM",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37947,
	"target": 6841,
	"type": 926275,
	"label": "TISSUE PLASMINOGEN ACTIVATOR GLYCOSYLATION VARIANTS, GLYCOSYLATED AT ANY ONE OF POSITIONS 103 TO 105 AND DEVOID OF GLYCOSYLATION AT POSITION 117, WITH IMPROVED THERAPEUTIC PROPERTIES, METHOD OF PREPARING AND COMPOSITIONS COMPRISING THEM",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 926275,
	"label": "TISSUE PLASMINOGEN ACTIVATOR GLYCOSYLATION VARIANTS, GLYCOSYLATED AT ANY ONE OF POSITIONS 103 TO 105 AND DEVOID OF GLYCOSYLATION AT POSITION 117, WITH IMPROVED THERAPEUTIC PROPERTIES, METHOD OF PREPARING AND COMPOSITIONS COMPRISING THEM",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 926275,
	"label": "TISSUE PLASMINOGEN ACTIVATOR GLYCOSYLATION VARIANTS, GLYCOSYLATED AT ANY ONE OF POSITIONS 103 TO 105 AND DEVOID OF GLYCOSYLATION AT POSITION 117, WITH IMPROVED THERAPEUTIC PROPERTIES, METHOD OF PREPARING AND COMPOSITIONS COMPRISING THEM",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 927801,
	"label": "REGULACION DE GENES EN CELULAS DE MAMIFERO DEPENDIENTE DE ECDIESTEROIDES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 927801,
	"label": "REGULACION DE GENES EN CELULAS DE MAMIFERO DEPENDIENTE DE ECDIESTEROIDES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 927801,
	"label": "REGULACION DE GENES EN CELULAS DE MAMIFERO DEPENDIENTE DE ECDIESTEROIDES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 927828,
	"label": "FUNKTIONALISIERTE TRAEGERMATERIALIEN FUER GLEICHZEITIGE SYNTHESE UND DIREKTMARKIERUNG VON OLIGONUKLEOTIDEN ALS PRIMER FUER MATRIZENABHAENGIGE ENZYMATISCHE NUKLEINSAEURESYNTHESEN",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 6854,
	"target": 6816,
	"type": 928081,
	"label": "INTERFERON-PEG CONJUGATES INVOLVING UNIQUE LINKAGES, THEIR PREPARATION AND COMPOSITIONS THEREOF; AND CONJUGATION REAGENTS",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 928604,
	"label": "N-acetylglucosaminyltransferase V proteins and coding sequences",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 32734,
	"target": 6795,
	"type": 928928,
	"label": "PREPARATION OF PHARMACEUTICAL COMPOSITIONS USING COMPOUND CAPABLE OF SPECIFIC BINDING TO A RELAXIN RECEPTOR IN THE ATRIUM OF THE HEART",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 929954,
	"label": "NUEVOS CONJUGADOS PARA INTRODUCIR ACIDO NUCLEICO DENTRO DE CELULAS EUCARIOTICAS SUPERIORES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 930503,
	"label": "Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav.",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 930503,
	"label": "Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav.",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 930503,
	"label": "Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav.",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 930503,
	"label": "Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav.",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 56836,
	"target": 37993,
	"type": 930503,
	"label": "Omformede monoklonale antistoffer mot en immunoglobulin isotype, konjugat, fremgangsmate, DNA, hybridvektor, vertscelleanvendelse, farmasoytisk sammensetning og testkit derav.",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 7409,
	"target": 6382,
	"type": 930861,
	"label": "1,4-DISUBSTITUTED PIPERAZINES USEFUL FOR TREATMENT OF PATIENTS WITH ASTHMA AND RESPIRATORY WAY INFLAMMATION, METHOD OF THEIR SYNTHESIS, DRUGS BASED ON THEREOF AND A METHOD OF PREPARING",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 931081,
	"label": "Nye rensete og isolerte neurotrofiske proteiner, nukleinsyresekvensen som koder for disse proteiner, ny vektor og vertscelle som inneholder nevnte vektor, en fremgangsmate for fremstilling av nevnte proteiner, en innretning for a behandle nerveskade, en farmasoytisk sammensetning samt anvendelse av nevnte proteiner.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 931081,
	"label": "Nye rensete og isolerte neurotrofiske proteiner, nukleinsyresekvensen som koder for disse proteiner, ny vektor og vertscelle som inneholder nevnte vektor, en fremgangsmate for fremstilling av nevnte proteiner, en innretning for a behandle nerveskade, en farmasoytisk sammensetning samt anvendelse av nevnte proteiner.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 931081,
	"label": "Nye rensete og isolerte neurotrofiske proteiner, nukleinsyresekvensen som koder for disse proteiner, ny vektor og vertscelle som inneholder nevnte vektor, en fremgangsmate for fremstilling av nevnte proteiner, en innretning for a behandle nerveskade, en farmasoytisk sammensetning samt anvendelse av nevnte proteiner.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 931136,
	"label": "Anvendelse av IFN-8, IL-2 eller en kombinasjon derav for fremstilling av et medikament for behandling/profylakse avinfeksjoner hos transplantatmottakere som underkastesimmunundertrykkende syklosporinterapi etter transplantasjon",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 931854,
	"label": "NEW MEGAKARYOCYTE-MULTIPLYING FACTOR",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 931859,
	"label": "22-Oxacholecalciferolderivater og fremgangsmåde til fremstilling deraf",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 931859,
	"label": "22-Oxacholecalciferolderivater og fremgangsmåde til fremstilling deraf",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 931859,
	"label": "22-Oxacholecalciferolderivater og fremgangsmåde til fremstilling deraf",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 931919,
	"label": "BISPEZIFISCHE IMMUNOADHESINE",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 931934,
	"label": "COMPOCICION FARMACEUTICA QUE CONTIENE UN ANTAGONISTA DE LFA-1 PARA EL TRATAMIENTO DE TRANSTORNOS O DESORDENES MEDIADOS POR EL LFA-1",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 931934,
	"label": "COMPOCICION FARMACEUTICA QUE CONTIENE UN ANTAGONISTA DE LFA-1 PARA EL TRATAMIENTO DE TRANSTORNOS O DESORDENES MEDIADOS POR EL LFA-1",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 931934,
	"label": "COMPOCICION FARMACEUTICA QUE CONTIENE UN ANTAGONISTA DE LFA-1 PARA EL TRATAMIENTO DE TRANSTORNOS O DESORDENES MEDIADOS POR EL LFA-1",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 932139,
	"label": "ESTREPTAVIDINA DE NUCLEO RECOMBINANTE.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 932139,
	"label": "ESTREPTAVIDINA DE NUCLEO RECOMBINANTE.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 932139,
	"label": "ESTREPTAVIDINA DE NUCLEO RECOMBINANTE.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 932597,
	"label": "ANTIBODIES, METHOD OF OBTAINING THEM, REAGENT FOR IMMUNOLOGICAL DETERMINATION OF N-TERMINAL GLUCONATED HEMOGLOBIN, CONTAINING AT LEAST ONE ANTOBODY AS WELL AS SIMULTANEOUS DETERMINATION OF HBALC AND HEMOGLOBIN VARIANTS",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 932648,
	"label": "Nucleic acids encoding eck receptor ligands",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 932648,
	"label": "Nucleic acids encoding eck receptor ligands",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 932648,
	"label": "Nucleic acids encoding eck receptor ligands",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 932648,
	"label": "Nucleic acids encoding eck receptor ligands",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 56833,
	"target": 38181,
	"type": 932648,
	"label": "Nucleic acids encoding eck receptor ligands",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 932817,
	"label": "TISSUE PLASMINOGEN ACTIVATOR VARIANTS AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 932817,
	"label": "TISSUE PLASMINOGEN ACTIVATOR VARIANTS AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37875,
	"target": 6841,
	"type": 932817,
	"label": "TISSUE PLASMINOGEN ACTIVATOR VARIANTS AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 6841,
	"type": 932817,
	"label": "TISSUE PLASMINOGEN ACTIVATOR VARIANTS AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 932817,
	"label": "TISSUE PLASMINOGEN ACTIVATOR VARIANTS AND THEIR PREPARATION AND USE",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 933009,
	"label": "DERIVADOS FLUORADOS DE LA VITAMINA D3 POSICIONES FARMACEUTICAS ELABORADAS A PARTIR DE ESTOS DERIVA DOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 933009,
	"label": "DERIVADOS FLUORADOS DE LA VITAMINA D3 POSICIONES FARMACEUTICAS ELABORADAS A PARTIR DE ESTOS DERIVA DOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 933009,
	"label": "DERIVADOS FLUORADOS DE LA VITAMINA D3 POSICIONES FARMACEUTICAS ELABORADAS A PARTIR DE ESTOS DERIVA DOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 933014,
	"label": "FLUORIDATED VITAMIN D3 ANALOGUES, INTERMEDIATES FOR PREPARATION THEREOF, METHOD FOR PREPARATION SUCH FLUORINATED VITAMIN D3 ANALOGUE, PHARMACEUTICAL COMPOSITION CONTAINING ANALOGUES OF FLUORINATED VITAMINE D3 AND USE OF SUCH ANALOGUES IN PRODUCTION OF PHARMACEUTICAL COMPOSITIONS IN HEALING OF OSTEOPOROSIS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 933014,
	"label": "FLUORIDATED VITAMIN D3 ANALOGUES, INTERMEDIATES FOR PREPARATION THEREOF, METHOD FOR PREPARATION SUCH FLUORINATED VITAMIN D3 ANALOGUE, PHARMACEUTICAL COMPOSITION CONTAINING ANALOGUES OF FLUORINATED VITAMINE D3 AND USE OF SUCH ANALOGUES IN PRODUCTION OF PHARMACEUTICAL COMPOSITIONS IN HEALING OF OSTEOPOROSIS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 933014,
	"label": "FLUORIDATED VITAMIN D3 ANALOGUES, INTERMEDIATES FOR PREPARATION THEREOF, METHOD FOR PREPARATION SUCH FLUORINATED VITAMIN D3 ANALOGUE, PHARMACEUTICAL COMPOSITION CONTAINING ANALOGUES OF FLUORINATED VITAMINE D3 AND USE OF SUCH ANALOGUES IN PRODUCTION OF PHARMACEUTICAL COMPOSITIONS IN HEALING OF OSTEOPOROSIS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 933045,
	"label": "VITAMINE D3 ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS AN ACTIVE MATTER AND THE USE THEREOF IN THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 933045,
	"label": "VITAMINE D3 ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS AN ACTIVE MATTER AND THE USE THEREOF IN THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 933045,
	"label": "VITAMINE D3 ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS AN ACTIVE MATTER AND THE USE THEREOF IN THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 933065,
	"label": "PROCEDES POUR LA PREPARATION DE CONJUGUE PEG-IFN ALPHA PHYSIOLOGIQUEMENT ACTIF, ET POUR LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES LE CONTENANT ET LEUR UTILISATION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 933065,
	"label": "PROCEDES POUR LA PREPARATION DE CONJUGUE PEG-IFN ALPHA PHYSIOLOGIQUEMENT ACTIF, ET POUR LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES LE CONTENANT ET LEUR UTILISATION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7510,
	"target": 6816,
	"type": 933065,
	"label": "PROCEDES POUR LA PREPARATION DE CONJUGUE PEG-IFN ALPHA PHYSIOLOGIQUEMENT ACTIF, ET POUR LA PREPARATION DE COMPOSITIONS PHARMACEUTIQUES LE CONTENANT ET LEUR UTILISATION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32779,
	"target": 32769,
	"type": 933083,
	"label": "IMMUNOLOGICAL DETERMINATION METHOD USING OLIGOMERIZED RECEIVERS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37875,
	"target": 32694,
	"type": 933737,
	"label": "ANTIBODIES TO ISOLATED BIOLOGICALLY ACTIVE HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RELATED PROTEIN, THEIR USE AND MEDICAMENTS COMPRISING THEM",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 934467,
	"label": "REZEPTOR DES OB-PROTEINS UND VERWANDTE ZUSAMMENSETZUNGEN UND VERFAHREN",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 934483,
	"label": "UTILIZACION DE TROMBOPOYETINA COMO MEDICAMENTO PARA LA TERAPIA Y LA PREVENCION DE TROMBOCITOPENIA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 934483,
	"label": "UTILIZACION DE TROMBOPOYETINA COMO MEDICAMENTO PARA LA TERAPIA Y LA PREVENCION DE TROMBOCITOPENIA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 934483,
	"label": "UTILIZACION DE TROMBOPOYETINA COMO MEDICAMENTO PARA LA TERAPIA Y LA PREVENCION DE TROMBOCITOPENIA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 934483,
	"label": "UTILIZACION DE TROMBOPOYETINA COMO MEDICAMENTO PARA LA TERAPIA Y LA PREVENCION DE TROMBOCITOPENIA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 934483,
	"label": "UTILIZACION DE TROMBOPOYETINA COMO MEDICAMENTO PARA LA TERAPIA Y LA PREVENCION DE TROMBOCITOPENIA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6566,
	"type": 934507,
	"label": "ISOLIERUNG UND ZÜCHTUNG VON SCHWANNZELLEN",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 935147,
	"label": "PRODUCCION MEJORADA DE RIBOFLAVINA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7511,
	"target": 7487,
	"type": 935367,
	"label": "Solid instant-release form of administration, process for preparing such form of administration and use of therapeutic active substances when preparing such solid instant-release form of administration",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 936121,
	"label": "Termostabilt DNA polymerase-enzym, nukleinsyresekvens som koder for enzymet, vektor og vertscelle som omfatter nukleinsyresekvensen, fremgangsmate for fremstilling av, og anvendelse av termostabilt DNA-polymerase-enzym, samt blanding, fremgangsmate og testsett hvor enzymet inngar.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 936121,
	"label": "Termostabilt DNA polymerase-enzym, nukleinsyresekvens som koder for enzymet, vektor og vertscelle som omfatter nukleinsyresekvensen, fremgangsmate for fremstilling av, og anvendelse av termostabilt DNA-polymerase-enzym, samt blanding, fremgangsmate og testsett hvor enzymet inngar.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 936121,
	"label": "Termostabilt DNA polymerase-enzym, nukleinsyresekvens som koder for enzymet, vektor og vertscelle som omfatter nukleinsyresekvensen, fremgangsmate for fremstilling av, og anvendelse av termostabilt DNA-polymerase-enzym, samt blanding, fremgangsmate og testsett hvor enzymet inngar.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 936464,
	"label": "ANTIKÖRPER GEGEN CD 18 ZUR VERWENDUNG GEGEN   GEHIRNSCHLAG",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 936508,
	"label": "Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 936508,
	"label": "Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 936508,
	"label": "Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7409,
	"target": 6841,
	"type": 936508,
	"label": "Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 7409,
	"type": 936508,
	"label": "Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 937749,
	"label": "Polypeptide comprising kunitz-type serine protease inhibitor",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 937772,
	"label": "PROCESS FOR CONTROLLING THE AMOUNT OF SIALIC ACID PRESENTON AN OLIGOSACCHARIDE SIDE CHAUN OF A GLYCOPROTEIN, PROCESS FOR PRODUCING CHIMERIC GLYCOPROTEIN, PREPARATION, COMPRISING CHIMERIC GLYCOPROTEIN, AND THERAPEUTIC COMPOSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 937772,
	"label": "PROCESS FOR CONTROLLING THE AMOUNT OF SIALIC ACID PRESENTON AN OLIGOSACCHARIDE SIDE CHAUN OF A GLYCOPROTEIN, PROCESS FOR PRODUCING CHIMERIC GLYCOPROTEIN, PREPARATION, COMPRISING CHIMERIC GLYCOPROTEIN, AND THERAPEUTIC COMPOSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 937772,
	"label": "PROCESS FOR CONTROLLING THE AMOUNT OF SIALIC ACID PRESENTON AN OLIGOSACCHARIDE SIDE CHAUN OF A GLYCOPROTEIN, PROCESS FOR PRODUCING CHIMERIC GLYCOPROTEIN, PREPARATION, COMPRISING CHIMERIC GLYCOPROTEIN, AND THERAPEUTIC COMPOSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 937772,
	"label": "PROCESS FOR CONTROLLING THE AMOUNT OF SIALIC ACID PRESENTON AN OLIGOSACCHARIDE SIDE CHAUN OF A GLYCOPROTEIN, PROCESS FOR PRODUCING CHIMERIC GLYCOPROTEIN, PREPARATION, COMPRISING CHIMERIC GLYCOPROTEIN, AND THERAPEUTIC COMPOSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 937772,
	"label": "PROCESS FOR CONTROLLING THE AMOUNT OF SIALIC ACID PRESENTON AN OLIGOSACCHARIDE SIDE CHAUN OF A GLYCOPROTEIN, PROCESS FOR PRODUCING CHIMERIC GLYCOPROTEIN, PREPARATION, COMPRISING CHIMERIC GLYCOPROTEIN, AND THERAPEUTIC COMPOSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 938048,
	"label": "25-Hydroxy-16-ene-26,27-bishomo-cholecalciferol derivatives, their use, intermediates and pharmaceutical mixtures",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 938048,
	"label": "25-Hydroxy-16-ene-26,27-bishomo-cholecalciferol derivatives, their use, intermediates and pharmaceutical mixtures",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 938048,
	"label": "25-Hydroxy-16-ene-26,27-bishomo-cholecalciferol derivatives, their use, intermediates and pharmaceutical mixtures",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7487,
	"target": 6371,
	"type": 940015,
	"label": "DIAMINOPYRIMIDINE, DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND IHRE VERWENDUNG ALS ANTIBAKTERIELLE MITTEL",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 6852,
	"target": 6795,
	"type": 940126,
	"label": "PROTEINAS DE FUSION DE UN DOMINIO DE FACTOR TISULAR-DOMINIO DE KUNITZ COMO INHIBIDORES DEL FACTOR VIIA.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 6852,
	"type": 940126,
	"label": "PROTEINAS DE FUSION DE UN DOMINIO DE FACTOR TISULAR-DOMINIO DE KUNITZ COMO INHIBIDORES DEL FACTOR VIIA.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 940126,
	"label": "PROTEINAS DE FUSION DE UN DOMINIO DE FACTOR TISULAR-DOMINIO DE KUNITZ COMO INHIBIDORES DEL FACTOR VIIA.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 940430,
	"label": "DERIVATIVES OF FUSED HETEROCYCLES SUBSTITUTED ON THE AMINOGROUP, PROCESS FOR PRODUCING THEM, THEIR USE AND PHARMACEUTICAL COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 940430,
	"label": "DERIVATIVES OF FUSED HETEROCYCLES SUBSTITUTED ON THE AMINOGROUP, PROCESS FOR PRODUCING THEM, THEIR USE AND PHARMACEUTICAL COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 31939,
	"target": 7450,
	"type": 940430,
	"label": "DERIVATIVES OF FUSED HETEROCYCLES SUBSTITUTED ON THE AMINOGROUP, PROCESS FOR PRODUCING THEM, THEIR USE AND PHARMACEUTICAL COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 940679,
	"label": "VITAMIN D3 DERIVATIVES HAVING A SUBSTITUENT AT THE 2-POSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 940679,
	"label": "VITAMIN D3 DERIVATIVES HAVING A SUBSTITUENT AT THE 2-POSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 940679,
	"label": "VITAMIN D3 DERIVATIVES HAVING A SUBSTITUENT AT THE 2-POSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 37875,
	"type": 941223,
	"label": "Antibodies and immunoassay for the detection of MIA",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 941223,
	"label": "Antibodies and immunoassay for the detection of MIA",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56836,
	"target": 37875,
	"type": 941223,
	"label": "Antibodies and immunoassay for the detection of MIA",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 941235,
	"label": "Verfahren zur entkoppelten, direkten, exponentiellen Amplifikation und Sequenzierung von DNA Molekülen unter Zugabe einer zweiten thermostabilen DNA Polymerase und dessen Anwendung",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 941452,
	"label": "ANTICUERPOS ANTI-CD30 QUE EVITAN LA ESCISION PROTEOLITICA Y LIBERACION DEL ANTIGENO CD30 FIJADO A LA MEMBRANA.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 941452,
	"label": "ANTICUERPOS ANTI-CD30 QUE EVITAN LA ESCISION PROTEOLITICA Y LIBERACION DEL ANTIGENO CD30 FIJADO A LA MEMBRANA.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 941452,
	"label": "ANTICUERPOS ANTI-CD30 QUE EVITAN LA ESCISION PROTEOLITICA Y LIBERACION DEL ANTIGENO CD30 FIJADO A LA MEMBRANA.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 941452,
	"label": "ANTICUERPOS ANTI-CD30 QUE EVITAN LA ESCISION PROTEOLITICA Y LIBERACION DEL ANTIGENO CD30 FIJADO A LA MEMBRANA.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 941452,
	"label": "ANTICUERPOS ANTI-CD30 QUE EVITAN LA ESCISION PROTEOLITICA Y LIBERACION DEL ANTIGENO CD30 FIJADO A LA MEMBRANA.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 941529,
	"label": "USE OF VITAMIN D DERIVATIVE FOR TREATING DERMATOLOGICAL STATES, VITAMIN D DERIVATIVE, PROCESS OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7360,
	"target": 6429,
	"type": 941529,
	"label": "USE OF VITAMIN D DERIVATIVE FOR TREATING DERMATOLOGICAL STATES, VITAMIN D DERIVATIVE, PROCESS OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 941529,
	"label": "USE OF VITAMIN D DERIVATIVE FOR TREATING DERMATOLOGICAL STATES, VITAMIN D DERIVATIVE, PROCESS OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 941529,
	"label": "USE OF VITAMIN D DERIVATIVE FOR TREATING DERMATOLOGICAL STATES, VITAMIN D DERIVATIVE, PROCESS OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 7360,
	"type": 941529,
	"label": "USE OF VITAMIN D DERIVATIVE FOR TREATING DERMATOLOGICAL STATES, VITAMIN D DERIVATIVE, PROCESS OF ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 941680,
	"label": "INHIBIDOR DE LA DESCOMPOSICION DE PROTEINAS MUSCULARES QUE CONTIENEN ANTICUERPOS FRENTE AL RECEPTOR DE IL-6.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 941680,
	"label": "INHIBIDOR DE LA DESCOMPOSICION DE PROTEINAS MUSCULARES QUE CONTIENEN ANTICUERPOS FRENTE AL RECEPTOR DE IL-6.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 941680,
	"label": "INHIBIDOR DE LA DESCOMPOSICION DE PROTEINAS MUSCULARES QUE CONTIENEN ANTICUERPOS FRENTE AL RECEPTOR DE IL-6.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 941680,
	"label": "INHIBIDOR DE LA DESCOMPOSICION DE PROTEINAS MUSCULARES QUE CONTIENEN ANTICUERPOS FRENTE AL RECEPTOR DE IL-6.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 941680,
	"label": "INHIBIDOR DE LA DESCOMPOSICION DE PROTEINAS MUSCULARES QUE CONTIENEN ANTICUERPOS FRENTE AL RECEPTOR DE IL-6.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 941835,
	"label": "DNA encoding LST-1 protein and process for recombinant production of LST-1 protein",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 941957,
	"label": "THERMOLABILE URACIL-DNA-GLYKOSYLASE, VERFAHREN ZU DEREN HERSTELLUNG UND VERWENDUNG ZUR ENTFERNUNG VON URACIL AUS DNA",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 942025,
	"label": "Verwendung von Vitamin D Derivaten zur Herstellung eines Medikaments zur Behandlung von BÖSARTIGEN TUMORMETASTASE",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 942025,
	"label": "Verwendung von Vitamin D Derivaten zur Herstellung eines Medikaments zur Behandlung von BÖSARTIGEN TUMORMETASTASE",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6431,
	"type": 942025,
	"label": "Verwendung von Vitamin D Derivaten zur Herstellung eines Medikaments zur Behandlung von BÖSARTIGEN TUMORMETASTASE",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 942025,
	"label": "Verwendung von Vitamin D Derivaten zur Herstellung eines Medikaments zur Behandlung von BÖSARTIGEN TUMORMETASTASE",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7509,
	"target": 6431,
	"type": 942025,
	"label": "Verwendung von Vitamin D Derivaten zur Herstellung eines Medikaments zur Behandlung von BÖSARTIGEN TUMORMETASTASE",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37875,
	"type": 942042,
	"label": "METODO DE TRATAMENTO DE LESAO DE CELULAS DO GANGLIO RETINAL UTILIZANDO O PRODUTO PROTEICO FACTOR NEUROTROFICO DERIVADO DA LINHA DE CELULAS DA GLIA (GDNF)",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37875,
	"target": 32694,
	"type": 942042,
	"label": "METODO DE TRATAMENTO DE LESAO DE CELULAS DO GANGLIO RETINAL UTILIZANDO O PRODUTO PROTEICO FACTOR NEUROTROFICO DERIVADO DA LINHA DE CELULAS DA GLIA (GDNF)",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 942042,
	"label": "METODO DE TRATAMENTO DE LESAO DE CELULAS DO GANGLIO RETINAL UTILIZANDO O PRODUTO PROTEICO FACTOR NEUROTROFICO DERIVADO DA LINHA DE CELULAS DA GLIA (GDNF)",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 943080,
	"label": "Use of hydrophobic interaction chromatography to purify polyethylene glycols",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 944042,
	"label": "Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32788,
	"target": 7358,
	"type": 944042,
	"label": "Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32788,
	"target": 6816,
	"type": 944042,
	"label": "Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37996,
	"target": 37864,
	"type": 944059,
	"label": "DERIVATIVES OF OB PROTEIN, CHIMERIC OB POLYPEPTIDES, PREPARATIONS FOR TREATING OBESITY AND OTHER PHYSIOLOGICAL STATES AND METHOD OF TREATING BY MAKING USE OF THOSE PREPARATIONS, ENCODING SEQUENCE FOR OB PROTEIN, EXPRESSION VECTOR CARRYING THIS SEQUENCE, CELLS TRANSFORMED BY THIS VECTOR AND CULTIVATION PROCESS THEREOF AND METHOD OF TRIGGERING GROWTH OF CELLS BY MAKING USE OF THE OB PROTEIN",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 944240,
	"label": "TAB1 protein and DNA coding therefore",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 944240,
	"label": "TAB1 protein and DNA coding therefore",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 944240,
	"label": "TAB1 protein and DNA coding therefore",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 944764,
	"label": "FÜR EINE PROTEIN-KINASE KODIERENDE DNA",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7358,
	"target": 6795,
	"type": 944872,
	"label": "VERFAHREN ZUR VERRINGERUNG UND ZUR ERHALTUNG VON VERRINGERTEN BLUTSPIEGELN VON LIPIDEN MITTELS ZUBEREITUNGEN VON OB-PROTEINEN",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 945650,
	"label": "MPL LIGAND ANALOGS HAVING ONE OR MORE CHANGED GLYCOSYLATION SITES USES FOR THESE LIGAND ANALOGS AND DNA SEQUENCES ENCODING THEM",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 945650,
	"label": "MPL LIGAND ANALOGS HAVING ONE OR MORE CHANGED GLYCOSYLATION SITES USES FOR THESE LIGAND ANALOGS AND DNA SEQUENCES ENCODING THEM",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 945650,
	"label": "MPL LIGAND ANALOGS HAVING ONE OR MORE CHANGED GLYCOSYLATION SITES USES FOR THESE LIGAND ANALOGS AND DNA SEQUENCES ENCODING THEM",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 945650,
	"label": "MPL LIGAND ANALOGS HAVING ONE OR MORE CHANGED GLYCOSYLATION SITES USES FOR THESE LIGAND ANALOGS AND DNA SEQUENCES ENCODING THEM",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 945650,
	"label": "MPL LIGAND ANALOGS HAVING ONE OR MORE CHANGED GLYCOSYLATION SITES USES FOR THESE LIGAND ANALOGS AND DNA SEQUENCES ENCODING THEM",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 945654,
	"label": "Fremgangsmate for a sekretere et aktuelt heterologt polypeptid i en celle, nukleinsyre som koder for en sekresjonssignalsekvensvariant av STII og en variant av STII-sekresjonssignalsekvensen.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 945654,
	"label": "Fremgangsmate for a sekretere et aktuelt heterologt polypeptid i en celle, nukleinsyre som koder for en sekresjonssignalsekvensvariant av STII og en variant av STII-sekresjonssignalsekvensen.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 945654,
	"label": "Fremgangsmate for a sekretere et aktuelt heterologt polypeptid i en celle, nukleinsyre som koder for en sekresjonssignalsekvensvariant av STII og en variant av STII-sekresjonssignalsekvensen.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 946685,
	"label": "Compositions and methods of treating thrombocytopenia with IL-15",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 946685,
	"label": "Compositions and methods of treating thrombocytopenia with IL-15",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 946685,
	"label": "Compositions and methods of treating thrombocytopenia with IL-15",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 946854,
	"label": "Compositions comprising gas6 polypeptides and articles of manufacture comprising the same",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 946854,
	"label": "Compositions comprising gas6 polypeptides and articles of manufacture comprising the same",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 946854,
	"label": "Compositions comprising gas6 polypeptides and articles of manufacture comprising the same",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 947250,
	"label": "PROCEDE POUR LA PREPARATION DE COMPOSE PHARMACEUTIQUE ET POUR COMPOSITION PHARMACEUTIQUE LE CONTENANT, ET PROCEDE POUR SA PRODUCTION ET SON UTILISATION DANS LE TRAITEMENT DES MALADIES HYPERPROLIFERATIVES POUR LA PEAU",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 947250,
	"label": "PROCEDE POUR LA PREPARATION DE COMPOSE PHARMACEUTIQUE ET POUR COMPOSITION PHARMACEUTIQUE LE CONTENANT, ET PROCEDE POUR SA PRODUCTION ET SON UTILISATION DANS LE TRAITEMENT DES MALADIES HYPERPROLIFERATIVES POUR LA PEAU",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 947250,
	"label": "PROCEDE POUR LA PREPARATION DE COMPOSE PHARMACEUTIQUE ET POUR COMPOSITION PHARMACEUTIQUE LE CONTENANT, ET PROCEDE POUR SA PRODUCTION ET SON UTILISATION DANS LE TRAITEMENT DES MALADIES HYPERPROLIFERATIVES POUR LA PEAU",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 7508,
	"type": 947250,
	"label": "PROCEDE POUR LA PREPARATION DE COMPOSE PHARMACEUTIQUE ET POUR COMPOSITION PHARMACEUTIQUE LE CONTENANT, ET PROCEDE POUR SA PRODUCTION ET SON UTILISATION DANS LE TRAITEMENT DES MALADIES HYPERPROLIFERATIVES POUR LA PEAU",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 947250,
	"label": "PROCEDE POUR LA PREPARATION DE COMPOSE PHARMACEUTIQUE ET POUR COMPOSITION PHARMACEUTIQUE LE CONTENANT, ET PROCEDE POUR SA PRODUCTION ET SON UTILISATION DANS LE TRAITEMENT DES MALADIES HYPERPROLIFERATIVES POUR LA PEAU",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 947732,
	"label": "POLYPEPTIDE HAVING Erythrina Caffra DE-3 INHIBITORY ACTIVITY WHICH REVERSIBLY AND SELECTIVELY BINDS TO SERINE PROTEASES AND ITS USES IN PURIFYING SUCH PROTEASES",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37947,
	"target": 37864,
	"type": 947732,
	"label": "POLYPEPTIDE HAVING Erythrina Caffra DE-3 INHIBITORY ACTIVITY WHICH REVERSIBLY AND SELECTIVELY BINDS TO SERINE PROTEASES AND ITS USES IN PURIFYING SUCH PROTEASES",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 947732,
	"label": "POLYPEPTIDE HAVING Erythrina Caffra DE-3 INHIBITORY ACTIVITY WHICH REVERSIBLY AND SELECTIVELY BINDS TO SERINE PROTEASES AND ITS USES IN PURIFYING SUCH PROTEASES",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 947882,
	"label": "PROCEDIMIENTO PARA LA REDUCCION DE LA FORMACION DE ARTEFACTOS DURANTE LA TRANSCRIPCION DE ACIDOS RIBONUCLEICOS EN ACIDOS DESOXIRRIBONUCLEICOS.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38138,
	"target": 6241,
	"type": 948337,
	"label": "PROCEDIMIENTO PARA LA PRODUCCION DE LIPESTATINA Y TETRAHIDROLIPESTATINA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 948376,
	"label": "Produktion af biotin ved fermentering",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 948828,
	"label": "Method for the treatment of colon epithelial cells in vivo",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 948828,
	"label": "Method for the treatment of colon epithelial cells in vivo",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 948828,
	"label": "Method for the treatment of colon epithelial cells in vivo",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 948828,
	"label": "Method for the treatment of colon epithelial cells in vivo",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 948828,
	"label": "Method for the treatment of colon epithelial cells in vivo",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 6795,
	"target": 6215,
	"type": 949129,
	"label": "VERWENDUNG EINES PM-1 ANTIKÖRPERS ODER EINES MH 166 ANTIKÖRPERS ZUR VERSTÄRKUNG DES ANTI-TUMOR-EFFEKTES VON CISPLATIN ODER CARBOPLATIN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 949129,
	"label": "VERWENDUNG EINES PM-1 ANTIKÖRPERS ODER EINES MH 166 ANTIKÖRPERS ZUR VERSTÄRKUNG DES ANTI-TUMOR-EFFEKTES VON CISPLATIN ODER CARBOPLATIN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 6215,
	"type": 949129,
	"label": "VERWENDUNG EINES PM-1 ANTIKÖRPERS ODER EINES MH 166 ANTIKÖRPERS ZUR VERSTÄRKUNG DES ANTI-TUMOR-EFFEKTES VON CISPLATIN ODER CARBOPLATIN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 949907,
	"label": "Pantropisk neurotrofinpolypeptid, fremgangsmate for fremstilling av dette, isolert nukleinsyre, ekspresjonsvektor, vertscelle samt farmasoytisk preparat",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 949907,
	"label": "Pantropisk neurotrofinpolypeptid, fremgangsmate for fremstilling av dette, isolert nukleinsyre, ekspresjonsvektor, vertscelle samt farmasoytisk preparat",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 949907,
	"label": "Pantropisk neurotrofinpolypeptid, fremgangsmate for fremstilling av dette, isolert nukleinsyre, ekspresjonsvektor, vertscelle samt farmasoytisk preparat",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37893,
	"target": 37887,
	"type": 950034,
	"label": "UTILIZACAO DO FACTOR DE CELULAS ESTAMINAIS E DO RECEPTOR DE INTERLEUCINA 6 SOLUVEL PARA A EXPANSAO EX VIVO DE CELULAS HEMATOPOIETICAS MULTIPOTENTES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37887,
	"target": 37875,
	"type": 950034,
	"label": "UTILIZACAO DO FACTOR DE CELULAS ESTAMINAIS E DO RECEPTOR DE INTERLEUCINA 6 SOLUVEL PARA A EXPANSAO EX VIVO DE CELULAS HEMATOPOIETICAS MULTIPOTENTES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37893,
	"target": 37875,
	"type": 950034,
	"label": "UTILIZACAO DO FACTOR DE CELULAS ESTAMINAIS E DO RECEPTOR DE INTERLEUCINA 6 SOLUVEL PARA A EXPANSAO EX VIVO DE CELULAS HEMATOPOIETICAS MULTIPOTENTES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7425,
	"target": 7360,
	"type": 950590,
	"label": "PEPTIDEOS NATRIURETICOS AURICULARES ESPECIFICOS DERECEPTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 950590,
	"label": "PEPTIDEOS NATRIURETICOS AURICULARES ESPECIFICOS DERECEPTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7425,
	"target": 6795,
	"type": 950590,
	"label": "PEPTIDEOS NATRIURETICOS AURICULARES ESPECIFICOS DERECEPTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 7425,
	"type": 950590,
	"label": "PEPTIDEOS NATRIURETICOS AURICULARES ESPECIFICOS DERECEPTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 7360,
	"type": 950590,
	"label": "PEPTIDEOS NATRIURETICOS AURICULARES ESPECIFICOS DERECEPTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 950740,
	"label": "Novel polypeptides and coagulation therapy",
	"group": "Gilead",
	"time": 2004,
	"strength": 1
}, {
	"source": 38237,
	"target": 32770,
	"type": 951764,
	"label": "Antibodies specific for Rse receptor protein tyrosine kinase",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 951764,
	"label": "Antibodies specific for Rse receptor protein tyrosine kinase",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38237,
	"target": 6795,
	"type": 951764,
	"label": "Antibodies specific for Rse receptor protein tyrosine kinase",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32734,
	"target": 32694,
	"type": 951778,
	"label": "PROCEDIMIENTO PARA LA PURIFICACION DE POLIPEPTIDOS.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 952768,
	"label": "Antibodies specific for human adseverin",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 952768,
	"label": "Antibodies specific for human adseverin",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 6841,
	"type": 952768,
	"label": "Antibodies specific for human adseverin",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 952768,
	"label": "Antibodies specific for human adseverin",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 952768,
	"label": "Antibodies specific for human adseverin",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 952921,
	"label": "Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 953011,
	"label": "Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing CDRs or the variable region from the mouse monoclonal antibody, WS-4",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 7511,
	"type": 953011,
	"label": "Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing CDRs or the variable region from the mouse monoclonal antibody, WS-4",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 7511,
	"type": 953011,
	"label": "Recombinant CDR-grafted and chimeric anti-IL-8 antibodies containing CDRs or the variable region from the mouse monoclonal antibody, WS-4",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 953784,
	"label": "APOPTOSIS MODULATING PROTEIN AND NUCLEOTIDE SEQUENCE COMPOSITIONS USING BCL-2 HOMOLOGS TERMED CDN-1, CDN-2 AND CDN3",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 953784,
	"label": "APOPTOSIS MODULATING PROTEIN AND NUCLEOTIDE SEQUENCE COMPOSITIONS USING BCL-2 HOMOLOGS TERMED CDN-1, CDN-2 AND CDN3",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 953784,
	"label": "APOPTOSIS MODULATING PROTEIN AND NUCLEOTIDE SEQUENCE COMPOSITIONS USING BCL-2 HOMOLOGS TERMED CDN-1, CDN-2 AND CDN3",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37993,
	"target": 6795,
	"type": 953784,
	"label": "APOPTOSIS MODULATING PROTEIN AND NUCLEOTIDE SEQUENCE COMPOSITIONS USING BCL-2 HOMOLOGS TERMED CDN-1, CDN-2 AND CDN3",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 953784,
	"label": "APOPTOSIS MODULATING PROTEIN AND NUCLEOTIDE SEQUENCE COMPOSITIONS USING BCL-2 HOMOLOGS TERMED CDN-1, CDN-2 AND CDN3",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6352,
	"type": 954072,
	"label": "VESICULAS DE VINCA ALCALOIDES CON MEJOR EFICACIA Y PROPIEDADES DE DIRECCION A TUMORES.",
	"group": "Gilead",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 955248,
	"label": "PROCEDIMIENTO PARA LA SELECCION DE CELULAS HUESPED DE EXPRESION ELEVADA.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 955248,
	"label": "PROCEDIMIENTO PARA LA SELECCION DE CELULAS HUESPED DE EXPRESION ELEVADA.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 955248,
	"label": "PROCEDIMIENTO PARA LA SELECCION DE CELULAS HUESPED DE EXPRESION ELEVADA.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38065,
	"target": 37947,
	"type": 955248,
	"label": "PROCEDIMIENTO PARA LA SELECCION DE CELULAS HUESPED DE EXPRESION ELEVADA.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 955248,
	"label": "PROCEDIMIENTO PARA LA SELECCION DE CELULAS HUESPED DE EXPRESION ELEVADA.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 955449,
	"label": "PROCEDIMIENTO PARA LA IDENTIFICACION ESPECIFICA EN GENERO Y ESPECIE DE LEGIONELAS.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7425,
	"target": 6371,
	"type": 956549,
	"label": "PROCEDE POUR LA PREPARATION DE DERIVES DE PYRIMIDINEDIONE ET -TRIONE,  TRIAZINEDIONE ET QUINAZOLINEDIONE, PROCEDE DE PREPARATION DE COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 956553,
	"label": "Die Verwendung der 3'-wesentlichen Bearbeitungswirksamkeit von DNS-Polymerase",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 956553,
	"label": "Die Verwendung der 3'-wesentlichen Bearbeitungswirksamkeit von DNS-Polymerase",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38237,
	"target": 32478,
	"type": 956553,
	"label": "Die Verwendung der 3'-wesentlichen Bearbeitungswirksamkeit von DNS-Polymerase",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6215,
	"type": 957213,
	"label": "TRINUCLEAR CATIONIC PLATINUM COMPLEXES HAVING ANTITUMOR ACTIVITY, METHOD OF PREPARING THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID COMPLEXES",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 957979,
	"label": "METHODS AND MEDICAMENTS USING UNBOUND MYELOPROLIFERATIVE LEUKAEMIA VIRUS (MPL) RECEPTOR TO INCREASE PLATELETS IN MAMMALS",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 957979,
	"label": "METHODS AND MEDICAMENTS USING UNBOUND MYELOPROLIFERATIVE LEUKAEMIA VIRUS (MPL) RECEPTOR TO INCREASE PLATELETS IN MAMMALS",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 957979,
	"label": "METHODS AND MEDICAMENTS USING UNBOUND MYELOPROLIFERATIVE LEUKAEMIA VIRUS (MPL) RECEPTOR TO INCREASE PLATELETS IN MAMMALS",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 958164,
	"label": "PROTEINA DEL CICLO CELULAR DE MAMIFERO.",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7409,
	"target": 6841,
	"type": 958173,
	"label": "PHARMAZEUTISCHE AKZEPTABEL DNASE ZUSAMMENSETZUNG",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 56833,
	"target": 38232,
	"type": 958415,
	"label": "ASSAYS UND VORRICHTUNGEN ZUM NACHWEIS VON EXTRAHEPATISCHER BILIÄRERATRESIE",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 958425,
	"label": "Fremgangsmåder til udførelse af calciumphosphattransfektion",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 958532,
	"label": "Method and kits for determining messenger RNA molecules in a sample",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 958532,
	"label": "Method and kits for determining messenger RNA molecules in a sample",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38237,
	"target": 32478,
	"type": 958532,
	"label": "Method and kits for determining messenger RNA molecules in a sample",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 6841,
	"target": 6838,
	"type": 959201,
	"label": "ZUSAMMENSETZUNGEN AUS EINER THROMBOLYTISCH WIRKENDE SUBSTANZ UND ANTIKOAGULANTIEN, UND IHRE VERWENDUNGEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6345,
	"type": 959234,
	"label": "Fremgangsmate for syntese av 6,9-bis[(2-aminoetyl)amino]benzo[g]isokinolin-5,10-dion og dets dimaleatsalt, samt dimaleatsaltet fremstilt ved fremgangsmaten",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 960162,
	"label": "Fremgangsmate for rensing av serinproteaser ved anvendelse av et immobilisert polypeptid med samme aktivitet som inhibitor DE-3 fra E. caffra, samt fremstilling og anvendelse av nevnte polypeptid",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 960162,
	"label": "Fremgangsmate for rensing av serinproteaser ved anvendelse av et immobilisert polypeptid med samme aktivitet som inhibitor DE-3 fra E. caffra, samt fremstilling og anvendelse av nevnte polypeptid",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37947,
	"type": 960162,
	"label": "Fremgangsmate for rensing av serinproteaser ved anvendelse av et immobilisert polypeptid med samme aktivitet som inhibitor DE-3 fra E. caffra, samt fremstilling og anvendelse av nevnte polypeptid",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32788,
	"target": 32777,
	"type": 960220,
	"label": "FÜR DAS IGG-FC-BINDENDE PROTEIN KODIERENDES GEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 960220,
	"label": "FÜR DAS IGG-FC-BINDENDE PROTEIN KODIERENDES GEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32777,
	"type": 960220,
	"label": "FÜR DAS IGG-FC-BINDENDE PROTEIN KODIERENDES GEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 961272,
	"label": "TRATAMIENTO DEL SINDROME DE INSENSIBILIDAD PARCIAL A LA HORMONA DE CRECIMIENTO.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32734,
	"target": 7360,
	"type": 961272,
	"label": "TRATAMIENTO DEL SINDROME DE INSENSIBILIDAD PARCIAL A LA HORMONA DE CRECIMIENTO.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32734,
	"target": 6795,
	"type": 961272,
	"label": "TRATAMIENTO DEL SINDROME DE INSENSIBILIDAD PARCIAL A LA HORMONA DE CRECIMIENTO.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 961476,
	"label": "FACTOR NEUROTROFICO DERIVADO DAS CELULAS GLIAIS UTILIZADO COMO AGENTE NEUROPROTECTOR",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 961476,
	"label": "FACTOR NEUROTROFICO DERIVADO DAS CELULAS GLIAIS UTILIZADO COMO AGENTE NEUROPROTECTOR",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 961476,
	"label": "FACTOR NEUROTROFICO DERIVADO DAS CELULAS GLIAIS UTILIZADO COMO AGENTE NEUROPROTECTOR",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7510,
	"target": 6854,
	"type": 961624,
	"label": "Use of erythropoietin in the treatment of rheumatoid arthritis",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 961699,
	"label": "Composto composição farmacêutica processo para a produção do composto e uso",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 961699,
	"label": "Composto composição farmacêutica processo para a produção do composto e uso",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 961699,
	"label": "Composto composição farmacêutica processo para a produção do composto e uso",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 961699,
	"label": "Composto composição farmacêutica processo para a produção do composto e uso",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 961699,
	"label": "Composto composição farmacêutica processo para a produção do composto e uso",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 962233,
	"label": "MITTEL ZUR BEHANDLUNG VON KACHEXIE DIE IM ZUSAMMENHANG MIT TUMOREN STEHT",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6431,
	"type": 962233,
	"label": "MITTEL ZUR BEHANDLUNG VON KACHEXIE DIE IM ZUSAMMENHANG MIT TUMOREN STEHT",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 962233,
	"label": "MITTEL ZUR BEHANDLUNG VON KACHEXIE DIE IM ZUSAMMENHANG MIT TUMOREN STEHT",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 962260,
	"label": "AFAMIN: EIN MENSCHLICHES SERUM ALBUMIN ÄHNLICHES PROTEIN",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 962260,
	"label": "AFAMIN: EIN MENSCHLICHES SERUM ALBUMIN ÄHNLICHES PROTEIN",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 962260,
	"label": "AFAMIN: EIN MENSCHLICHES SERUM ALBUMIN ÄHNLICHES PROTEIN",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 56836,
	"target": 38181,
	"type": 962260,
	"label": "AFAMIN: EIN MENSCHLICHES SERUM ALBUMIN ÄHNLICHES PROTEIN",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 56836,
	"target": 37986,
	"type": 962260,
	"label": "AFAMIN: EIN MENSCHLICHES SERUM ALBUMIN ÄHNLICHES PROTEIN",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6215,
	"type": 962690,
	"label": "COMPLEJOS CATIONICOS TRINUCLEARES DE PLATINO QUE TIENEN UNA ACTIVIDAD ANTITUMORAL Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 962829,
	"label": "CEBADORES DE OLIGONUCLEOTIDOS PARA LA AMPLIFICACION DEL ACIDO NUCLEICO DEL VHC.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 963512,
	"label": "Bakteriell fermenteringsprosess for fremstilling av et rekombinant protein, samt fremgangsmate for reduksjon av naeringsutfelling i en prosess.",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 964824,
	"label": "PROCESS FOR IMPROVED RECOMBINANT PRODUCTION OF DISULPHIDE BOND-CONTAINING POLYPEPTIDES VIA A PROTEIN DISULFIDE ISOMERASE",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38059,
	"target": 37986,
	"type": 966158,
	"label": "VECTOR DE EXPRESION PROCARIOTA MINIMO QUE NO PUEDE SER RECOMBINADO EN FORMA HOMOLOGA CON EL GENOMA DE ORGANISMOS PROCARIOTAS, UNA CELULA HOSPEDADORA PROCARIOTA QUE CONTIENE DICHO VECTOR, UN PROCESO PARA LA CONSTRUCCION DE UN SISTEMA DE EXPRESION PROCARIOTA Y UN PROCESO PARA LA PRODUCCION DE UNA PROT",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 966799,
	"label": "IKK-alpha PROTEIN, NUCLEIC ACID ENCODING THE SAME AND METHOD",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 966799,
	"label": "IKK-alpha PROTEIN, NUCLEIC ACID ENCODING THE SAME AND METHOD",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 966799,
	"label": "IKK-alpha PROTEIN, NUCLEIC ACID ENCODING THE SAME AND METHOD",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 966800,
	"label": "IKK-beta-proteiner, nukleinsyrer og fremgangsmåder",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 966800,
	"label": "IKK-beta-proteiner, nukleinsyrer og fremgangsmåder",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 966800,
	"label": "IKK-beta-proteiner, nukleinsyrer og fremgangsmåder",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 966800,
	"label": "IKK-beta-proteiner, nukleinsyrer og fremgangsmåder",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38237,
	"target": 37899,
	"type": 966800,
	"label": "IKK-beta-proteiner, nukleinsyrer og fremgangsmåder",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 966828,
	"label": "USE OF INTERFERON CONSENSUS IN THE PREPARATION OF A MEDICAMENT, COMBINATION AND PHARMACEUTICAL COMPOSITION COMPRISING INTERFERON CONSENSUS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32254,
	"target": 7450,
	"type": 966831,
	"label": "NUEVOS MITOGENOS ESPECIFICOS DE OSTEOBLASTOS, METODOS PARA PREPARARLOS Y DROGAS QUE CONTIENEN TALES COMPUESTOS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 967059,
	"label": "PROCESS FOR THE PRODUCTION OF SUSPENSION PACKING CELL LINES FOR RETROVIRUS VECTORS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 967059,
	"label": "PROCESS FOR THE PRODUCTION OF SUSPENSION PACKING CELL LINES FOR RETROVIRUS VECTORS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 967059,
	"label": "PROCESS FOR THE PRODUCTION OF SUSPENSION PACKING CELL LINES FOR RETROVIRUS VECTORS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 967059,
	"label": "PROCESS FOR THE PRODUCTION OF SUSPENSION PACKING CELL LINES FOR RETROVIRUS VECTORS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 967059,
	"label": "PROCESS FOR THE PRODUCTION OF SUSPENSION PACKING CELL LINES FOR RETROVIRUS VECTORS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6892,
	"target": 6854,
	"type": 967858,
	"label": "INMUNOGENOS QUIMERICOS TIPO EXOTOXINA A DE PSEUDOMONAS PARA PROVOCAR UNA RESPUESTA INMUNITARIA MEDIADA POR IGA SECRETORA.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38042,
	"target": 32632,
	"type": 967858,
	"label": "INMUNOGENOS QUIMERICOS TIPO EXOTOXINA A DE PSEUDOMONAS PARA PROVOCAR UNA RESPUESTA INMUNITARIA MEDIADA POR IGA SECRETORA.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32632,
	"target": 6892,
	"type": 967858,
	"label": "INMUNOGENOS QUIMERICOS TIPO EXOTOXINA A DE PSEUDOMONAS PARA PROVOCAR UNA RESPUESTA INMUNITARIA MEDIADA POR IGA SECRETORA.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32632,
	"target": 6854,
	"type": 967858,
	"label": "INMUNOGENOS QUIMERICOS TIPO EXOTOXINA A DE PSEUDOMONAS PARA PROVOCAR UNA RESPUESTA INMUNITARIA MEDIADA POR IGA SECRETORA.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38042,
	"target": 6892,
	"type": 967858,
	"label": "INMUNOGENOS QUIMERICOS TIPO EXOTOXINA A DE PSEUDOMONAS PARA PROVOCAR UNA RESPUESTA INMUNITARIA MEDIADA POR IGA SECRETORA.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 31571,
	"target": 6169,
	"type": 969929,
	"label": "COMPUESTOS DERIVADOS DE HIDRAZIDA, SU USO, UN PROCESO PARA FABRICARLOS, MEDICAMENTOS QUE LOS CONTIENEN, UN PROCESO PARA PRODUCIR UN MEDICAMENTO, COMPUESTOS uTILES COMO INTERMEDIARIOS PARA PREPARAR DICHOS COMPUESTOS Y ÁCIDOS CARBOXíLICOS uTILES PARA PREPARAR DICHOS COMPUESTOS Y DICHOS INTERMEDIARIOS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 970761,
	"label": "Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 970761,
	"label": "Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 970761,
	"label": "Anvendelse af et neurturinprotein-produkt til forebyggelse og behandling af hørenedsættelse",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 971192,
	"label": "Recombinant Drosophila deoxynucleotide kinase useful for preparing nucleoside monophosphates by phosphorylating nucleosides",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30171,
	"target": 7507,
	"type": 971729,
	"label": "Substituted benzene compounds as antiproliferative and cholesterol lowering agents",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7424,
	"target": 6795,
	"type": 972598,
	"label": "Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 7424,
	"type": 972598,
	"label": "Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 972598,
	"label": "Methods for treating clinical manifestations of GH/GF axis dysregulation by administration of an IGF-I variant",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 973683,
	"label": "ZUSAMMENSETZUNGEN AUS KONJUGATEN DES STABILEN, AKTIVEN, MENSCHLICHEN OB PROTEINS MIT DER FC KETTE VON IMMUNOGLOBULINEN UND DAMIT ZUSAMMENHÄNGENDE VERFAHREN",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 973683,
	"label": "ZUSAMMENSETZUNGEN AUS KONJUGATEN DES STABILEN, AKTIVEN, MENSCHLICHEN OB PROTEINS MIT DER FC KETTE VON IMMUNOGLOBULINEN UND DAMIT ZUSAMMENHÄNGENDE VERFAHREN",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 973683,
	"label": "ZUSAMMENSETZUNGEN AUS KONJUGATEN DES STABILEN, AKTIVEN, MENSCHLICHEN OB PROTEINS MIT DER FC KETTE VON IMMUNOGLOBULINEN UND DAMIT ZUSAMMENHÄNGENDE VERFAHREN",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37904,
	"type": 973696,
	"label": "MONOCLONAL ANTIBODY PREPARED USING INTEGRIN-ASSOCIATED PROTEIN, ITS FRAGMENT FAB, FAB' OR F(AB')2, HYBRIDOMA PRODUCING MONOCLONAL ANTIBODY (VARIANT), ANTILEUKEMIC AGENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 973696,
	"label": "MONOCLONAL ANTIBODY PREPARED USING INTEGRIN-ASSOCIATED PROTEIN, ITS FRAGMENT FAB, FAB' OR F(AB')2, HYBRIDOMA PRODUCING MONOCLONAL ANTIBODY (VARIANT), ANTILEUKEMIC AGENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 973696,
	"label": "MONOCLONAL ANTIBODY PREPARED USING INTEGRIN-ASSOCIATED PROTEIN, ITS FRAGMENT FAB, FAB' OR F(AB')2, HYBRIDOMA PRODUCING MONOCLONAL ANTIBODY (VARIANT), ANTILEUKEMIC AGENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 973696,
	"label": "MONOCLONAL ANTIBODY PREPARED USING INTEGRIN-ASSOCIATED PROTEIN, ITS FRAGMENT FAB, FAB' OR F(AB')2, HYBRIDOMA PRODUCING MONOCLONAL ANTIBODY (VARIANT), ANTILEUKEMIC AGENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 973696,
	"label": "MONOCLONAL ANTIBODY PREPARED USING INTEGRIN-ASSOCIATED PROTEIN, ITS FRAGMENT FAB, FAB' OR F(AB')2, HYBRIDOMA PRODUCING MONOCLONAL ANTIBODY (VARIANT), ANTILEUKEMIC AGENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 973797,
	"label": "AUS EINER MENSCHLICHEN GLIAL ZELLLINIE- ABGELEITETER PROMOTOR EINES NEUROTROPHISCHEN FAKTORS, DIESEN ENTHALTENDE VEKTOREN UND METHODEN ZUM SCREENEN VON VERBINDUNGEN DAMIT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 973797,
	"label": "AUS EINER MENSCHLICHEN GLIAL ZELLLINIE- ABGELEITETER PROMOTOR EINES NEUROTROPHISCHEN FAKTORS, DIESEN ENTHALTENDE VEKTOREN UND METHODEN ZUM SCREENEN VON VERBINDUNGEN DAMIT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 973797,
	"label": "AUS EINER MENSCHLICHEN GLIAL ZELLLINIE- ABGELEITETER PROMOTOR EINES NEUROTROPHISCHEN FAKTORS, DIESEN ENTHALTENDE VEKTOREN UND METHODEN ZUM SCREENEN VON VERBINDUNGEN DAMIT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32003,
	"target": 31995,
	"type": 974093,
	"label": "DERIVADOS DE PIPERIDINA, UN PROCESO PARA SU PREPARACION, MEDICAMENTOS QUE LOS COMPRENDEN Y EL USO DE DICHOS DERIVADOS PARA LA MANUFACTURA DE UN MEDICAMENTO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 974641,
	"label": "Therapeutic agent for cachexia comprising a substance capable of inhibiting the binding between a parathyroid hormone related peptide and a receptor thereof as an active ingredient",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 32769,
	"type": 974641,
	"label": "Therapeutic agent for cachexia comprising a substance capable of inhibiting the binding between a parathyroid hormone related peptide and a receptor thereof as an active ingredient",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32769,
	"type": 974641,
	"label": "Therapeutic agent for cachexia comprising a substance capable of inhibiting the binding between a parathyroid hormone related peptide and a receptor thereof as an active ingredient",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32769,
	"target": 6795,
	"type": 974641,
	"label": "Therapeutic agent for cachexia comprising a substance capable of inhibiting the binding between a parathyroid hormone related peptide and a receptor thereof as an active ingredient",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 6795,
	"type": 974641,
	"label": "Therapeutic agent for cachexia comprising a substance capable of inhibiting the binding between a parathyroid hormone related peptide and a receptor thereof as an active ingredient",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 975732,
	"label": "Zymogenic protease precursors that can be autocatalytically activated and their use",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 28538,
	"target": 7450,
	"type": 975772,
	"label": "New benzazulene derivatives having alpha v beta 3 vitronectin receptor antagonist activity, used e.g. as bone resorption inhibitors",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 975810,
	"label": "Natural humanized antibody, method of production and pharmaceutical composition",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 975810,
	"label": "Natural humanized antibody, method of production and pharmaceutical composition",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 975810,
	"label": "Natural humanized antibody, method of production and pharmaceutical composition",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 975810,
	"label": "Natural humanized antibody, method of production and pharmaceutical composition",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 975810,
	"label": "Natural humanized antibody, method of production and pharmaceutical composition",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 976041,
	"label": "COMPOSITION PHARMACEUTIQUE DE PROTEINES HEDGEHOG, PROCÉDÉ POUR SA PRÉPARATION, ET SON UTILISATION POUR LA LIBÉRATION DE CES PROTEINES SUR LES OS ET LE CARTILAGE.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6203,
	"target": 6191,
	"type": 976809,
	"label": "Forbindelsen 9-cis retinsyre for anvendelse ved behandling av eksem samt anvendelse av denne for fremstilling av medikament for behandling av eksem.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7510,
	"target": 6203,
	"type": 976809,
	"label": "Forbindelsen 9-cis retinsyre for anvendelse ved behandling av eksem samt anvendelse av denne for fremstilling av medikament for behandling av eksem.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7510,
	"target": 6191,
	"type": 976809,
	"label": "Forbindelsen 9-cis retinsyre for anvendelse ved behandling av eksem samt anvendelse av denne for fremstilling av medikament for behandling av eksem.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 976823,
	"label": "PEPTIDOS METILADOS, HOMOLOGOS DEL SMD, QUE REACCIONAN CON LOS ANTICUERPOS DE LOS SUEROS DE SERES VIVOS AFECTADOS CON LUPUS ERITEMATOSO SISTEMICO.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 977627,
	"label": "Process for preparing anti-human antigen receptor, anti-human antigen receptor per se, VH and VL chain, kit for the selection of anti-human antigen receptors and pharmaceutical composition containing such a receptor",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 977627,
	"label": "Process for preparing anti-human antigen receptor, anti-human antigen receptor per se, VH and VL chain, kit for the selection of anti-human antigen receptors and pharmaceutical composition containing such a receptor",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 977627,
	"label": "Process for preparing anti-human antigen receptor, anti-human antigen receptor per se, VH and VL chain, kit for the selection of anti-human antigen receptors and pharmaceutical composition containing such a receptor",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32771,
	"target": 6795,
	"type": 977627,
	"label": "Process for preparing anti-human antigen receptor, anti-human antigen receptor per se, VH and VL chain, kit for the selection of anti-human antigen receptors and pharmaceutical composition containing such a receptor",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 977627,
	"label": "Process for preparing anti-human antigen receptor, anti-human antigen receptor per se, VH and VL chain, kit for the selection of anti-human antigen receptors and pharmaceutical composition containing such a receptor",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 977648,
	"label": "compostos análogos de vitamina d3, processo para a sua preparação e utilização dos mesmos para a preparação de medicamentos para o tratamento de hiperparatiroidismo primário e secundário, osteodistrofia renal, doenças de auto imunização, esclerose múltipla ou lúpus, e doenças neoplásticas.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 977648,
	"label": "compostos análogos de vitamina d3, processo para a sua preparação e utilização dos mesmos para a preparação de medicamentos para o tratamento de hiperparatiroidismo primário e secundário, osteodistrofia renal, doenças de auto imunização, esclerose múltipla ou lúpus, e doenças neoplásticas.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 977648,
	"label": "compostos análogos de vitamina d3, processo para a sua preparação e utilização dos mesmos para a preparação de medicamentos para o tratamento de hiperparatiroidismo primário e secundário, osteodistrofia renal, doenças de auto imunização, esclerose múltipla ou lúpus, e doenças neoplásticas.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 977648,
	"label": "compostos análogos de vitamina d3, processo para a sua preparação e utilização dos mesmos para a preparação de medicamentos para o tratamento de hiperparatiroidismo primário e secundário, osteodistrofia renal, doenças de auto imunização, esclerose múltipla ou lúpus, e doenças neoplásticas.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6431,
	"type": 977648,
	"label": "compostos análogos de vitamina d3, processo para a sua preparação e utilização dos mesmos para a preparação de medicamentos para o tratamento de hiperparatiroidismo primário e secundário, osteodistrofia renal, doenças de auto imunização, esclerose múltipla ou lúpus, e doenças neoplásticas.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 977777,
	"label": "Antibodies to DcR3 Polypeptide, a TNFR Homolog",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 979211,
	"label": "CONJUGADO DE PROTEINA ERIZO, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA QUE LO CONTIENE, PROCEDIMIENTO PARA SU PREPARACION, PROTEINA ERIZO Y SUEMPLEO PARA LA OBTENCION DE DICHO CONJUGADO",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6939,
	"target": 6812,
	"type": 979211,
	"label": "CONJUGADO DE PROTEINA ERIZO, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA QUE LO CONTIENE, PROCEDIMIENTO PARA SU PREPARACION, PROTEINA ERIZO Y SUEMPLEO PARA LA OBTENCION DE DICHO CONJUGADO",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6939,
	"target": 6795,
	"type": 979211,
	"label": "CONJUGADO DE PROTEINA ERIZO, PROCESO PARA SU PREPARACION, COMPOSICION FARMACEUTICA QUE LO CONTIENE, PROCEDIMIENTO PARA SU PREPARACION, PROTEINA ERIZO Y SUEMPLEO PARA LA OBTENCION DE DICHO CONJUGADO",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 979986,
	"label": "1,3-dihydroxy-20,20-dialkyl-vitamin d<sub>3</sub> analogs",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 979986,
	"label": "1,3-dihydroxy-20,20-dialkyl-vitamin d<sub>3</sub> analogs",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 979986,
	"label": "1,3-dihydroxy-20,20-dialkyl-vitamin d<sub>3</sub> analogs",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 979986,
	"label": "1,3-dihydroxy-20,20-dialkyl-vitamin d<sub>3</sub> analogs",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6431,
	"type": 979986,
	"label": "1,3-dihydroxy-20,20-dialkyl-vitamin d<sub>3</sub> analogs",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 980068,
	"label": "Highly active eukaryotic alkaline phosphatase and a process for producing it",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 980068,
	"label": "Highly active eukaryotic alkaline phosphatase and a process for producing it",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 980068,
	"label": "Highly active eukaryotic alkaline phosphatase and a process for producing it",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 980068,
	"label": "Highly active eukaryotic alkaline phosphatase and a process for producing it",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 980068,
	"label": "Highly active eukaryotic alkaline phosphatase and a process for producing it",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 56833,
	"target": 38232,
	"type": 980114,
	"label": "Verfahren und Reagenz zum Nachweis apoptotischer Zellen bzw. einer bei Apoptose aktivierten Protease",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 981824,
	"label": "GALACTOSYLIERTE GLYKOPROTEINE ENTHALTENDE ZUSAMMENSETZUNGEN UND VERFAHREN ZUR DEREN HERSTELLUNG",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 981846,
	"label": "NEUROREGULINA ESPECIFICA DEL RECEPTOR DE ERBB4, LIGANDOS RELACIONADOS Y USOS DE LOS MISMOS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 981846,
	"label": "NEUROREGULINA ESPECIFICA DEL RECEPTOR DE ERBB4, LIGANDOS RELACIONADOS Y USOS DE LOS MISMOS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 981846,
	"label": "NEUROREGULINA ESPECIFICA DEL RECEPTOR DE ERBB4, LIGANDOS RELACIONADOS Y USOS DE LOS MISMOS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 981846,
	"label": "NEUROREGULINA ESPECIFICA DEL RECEPTOR DE ERBB4, LIGANDOS RELACIONADOS Y USOS DE LOS MISMOS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 981846,
	"label": "NEUROREGULINA ESPECIFICA DEL RECEPTOR DE ERBB4, LIGANDOS RELACIONADOS Y USOS DE LOS MISMOS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 982147,
	"label": "New gene with upregulated expression in metastatic human tumor cells and a protein coded thereby, methods of production, and use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32754,
	"type": 982147,
	"label": "New gene with upregulated expression in metastatic human tumor cells and a protein coded thereby, methods of production, and use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 32754,
	"type": 982147,
	"label": "New gene with upregulated expression in metastatic human tumor cells and a protein coded thereby, methods of production, and use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32754,
	"target": 6795,
	"type": 982147,
	"label": "New gene with upregulated expression in metastatic human tumor cells and a protein coded thereby, methods of production, and use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 982147,
	"label": "New gene with upregulated expression in metastatic human tumor cells and a protein coded thereby, methods of production, and use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 982291,
	"label": "ANTIBODY OR FRAGMENTS THEREOF THAT BIND POLYPEPTIDES STIMULATING NEURONAL GROWTH",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 982291,
	"label": "ANTIBODY OR FRAGMENTS THEREOF THAT BIND POLYPEPTIDES STIMULATING NEURONAL GROWTH",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 982291,
	"label": "ANTIBODY OR FRAGMENTS THEREOF THAT BIND POLYPEPTIDES STIMULATING NEURONAL GROWTH",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 982291,
	"label": "ANTIBODY OR FRAGMENTS THEREOF THAT BIND POLYPEPTIDES STIMULATING NEURONAL GROWTH",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 7510,
	"type": 982291,
	"label": "ANTIBODY OR FRAGMENTS THEREOF THAT BIND POLYPEPTIDES STIMULATING NEURONAL GROWTH",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7510,
	"target": 6841,
	"type": 982626,
	"label": "COMBINATION THERAPY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 7510,
	"type": 982626,
	"label": "COMBINATION THERAPY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 6841,
	"type": 982626,
	"label": "COMBINATION THERAPY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 982700,
	"label": "SMOOTHENED PROTEINS, ANTIBODIES, NUCLEIC ACID ENCODING THE SAME, CHIMERIC PROTEINS, VECTORS, HOST CELLS, PROCESS FOR MANUFACTURE AND USES THEREOF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 982700,
	"label": "SMOOTHENED PROTEINS, ANTIBODIES, NUCLEIC ACID ENCODING THE SAME, CHIMERIC PROTEINS, VECTORS, HOST CELLS, PROCESS FOR MANUFACTURE AND USES THEREOF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 982700,
	"label": "SMOOTHENED PROTEINS, ANTIBODIES, NUCLEIC ACID ENCODING THE SAME, CHIMERIC PROTEINS, VECTORS, HOST CELLS, PROCESS FOR MANUFACTURE AND USES THEREOF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 982850,
	"label": "UNA FAMILIA DE GENES QUE CODIFICAN PEPTIDOS RELACIONADOS CON LA APOPTOSIS, PEPTIDOS CODIFICADOS POR ELLOS Y LOS METODOS DE USO DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 982850,
	"label": "UNA FAMILIA DE GENES QUE CODIFICAN PEPTIDOS RELACIONADOS CON LA APOPTOSIS, PEPTIDOS CODIFICADOS POR ELLOS Y LOS METODOS DE USO DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 982850,
	"label": "UNA FAMILIA DE GENES QUE CODIFICAN PEPTIDOS RELACIONADOS CON LA APOPTOSIS, PEPTIDOS CODIFICADOS POR ELLOS Y LOS METODOS DE USO DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 6795,
	"target": 6241,
	"type": 983327,
	"label": "Tetrahydrolipstatin for preparing oral pharmaceutical composition intended for the treatment of type II diabetes mellitus",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 983492,
	"label": "VERWENDUNG VON SYNERGISTISCHEN ZUSAMMENSETZUNGEN VON IL-12 UND IFN-ALPHA FÜR DIE BEHANDLUNG VON INFEKTIÖSEN KRANKHEITEN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 983804,
	"label": "Variants of vascular endothelial cell growth factors having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 983804,
	"label": "Variants of vascular endothelial cell growth factors having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 983804,
	"label": "Variants of vascular endothelial cell growth factors having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32694,
	"target": 7507,
	"type": 983804,
	"label": "Variants of vascular endothelial cell growth factors having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 983804,
	"label": "Variants of vascular endothelial cell growth factors having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 983903,
	"label": "Colagenase recombinante do tipo i de clostridium histolytucum e o uso da mesma para o isolamento de células e de grupos de células",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38164,
	"target": 37864,
	"type": 984112,
	"label": "MODIFIZIERTE DNA POLYMERASE AUS CORBOXYDOTHERMUS HYDROGENOFORMANS UND DEREN VERWENDUNG FÜR GEKOPPELTE REVERSE TRANSKRIPTION UND POLYMERASE- KETTENREAKTION",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 984430,
	"label": "Un agente preventivo o terapéutico para enfermedades mediadas por células t sensibilizadas que comprende un antagonista de il-6 como ingrediente activo",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 7510,
	"type": 984430,
	"label": "Un agente preventivo o terapéutico para enfermedades mediadas por células t sensibilizadas que comprende un antagonista de il-6 como ingrediente activo",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 984430,
	"label": "Un agente preventivo o terapéutico para enfermedades mediadas por células t sensibilizadas que comprende un antagonista de il-6 como ingrediente activo",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 984583,
	"label": "LECTINAS DE TIPO C.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 984583,
	"label": "LECTINAS DE TIPO C.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 984583,
	"label": "LECTINAS DE TIPO C.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 984583,
	"label": "LECTINAS DE TIPO C.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 984583,
	"label": "LECTINAS DE TIPO C.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 984728,
	"label": "ANTIKÖRPERMUTANTE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 984728,
	"label": "ANTIKÖRPERMUTANTE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 984728,
	"label": "ANTIKÖRPERMUTANTE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 984728,
	"label": "ANTIKÖRPERMUTANTE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 984728,
	"label": "ANTIKÖRPERMUTANTE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 31912,
	"target": 7417,
	"type": 984765,
	"label": "ARYL AND HETEROARYL SUBSTITUTED FUSED PYRROLE DERIVATIVES, AS ANTIINFLAMMATORY AGENTS CONTAINING THE SAME",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 7425,
	"target": 7384,
	"type": 984825,
	"label": "Novel benzopyran derivatives",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 6795,
	"target": 6290,
	"type": 985162,
	"label": "DERIVADOS DE TIAZOL, PROCEDIMIENTO PARA SU PREPARACION, COMPOSICION FARMACEUTICA QUE LOS CONTIENE, COMPUESTOS INTERMEDIARIOS Y SU USO PARA LA MANUFACTURADE UN MEDICAMENTO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 31308,
	"target": 6795,
	"type": 985162,
	"label": "DERIVADOS DE TIAZOL, PROCEDIMIENTO PARA SU PREPARACION, COMPOSICION FARMACEUTICA QUE LOS CONTIENE, COMPUESTOS INTERMEDIARIOS Y SU USO PARA LA MANUFACTURADE UN MEDICAMENTO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 31308,
	"target": 6290,
	"type": 985162,
	"label": "DERIVADOS DE TIAZOL, PROCEDIMIENTO PARA SU PREPARACION, COMPOSICION FARMACEUTICA QUE LOS CONTIENE, COMPUESTOS INTERMEDIARIOS Y SU USO PARA LA MANUFACTURADE UN MEDICAMENTO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 31308,
	"target": 7450,
	"type": 985186,
	"label": "DERIVADOS DE TIAZOL, PROCEDIMIENTO PARA SU PREPARACION, PREPARACIONES FARMACEUTICAS QUE LOS CONTIENEN, COMPUESTOS INTERMEDIARIOS Y SU USO PARA LAMANUFACTURA DE UN MEDICAMENTO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 985644,
	"label": "CRISTALES DE UN DERIVADO DE VITAMINA D Y UN METODO PARA LA PREPARACION DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 985783,
	"label": "Intermediates for preparation of 16-ene-vitamin D derivatives",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 985783,
	"label": "Intermediates for preparation of 16-ene-vitamin D derivatives",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 985783,
	"label": "Intermediates for preparation of 16-ene-vitamin D derivatives",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 986309,
	"label": "UN PROCEDIMIENTO PARA EL DIAGNOSTICO DE UNA INFECCION POR HIV MEDIANTE UN INMUNOENSAYO, PROCEDIMIENTO PARA LA DETECCION DE ANTICUERPOS CONTRA HIV,ANTICUERPOS MONOCLONALES CONTRA EL ANTIGENO p24 DEL HIV1, USO DE DICHOS ANTICUERPOS MONOCLONALES, UN KIT DE REACTIVOS PARA LA DETECCION DE UNA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 986309,
	"label": "UN PROCEDIMIENTO PARA EL DIAGNOSTICO DE UNA INFECCION POR HIV MEDIANTE UN INMUNOENSAYO, PROCEDIMIENTO PARA LA DETECCION DE ANTICUERPOS CONTRA HIV,ANTICUERPOS MONOCLONALES CONTRA EL ANTIGENO p24 DEL HIV1, USO DE DICHOS ANTICUERPOS MONOCLONALES, UN KIT DE REACTIVOS PARA LA DETECCION DE UNA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 56836,
	"target": 37986,
	"type": 986309,
	"label": "UN PROCEDIMIENTO PARA EL DIAGNOSTICO DE UNA INFECCION POR HIV MEDIANTE UN INMUNOENSAYO, PROCEDIMIENTO PARA LA DETECCION DE ANTICUERPOS CONTRA HIV,ANTICUERPOS MONOCLONALES CONTRA EL ANTIGENO p24 DEL HIV1, USO DE DICHOS ANTICUERPOS MONOCLONALES, UN KIT DE REACTIVOS PARA LA DETECCION DE UNA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 986505,
	"label": "EXENDIN ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 986615,
	"label": "Antibodies which specifically bind to a novel  kappa / mu -like protein tyrosineospatase, PTP lambda , and hybridoma cell lines producing the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 986615,
	"label": "Antibodies which specifically bind to a novel  kappa / mu -like protein tyrosineospatase, PTP lambda , and hybridoma cell lines producing the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 986615,
	"label": "Antibodies which specifically bind to a novel  kappa / mu -like protein tyrosineospatase, PTP lambda , and hybridoma cell lines producing the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 987113,
	"label": "Receptor protein designated 2F1, DNA encoding 2F1, preparation and use thereof",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 987113,
	"label": "Receptor protein designated 2F1, DNA encoding 2F1, preparation and use thereof",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 987113,
	"label": "Receptor protein designated 2F1, DNA encoding 2F1, preparation and use thereof",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 987479,
	"label": "MITTEL GEGEN MYELOME, WELCHES ZUSAMMEN MIT ANTITUMORWIRKSTOFFEN AUF DER BASIS VON STICKSTOFF-SENFGASEN VERWENDET WERDEN KANN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 987479,
	"label": "MITTEL GEGEN MYELOME, WELCHES ZUSAMMEN MIT ANTITUMORWIRKSTOFFEN AUF DER BASIS VON STICKSTOFF-SENFGASEN VERWENDET WERDEN KANN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 987479,
	"label": "MITTEL GEGEN MYELOME, WELCHES ZUSAMMEN MIT ANTITUMORWIRKSTOFFEN AUF DER BASIS VON STICKSTOFF-SENFGASEN VERWENDET WERDEN KANN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 988483,
	"label": "Engineered human DNase I with DNA hydrolytic activity at least 50 percent greater than native human DNase I",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38237,
	"target": 38184,
	"type": 988698,
	"label": "Antibody an O-fucosyl transferase",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 988698,
	"label": "Antibody an O-fucosyl transferase",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38237,
	"target": 37899,
	"type": 988698,
	"label": "Antibody an O-fucosyl transferase",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 989227,
	"label": "an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 989227,
	"label": "an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 989227,
	"label": "an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32772,
	"type": 989227,
	"label": "an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 989227,
	"label": "an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 989320,
	"label": "Thermostable nucleic acid polymerase with 3'-5' proofreading exonuclease ability from Thermococcus gorgonarius",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37999,
	"target": 32694,
	"type": 989448,
	"label": "Nucleic acid sequences encoding VEGF-like factors and uses thereof",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 989448,
	"label": "Nucleic acid sequences encoding VEGF-like factors and uses thereof",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37999,
	"target": 6795,
	"type": 989448,
	"label": "Nucleic acid sequences encoding VEGF-like factors and uses thereof",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 989807,
	"label": "Oligonucleotide starters for reproducing a nucleic acid of human immunological deficiency virus of type 1 (HIV-1), sets for detecting and methods of reproducing a nucleic acid of human immunological deficiency virus of type 1 (HIV-1)",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 990427,
	"label": "ANTICUERPOS MONOCLONALES CONTRA UN COMPLEJO DE ACT HUMANA Y UNA PROTEASA DE SERINA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 990427,
	"label": "ANTICUERPOS MONOCLONALES CONTRA UN COMPLEJO DE ACT HUMANA Y UNA PROTEASA DE SERINA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 990427,
	"label": "ANTICUERPOS MONOCLONALES CONTRA UN COMPLEJO DE ACT HUMANA Y UNA PROTEASA DE SERINA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 991406,
	"label": "ANTICUERPOS MONOCLONALES CONTRA EL EPITOPE YPYDVPDYA, PROCEDIMIENTO PARA SU OBTENCION Y USO DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 991406,
	"label": "ANTICUERPOS MONOCLONALES CONTRA EL EPITOPE YPYDVPDYA, PROCEDIMIENTO PARA SU OBTENCION Y USO DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 991406,
	"label": "ANTICUERPOS MONOCLONALES CONTRA EL EPITOPE YPYDVPDYA, PROCEDIMIENTO PARA SU OBTENCION Y USO DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 32612,
	"type": 991406,
	"label": "ANTICUERPOS MONOCLONALES CONTRA EL EPITOPE YPYDVPDYA, PROCEDIMIENTO PARA SU OBTENCION Y USO DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 32612,
	"type": 991406,
	"label": "ANTICUERPOS MONOCLONALES CONTRA EL EPITOPE YPYDVPDYA, PROCEDIMIENTO PARA SU OBTENCION Y USO DE LOS MISMOS.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6215,
	"type": 991500,
	"label": "COMPLEJO DE BIS-PLATINO, METODO PARA SU PREPARACION Y USO DEL MISMO EN LA PREPARACION DE UNA COMPOSICION FARMACEUTICA",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 991590,
	"label": "Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 991590,
	"label": "Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 991590,
	"label": "Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 991962,
	"label": "oligonucleotìdeos, método para amplificação de uma seqüência alvo de ácido nucléico e kit para realizar uma reação de amplificação de ácido nucléico.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 992379,
	"label": "HUMANIZED ANTI-CD11a ANTIBODIES CONTAINING A VARIABLE DOMAIN HAVING AMINO ACIDS FROM A NON-HUMAN ANTIBODY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 992379,
	"label": "HUMANIZED ANTI-CD11a ANTIBODIES CONTAINING A VARIABLE DOMAIN HAVING AMINO ACIDS FROM A NON-HUMAN ANTIBODY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 992379,
	"label": "HUMANIZED ANTI-CD11a ANTIBODIES CONTAINING A VARIABLE DOMAIN HAVING AMINO ACIDS FROM A NON-HUMAN ANTIBODY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 992379,
	"label": "HUMANIZED ANTI-CD11a ANTIBODIES CONTAINING A VARIABLE DOMAIN HAVING AMINO ACIDS FROM A NON-HUMAN ANTIBODY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 992379,
	"label": "HUMANIZED ANTI-CD11a ANTIBODIES CONTAINING A VARIABLE DOMAIN HAVING AMINO ACIDS FROM A NON-HUMAN ANTIBODY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 992430,
	"label": "Renset termostabil DNA-polymerase fra Carboxydothermus hydrogenoformans, isolert DNA-sekvens som koder for denne, vektor inneholdende sekvensen, mikrobiell vert som omfatter vektoren, fremgangsmate for fremstilling av DNA-polymerasen, fremgangsmate for amplifisering av DNA, DNA-kloning og DNA-sekvensering, DNA-merking og reverstranskripsjon ved anvendelse av polymerasen.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 992430,
	"label": "Renset termostabil DNA-polymerase fra Carboxydothermus hydrogenoformans, isolert DNA-sekvens som koder for denne, vektor inneholdende sekvensen, mikrobiell vert som omfatter vektoren, fremgangsmate for fremstilling av DNA-polymerasen, fremgangsmate for amplifisering av DNA, DNA-kloning og DNA-sekvensering, DNA-merking og reverstranskripsjon ved anvendelse av polymerasen.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 992430,
	"label": "Renset termostabil DNA-polymerase fra Carboxydothermus hydrogenoformans, isolert DNA-sekvens som koder for denne, vektor inneholdende sekvensen, mikrobiell vert som omfatter vektoren, fremgangsmate for fremstilling av DNA-polymerasen, fremgangsmate for amplifisering av DNA, DNA-kloning og DNA-sekvensering, DNA-merking og reverstranskripsjon ved anvendelse av polymerasen.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 992430,
	"label": "Renset termostabil DNA-polymerase fra Carboxydothermus hydrogenoformans, isolert DNA-sekvens som koder for denne, vektor inneholdende sekvensen, mikrobiell vert som omfatter vektoren, fremgangsmate for fremstilling av DNA-polymerasen, fremgangsmate for amplifisering av DNA, DNA-kloning og DNA-sekvensering, DNA-merking og reverstranskripsjon ved anvendelse av polymerasen.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 992430,
	"label": "Renset termostabil DNA-polymerase fra Carboxydothermus hydrogenoformans, isolert DNA-sekvens som koder for denne, vektor inneholdende sekvensen, mikrobiell vert som omfatter vektoren, fremgangsmate for fremstilling av DNA-polymerasen, fremgangsmate for amplifisering av DNA, DNA-kloning og DNA-sekvensering, DNA-merking og reverstranskripsjon ved anvendelse av polymerasen.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 993600,
	"label": "UTILIZACOES DE GDNF E DE RECEPTORES DE GDNF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 993600,
	"label": "UTILIZACOES DE GDNF E DE RECEPTORES DE GDNF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 993600,
	"label": "UTILIZACOES DE GDNF E DE RECEPTORES DE GDNF",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 993712,
	"label": "Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 994580,
	"label": "PROTEIN TYROSIN-PHOSPHATASEN VON HEMATOPOIETISCHEN ZELLEN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7509,
	"target": 7425,
	"type": 994617,
	"label": "VERWENDUNG VON TETRAHYDROBETACARBOLIN-DERIVATEN ZUR VORBEUGUNG DER METASTASENBILDUNG",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7425,
	"target": 6301,
	"type": 994617,
	"label": "VERWENDUNG VON TETRAHYDROBETACARBOLIN-DERIVATEN ZUR VORBEUGUNG DER METASTASENBILDUNG",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7509,
	"target": 6301,
	"type": 994617,
	"label": "VERWENDUNG VON TETRAHYDROBETACARBOLIN-DERIVATEN ZUR VORBEUGUNG DER METASTASENBILDUNG",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 995578,
	"label": "RECOMBINACION DIRIGIDA DE ADN MEDIADA POR CAMBIO DE CLASE.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 995578,
	"label": "RECOMBINACION DIRIGIDA DE ADN MEDIADA POR CAMBIO DE CLASE.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 995578,
	"label": "RECOMBINACION DIRIGIDA DE ADN MEDIADA POR CAMBIO DE CLASE.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 995578,
	"label": "RECOMBINACION DIRIGIDA DE ADN MEDIADA POR CAMBIO DE CLASE.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 995578,
	"label": "RECOMBINACION DIRIGIDA DE ADN MEDIADA POR CAMBIO DE CLASE.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 995677,
	"label": "EXPRESSION VON HGV-ANTIGENEN UND DEREN VERWENDUNG",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32771,
	"target": 6795,
	"type": 995911,
	"label": "GEN ASOCIADO AL CARCINOMA DE MAMA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 996228,
	"label": "DNA POLIMERAS QUIMERICAS MUTANTES.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 996341,
	"label": "REMEDIES FOR LYMPHOCYTIC TUMORS, AN ANTIBODY, CHIMERIC ANTIBODY AND MODIFIED ANTIBODY",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 996341,
	"label": "REMEDIES FOR LYMPHOCYTIC TUMORS, AN ANTIBODY, CHIMERIC ANTIBODY AND MODIFIED ANTIBODY",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 996341,
	"label": "REMEDIES FOR LYMPHOCYTIC TUMORS, AN ANTIBODY, CHIMERIC ANTIBODY AND MODIFIED ANTIBODY",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 996341,
	"label": "REMEDIES FOR LYMPHOCYTIC TUMORS, AN ANTIBODY, CHIMERIC ANTIBODY AND MODIFIED ANTIBODY",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 996341,
	"label": "REMEDIES FOR LYMPHOCYTIC TUMORS, AN ANTIBODY, CHIMERIC ANTIBODY AND MODIFIED ANTIBODY",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 996554,
	"label": "Methods of modulating appetite using agouti-related transcript polypeptides",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 996554,
	"label": "Methods of modulating appetite using agouti-related transcript polypeptides",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 996554,
	"label": "Methods of modulating appetite using agouti-related transcript polypeptides",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 996554,
	"label": "Methods of modulating appetite using agouti-related transcript polypeptides",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 996554,
	"label": "Methods of modulating appetite using agouti-related transcript polypeptides",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7510,
	"target": 7487,
	"type": 997943,
	"label": "use of ketone substituted indanone derivatives for treating cell proliferation disorders and compositions thereof",
	"group": "Gilead",
	"time": 1997,
	"strength": 1
}, {
	"source": 7487,
	"target": 6157,
	"type": 997943,
	"label": "use of ketone substituted indanone derivatives for treating cell proliferation disorders and compositions thereof",
	"group": "Gilead",
	"time": 1997,
	"strength": 1
}, {
	"source": 7510,
	"target": 6157,
	"type": 997943,
	"label": "use of ketone substituted indanone derivatives for treating cell proliferation disorders and compositions thereof",
	"group": "Gilead",
	"time": 1997,
	"strength": 1
}, {
	"source": 38065,
	"target": 32698,
	"type": 1000702,
	"label": "Enhanced transgene expression in specific tissues of the gastrointestinal tract",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 28540,
	"target": 28528,
	"type": 1008222,
	"label": "WERKWIJZE VOOR DE BEREIDING VAN FARMACEUTISCHE PREPARATEN EN DE DOOR TOEPASSING DAARVAN VERVAARDIGDE VOORWERPEN, ALSMEDE WERKWIJZE TER BEREIDING VAN ANTI-INFLAMMATOIR, ANALGETISCH, ANTIPYRETISCH EN ANTIPRURITISCH WERKZAME VERBINDINGEN.",
	"group": "Roche",
	"time": 1969,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1008227,
	"label": "Protein formulation",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 1010558,
	"label": "Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 7409,
	"type": 1010558,
	"label": "Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37993,
	"target": 7409,
	"type": 1010558,
	"label": "Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37878,
	"target": 37875,
	"type": 1011321,
	"label": "KULTURMEDIUM ZUR KULTIVIERUNG TIERISCHER ZELLEN UND VERFAHREN ZUR HERSTELLUNG VON PROTEINEN DURCH DESSEN VERWENDUNG",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6816,
	"target": 6812,
	"type": 1011466,
	"label": "Heterominiantistoffer",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7508,
	"target": 6816,
	"type": 1011466,
	"label": "Heterominiantistoffer",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7508,
	"target": 6812,
	"type": 1011466,
	"label": "Heterominiantistoffer",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1011466,
	"label": "Heterominiantistoffer",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 1011466,
	"label": "Heterominiantistoffer",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1011565,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL ANTIGENO IA-2 DE LAS CELULAS DE LOS ISLOTES DE LANGERHANS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1011565,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL ANTIGENO IA-2 DE LAS CELULAS DE LOS ISLOTES DE LANGERHANS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1011565,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL ANTIGENO IA-2 DE LAS CELULAS DE LOS ISLOTES DE LANGERHANS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 32777,
	"type": 1011565,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL ANTIGENO IA-2 DE LAS CELULAS DE LOS ISLOTES DE LANGERHANS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32777,
	"type": 1011565,
	"label": "ANTICUERPOS MONOCLONALES HUMANOS CONTRA EL ANTIGENO IA-2 DE LAS CELULAS DE LOS ISLOTES DE LANGERHANS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38065,
	"target": 37993,
	"type": 1012467,
	"label": "Single-chain multifunctional polypeptide, polynucleotide, vector containing this polynucleotide, cell transformed with this polynucleotide, agent containing this polypeptide, polynucleotide or vector and their use as well as method for identification",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1012467,
	"label": "Single-chain multifunctional polypeptide, polynucleotide, vector containing this polynucleotide, cell transformed with this polynucleotide, agent containing this polypeptide, polynucleotide or vector and their use as well as method for identification",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38065,
	"target": 32770,
	"type": 1012467,
	"label": "Single-chain multifunctional polypeptide, polynucleotide, vector containing this polynucleotide, cell transformed with this polynucleotide, agent containing this polypeptide, polynucleotide or vector and their use as well as method for identification",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 56765,
	"target": 38065,
	"type": 1012467,
	"label": "Single-chain multifunctional polypeptide, polynucleotide, vector containing this polynucleotide, cell transformed with this polynucleotide, agent containing this polypeptide, polynucleotide or vector and their use as well as method for identification",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 56765,
	"target": 37993,
	"type": 1012467,
	"label": "Single-chain multifunctional polypeptide, polynucleotide, vector containing this polynucleotide, cell transformed with this polynucleotide, agent containing this polypeptide, polynucleotide or vector and their use as well as method for identification",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1012829,
	"label": "TRANSFECTACONEN, DIE KALCIUMPHOSPHAT UND EINE NUCLEINSÄURE ENTHALTEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1013819,
	"label": "APOPTOSIS INDUZIERENDER FAKTOR",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1013819,
	"label": "APOPTOSIS INDUZIERENDER FAKTOR",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1013819,
	"label": "APOPTOSIS INDUZIERENDER FAKTOR",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 1014614,
	"label": "AMPLIFICACION DEL ADN DE UNA UNICA CELULA.",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 31308,
	"target": 30171,
	"type": 1014713,
	"label": "ARYLSULFONANILIDE UREA-DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 1015263,
	"label": "Arylsulfonanilide phosphates",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7487,
	"target": 6447,
	"type": 1015263,
	"label": "Arylsulfonanilide phosphates",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6447,
	"type": 1015263,
	"label": "Arylsulfonanilide phosphates",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7424,
	"target": 7358,
	"type": 1015726,
	"label": "DERIVADOS DEL TIAZOL, UN PROCEDIMIENTO PARA SU OBTENCION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y EL EMPLEO DE LOS MISMOS PARA LA PREPARACION DEMEDICAMENTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 1015726,
	"label": "DERIVADOS DEL TIAZOL, UN PROCEDIMIENTO PARA SU OBTENCION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y EL EMPLEO DE LOS MISMOS PARA LA PREPARACION DEMEDICAMENTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 1015726,
	"label": "DERIVADOS DEL TIAZOL, UN PROCEDIMIENTO PARA SU OBTENCION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y EL EMPLEO DE LOS MISMOS PARA LA PREPARACION DEMEDICAMENTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 1016066,
	"label": "Process for the preparation of ED-71",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1016833,
	"label": "HOCHEFFIZIENTE UND KONTROLLIERTE EXPRESSION VON EXOGENEN GENEN IN E. COLI",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1016833,
	"label": "HOCHEFFIZIENTE UND KONTROLLIERTE EXPRESSION VON EXOGENEN GENEN IN E. COLI",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1016833,
	"label": "HOCHEFFIZIENTE UND KONTROLLIERTE EXPRESSION VON EXOGENEN GENEN IN E. COLI",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1016833,
	"label": "HOCHEFFIZIENTE UND KONTROLLIERTE EXPRESSION VON EXOGENEN GENEN IN E. COLI",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1016833,
	"label": "HOCHEFFIZIENTE UND KONTROLLIERTE EXPRESSION VON EXOGENEN GENEN IN E. COLI",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 1016852,
	"label": "UTILIZACION DE HETEROGUBLINA COMO FACTOR DE CRECIMIENTO DE CELULAS EPITELIALES.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 32771,
	"type": 1016983,
	"label": "GEN GENOMICO QUE CODIFICA LA PROTEINA ANTIGENICA HM1.24 Y SU PROMOTOR.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32771,
	"target": 6795,
	"type": 1016983,
	"label": "GEN GENOMICO QUE CODIFICA LA PROTEINA ANTIGENICA HM1.24 Y SU PROMOTOR.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1016983,
	"label": "GEN GENOMICO QUE CODIFICA LA PROTEINA ANTIGENICA HM1.24 Y SU PROMOTOR.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 1018395,
	"label": "PROCEDIMIENTO DE CULTIVO DE CELULAS PARA LA PRODUCCION DE GLICOPROTEINAS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 1019509,
	"label": "Determination of apoptotic products in tumor patients undergoing therapy",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1020001,
	"label": "GEN QUE CODIFICA UN TRANSPORTADOR DE ANION ORGANICO.",
	"group": "Gilead",
	"time": 1999,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1020001,
	"label": "GEN QUE CODIFICA UN TRANSPORTADOR DE ANION ORGANICO.",
	"group": "Gilead",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1020001,
	"label": "GEN QUE CODIFICA UN TRANSPORTADOR DE ANION ORGANICO.",
	"group": "Gilead",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1020001,
	"label": "GEN QUE CODIFICA UN TRANSPORTADOR DE ANION ORGANICO.",
	"group": "Gilead",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1020001,
	"label": "GEN QUE CODIFICA UN TRANSPORTADOR DE ANION ORGANICO.",
	"group": "Gilead",
	"time": 1999,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 1020774,
	"label": "AEROTRICINAS, COMPUESTOS RELACIONADOS, COMPOSICION FARMACEUTICA, EMPLEO DE DICHOS COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS, CULTIVO BIOLOGICAMENTEPURO DE DEUTEROMICOTINA NR7379, Y PROCEDIMIENTO PARA LA PREPARACION DE DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 7487,
	"type": 1020774,
	"label": "AEROTRICINAS, COMPUESTOS RELACIONADOS, COMPOSICION FARMACEUTICA, EMPLEO DE DICHOS COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS, CULTIVO BIOLOGICAMENTEPURO DE DEUTEROMICOTINA NR7379, Y PROCEDIMIENTO PARA LA PREPARACION DE DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1020774,
	"label": "AEROTRICINAS, COMPUESTOS RELACIONADOS, COMPOSICION FARMACEUTICA, EMPLEO DE DICHOS COMPUESTOS PARA LA PREPARACION DE MEDICAMENTOS, CULTIVO BIOLOGICAMENTEPURO DE DEUTEROMICOTINA NR7379, Y PROCEDIMIENTO PARA LA PREPARACION DE DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7358,
	"target": 6795,
	"type": 1021943,
	"label": "MITTEL ZUR VORBEUGUNG ODER BEHANDLUNG VON PANKREATITIS DIE ANTI-IL-6 RECEPTOR ANTIKÖRPER ALS AKTIVE KOMPONENTE ENTHALTEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 7358,
	"type": 1021943,
	"label": "MITTEL ZUR VORBEUGUNG ODER BEHANDLUNG VON PANKREATITIS DIE ANTI-IL-6 RECEPTOR ANTIKÖRPER ALS AKTIVE KOMPONENTE ENTHALTEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1021943,
	"label": "MITTEL ZUR VORBEUGUNG ODER BEHANDLUNG VON PANKREATITIS DIE ANTI-IL-6 RECEPTOR ANTIKÖRPER ALS AKTIVE KOMPONENTE ENTHALTEN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 1022445,
	"label": "SINERGIA DE LOS ANTICUERPOS ANTI-HER-2 Y DE LOS LIGANDS PARA L'APO-2.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 1022445,
	"label": "SINERGIA DE LOS ANTICUERPOS ANTI-HER-2 Y DE LOS LIGANDS PARA L'APO-2.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1022445,
	"label": "SINERGIA DE LOS ANTICUERPOS ANTI-HER-2 Y DE LOS LIGANDS PARA L'APO-2.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 1022445,
	"label": "SINERGIA DE LOS ANTICUERPOS ANTI-HER-2 Y DE LOS LIGANDS PARA L'APO-2.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32772,
	"target": 6812,
	"type": 1022445,
	"label": "SINERGIA DE LOS ANTICUERPOS ANTI-HER-2 Y DE LOS LIGANDS PARA L'APO-2.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 1022449,
	"label": "Methods for determining binding of an analyte to a receptor",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 1022449,
	"label": "Methods for determining binding of an analyte to a receptor",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1022449,
	"label": "Methods for determining binding of an analyte to a receptor",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1022449,
	"label": "Methods for determining binding of an analyte to a receptor",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32777,
	"target": 6795,
	"type": 1022449,
	"label": "Methods for determining binding of an analyte to a receptor",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 6841,
	"type": 1022529,
	"label": "Diisopropyl fluorophosphatase and the utilization and production thereof",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1022546,
	"label": "New chimeric polymerase with 5'-3'-polymerase activity, and optionally proofreading activity, used for polymerase chain reactions and sequencing",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1022546,
	"label": "New chimeric polymerase with 5'-3'-polymerase activity, and optionally proofreading activity, used for polymerase chain reactions and sequencing",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1022546,
	"label": "New chimeric polymerase with 5'-3'-polymerase activity, and optionally proofreading activity, used for polymerase chain reactions and sequencing",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1022546,
	"label": "New chimeric polymerase with 5'-3'-polymerase activity, and optionally proofreading activity, used for polymerase chain reactions and sequencing",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1022546,
	"label": "New chimeric polymerase with 5'-3'-polymerase activity, and optionally proofreading activity, used for polymerase chain reactions and sequencing",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 7360,
	"type": 1023031,
	"label": "ULTRAVIOLETT-BESTRAHLUNGSVORRICHTUNG FÜR PHOTOCHEMISCHE REAKTIONEN UND VERFAHREN ZUR ZUBEREITUNG VON VITAMIN-D-PRÄPARATEN UNTER VERWENDUNG DER VORRICHTUNG",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37904,
	"target": 37899,
	"type": 1023707,
	"label": "Epìtopos nas proteìnas do envelope viral e anticorpos especìficos direcionados contra estes epìtopos; e uso para a detecção dos antìgenos virais do hcv no tecido do hospedeiro",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 1023707,
	"label": "Epìtopos nas proteìnas do envelope viral e anticorpos especìficos direcionados contra estes epìtopos; e uso para a detecção dos antìgenos virais do hcv no tecido do hospedeiro",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1023707,
	"label": "Epìtopos nas proteìnas do envelope viral e anticorpos especìficos direcionados contra estes epìtopos; e uso para a detecção dos antìgenos virais do hcv no tecido do hospedeiro",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 1024096,
	"label": "UTILIZACIONES DE AGONISTAS Y ANTAGONISTAS DEL RECEPTOR EPH PARA EL TRATAMIENTO DE TRASTORNOS VASCULARES.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1024096,
	"label": "UTILIZACIONES DE AGONISTAS Y ANTAGONISTAS DEL RECEPTOR EPH PARA EL TRATAMIENTO DE TRASTORNOS VASCULARES.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 1024096,
	"label": "UTILIZACIONES DE AGONISTAS Y ANTAGONISTAS DEL RECEPTOR EPH PARA EL TRATAMIENTO DE TRASTORNOS VASCULARES.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1024096,
	"label": "UTILIZACIONES DE AGONISTAS Y ANTAGONISTAS DEL RECEPTOR EPH PARA EL TRATAMIENTO DE TRASTORNOS VASCULARES.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 6812,
	"type": 1024096,
	"label": "UTILIZACIONES DE AGONISTAS Y ANTAGONISTAS DEL RECEPTOR EPH PARA EL TRATAMIENTO DE TRASTORNOS VASCULARES.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38042,
	"target": 37993,
	"type": 1024611,
	"label": "METHOD AND SET FOR DETECTING GENE ENCODING MEMBRANE-BOUND PROTEIN, VECTOR (VARIANTS)",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1024611,
	"label": "METHOD AND SET FOR DETECTING GENE ENCODING MEMBRANE-BOUND PROTEIN, VECTOR (VARIANTS)",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38042,
	"target": 32770,
	"type": 1024611,
	"label": "METHOD AND SET FOR DETECTING GENE ENCODING MEMBRANE-BOUND PROTEIN, VECTOR (VARIANTS)",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 32697,
	"type": 1024679,
	"label": "Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1024679,
	"label": "Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32697,
	"type": 1024679,
	"label": "Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 1024679,
	"label": "Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1024679,
	"label": "Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1024982,
	"label": "ÜBEREXPRESSION VON GEWÜNSCHTEN PROTEINEN IN EUKARYOTISCHEN ZELLEN MITTELS ÜBEREXPRESSION VON CYCLIN D1",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1024982,
	"label": "ÜBEREXPRESSION VON GEWÜNSCHTEN PROTEINEN IN EUKARYOTISCHEN ZELLEN MITTELS ÜBEREXPRESSION VON CYCLIN D1",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1024982,
	"label": "ÜBEREXPRESSION VON GEWÜNSCHTEN PROTEINEN IN EUKARYOTISCHEN ZELLEN MITTELS ÜBEREXPRESSION VON CYCLIN D1",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1026599,
	"label": "CHIMAERIC ANTIBODIES CONTAINING THE LIGAND DOMAIN OF CD4",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1026599,
	"label": "CHIMAERIC ANTIBODIES CONTAINING THE LIGAND DOMAIN OF CD4",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37864,
	"target": 6854,
	"type": 1026599,
	"label": "CHIMAERIC ANTIBODIES CONTAINING THE LIGAND DOMAIN OF CD4",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1026599,
	"label": "CHIMAERIC ANTIBODIES CONTAINING THE LIGAND DOMAIN OF CD4",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 1026599,
	"label": "CHIMAERIC ANTIBODIES CONTAINING THE LIGAND DOMAIN OF CD4",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 1028712,
	"label": "Anvendelse av en bispesifikk antistoffkonstruksjon som er rettet mot CCR5 og CD3 for fremstilling av en farmasoytisk sammensetning for behandling av kronisk artritt, autoimmunesykdommer, allergiske reaksjoner eller for reduksjon av kjemokinreseptoruttrykk",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1028712,
	"label": "Anvendelse av en bispesifikk antistoffkonstruksjon som er rettet mot CCR5 og CD3 for fremstilling av en farmasoytisk sammensetning for behandling av kronisk artritt, autoimmunesykdommer, allergiske reaksjoner eller for reduksjon av kjemokinreseptoruttrykk",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1028712,
	"label": "Anvendelse av en bispesifikk antistoffkonstruksjon som er rettet mot CCR5 og CD3 for fremstilling av en farmasoytisk sammensetning for behandling av kronisk artritt, autoimmunesykdommer, allergiske reaksjoner eller for reduksjon av kjemokinreseptoruttrykk",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1028712,
	"label": "Anvendelse av en bispesifikk antistoffkonstruksjon som er rettet mot CCR5 og CD3 for fremstilling av en farmasoytisk sammensetning for behandling av kronisk artritt, autoimmunesykdommer, allergiske reaksjoner eller for reduksjon av kjemokinreseptoruttrykk",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 1028712,
	"label": "Anvendelse av en bispesifikk antistoffkonstruksjon som er rettet mot CCR5 og CD3 for fremstilling av en farmasoytisk sammensetning for behandling av kronisk artritt, autoimmunesykdommer, allergiske reaksjoner eller for reduksjon av kjemokinreseptoruttrykk",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 1029238,
	"label": "PROCESS FOR RECOVERING HETEROLOGOUS POLYPEPTIDE FROM BACTERIAL REFRACTILE PARTICLES",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1029874,
	"label": "Chandra: a novel th1-specific gene",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 6854,
	"type": 1029874,
	"label": "Chandra: a novel th1-specific gene",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1029874,
	"label": "Chandra: a novel th1-specific gene",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38071,
	"target": 38042,
	"type": 1029978,
	"label": "Peptid, DNA, vektor, celle, fremgangsmate for undersokelse av hvorvidt et peptid som kodes for av et cDNA som skal testes inneholder sekretorisk evne, samt fremgangsmate for isolering av et cDNA som koder for et peptid med sekretorisk evne",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 1029978,
	"label": "Peptid, DNA, vektor, celle, fremgangsmate for undersokelse av hvorvidt et peptid som kodes for av et cDNA som skal testes inneholder sekretorisk evne, samt fremgangsmate for isolering av et cDNA som koder for et peptid med sekretorisk evne",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38071,
	"target": 37899,
	"type": 1029978,
	"label": "Peptid, DNA, vektor, celle, fremgangsmate for undersokelse av hvorvidt et peptid som kodes for av et cDNA som skal testes inneholder sekretorisk evne, samt fremgangsmate for isolering av et cDNA som koder for et peptid med sekretorisk evne",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 1030471,
	"label": "A hepatitis B vaccine formulation incorporating a bile acid salt",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37862,
	"target": 6854,
	"type": 1030471,
	"label": "A hepatitis B vaccine formulation incorporating a bile acid salt",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 1030471,
	"label": "A hepatitis B vaccine formulation incorporating a bile acid salt",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 1031488,
	"label": "Methods and substances for recruiting therapeutic agents to solid issues comprising two single chain VH-VL bifunctional binding molecules.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38004,
	"target": 37864,
	"type": 1032559,
	"label": "Polypeptides with interleukin 16 activity, process for the preparation and use thereof",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 32698,
	"type": 1032559,
	"label": "Polypeptides with interleukin 16 activity, process for the preparation and use thereof",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38004,
	"target": 32698,
	"type": 1032559,
	"label": "Polypeptides with interleukin 16 activity, process for the preparation and use thereof",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 1032559,
	"label": "Polypeptides with interleukin 16 activity, process for the preparation and use thereof",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1032559,
	"label": "Polypeptides with interleukin 16 activity, process for the preparation and use thereof",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 1033337,
	"label": "SERUM CALCIUM DEPRESSING FACTOR.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 7450,
	"target": 6841,
	"type": 1033337,
	"label": "SERUM CALCIUM DEPRESSING FACTOR.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 7450,
	"target": 6795,
	"type": 1033337,
	"label": "SERUM CALCIUM DEPRESSING FACTOR.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37947,
	"target": 7450,
	"type": 1033337,
	"label": "SERUM CALCIUM DEPRESSING FACTOR.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37947,
	"target": 6841,
	"type": 1033337,
	"label": "SERUM CALCIUM DEPRESSING FACTOR.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1033400,
	"label": "DELIVERY OF PROTEINS ACROSS POLAR EPITHELIAL CELL LAYERS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6166,
	"type": 1033564,
	"label": "Tissue factor antagonists and methods of use thereof",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1036180,
	"label": "HUMAN IMMUNE INTERFERON,ITS PREPARATION AND PURIFICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1036754,
	"label": "Novel gene encoding brain-specific membrane protein",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1036754,
	"label": "Novel gene encoding brain-specific membrane protein",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 1036754,
	"label": "Novel gene encoding brain-specific membrane protein",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1037306,
	"label": "DNA SEQUENCE FOR EXPRESSION IN AN E. COLI HOST OF A POLYPEPTIDE WITH THE PROPERTIES OF HUMAN BASIC FIBROBLAST GROWTH FACTOR AND ITS USE IN THE PRODUCTION OF THIS PROTEIN",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 38004,
	"target": 37986,
	"type": 1040330,
	"label": "MULTIMER FORMS OF INTERLEUKIN-16 (IL-16), PROCESS FOR THE PREPARATION AND USE THEREOF.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1040330,
	"label": "MULTIMER FORMS OF INTERLEUKIN-16 (IL-16), PROCESS FOR THE PREPARATION AND USE THEREOF.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38004,
	"target": 37864,
	"type": 1040330,
	"label": "MULTIMER FORMS OF INTERLEUKIN-16 (IL-16), PROCESS FOR THE PREPARATION AND USE THEREOF.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 38004,
	"type": 1040330,
	"label": "MULTIMER FORMS OF INTERLEUKIN-16 (IL-16), PROCESS FOR THE PREPARATION AND USE THEREOF.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1040330,
	"label": "MULTIMER FORMS OF INTERLEUKIN-16 (IL-16), PROCESS FOR THE PREPARATION AND USE THEREOF.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38065,
	"target": 37996,
	"type": 1040554,
	"label": "Gene therapy vector for the treatment of low or defective red blood cell production",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37996,
	"target": 6795,
	"type": 1040554,
	"label": "Gene therapy vector for the treatment of low or defective red blood cell production",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 1040554,
	"label": "Gene therapy vector for the treatment of low or defective red blood cell production",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 1040594,
	"label": "METHODEN UND ZUSAMMENSETZUNGEN BESTEHEND AUS GLYKOPROTEIN-GLYKOFORMEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7511,
	"target": 6795,
	"type": 1040594,
	"label": "METHODEN UND ZUSAMMENSETZUNGEN BESTEHEND AUS GLYKOPROTEIN-GLYKOFORMEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32772,
	"target": 7511,
	"type": 1040594,
	"label": "METHODEN UND ZUSAMMENSETZUNGEN BESTEHEND AUS GLYKOPROTEIN-GLYKOFORMEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32777,
	"target": 7511,
	"type": 1040594,
	"label": "METHODEN UND ZUSAMMENSETZUNGEN BESTEHEND AUS GLYKOPROTEIN-GLYKOFORMEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32772,
	"target": 6795,
	"type": 1040594,
	"label": "METHODEN UND ZUSAMMENSETZUNGEN BESTEHEND AUS GLYKOPROTEIN-GLYKOFORMEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1041049,
	"label": "Genes associated with obesity and methods for using the same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37947,
	"target": 37862,
	"type": 1041049,
	"label": "Genes associated with obesity and methods for using the same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37947,
	"target": 37859,
	"type": 1041049,
	"label": "Genes associated with obesity and methods for using the same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7425,
	"target": 7360,
	"type": 1042401,
	"label": "Method of treating disease states by the administration of 1 alpha ,25,26-trihydroxycholecalciferol",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 1042401,
	"label": "Method of treating disease states by the administration of 1 alpha ,25,26-trihydroxycholecalciferol",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 1042401,
	"label": "Method of treating disease states by the administration of 1 alpha ,25,26-trihydroxycholecalciferol",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 7360,
	"target": 6429,
	"type": 1042401,
	"label": "Method of treating disease states by the administration of 1 alpha ,25,26-trihydroxycholecalciferol",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 7425,
	"target": 6429,
	"type": 1042401,
	"label": "Method of treating disease states by the administration of 1 alpha ,25,26-trihydroxycholecalciferol",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1043748,
	"label": "Compounds with antitumor activity",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 56836,
	"target": 56833,
	"type": 1045469,
	"label": "Antagonists to insulin receptor tyrosine kinase inhibitor",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37999,
	"target": 37864,
	"type": 1045988,
	"label": "Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 1045988,
	"label": "Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37999,
	"target": 32694,
	"type": 1045988,
	"label": "Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1045988,
	"label": "Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1045988,
	"label": "Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56833,
	"target": 37986,
	"type": 1047970,
	"label": "Method for the quantitative determination of telomerase activity",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1048403,
	"label": "Conjugates of liposomes or microbeads and antibodies specific for T lymphocytes and their use as in vivo immune modulators",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1048802,
	"label": "Toxoplasma gondii antigen Tg20",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7497,
	"target": 7487,
	"type": 1049125,
	"label": "FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7487,
	"target": 7358,
	"type": 1049125,
	"label": "FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7497,
	"target": 7358,
	"type": 1049125,
	"label": "FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 1049125,
	"label": "FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7487,
	"target": 6816,
	"type": 1049125,
	"label": "FremgangsmÕter for fornyet behandling av pasienter rammet av hepatitt C ved anvendelse av konsensus-interferon",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37999,
	"target": 37899,
	"type": 1053768,
	"label": "Polipeptídeo ligante de mpl agonista de mpl fragmento de polipeptídeo polipeptídeo quimera anticorpo linha de célula de hibridoma molécula de ácido nucleico molécula de DNA vetor de express o célula hospedeira processo de uso de uma molécula de ácido nucleico método de determinaç o da presença de polipeptideo ligante de mpl método de amplificação composição método para tratamento de um mamífero processo para a biossíntese de um polipeptídeo ligante de mpl humano",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 1053768,
	"label": "Polipeptídeo ligante de mpl agonista de mpl fragmento de polipeptídeo polipeptídeo quimera anticorpo linha de célula de hibridoma molécula de ácido nucleico molécula de DNA vetor de express o célula hospedeira processo de uso de uma molécula de ácido nucleico método de determinaç o da presença de polipeptideo ligante de mpl método de amplificação composição método para tratamento de um mamífero processo para a biossíntese de um polipeptídeo ligante de mpl humano",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37999,
	"target": 32694,
	"type": 1053768,
	"label": "Polipeptídeo ligante de mpl agonista de mpl fragmento de polipeptídeo polipeptídeo quimera anticorpo linha de célula de hibridoma molécula de ácido nucleico molécula de DNA vetor de express o célula hospedeira processo de uso de uma molécula de ácido nucleico método de determinaç o da presença de polipeptideo ligante de mpl método de amplificação composição método para tratamento de um mamífero processo para a biossíntese de um polipeptídeo ligante de mpl humano",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1053768,
	"label": "Polipeptídeo ligante de mpl agonista de mpl fragmento de polipeptídeo polipeptídeo quimera anticorpo linha de célula de hibridoma molécula de ácido nucleico molécula de DNA vetor de express o célula hospedeira processo de uso de uma molécula de ácido nucleico método de determinaç o da presença de polipeptideo ligante de mpl método de amplificação composição método para tratamento de um mamífero processo para a biossíntese de um polipeptídeo ligante de mpl humano",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1053768,
	"label": "Polipeptídeo ligante de mpl agonista de mpl fragmento de polipeptídeo polipeptídeo quimera anticorpo linha de célula de hibridoma molécula de ácido nucleico molécula de DNA vetor de express o célula hospedeira processo de uso de uma molécula de ácido nucleico método de determinaç o da presença de polipeptideo ligante de mpl método de amplificação composição método para tratamento de um mamífero processo para a biossíntese de um polipeptídeo ligante de mpl humano",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7409,
	"target": 7358,
	"type": 1054377,
	"label": "HUMANE MONOKLONALE ANTIKÖRPER GEGEN DEN TGF-BETA II REZEPTOR UND DESSEN MEDIZINISCHE VERWENDUNG",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 7409,
	"type": 1054377,
	"label": "HUMANE MONOKLONALE ANTIKÖRPER GEGEN DEN TGF-BETA II REZEPTOR UND DESSEN MEDIZINISCHE VERWENDUNG",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 7358,
	"type": 1054377,
	"label": "HUMANE MONOKLONALE ANTIKÖRPER GEGEN DEN TGF-BETA II REZEPTOR UND DESSEN MEDIZINISCHE VERWENDUNG",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 1055172,
	"label": "APTAMERS SPECIFIC FOR BIOMOLECULES AND METHODS OF MAKING",
	"group": "Gilead",
	"time": 1992,
	"strength": 1
}, {
	"source": 7360,
	"target": 6429,
	"type": 1055188,
	"label": "PHARMACEUTICAL COMPOSITIONS CONTAINING 24,24-DIFLUORO-1ALPHA,25-DIHYDROXY-CHOLECALCIFEROL ACTIVE AGAINST OSTEOPOROSIS AND IN THE PREVENTION OF MILK FEVER",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 1057172,
	"label": "NEW GENE WITH DOWN-REGULATED EXPRESSION IN METASTATIC HUMAN MELANOMA CELLS AND A PROTEIN CODED THEREBY, METHODS OF PRODUCTION, AND USE THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1057172,
	"label": "NEW GENE WITH DOWN-REGULATED EXPRESSION IN METASTATIC HUMAN MELANOMA CELLS AND A PROTEIN CODED THEREBY, METHODS OF PRODUCTION, AND USE THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 32772,
	"type": 1057172,
	"label": "NEW GENE WITH DOWN-REGULATED EXPRESSION IN METASTATIC HUMAN MELANOMA CELLS AND A PROTEIN CODED THEREBY, METHODS OF PRODUCTION, AND USE THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 32772,
	"type": 1057172,
	"label": "NEW GENE WITH DOWN-REGULATED EXPRESSION IN METASTATIC HUMAN MELANOMA CELLS AND A PROTEIN CODED THEREBY, METHODS OF PRODUCTION, AND USE THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 38181,
	"type": 1057172,
	"label": "NEW GENE WITH DOWN-REGULATED EXPRESSION IN METASTATIC HUMAN MELANOMA CELLS AND A PROTEIN CODED THEREBY, METHODS OF PRODUCTION, AND USE THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1058305,
	"label": "LOSLÖSENDES PROTEIN 5 - UCP5",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 6488,
	"type": 1058305,
	"label": "LOSLÖSENDES PROTEIN 5 - UCP5",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 6488,
	"type": 1058305,
	"label": "LOSLÖSENDES PROTEIN 5 - UCP5",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37988,
	"target": 6795,
	"type": 1058487,
	"label": "Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1058676,
	"label": "GENE WHICH ENABLES CANCER CELLS TO RETURN TO NORMAL",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1058676,
	"label": "GENE WHICH ENABLES CANCER CELLS TO RETURN TO NORMAL",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 1058676,
	"label": "GENE WHICH ENABLES CANCER CELLS TO RETURN TO NORMAL",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1058676,
	"label": "GENE WHICH ENABLES CANCER CELLS TO RETURN TO NORMAL",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1058676,
	"label": "GENE WHICH ENABLES CANCER CELLS TO RETURN TO NORMAL",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38042,
	"target": 37900,
	"type": 1059019,
	"label": "APO-2DCR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 1059019,
	"label": "APO-2DCR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38042,
	"target": 32770,
	"type": 1059019,
	"label": "APO-2DCR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 1059019,
	"label": "APO-2DCR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37900,
	"target": 6812,
	"type": 1059019,
	"label": "APO-2DCR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1063521,
	"label": "Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7384,
	"type": 1065020,
	"label": "Optically active chroman and thiochroman derivatives",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7384,
	"type": 1065027,
	"label": "3-methyl-chroman and -thiochroman derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 7384,
	"type": 1065030,
	"label": "3-ethyl-, 3-propyl- or 3-butyl-chroman and -thiochroman derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 31747,
	"target": 7380,
	"type": 1065036,
	"label": "COMPOUNDS WITH HYDROXYCARBONYL-HALOGENALKYL BY-SIDE CHAINS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 1066139,
	"label": "Novel human RNA helicase, helicain",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37960,
	"target": 37864,
	"type": 1066139,
	"label": "Novel human RNA helicase, helicain",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56833,
	"target": 37960,
	"type": 1066139,
	"label": "Novel human RNA helicase, helicain",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 37960,
	"type": 1066139,
	"label": "Novel human RNA helicase, helicain",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56833,
	"target": 37864,
	"type": 1066139,
	"label": "Novel human RNA helicase, helicain",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1069567,
	"label": "Human TAK1 DNA encoding the same",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 30171,
	"target": 6795,
	"type": 1069877,
	"label": "Arylsulfonanilide derivatives",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37897,
	"type": 1071104,
	"label": "Cancer cells capable of tumorigenesis but incapable of infiltration and metastasis, process for preparing the same, and method for screening gene relating to metastasis by using the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1071104,
	"label": "Cancer cells capable of tumorigenesis but incapable of infiltration and metastasis, process for preparing the same, and method for screening gene relating to metastasis by using the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37897,
	"type": 1071104,
	"label": "Cancer cells capable of tumorigenesis but incapable of infiltration and metastasis, process for preparing the same, and method for screening gene relating to metastasis by using the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37897,
	"target": 32754,
	"type": 1071104,
	"label": "Cancer cells capable of tumorigenesis but incapable of infiltration and metastasis, process for preparing the same, and method for screening gene relating to metastasis by using the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 32754,
	"type": 1071104,
	"label": "Cancer cells capable of tumorigenesis but incapable of infiltration and metastasis, process for preparing the same, and method for screening gene relating to metastasis by using the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1074192,
	"label": "Modulation of enos activity and therapeutic uses thereof",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1074237,
	"label": "FORMA ACTIVA DE UNA PROTEINA HEDGEHOG (PROTEINA ERIZO), PROCESO PARA SU PRODUCCION RECOMBINANTE Y SU UTILIZACION TERAPEUTICA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1074237,
	"label": "FORMA ACTIVA DE UNA PROTEINA HEDGEHOG (PROTEINA ERIZO), PROCESO PARA SU PRODUCCION RECOMBINANTE Y SU UTILIZACION TERAPEUTICA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1074237,
	"label": "FORMA ACTIVA DE UNA PROTEINA HEDGEHOG (PROTEINA ERIZO), PROCESO PARA SU PRODUCCION RECOMBINANTE Y SU UTILIZACION TERAPEUTICA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 1075835,
	"label": "Bispecific molecules cross-linking itim and itam for therapy",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1075835,
	"label": "Bispecific molecules cross-linking itim and itam for therapy",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1075835,
	"label": "Bispecific molecules cross-linking itim and itam for therapy",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1077827,
	"label": "Recombinant polynucleotides encoding CYP7 promoter-binding factors",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 1079976,
	"label": "PROCESSO PARA A PREPARACAO DE DERIVADOS DE PIRIDONA TRICICLICOS E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1080277,
	"label": "Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 1080277,
	"label": "Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 1080277,
	"label": "Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 1080277,
	"label": "Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1080277,
	"label": "Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1080747,
	"label": "Anvendelse av et interleukin-6 antistoff eller interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandling av unormal synovialcelle-vekst.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1080747,
	"label": "Anvendelse av et interleukin-6 antistoff eller interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandling av unormal synovialcelle-vekst.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1080747,
	"label": "Anvendelse av et interleukin-6 antistoff eller interleukin-6 reseptorantistoff for fremstilling av en farmasoytisk blanding for behandling av unormal synovialcelle-vekst.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 1081041,
	"label": "Human interferon-epsi(IFN-epsi), a type I interferon",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6816,
	"type": 1081041,
	"label": "Human interferon-epsi(IFN-epsi), a type I interferon",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1081041,
	"label": "Human interferon-epsi(IFN-epsi), a type I interferon",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7432,
	"target": 6795,
	"type": 1082350,
	"label": "BOVINE GROWTH HORMONE ANALOGS",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 7432,
	"type": 1082350,
	"label": "BOVINE GROWTH HORMONE ANALOGS",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1082350,
	"label": "BOVINE GROWTH HORMONE ANALOGS",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 32700,
	"target": 32696,
	"type": 1084208,
	"label": "N-Terminally chemically modified protein compositions and methods",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 31580,
	"target": 6241,
	"type": 1084655,
	"label": "3,5-DIHYDROXY-7-(1-ACYLOXY-HEXAHYDRO-NAPHTH-8-YL) HEPTANOIC ACID DERIVATIVES, LACTONES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1086221,
	"label": "Mutantes deficientes de redutase de l-sorbose geneticamente engenheirados.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1086297,
	"label": "Method of isolation of rna-binding compounds",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1086297,
	"label": "Method of isolation of rna-binding compounds",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 1086297,
	"label": "Method of isolation of rna-binding compounds",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1086297,
	"label": "Method of isolation of rna-binding compounds",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 1086297,
	"label": "Method of isolation of rna-binding compounds",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32777,
	"target": 6795,
	"type": 1086478,
	"label": "Treating atopic dermatitis with ige antagonists",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 1091399,
	"label": "RH SIGNAL PEPTIDE USED FOR IMPROVING SECRETION OF NGF POLYPEPTIDES AND PREPARING MET-LESS NGF POLYPEPTIDES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1091399,
	"label": "RH SIGNAL PEPTIDE USED FOR IMPROVING SECRETION OF NGF POLYPEPTIDES AND PREPARING MET-LESS NGF POLYPEPTIDES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 1091399,
	"label": "RH SIGNAL PEPTIDE USED FOR IMPROVING SECRETION OF NGF POLYPEPTIDES AND PREPARING MET-LESS NGF POLYPEPTIDES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 1091399,
	"label": "RH SIGNAL PEPTIDE USED FOR IMPROVING SECRETION OF NGF POLYPEPTIDES AND PREPARING MET-LESS NGF POLYPEPTIDES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1091399,
	"label": "RH SIGNAL PEPTIDE USED FOR IMPROVING SECRETION OF NGF POLYPEPTIDES AND PREPARING MET-LESS NGF POLYPEPTIDES",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 7384,
	"type": 1092639,
	"label": "Metal salts of 3-methyl-chromane or thiochromane derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 7384,
	"type": 1092647,
	"label": "3-methyl -chromane or thiochromane derivatives",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31784,
	"target": 7507,
	"type": 1094548,
	"label": "COMPOSTOS SAIS DE ADICAO DE ACIDO,PROCESSO DE PREPARACAO DE COMPOSTOS,MEDIAMENTOS,USO E METODO PARA REDUZIR E/OU ELIMINAR A RESISTENCIA MULTIPLA A CITOSTATICOS",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 1096490,
	"label": "Azepine or larger medium ring derivatives and their use as pharmaceuticals",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1099624,
	"label": "DNA FRAGMENT ENCODING IMMUNOGENIC SURFACE MEROSOITE POLYPEPTIDE, IMMUNOGENIC POLYPEPTIDE (VARIANTS) AND A METHOD OF ITS PREPARING, RECOMBINANT PLASMID DNA AND A METHOD OF ITS PREPARING, A METHOD OF PREPARING RECOMBINANT VIRUS OF VACCINE, A METHOD OF PREPARING MICROORGANISM, VACCINE AGAINST COCCIDIOSIS IN POULTRY",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 1099624,
	"label": "DNA FRAGMENT ENCODING IMMUNOGENIC SURFACE MEROSOITE POLYPEPTIDE, IMMUNOGENIC POLYPEPTIDE (VARIANTS) AND A METHOD OF ITS PREPARING, RECOMBINANT PLASMID DNA AND A METHOD OF ITS PREPARING, A METHOD OF PREPARING RECOMBINANT VIRUS OF VACCINE, A METHOD OF PREPARING MICROORGANISM, VACCINE AGAINST COCCIDIOSIS IN POULTRY",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 1099624,
	"label": "DNA FRAGMENT ENCODING IMMUNOGENIC SURFACE MEROSOITE POLYPEPTIDE, IMMUNOGENIC POLYPEPTIDE (VARIANTS) AND A METHOD OF ITS PREPARING, RECOMBINANT PLASMID DNA AND A METHOD OF ITS PREPARING, A METHOD OF PREPARING RECOMBINANT VIRUS OF VACCINE, A METHOD OF PREPARING MICROORGANISM, VACCINE AGAINST COCCIDIOSIS IN POULTRY",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 1100311,
	"label": "Reconstituted human anti-human 1.24 antibody",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1100311,
	"label": "Reconstituted human anti-human 1.24 antibody",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 1100311,
	"label": "Reconstituted human anti-human 1.24 antibody",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56836,
	"target": 32779,
	"type": 1100311,
	"label": "Reconstituted human anti-human 1.24 antibody",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 1100311,
	"label": "Reconstituted human anti-human 1.24 antibody",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32777,
	"target": 6795,
	"type": 1101059,
	"label": "METHODS FOR TREATMENT OF ALLERGIC DISEASES WITH IgE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6957,
	"type": 1103337,
	"label": "Nucleic acid ligands to the prostate specific membrane antigen",
	"group": "Gilead",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1103337,
	"label": "Nucleic acid ligands to the prostate specific membrane antigen",
	"group": "Gilead",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6957,
	"type": 1103337,
	"label": "Nucleic acid ligands to the prostate specific membrane antigen",
	"group": "Gilead",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1103764,
	"label": "TREATING AGENT FOR MYOCARDIAL INFARCTION CONTAINING ANTI-IL-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1103764,
	"label": "TREATING AGENT FOR MYOCARDIAL INFARCTION CONTAINING ANTI-IL-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 1103764,
	"label": "TREATING AGENT FOR MYOCARDIAL INFARCTION CONTAINING ANTI-IL-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 1103764,
	"label": "TREATING AGENT FOR MYOCARDIAL INFARCTION CONTAINING ANTI-IL-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1103764,
	"label": "TREATING AGENT FOR MYOCARDIAL INFARCTION CONTAINING ANTI-IL-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1103774,
	"label": "PREVENTIVE AND TREATING AGENT FOR APOPLEXY AND BRAIN EDEMA INCLUDING IL-8 BOND INHIBITOR AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 1105756,
	"label": "DERIVADOS DE LA VITAMINA D, SU UTILIZACION Y MEDICAMENTOS QUE LOS CONTIENEN.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1106071,
	"label": "HEREGULIN POLYPEPTIDE COMPOSITIONS, SEQUENCES, ANTIBODIES, PURIFICATION, AMPLIFICATION AND DIAGNOSTIC TESTS",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1107247,
	"label": "Canine OB protein compositions and method for recombinant prodn.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1107247,
	"label": "Canine OB protein compositions and method for recombinant prodn.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1107247,
	"label": "Canine OB protein compositions and method for recombinant prodn.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1107247,
	"label": "Canine OB protein compositions and method for recombinant prodn.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1107247,
	"label": "Canine OB protein compositions and method for recombinant prodn.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1107948,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ET PROTEIN I EN VAERTSCELLEKULTUR, DNA-SEKVENS DER KODER FOR ET DHFR-PROTEIN VEKTOR FOR DNA-SEKVENSEN OG VEKTOR FOR DENNE OG EN ANDEN DNA-SEKVENS DER KODER FOR PROTEINET OG SELEKTERING AF TRANSFICEREDE EUKARYOTISKE CELLER",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 1107948,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ET PROTEIN I EN VAERTSCELLEKULTUR, DNA-SEKVENS DER KODER FOR ET DHFR-PROTEIN VEKTOR FOR DNA-SEKVENSEN OG VEKTOR FOR DENNE OG EN ANDEN DNA-SEKVENS DER KODER FOR PROTEINET OG SELEKTERING AF TRANSFICEREDE EUKARYOTISKE CELLER",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38065,
	"target": 32694,
	"type": 1107948,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ET PROTEIN I EN VAERTSCELLEKULTUR, DNA-SEKVENS DER KODER FOR ET DHFR-PROTEIN VEKTOR FOR DNA-SEKVENSEN OG VEKTOR FOR DENNE OG EN ANDEN DNA-SEKVENS DER KODER FOR PROTEINET OG SELEKTERING AF TRANSFICEREDE EUKARYOTISKE CELLER",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1108034,
	"label": "GRNF4, A GDNF-RELATED NEUROTROPHIC FACTOR",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1108034,
	"label": "GRNF4, A GDNF-RELATED NEUROTROPHIC FACTOR",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1108034,
	"label": "GRNF4, A GDNF-RELATED NEUROTROPHIC FACTOR",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 1108034,
	"label": "GRNF4, A GDNF-RELATED NEUROTROPHIC FACTOR",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 56836,
	"target": 37864,
	"type": 1108034,
	"label": "GRNF4, A GDNF-RELATED NEUROTROPHIC FACTOR",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 1109147,
	"label": "HYBRID RECOMBINANT PROTEIN CODED FOR BY A TWO PART FUSED SEQUENCE COMPRISING A HUMAN IL-5 DNA SEQUENCE AND AN IMMUNOGLOBULIN DNA SEQUENCE; PROCESSES",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1109147,
	"label": "HYBRID RECOMBINANT PROTEIN CODED FOR BY A TWO PART FUSED SEQUENCE COMPRISING A HUMAN IL-5 DNA SEQUENCE AND AN IMMUNOGLOBULIN DNA SEQUENCE; PROCESSES",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 1109147,
	"label": "HYBRID RECOMBINANT PROTEIN CODED FOR BY A TWO PART FUSED SEQUENCE COMPRISING A HUMAN IL-5 DNA SEQUENCE AND AN IMMUNOGLOBULIN DNA SEQUENCE; PROCESSES",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1109147,
	"label": "HYBRID RECOMBINANT PROTEIN CODED FOR BY A TWO PART FUSED SEQUENCE COMPRISING A HUMAN IL-5 DNA SEQUENCE AND AN IMMUNOGLOBULIN DNA SEQUENCE; PROCESSES",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 1109147,
	"label": "HYBRID RECOMBINANT PROTEIN CODED FOR BY A TWO PART FUSED SEQUENCE COMPRISING A HUMAN IL-5 DNA SEQUENCE AND AN IMMUNOGLOBULIN DNA SEQUENCE; PROCESSES",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1113122,
	"label": "Novel metalloprotease containing a thrombospondin domain (MPTS protein) is useful to treat aggrecan associated disease including rheumatoid arthritis and osteoarthritis",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37947,
	"target": 37862,
	"type": 1113122,
	"label": "Novel metalloprotease containing a thrombospondin domain (MPTS protein) is useful to treat aggrecan associated disease including rheumatoid arthritis and osteoarthritis",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37947,
	"target": 37859,
	"type": 1113122,
	"label": "Novel metalloprotease containing a thrombospondin domain (MPTS protein) is useful to treat aggrecan associated disease including rheumatoid arthritis and osteoarthritis",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38232,
	"target": 37947,
	"type": 1113122,
	"label": "Novel metalloprotease containing a thrombospondin domain (MPTS protein) is useful to treat aggrecan associated disease including rheumatoid arthritis and osteoarthritis",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38232,
	"target": 37862,
	"type": 1113122,
	"label": "Novel metalloprotease containing a thrombospondin domain (MPTS protein) is useful to treat aggrecan associated disease including rheumatoid arthritis and osteoarthritis",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1113428,
	"label": "Method of screening apoptosis inducing substances",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1114385,
	"label": "DNA ENCODING PROTEASE X FROM STREPTOMYCES LIVIDANS, RECOMBINANT PROTEASE X AND ANALOGUES; ANTIBODIES, HOSTS",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37864,
	"target": 6841,
	"type": 1114385,
	"label": "DNA ENCODING PROTEASE X FROM STREPTOMYCES LIVIDANS, RECOMBINANT PROTEASE X AND ANALOGUES; ANTIBODIES, HOSTS",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 1114385,
	"label": "DNA ENCODING PROTEASE X FROM STREPTOMYCES LIVIDANS, RECOMBINANT PROTEASE X AND ANALOGUES; ANTIBODIES, HOSTS",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 32478,
	"target": 7507,
	"type": 1114518,
	"label": "MODIFIED OLIGONUCLEOTIDES AND INTERMEDIATES USEFUL IN NUCLEIC ACID THERAPEUTICS.",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 1115530,
	"label": "METHOD FOR THE INDUCTION OF A CYTOTOXIC T CELL RESPONSE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 1118147,
	"label": "HEPATITIS VIRUS SENTINEL VIRUS I (SVI).",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 30485,
	"target": 27540,
	"type": 1118168,
	"label": "DEUTERATED CHOLECALCIFEROL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 27540,
	"target": 6431,
	"type": 1118168,
	"label": "DEUTERATED CHOLECALCIFEROL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 1118168,
	"label": "DEUTERATED CHOLECALCIFEROL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1120368,
	"label": "HEK5, HEK7, HEK8, HEK11 AND NEW EPH-LIKE RECEPTOR PROTEIN TYROSINE KINASE",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 1120657,
	"label": "PLASMODIUM FALCIPARUM MEROZOITE EPITOPE PEPTIDES, PEPTIDE CONJUGATES, DNA AND ANTIBODIES",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30951,
	"target": 30816,
	"type": 1122104,
	"label": "Hydroxamic acid derivatives",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1122533,
	"label": "HUMANT VAEKSTHORMON FRIT FOR ANDRE PROTEINER FORBUNDET MED DETS NATIVE MILJOE, UDTRYKKELSESMEDIUM, SOM KAN FREMBRINGE PRODUKTION AF PRAE-HGH I EN PROKARYOTISK VAERTSCELLE, PROKARYOTISK VAERT TRANSFORMERET DERMED OG FREMGANGSMAADE TIL FREMSTILLING AF MODENT HGH",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 1124970,
	"label": "Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1124970,
	"label": "Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 1124970,
	"label": "Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 1125337,
	"label": "Compositions and methods for screening drug libraries",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1126856,
	"label": "Nucleic acids encoding tumor necrosis factor (TNF) receptor homologs",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37859,
	"type": 1126856,
	"label": "Nucleic acids encoding tumor necrosis factor (TNF) receptor homologs",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37859,
	"type": 1126856,
	"label": "Nucleic acids encoding tumor necrosis factor (TNF) receptor homologs",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37859,
	"target": 6795,
	"type": 1126856,
	"label": "Nucleic acids encoding tumor necrosis factor (TNF) receptor homologs",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1126856,
	"label": "Nucleic acids encoding tumor necrosis factor (TNF) receptor homologs",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1127648,
	"label": "Method of inhibiting metastasis by anti- alpha 6-integrin-antibodies",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 1127648,
	"label": "Method of inhibiting metastasis by anti- alpha 6-integrin-antibodies",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56836,
	"target": 32770,
	"type": 1127648,
	"label": "Method of inhibiting metastasis by anti- alpha 6-integrin-antibodies",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1127822,
	"label": "USE OF AL-2 NEUROTROPHIC FACTOR OR PORTION THEREOF IN THE PREPARATION OF A MEDICAMENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1127822,
	"label": "USE OF AL-2 NEUROTROPHIC FACTOR OR PORTION THEREOF IN THE PREPARATION OF A MEDICAMENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1127822,
	"label": "USE OF AL-2 NEUROTROPHIC FACTOR OR PORTION THEREOF IN THE PREPARATION OF A MEDICAMENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 1127822,
	"label": "USE OF AL-2 NEUROTROPHIC FACTOR OR PORTION THEREOF IN THE PREPARATION OF A MEDICAMENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 1127822,
	"label": "USE OF AL-2 NEUROTROPHIC FACTOR OR PORTION THEREOF IN THE PREPARATION OF A MEDICAMENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1128839,
	"label": "VERFAHREN ZUM IMMUNOCHEMISCHEN TESTEN DES ANTI- HM1.24-ANTIKÖRPERS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1128839,
	"label": "VERFAHREN ZUM IMMUNOCHEMISCHEN TESTEN DES ANTI- HM1.24-ANTIKÖRPERS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 1128839,
	"label": "VERFAHREN ZUM IMMUNOCHEMISCHEN TESTEN DES ANTI- HM1.24-ANTIKÖRPERS",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 1130247,
	"label": "8-phenyl-1,6-naphthyridin-5-ones",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6854,
	"target": 6812,
	"type": 1131580,
	"label": "MOLECULES TARGETING CD40 WHICH DO NOT ACTIVATE CD40-EXPRESSING CELLS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 1134077,
	"label": "TWO-CHAIN POLYDEOXY RIBONUCLOTIDE FOR CODING MATURED HUMAN IL-2",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 32698,
	"type": 1134077,
	"label": "TWO-CHAIN POLYDEOXY RIBONUCLOTIDE FOR CODING MATURED HUMAN IL-2",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 1134077,
	"label": "TWO-CHAIN POLYDEOXY RIBONUCLOTIDE FOR CODING MATURED HUMAN IL-2",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37993,
	"target": 37904,
	"type": 1134124,
	"label": "anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37904,
	"target": 32772,
	"type": 1134124,
	"label": "anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37993,
	"target": 32772,
	"type": 1134124,
	"label": "anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56836,
	"target": 37993,
	"type": 1134124,
	"label": "anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56836,
	"target": 37904,
	"type": 1134124,
	"label": "anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1134511,
	"label": "Macrophage stimulating protein for the treatment of gastrointestinal disorders",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 32501,
	"target": 6169,
	"type": 1134622,
	"label": "D-HOMOSTEROIDS,THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 7424,
	"type": 1140120,
	"label": "COMPUESTOS QUE INHIBEN LA PROCOLAGENO C-PROTEINASA.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1140221,
	"label": "AGENT FOR TREATMENT OF CHRONIC RHEUMATOID ARTHRITIS CONTAINING ANTI-IL-8 ANTIBODY AS ACTIVE COMPONENT",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1143802,
	"label": "DNA CODING MODIFIED ANTIBODY OR COMPOUND WITH TPO AGONIST ACTIVITY, METHOD OF PRODUCING THEM AND ANIMAL CELL OR MICROORGANISM PRODUCING THEM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 1143802,
	"label": "DNA CODING MODIFIED ANTIBODY OR COMPOUND WITH TPO AGONIST ACTIVITY, METHOD OF PRODUCING THEM AND ANIMAL CELL OR MICROORGANISM PRODUCING THEM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 1143802,
	"label": "DNA CODING MODIFIED ANTIBODY OR COMPOUND WITH TPO AGONIST ACTIVITY, METHOD OF PRODUCING THEM AND ANIMAL CELL OR MICROORGANISM PRODUCING THEM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32771,
	"target": 7508,
	"type": 1143802,
	"label": "DNA CODING MODIFIED ANTIBODY OR COMPOUND WITH TPO AGONIST ACTIVITY, METHOD OF PRODUCING THEM AND ANIMAL CELL OR MICROORGANISM PRODUCING THEM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1143802,
	"label": "DNA CODING MODIFIED ANTIBODY OR COMPOUND WITH TPO AGONIST ACTIVITY, METHOD OF PRODUCING THEM AND ANIMAL CELL OR MICROORGANISM PRODUCING THEM",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7487,
	"target": 6290,
	"type": 1144749,
	"label": "USE OF N-(4-ARYL-THIAZOL-2-YL)-SULFONAMIDE DERIVATIVES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS TREATING NEUROLOGICAL DISORDERS, NEW DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1145430,
	"label": "HUMAN HOMOLOG OF THE DROSOPHILA PROTEIN  FUSED , VECTORS COMPRISING IT AND CELLS TRANSFORMED WITH SAID VECTORS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38237,
	"target": 37899,
	"type": 1145430,
	"label": "HUMAN HOMOLOG OF THE DROSOPHILA PROTEIN  FUSED , VECTORS COMPRISING IT AND CELLS TRANSFORMED WITH SAID VECTORS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38237,
	"target": 37862,
	"type": 1145430,
	"label": "HUMAN HOMOLOG OF THE DROSOPHILA PROTEIN  FUSED , VECTORS COMPRISING IT AND CELLS TRANSFORMED WITH SAID VECTORS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 32788,
	"type": 1145430,
	"label": "HUMAN HOMOLOG OF THE DROSOPHILA PROTEIN  FUSED , VECTORS COMPRISING IT AND CELLS TRANSFORMED WITH SAID VECTORS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 1145430,
	"label": "HUMAN HOMOLOG OF THE DROSOPHILA PROTEIN  FUSED , VECTORS COMPRISING IT AND CELLS TRANSFORMED WITH SAID VECTORS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 56833,
	"target": 37960,
	"type": 1148467,
	"label": "High-throughput screening assays for modulators of nucleic acid topoisomerases",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 1149740,
	"label": "RECOMBINANT LEUKOCYTE, FIBROBLAST, OR IMMUNE INTERFERONS (RIFN-#A#, B OR #G#) WITH ONE CYS RESIDUE REPLACED",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 6816,
	"type": 1149740,
	"label": "RECOMBINANT LEUKOCYTE, FIBROBLAST, OR IMMUNE INTERFERONS (RIFN-#A#, B OR #G#) WITH ONE CYS RESIDUE REPLACED",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1149740,
	"label": "RECOMBINANT LEUKOCYTE, FIBROBLAST, OR IMMUNE INTERFERONS (RIFN-#A#, B OR #G#) WITH ONE CYS RESIDUE REPLACED",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 6816,
	"type": 1155321,
	"label": "EXPRESSION VECTOR HAVING A PROMOTER/REGULATOR REGION DERIVED FROM YEAST REPRESSIBLE ACID PHOSPHATASE (PH05)GENE AND A STRUCTURAL GENE CODING FOR HUMAN LEUCOCYTE INTERFERON",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 30950,
	"target": 6272,
	"type": 1156377,
	"label": "Hydroxylamine derivatives and their use as metalloproteinase inhibiting agents",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 1157274,
	"label": "IL-16 Aktivitesine sahip islenmis polipeptidler, bunlari üretmeye mahsus yöntemler ve bunlarin kullanimi.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 1157518,
	"label": "Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (Fc&gamma;R), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1157518,
	"label": "Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (Fc&gamma;R), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 32777,
	"type": 1157518,
	"label": "Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (Fc&gamma;R), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1157518,
	"label": "Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (Fc&gamma;R), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 32777,
	"type": 1157518,
	"label": "Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (Fc&gamma;R), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7409,
	"target": 6812,
	"type": 1157798,
	"label": "TRAITEMENT DE L'ASTHME A L'AIDE DE LA TNFR-IG",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1158040,
	"label": "Purified sciatic nerve ciliary neurotrophic factor - and recombinant CNTF, useful for reducing damage to nervous system caused by disease or injury",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1158040,
	"label": "Purified sciatic nerve ciliary neurotrophic factor - and recombinant CNTF, useful for reducing damage to nervous system caused by disease or injury",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1158040,
	"label": "Purified sciatic nerve ciliary neurotrophic factor - and recombinant CNTF, useful for reducing damage to nervous system caused by disease or injury",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1158040,
	"label": "Purified sciatic nerve ciliary neurotrophic factor - and recombinant CNTF, useful for reducing damage to nervous system caused by disease or injury",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1158040,
	"label": "Purified sciatic nerve ciliary neurotrophic factor - and recombinant CNTF, useful for reducing damage to nervous system caused by disease or injury",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1159211,
	"label": "PROCESSO PARA A PRODUCAO DE ANALOGOS DO FACTOR DE CRESCIMENTO DE FIBROBLASTOS",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1159211,
	"label": "PROCESSO PARA A PRODUCAO DE ANALOGOS DO FACTOR DE CRESCIMENTO DE FIBROBLASTOS",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1159211,
	"label": "PROCESSO PARA A PRODUCAO DE ANALOGOS DO FACTOR DE CRESCIMENTO DE FIBROBLASTOS",
	"group": "Amgen",
	"time": 1988,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1159536,
	"label": " DOLLAR I(CANDIDA ALBICANS) SRB-7",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1159536,
	"label": " DOLLAR I(CANDIDA ALBICANS) SRB-7",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1159536,
	"label": " DOLLAR I(CANDIDA ALBICANS) SRB-7",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7508,
	"target": 6841,
	"type": 1159848,
	"label": "COMBINATION OF A PROCOAGULANT AND A CYTOKINE OR AN INDUCER OF CYTOKINE PRODUCTION  FOR THE TREATMENT OF TUMORS",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 1160130,
	"label": "Materials and methods to inhibit hodgkin and reed sternberg cell growth",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 1160740,
	"label": "DNA CODING FOR CALDECRIN AND PROCESS FOR PRODUCING CALDECRIN BY USING THE DNA",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 7360,
	"type": 1160740,
	"label": "DNA CODING FOR CALDECRIN AND PROCESS FOR PRODUCING CALDECRIN BY USING THE DNA",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1160740,
	"label": "DNA CODING FOR CALDECRIN AND PROCESS FOR PRODUCING CALDECRIN BY USING THE DNA",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 1162689,
	"label": "Peptide ligands for the erythropoietin receptor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1165280,
	"label": "LIPOTEICTIOIC ACID ANTITOMOR AGENT",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 6478,
	"type": 1166017,
	"label": "Process for preparing 5-dithio-modified oligonucleotides",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 1166275,
	"label": "VITAMIN D DERIVATIVE HAVING A SUBSTITUTENT AT THE 2 BETA-POSITION",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 1166275,
	"label": "VITAMIN D DERIVATIVE HAVING A SUBSTITUTENT AT THE 2 BETA-POSITION",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 1166275,
	"label": "VITAMIN D DERIVATIVE HAVING A SUBSTITUTENT AT THE 2 BETA-POSITION",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32771,
	"target": 6795,
	"type": 1166321,
	"label": "Protein and gene participating in the differentiation of immortalized cells",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 1168478,
	"label": "THERAPEUTIC AGENT FOR ACUTE LUNG INJURY RESULTING FROM INDIRECT CAUSES COMPRISING ANTI-IL-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 7409,
	"type": 1168478,
	"label": "THERAPEUTIC AGENT FOR ACUTE LUNG INJURY RESULTING FROM INDIRECT CAUSES COMPRISING ANTI-IL-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1168478,
	"label": "THERAPEUTIC AGENT FOR ACUTE LUNG INJURY RESULTING FROM INDIRECT CAUSES COMPRISING ANTI-IL-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 1169570,
	"label": "Chimeric human trkA-IgG polypeptides which bind to human nerve growth factor.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1169570,
	"label": "Chimeric human trkA-IgG polypeptides which bind to human nerve growth factor.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 1169570,
	"label": "Chimeric human trkA-IgG polypeptides which bind to human nerve growth factor.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 56836,
	"target": 6854,
	"type": 1170728,
	"label": "REAGENT FOR IMMUNITY METHOD",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32501,
	"target": 6241,
	"type": 1170757,
	"label": "Analogifremgangsmåde til fremstilling af 17a-hydroxy-6,7-methylen-3-oxo-D-homo-17aalfa-pregna-4,16-dien-21-carboxylsyrer eller de tilsvarende lactoner eller salte deraf.",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 56804,
	"target": 6854,
	"type": 1170901,
	"label": "QUANTITATIVE DETERMINATION OF IMMUNOLOGICALLY ACTIVE SUBSTANCE IN ANALYSING SAMPLE",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 38184,
	"target": 7409,
	"type": 1172194,
	"label": "SEPTICEMIA-TREATING AGENT CONTAINING ANTI-INTERLEUKIN-8 ANTIBODY AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 1174027,
	"label": "HUMANISIERTER ANTIKÖRPER GEGEN DEN MENSCHLICHEN GEWEBEFAKTOR (TF) UND VERFAHREN FÜR DIE KONSTRUKTION EINES SOLCHEN HUMANISIERTEN ANTIKÖRPERS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1174027,
	"label": "HUMANISIERTER ANTIKÖRPER GEGEN DEN MENSCHLICHEN GEWEBEFAKTOR (TF) UND VERFAHREN FÜR DIE KONSTRUKTION EINES SOLCHEN HUMANISIERTEN ANTIKÖRPERS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1174027,
	"label": "HUMANISIERTER ANTIKÖRPER GEGEN DEN MENSCHLICHEN GEWEBEFAKTOR (TF) UND VERFAHREN FÜR DIE KONSTRUKTION EINES SOLCHEN HUMANISIERTEN ANTIKÖRPERS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1174027,
	"label": "HUMANISIERTER ANTIKÖRPER GEGEN DEN MENSCHLICHEN GEWEBEFAKTOR (TF) UND VERFAHREN FÜR DIE KONSTRUKTION EINES SOLCHEN HUMANISIERTEN ANTIKÖRPERS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1174027,
	"label": "HUMANISIERTER ANTIKÖRPER GEGEN DEN MENSCHLICHEN GEWEBEFAKTOR (TF) UND VERFAHREN FÜR DIE KONSTRUKTION EINES SOLCHEN HUMANISIERTEN ANTIKÖRPERS.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 7358,
	"type": 1174246,
	"label": "Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37893,
	"target": 37875,
	"type": 1176296,
	"label": "Culturing mammalian cells in contact with cell surface proteins",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38059,
	"target": 38042,
	"type": 1177614,
	"label": "Translation regulation system and methods for use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38042,
	"target": 37988,
	"type": 1177614,
	"label": "Translation regulation system and methods for use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38059,
	"target": 37988,
	"type": 1177614,
	"label": "Translation regulation system and methods for use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 1178598,
	"label": "Use of erythropoietin for treating liver diseases associated with iron overload",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7358,
	"target": 6812,
	"type": 1178598,
	"label": "Use of erythropoietin for treating liver diseases associated with iron overload",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 1178598,
	"label": "Use of erythropoietin for treating liver diseases associated with iron overload",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1179642,
	"label": "PROTEINAS E PEPTIDOS PREPRO QUIMERICOS, MOLECULAS DE ACIDO NUCLEICO QUE OS CODIFICAM, E PROCESSO DE PRODUCAO DE UMA NEUROTROFINA",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1179642,
	"label": "PROTEINAS E PEPTIDOS PREPRO QUIMERICOS, MOLECULAS DE ACIDO NUCLEICO QUE OS CODIFICAM, E PROCESSO DE PRODUCAO DE UMA NEUROTROFINA",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1179642,
	"label": "PROTEINAS E PEPTIDOS PREPRO QUIMERICOS, MOLECULAS DE ACIDO NUCLEICO QUE OS CODIFICAM, E PROCESSO DE PRODUCAO DE UMA NEUROTROFINA",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 1179642,
	"label": "PROTEINAS E PEPTIDOS PREPRO QUIMERICOS, MOLECULAS DE ACIDO NUCLEICO QUE OS CODIFICAM, E PROCESSO DE PRODUCAO DE UMA NEUROTROFINA",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 1179642,
	"label": "PROTEINAS E PEPTIDOS PREPRO QUIMERICOS, MOLECULAS DE ACIDO NUCLEICO QUE OS CODIFICAM, E PROCESSO DE PRODUCAO DE UMA NEUROTROFINA",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 1179833,
	"label": "USE OF CHIMERIC PROTEIN BINDING TNF IN THE PREPARATION OF A PHARMACEUTICAL PREPARATION FOR TREATING AUTO-IMMUNE DISEASES",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 1179833,
	"label": "USE OF CHIMERIC PROTEIN BINDING TNF IN THE PREPARATION OF A PHARMACEUTICAL PREPARATION FOR TREATING AUTO-IMMUNE DISEASES",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 1179833,
	"label": "USE OF CHIMERIC PROTEIN BINDING TNF IN THE PREPARATION OF A PHARMACEUTICAL PREPARATION FOR TREATING AUTO-IMMUNE DISEASES",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1181278,
	"label": "Vitamin d receptor isoform protein",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 1181278,
	"label": "Vitamin d receptor isoform protein",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1181278,
	"label": "Vitamin d receptor isoform protein",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1182084,
	"label": "LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32788,
	"target": 32754,
	"type": 1182084,
	"label": "LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37862,
	"target": 32788,
	"type": 1182084,
	"label": "LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 1182084,
	"label": "LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37862,
	"target": 32754,
	"type": 1182084,
	"label": "LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1183037,
	"label": "MUTEINES OF TUMOR NECROTIC FACTOR /TNF/, DNA SEQUENCE INCLUDING MUTEINE ENCODING DNA, VECTOR, METHOD OF OBTAINING TNF MUTEINE AND PHARMACEUTICAL PREPARATION",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 1183037,
	"label": "MUTEINES OF TUMOR NECROTIC FACTOR /TNF/, DNA SEQUENCE INCLUDING MUTEINE ENCODING DNA, VECTOR, METHOD OF OBTAINING TNF MUTEINE AND PHARMACEUTICAL PREPARATION",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 1183037,
	"label": "MUTEINES OF TUMOR NECROTIC FACTOR /TNF/, DNA SEQUENCE INCLUDING MUTEINE ENCODING DNA, VECTOR, METHOD OF OBTAINING TNF MUTEINE AND PHARMACEUTICAL PREPARATION",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 1184748,
	"label": "NOVEL BOVINE GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR VARIANT",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38065,
	"target": 32734,
	"type": 1187994,
	"label": "MODULATORS OF THE CONSTITUTIVE ADROSTANE RECEPTOR (CAR): SCREENING AND TREATMENT OF HYPERCHOLESTEROLEMIA",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6466,
	"type": 1189059,
	"label": "RETINOIDCARBOXYLSYRE-MONO- OG -DISACCHARIDESTERE, DISSE ESTERE TIL ANVENDELSE SOM LAEGEMIDLER, ISAER TIL BEHANDLING AF NEOPLASI, ACNE ELLER PSORIASIS, FREMGANGSMAADE TIL FREMSTILLING DERAF, FARMACEUTISKE PRAEPARATER INDEHOLDENDE DISSE ESTERE SAMT ANVENDELSE AF ESTERNE TIL FREMSTILLING AF ET MIDDEL TIL BEHANDLING AF NEOPLASI, ACNE ELLER PSORIASIS",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32770,
	"target": 32754,
	"type": 1189446,
	"label": "ANTICUERPO ANTAGONISTA CONTRA LA PROTEINA TIROSINA QUINASA SAL-S1.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 1189446,
	"label": "ANTICUERPO ANTAGONISTA CONTRA LA PROTEINA TIROSINA QUINASA SAL-S1.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32788,
	"target": 32754,
	"type": 1189446,
	"label": "ANTICUERPO ANTAGONISTA CONTRA LA PROTEINA TIROSINA QUINASA SAL-S1.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32754,
	"target": 6795,
	"type": 1189446,
	"label": "ANTICUERPO ANTAGONISTA CONTRA LA PROTEINA TIROSINA QUINASA SAL-S1.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1189446,
	"label": "ANTICUERPO ANTAGONISTA CONTRA LA PROTEINA TIROSINA QUINASA SAL-S1.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 1190220,
	"label": "VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2 alpha -POSITION",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 1192281,
	"label": "Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 1192281,
	"label": "Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 7424,
	"type": 1192281,
	"label": "Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1196577,
	"label": "Mammalian blood loss-induced gene, kd312",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1196577,
	"label": "Mammalian blood loss-induced gene, kd312",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1196577,
	"label": "Mammalian blood loss-induced gene, kd312",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1196577,
	"label": "Mammalian blood loss-induced gene, kd312",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1196577,
	"label": "Mammalian blood loss-induced gene, kd312",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1198613,
	"label": "NOVEL ARMADILLO REPEAT-CONTAINING PROTEIN ALEX1",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1198613,
	"label": "NOVEL ARMADILLO REPEAT-CONTAINING PROTEIN ALEX1",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1198613,
	"label": "NOVEL ARMADILLO REPEAT-CONTAINING PROTEIN ALEX1",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6471,
	"target": 6263,
	"type": 1198652,
	"label": "Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38042,
	"target": 37993,
	"type": 1201618,
	"label": "Antibody against human parathormone related peptides",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 38042,
	"type": 1201618,
	"label": "Antibody against human parathormone related peptides",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1201618,
	"label": "Antibody against human parathormone related peptides",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 1201618,
	"label": "Antibody against human parathormone related peptides",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38042,
	"target": 32779,
	"type": 1201618,
	"label": "Antibody against human parathormone related peptides",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1202355,
	"label": "ANALOGS OF ACIDIC FIBROBLAST GROWTH FACTOR HAVING ENHANCED STABILITY AND BIOLOGICAL ACTIVITY.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1202355,
	"label": "ANALOGS OF ACIDIC FIBROBLAST GROWTH FACTOR HAVING ENHANCED STABILITY AND BIOLOGICAL ACTIVITY.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1202355,
	"label": "ANALOGS OF ACIDIC FIBROBLAST GROWTH FACTOR HAVING ENHANCED STABILITY AND BIOLOGICAL ACTIVITY.",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 1204998,
	"label": "Trombin ile aktiflestirilebilen plazminojen aktiflestiricisi.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1204998,
	"label": "Trombin ile aktiflestirilebilen plazminojen aktiflestiricisi.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 6841,
	"type": 1204998,
	"label": "Trombin ile aktiflestirilebilen plazminojen aktiflestiricisi.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1204998,
	"label": "Trombin ile aktiflestirilebilen plazminojen aktiflestiricisi.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 1204998,
	"label": "Trombin ile aktiflestirilebilen plazminojen aktiflestiricisi.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32788,
	"target": 32620,
	"type": 1210172,
	"label": "HTLV-I / HIV-1 FUSION PROTEINS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 1210172,
	"label": "HTLV-I / HIV-1 FUSION PROTEINS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 32620,
	"type": 1210172,
	"label": "HTLV-I / HIV-1 FUSION PROTEINS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1210232,
	"label": "GLYKOSYLIERUNGS-ENGINEERING VON ANTIKÖRPERN ZUR VERBESSERUNG DER ANTIKÖRPERABHÄNGIGEN ZELLVERMITTELTEN ZYTOTOXIZITÄT",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1210232,
	"label": "GLYKOSYLIERUNGS-ENGINEERING VON ANTIKÖRPERN ZUR VERBESSERUNG DER ANTIKÖRPERABHÄNGIGEN ZELLVERMITTELTEN ZYTOTOXIZITÄT",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 1210232,
	"label": "GLYKOSYLIERUNGS-ENGINEERING VON ANTIKÖRPERN ZUR VERBESSERUNG DER ANTIKÖRPERABHÄNGIGEN ZELLVERMITTELTEN ZYTOTOXIZITÄT",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1210232,
	"label": "GLYKOSYLIERUNGS-ENGINEERING VON ANTIKÖRPERN ZUR VERBESSERUNG DER ANTIKÖRPERABHÄNGIGEN ZELLVERMITTELTEN ZYTOTOXIZITÄT",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 1210232,
	"label": "GLYKOSYLIERUNGS-ENGINEERING VON ANTIKÖRPERN ZUR VERBESSERUNG DER ANTIKÖRPERABHÄNGIGEN ZELLVERMITTELTEN ZYTOTOXIZITÄT",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 31572,
	"target": 6185,
	"type": 1210760,
	"label": "Lxr modulators",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1211267,
	"label": "Transcriptional regulatory factor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1211267,
	"label": "Transcriptional regulatory factor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1211267,
	"label": "Transcriptional regulatory factor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1211267,
	"label": "Transcriptional regulatory factor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1211267,
	"label": "Transcriptional regulatory factor",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1213099,
	"label": "Transgenic mouse hepatitis C virus model comprising a hepatitis C viral fragment",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 1214218,
	"label": "HUMAN MONOCLONAL ANTIBODIES AGAINST OXIDIZED LDL RECEPTOR AND PHARMACEUTICAL USES THEREOF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 1214218,
	"label": "HUMAN MONOCLONAL ANTIBODIES AGAINST OXIDIZED LDL RECEPTOR AND PHARMACEUTICAL USES THEREOF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1214218,
	"label": "HUMAN MONOCLONAL ANTIBODIES AGAINST OXIDIZED LDL RECEPTOR AND PHARMACEUTICAL USES THEREOF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 7424,
	"type": 1214218,
	"label": "HUMAN MONOCLONAL ANTIBODIES AGAINST OXIDIZED LDL RECEPTOR AND PHARMACEUTICAL USES THEREOF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 7424,
	"type": 1214218,
	"label": "HUMAN MONOCLONAL ANTIBODIES AGAINST OXIDIZED LDL RECEPTOR AND PHARMACEUTICAL USES THEREOF",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 1214376,
	"label": "Analogs of cationic proteins like NT-3 (neurotrophin-3) and BDNF (brain derived neurotrophic factor) that are circulated more readily due to a lower isoelectric point and a lower protein charge relative to the native protein",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1214883,
	"label": "Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1214883,
	"label": "Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1214883,
	"label": "Secretion of glycosylated proteins using a tissue plasminogen activator pro-sequence",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1220256,
	"label": "Thrombocytopoiesis stimulating factor",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1222050,
	"label": "Co-administration of a tissue plasminogen activator, anti-CD11b antibody and anti-CD18 antibody in stroke",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 1224622,
	"label": "ANTIKÖRPER GEGEN DENDRITISCHE ZELLEN UND MENSCHLICHE DENDRITISCHE ZELLPOPULATIONEN UND DEREN VERWENDUNGEN",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1225067,
	"label": "Molecules targeting cd40 and tumor cells",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1225067,
	"label": "Molecules targeting cd40 and tumor cells",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1225067,
	"label": "Molecules targeting cd40 and tumor cells",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1225067,
	"label": "Molecules targeting cd40 and tumor cells",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1225067,
	"label": "Molecules targeting cd40 and tumor cells",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 56833,
	"target": 38237,
	"type": 1226327,
	"label": "T2k kinase assays",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1226343,
	"label": "Fibroblast growth factor-like molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1226343,
	"label": "Fibroblast growth factor-like molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1226343,
	"label": "Fibroblast growth factor-like molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1226343,
	"label": "Fibroblast growth factor-like molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1226343,
	"label": "Fibroblast growth factor-like molecules and uses thereof",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32738,
	"target": 32478,
	"type": 1229289,
	"label": "Procedimiento para el tipado de alelos de HLA",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38164,
	"target": 32738,
	"type": 1229289,
	"label": "Procedimiento para el tipado de alelos de HLA",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 1229289,
	"label": "Procedimiento para el tipado de alelos de HLA",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32734,
	"target": 6795,
	"type": 1229899,
	"label": "G PROTEIN COUPLED RECEPTORS",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 1234926,
	"label": "3-methylated vitamin d derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30485,
	"target": 7511,
	"type": 1234926,
	"label": "3-methylated vitamin d derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 1234926,
	"label": "3-methylated vitamin d derivatives",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1235097,
	"label": "INTERLEUKIN II ANALOGS",
	"group": "Amgen",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1235097,
	"label": "INTERLEUKIN II ANALOGS",
	"group": "Amgen",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 1235097,
	"label": "INTERLEUKIN II ANALOGS",
	"group": "Amgen",
	"time": 1989,
	"strength": 1
}, {
	"source": 32788,
	"target": 7510,
	"type": 1235097,
	"label": "INTERLEUKIN II ANALOGS",
	"group": "Amgen",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 7510,
	"type": 1235097,
	"label": "INTERLEUKIN II ANALOGS",
	"group": "Amgen",
	"time": 1989,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 1240000,
	"label": "NEW 17-KDA BRUCELLA ABORTUS ANTIGEN, RECOMBINANT POLYPEPTIDES, NUCLEIC ACIDS FOR CODING FOR THE SAME AND USE THEREOF IN DIAGNOSTIC AND PROPHYLACTIC METHODS AND KITS",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37864,
	"target": 6854,
	"type": 1240000,
	"label": "NEW 17-KDA BRUCELLA ABORTUS ANTIGEN, RECOMBINANT POLYPEPTIDES, NUCLEIC ACIDS FOR CODING FOR THE SAME AND USE THEREOF IN DIAGNOSTIC AND PROPHYLACTIC METHODS AND KITS",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38042,
	"target": 6854,
	"type": 1240000,
	"label": "NEW 17-KDA BRUCELLA ABORTUS ANTIGEN, RECOMBINANT POLYPEPTIDES, NUCLEIC ACIDS FOR CODING FOR THE SAME AND USE THEREOF IN DIAGNOSTIC AND PROPHYLACTIC METHODS AND KITS",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 32769,
	"type": 1240608,
	"label": "Hiperkalsemik krizler için terapötik aktif madde.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1240833,
	"label": "Composições, proteìna, polinucleotìdeo, método de geração de resposta imunológica em mamìferos, método de detecção, composição farmacêutica, anticorpo, animal transgênico não humano, hibridoma, método de fornecimento de agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 1240833,
	"label": "Composições, proteìna, polinucleotìdeo, método de geração de resposta imunológica em mamìferos, método de detecção, composição farmacêutica, anticorpo, animal transgênico não humano, hibridoma, método de fornecimento de agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1240833,
	"label": "Composições, proteìna, polinucleotìdeo, método de geração de resposta imunológica em mamìferos, método de detecção, composição farmacêutica, anticorpo, animal transgênico não humano, hibridoma, método de fornecimento de agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1240833,
	"label": "Composições, proteìna, polinucleotìdeo, método de geração de resposta imunológica em mamìferos, método de detecção, composição farmacêutica, anticorpo, animal transgênico não humano, hibridoma, método de fornecimento de agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 1240833,
	"label": "Composições, proteìna, polinucleotìdeo, método de geração de resposta imunológica em mamìferos, método de detecção, composição farmacêutica, anticorpo, animal transgênico não humano, hibridoma, método de fornecimento de agente citotóxico ou agente de diagnóstico e método de inibição do crescimento de células cancerosas",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 1241518,
	"label": "POLIPEPTIDO DE ORIGEN NO NATURAL QUE TIENE LA ACTIVIDAD DEL FACTOR RECOMBINANTE DE ESTIMULACION DEL RECEPTOR NEU Y PROCESO PARA LA PRODUCCION DEL MIS MO.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 1241518,
	"label": "POLIPEPTIDO DE ORIGEN NO NATURAL QUE TIENE LA ACTIVIDAD DEL FACTOR RECOMBINANTE DE ESTIMULACION DEL RECEPTOR NEU Y PROCESO PARA LA PRODUCCION DEL MIS MO.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1241518,
	"label": "POLIPEPTIDO DE ORIGEN NO NATURAL QUE TIENE LA ACTIVIDAD DEL FACTOR RECOMBINANTE DE ESTIMULACION DEL RECEPTOR NEU Y PROCESO PARA LA PRODUCCION DEL MIS MO.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1242144,
	"label": "Monoclonal antibodies to leukemia inhibitory factor and their use in immunoassays",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1243073,
	"label": "Reaktionsbeutelvorrichtung zur Durchführung von mehrstufigen Kultivierungs/Separations-Vorgängen und/oder Reaktionen",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1246266,
	"label": "Pharmaceutical compositions containing an mpl ligand.",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1246417,
	"label": "Cell-based drug screens for regulators of gene expression",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38071,
	"target": 37986,
	"type": 1246603,
	"label": "METHOD OF GENE TRANSFER INTO CHICKENS AND OTHER AVIAN SPECIES.",
	"group": "Amgen",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 38004,
	"type": 1246981,
	"label": "PHARMACEUTICAL PREPARATION FOR TREATMENT OF THROMBOCYTOPENIC OR PLATELET FUNCTION-DEFICIENT DISEASE",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38004,
	"target": 6795,
	"type": 1246981,
	"label": "PHARMACEUTICAL PREPARATION FOR TREATMENT OF THROMBOCYTOPENIC OR PLATELET FUNCTION-DEFICIENT DISEASE",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1246981,
	"label": "PHARMACEUTICAL PREPARATION FOR TREATMENT OF THROMBOCYTOPENIC OR PLATELET FUNCTION-DEFICIENT DISEASE",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 7507,
	"target": 6484,
	"type": 1249528,
	"label": "HUMAN INTERLEUKIN-6 RECEPTOR-DEVELOPING INHIBITOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1249528,
	"label": "HUMAN INTERLEUKIN-6 RECEPTOR-DEVELOPING INHIBITOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 6484,
	"type": 1249528,
	"label": "HUMAN INTERLEUKIN-6 RECEPTOR-DEVELOPING INHIBITOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 1251140,
	"label": "ANTI-INTEGRIN  alpha 3 ANTIBODY COMPLEXES",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 6957,
	"target": 6816,
	"type": 1251140,
	"label": "ANTI-INTEGRIN  alpha 3 ANTIBODY COMPLEXES",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 6957,
	"target": 6795,
	"type": 1251140,
	"label": "ANTI-INTEGRIN  alpha 3 ANTIBODY COMPLEXES",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 1251140,
	"label": "ANTI-INTEGRIN  alpha 3 ANTIBODY COMPLEXES",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 6957,
	"type": 1251140,
	"label": "ANTI-INTEGRIN  alpha 3 ANTIBODY COMPLEXES",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 6471,
	"target": 6352,
	"type": 1252988,
	"label": "Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6352,
	"target": 6229,
	"type": 1252988,
	"label": "Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6471,
	"target": 6229,
	"type": 1252988,
	"label": "Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6841,
	"target": 6471,
	"type": 1252988,
	"label": "Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6841,
	"target": 6352,
	"type": 1252988,
	"label": "Método de fornecimento de um agente ativo a um tipo celular de interesse, composição farmacêutica, pró-droga ativada por caspase, kit, método de tratamento de mamìferos, uso de um conjugado de caspase e uso de um pró-agente",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31580,
	"target": 31570,
	"type": 1256239,
	"label": "SUBSTITUTED AMINOSPIROTHIAZINES",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1258835,
	"label": "APOLIPOPROTEIN-A-I REGULATION OF T-CELL SIGNALLING",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 1258835,
	"label": "APOLIPOPROTEIN-A-I REGULATION OF T-CELL SIGNALLING",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1258835,
	"label": "APOLIPOPROTEIN-A-I REGULATION OF T-CELL SIGNALLING",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 29057,
	"target": 7409,
	"type": 1260159,
	"label": "2,3-DIHYDROXYPHENYL(CARBONYL)ALKOXY SUBSTITUTED NAPHTHALENE-CARBOXYLIC AND -ACETIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 1261151,
	"label": "FACTORES BIOLOGICOS CON ACTIVIDAD BIOLOGICA MEJOR ADA, A BASE DE COPOLIMEROS DE POLIOXIMETILENO-OXIETILENO EN CONJUNCION CON BIOMOLECULAS.",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 1264933,
	"label": "AP0-2LI and APO-3 apoptosis polypeptides",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32779,
	"target": 6812,
	"type": 1264933,
	"label": "AP0-2LI and APO-3 apoptosis polypeptides",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 6812,
	"type": 1264933,
	"label": "AP0-2LI and APO-3 apoptosis polypeptides",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1267664,
	"label": "Method of preventing acute rejection following solid organ transplantation",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37993,
	"target": 32772,
	"type": 1268432,
	"label": "Anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56836,
	"target": 37993,
	"type": 1268432,
	"label": "Anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56836,
	"target": 32772,
	"type": 1268432,
	"label": "Anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31580,
	"target": 6241,
	"type": 1268680,
	"label": "PHARMACEUTICAL COMPOSITIONS COMPRISING 3,5-DIHYDROXY-7-(1-ACYLOXYHEXAHYDRONAPHTH-8-YL)-HEPTANOIC ACID AND LACTONE DERIVATIVES",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1270135,
	"label": "Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1270135,
	"label": "Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1270135,
	"label": "Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 1270135,
	"label": "Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37862,
	"type": 1270135,
	"label": "Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet.",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32700,
	"target": 32697,
	"type": 1270596,
	"label": "STABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIOSTABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIONS AND METHODS                                    NS AND METHODS",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 6961,
	"target": 6957,
	"type": 1270596,
	"label": "STABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIOSTABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIONS AND METHODS                                    NS AND METHODS",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 6957,
	"target": 6795,
	"type": 1270596,
	"label": "STABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIOSTABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIONS AND METHODS                                    NS AND METHODS",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 6961,
	"target": 6795,
	"type": 1270596,
	"label": "STABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIOSTABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIONS AND METHODS                                    NS AND METHODS",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7508,
	"target": 6961,
	"type": 1270596,
	"label": "STABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIOSTABLE N-TERMINALLY LINKED DTPA:PROTEIN COMPOSITIONS AND METHODS                                    NS AND METHODS",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 32788,
	"target": 32698,
	"type": 1271192,
	"label": "PROCESSO PARA A PREPARACAO DE PROTEINAS HIBRIDAS DA INTERLEUCEMIA -2 RECOMBINANTE E DE COMPOSICOES FARMACEUTICAS QUE AS CONTEM",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 1271192,
	"label": "PROCESSO PARA A PREPARACAO DE PROTEINAS HIBRIDAS DA INTERLEUCEMIA -2 RECOMBINANTE E DE COMPOSICOES FARMACEUTICAS QUE AS CONTEM",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 1271192,
	"label": "PROCESSO PARA A PREPARACAO DE PROTEINAS HIBRIDAS DA INTERLEUCEMIA -2 RECOMBINANTE E DE COMPOSICOES FARMACEUTICAS QUE AS CONTEM",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37864,
	"target": 32698,
	"type": 1271192,
	"label": "PROCESSO PARA A PREPARACAO DE PROTEINAS HIBRIDAS DA INTERLEUCEMIA -2 RECOMBINANTE E DE COMPOSICOES FARMACEUTICAS QUE AS CONTEM",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32698,
	"target": 7510,
	"type": 1271192,
	"label": "PROCESSO PARA A PREPARACAO DE PROTEINAS HIBRIDAS DA INTERLEUCEMIA -2 RECOMBINANTE E DE COMPOSICOES FARMACEUTICAS QUE AS CONTEM",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1271489,
	"label": "Methods for regulating protein conformation using molecular chaperones",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1271489,
	"label": "Methods for regulating protein conformation using molecular chaperones",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 1271489,
	"label": "Methods for regulating protein conformation using molecular chaperones",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 1271489,
	"label": "Methods for regulating protein conformation using molecular chaperones",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1271489,
	"label": "Methods for regulating protein conformation using molecular chaperones",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1278908,
	"label": "Delta-related polypeptides",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 1278908,
	"label": "Delta-related polypeptides",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37859,
	"type": 1278908,
	"label": "Delta-related polypeptides",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 1280751,
	"label": "Vitamin d derivatives",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 1280751,
	"label": "Vitamin d derivatives",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 1280751,
	"label": "Vitamin d derivatives",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1282148,
	"label": "Receptor specific brain natriuretic peptide (bnp)",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1282148,
	"label": "Receptor specific brain natriuretic peptide (bnp)",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1282148,
	"label": "Receptor specific brain natriuretic peptide (bnp)",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37859,
	"target": 6795,
	"type": 1282148,
	"label": "Receptor specific brain natriuretic peptide (bnp)",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 1282148,
	"label": "Receptor specific brain natriuretic peptide (bnp)",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1283779,
	"label": "Angiogeneesin inhibitio käyttämällä interleukiini-12:ta",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1284211,
	"label": "Differentiation regulatory factor expressed specifically in testis",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 1284211,
	"label": "Differentiation regulatory factor expressed specifically in testis",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 1284211,
	"label": "Differentiation regulatory factor expressed specifically in testis",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1285737,
	"label": "Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos  isolados",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1285737,
	"label": "Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos  isolados",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 1285737,
	"label": "Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos  isolados",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1285737,
	"label": "Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos  isolados",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1285737,
	"label": "Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos  isolados",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1288503,
	"label": "NOVEL CHIMPANZEE ERYTHROPOIETIN (CHEPO) POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 1288503,
	"label": "NOVEL CHIMPANZEE ERYTHROPOIETIN (CHEPO) POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1288503,
	"label": "NOVEL CHIMPANZEE ERYTHROPOIETIN (CHEPO) POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6854,
	"target": 6229,
	"type": 1289624,
	"label": "TRATAMIENTO CON ANTICUERPOS ANTI-ERBB2.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1289624,
	"label": "TRATAMIENTO CON ANTICUERPOS ANTI-ERBB2.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 1289624,
	"label": "TRATAMIENTO CON ANTICUERPOS ANTI-ERBB2.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 1289624,
	"label": "TRATAMIENTO CON ANTICUERPOS ANTI-ERBB2.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32772,
	"target": 6854,
	"type": 1289624,
	"label": "TRATAMIENTO CON ANTICUERPOS ANTI-ERBB2.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 1292150,
	"label": "Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 1292150,
	"label": "Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 7358,
	"target": 6795,
	"type": 1292150,
	"label": "Ifn-con qumicamente modificado composição farmacêutica preparação processo de tratamento de um paciente possuindo uma condição tratável com ifn-con e processo de liberação de um interferon",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1292300,
	"label": "Diagnostic method for detection of placental-derived prostate growth factors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1292300,
	"label": "Diagnostic method for detection of placental-derived prostate growth factors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1292300,
	"label": "Diagnostic method for detection of placental-derived prostate growth factors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1292300,
	"label": "Diagnostic method for detection of placental-derived prostate growth factors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 1292300,
	"label": "Diagnostic method for detection of placental-derived prostate growth factors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1292480,
	"label": "Immunoassay of anti-hm1.24 antibody",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38042,
	"target": 37947,
	"type": 1293821,
	"label": "Subtilisin variants capable of cleaving substrates containing dibasic residues",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 6909,
	"target": 6854,
	"type": 1294188,
	"label": "IMMUNOSUPPRESSIVE AGENT",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37996,
	"target": 6795,
	"type": 1296112,
	"label": "A PROTEIN WITH AN AMINO ACID SEQUENCE IDENTITY OF ABOUT 26% RELATIVE TO HUMAN GROWTH HORMONE AND ABOUT 67% RELATIVE TO BOVINE PLACENTAL LACTOGEN; NUCLEIC ACID ENCODING IT, CELL-LINES AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7509,
	"target": 6502,
	"type": 1299828,
	"label": "COMBINATIONS OF ANTI-TISSUE FACTOR ANTIBODIES AND ANTICOAGULANT AND/OR ANTIPLATELET AGENTS.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1299828,
	"label": "COMBINATIONS OF ANTI-TISSUE FACTOR ANTIBODIES AND ANTICOAGULANT AND/OR ANTIPLATELET AGENTS.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7509,
	"type": 1299828,
	"label": "COMBINATIONS OF ANTI-TISSUE FACTOR ANTIBODIES AND ANTICOAGULANT AND/OR ANTIPLATELET AGENTS.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 6502,
	"type": 1299828,
	"label": "COMBINATIONS OF ANTI-TISSUE FACTOR ANTIBODIES AND ANTICOAGULANT AND/OR ANTIPLATELET AGENTS.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 7509,
	"type": 1299828,
	"label": "COMBINATIONS OF ANTI-TISSUE FACTOR ANTIBODIES AND ANTICOAGULANT AND/OR ANTIPLATELET AGENTS.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 1299945,
	"label": "Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 1299945,
	"label": "Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1299945,
	"label": "Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 1299945,
	"label": "Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 32772,
	"type": 1299945,
	"label": "Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1301759,
	"label": "IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1301759,
	"label": "IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1301759,
	"label": "IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 1301759,
	"label": "IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 1301759,
	"label": "IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7425,
	"target": 7424,
	"type": 1303613,
	"label": "Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 1306775,
	"label": "METHOD OF PREPARING A HETEROMULTIMER POLYPEPTIDE HAVING TWO POLYPEPTIDES MEETING AT AN INTERFACE; THE FIRST POLYPEPTIDE CONTAINING A PROTUBERANCE AND/OR THE SECOND POLYPEPTIDE CONTAINING A CAVITY WHICH FITS TOGETHER",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 1306775,
	"label": "METHOD OF PREPARING A HETEROMULTIMER POLYPEPTIDE HAVING TWO POLYPEPTIDES MEETING AT AN INTERFACE; THE FIRST POLYPEPTIDE CONTAINING A PROTUBERANCE AND/OR THE SECOND POLYPEPTIDE CONTAINING A CAVITY WHICH FITS TOGETHER",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1306775,
	"label": "METHOD OF PREPARING A HETEROMULTIMER POLYPEPTIDE HAVING TWO POLYPEPTIDES MEETING AT AN INTERFACE; THE FIRST POLYPEPTIDE CONTAINING A PROTUBERANCE AND/OR THE SECOND POLYPEPTIDE CONTAINING A CAVITY WHICH FITS TOGETHER",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 1306775,
	"label": "METHOD OF PREPARING A HETEROMULTIMER POLYPEPTIDE HAVING TWO POLYPEPTIDES MEETING AT AN INTERFACE; THE FIRST POLYPEPTIDE CONTAINING A PROTUBERANCE AND/OR THE SECOND POLYPEPTIDE CONTAINING A CAVITY WHICH FITS TOGETHER",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1306775,
	"label": "METHOD OF PREPARING A HETEROMULTIMER POLYPEPTIDE HAVING TWO POLYPEPTIDES MEETING AT AN INTERFACE; THE FIRST POLYPEPTIDE CONTAINING A PROTUBERANCE AND/OR THE SECOND POLYPEPTIDE CONTAINING A CAVITY WHICH FITS TOGETHER",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1306997,
	"label": "Nucleic acids encoding ligands for HEK4 receptors",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1306997,
	"label": "Nucleic acids encoding ligands for HEK4 receptors",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1306997,
	"label": "Nucleic acids encoding ligands for HEK4 receptors",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 7409,
	"type": 1306997,
	"label": "Nucleic acids encoding ligands for HEK4 receptors",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 7409,
	"type": 1306997,
	"label": "Nucleic acids encoding ligands for HEK4 receptors",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1308281,
	"label": "A process for amplifying DNA using a thermostable DNA polymerase from Anaerocellum thermophilum characterised in that it works in the presence of magnesium ions and the absence of manganese ions",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1308281,
	"label": "A process for amplifying DNA using a thermostable DNA polymerase from Anaerocellum thermophilum characterised in that it works in the presence of magnesium ions and the absence of manganese ions",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1308281,
	"label": "A process for amplifying DNA using a thermostable DNA polymerase from Anaerocellum thermophilum characterised in that it works in the presence of magnesium ions and the absence of manganese ions",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38004,
	"target": 37986,
	"type": 1308319,
	"label": "MODIFIZIERTES CYTOKIN FÜR SEINE STABILIZIERUNG",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 38004,
	"type": 1308319,
	"label": "MODIFIZIERTES CYTOKIN FÜR SEINE STABILIZIERUNG",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1308319,
	"label": "MODIFIZIERTES CYTOKIN FÜR SEINE STABILIZIERUNG",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 1308319,
	"label": "MODIFIZIERTES CYTOKIN FÜR SEINE STABILIZIERUNG",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38004,
	"target": 32698,
	"type": 1308319,
	"label": "MODIFIZIERTES CYTOKIN FÜR SEINE STABILIZIERUNG",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7425,
	"target": 6376,
	"type": 1308494,
	"label": "PHARMACEUTICAL AGENTS CONTAINING METHOTREXATE DERIVATIVES",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 1309048,
	"label": "Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 6471,
	"type": 1309048,
	"label": "Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56836,
	"target": 6471,
	"type": 1309048,
	"label": "Anticorpo isolado, composição, ácido nucleico, vetor, célula hospedeira, método para fazer um anticorpo anti-erbb2, método para a determinação da presença de erbb2, kit, método paa a indução da morte celular e artigo manufaturado",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1310685,
	"label": "PROTEINA RECEPTORA DE HEMATOPOYETINA NOVEDOSA, NR10.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1310685,
	"label": "PROTEINA RECEPTORA DE HEMATOPOYETINA NOVEDOSA, NR10.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 1310685,
	"label": "PROTEINA RECEPTORA DE HEMATOPOYETINA NOVEDOSA, NR10.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1310685,
	"label": "PROTEINA RECEPTORA DE HEMATOPOYETINA NOVEDOSA, NR10.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1310685,
	"label": "PROTEINA RECEPTORA DE HEMATOPOYETINA NOVEDOSA, NR10.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1311409,
	"label": "TISSUE FACTOR PROTEIN VARIANTS WITH INCREASED AFFINITY FOR COAGULATION FACTOR FVII/FVIIA",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6838,
	"target": 6795,
	"type": 1313853,
	"label": "Nucleic acid encoding human signal transducer and activator of transcription 4",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6838,
	"type": 1313853,
	"label": "Nucleic acid encoding human signal transducer and activator of transcription 4",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1313853,
	"label": "Nucleic acid encoding human signal transducer and activator of transcription 4",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 1314503,
	"label": "METHOD FOR PREVENTING OR TREATING LIVER DISEASE",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1320387,
	"label": "Novel bHLH type transcription factor genes DEC2",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1320387,
	"label": "Novel bHLH type transcription factor genes DEC2",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1320387,
	"label": "Novel bHLH type transcription factor genes DEC2",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 1320967,
	"label": "THIENOTRIAZOLODIAZEPINE DERIVATIVES, PREPARATION, INTERMEDIATES AND PHARMACEUTICAL COMPOSITIONS THEREOF",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1321295,
	"label": "Polynucleotides encoding a telomerase component TP2",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 1321295,
	"label": "Polynucleotides encoding a telomerase component TP2",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37862,
	"target": 6854,
	"type": 1321295,
	"label": "Polynucleotides encoding a telomerase component TP2",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 1321295,
	"label": "Polynucleotides encoding a telomerase component TP2",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 1321295,
	"label": "Polynucleotides encoding a telomerase component TP2",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1321581,
	"label": "RECOMBINED OBESITY PROTEINS (OB), FUSION PROTEINS, EXPRESSION VECTORS, SEQUENTIAL DNAS, TRANSFORMED E, COLLIE CELLS, METHOD OF OBTAINING RECOMBINED HUMAN OR MOUSE'S OBESITY PROTEIN AND PHARMACEUTIC COMPOSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1321581,
	"label": "RECOMBINED OBESITY PROTEINS (OB), FUSION PROTEINS, EXPRESSION VECTORS, SEQUENTIAL DNAS, TRANSFORMED E, COLLIE CELLS, METHOD OF OBTAINING RECOMBINED HUMAN OR MOUSE'S OBESITY PROTEIN AND PHARMACEUTIC COMPOSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1321581,
	"label": "RECOMBINED OBESITY PROTEINS (OB), FUSION PROTEINS, EXPRESSION VECTORS, SEQUENTIAL DNAS, TRANSFORMED E, COLLIE CELLS, METHOD OF OBTAINING RECOMBINED HUMAN OR MOUSE'S OBESITY PROTEIN AND PHARMACEUTIC COMPOSITION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 1321840,
	"label": "'PATCHED-2' PROTEIN AUS WIRBELTIEREN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37862,
	"target": 32788,
	"type": 1321840,
	"label": "'PATCHED-2' PROTEIN AUS WIRBELTIEREN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 1321840,
	"label": "'PATCHED-2' PROTEIN AUS WIRBELTIEREN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 56834,
	"target": 37887,
	"type": 1322958,
	"label": "VERFAHREN ZUM SCREENEN VON POTENZIELLEN VERBINDUNGEN FÜR DAS AUFFINDEN VON EINEM ANTI- TUMOR-ARZNEISTOFF",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 1323619,
	"label": "ACTIN-RESISTANT VARIANTS OF HUMAN DNase I, NUCLEIC ACIDS ENCODING SUCH VARIANTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7409,
	"target": 6841,
	"type": 1323619,
	"label": "ACTIN-RESISTANT VARIANTS OF HUMAN DNase I, NUCLEIC ACIDS ENCODING SUCH VARIANTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 1323619,
	"label": "ACTIN-RESISTANT VARIANTS OF HUMAN DNase I, NUCLEIC ACIDS ENCODING SUCH VARIANTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 7409,
	"type": 1323619,
	"label": "ACTIN-RESISTANT VARIANTS OF HUMAN DNase I, NUCLEIC ACIDS ENCODING SUCH VARIANTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 1323619,
	"label": "ACTIN-RESISTANT VARIANTS OF HUMAN DNase I, NUCLEIC ACIDS ENCODING SUCH VARIANTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE THEREOF IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37999,
	"target": 32694,
	"type": 1327390,
	"label": "Gene of factor strenthening coding cell with large nucleus",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1327390,
	"label": "Gene of factor strenthening coding cell with large nucleus",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37999,
	"target": 6795,
	"type": 1327390,
	"label": "Gene of factor strenthening coding cell with large nucleus",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1328440,
	"label": "Peptide suppressing I kappa B alpha  phosphorylation",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32769,
	"target": 7511,
	"type": 1330419,
	"label": "THERAPEUTIC AGENT FOR DISEASES CAUSED BY PTH OR PTHRP",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 1332089,
	"label": "5,6- i TRANS /i -2-ALKYLVITAMIN D DERIVATIVES",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1333112,
	"label": "Chemeric human interferon-z                       receptor/immunoglobulin polypeptides, dna         sequences coding for these polypeptides and their production",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1333112,
	"label": "Chemeric human interferon-z                       receptor/immunoglobulin polypeptides, dna         sequences coding for these polypeptides and their production",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1333112,
	"label": "Chemeric human interferon-z                       receptor/immunoglobulin polypeptides, dna         sequences coding for these polypeptides and their production",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56833,
	"target": 6795,
	"type": 1333769,
	"label": "A NOVEL EUKARYOTIC TRANSCRIPTION PROTEIN: HOST CELL FACTOR",
	"group": "Amgen",
	"time": 1993,
	"strength": 1
}, {
	"source": 32769,
	"target": 6795,
	"type": 1335229,
	"label": "UNA MUTEINA OB, UNA SECUENCIA DE ADN, UN VECTOR DE EXPRESION UNA CELULA HOSPEDADORA PROCARIOTA O DE MAMIFERO, UN BACULOVIRUS RECOMBINANTE, UNA CELULAHOSPEDADORA, UN METODO PARA LA PRODUCCION DE UNA MUTEINA OB, UNA COMPOSICION FARMACEUTICA, EL USO DE UNA PROTEINA OB PARA LA PREPARACION DE UNA COMPOSI",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1335832,
	"label": "Junctional adhesion molecule (jam), a transmembrane protein of tight junctions",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1335832,
	"label": "Junctional adhesion molecule (jam), a transmembrane protein of tight junctions",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 1335832,
	"label": "Junctional adhesion molecule (jam), a transmembrane protein of tight junctions",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1335832,
	"label": "Junctional adhesion molecule (jam), a transmembrane protein of tight junctions",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1335832,
	"label": "Junctional adhesion molecule (jam), a transmembrane protein of tight junctions",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32788,
	"target": 32777,
	"type": 1338219,
	"label": "METHOD FOR MEASURING AUTO IMMUNE DISEASE ASSOCIATED ANTIGEN",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 1338219,
	"label": "METHOD FOR MEASURING AUTO IMMUNE DISEASE ASSOCIATED ANTIGEN",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 1338219,
	"label": "METHOD FOR MEASURING AUTO IMMUNE DISEASE ASSOCIATED ANTIGEN",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 1338219,
	"label": "METHOD FOR MEASURING AUTO IMMUNE DISEASE ASSOCIATED ANTIGEN",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 56836,
	"target": 32788,
	"type": 1338219,
	"label": "METHOD FOR MEASURING AUTO IMMUNE DISEASE ASSOCIATED ANTIGEN",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 6795,
	"target": 6483,
	"type": 1340537,
	"label": "IDENTIFICATION OF MODULATORS OF THE INTERFERON GAMMA SIGNALING PATHWAY AND THEIR USE IN RESTENOSIS TREATMENT",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1341039,
	"label": "Glucagon antagonists",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1341039,
	"label": "Glucagon antagonists",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1341039,
	"label": "Glucagon antagonists",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1341119,
	"label": "Transgenic non-human animals for producing specific isotypes of human antibodies via non-cognate switch regions",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1341119,
	"label": "Transgenic non-human animals for producing specific isotypes of human antibodies via non-cognate switch regions",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 38065,
	"type": 1341119,
	"label": "Transgenic non-human animals for producing specific isotypes of human antibodies via non-cognate switch regions",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 1341119,
	"label": "Transgenic non-human animals for producing specific isotypes of human antibodies via non-cognate switch regions",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1341119,
	"label": "Transgenic non-human animals for producing specific isotypes of human antibodies via non-cognate switch regions",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1342546,
	"label": "COMPUESTOS DERIVADOS DE AMINOACIDOS, SU USO, PROCEDIMIENTO DE FABRICACION, MEDICAMENTOS QUE LOS CONTIENEN Y ACETALES Y DIOXABOROLANOS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37893,
	"type": 1343244,
	"label": "Method for preparing cell fraction containing hematopoietic stem cells",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32772,
	"target": 32754,
	"type": 1343250,
	"label": "METHODS AND COMPOSITIONS FOR DETERMINING HER-2/NEUMETHODS AND COMPOSITIONS FOR DETERMINING HER-2/NEU EXPRESSION                                        EXPRESSION",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1343533,
	"label": "Hvem polypeptides and uses thereof",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1343533,
	"label": "Hvem polypeptides and uses thereof",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1343533,
	"label": "Hvem polypeptides and uses thereof",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1343533,
	"label": "Hvem polypeptides and uses thereof",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1343533,
	"label": "Hvem polypeptides and uses thereof",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38004,
	"target": 37864,
	"type": 1343901,
	"label": "NUCLEIC ACIDS ENCODING PROCESSED POLYPEPTIDES WITH IL-16 ACTIVITY, PREPARATIONS CONTAINING SAID POLYPEPTIDES, PROCESSES FOR THEIR PRODUCTION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 32698,
	"type": 1343901,
	"label": "NUCLEIC ACIDS ENCODING PROCESSED POLYPEPTIDES WITH IL-16 ACTIVITY, PREPARATIONS CONTAINING SAID POLYPEPTIDES, PROCESSES FOR THEIR PRODUCTION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38004,
	"target": 32698,
	"type": 1343901,
	"label": "NUCLEIC ACIDS ENCODING PROCESSED POLYPEPTIDES WITH IL-16 ACTIVITY, PREPARATIONS CONTAINING SAID POLYPEPTIDES, PROCESSES FOR THEIR PRODUCTION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 1343901,
	"label": "NUCLEIC ACIDS ENCODING PROCESSED POLYPEPTIDES WITH IL-16 ACTIVITY, PREPARATIONS CONTAINING SAID POLYPEPTIDES, PROCESSES FOR THEIR PRODUCTION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1343901,
	"label": "NUCLEIC ACIDS ENCODING PROCESSED POLYPEPTIDES WITH IL-16 ACTIVITY, PREPARATIONS CONTAINING SAID POLYPEPTIDES, PROCESSES FOR THEIR PRODUCTION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37996,
	"target": 32708,
	"type": 1345728,
	"label": "Glycoprotein hormone family member",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 32708,
	"target": 6795,
	"type": 1345728,
	"label": "Glycoprotein hormone family member",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37996,
	"target": 6795,
	"type": 1345728,
	"label": "Glycoprotein hormone family member",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 31939,
	"target": 6290,
	"type": 1348034,
	"label": "1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 1350111,
	"label": "Modifizierte Phytasen",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6133,
	"type": 1350521,
	"label": "A METHOD OF USING A TETRAHYDRONAPHTHALENE DERIVATIVE FOR THE TREATMENT OR PREVENTION OF PRECANCEROSES AND BENIGN AND MALIGNANT TUMOURS OF EPITHELIAL AND MESENCHYMAL NATURE",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32440,
	"target": 6471,
	"type": 1352100,
	"label": "Tetracyclic compounds, processes for their preparation, their use and pharmaceutical compositions.",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 37893,
	"target": 37887,
	"type": 1353246,
	"label": "Lymphotoxin and thrombopoietin for use in the treatment of cancer.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37864,
	"target": 32478,
	"type": 1354009,
	"label": "Muteína, sequência de DNA, vetor, célula, sequência de RNA composto, processo para sua preparação, composição farmacêutica e uso.",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1355438,
	"label": "PLATELET AGGREGATION INHIBITORS AND RELATED MOLECULES",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1356353,
	"label": "Antagonistas de cd40 para uso em tratamento de psorìase e outras condições inflamatórias de pele",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 32694,
	"type": 1356545,
	"label": "Forbindelse med modifiserte peptider, DNA, ekspresjonsvektor, vertscelle og farmasoytisk preparat, anvendelse av forbindelsene og fremgangsmate for fremstilling av en farmakologisk aktiv forbindelse",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1357855,
	"label": "Polynucleotides having ABC1 promoter activity, recombinant vectors, host cells and kits comprising the same, and method for screening a test compound of ABC1 expression modulating activity",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1357855,
	"label": "Polynucleotides having ABC1 promoter activity, recombinant vectors, host cells and kits comprising the same, and method for screening a test compound of ABC1 expression modulating activity",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1357855,
	"label": "Polynucleotides having ABC1 promoter activity, recombinant vectors, host cells and kits comprising the same, and method for screening a test compound of ABC1 expression modulating activity",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1357855,
	"label": "Polynucleotides having ABC1 promoter activity, recombinant vectors, host cells and kits comprising the same, and method for screening a test compound of ABC1 expression modulating activity",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1357855,
	"label": "Polynucleotides having ABC1 promoter activity, recombinant vectors, host cells and kits comprising the same, and method for screening a test compound of ABC1 expression modulating activity",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 1364079,
	"label": "ANTI-SELECTING ANTIBODIES FOR PREVENTING A MULTIORGAN INSUFFICIENCY CAUSED BY A MULTIORGAN LESION AND FOR PREWVENTING ACTUE MULTIORGAN LESIONS RESULTING FROM APPLIANCE OF EXTRACORPOREAL CIRCULATION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32770,
	"target": 7409,
	"type": 1364079,
	"label": "ANTI-SELECTING ANTIBODIES FOR PREVENTING A MULTIORGAN INSUFFICIENCY CAUSED BY A MULTIORGAN LESION AND FOR PREWVENTING ACTUE MULTIORGAN LESIONS RESULTING FROM APPLIANCE OF EXTRACORPOREAL CIRCULATION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1364079,
	"label": "ANTI-SELECTING ANTIBODIES FOR PREVENTING A MULTIORGAN INSUFFICIENCY CAUSED BY A MULTIORGAN LESION AND FOR PREWVENTING ACTUE MULTIORGAN LESIONS RESULTING FROM APPLIANCE OF EXTRACORPOREAL CIRCULATION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32772,
	"target": 32754,
	"type": 1366046,
	"label": "UN PROCEDIMIENTO PARA LA PREPARACION DE ANTICUERPOS ESPECIFICOS PARA UNO DE LOS MIEMBROS DE LA FAMILIA P 2 DE PROTEINAS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 56836,
	"target": 32772,
	"type": 1366046,
	"label": "UN PROCEDIMIENTO PARA LA PREPARACION DE ANTICUERPOS ESPECIFICOS PARA UNO DE LOS MIEMBROS DE LA FAMILIA P 2 DE PROTEINAS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 56836,
	"target": 32754,
	"type": 1366046,
	"label": "UN PROCEDIMIENTO PARA LA PREPARACION DE ANTICUERPOS ESPECIFICOS PARA UNO DE LOS MIEMBROS DE LA FAMILIA P 2 DE PROTEINAS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 56833,
	"target": 38237,
	"type": 1367893,
	"label": "VERFAHREN ZUM SCREENEN VON VERBINDUNGEN, DIE DIE PRODUKTION VON ENTZÜNDUNGSZYTOKINEN INHIBIEREN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38237,
	"target": 6795,
	"type": 1367893,
	"label": "VERFAHREN ZUM SCREENEN VON VERBINDUNGEN, DIE DIE PRODUKTION VON ENTZÜNDUNGSZYTOKINEN INHIBIEREN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 56833,
	"target": 6795,
	"type": 1367893,
	"label": "VERFAHREN ZUM SCREENEN VON VERBINDUNGEN, DIE DIE PRODUKTION VON ENTZÜNDUNGSZYTOKINEN INHIBIEREN",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1368173,
	"label": "PHARMACEUTICAL COMPOSITIONS INCLUDING VARIANTS OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR HAVING ALTERERD PHARMACOLOGICAL PROPERTIES",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 1368822,
	"label": "Bak promotor expression system",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 1371888,
	"label": "Interleukin-1 receptor-associated protein kinase and assays",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 7510,
	"type": 1371888,
	"label": "Interleukin-1 receptor-associated protein kinase and assays",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1371888,
	"label": "Interleukin-1 receptor-associated protein kinase and assays",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 6854,
	"target": 6484,
	"type": 1372031,
	"label": "Purificação ou\e concentração de dna através de separação por filtração de fluxo cruzado de endotoxinas de uma preparação de ácidos nucléicos",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1373556,
	"label": "Hepatocyte growth factor receptor antagonist antibodies and uses thereof",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1373556,
	"label": "Hepatocyte growth factor receptor antagonist antibodies and uses thereof",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1373556,
	"label": "Hepatocyte growth factor receptor antagonist antibodies and uses thereof",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1373972,
	"label": "Processo contìnuo de fermentação",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1373972,
	"label": "Processo contìnuo de fermentação",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1373972,
	"label": "Processo contìnuo de fermentação",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 1375161,
	"label": "Anti-ige gene therapy",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37875,
	"target": 6550,
	"type": 1375598,
	"label": "NOVEL CELL LINE AND SCREENING METHOD WITH THE USE OF THE SAME",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1376049,
	"label": "TRANSGENIC MAMMALS AS MODELS FOR THROMBOCYTOPENIA AND/OR MEGAKARYOCYTE LEUKEMIA.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1376049,
	"label": "TRANSGENIC MAMMALS AS MODELS FOR THROMBOCYTOPENIA AND/OR MEGAKARYOCYTE LEUKEMIA.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 1376049,
	"label": "TRANSGENIC MAMMALS AS MODELS FOR THROMBOCYTOPENIA AND/OR MEGAKARYOCYTE LEUKEMIA.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32595,
	"type": 1376049,
	"label": "TRANSGENIC MAMMALS AS MODELS FOR THROMBOCYTOPENIA AND/OR MEGAKARYOCYTE LEUKEMIA.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32595,
	"type": 1376049,
	"label": "TRANSGENIC MAMMALS AS MODELS FOR THROMBOCYTOPENIA AND/OR MEGAKARYOCYTE LEUKEMIA.",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 1378725,
	"label": "OB PROTEIN COMPOSITIONS AND METHODS",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1378849,
	"label": "Cytochrome C and polynucleotides encoding cytochrome C",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1379244,
	"label": "ANTIGENIC PROTEIN SPECIFIC FOR BLOOD-PROPAGATED NON-A NON-B HEPATITIS, DNA WICH CODES FOR SAID PROTEIN, AND METHOD OF PRODUCING SAID PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1379244,
	"label": "ANTIGENIC PROTEIN SPECIFIC FOR BLOOD-PROPAGATED NON-A NON-B HEPATITIS, DNA WICH CODES FOR SAID PROTEIN, AND METHOD OF PRODUCING SAID PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1379244,
	"label": "ANTIGENIC PROTEIN SPECIFIC FOR BLOOD-PROPAGATED NON-A NON-B HEPATITIS, DNA WICH CODES FOR SAID PROTEIN, AND METHOD OF PRODUCING SAID PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37864,
	"target": 6854,
	"type": 1379244,
	"label": "ANTIGENIC PROTEIN SPECIFIC FOR BLOOD-PROPAGATED NON-A NON-B HEPATITIS, DNA WICH CODES FOR SAID PROTEIN, AND METHOD OF PRODUCING SAID PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 1379244,
	"label": "ANTIGENIC PROTEIN SPECIFIC FOR BLOOD-PROPAGATED NON-A NON-B HEPATITIS, DNA WICH CODES FOR SAID PROTEIN, AND METHOD OF PRODUCING SAID PROTEIN",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1379275,
	"label": "FUSION PEPTIDES COMPRISING A PEPTIDE LIGAND DOMAIN AND A MULTIMERIZATION DOMAIN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 1379275,
	"label": "FUSION PEPTIDES COMPRISING A PEPTIDE LIGAND DOMAIN AND A MULTIMERIZATION DOMAIN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 1379275,
	"label": "FUSION PEPTIDES COMPRISING A PEPTIDE LIGAND DOMAIN AND A MULTIMERIZATION DOMAIN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6795,
	"target": 6478,
	"type": 1380184,
	"label": "Interleukin ve pirimidin nükleositlerinin kompozisyonlari",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1380184,
	"label": "Interleukin ve pirimidin nükleositlerinin kompozisyonlari",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 1380184,
	"label": "Interleukin ve pirimidin nükleositlerinin kompozisyonlari",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7358,
	"target": 6213,
	"type": 1382179,
	"label": "COMPOSITIONS AND METHODS FOR RAISING HDL CHOLESTEROL LEVELS",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 1382916,
	"label": "SELEX-VERFAHREN OHNE TRANSKRIPTION",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 37859,
	"target": 6483,
	"type": 1383601,
	"label": "Novel polynucleotides and method for the use of thereof",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6962,
	"target": 6957,
	"type": 1384074,
	"label": "Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7510,
	"target": 6962,
	"type": 1384074,
	"label": "Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7510,
	"target": 6957,
	"type": 1384074,
	"label": "Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 1384074,
	"label": "Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 1384074,
	"label": "Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1384146,
	"label": "LYMPHOCYTIC ACTIVATION SUPPRESSANT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1384146,
	"label": "LYMPHOCYTIC ACTIVATION SUPPRESSANT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 6795,
	"type": 1384146,
	"label": "LYMPHOCYTIC ACTIVATION SUPPRESSANT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1384368,
	"label": "Multifunksjonelle polypeptider som omfatter bindingssete for en epitope av NKG2D reseptorkomplekset",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 7424,
	"type": 1384368,
	"label": "Multifunksjonelle polypeptider som omfatter bindingssete for en epitope av NKG2D reseptorkomplekset",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 7424,
	"type": 1384368,
	"label": "Multifunksjonelle polypeptider som omfatter bindingssete for en epitope av NKG2D reseptorkomplekset",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 7425,
	"type": 1384967,
	"label": "Preventives/remedies for granuloma",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 1385306,
	"label": "Biologisesti aktiivisia polypeptidifuusiodimeereja",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 1385306,
	"label": "Biologisesti aktiivisia polypeptidifuusiodimeereja",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1385306,
	"label": "Biologisesti aktiivisia polypeptidifuusiodimeereja",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1385306,
	"label": "Biologisesti aktiivisia polypeptidifuusiodimeereja",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 1385306,
	"label": "Biologisesti aktiivisia polypeptidifuusiodimeereja",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 6795,
	"target": 6229,
	"type": 1387069,
	"label": "Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1387069,
	"label": "Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 1387069,
	"label": "Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 1387069,
	"label": "Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32772,
	"target": 6795,
	"type": 1387069,
	"label": "Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 1388410,
	"label": "CANINE GRANULOCYTE COLONY STIMULATING FACTOR (CANINE G-CSF), RELATED POLYPEPTIDES, DNA ENCODING THESE FACTORS, AND COMPOSITIONS FOR TREATING CANINE AND FELINE ANIMALS",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1388410,
	"label": "CANINE GRANULOCYTE COLONY STIMULATING FACTOR (CANINE G-CSF), RELATED POLYPEPTIDES, DNA ENCODING THESE FACTORS, AND COMPOSITIONS FOR TREATING CANINE AND FELINE ANIMALS",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 7487,
	"target": 6816,
	"type": 1388410,
	"label": "CANINE GRANULOCYTE COLONY STIMULATING FACTOR (CANINE G-CSF), RELATED POLYPEPTIDES, DNA ENCODING THESE FACTORS, AND COMPOSITIONS FOR TREATING CANINE AND FELINE ANIMALS",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 32697,
	"type": 1388410,
	"label": "CANINE GRANULOCYTE COLONY STIMULATING FACTOR (CANINE G-CSF), RELATED POLYPEPTIDES, DNA ENCODING THESE FACTORS, AND COMPOSITIONS FOR TREATING CANINE AND FELINE ANIMALS",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 1388410,
	"label": "CANINE GRANULOCYTE COLONY STIMULATING FACTOR (CANINE G-CSF), RELATED POLYPEPTIDES, DNA ENCODING THESE FACTORS, AND COMPOSITIONS FOR TREATING CANINE AND FELINE ANIMALS",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 32770,
	"target": 32478,
	"type": 1390856,
	"label": "Nucleic acids encoding NTR3, a member of the TNF-receptor supergene family",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1390943,
	"label": "Immortalized epithelial tumor cell",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1390943,
	"label": "Immortalized epithelial tumor cell",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1390943,
	"label": "Immortalized epithelial tumor cell",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1390943,
	"label": "Immortalized epithelial tumor cell",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 1390943,
	"label": "Immortalized epithelial tumor cell",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1392351,
	"label": "Anticuerpos para inhibir la coagulación de la sangre y métodos de utilización de los mismos",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1392351,
	"label": "Anticuerpos para inhibir la coagulación de la sangre y métodos de utilización de los mismos",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 1392351,
	"label": "Anticuerpos para inhibir la coagulación de la sangre y métodos de utilización de los mismos",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1392351,
	"label": "Anticuerpos para inhibir la coagulación de la sangre y métodos de utilización de los mismos",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 1392351,
	"label": "Anticuerpos para inhibir la coagulación de la sangre y métodos de utilización de los mismos",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1392496,
	"label": "HTLV-I ENV GP21 DERIVED POLYPEPTIDES, NUCLEOTIDE SEQUENCES, VECTORS, HYBRID POLYPEPTIDES, HOSTS, IMMUNOASSAYS, AND PRODUCTION OF THE POLYPEPTIDES BY RECOMBINANT METHODS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1392496,
	"label": "HTLV-I ENV GP21 DERIVED POLYPEPTIDES, NUCLEOTIDE SEQUENCES, VECTORS, HYBRID POLYPEPTIDES, HOSTS, IMMUNOASSAYS, AND PRODUCTION OF THE POLYPEPTIDES BY RECOMBINANT METHODS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 32620,
	"type": 1392496,
	"label": "HTLV-I ENV GP21 DERIVED POLYPEPTIDES, NUCLEOTIDE SEQUENCES, VECTORS, HYBRID POLYPEPTIDES, HOSTS, IMMUNOASSAYS, AND PRODUCTION OF THE POLYPEPTIDES BY RECOMBINANT METHODS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 32620,
	"type": 1392496,
	"label": "HTLV-I ENV GP21 DERIVED POLYPEPTIDES, NUCLEOTIDE SEQUENCES, VECTORS, HYBRID POLYPEPTIDES, HOSTS, IMMUNOASSAYS, AND PRODUCTION OF THE POLYPEPTIDES BY RECOMBINANT METHODS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56834,
	"target": 38181,
	"type": 1392496,
	"label": "HTLV-I ENV GP21 DERIVED POLYPEPTIDES, NUCLEOTIDE SEQUENCES, VECTORS, HYBRID POLYPEPTIDES, HOSTS, IMMUNOASSAYS, AND PRODUCTION OF THE POLYPEPTIDES BY RECOMBINANT METHODS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37875,
	"type": 1394083,
	"label": "PREPARING CANCER VACCINES CONTAINING AUTOLOGOUS TUMOUR CELLS CHARACTERISED IN THAT TUMOUR CELLS OR FIRBROBLASTS ARE CULTIVATED AND TRANSFECTED EX VIVO WITH A COMPOSITION OF DNA AND A DNA BINDING MOLECULE CONJUGATE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37875,
	"target": 32612,
	"type": 1394083,
	"label": "PREPARING CANCER VACCINES CONTAINING AUTOLOGOUS TUMOUR CELLS CHARACTERISED IN THAT TUMOUR CELLS OR FIRBROBLASTS ARE CULTIVATED AND TRANSFECTED EX VIVO WITH A COMPOSITION OF DNA AND A DNA BINDING MOLECULE CONJUGATE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32612,
	"type": 1394083,
	"label": "PREPARING CANCER VACCINES CONTAINING AUTOLOGOUS TUMOUR CELLS CHARACTERISED IN THAT TUMOUR CELLS OR FIRBROBLASTS ARE CULTIVATED AND TRANSFECTED EX VIVO WITH A COMPOSITION OF DNA AND A DNA BINDING MOLECULE CONJUGATE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32612,
	"target": 6795,
	"type": 1394083,
	"label": "PREPARING CANCER VACCINES CONTAINING AUTOLOGOUS TUMOUR CELLS CHARACTERISED IN THAT TUMOUR CELLS OR FIRBROBLASTS ARE CULTIVATED AND TRANSFECTED EX VIVO WITH A COMPOSITION OF DNA AND A DNA BINDING MOLECULE CONJUGATE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 1394083,
	"label": "PREPARING CANCER VACCINES CONTAINING AUTOLOGOUS TUMOUR CELLS CHARACTERISED IN THAT TUMOUR CELLS OR FIRBROBLASTS ARE CULTIVATED AND TRANSFECTED EX VIVO WITH A COMPOSITION OF DNA AND A DNA BINDING MOLECULE CONJUGATE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1394372,
	"label": "Novel (DKR) polypeptides",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1394372,
	"label": "Novel (DKR) polypeptides",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1394372,
	"label": "Novel (DKR) polypeptides",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1394372,
	"label": "Novel (DKR) polypeptides",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 1394372,
	"label": "Novel (DKR) polypeptides",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 1394525,
	"label": "Aspergillus sojae recombinante, métodos para introduzir uma sequência de ácido nucleico em aspergillus sojae, para selecionar aspergillus sojae transformado ou transfectado, para produzir aspergillus sojae recombinante, aspergillus sojae mutante ou recombinante, fungo recombinante processos de expressão de uma sequência de ácido, nucleico introduzida, para a expressão de uma proteìna ou polipeptìdeo, para a produção de uma proteìna ou polipeptìdeo, e, para produzir uma fitase ou uma proteìna ten",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1396092,
	"label": "PROCESSOS PARA A PREPARACAO DE UM POLIPEPTIDIO,PARA A PREPARACAO DE UM GENE SINTETICO,PARA A PREPARACAO DE UM VETOR DE EXPRESSAO,PARA A PREPARACAO DE UM TRANSFORMANTE BACTERIANO,PARA A DETERMINACAO DE ANTICORPOS E DE VIRUS,PARA A PREPARACAO DE VACINA,VACINAS,ANTICORPOS,POLIPEPTIDOS,GENE,VETOR,TRANSFORMANTE,KIT DE TESTE",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1396092,
	"label": "PROCESSOS PARA A PREPARACAO DE UM POLIPEPTIDIO,PARA A PREPARACAO DE UM GENE SINTETICO,PARA A PREPARACAO DE UM VETOR DE EXPRESSAO,PARA A PREPARACAO DE UM TRANSFORMANTE BACTERIANO,PARA A DETERMINACAO DE ANTICORPOS E DE VIRUS,PARA A PREPARACAO DE VACINA,VACINAS,ANTICORPOS,POLIPEPTIDOS,GENE,VETOR,TRANSFORMANTE,KIT DE TESTE",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 1396092,
	"label": "PROCESSOS PARA A PREPARACAO DE UM POLIPEPTIDIO,PARA A PREPARACAO DE UM GENE SINTETICO,PARA A PREPARACAO DE UM VETOR DE EXPRESSAO,PARA A PREPARACAO DE UM TRANSFORMANTE BACTERIANO,PARA A DETERMINACAO DE ANTICORPOS E DE VIRUS,PARA A PREPARACAO DE VACINA,VACINAS,ANTICORPOS,POLIPEPTIDOS,GENE,VETOR,TRANSFORMANTE,KIT DE TESTE",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38184,
	"target": 7510,
	"type": 1398014,
	"label": "proteínas                                        T e profilaxia de doenças mediadas por quinases deTzepanos novos e seus homólogos de anel par terapiT",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 1399737,
	"label": "Serum-free medium for culturing animal cells",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1401900,
	"label": "NUCLEIC ACID MOLECULES ENCODING HEREGULIN VARIANTS, COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1401900,
	"label": "NUCLEIC ACID MOLECULES ENCODING HEREGULIN VARIANTS, COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1401900,
	"label": "NUCLEIC ACID MOLECULES ENCODING HEREGULIN VARIANTS, COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1401900,
	"label": "NUCLEIC ACID MOLECULES ENCODING HEREGULIN VARIANTS, COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 1401900,
	"label": "NUCLEIC ACID MOLECULES ENCODING HEREGULIN VARIANTS, COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND USE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1402864,
	"label": "COMPOSICIONES Y PROCEDIMIENTOS PARA EL TRATAMIENTO DE TUMORES.",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1403290,
	"label": "Method for cell lysis or inhibition of cell growth a bispecific molecule binding tnf-r1 and fas antigen a pharmaceutical composition containing it and its use",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1403290,
	"label": "Method for cell lysis or inhibition of cell growth a bispecific molecule binding tnf-r1 and fas antigen a pharmaceutical composition containing it and its use",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 1403290,
	"label": "Method for cell lysis or inhibition of cell growth a bispecific molecule binding tnf-r1 and fas antigen a pharmaceutical composition containing it and its use",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1403290,
	"label": "Method for cell lysis or inhibition of cell growth a bispecific molecule binding tnf-r1 and fas antigen a pharmaceutical composition containing it and its use",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 32771,
	"type": 1403290,
	"label": "Method for cell lysis or inhibition of cell growth a bispecific molecule binding tnf-r1 and fas antigen a pharmaceutical composition containing it and its use",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1403695,
	"label": "Cloned tetrodotoxin-sensitive sodium channel  alpha -subunit and a splice variant thereof",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6795,
	"target": 6215,
	"type": 1403885,
	"label": "Protein conjugates with a water-soluble biocompatible, biodegradable polymer",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1403885,
	"label": "Protein conjugates with a water-soluble biocompatible, biodegradable polymer",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 6215,
	"type": 1403885,
	"label": "Protein conjugates with a water-soluble biocompatible, biodegradable polymer",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 1405437,
	"label": "VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2 alpha -POSITION",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30485,
	"target": 7511,
	"type": 1405437,
	"label": "VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2 alpha -POSITION",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 1405437,
	"label": "VITAMIN D DERIVATIVES HAVING SUBSTITUENTS AT THE 2 alpha -POSITION",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1406336,
	"label": "Reconstructed human antibody against human interleukin-6",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1406336,
	"label": "Reconstructed human antibody against human interleukin-6",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 1406336,
	"label": "Reconstructed human antibody against human interleukin-6",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1410117,
	"label": "INTERLEUKIN-12 RECEPTOR PROTEIN AND DNA, IMMUNOGLOBULIN CAPABLE OF BINDING THE PROTEIN AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 1410117,
	"label": "INTERLEUKIN-12 RECEPTOR PROTEIN AND DNA, IMMUNOGLOBULIN CAPABLE OF BINDING THE PROTEIN AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56836,
	"target": 32770,
	"type": 1410117,
	"label": "INTERLEUKIN-12 RECEPTOR PROTEIN AND DNA, IMMUNOGLOBULIN CAPABLE OF BINDING THE PROTEIN AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1410117,
	"label": "INTERLEUKIN-12 RECEPTOR PROTEIN AND DNA, IMMUNOGLOBULIN CAPABLE OF BINDING THE PROTEIN AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1410117,
	"label": "INTERLEUKIN-12 RECEPTOR PROTEIN AND DNA, IMMUNOGLOBULIN CAPABLE OF BINDING THE PROTEIN AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7425,
	"target": 7422,
	"type": 1410905,
	"label": "Novel antiandrogenic agent",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 1410905,
	"label": "Novel antiandrogenic agent",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 1410905,
	"label": "Novel antiandrogenic agent",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31580,
	"target": 31570,
	"type": 1414324,
	"label": "Racemiske eller optisk aktive cyclopenta[f][l]benzopyraner til anvendelse som mellemprodukter ved fremstillingen af 19-nor-steroider.",
	"group": "Roche",
	"time": 1968,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1414461,
	"label": "I-(KAPPA)- B(KINASES)",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1414461,
	"label": "I-(KAPPA)- B(KINASES)",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 1414461,
	"label": "I-(KAPPA)- B(KINASES)",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38237,
	"target": 37899,
	"type": 1414461,
	"label": "I-(KAPPA)- B(KINASES)",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38237,
	"target": 37862,
	"type": 1414461,
	"label": "I-(KAPPA)- B(KINASES)",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 6957,
	"target": 6484,
	"type": 1414752,
	"label": "Nucleic acid ligands to CD40ligand",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 6957,
	"type": 1414752,
	"label": "Nucleic acid ligands to CD40ligand",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 6484,
	"type": 1414752,
	"label": "Nucleic acid ligands to CD40ligand",
	"group": "Gilead",
	"time": 2000,
	"strength": 1
}, {
	"source": 56833,
	"target": 37986,
	"type": 1417936,
	"label": "Nucleic acid encoding N-acetylmuramidase M1",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 1417936,
	"label": "Nucleic acid encoding N-acetylmuramidase M1",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 56833,
	"target": 6841,
	"type": 1417936,
	"label": "Nucleic acid encoding N-acetylmuramidase M1",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 32788,
	"target": 32656,
	"type": 1419746,
	"label": "COMPOUNDS COMPRISING A REPRESENTATIVE OF A B-CELL EPITOPE COUPLED TO A REPRESENTATIVE OF A HELPER T-CELL EPITOPE AND VACCINES THEREFROM",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 6390,
	"target": 6376,
	"type": 1419861,
	"label": "Remedies for myocardial infarction",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 1421241,
	"label": "A NOVEL Bak BINDING PROTEIN, DNA ENCODING THE PROTEIN, AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32777,
	"target": 6795,
	"type": 1422107,
	"label": "Methods for treatment of interstitial cystitis",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 1422975,
	"label": "PROPHYLACTIC OR THERAPEUTIC AGENT FOR ARTERIOSCLEROSIS",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1423832,
	"label": "RENATURATION OF RECOMBINANT PLATELET-DERIVED GROWTH FACTOR (PDGF); MIXED DISULPHIDE COMPOUND OR PDGF; PURE PDGF MONOMER; AND MIXED DIMERIC RECOMBINANT PDGF",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1424451,
	"label": "Cytochrome c oxidase complex from Gluconobacter oxydans",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38067,
	"target": 37899,
	"type": 1426913,
	"label": "MODIFIED ADENOVIRAL FIBRE AND USES THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 1428068,
	"label": "Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratame",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1428068,
	"label": "Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratame",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1428068,
	"label": "Anticorpo monoclonal anti-trkc agonista, cadeia pesada de anticorpo anti-trkc, cadeia leve de anticorpo anti-trkc, cadeia pesada de anticorpo anti-trkc murino, cadeia pesada de anticorpo anti-trkc humano, anticorpo agonista anti-trkc murino, anticorpo agonista anti-trkc humano, moléculas de ácido nucléico isolado, moléculas de ácido nucléico, vetor, linhagens de células hospedeiras, linhagens de células de hibridoma, célula hospedeira, polipeptìdeo, composição farmacêutica, método para o tratame",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1428995,
	"label": "Novel antisense oligonucleotide derivatives against wilms's tumor gene",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6471,
	"target": 6229,
	"type": 1430862,
	"label": "Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6471,
	"type": 1430862,
	"label": "Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 1430862,
	"label": "Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 1430862,
	"label": "Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32772,
	"target": 6471,
	"type": 1430862,
	"label": "Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 1433650,
	"label": "PREPARATION OF MEDICAMENTS FOR STIMULATING MEGAKARYOCYTE PRODUCTION USING G-CSF.",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1435579,
	"label": "Nucleic acids encoding BAZ1alpha transcriptional regulator and methods of use",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37889,
	"target": 32770,
	"type": 1439786,
	"label": "Process for producing tumoricide T-lymphocytes",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1440054,
	"label": "[ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1440054,
	"label": "[ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1440054,
	"label": "[ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37864,
	"target": 32698,
	"type": 1440054,
	"label": "[ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 1440054,
	"label": "[ALA IL-8]77 and [SER IL-8]72 as Leukocyte adhesion inhibitors",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 32772,
	"target": 32754,
	"type": 1441454,
	"label": "ASSAYS AND ANTIBODIES FOR N--i(myc) PROTEINS.",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 56834,
	"target": 32772,
	"type": 1441454,
	"label": "ASSAYS AND ANTIBODIES FOR N--i(myc) PROTEINS.",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 56834,
	"target": 32754,
	"type": 1441454,
	"label": "ASSAYS AND ANTIBODIES FOR N--i(myc) PROTEINS.",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 32754,
	"target": 6795,
	"type": 1441454,
	"label": "ASSAYS AND ANTIBODIES FOR N--i(myc) PROTEINS.",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 32772,
	"target": 6795,
	"type": 1441454,
	"label": "ASSAYS AND ANTIBODIES FOR N--i(myc) PROTEINS.",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 1443695,
	"label": "MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALPHA, MEDICAMENTS AND KIT COMPRISING THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 6816,
	"target": 6241,
	"type": 1443695,
	"label": "MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALPHA, MEDICAMENTS AND KIT COMPRISING THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7358,
	"target": 6241,
	"type": 1443695,
	"label": "MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALPHA, MEDICAMENTS AND KIT COMPRISING THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1447223,
	"label": "A method for the treatment of bacterial and fungal infections using tumor necrosis factor-alpha infective agents",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1448632,
	"label": "CHIMERIC OPG POLYPEPTIDES",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7511,
	"target": 6795,
	"type": 1448632,
	"label": "CHIMERIC OPG POLYPEPTIDES",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 7511,
	"type": 1448632,
	"label": "CHIMERIC OPG POLYPEPTIDES",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 7511,
	"type": 1448632,
	"label": "CHIMERIC OPG POLYPEPTIDES",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1448632,
	"label": "CHIMERIC OPG POLYPEPTIDES",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 1449267,
	"label": "PROTEIN PROTECTION; METHOD FOR STABILISING AEROSOLISED PROTEINS BY ADDING A WATER-SOLUBLE POLAR ORGANIC COMPOUND TO THE AQUEOUS SOLUTION PRIOR TO AEROSOLISATION",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1450056,
	"label": "PLASMODIUM SPOROZOITE ANTIGEN, DNA, VECTORS, TRANSFORMED MICROORGANISMS AND PREPARATION, IMMUNOGENIC COMPOSITIONS AND POLYPEPTIDES CONTAINING EPITOPES OF THE ANTIGEN",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 1451164,
	"label": "INDOLE DERIVATIVES AND MONO- AND DIAZAINDOLE DERIVATIVES",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37960,
	"type": 1451294,
	"label": "GANZ-ZELL KATALYSATOR DER EINE HYDANTOINASE, EINE RACEMASE UND EINE CARBAMOYLASE ENTHÄLT",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32788,
	"target": 32734,
	"type": 1452337,
	"label": "Nucleic acids encoding hybrid receptor molecules",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1452337,
	"label": "Nucleic acids encoding hybrid receptor molecules",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1452337,
	"label": "Nucleic acids encoding hybrid receptor molecules",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1452337,
	"label": "Nucleic acids encoding hybrid receptor molecules",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 1452337,
	"label": "Nucleic acids encoding hybrid receptor molecules",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1453595,
	"label": "Osteolevin gene polymorphisms",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1454958,
	"label": "Method of identifying agents that modulate UCP2 promoter activity",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1454958,
	"label": "Method of identifying agents that modulate UCP2 promoter activity",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 1454958,
	"label": "Method of identifying agents that modulate UCP2 promoter activity",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1454958,
	"label": "Method of identifying agents that modulate UCP2 promoter activity",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1454958,
	"label": "Method of identifying agents that modulate UCP2 promoter activity",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 1455034,
	"label": "24-HOMO-26,27-HEXAFLUORO-CHOLECALCIFEROLS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 1455034,
	"label": "24-HOMO-26,27-HEXAFLUORO-CHOLECALCIFEROLS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 1455034,
	"label": "24-HOMO-26,27-HEXAFLUORO-CHOLECALCIFEROLS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 7508,
	"type": 1455034,
	"label": "24-HOMO-26,27-HEXAFLUORO-CHOLECALCIFEROLS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 1455034,
	"label": "24-HOMO-26,27-HEXAFLUORO-CHOLECALCIFEROLS.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32772,
	"target": 32754,
	"type": 1457551,
	"label": "MAMMAMODULIN, ANTIBODIES THEREFOR, AND PHARMACEUTICAL COMPOSITIONS, TREATMENT OF BREAST CANCER",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1457551,
	"label": "MAMMAMODULIN, ANTIBODIES THEREFOR, AND PHARMACEUTICAL COMPOSITIONS, TREATMENT OF BREAST CANCER",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32772,
	"type": 1457551,
	"label": "MAMMAMODULIN, ANTIBODIES THEREFOR, AND PHARMACEUTICAL COMPOSITIONS, TREATMENT OF BREAST CANCER",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 32754,
	"type": 1457551,
	"label": "MAMMAMODULIN, ANTIBODIES THEREFOR, AND PHARMACEUTICAL COMPOSITIONS, TREATMENT OF BREAST CANCER",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 32772,
	"type": 1457551,
	"label": "MAMMAMODULIN, ANTIBODIES THEREFOR, AND PHARMACEUTICAL COMPOSITIONS, TREATMENT OF BREAST CANCER",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1457604,
	"label": "Recombination producing of carotenoid especially astaxanthin and its utilized biological material",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1457604,
	"label": "Recombination producing of carotenoid especially astaxanthin and its utilized biological material",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1457604,
	"label": "Recombination producing of carotenoid especially astaxanthin and its utilized biological material",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1460908,
	"label": "Efficient construction of gene targeting vectors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1460908,
	"label": "Efficient construction of gene targeting vectors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1460908,
	"label": "Efficient construction of gene targeting vectors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 1460908,
	"label": "Efficient construction of gene targeting vectors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 1460908,
	"label": "Efficient construction of gene targeting vectors",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 1464036,
	"label": "1-methyl-20-epi-vitamin d derivative",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 1464398,
	"label": "RESPIRATORY BURST SUPPRESSION FACTOR, ANTIBODIES AGAINST IT AND COMPOSITIONS",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 7409,
	"type": 1464398,
	"label": "RESPIRATORY BURST SUPPRESSION FACTOR, ANTIBODIES AGAINST IT AND COMPOSITIONS",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1464398,
	"label": "RESPIRATORY BURST SUPPRESSION FACTOR, ANTIBODIES AGAINST IT AND COMPOSITIONS",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1465057,
	"label": "Transcriptional promoter of the murine obesity gene",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 1466619,
	"label": "PHOSPHATASES WHICH ACTIVATE MAP KINASE PATHWAYS.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1466619,
	"label": "PHOSPHATASES WHICH ACTIVATE MAP KINASE PATHWAYS.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 7409,
	"type": 1466619,
	"label": "PHOSPHATASES WHICH ACTIVATE MAP KINASE PATHWAYS.",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6191,
	"type": 1467899,
	"label": "PROCESSO PARA A PREPARACAO DE COMPOSICOES FARMACEUTICAS CONTENDO O FACTOR BETA DE TRANSFORMACAO DO CRESCIMENTO (TGF-BETA)",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32689,
	"target": 7507,
	"type": 1467899,
	"label": "PROCESSO PARA A PREPARACAO DE COMPOSICOES FARMACEUTICAS CONTENDO O FACTOR BETA DE TRANSFORMACAO DO CRESCIMENTO (TGF-BETA)",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32689,
	"target": 6191,
	"type": 1467899,
	"label": "PROCESSO PARA A PREPARACAO DE COMPOSICOES FARMACEUTICAS CONTENDO O FACTOR BETA DE TRANSFORMACAO DO CRESCIMENTO (TGF-BETA)",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 1468932,
	"label": "HIV ENVELOPE POLYPEPTIDES.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7358,
	"target": 6812,
	"type": 1470556,
	"label": "Method of extending the plasma half-life of deletion variants of hepatocyte growth factor",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 1470687,
	"label": "DERIVADOS DEL 24-NOR-SECOCOLA-5,7-DIENO, SU USO, PROCEDIMIENTO PARA PREPARARLOS, COMPOSICION FARMACEUTICA, Y COMPUESTOS UTILES COMO INTERMEDIOS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 1470687,
	"label": "DERIVADOS DEL 24-NOR-SECOCOLA-5,7-DIENO, SU USO, PROCEDIMIENTO PARA PREPARARLOS, COMPOSICION FARMACEUTICA, Y COMPUESTOS UTILES COMO INTERMEDIOS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 1470687,
	"label": "DERIVADOS DEL 24-NOR-SECOCOLA-5,7-DIENO, SU USO, PROCEDIMIENTO PARA PREPARARLOS, COMPOSICION FARMACEUTICA, Y COMPUESTOS UTILES COMO INTERMEDIOS",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1470980,
	"label": "Efficient construction of vectors for gene targeting using phage-plasmid recombination",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1471192,
	"label": "Rat st38.2 chemokine",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37999,
	"target": 37986,
	"type": 1471192,
	"label": "Rat st38.2 chemokine",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37999,
	"type": 1471192,
	"label": "Rat st38.2 chemokine",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37999,
	"type": 1471192,
	"label": "Rat st38.2 chemokine",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1471192,
	"label": "Rat st38.2 chemokine",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 1471402,
	"label": "Process for the preparation of peptides by way of streptavidin fusion proteins",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 1471402,
	"label": "Process for the preparation of peptides by way of streptavidin fusion proteins",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 1471402,
	"label": "Process for the preparation of peptides by way of streptavidin fusion proteins",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 1473892,
	"label": "UN COMPUESTO DE 3-EPI VITAMINA D3 AISLADO, UNA COMPOSICION FARMACEUITICA QUE LO COMPRENDE, DICHO COMPUESTO ENVASADO, METODOS PARA TRATAR UN DESORDENRELACIONADO CON UNA ACTIVIDAD ANORMAL DE UNA CELULA SENSIBLE A LA VITAMINA D3, PARA REDUCIR LA ACTIVIDAD DE UNA CELULA HIPERPROLIFERATIVA DE LA PIEL, PA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1475539,
	"label": "M. tuberculosis RNA polymerase alpha subunit",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1475539,
	"label": "M. tuberculosis RNA polymerase alpha subunit",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1475539,
	"label": "M. tuberculosis RNA polymerase alpha subunit",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1475539,
	"label": "M. tuberculosis RNA polymerase alpha subunit",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1475539,
	"label": "M. tuberculosis RNA polymerase alpha subunit",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37999,
	"target": 32694,
	"type": 1475552,
	"label": "Novel protein with chemokine activity",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37904,
	"target": 37875,
	"type": 1475942,
	"label": "MONOCLONAL ANTIBODY INTERACTING WITH SURFACE AGENT OF STROMA CELLS AND HYBRIDOMA FOR PRODUCING IT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 1475942,
	"label": "MONOCLONAL ANTIBODY INTERACTING WITH SURFACE AGENT OF STROMA CELLS AND HYBRIDOMA FOR PRODUCING IT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 37875,
	"type": 1475942,
	"label": "MONOCLONAL ANTIBODY INTERACTING WITH SURFACE AGENT OF STROMA CELLS AND HYBRIDOMA FOR PRODUCING IT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37875,
	"target": 32770,
	"type": 1475942,
	"label": "MONOCLONAL ANTIBODY INTERACTING WITH SURFACE AGENT OF STROMA CELLS AND HYBRIDOMA FOR PRODUCING IT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 1475942,
	"label": "MONOCLONAL ANTIBODY INTERACTING WITH SURFACE AGENT OF STROMA CELLS AND HYBRIDOMA FOR PRODUCING IT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 1480163,
	"label": "GENE DERIVED FROM HUMAN CARTILAGINOUS CELL",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37875,
	"target": 32694,
	"type": 1480163,
	"label": "GENE DERIVED FROM HUMAN CARTILAGINOUS CELL",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 32694,
	"type": 1480163,
	"label": "GENE DERIVED FROM HUMAN CARTILAGINOUS CELL",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 31939,
	"target": 31937,
	"type": 1481083,
	"label": "PROCESSO PARA A PREPARACAO DE NOVOS DERIVADOS DA PURINA E DE COMPOSICOES FARMACEUTICAS QUE OS CONTEM",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7359,
	"target": 6795,
	"type": 1484893,
	"label": "Cyclic motilin receptor antagonists",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 1484981,
	"label": "NOVEL PRIMERS AND METHODS FOR THE DETECTION OF DISSEMINATED TUMOR CELLS",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 1488213,
	"label": "Novel guanidino derivatives as inhibitors of cell adhesion",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31939,
	"target": 7509,
	"type": 1488213,
	"label": "Novel guanidino derivatives as inhibitors of cell adhesion",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 1488213,
	"label": "Novel guanidino derivatives as inhibitors of cell adhesion",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37947,
	"target": 32694,
	"type": 1489760,
	"label": "PEPTIDES COMPRISING EPIDERMAL GROWTH FACTOR DOMAIN FRAGMENTS OF CLOTTING FACTOR 1X AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1489760,
	"label": "PEPTIDES COMPRISING EPIDERMAL GROWTH FACTOR DOMAIN FRAGMENTS OF CLOTTING FACTOR 1X AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 1489760,
	"label": "PEPTIDES COMPRISING EPIDERMAL GROWTH FACTOR DOMAIN FRAGMENTS OF CLOTTING FACTOR 1X AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 1490242,
	"label": "Reconstituted human antibody against human medulloblastomatous cell",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32771,
	"target": 6795,
	"type": 1490242,
	"label": "Reconstituted human antibody against human medulloblastomatous cell",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1490242,
	"label": "Reconstituted human antibody against human medulloblastomatous cell",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 1490793,
	"label": "Method for suppressing graft-versus-host-disease",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37878,
	"target": 6812,
	"type": 1490793,
	"label": "Method for suppressing graft-versus-host-disease",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37878,
	"target": 6795,
	"type": 1490793,
	"label": "Method for suppressing graft-versus-host-disease",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 1491610,
	"label": "APAF-1, THE CED-4 HUMAN HOMOLOG, AN ACTIVATOR OF CASPASE-3",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1491610,
	"label": "APAF-1, THE CED-4 HUMAN HOMOLOG, AN ACTIVATOR OF CASPASE-3",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 1491610,
	"label": "APAF-1, THE CED-4 HUMAN HOMOLOG, AN ACTIVATOR OF CASPASE-3",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 1491610,
	"label": "APAF-1, THE CED-4 HUMAN HOMOLOG, AN ACTIVATOR OF CASPASE-3",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 7510,
	"type": 1491610,
	"label": "APAF-1, THE CED-4 HUMAN HOMOLOG, AN ACTIVATOR OF CASPASE-3",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 1492392,
	"label": "CHIMAERISK POLYPEPTID,FREMGANGSMAADE TIL DETS FREMSTILLING,KLONINGSMEDIUM OG MIKROBIELLE TRANSFORMANTER TIL ANVENDELSE VED FREMGANGSMAADEN SAMT FREMGANGSMAADE TIL FREMSTILLING AF HUMANT INSULIN",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 1492900,
	"label": "Remedial agent for osteoporosis",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1493273,
	"label": "Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1493273,
	"label": "Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 1493273,
	"label": "Fremgangsmåde til kontinuert produktion af et önsket heterologt protein i en eukaryotisk værtcelle, vektor, som tilförer denne evne, og celler transformeret med vektoren",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 31912,
	"target": 31197,
	"type": 1495329,
	"label": "DERIVADOS DE AMINOACIDOS, PROCESSO PARA A PREPARACAO DE UM COMPOSTO, MEDICAMENTO, INVENCAO E PROCESSO PARA O TRATAMENTO OU PREVENCAO DE PRESSAO ELEVADA",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 1496098,
	"label": "Mammal with enhanced liver expression of a transgene",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 32698,
	"type": 1496098,
	"label": "Mammal with enhanced liver expression of a transgene",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 32694,
	"type": 1496098,
	"label": "Mammal with enhanced liver expression of a transgene",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 1496098,
	"label": "Mammal with enhanced liver expression of a transgene",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 1496098,
	"label": "Mammal with enhanced liver expression of a transgene",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 1498263,
	"label": "OLIGONUCLEOTIDE PROBES AND THEIR USE IN IDENTIFYING SEPTICEMIA-CAUSING BACTERIA",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7424,
	"target": 7409,
	"type": 1499091,
	"label": "Remedies for ischemic disease of the limbs comprising administration of G-CSF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1502118,
	"label": "Protein having PDZ domain sequence",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 31189,
	"target": 7507,
	"type": 1502140,
	"label": "TELOMERASE INHIBITOR",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7487,
	"target": 6241,
	"type": 1508654,
	"label": "PHARMACEUTICAL COMPOSITION CONTAINING WATER SOLUBLE BASIC AUTIBIOTIC AND GLUCOSACCHARIC ACID COMPOUND",
	"group": "Roche",
	"time": 1975,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1510023,
	"label": "AIDS VIRUS ANTIGENS: ENV/GAG POLYPEPTIDES: PRODUCTION BY GENETIC ENGINEERING TECHNIQUES: VACCINES, AND METHODS OF DIAGNOSTIC TESTING",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 31912,
	"target": 6382,
	"type": 1513966,
	"label": "FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA 7-FENYL-, NAFTYL- OCH BENSOFURANYLISOTIAZOLO/4,5-D/-1,2,3-TRIAZIN-4(3H)-ONER",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1517529,
	"label": "ANALOGS OF ACIDIC FIBROBLAST GROWTH FACTOR HAVING ENHANCED STABILITY AND BIOLOGICAL ACTIVITY.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1517529,
	"label": "ANALOGS OF ACIDIC FIBROBLAST GROWTH FACTOR HAVING ENHANCED STABILITY AND BIOLOGICAL ACTIVITY.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1517529,
	"label": "ANALOGS OF ACIDIC FIBROBLAST GROWTH FACTOR HAVING ENHANCED STABILITY AND BIOLOGICAL ACTIVITY.",
	"group": "Amgen",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1517727,
	"label": "Polynucleotides encoding hOCTN1 polypeptide",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1517727,
	"label": "Polynucleotides encoding hOCTN1 polypeptide",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1517727,
	"label": "Polynucleotides encoding hOCTN1 polypeptide",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 1518055,
	"label": "PCR primers for detection of legionella species and methods for controlling visual intensity in hybridization assays",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 1523451,
	"label": "Methods, compositions and modes of delivery for the treatment of emphysema using 13-cis-retinoic acid",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 1526170,
	"label": "SECRETORY LEUKOCYTE PROTEASE INHIBITOR DRY POWDER PHARMACEUTICAL COMPOSITIONS",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 1529211,
	"label": "COMPUESTOS DERIVADOS DE 24a, 24b-DIHOMO-9,10-SECOCOLESTANO POLINSATURADO, SU USO, PROCEDIMIENTO PARA PREPARARLOS, COMPUESTOS UTILES COMO INTERMEDIARIOS,Y UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO COMPUESTO DERIVADO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 1529211,
	"label": "COMPUESTOS DERIVADOS DE 24a, 24b-DIHOMO-9,10-SECOCOLESTANO POLINSATURADO, SU USO, PROCEDIMIENTO PARA PREPARARLOS, COMPUESTOS UTILES COMO INTERMEDIARIOS,Y UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO COMPUESTO DERIVADO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 1529211,
	"label": "COMPUESTOS DERIVADOS DE 24a, 24b-DIHOMO-9,10-SECOCOLESTANO POLINSATURADO, SU USO, PROCEDIMIENTO PARA PREPARARLOS, COMPUESTOS UTILES COMO INTERMEDIARIOS,Y UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO COMPUESTO DERIVADO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 1529211,
	"label": "COMPUESTOS DERIVADOS DE 24a, 24b-DIHOMO-9,10-SECOCOLESTANO POLINSATURADO, SU USO, PROCEDIMIENTO PARA PREPARARLOS, COMPUESTOS UTILES COMO INTERMEDIARIOS,Y UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO COMPUESTO DERIVADO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 1529211,
	"label": "COMPUESTOS DERIVADOS DE 24a, 24b-DIHOMO-9,10-SECOCOLESTANO POLINSATURADO, SU USO, PROCEDIMIENTO PARA PREPARARLOS, COMPUESTOS UTILES COMO INTERMEDIARIOS,Y UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO COMPUESTO DERIVADO",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 31081,
	"target": 7507,
	"type": 1529262,
	"label": "Fxr modulators",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1530750,
	"label": "CLONING CARTRIDGES AND EXPRESSION VECTORS IN GRAM-NEGATIVE BACTERIA",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1530750,
	"label": "CLONING CARTRIDGES AND EXPRESSION VECTORS IN GRAM-NEGATIVE BACTERIA",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 1530750,
	"label": "CLONING CARTRIDGES AND EXPRESSION VECTORS IN GRAM-NEGATIVE BACTERIA",
	"group": "Amgen",
	"time": 1991,
	"strength": 1
}, {
	"source": 7508,
	"target": 7425,
	"type": 1533814,
	"label": "N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7425,
	"target": 6360,
	"type": 1533814,
	"label": "N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 6360,
	"type": 1533814,
	"label": "N-PYRIDYL CARBOXAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 1535084,
	"label": "Use of an anti-cd40 antibody and an anti-cd20 antibody for the preparation of medicaments for the treatment of a neoplastic disease",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 1535084,
	"label": "Use of an anti-cd40 antibody and an anti-cd20 antibody for the preparation of medicaments for the treatment of a neoplastic disease",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1535084,
	"label": "Use of an anti-cd40 antibody and an anti-cd20 antibody for the preparation of medicaments for the treatment of a neoplastic disease",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 1535910,
	"label": "2-mercapto-[1,3]thiazolo[5,4-b]pyridine derivatives and pharmaceutical compositions comprising them for treating cardiovascular diseases",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7360,
	"target": 6376,
	"type": 1535910,
	"label": "2-mercapto-[1,3]thiazolo[5,4-b]pyridine derivatives and pharmaceutical compositions comprising them for treating cardiovascular diseases",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 1535910,
	"label": "2-mercapto-[1,3]thiazolo[5,4-b]pyridine derivatives and pharmaceutical compositions comprising them for treating cardiovascular diseases",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 1536260,
	"label": "METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6957,
	"target": 6795,
	"type": 1537336,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6957,
	"type": 1537336,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1537336,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1537336,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 6957,
	"type": 1537336,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 1542840,
	"label": "USO DE IFN-ALFA Y AMANTADINE PARA EL TRATAMIENTO DE HEPATITIS C CRONICA USO DE IFN-ALFA",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6429,
	"target": 6427,
	"type": 1543162,
	"label": "DERIVADOS DE D-HOMO-9,10-SECO-COLESTA-23-IN-3,25-DIOL",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1543561,
	"label": "Steroid hormone binding protein",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37862,
	"target": 32734,
	"type": 1543561,
	"label": "Steroid hormone binding protein",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 32734,
	"type": 1543561,
	"label": "Steroid hormone binding protein",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1543675,
	"label": "Nucleic acids encoding murine UCP3 genes",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1543675,
	"label": "Nucleic acids encoding murine UCP3 genes",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1543675,
	"label": "Nucleic acids encoding murine UCP3 genes",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1543675,
	"label": "Nucleic acids encoding murine UCP3 genes",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1543675,
	"label": "Nucleic acids encoding murine UCP3 genes",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1544151,
	"label": "Assays for identifying agents which affect regulators of UCP3 gene expression",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1544151,
	"label": "Assays for identifying agents which affect regulators of UCP3 gene expression",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1544151,
	"label": "Assays for identifying agents which affect regulators of UCP3 gene expression",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1544151,
	"label": "Assays for identifying agents which affect regulators of UCP3 gene expression",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1544151,
	"label": "Assays for identifying agents which affect regulators of UCP3 gene expression",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 1545521,
	"label": "NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32788,
	"target": 32777,
	"type": 1545521,
	"label": "NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32788,
	"target": 32772,
	"type": 1545521,
	"label": "NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 1545521,
	"label": "NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 32777,
	"type": 1545521,
	"label": "NON-HUMAN PRIMATE Fc RECEPTORS AND METHODS OF USE",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 1545753,
	"label": "METHODS FOR USING ANTI-MUC18 ANTIBODIES",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 1545753,
	"label": "METHODS FOR USING ANTI-MUC18 ANTIBODIES",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7509,
	"target": 6962,
	"type": 1545753,
	"label": "METHODS FOR USING ANTI-MUC18 ANTIBODIES",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32772,
	"target": 7509,
	"type": 1545753,
	"label": "METHODS FOR USING ANTI-MUC18 ANTIBODIES",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 1545753,
	"label": "METHODS FOR USING ANTI-MUC18 ANTIBODIES",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 1546479,
	"label": "Androstane derivative having substituent in 7- abd 17--positions",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1546575,
	"label": "Methods for stabilizing proteins",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7409,
	"target": 6333,
	"type": 1549521,
	"label": "COMPUESTOS DERIVADOS DE 4-PIPERIDINILAMINA, SU EMPLEO, UN PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32779,
	"target": 32694,
	"type": 1550676,
	"label": "Nucleic acid encoding modified human thymic stromal lymphopoietin",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 32779,
	"type": 1550676,
	"label": "Nucleic acid encoding modified human thymic stromal lymphopoietin",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 1550676,
	"label": "Nucleic acid encoding modified human thymic stromal lymphopoietin",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1551718,
	"label": "Novel sulfurylase-luciferase fusion proteins and thermostable sulfurylase",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1551718,
	"label": "Novel sulfurylase-luciferase fusion proteins and thermostable sulfurylase",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1551718,
	"label": "Novel sulfurylase-luciferase fusion proteins and thermostable sulfurylase",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1551718,
	"label": "Novel sulfurylase-luciferase fusion proteins and thermostable sulfurylase",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1551718,
	"label": "Novel sulfurylase-luciferase fusion proteins and thermostable sulfurylase",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 1553123,
	"label": "2-SUBSTITUTED VITAMIN D DERIVATIVES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 1553123,
	"label": "2-SUBSTITUTED VITAMIN D DERIVATIVES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 1553123,
	"label": "2-SUBSTITUTED VITAMIN D DERIVATIVES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 30485,
	"target": 7508,
	"type": 1553123,
	"label": "2-SUBSTITUTED VITAMIN D DERIVATIVES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 1553123,
	"label": "2-SUBSTITUTED VITAMIN D DERIVATIVES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 1554522,
	"label": "CELL PROLIFERATION INHIBITOR CONTAINING ANTI-PepT ANTIBODY",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1554522,
	"label": "CELL PROLIFERATION INHIBITOR CONTAINING ANTI-PepT ANTIBODY",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1554522,
	"label": "CELL PROLIFERATION INHIBITOR CONTAINING ANTI-PepT ANTIBODY",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 1554978,
	"label": "USE OF BISINDOLMALEIMIDE AND GEMCITABINE FOR THE TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1555686,
	"label": "ANTICUERPOS DR4 HUMANOS Y UTILIZACIONES DE LOS MISMOS.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1555686,
	"label": "ANTICUERPOS DR4 HUMANOS Y UTILIZACIONES DE LOS MISMOS.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 1555686,
	"label": "ANTICUERPOS DR4 HUMANOS Y UTILIZACIONES DE LOS MISMOS.",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7511,
	"target": 7508,
	"type": 1557888,
	"label": "Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og athferthir til notkunar theirra",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7508,
	"target": 6483,
	"type": 1557888,
	"label": "Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og athferthir til notkunar theirra",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7511,
	"target": 6483,
	"type": 1557888,
	"label": "Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og athferthir til notkunar theirra",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 1558408,
	"label": "METHODS FOR THE RECOMBINANT PRODUCTION OF PEPTIDIC ANTIVIRAL FUSION INHIBITORS, AND ACETYLATION OF GP41 FRAGMENTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1558408,
	"label": "METHODS FOR THE RECOMBINANT PRODUCTION OF PEPTIDIC ANTIVIRAL FUSION INHIBITORS, AND ACETYLATION OF GP41 FRAGMENTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 1558408,
	"label": "METHODS FOR THE RECOMBINANT PRODUCTION OF PEPTIDIC ANTIVIRAL FUSION INHIBITORS, AND ACETYLATION OF GP41 FRAGMENTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 1558408,
	"label": "METHODS FOR THE RECOMBINANT PRODUCTION OF PEPTIDIC ANTIVIRAL FUSION INHIBITORS, AND ACETYLATION OF GP41 FRAGMENTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1558408,
	"label": "METHODS FOR THE RECOMBINANT PRODUCTION OF PEPTIDIC ANTIVIRAL FUSION INHIBITORS, AND ACETYLATION OF GP41 FRAGMENTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37999,
	"type": 1558679,
	"label": "ANTIKÖRPERKONSTRUKTION UNTER VERWENDUNG EINER MRL/LPR-MAUS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37999,
	"target": 32770,
	"type": 1558679,
	"label": "ANTIKÖRPERKONSTRUKTION UNTER VERWENDUNG EINER MRL/LPR-MAUS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1558679,
	"label": "ANTIKÖRPERKONSTRUKTION UNTER VERWENDUNG EINER MRL/LPR-MAUS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7409,
	"target": 6185,
	"type": 1559444,
	"label": "COMPUESTOS AGONISTAS DE RETINOIDES DE ALQUIL UREA, SU UTILIZACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y MEDICAMENTOS BASADOS EN DICHOS COMPUESTOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38042,
	"target": 6795,
	"type": 1560165,
	"label": "Tall-1 receptor molecules and uses thereof",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 1560537,
	"label": "Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 1560537,
	"label": "Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 1560537,
	"label": "Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 1560537,
	"label": "Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 6795,
	"type": 1560537,
	"label": "Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1561044,
	"label": "agente de ligação especìfico, hibridoma, conjugado, molécula de ácido nucleico, vetor, célula hospedeira, métodos de fabricar um agente de ligação especìfico, de fabricar um anticorpo, de unibir a angiogênese indesejada em um mamìfero e de tratar cáncer em um mamìfero, composição farmacêutica, métodos de modular ou inibir a atividade da angiopoietina-2, de modular pelo menos um dentre a permeabilidade vascular ou o vazamento de plasma em um mamìfero, de tratar doença e de detectar o nìvel de ang",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 1561304,
	"label": "METODOS PARA IDENTIFICACION DE ENZIMAS CON ACTIVACION CITOTOXICA PARA EL COMBATE DE TUMORES YCOMPUESTOSANTI-CANCERIGENOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6371,
	"target": 6229,
	"type": 1561304,
	"label": "METODOS PARA IDENTIFICACION DE ENZIMAS CON ACTIVACION CITOTOXICA PARA EL COMBATE DE TUMORES YCOMPUESTOSANTI-CANCERIGENOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6382,
	"target": 6229,
	"type": 1561304,
	"label": "METODOS PARA IDENTIFICACION DE ENZIMAS CON ACTIVACION CITOTOXICA PARA EL COMBATE DE TUMORES YCOMPUESTOSANTI-CANCERIGENOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1562908,
	"label": "In vitro-fremgangsmate for a indusere deling av endotelceller, forsterke overlevelse for endotelceller eller indusere angiogenese ved a bringe cellene i kontakt med Bv8, og anvendelse av Bv8 i fremstillingen av et medikament til behandling av en tilstand som er assosiert med hormonproduserende vev.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 7425,
	"type": 1562908,
	"label": "In vitro-fremgangsmate for a indusere deling av endotelceller, forsterke overlevelse for endotelceller eller indusere angiogenese ved a bringe cellene i kontakt med Bv8, og anvendelse av Bv8 i fremstillingen av et medikament til behandling av en tilstand som er assosiert med hormonproduserende vev.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 7425,
	"type": 1562908,
	"label": "In vitro-fremgangsmate for a indusere deling av endotelceller, forsterke overlevelse for endotelceller eller indusere angiogenese ved a bringe cellene i kontakt med Bv8, og anvendelse av Bv8 i fremstillingen av et medikament til behandling av en tilstand som er assosiert med hormonproduserende vev.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37904,
	"target": 37859,
	"type": 1563387,
	"label": "ANTIBODIES RAISED AGAINST alpha-INTERFERON",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37993,
	"target": 37904,
	"type": 1563387,
	"label": "ANTIBODIES RAISED AGAINST alpha-INTERFERON",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37993,
	"target": 37859,
	"type": 1563387,
	"label": "ANTIBODIES RAISED AGAINST alpha-INTERFERON",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 1563387,
	"label": "ANTIBODIES RAISED AGAINST alpha-INTERFERON",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37904,
	"type": 1563387,
	"label": "ANTIBODIES RAISED AGAINST alpha-INTERFERON",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37904,
	"target": 37899,
	"type": 1563412,
	"label": "Treatment involving DKK-1 or antagonists thereof.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 1563412,
	"label": "Treatment involving DKK-1 or antagonists thereof.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1563412,
	"label": "Treatment involving DKK-1 or antagonists thereof.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37999,
	"target": 37986,
	"type": 1563423,
	"label": "FREMGANGSMÅDE TIL FREMSTILLING AF POLYPEPTIDER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37999,
	"type": 1563423,
	"label": "FREMGANGSMÅDE TIL FREMSTILLING AF POLYPEPTIDER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1563423,
	"label": "FREMGANGSMÅDE TIL FREMSTILLING AF POLYPEPTIDER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1564202,
	"label": "Methods of inhibiting transmission of a costimulatory signal of lymphocytes",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 1566023,
	"label": "2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 7424,
	"target": 7360,
	"type": 1566072,
	"label": "Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 1566072,
	"label": "Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 1566072,
	"label": "Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 30251,
	"target": 7507,
	"type": 1566072,
	"label": "Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 30251,
	"target": 7424,
	"type": 1566072,
	"label": "Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1566241,
	"label": "Fully human antibody Fab fragments with human interferon-gamma neutralizing activity",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 1566955,
	"label": "Use of a polypeptide in the manufacture of a medicament for inducing angiogenesis or liver regeneration",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1566955,
	"label": "Use of a polypeptide in the manufacture of a medicament for inducing angiogenesis or liver regeneration",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 1566955,
	"label": "Use of a polypeptide in the manufacture of a medicament for inducing angiogenesis or liver regeneration",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 1567295,
	"label": "AMPLIFIED ONCOGENES AND THEIR INVOLVEMENT IN CANCER",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 1567377,
	"label": "Derivados de 8-metóxi-(1,2,4)triazolo(1, 5-a)piridina e seus usos como ligantes do receptor de adenosina",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 1567556,
	"label": "Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 1567592,
	"label": "Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1567592,
	"label": "Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1567592,
	"label": "Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 1568336,
	"label": "Composto, método para produzir um composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade relacionada com os ossos em um paciente e sua utilização",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 1568336,
	"label": "Composto, método para produzir um composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade relacionada com os ossos em um paciente e sua utilização",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 1568336,
	"label": "Composto, método para produzir um composto, composição farmacêutica que compreende o mesmo, método para tratar uma enfermidade relacionada com os ossos em um paciente e sua utilização",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1568522,
	"label": "A DNA SEQUENCE AND ENCODED POLYPEPTIDE USEFUL IN THE DIAGNOSIS OF HEPATITIS DISEASE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1568522,
	"label": "A DNA SEQUENCE AND ENCODED POLYPEPTIDE USEFUL IN THE DIAGNOSIS OF HEPATITIS DISEASE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1568522,
	"label": "A DNA SEQUENCE AND ENCODED POLYPEPTIDE USEFUL IN THE DIAGNOSIS OF HEPATITIS DISEASE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37859,
	"target": 6795,
	"type": 1568522,
	"label": "A DNA SEQUENCE AND ENCODED POLYPEPTIDE USEFUL IN THE DIAGNOSIS OF HEPATITIS DISEASE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 1568522,
	"label": "A DNA SEQUENCE AND ENCODED POLYPEPTIDE USEFUL IN THE DIAGNOSIS OF HEPATITIS DISEASE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7510,
	"target": 7464,
	"type": 1569467,
	"label": "Trifluorometilpurinas como inibidores da fosfodiesterase 4",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7450,
	"target": 7424,
	"type": 1570279,
	"label": "Agent for treatment of metabolic bone disease",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1570327,
	"label": "HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES HLA-A24",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1570327,
	"label": "HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES HLA-A24",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1570327,
	"label": "HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES HLA-A24",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 1570327,
	"label": "HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES HLA-A24",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 6854,
	"type": 1570327,
	"label": "HLA-A24-RESTRICTED CANCER ANTIGEN PEPTIDES HLA-A24",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1573451,
	"label": "ACHAETE-SCUTE LIKE-2 POLYPEPTIDES AND ENCODING NUCLEIC ACIDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 1573451,
	"label": "ACHAETE-SCUTE LIKE-2 POLYPEPTIDES AND ENCODING NUCLEIC ACIDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1573451,
	"label": "ACHAETE-SCUTE LIKE-2 POLYPEPTIDES AND ENCODING NUCLEIC ACIDS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1573453,
	"label": "METHODS FOR SCREENING FOR AGENTS THAT MODULATE HEPATOCELLULAR CARCINOMA DEVELOPMENT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 1573453,
	"label": "METHODS FOR SCREENING FOR AGENTS THAT MODULATE HEPATOCELLULAR CARCINOMA DEVELOPMENT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 1573453,
	"label": "METHODS FOR SCREENING FOR AGENTS THAT MODULATE HEPATOCELLULAR CARCINOMA DEVELOPMENT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6808,
	"target": 6795,
	"type": 1576088,
	"label": "Método para preparar uma mistura isomérica predeterminada ou não dos análogos de ciclosporina a modificados no resìduo de 1-aminoácido, métodopara produzir uma mistura enriquecida com e-isÈmero ou com z-isÈmero de análogos de ciclosporina a modificados no resìduo de 1-aminoácido, mistura de (e) e (z)-isÈmeros, composição, método para a sìntese estereoseletiva do z-isÈmero de isatx247, método para a preparação de aldeìdo do ciclosporina a",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32788,
	"target": 32777,
	"type": 1576689,
	"label": "anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 1576689,
	"label": "anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37859,
	"target": 32788,
	"type": 1576689,
	"label": "anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37859,
	"target": 32777,
	"type": 1576689,
	"label": "anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 1576689,
	"label": "anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 1579686,
	"label": "REMEDY FOR LUNG CANCER",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7409,
	"target": 6483,
	"type": 1579686,
	"label": "REMEDY FOR LUNG CANCER",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 1579686,
	"label": "REMEDY FOR LUNG CANCER",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1579686,
	"label": "REMEDY FOR LUNG CANCER",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 7409,
	"type": 1579686,
	"label": "REMEDY FOR LUNG CANCER",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 1580132,
	"label": "DIMERIC POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF TUMORS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7360,
	"target": 6290,
	"type": 1582737,
	"label": "LXR MODULATORS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 1583301,
	"label": "PROTEIN PURIFICATION METHOD",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 30972,
	"target": 7509,
	"type": 1583307,
	"label": "COMPUESTOS ARILSULFONAMIDOBENCILICOS.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1583485,
	"label": "COMPLEXES AND METHODS OF USING SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 32595,
	"type": 1583485,
	"label": "COMPLEXES AND METHODS OF USING SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32595,
	"target": 6854,
	"type": 1583485,
	"label": "COMPLEXES AND METHODS OF USING SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32595,
	"target": 6795,
	"type": 1583485,
	"label": "COMPLEXES AND METHODS OF USING SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 1583485,
	"label": "COMPLEXES AND METHODS OF USING SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7437,
	"target": 7424,
	"type": 1583569,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 1584517,
	"label": "Gene amplification in cancer",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 38164,
	"type": 1584517,
	"label": "Gene amplification in cancer",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 32478,
	"type": 1584517,
	"label": "Gene amplification in cancer",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 1584691,
	"label": "ANTIBODY VARIANTS CAPABLE OF BINDING TO THE EXRACELLULAR DOMAIN OF HER2 AND ARTICLE OF MANUFACTURE COMPRISING SAID ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 1584691,
	"label": "ANTIBODY VARIANTS CAPABLE OF BINDING TO THE EXRACELLULAR DOMAIN OF HER2 AND ARTICLE OF MANUFACTURE COMPRISING SAID ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 1584691,
	"label": "ANTIBODY VARIANTS CAPABLE OF BINDING TO THE EXRACELLULAR DOMAIN OF HER2 AND ARTICLE OF MANUFACTURE COMPRISING SAID ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1584691,
	"label": "ANTIBODY VARIANTS CAPABLE OF BINDING TO THE EXRACELLULAR DOMAIN OF HER2 AND ARTICLE OF MANUFACTURE COMPRISING SAID ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32772,
	"target": 7508,
	"type": 1584691,
	"label": "ANTIBODY VARIANTS CAPABLE OF BINDING TO THE EXRACELLULAR DOMAIN OF HER2 AND ARTICLE OF MANUFACTURE COMPRISING SAID ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 1584988,
	"label": "IMIDAZO-CONDENSED COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 1586089,
	"label": "DERIVADOS DE ESTRONA Y PROCEDIMIENTOS PARA PRODUCIRLOS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7450,
	"target": 6419,
	"type": 1586089,
	"label": "DERIVADOS DE ESTRONA Y PROCEDIMIENTOS PARA PRODUCIRLOS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6419,
	"type": 1586089,
	"label": "DERIVADOS DE ESTRONA Y PROCEDIMIENTOS PARA PRODUCIRLOS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 1587302,
	"label": "METHOD OF ASSAYING ACTIVITY OF BINDING TO VITAMIN D3 RECEPTOR USING FLUORESCENCE POLARIZATION",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 1587302,
	"label": "METHOD OF ASSAYING ACTIVITY OF BINDING TO VITAMIN D3 RECEPTOR USING FLUORESCENCE POLARIZATION",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 1587302,
	"label": "METHOD OF ASSAYING ACTIVITY OF BINDING TO VITAMIN D3 RECEPTOR USING FLUORESCENCE POLARIZATION",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1588107,
	"label": "ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1590661,
	"label": "NUCLEIC ACID MOLECULE ENCODING A gp 130 - LIKE MONOCYTE RECEPTOR (GLM-R) POLYPEPTIDE AND ITS USE FOR PRODUCING A GLM-R POLYPEPTIDE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1590661,
	"label": "NUCLEIC ACID MOLECULE ENCODING A gp 130 - LIKE MONOCYTE RECEPTOR (GLM-R) POLYPEPTIDE AND ITS USE FOR PRODUCING A GLM-R POLYPEPTIDE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 32779,
	"type": 1590661,
	"label": "NUCLEIC ACID MOLECULE ENCODING A gp 130 - LIKE MONOCYTE RECEPTOR (GLM-R) POLYPEPTIDE AND ITS USE FOR PRODUCING A GLM-R POLYPEPTIDE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 1590661,
	"label": "NUCLEIC ACID MOLECULE ENCODING A gp 130 - LIKE MONOCYTE RECEPTOR (GLM-R) POLYPEPTIDE AND ITS USE FOR PRODUCING A GLM-R POLYPEPTIDE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 1590661,
	"label": "NUCLEIC ACID MOLECULE ENCODING A gp 130 - LIKE MONOCYTE RECEPTOR (GLM-R) POLYPEPTIDE AND ITS USE FOR PRODUCING A GLM-R POLYPEPTIDE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1594045,
	"label": "ANTICUERPOS ESPECIFICOS PARA DOS REGIONES DEL PEPTIDO AMILOIDE BETA (BETA A4); ACIDOS NUCLEICOS QUE LOS CODIFICAN; COMPOSICION QUE LOS COMPRENDE; KIT QUE COMPRENDEN LOS ANTICUERPOS; PROCEDIMIENTO DE PREPARACION; USOS PARA PREVENIR Y TRATAR ENFERMEDAD",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1594045,
	"label": "ANTICUERPOS ESPECIFICOS PARA DOS REGIONES DEL PEPTIDO AMILOIDE BETA (BETA A4); ACIDOS NUCLEICOS QUE LOS CODIFICAN; COMPOSICION QUE LOS COMPRENDE; KIT QUE COMPRENDEN LOS ANTICUERPOS; PROCEDIMIENTO DE PREPARACION; USOS PARA PREVENIR Y TRATAR ENFERMEDAD",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37862,
	"type": 1594045,
	"label": "ANTICUERPOS ESPECIFICOS PARA DOS REGIONES DEL PEPTIDO AMILOIDE BETA (BETA A4); ACIDOS NUCLEICOS QUE LOS CODIFICAN; COMPOSICION QUE LOS COMPRENDE; KIT QUE COMPRENDEN LOS ANTICUERPOS; PROCEDIMIENTO DE PREPARACION; USOS PARA PREVENIR Y TRATAR ENFERMEDAD",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 6854,
	"type": 1594045,
	"label": "ANTICUERPOS ESPECIFICOS PARA DOS REGIONES DEL PEPTIDO AMILOIDE BETA (BETA A4); ACIDOS NUCLEICOS QUE LOS CODIFICAN; COMPOSICION QUE LOS COMPRENDE; KIT QUE COMPRENDEN LOS ANTICUERPOS; PROCEDIMIENTO DE PREPARACION; USOS PARA PREVENIR Y TRATAR ENFERMEDAD",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 6854,
	"type": 1594045,
	"label": "ANTICUERPOS ESPECIFICOS PARA DOS REGIONES DEL PEPTIDO AMILOIDE BETA (BETA A4); ACIDOS NUCLEICOS QUE LOS CODIFICAN; COMPOSICION QUE LOS COMPRENDE; KIT QUE COMPRENDEN LOS ANTICUERPOS; PROCEDIMIENTO DE PREPARACION; USOS PARA PREVENIR Y TRATAR ENFERMEDAD",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56804,
	"target": 6957,
	"type": 1595390,
	"label": "Methods for identifying agents that modulate mast cell degranulation",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32022,
	"target": 7409,
	"type": 1595586,
	"label": "PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6854,
	"target": 6812,
	"type": 1596022,
	"label": "HM1.24-UTILIZING CANCER VACCINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1596022,
	"label": "HM1.24-UTILIZING CANCER VACCINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1596022,
	"label": "HM1.24-UTILIZING CANCER VACCINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 1596022,
	"label": "HM1.24-UTILIZING CANCER VACCINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 1596022,
	"label": "HM1.24-UTILIZING CANCER VACCINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6795,
	"target": 6483,
	"type": 1596883,
	"label": "Modulation of forkhead box o1a expression",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1596883,
	"label": "Modulation of forkhead box o1a expression",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 1596883,
	"label": "Modulation of forkhead box o1a expression",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 1596968,
	"label": "ANTIBODIES FIGHTING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) AND THEIR APPLICATION",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 7510,
	"type": 1596968,
	"label": "ANTIBODIES FIGHTING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) AND THEIR APPLICATION",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1596968,
	"label": "ANTIBODIES FIGHTING MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) AND THEIR APPLICATION",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1597533,
	"label": "HBV MUTATIONS ASSOCIATED WITH REDUCED SUSCEPTIBILITY TO ADEFOVIR.",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 37900,
	"type": 1598804,
	"label": "High affinity monoclonal antibody for recognizing the estrogen receptor (er) and method for creating the antibody",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 1598804,
	"label": "High affinity monoclonal antibody for recognizing the estrogen receptor (er) and method for creating the antibody",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1598804,
	"label": "High affinity monoclonal antibody for recognizing the estrogen receptor (er) and method for creating the antibody",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 1598805,
	"label": "High affinity monoclonal antibody for recognizing the progesterone receptor (pr) and method for creating the antibody",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 37900,
	"type": 1598805,
	"label": "High affinity monoclonal antibody for recognizing the progesterone receptor (pr) and method for creating the antibody",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 1598805,
	"label": "High affinity monoclonal antibody for recognizing the progesterone receptor (pr) and method for creating the antibody",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1598805,
	"label": "High affinity monoclonal antibody for recognizing the progesterone receptor (pr) and method for creating the antibody",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 1598805,
	"label": "High affinity monoclonal antibody for recognizing the progesterone receptor (pr) and method for creating the antibody",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7450,
	"target": 7360,
	"type": 1599801,
	"label": "7F4 GENE TRANSGENIC ANIMAL",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 7450,
	"type": 1599801,
	"label": "7F4 GENE TRANSGENIC ANIMAL",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 7360,
	"type": 1599801,
	"label": "7F4 GENE TRANSGENIC ANIMAL",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1599835,
	"label": "Method for removing DNA contaminants from a protein-containing sample",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 32769,
	"type": 1599835,
	"label": "Method for removing DNA contaminants from a protein-containing sample",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 32769,
	"type": 1599835,
	"label": "Method for removing DNA contaminants from a protein-containing sample",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32769,
	"target": 32527,
	"type": 1599835,
	"label": "Method for removing DNA contaminants from a protein-containing sample",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 32527,
	"type": 1599835,
	"label": "Method for removing DNA contaminants from a protein-containing sample",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32769,
	"target": 7507,
	"type": 1599971,
	"label": "THERAPEUTIC AGENT FOR CHONDROMA AND CHONDROSARCOMA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 1600157,
	"label": "TRANSPLANTABLE CELL WITH IMMUNE MODULATOR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37878,
	"target": 32698,
	"type": 1600157,
	"label": "TRANSPLANTABLE CELL WITH IMMUNE MODULATOR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32698,
	"type": 1600157,
	"label": "TRANSPLANTABLE CELL WITH IMMUNE MODULATOR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1600326,
	"label": "Bispecific antibody substituting for functional proteins wherein the antibody can recognize both a proteolytic enzyme and a substrate thereof such as blood coagulation/fibrinolysis associated factors",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 1600326,
	"label": "Bispecific antibody substituting for functional proteins wherein the antibody can recognize both a proteolytic enzyme and a substrate thereof such as blood coagulation/fibrinolysis associated factors",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1600326,
	"label": "Bispecific antibody substituting for functional proteins wherein the antibody can recognize both a proteolytic enzyme and a substrate thereof such as blood coagulation/fibrinolysis associated factors",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 1600953,
	"label": "Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7510,
	"target": 7464,
	"type": 1604685,
	"label": "Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7464,
	"target": 7409,
	"type": 1604685,
	"label": "Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 1604685,
	"label": "Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 32478,
	"type": 1608671,
	"label": "Method for predicting response to epidermal growth factor receptor-directed therapy",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 30814,
	"target": 7507,
	"type": 1608873,
	"label": "SUBSTITUTED ANTHRANILIC AMIDE DERIVATIVES AND METHODS OF USE.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 7409,
	"type": 1609842,
	"label": "anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6476,
	"target": 6462,
	"type": 1609975,
	"label": "Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 6462,
	"target": 6371,
	"type": 1609975,
	"label": "Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 6476,
	"target": 6371,
	"type": 1609975,
	"label": "Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6476,
	"type": 1609975,
	"label": "Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6462,
	"type": 1609975,
	"label": "Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1610309,
	"label": "APO-2 ligand/trail variants and uses thereof",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37999,
	"target": 7507,
	"type": 1610309,
	"label": "APO-2 ligand/trail variants and uses thereof",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37999,
	"target": 6795,
	"type": 1610309,
	"label": "APO-2 ligand/trail variants and uses thereof",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7497,
	"target": 6816,
	"type": 1615443,
	"label": "Application of L-FMAU for preparation of medicament for combination therapies of hepatitis b virus infection",
	"group": "Gilead",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1618288,
	"label": "VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODULATION UND ZUM NACHWEIS VON WISP-AKTIVITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1618288,
	"label": "VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODULATION UND ZUM NACHWEIS VON WISP-AKTIVITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32771,
	"target": 6854,
	"type": 1618288,
	"label": "VERFAHREN UND ZUSAMMENSETZUNGEN ZUR MODULATION UND ZUM NACHWEIS VON WISP-AKTIVITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56740,
	"target": 30485,
	"type": 1619154,
	"label": "Ferrocene compounds and uses thereof",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 30630,
	"type": 1619485,
	"label": "2,3-DIHYDROISOINDOL-1-ONES POSSESSING INHIBITORY EFFECT ON MAO B ACTIVITY",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 30630,
	"target": 7360,
	"type": 1619485,
	"label": "2,3-DIHYDROISOINDOL-1-ONES POSSESSING INHIBITORY EFFECT ON MAO B ACTIVITY",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 1619485,
	"label": "2,3-DIHYDROISOINDOL-1-ONES POSSESSING INHIBITORY EFFECT ON MAO B ACTIVITY",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6795,
	"target": 6417,
	"type": 1619591,
	"label": "COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1619591,
	"label": "COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6417,
	"type": 1619591,
	"label": "COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7358,
	"target": 6376,
	"type": 1620997,
	"label": "Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 1622295,
	"label": "COMPUESTOS DERIVADOS DE 7-AZA-QUINAZOLINA SUSTITUIDA, INHIBIDORES DE QUINASA P38; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA; Y SU USO PARA TRATAR ARTRITIS, ENFERMEDAD DE CROHN, ALZHEIMER, ASMA, ATAQUE AL CORAZON.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7359,
	"target": 6795,
	"type": 1622312,
	"label": "Method of preventing beta cell disruption in pancreatic Langerhans' islets",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32777,
	"target": 6795,
	"type": 1622320,
	"label": "Formulaciones de anticuerpos y de proteínas a concentración elevada",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6471,
	"type": 1622980,
	"label": "METHOD OF DRUG LOADING IN LIPOSOMES BY GRADIENT",
	"group": "Gilead",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 1624171,
	"label": "COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 1624234,
	"label": "ANTIKÖRPER GEGEN GESCHÄDIGTES GEWEBE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 32772,
	"type": 1624234,
	"label": "ANTIKÖRPER GEGEN GESCHÄDIGTES GEWEBE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 1624234,
	"label": "ANTIKÖRPER GEGEN GESCHÄDIGTES GEWEBE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1625066,
	"label": "NOVEL CANCER-ASSOCIATED GENE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1625066,
	"label": "NOVEL CANCER-ASSOCIATED GENE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1625066,
	"label": "NOVEL CANCER-ASSOCIATED GENE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 1625066,
	"label": "NOVEL CANCER-ASSOCIATED GENE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 1625066,
	"label": "NOVEL CANCER-ASSOCIATED GENE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31056,
	"target": 7507,
	"type": 1625586,
	"label": "Polymorfe former av {6,7-Bis(2-metoksy-etoksy) kinazolin-4-yl(3-etynyl-fenyl)aminhydroklorid, fremgangsmate for fremstilling av slike, farmasoytisk preparat omfattende slike, slike forbindelser for anvendelse som medikament samt slike forbindelser for behandling av sykdommer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 1626530,
	"label": "Method for identifying antigen specific b cells",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1627124,
	"label": "PHARMACEUTICAL COMPOSITIONS CONTAINING AN INTERLEUKIN-6 ANTIBODY FOR USE IN TREATING SPINAL CORD INJURY",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 1627135,
	"label": "Deazaflavin compounds and methods of use thereof",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 1627135,
	"label": "Deazaflavin compounds and methods of use thereof",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 1627135,
	"label": "Deazaflavin compounds and methods of use thereof",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1628754,
	"label": "DNA encoding a mast cell-derived membrane protein",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1628754,
	"label": "DNA encoding a mast cell-derived membrane protein",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1628754,
	"label": "DNA encoding a mast cell-derived membrane protein",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 30606,
	"type": 1628929,
	"label": "Composto, composição farmacêutica, uso de um composto e, método para modular mchr",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 30606,
	"target": 7360,
	"type": 1628929,
	"label": "Composto, composição farmacêutica, uso de um composto e, método para modular mchr",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 1628929,
	"label": "Composto, composição farmacêutica, uso de um composto e, método para modular mchr",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 1629423,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1629481,
	"label": "INTRON FUSION CONSTRUCT AND METHOD OF USING FOR SELECTING HIGH-EXPRESSING PRODUCTION CELL LINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1629481,
	"label": "INTRON FUSION CONSTRUCT AND METHOD OF USING FOR SELECTING HIGH-EXPRESSING PRODUCTION CELL LINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 1629481,
	"label": "INTRON FUSION CONSTRUCT AND METHOD OF USING FOR SELECTING HIGH-EXPRESSING PRODUCTION CELL LINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1629481,
	"label": "INTRON FUSION CONSTRUCT AND METHOD OF USING FOR SELECTING HIGH-EXPRESSING PRODUCTION CELL LINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1629481,
	"label": "INTRON FUSION CONSTRUCT AND METHOD OF USING FOR SELECTING HIGH-EXPRESSING PRODUCTION CELL LINES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 1629608,
	"label": "DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAY",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1630110,
	"label": "Process for producing antibodies",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1630110,
	"label": "Process for producing antibodies",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1630110,
	"label": "Process for producing antibodies",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 1630110,
	"label": "Process for producing antibodies",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1630110,
	"label": "Process for producing antibodies",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 1630618,
	"label": "Method for the detection of pathogenic gram positive bacteria from the genera staphylococcus, enterococcus and streptococcus",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1631266,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 1631266,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 1631266,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1633030,
	"label": "AGONIST ANTIBODY AGAINST HETERORECEPTOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1633030,
	"label": "AGONIST ANTIBODY AGAINST HETERORECEPTOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1633030,
	"label": "AGONIST ANTIBODY AGAINST HETERORECEPTOR",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 1634873,
	"label": "Novel compositions and methods for the treatment of immune related disease",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 32754,
	"type": 1635607,
	"label": "Compositions and methods for the diagnosis and treatment of tumor",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 1635607,
	"label": "Compositions and methods for the diagnosis and treatment of tumor",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 32754,
	"type": 1635607,
	"label": "Compositions and methods for the diagnosis and treatment of tumor",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32754,
	"target": 6795,
	"type": 1635607,
	"label": "Compositions and methods for the diagnosis and treatment of tumor",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 1635607,
	"label": "Compositions and methods for the diagnosis and treatment of tumor",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38042,
	"target": 6812,
	"type": 1636177,
	"label": "OB fusion protein compositions and methods",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 1637459,
	"label": "COMBINATION THERAPY WITH CO-STIMULATORY FACTORS.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 6816,
	"target": 6478,
	"type": 1640851,
	"label": "-MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37993,
	"target": 32769,
	"type": 1641429,
	"label": "ANTICUERPOS DIRIGIDOS FRENTE A LA HORMONA PARATIROIDEA (PTH) Y USOS DE LOS MISMOS.",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 32779,
	"target": 32777,
	"type": 1641664,
	"label": "METHODS AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 1641664,
	"label": "METHODS AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1641664,
	"label": "METHODS AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 1641664,
	"label": "METHODS AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 1641664,
	"label": "METHODS AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7497,
	"target": 6500,
	"type": 1642178,
	"label": "DERIVADOS DE NUCLEOSIDO ANTIVIRALES",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 1644163,
	"label": "METHODS FOR PRODUCING HUMANIZED ANTIBODIES AND IMPROVING YIELD OF ANTIBODIES OR ANTIGEN BINDING FRAGMENTS IN CELL CULTURE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1644163,
	"label": "METHODS FOR PRODUCING HUMANIZED ANTIBODIES AND IMPROVING YIELD OF ANTIBODIES OR ANTIGEN BINDING FRAGMENTS IN CELL CULTURE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 1644163,
	"label": "METHODS FOR PRODUCING HUMANIZED ANTIBODIES AND IMPROVING YIELD OF ANTIBODIES OR ANTIGEN BINDING FRAGMENTS IN CELL CULTURE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 32777,
	"type": 1644163,
	"label": "METHODS FOR PRODUCING HUMANIZED ANTIBODIES AND IMPROVING YIELD OF ANTIBODIES OR ANTIGEN BINDING FRAGMENTS IN CELL CULTURE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32777,
	"type": 1644163,
	"label": "METHODS FOR PRODUCING HUMANIZED ANTIBODIES AND IMPROVING YIELD OF ANTIBODIES OR ANTIGEN BINDING FRAGMENTS IN CELL CULTURE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 1644174,
	"label": "Nucleic acids encoding a fusion polypeptide having ß(1,4) -n-acetylglucosaminyl transferase iii activity or ß(1,4)-galactosyl transferase activity and comprising a golgi localization domain of human mannosidase ii and uses thereof",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38042,
	"target": 32772,
	"type": 1644174,
	"label": "Nucleic acids encoding a fusion polypeptide having ß(1,4) -n-acetylglucosaminyl transferase iii activity or ß(1,4)-galactosyl transferase activity and comprising a golgi localization domain of human mannosidase ii and uses thereof",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38042,
	"target": 32770,
	"type": 1644174,
	"label": "Nucleic acids encoding a fusion polypeptide having ß(1,4) -n-acetylglucosaminyl transferase iii activity or ß(1,4)-galactosyl transferase activity and comprising a golgi localization domain of human mannosidase ii and uses thereof",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1644174,
	"label": "Nucleic acids encoding a fusion polypeptide having ß(1,4) -n-acetylglucosaminyl transferase iii activity or ß(1,4)-galactosyl transferase activity and comprising a golgi localization domain of human mannosidase ii and uses thereof",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 6795,
	"type": 1644174,
	"label": "Nucleic acids encoding a fusion polypeptide having ß(1,4) -n-acetylglucosaminyl transferase iii activity or ß(1,4)-galactosyl transferase activity and comprising a golgi localization domain of human mannosidase ii and uses thereof",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38065,
	"target": 7508,
	"type": 1645015,
	"label": "WT1 GENE TRANSGENIC ANIMAL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32689,
	"target": 6795,
	"type": 1645331,
	"label": "Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 6550,
	"target": 6376,
	"type": 1645928,
	"label": "PYRIMIDINE COMPOUNDS WITH SELECTIVE INHIBITION OF ¦-¦ AND L¦L¦ ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6550,
	"type": 1645928,
	"label": "PYRIMIDINE COMPOUNDS WITH SELECTIVE INHIBITION OF ¦-¦ AND L¦L¦ ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 1645928,
	"label": "PYRIMIDINE COMPOUNDS WITH SELECTIVE INHIBITION OF ¦-¦ AND L¦L¦ ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1658770,
	"label": "A System for antibody expression and assembly",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 1658770,
	"label": "A System for antibody expression and assembly",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1658770,
	"label": "A System for antibody expression and assembly",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 1658770,
	"label": "A System for antibody expression and assembly",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 1658770,
	"label": "A System for antibody expression and assembly",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32501,
	"target": 6417,
	"type": 1659901,
	"label": "NOUVEAUX 19-NOR-D-HOMO-PREGNANES UTILES COMME MEDICAMENTS ET LEUR PROCEDE DE PREPARATION",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 6854,
	"target": 6483,
	"type": 1660501,
	"label": "VERFAHREN ZUR HERSTELLUNG VON NEUEN PSORALENDERIVATEN.",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 32478,
	"target": 6854,
	"type": 1660501,
	"label": "VERFAHREN ZUR HERSTELLUNG VON NEUEN PSORALENDERIVATEN.",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 32478,
	"target": 6483,
	"type": 1660501,
	"label": "VERFAHREN ZUR HERSTELLUNG VON NEUEN PSORALENDERIVATEN.",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 6957,
	"target": 6539,
	"type": 1662735,
	"label": "WERKWIJZE VOOR HET STABILISEREN VAN EEN REAGENS, GESCHIKT VOOR DE BEREIDING VAN EEN RADIOFARMACEUTICUM, ALSMEDE WERKWIJZE VOOR HET BEREIDEN VAN EEN GESTABILISEERD RADIOFARMACEUTICUM.",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1689664,
	"label": "Polypeptide producing cells",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1689664,
	"label": "Polypeptide producing cells",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 1689664,
	"label": "Polypeptide producing cells",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 38065,
	"type": 1689664,
	"label": "Polypeptide producing cells",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1689664,
	"label": "Polypeptide producing cells",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 1691068,
	"label": "anticorpos isolados, polipeptìdeos imunoglobulina, anticorpo ifnar2, molécula de acido nucléico, célula hospedeira, linhagem celular, método de produção do anticorpo, composição, método para diagnosticar a presença de ifnar2, método de tratamento de uma doença e métodos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 7360,
	"type": 1691575,
	"label": "composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7360,
	"target": 6290,
	"type": 1691575,
	"label": "composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 6290,
	"type": 1691575,
	"label": "composto, processo para sua preparaÇço, composiÇço farmacÊutica, uso de um composto e mÉtodo de tratamento de doenÇa ou desosrdem metabàlica.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 32769,
	"type": 1692332,
	"label": "Process for producing recombinant polypeptides via a glycerol phosphate or sugar phosphate feed",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1692570,
	"label": "anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1692570,
	"label": "anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1692570,
	"label": "anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 1692570,
	"label": "anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 1692570,
	"label": "anticorpos, anticorpos anti c-met humanizados, método de inibição de proliferação celular de c-met ativado, método de modulação de uma doença associada com descontrole de sinalização de hgf/c-met, método para o tratamento de um sujeito com cáncer, método para o tratamento de um distúrbio proliferativo, ácido nucléico, célula hospedeira e composição",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 1692798,
	"label": "quinazolinilmetilenotiazolinonas como inibidores de cdk1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37947,
	"target": 7507,
	"type": 1692831,
	"label": "anticorpos isolados e método de tratamento de uma doença associada com descontrole da sinalização do hgf/c-met",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1692939,
	"label": "METHOD FOR PRODUCING SOLUBLE MULTIPASS TRANSMEMBRANE PROTEINS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 1693496,
	"label": "ANTIBODIES NEUTRALISING GRANULOCYTIC MACROPHAGEAL COLONY-STIMULATING HUMAN FACTOR",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 7508,
	"type": 1693496,
	"label": "ANTIBODIES NEUTRALISING GRANULOCYTIC MACROPHAGEAL COLONY-STIMULATING HUMAN FACTOR",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 1693496,
	"label": "ANTIBODIES NEUTRALISING GRANULOCYTIC MACROPHAGEAL COLONY-STIMULATING HUMAN FACTOR",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 1693706,
	"label": "anticorpo isolado, conjugado de droga e anticorpo, formulação farmacêutica, método de inibição da proliferação celular, método de tratamento de cáncer, teste de detecção de células cancerosas, artigo industrializado, uso de um composto conjugado de droga e anticorpo e uso de uma formulação farmacêutica",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1693706,
	"label": "anticorpo isolado, conjugado de droga e anticorpo, formulação farmacêutica, método de inibição da proliferação celular, método de tratamento de cáncer, teste de detecção de células cancerosas, artigo industrializado, uso de um composto conjugado de droga e anticorpo e uso de uma formulação farmacêutica",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 1693706,
	"label": "anticorpo isolado, conjugado de droga e anticorpo, formulação farmacêutica, método de inibição da proliferação celular, método de tratamento de cáncer, teste de detecção de células cancerosas, artigo industrializado, uso de um composto conjugado de droga e anticorpo e uso de uma formulação farmacêutica",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1694014,
	"label": "Methods and compositions related to B cell assays",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 1694496,
	"label": "MONKEY IMMUNOGLOBULIN SEQUENCES",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1694496,
	"label": "MONKEY IMMUNOGLOBULIN SEQUENCES",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 37859,
	"type": 1694496,
	"label": "MONKEY IMMUNOGLOBULIN SEQUENCES",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37859,
	"target": 32779,
	"type": 1694496,
	"label": "MONKEY IMMUNOGLOBULIN SEQUENCES",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 1694496,
	"label": "MONKEY IMMUNOGLOBULIN SEQUENCES",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 56765,
	"type": 1694731,
	"label": "COP1-MOLEKÜLE UND VERWENDUNGEN DAVON",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7508,
	"target": 6489,
	"type": 1694731,
	"label": "COP1-MOLEKÜLE UND VERWENDUNGEN DAVON",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56765,
	"target": 7508,
	"type": 1694731,
	"label": "COP1-MOLEKÜLE UND VERWENDUNGEN DAVON",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 7508,
	"type": 1694731,
	"label": "COP1-MOLEKÜLE UND VERWENDUNGEN DAVON",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56765,
	"target": 6489,
	"type": 1694731,
	"label": "COP1-MOLEKÜLE UND VERWENDUNGEN DAVON",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 1695137,
	"label": "método de aumento do esgotamento de células b em mamìferos, método de aumento da eficácia do esgotamento de células b, método de tratamento de malignidade ou neoplasma de células b, método de alìvio de disfunção autoimunológica regulada por células b, método de esgotamento das células b e composição",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 1695303,
	"label": "método de identificação de uma substáncia inibidora candidata e molécula antagonista",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1695352,
	"label": "Inhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 1695892,
	"label": "COMBINATION OF APO2L/TRAIL AND EGFR INHIBITOR FOR CANCER TREATMENT, METHOD IN VITRO OF APOPTOSIS INCREASE AND APPLICATION OF COMBINATION FOR OBTAINING MEDICATION FOR CANCER TREATMENT",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1695892,
	"label": "COMBINATION OF APO2L/TRAIL AND EGFR INHIBITOR FOR CANCER TREATMENT, METHOD IN VITRO OF APOPTOSIS INCREASE AND APPLICATION OF COMBINATION FOR OBTAINING MEDICATION FOR CANCER TREATMENT",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 1695892,
	"label": "COMBINATION OF APO2L/TRAIL AND EGFR INHIBITOR FOR CANCER TREATMENT, METHOD IN VITRO OF APOPTOSIS INCREASE AND APPLICATION OF COMBINATION FOR OBTAINING MEDICATION FOR CANCER TREATMENT",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 32769,
	"type": 1695998,
	"label": "Nucleic acids encoding hamster 1GF-1 proteins and methods thereof",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 1697918,
	"label": "COMPOSITIONS AND METHODS FOR TREATMENT OF NON-HODGKIN'S LYMPHOMA",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1697925,
	"label": "composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6802,
	"target": 6795,
	"type": 1698032,
	"label": "COMPUESTOS PARA INHIBICION ENZIMATICA DE PROTEASOMA.",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1698328,
	"label": "Antistoffer rettet mod GPNMB og anvendelser deraf",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1698328,
	"label": "Antistoffer rettet mod GPNMB og anvendelser deraf",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 1698328,
	"label": "Antistoffer rettet mod GPNMB og anvendelser deraf",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 1698328,
	"label": "Antistoffer rettet mod GPNMB og anvendelser deraf",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 1698328,
	"label": "Antistoffer rettet mod GPNMB og anvendelser deraf",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 1699702,
	"label": "método de tratamento de disfunção ocular em mamìferos",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 1699702,
	"label": "método de tratamento de disfunção ocular em mamìferos",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1699702,
	"label": "método de tratamento de disfunção ocular em mamìferos",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1699823,
	"label": "COMPOSICIONES QUE COMPRENDEN POLIPEPTIDOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 1699823,
	"label": "COMPOSICIONES QUE COMPRENDEN POLIPEPTIDOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1699823,
	"label": "COMPOSICIONES QUE COMPRENDEN POLIPEPTIDOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 1699823,
	"label": "COMPOSICIONES QUE COMPRENDEN POLIPEPTIDOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 6854,
	"type": 1699823,
	"label": "COMPOSICIONES QUE COMPRENDEN POLIPEPTIDOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1699844,
	"label": "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSIS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1700537,
	"label": "ENSAYOS Y PROCEDIMIENTOS QUE UTILIZAN BIOMARCADORES.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56765,
	"target": 38237,
	"type": 1700537,
	"label": "ENSAYOS Y PROCEDIMIENTOS QUE UTILIZAN BIOMARCADORES.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38237,
	"target": 7507,
	"type": 1700537,
	"label": "ENSAYOS Y PROCEDIMIENTOS QUE UTILIZAN BIOMARCADORES.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38237,
	"target": 6854,
	"type": 1700537,
	"label": "ENSAYOS Y PROCEDIMIENTOS QUE UTILIZAN BIOMARCADORES.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56765,
	"target": 7507,
	"type": 1700537,
	"label": "ENSAYOS Y PROCEDIMIENTOS QUE UTILIZAN BIOMARCADORES.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1700764,
	"label": "ANTICUERPO ANTI-GLIPICANO 3 QUE TIENE CADENA DE AZUCAR MODIFICADA",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1700764,
	"label": "ANTICUERPO ANTI-GLIPICANO 3 QUE TIENE CADENA DE AZUCAR MODIFICADA",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1700764,
	"label": "ANTICUERPO ANTI-GLIPICANO 3 QUE TIENE CADENA DE AZUCAR MODIFICADA",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 1700799,
	"label": "Indole-pyrimidine derivatives and their use as inhibitors of phosphatidylinositol 3-kinase (PI3K)",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37878,
	"target": 37875,
	"type": 1700979,
	"label": "A method of culturing a cell and use of the same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 1700979,
	"label": "A method of culturing a cell and use of the same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 1700979,
	"label": "A method of culturing a cell and use of the same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1700979,
	"label": "A method of culturing a cell and use of the same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38181,
	"target": 37878,
	"type": 1700979,
	"label": "A method of culturing a cell and use of the same",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 1702975,
	"label": "anti-robo1 antibody for preparing medicine for cancer diagnosis and treatment and related diagnosis kit",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 1702975,
	"label": "anti-robo1 antibody for preparing medicine for cancer diagnosis and treatment and related diagnosis kit",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 1702975,
	"label": "anti-robo1 antibody for preparing medicine for cancer diagnosis and treatment and related diagnosis kit",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1702975,
	"label": "anti-robo1 antibody for preparing medicine for cancer diagnosis and treatment and related diagnosis kit",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1702975,
	"label": "anti-robo1 antibody for preparing medicine for cancer diagnosis and treatment and related diagnosis kit",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6376,
	"target": 6360,
	"type": 1703110,
	"label": "Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6360,
	"target": 6341,
	"type": 1703110,
	"label": "Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6376,
	"target": 6341,
	"type": 1703110,
	"label": "Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor)",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6376,
	"target": 6341,
	"type": 1703111,
	"label": "Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6539,
	"target": 6376,
	"type": 1703111,
	"label": "Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6539,
	"target": 6341,
	"type": 1703111,
	"label": "Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1703146,
	"label": "anticorpo isolado ou região de ligação de antìgeno do mesmo, célula de hibridoma, célula de transfectoma, anticorpo monoclonal ou região de ligação de antìgeno do mesmo, animal não humano transgênico, método para produzir um anticorpo ou região de ligação de antìgeno do mesmo, composição farmacêutica, uso do anticorpo ou região de ligação de antìgeno, polipeptìdeo isolado, imunoensaio, e, método para identificar um composto",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1703146,
	"label": "anticorpo isolado ou região de ligação de antìgeno do mesmo, célula de hibridoma, célula de transfectoma, anticorpo monoclonal ou região de ligação de antìgeno do mesmo, animal não humano transgênico, método para produzir um anticorpo ou região de ligação de antìgeno do mesmo, composição farmacêutica, uso do anticorpo ou região de ligação de antìgeno, polipeptìdeo isolado, imunoensaio, e, método para identificar um composto",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 1703146,
	"label": "anticorpo isolado ou região de ligação de antìgeno do mesmo, célula de hibridoma, célula de transfectoma, anticorpo monoclonal ou região de ligação de antìgeno do mesmo, animal não humano transgênico, método para produzir um anticorpo ou região de ligação de antìgeno do mesmo, composição farmacêutica, uso do anticorpo ou região de ligação de antìgeno, polipeptìdeo isolado, imunoensaio, e, método para identificar um composto",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1703146,
	"label": "anticorpo isolado ou região de ligação de antìgeno do mesmo, célula de hibridoma, célula de transfectoma, anticorpo monoclonal ou região de ligação de antìgeno do mesmo, animal não humano transgênico, método para produzir um anticorpo ou região de ligação de antìgeno do mesmo, composição farmacêutica, uso do anticorpo ou região de ligação de antìgeno, polipeptìdeo isolado, imunoensaio, e, método para identificar um composto",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 1703146,
	"label": "anticorpo isolado ou região de ligação de antìgeno do mesmo, célula de hibridoma, célula de transfectoma, anticorpo monoclonal ou região de ligação de antìgeno do mesmo, animal não humano transgênico, método para produzir um anticorpo ou região de ligação de antìgeno do mesmo, composição farmacêutica, uso do anticorpo ou região de ligação de antìgeno, polipeptìdeo isolado, imunoensaio, e, método para identificar um composto",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31846,
	"target": 6376,
	"type": 1703379,
	"label": "PHOSPHONATE SUBSTITUTED KINASE INHIBITORS",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 6892,
	"target": 6795,
	"type": 1704491,
	"label": "PHARMACEUTICAL FORMULATIONS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1704527,
	"label": "molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1704527,
	"label": "molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 1704527,
	"label": "molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1704527,
	"label": "molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 1704527,
	"label": "molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 1704551,
	"label": "oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 1704551,
	"label": "oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 1704551,
	"label": "oxadiazolil pirazol-piridiminas como antagonistas de mglur2, processo para sua preparação, composição farmacêutica que os contém e uso dos mesmo",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 1705160,
	"label": "METHOD OF REINFORCING ANTIBODY ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 1705160,
	"label": "METHOD OF REINFORCING ANTIBODY ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1705160,
	"label": "METHOD OF REINFORCING ANTIBODY ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 1705160,
	"label": "METHOD OF REINFORCING ANTIBODY ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 32779,
	"type": 1705160,
	"label": "METHOD OF REINFORCING ANTIBODY ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 7455,
	"type": 1705467,
	"label": "Lipid-based dispersions useful for drug delivery",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 7511,
	"target": 7490,
	"type": 1705652,
	"label": "METHOD OF TREATING ARTHRITIS AND PROMOTING GROWTH OF ARTICULAR CHONDROCYTES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7490,
	"target": 7450,
	"type": 1705652,
	"label": "METHOD OF TREATING ARTHRITIS AND PROMOTING GROWTH OF ARTICULAR CHONDROCYTES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7511,
	"target": 7450,
	"type": 1705652,
	"label": "METHOD OF TREATING ARTHRITIS AND PROMOTING GROWTH OF ARTICULAR CHONDROCYTES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 1705836,
	"label": "M13 VIRUS MAJOR COAT PROTEIN VARIANTS FOR C-TERMINAL AND BI-TERMINAL DISPLAY OF A HETEROLOGOUS PROTEIN",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6812,
	"target": 6471,
	"type": 1705857,
	"label": "Method of treating colorectal cancer tumor",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 1705857,
	"label": "Method of treating colorectal cancer tumor",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38237,
	"target": 6812,
	"type": 1705857,
	"label": "Method of treating colorectal cancer tumor",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38237,
	"target": 6471,
	"type": 1705857,
	"label": "Method of treating colorectal cancer tumor",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 6812,
	"type": 1705857,
	"label": "Method of treating colorectal cancer tumor",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 1706967,
	"label": "COMPOSITIONS AND METHODS FOR INCREASING THE STABILITY OF ANTIBODIES",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7360,
	"target": 6376,
	"type": 1707022,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptp-1b, e utilização dos compostos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 1707022,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptp-1b, e utilização dos compostos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 1707022,
	"label": "compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de ptp-1b, e utilização dos compostos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 1707541,
	"label": "Antibodies with altered effector functions",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 1707541,
	"label": "Antibodies with altered effector functions",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 1707541,
	"label": "Antibodies with altered effector functions",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 1707541,
	"label": "Antibodies with altered effector functions",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 1707541,
	"label": "Antibodies with altered effector functions",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 1707681,
	"label": "CELL DEATH INDUCING AGENTS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 1707681,
	"label": "CELL DEATH INDUCING AGENTS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 1707681,
	"label": "CELL DEATH INDUCING AGENTS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1707681,
	"label": "CELL DEATH INDUCING AGENTS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 1707681,
	"label": "CELL DEATH INDUCING AGENTS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6390,
	"target": 6333,
	"type": 1709108,
	"label": "1-SULFONYL-PIPERIDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 1709464,
	"label": "Liofilizados de proteínas concentrados, procedimientos y usos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 6812,
	"type": 1709464,
	"label": "Liofilizados de proteínas concentrados, procedimientos y usos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 1709464,
	"label": "Liofilizados de proteínas concentrados, procedimientos y usos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7479,
	"target": 7424,
	"type": 1709479,
	"label": "Aniline sulfonamide derivatives and their uses",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7424,
	"target": 6213,
	"type": 1709479,
	"label": "Aniline sulfonamide derivatives and their uses",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7479,
	"target": 6213,
	"type": 1709479,
	"label": "Aniline sulfonamide derivatives and their uses",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 30171,
	"target": 7479,
	"type": 1709479,
	"label": "Aniline sulfonamide derivatives and their uses",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 30171,
	"target": 7424,
	"type": 1709479,
	"label": "Aniline sulfonamide derivatives and their uses",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1709695,
	"label": "Compositions comprising cross-species-specific antibodies and uses thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1709695,
	"label": "Compositions comprising cross-species-specific antibodies and uses thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 1709695,
	"label": "Compositions comprising cross-species-specific antibodies and uses thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1709695,
	"label": "Compositions comprising cross-species-specific antibodies and uses thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1709695,
	"label": "Compositions comprising cross-species-specific antibodies and uses thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 1709811,
	"label": "Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 1709811,
	"label": "Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7509,
	"target": 6483,
	"type": 1709811,
	"label": "Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 1709811,
	"label": "Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 7509,
	"type": 1709811,
	"label": "Pharmaceutical antibody compositions with resistance to soluble CEA - comprising IgG1antibodies that bind to CEA",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1709812,
	"label": "composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição  farmacêuticas, e kits",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 1709812,
	"label": "composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição  farmacêuticas, e kits",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 1709812,
	"label": "composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição  farmacêuticas, e kits",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1709812,
	"label": "composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição  farmacêuticas, e kits",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7509,
	"type": 1709812,
	"label": "composições farmacêuticas com resistência a cea solúvel, processo de produção das mesmas, usos de anticorpo bi-especìfico de cadeia simples, molécula de ácido nucléico, vetor e hospedeiro na preparação de composição  farmacêuticas, e kits",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32772,
	"target": 6795,
	"type": 1710175,
	"label": "METHODS AND COMPOSITIONS FOR INHIBITING C-MET DIMERIZATION AND ACTIVATION",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 1710499,
	"label": "VERWENDUNG VON ADEFOVIR ODER TENOFOVIR ZUR HEMMUNG VON MMTV-ARTIGEN VIREN IM ZUSAMMENHANG MIT BRUSTKREBS UND PRIMÄRER BILIÄRER ZIRRHOSE",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 7425,
	"target": 7423,
	"type": 1710617,
	"label": "pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7423,
	"target": 7409,
	"type": 1710617,
	"label": "pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7425,
	"target": 7409,
	"type": 1710617,
	"label": "pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 1710617,
	"label": "pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7423,
	"type": 1710617,
	"label": "pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 37897,
	"type": 1710704,
	"label": "RNA INTERFERENCE MODULATOR OF HEDGEHOG SIGNALING AND USE FOR THE SAME",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37897,
	"target": 7507,
	"type": 1710704,
	"label": "RNA INTERFERENCE MODULATOR OF HEDGEHOG SIGNALING AND USE FOR THE SAME",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1710704,
	"label": "RNA INTERFERENCE MODULATOR OF HEDGEHOG SIGNALING AND USE FOR THE SAME",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1711180,
	"label": "ANTI-PROPERDIN ANTIBODIES, AND METHODS FOR MAKING AND USING SAME.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 1711180,
	"label": "ANTI-PROPERDIN ANTIBODIES, AND METHODS FOR MAKING AND USING SAME.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 1711180,
	"label": "ANTI-PROPERDIN ANTIBODIES, AND METHODS FOR MAKING AND USING SAME.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37999,
	"target": 6795,
	"type": 1711203,
	"label": "POLYPEPTIDES THAT BIND BAFF AND/OR APRIL",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6489,
	"target": 6483,
	"type": 1711639,
	"label": "modulador da dscr1, métodos de tratamento, método de melhoria de efeitos colaterais e método de inibição do crescimento de tumores",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 1711895,
	"label": "HUMANISIERTE ANTIKÖRPER GEGEN CD40 UND VERFAHREN ZU IHRER ANWENDUNG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1711895,
	"label": "HUMANISIERTE ANTIKÖRPER GEGEN CD40 UND VERFAHREN ZU IHRER ANWENDUNG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 1711895,
	"label": "HUMANISIERTE ANTIKÖRPER GEGEN CD40 UND VERFAHREN ZU IHRER ANWENDUNG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1711895,
	"label": "HUMANISIERTE ANTIKÖRPER GEGEN CD40 UND VERFAHREN ZU IHRER ANWENDUNG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 1711895,
	"label": "HUMANISIERTE ANTIKÖRPER GEGEN CD40 UND VERFAHREN ZU IHRER ANWENDUNG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7450,
	"type": 1712018,
	"label": "inibidores de catepsina k",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 1712055,
	"label": "ANTIKÖRPER, DIE KREBSERKRANKUNGEN MODIFIZIEREN",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 1712055,
	"label": "ANTIKÖRPER, DIE KREBSERKRANKUNGEN MODIFIZIEREN",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 1712055,
	"label": "ANTIKÖRPER, DIE KREBSERKRANKUNGEN MODIFIZIEREN",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 1712055,
	"label": "ANTIKÖRPER, DIE KREBSERKRANKUNGEN MODIFIZIEREN",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 1712055,
	"label": "ANTIKÖRPER, DIE KREBSERKRANKUNGEN MODIFIZIEREN",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 1712059,
	"label": "Cancerous disease modifying antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 1712059,
	"label": "Cancerous disease modifying antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 1712059,
	"label": "Cancerous disease modifying antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1712059,
	"label": "Cancerous disease modifying antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 1712059,
	"label": "Cancerous disease modifying antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1712597,
	"label": "Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 1712597,
	"label": "Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 1712597,
	"label": "Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1713291,
	"label": "ERBB2-ANTAGONISTEN FÜR DIE TUMORSCHMERZTHERAPIE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 1713291,
	"label": "ERBB2-ANTAGONISTEN FÜR DIE TUMORSCHMERZTHERAPIE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 1713291,
	"label": "ERBB2-ANTAGONISTEN FÜR DIE TUMORSCHMERZTHERAPIE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1713291,
	"label": "ERBB2-ANTAGONISTEN FÜR DIE TUMORSCHMERZTHERAPIE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1713291,
	"label": "ERBB2-ANTAGONISTEN FÜR DIE TUMORSCHMERZTHERAPIE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 32698,
	"type": 1713357,
	"label": "sistema de expressão para a preparação de proteìnas de fusão de il-15/fc e seu uso",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38042,
	"target": 37875,
	"type": 1713357,
	"label": "sistema de expressão para a preparação de proteìnas de fusão de il-15/fc e seu uso",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37875,
	"target": 32788,
	"type": 1713357,
	"label": "sistema de expressão para a preparação de proteìnas de fusão de il-15/fc e seu uso",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37875,
	"target": 32698,
	"type": 1713357,
	"label": "sistema de expressão para a preparação de proteìnas de fusão de il-15/fc e seu uso",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 1713357,
	"label": "sistema de expressão para a preparação de proteìnas de fusão de il-15/fc e seu uso",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6203,
	"type": 1713481,
	"label": "método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1713481,
	"label": "método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6203,
	"type": 1713481,
	"label": "método de aliviar um granuloma anular ou sarcóide, artigo manufaturado e uso de um antagonista de lfa-1",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7422,
	"target": 6272,
	"type": 1713627,
	"label": "NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 30951,
	"target": 7422,
	"type": 1713627,
	"label": "NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 30951,
	"target": 6272,
	"type": 1713627,
	"label": "NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 1714698,
	"label": "TRANSGENIC RO S A26-LUC I F ERAS E MICE FOR BIOLUMINESCENT IMAGING",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 1714778,
	"label": "Derivados de pirrolopiridina para el tratamiento de enfermedades cancerosas",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 1714778,
	"label": "Derivados de pirrolopiridina para el tratamiento de enfermedades cancerosas",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 1714778,
	"label": "Derivados de pirrolopiridina para el tratamiento de enfermedades cancerosas",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1715207,
	"label": "ANTICUERPOS BIESPECIFICOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 1715207,
	"label": "ANTICUERPOS BIESPECIFICOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1715207,
	"label": "ANTICUERPOS BIESPECIFICOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 1715207,
	"label": "ANTICUERPOS BIESPECIFICOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 1715207,
	"label": "ANTICUERPOS BIESPECIFICOS.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 6398,
	"target": 6390,
	"type": 1715623,
	"label": "moduladores de receptor seletivo do subtipo gaba-a heterocìclicos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6390,
	"target": 6360,
	"type": 1715623,
	"label": "moduladores de receptor seletivo do subtipo gaba-a heterocìclicos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6398,
	"target": 6360,
	"type": 1715623,
	"label": "moduladores de receptor seletivo do subtipo gaba-a heterocìclicos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6360,
	"target": 6301,
	"type": 1715623,
	"label": "moduladores de receptor seletivo do subtipo gaba-a heterocìclicos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6390,
	"target": 6301,
	"type": 1715623,
	"label": "moduladores de receptor seletivo do subtipo gaba-a heterocìclicos",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 1715692,
	"label": "DR5 ANTIBODIES AND USES THEREOF.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 1715692,
	"label": "DR5 ANTIBODIES AND USES THEREOF.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 1715692,
	"label": "DR5 ANTIBODIES AND USES THEREOF.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32772,
	"target": 7510,
	"type": 1715692,
	"label": "DR5 ANTIBODIES AND USES THEREOF.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1715692,
	"label": "DR5 ANTIBODIES AND USES THEREOF.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 1715829,
	"label": "DIAGNOSIS AND TREATMENT OF SIGLEC-6 ASSOCIATED DISEASES.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 1715829,
	"label": "DIAGNOSIS AND TREATMENT OF SIGLEC-6 ASSOCIATED DISEASES.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 1715829,
	"label": "DIAGNOSIS AND TREATMENT OF SIGLEC-6 ASSOCIATED DISEASES.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 1715877,
	"label": "ANTICUERPO ANTI-GLIPICANO 3 .",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1715877,
	"label": "ANTICUERPO ANTI-GLIPICANO 3 .",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1715877,
	"label": "ANTICUERPO ANTI-GLIPICANO 3 .",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 7358,
	"type": 1715877,
	"label": "ANTICUERPO ANTI-GLIPICANO 3 .",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 1715877,
	"label": "ANTICUERPO ANTI-GLIPICANO 3 .",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 1716746,
	"label": "SUSTRATO PARA LA ACTIVIDAD ENZIMATICA DE RPN 11.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 1716746,
	"label": "SUSTRATO PARA LA ACTIVIDAD ENZIMATICA DE RPN 11.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 1716746,
	"label": "SUSTRATO PARA LA ACTIVIDAD ENZIMATICA DE RPN 11.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6376,
	"target": 6302,
	"type": 1717025,
	"label": "Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 1717025,
	"label": "Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 1717025,
	"label": "Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32004,
	"target": 7507,
	"type": 1717025,
	"label": "Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32004,
	"target": 6376,
	"type": 1717025,
	"label": "Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer comprising a novel water-soluble prodrug",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 1717670,
	"label": "métodos de tratamento de doenças autoimunológicas em pacientes",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1717931,
	"label": "molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 1717931,
	"label": "molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 1717931,
	"label": "molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1717931,
	"label": "molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 1717931,
	"label": "molécula de ligação biespecìfica, seqüência de ácido nucléico, vetor, processo para a produção da molécula de ligação biespecìfica, composição, uso da molécula de ligação biespecìfica na preparação da composição farmacêutica, e kit",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 1718369,
	"label": "quinolinos 4-monossubstituìdos por tiazolinona",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 1718745,
	"label": "CANCER PROGNOSTIC, DIAGNOSTIC AND TREATMENT METHODS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7511,
	"target": 7510,
	"type": 1718853,
	"label": "DOSIS DE ANTICUERPOS EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LAS CELULAS B",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 1718853,
	"label": "DOSIS DE ANTICUERPOS EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LAS CELULAS B",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7511,
	"target": 6376,
	"type": 1718853,
	"label": "DOSIS DE ANTICUERPOS EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LAS CELULAS B",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 1718859,
	"label": "Ureas 1,3-diarilsustituidas como moduladores de la actividad quinasa",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 1719216,
	"label": "Anti-IL2 antistoffer",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 1719290,
	"label": "APOPTOSIS SENSITIVITY TO AP02L/TRAIL BY TESTING FOR GALNAC-T14 EXPRESSION IN CELL/TISSUE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1719290,
	"label": "APOPTOSIS SENSITIVITY TO AP02L/TRAIL BY TESTING FOR GALNAC-T14 EXPRESSION IN CELL/TISSUE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 1719290,
	"label": "APOPTOSIS SENSITIVITY TO AP02L/TRAIL BY TESTING FOR GALNAC-T14 EXPRESSION IN CELL/TISSUE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 1719305,
	"label": "inibidores pentacìclicos de quinase",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 1719476,
	"label": "Isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereof",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 1719476,
	"label": "Isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereof",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 7360,
	"type": 1719476,
	"label": "Isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereof",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1719824,
	"label": "PHARMACEUTICAL COMPOSITIONS CONTAINING AN INTERLEUKIN-6 ANTAGONIST",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 1720087,
	"label": "BEHANDLING AF CANCER MED HIDTIL UKENDTE ANTI-IL 13 MONOKLONALE ANTISTOFFER",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 7450,
	"type": 1720326,
	"label": "Methods of identifying agents that ameliorate or modulate effects of PRO1328 gene disruptions",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32777,
	"type": 1720377,
	"label": "ANTICUERPOS REPARADORES CON CDR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 1720377,
	"label": "ANTICUERPOS REPARADORES CON CDR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 1720377,
	"label": "ANTICUERPOS REPARADORES CON CDR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 1720377,
	"label": "ANTICUERPOS REPARADORES CON CDR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32777,
	"type": 1720377,
	"label": "ANTICUERPOS REPARADORES CON CDR.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1720420,
	"label": "Method and composition for angiogenesis inhibition",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 1720683,
	"label": "PYROLO [2,3-D] PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31965,
	"target": 7507,
	"type": 1720683,
	"label": "PYROLO [2,3-D] PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 31965,
	"target": 6376,
	"type": 1720683,
	"label": "PYROLO [2,3-D] PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1720786,
	"label": "polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1720786,
	"label": "polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1720786,
	"label": "polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 1721466,
	"label": "antagonista que inibe atividade de sinalização c-met de um polipeptìdeo c-met hiperestabilizado humano, método de tratamento de um tumor e uso do antagonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1721466,
	"label": "antagonista que inibe atividade de sinalização c-met de um polipeptìdeo c-met hiperestabilizado humano, método de tratamento de um tumor e uso do antagonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37988,
	"target": 32770,
	"type": 1721466,
	"label": "antagonista que inibe atividade de sinalização c-met de um polipeptìdeo c-met hiperestabilizado humano, método de tratamento de um tumor e uso do antagonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1721466,
	"label": "antagonista que inibe atividade de sinalização c-met de um polipeptìdeo c-met hiperestabilizado humano, método de tratamento de um tumor e uso do antagonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1721466,
	"label": "antagonista que inibe atividade de sinalização c-met de um polipeptìdeo c-met hiperestabilizado humano, método de tratamento de um tumor e uso do antagonista",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1721618,
	"label": "METHOD OF PRODUCING ANTIBODIES WITH MODIFIED FUCOSYLATION LEVEL.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 1721618,
	"label": "METHOD OF PRODUCING ANTIBODIES WITH MODIFIED FUCOSYLATION LEVEL.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1721618,
	"label": "METHOD OF PRODUCING ANTIBODIES WITH MODIFIED FUCOSYLATION LEVEL.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 1721687,
	"label": "Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56765,
	"target": 38065,
	"type": 1721687,
	"label": "Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56765,
	"target": 37899,
	"type": 1721687,
	"label": "Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 1721711,
	"label": "IMPROVING ANTIBODY EXPRESSION USING VECTORS CONTAINING INSULATOR ELEMENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1721711,
	"label": "IMPROVING ANTIBODY EXPRESSION USING VECTORS CONTAINING INSULATOR ELEMENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 1721711,
	"label": "IMPROVING ANTIBODY EXPRESSION USING VECTORS CONTAINING INSULATOR ELEMENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1721711,
	"label": "IMPROVING ANTIBODY EXPRESSION USING VECTORS CONTAINING INSULATOR ELEMENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1721711,
	"label": "IMPROVING ANTIBODY EXPRESSION USING VECTORS CONTAINING INSULATOR ELEMENTS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 6502,
	"type": 1722000,
	"label": "Treatment for antiphospholipid-syndrome-related pregnancy complications",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1722774,
	"label": "ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1722774,
	"label": "ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1722774,
	"label": "ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1722774,
	"label": "ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 1722774,
	"label": "ANTI-EpCAM IMMUNOGLOBULINS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6812,
	"target": 6290,
	"type": 1722834,
	"label": "Heterocyclic self-immolative linkers and conjugates",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 1723109,
	"label": "NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6816,
	"type": 1723256,
	"label": "IMIDAZO[4,5-D]PYRIMIDINES, THEIR USES AND METHODS OF PREPARATION.",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37875,
	"type": 1723649,
	"label": "Compositions and Methods for the Diagnosis and Treatment of Tumor",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 1723649,
	"label": "Compositions and Methods for the Diagnosis and Treatment of Tumor",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1723649,
	"label": "Compositions and Methods for the Diagnosis and Treatment of Tumor",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38065,
	"target": 32779,
	"type": 1723656,
	"label": "ANTICUERPOS ANTIAMILOIDES HUMANIZADOS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 6854,
	"type": 1723656,
	"label": "ANTICUERPOS ANTIAMILOIDES HUMANIZADOS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38065,
	"target": 6854,
	"type": 1723656,
	"label": "ANTICUERPOS ANTIAMILOIDES HUMANIZADOS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 30171,
	"target": 6185,
	"type": 1723898,
	"label": "compostos, processo para a manufatura dos compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de l-cpt1 e utilização dos mesmos",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 1724152,
	"label": "Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 1724212,
	"label": "INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6795,
	"target": 6484,
	"type": 1724213,
	"label": "métodos de prevenção ou melhoria de doença ocular, uso de um inibidor de complemento, uso  de um sirna especìfico para uma proteìna do sistema complemento e uso de um ácido nucleico que codifica um inibidor do sistema complemento",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6367,
	"target": 6301,
	"type": 1724219,
	"label": "AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 1724219,
	"label": "AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 1724219,
	"label": "AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6281,
	"type": 1724226,
	"label": "TETRACYCLIC KINASE INHIBITORS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1724549,
	"label": "constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 1724549,
	"label": "constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1724549,
	"label": "constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1724549,
	"label": "constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1724549,
	"label": "constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1725471,
	"label": "EXPRESSION-ENHANCED POLYPEPTIDES",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 1725471,
	"label": "EXPRESSION-ENHANCED POLYPEPTIDES",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 38181,
	"target": 32779,
	"type": 1725471,
	"label": "EXPRESSION-ENHANCED POLYPEPTIDES",
	"group": "Amgen",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1726075,
	"label": "Methods for Producing Polypeptides by Regulating Polypeptide Association",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1726075,
	"label": "Methods for Producing Polypeptides by Regulating Polypeptide Association",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 1726075,
	"label": "Methods for Producing Polypeptides by Regulating Polypeptide Association",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1726075,
	"label": "Methods for Producing Polypeptides by Regulating Polypeptide Association",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 1726075,
	"label": "Methods for Producing Polypeptides by Regulating Polypeptide Association",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 1726120,
	"label": "azolidinonas de 1,5-naftiridina substituìda como inibidores de cdk",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 1726120,
	"label": "azolidinonas de 1,5-naftiridina substituìda como inibidores de cdk",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 1726120,
	"label": "azolidinonas de 1,5-naftiridina substituìda como inibidores de cdk",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 1726125,
	"label": "Thermocycling of a Block Comprising Multiple Sample",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 1727616,
	"label": "Fremgangsmater for anvendelse av APO2L-reseptoragonister og NK-celleaktivatorer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7487,
	"target": 6816,
	"type": 1727616,
	"label": "Fremgangsmater for anvendelse av APO2L-reseptoragonister og NK-celleaktivatorer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 1727616,
	"label": "Fremgangsmater for anvendelse av APO2L-reseptoragonister og NK-celleaktivatorer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37889,
	"target": 7507,
	"type": 1727616,
	"label": "Fremgangsmater for anvendelse av APO2L-reseptoragonister og NK-celleaktivatorer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37889,
	"target": 7487,
	"type": 1727616,
	"label": "Fremgangsmater for anvendelse av APO2L-reseptoragonister og NK-celleaktivatorer",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 1727631,
	"label": "Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7375,
	"target": 6795,
	"type": 1727933,
	"label": "método de tratamento de um distúrbio autoimune, uso de um agonista de tccr, métodos para aumentar a expressão de il-10 e de socs3 em linfócitos, método para a seleção de agonistas tccr, anticorpo monoclonal, linhagem celular de hibridoma, métodos de tratamento ou supressão de uma resposta imune e método de inibição da produção de il-17, il-6 ou gm-csf",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 7375,
	"type": 1727933,
	"label": "método de tratamento de um distúrbio autoimune, uso de um agonista de tccr, métodos para aumentar a expressão de il-10 e de socs3 em linfócitos, método para a seleção de agonistas tccr, anticorpo monoclonal, linhagem celular de hibridoma, métodos de tratamento ou supressão de uma resposta imune e método de inibição da produção de il-17, il-6 ou gm-csf",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1727933,
	"label": "método de tratamento de um distúrbio autoimune, uso de um agonista de tccr, métodos para aumentar a expressão de il-10 e de socs3 em linfócitos, método para a seleção de agonistas tccr, anticorpo monoclonal, linhagem celular de hibridoma, métodos de tratamento ou supressão de uma resposta imune e método de inibição da produção de il-17, il-6 ou gm-csf",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1728457,
	"label": "composição, liofilizado, kit, e, processo para preparar uma composição",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6390,
	"target": 6371,
	"type": 1728671,
	"label": "Methods of using diaminopyrimidine as P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7409,
	"target": 6390,
	"type": 1728671,
	"label": "Methods of using diaminopyrimidine as P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 1728671,
	"label": "Methods of using diaminopyrimidine as P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 6812,
	"type": 1729194,
	"label": "Compositions and methods to modulate an immune response to an immunogenic therapeutic agent",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 1729219,
	"label": "Humanized anti-CD47 antibody",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 1729219,
	"label": "Humanized anti-CD47 antibody",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 1729219,
	"label": "Humanized anti-CD47 antibody",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 1729219,
	"label": "Humanized anti-CD47 antibody",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 1729219,
	"label": "Humanized anti-CD47 antibody",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 1729266,
	"label": "VARIANTS OF THE EXTRACELLULAR DOMAIN OF BCMA AND USES THEREOF",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 30845,
	"target": 30820,
	"type": 1777086,
	"label": "Verfahren zur Herstellung von Cyclopent(ij)isochinolin-Derivaten",
	"group": "Roche",
	"time": 1964,
	"strength": 1
}, {
	"source": 37875,
	"target": 32777,
	"type": 1792421,
	"label": "Polypeptides that bind an anti-tissue factor antibody and uses thereof",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1796074,
	"label": "A method for the preparation of a polypeptide of interest by enzymatic cleavage of fusion proteins using Granzyme B protease",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 1796074,
	"label": "A method for the preparation of a polypeptide of interest by enzymatic cleavage of fusion proteins using Granzyme B protease",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 1796074,
	"label": "A method for the preparation of a polypeptide of interest by enzymatic cleavage of fusion proteins using Granzyme B protease",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37947,
	"target": 37864,
	"type": 1796074,
	"label": "A method for the preparation of a polypeptide of interest by enzymatic cleavage of fusion proteins using Granzyme B protease",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 1796074,
	"label": "A method for the preparation of a polypeptide of interest by enzymatic cleavage of fusion proteins using Granzyme B protease",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 6795,
	"type": 1796169,
	"label": "MODULACION DE LA INTERACCION ENTRE LA CADENA BETA DE HGF Y C-MET.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 7359,
	"type": 1799789,
	"label": "USO DE ANTICUERPOS CONTRA EL RECEPTOR DE IL-6 (IL-6R) Y UN INMUNOSUPRESOR, PREFERENTEMENTE METOTREXATO, PORQUE SIRVE PARA PREPARAR UN MEDICAMENTO UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON IL-6, PREFERENTEMENTE, ARTRITIS REUMATOIDE.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7359,
	"target": 6376,
	"type": 1799789,
	"label": "USO DE ANTICUERPOS CONTRA EL RECEPTOR DE IL-6 (IL-6R) Y UN INMUNOSUPRESOR, PREFERENTEMENTE METOTREXATO, PORQUE SIRVE PARA PREPARAR UN MEDICAMENTO UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON IL-6, PREFERENTEMENTE, ARTRITIS REUMATOIDE.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 1799789,
	"label": "USO DE ANTICUERPOS CONTRA EL RECEPTOR DE IL-6 (IL-6R) Y UN INMUNOSUPRESOR, PREFERENTEMENTE METOTREXATO, PORQUE SIRVE PARA PREPARAR UN MEDICAMENTO UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON IL-6, PREFERENTEMENTE, ARTRITIS REUMATOIDE.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1799789,
	"label": "USO DE ANTICUERPOS CONTRA EL RECEPTOR DE IL-6 (IL-6R) Y UN INMUNOSUPRESOR, PREFERENTEMENTE METOTREXATO, PORQUE SIRVE PARA PREPARAR UN MEDICAMENTO UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON IL-6, PREFERENTEMENTE, ARTRITIS REUMATOIDE.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7359,
	"type": 1799789,
	"label": "USO DE ANTICUERPOS CONTRA EL RECEPTOR DE IL-6 (IL-6R) Y UN INMUNOSUPRESOR, PREFERENTEMENTE METOTREXATO, PORQUE SIRVE PARA PREPARAR UN MEDICAMENTO UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON IL-6, PREFERENTEMENTE, ARTRITIS REUMATOIDE.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7409,
	"target": 6290,
	"type": 1803526,
	"label": "METHOD FOR MAKING L-LYSINE SALT OF AZTREONAM AND A METHOD FOR DETERMINING LEVEL OF IMPURITIES IN THIS SALT",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 1810782,
	"label": "CONDENSED PIRIMIDINE DERIVATIVE AND PHARMACEUTICS WITH CRF RELATED ACTIVITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37904,
	"target": 32769,
	"type": 1810790,
	"label": "Method of detecting precursor with a monoclonal antibody binding to the amino acids 41-46 of brain natriuretic peptide",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32769,
	"target": 6854,
	"type": 1810790,
	"label": "Method of detecting precursor with a monoclonal antibody binding to the amino acids 41-46 of brain natriuretic peptide",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37904,
	"target": 6854,
	"type": 1810790,
	"label": "Method of detecting precursor with a monoclonal antibody binding to the amino acids 41-46 of brain natriuretic peptide",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38042,
	"target": 32770,
	"type": 1818521,
	"label": "ANTAGONISTS AND AGONISTS OF LDCAM AND METHODS OF USE.",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 1822376,
	"label": "PEPTIDOS ANTIGENICOS DE LA ARTRITIS REUMATOIDE (AR).",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32738,
	"target": 6854,
	"type": 1822376,
	"label": "PEPTIDOS ANTIGENICOS DE LA ARTRITIS REUMATOIDE (AR).",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32738,
	"target": 6795,
	"type": 1822376,
	"label": "PEPTIDOS ANTIGENICOS DE LA ARTRITIS REUMATOIDE (AR).",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6962,
	"target": 6854,
	"type": 1825374,
	"label": "RADIOACTIVE TAGGED FORMS OF CARCINOEMBRYONIC ANTIGEN AND  METHODS FOR THE PREPARATION THEREOF",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 1825374,
	"label": "RADIOACTIVE TAGGED FORMS OF CARCINOEMBRYONIC ANTIGEN AND  METHODS FOR THE PREPARATION THEREOF",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 1825374,
	"label": "RADIOACTIVE TAGGED FORMS OF CARCINOEMBRYONIC ANTIGEN AND  METHODS FOR THE PREPARATION THEREOF",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 32771,
	"target": 6854,
	"type": 1825374,
	"label": "RADIOACTIVE TAGGED FORMS OF CARCINOEMBRYONIC ANTIGEN AND  METHODS FOR THE PREPARATION THEREOF",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 56834,
	"target": 6962,
	"type": 1825374,
	"label": "RADIOACTIVE TAGGED FORMS OF CARCINOEMBRYONIC ANTIGEN AND  METHODS FOR THE PREPARATION THEREOF",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 6962,
	"target": 6854,
	"type": 1825375,
	"label": "FREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONINS ANFREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONISK ANTIGENMATERIALE OG EVENTYELT DE ENKELTE KOMPONENTER A OG/ELLERTIGENMATERIALE OG EVENTUELT DE ENKELTE KOMPONENTER A OG/ELLER B HERAF",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 1825375,
	"label": "FREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONINS ANFREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONISK ANTIGENMATERIALE OG EVENTYELT DE ENKELTE KOMPONENTER A OG/ELLERTIGENMATERIALE OG EVENTUELT DE ENKELTE KOMPONENTER A OG/ELLER B HERAF",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 1825375,
	"label": "FREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONINS ANFREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONISK ANTIGENMATERIALE OG EVENTYELT DE ENKELTE KOMPONENTER A OG/ELLERTIGENMATERIALE OG EVENTUELT DE ENKELTE KOMPONENTER A OG/ELLER B HERAF",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 32771,
	"target": 6854,
	"type": 1825375,
	"label": "FREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONINS ANFREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONISK ANTIGENMATERIALE OG EVENTYELT DE ENKELTE KOMPONENTER A OG/ELLERTIGENMATERIALE OG EVENTUELT DE ENKELTE KOMPONENTER A OG/ELLER B HERAF",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 56834,
	"target": 6962,
	"type": 1825375,
	"label": "FREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONINS ANFREMGANGSMADE TIL UDVINDING AF ET HUMANT CARCINOEMBRYONISK ANTIGENMATERIALE OG EVENTYELT DE ENKELTE KOMPONENTER A OG/ELLERTIGENMATERIALE OG EVENTUELT DE ENKELTE KOMPONENTER A OG/ELLER B HERAF",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 1825858,
	"label": "FREMGANGSMÅDER OG SAMMENSÆTNINGER TIL FOREBYGGELSE OG BEHANDLING AF SEPSIS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7487,
	"type": 1825858,
	"label": "FREMGANGSMÅDER OG SAMMENSÆTNINGER TIL FOREBYGGELSE OG BEHANDLING AF SEPSIS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 1825858,
	"label": "FREMGANGSMÅDER OG SAMMENSÆTNINGER TIL FOREBYGGELSE OG BEHANDLING AF SEPSIS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1829734,
	"label": "Humane anti-humane-DC3-bindingsmolekyler",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 39999,
	"target": 32771,
	"type": 1829734,
	"label": "Humane anti-humane-DC3-bindingsmolekyler",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 39999,
	"target": 32770,
	"type": 1829734,
	"label": "Humane anti-humane-DC3-bindingsmolekyler",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 1829734,
	"label": "Humane anti-humane-DC3-bindingsmolekyler",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 6854,
	"type": 1829734,
	"label": "Humane anti-humane-DC3-bindingsmolekyler",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 1829735,
	"label": "PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD3, ANTI-CD19 ANTIBODY CONSTRUCTS FOR THE TREATMENT OF B-CELL RELATED DISORDERS",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 1829735,
	"label": "PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD3, ANTI-CD19 ANTIBODY CONSTRUCTS FOR THE TREATMENT OF B-CELL RELATED DISORDERS",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1829735,
	"label": "PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD3, ANTI-CD19 ANTIBODY CONSTRUCTS FOR THE TREATMENT OF B-CELL RELATED DISORDERS",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 1829736,
	"label": "composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 1829736,
	"label": "composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 1829736,
	"label": "composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 1829736,
	"label": "composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1829736,
	"label": "composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 1841180,
	"label": "COMPUESTOS DERIVADOS DE ANILINA, AGONISTAS DE RECEPTORES ACTIVADORES DEL PROLIFERADOR DE PEROXISOMA (PPAR); PROCEDIMIENTO PARA SU PREPARACION; COMPOSICIONES FARMACEUTICAS; Y USO EN ENFERMEDADES MODULADAS POR AGONISTAS PPAR DELTA Y/O PPAR ALFA, COMO D",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6854,
	"target": 6390,
	"type": 1844991,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS OF GLIAL ORIGIN.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 1844991,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS OF GLIAL ORIGIN.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6390,
	"type": 1844991,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS OF GLIAL ORIGIN.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 1844991,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS OF GLIAL ORIGIN.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 1844991,
	"label": "COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS OF GLIAL ORIGIN.",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 1854738,
	"label": "Isoleret polypeptid med egenskaber som hpG-CSF, DNA-sekvens kodende for dette, plasmider indeholdende sekvensen, hermed transformerede/transficerede værtsceller, fremgangsmåde til fremstilling af polypeptidet, farmaceutisk præparat med indhold deraf ....",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 37899,
	"target": 32697,
	"type": 1854738,
	"label": "Isoleret polypeptid med egenskaber som hpG-CSF, DNA-sekvens kodende for dette, plasmider indeholdende sekvensen, hermed transformerede/transficerede værtsceller, fremgangsmåde til fremstilling af polypeptidet, farmaceutisk præparat med indhold deraf ....",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 1854738,
	"label": "Isoleret polypeptid med egenskaber som hpG-CSF, DNA-sekvens kodende for dette, plasmider indeholdende sekvensen, hermed transformerede/transficerede værtsceller, fremgangsmåde til fremstilling af polypeptidet, farmaceutisk præparat med indhold deraf ....",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 1854738,
	"label": "Isoleret polypeptid med egenskaber som hpG-CSF, DNA-sekvens kodende for dette, plasmider indeholdende sekvensen, hermed transformerede/transficerede værtsceller, fremgangsmåde til fremstilling af polypeptidet, farmaceutisk præparat med indhold deraf ....",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 1854738,
	"label": "Isoleret polypeptid med egenskaber som hpG-CSF, DNA-sekvens kodende for dette, plasmider indeholdende sekvensen, hermed transformerede/transficerede værtsceller, fremgangsmåde til fremstilling af polypeptidet, farmaceutisk præparat med indhold deraf ....",
	"group": "Amgen",
	"time": 1987,
	"strength": 1
}, {
	"source": 28540,
	"target": 28528,
	"type": 1856040,
	"label": "WERKWIJZE VOOR DE BEREIDING VAN VOOR DE FLUOROMETRIE GESCHIKTE VERBINDINGEN, ALSMEDE WERKWIJZE VOOR HET BEPALEN VAN PRIMAIRE AMINOGROEPEN BEVATTENDE VERBINDINGEN DAARMEDE.",
	"group": "Roche",
	"time": 1972,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 1862079,
	"label": "Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 1874878,
	"label": "Mikrobielt fremstillet humant Interleukin-1, fremgangsmåder til fremstilling deraf samt farmaceutiske preparater indeholdende dette, og dets anvendelse i behandling og profylakse",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 1874878,
	"label": "Mikrobielt fremstillet humant Interleukin-1, fremgangsmåder til fremstilling deraf samt farmaceutiske preparater indeholdende dette, og dets anvendelse i behandling og profylakse",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 32698,
	"type": 1874878,
	"label": "Mikrobielt fremstillet humant Interleukin-1, fremgangsmåder til fremstilling deraf samt farmaceutiske preparater indeholdende dette, og dets anvendelse i behandling og profylakse",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 1874878,
	"label": "Mikrobielt fremstillet humant Interleukin-1, fremgangsmåder til fremstilling deraf samt farmaceutiske preparater indeholdende dette, og dets anvendelse i behandling og profylakse",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1874878,
	"label": "Mikrobielt fremstillet humant Interleukin-1, fremgangsmåder til fremstilling deraf samt farmaceutiske preparater indeholdende dette, og dets anvendelse i behandling og profylakse",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 1901351,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF ET POLYPEPTID, DNA-SEKVENS, SOM KODER FOR POLYPEPTIDET, REPLICERBART MIKROBIELT UDTRYKKELSESMEDIUM, SOM I EN TRANSFORMANT-MIKROORGANISME ER I STAND TIL AT UDTRYKKE POLYPEPTIDET OG KULTUR AF EN MIKROORGANISME TRANSFORMERET DERMED",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 1910425,
	"label": "Leavo-dikotone reductase gene and its usage",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 1910425,
	"label": "Leavo-dikotone reductase gene and its usage",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 1910425,
	"label": "Leavo-dikotone reductase gene and its usage",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 1910425,
	"label": "Leavo-dikotone reductase gene and its usage",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 1910425,
	"label": "Leavo-dikotone reductase gene and its usage",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 1912091,
	"label": "COMPUESTOS DERIVADOS DE AMINOPIRIMIDINA Y AMINOPIRIDINA, SU EMPLEO, UN METODO PARA SU PREPARACION, COMPOSICIONES QUE LOS COMPRENDEN, Y COMPUESTOS INTERMEDIARIOS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 1918418,
	"label": "Anticorpos, cadeias pesadas e leves, composição farmacêutica e métodos de detecção do nìvel de opgl em amostra biológia e de tratamento",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 1918418,
	"label": "Anticorpos, cadeias pesadas e leves, composição farmacêutica e métodos de detecção do nìvel de opgl em amostra biológia e de tratamento",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 1918418,
	"label": "Anticorpos, cadeias pesadas e leves, composição farmacêutica e métodos de detecção do nìvel de opgl em amostra biológia e de tratamento",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 31571,
	"target": 30950,
	"type": 1944422,
	"label": "PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE FENIL-   ALANINA.",
	"group": "Roche",
	"time": 1969,
	"strength": 1
}, {
	"source": 30816,
	"target": 30815,
	"type": 1965488,
	"label": "2-(ARYLPROPYL)-1,2,3,4-TETRAHYDROISOQUINOLINES, INTERMEDIATES AND PROCESSES",
	"group": "Roche",
	"time": 1968,
	"strength": 1
}, {
	"source": 30815,
	"target": 30814,
	"type": 1968712,
	"label": "Novel Tetrahydro- quinoline Derivatives and a process for the manufacture thereof",
	"group": "Roche",
	"time": 1968,
	"strength": 1
}, {
	"source": 30816,
	"target": 30815,
	"type": 1968712,
	"label": "Novel Tetrahydro- quinoline Derivatives and a process for the manufacture thereof",
	"group": "Roche",
	"time": 1968,
	"strength": 1
}, {
	"source": 30816,
	"target": 30814,
	"type": 1968712,
	"label": "Novel Tetrahydro- quinoline Derivatives and a process for the manufacture thereof",
	"group": "Roche",
	"time": 1968,
	"strength": 1
}, {
	"source": 31912,
	"target": 30820,
	"type": 1971068,
	"label": "PROCESS FOR PREPARING TETRAHYDRO(2,1-D)-BENZO(F)(1,4) - DIAZEPIN - 6(7H)- ONES AND INTERMEDIATES",
	"group": "Roche",
	"time": 1967,
	"strength": 1
}, {
	"source": 7358,
	"target": 6169,
	"type": 1985760,
	"label": "UN PROCEDIMIENTO PARA LA PREPARACION DE UN NUEVO DERIVADO  DE ACIDO FLUORONICO.",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 2023331,
	"label": "FREMGANGSMADE TIL FREMSTILLING AF 1ALFA,25-DIHYDROXYCHOLECALCIFEROL, EN FORBINDELSE MED FORBEDREDE ANTIRAKITISKE EGENSKABER I FORHOLD TIL VITAMIN D2 OG D3, OG SOM HAR VERDI SOM TILSETNINGSSTOF TIL NERINGSMIDLER, OG ANGAR MELLEMPRODUKTER TIL FREMSTILLING HERAF",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 37897,
	"target": 6854,
	"type": 2074903,
	"label": "VERFAHREN ZUR HERSTELLUNG VON KARZINOEMBRYONISCHEM ANTIGEN",
	"group": "Roche",
	"time": 1973,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2083703,
	"label": "Gene de desidrogenase de d-sorbitol.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 2084254,
	"label": "TACI'er- og BR3-polypeptider og anvendelser derav",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 7511,
	"type": 2084254,
	"label": "TACI'er- og BR3-polypeptider og anvendelser derav",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 7511,
	"type": 2084254,
	"label": "TACI'er- og BR3-polypeptider og anvendelser derav",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2088138,
	"label": "Grupo de gene de frenolicina",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 2092469,
	"label": "TRUNCATED FORM OF INHIBITORY KAPPA B PROTEIN (IkB), ITS RECOMBINANT PRODUCTION, AND USES THEREOF.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 2096691,
	"label": "A photochemical process for the production of previtamin d3",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6841,
	"target": 6795,
	"type": 2098402,
	"label": "proteìna fitase de consenso e composição alimentìcia veterinária compreendendo a mesma.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 2098402,
	"label": "proteìna fitase de consenso e composição alimentìcia veterinária compreendendo a mesma.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 2098402,
	"label": "proteìna fitase de consenso e composição alimentìcia veterinária compreendendo a mesma.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 2105373,
	"label": "Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 2105373,
	"label": "Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 2105373,
	"label": "Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 32694,
	"type": 2114647,
	"label": "MONOCLONAL ANTI-HUMAN GRANULOCYTE COLONY STIMULATING FACTOR ANTIBODY",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2115749,
	"label": "Hybridization carrier and a process for preparing the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 2115749,
	"label": "Hybridization carrier and a process for preparing the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 2115749,
	"label": "Hybridization carrier and a process for preparing the same",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 2119850,
	"label": "Method of treating tumor cells by inhibiting growth factor receptor function",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6795,
	"target": 6539,
	"type": 2119850,
	"label": "Method of treating tumor cells by inhibiting growth factor receptor function",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 2119850,
	"label": "Method of treating tumor cells by inhibiting growth factor receptor function",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32772,
	"target": 6795,
	"type": 2119850,
	"label": "Method of treating tumor cells by inhibiting growth factor receptor function",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 6539,
	"type": 2119850,
	"label": "Method of treating tumor cells by inhibiting growth factor receptor function",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6962,
	"target": 6961,
	"type": 2129216,
	"label": "Polypeptide and protein derivatives and process for their preparation.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6961,
	"target": 6795,
	"type": 2129216,
	"label": "Polypeptide and protein derivatives and process for their preparation.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6962,
	"target": 6795,
	"type": 2129216,
	"label": "Polypeptide and protein derivatives and process for their preparation.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 2138170,
	"label": "Carcino-embryonic antigen derivatives lacking the carboxyl terminal end",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 2141983,
	"label": "METAL ION MEDIATED RECEPTOR BINDING OF POLYPEPTIDE HORMONES.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37996,
	"target": 37864,
	"type": 2145252,
	"label": "Method for refolding insoluble, misfolded insulin-like growth factor-1 into an active conformation",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37996,
	"type": 2145252,
	"label": "Method for refolding insoluble, misfolded insulin-like growth factor-1 into an active conformation",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 2145252,
	"label": "Method for refolding insoluble, misfolded insulin-like growth factor-1 into an active conformation",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 2147262,
	"label": "RECOMBINANT HUMAN INTERLEUKIN 6 WITH HOMOGENEOUS N-TERMINUS AND PRODUCTION THEREOF.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 2147262,
	"label": "RECOMBINANT HUMAN INTERLEUKIN 6 WITH HOMOGENEOUS N-TERMINUS AND PRODUCTION THEREOF.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 2147262,
	"label": "RECOMBINANT HUMAN INTERLEUKIN 6 WITH HOMOGENEOUS N-TERMINUS AND PRODUCTION THEREOF.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 2147262,
	"label": "RECOMBINANT HUMAN INTERLEUKIN 6 WITH HOMOGENEOUS N-TERMINUS AND PRODUCTION THEREOF.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 32698,
	"type": 2147262,
	"label": "RECOMBINANT HUMAN INTERLEUKIN 6 WITH HOMOGENEOUS N-TERMINUS AND PRODUCTION THEREOF.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 2158862,
	"label": "PRODUCTION OF GPA NEUROTROPHIC FACTOR.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 2167324,
	"label": "CHINESE HAMSTER OVARY CELL RETROVIRUS-LIKE C PARTICLES.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 32620,
	"type": 2167324,
	"label": "CHINESE HAMSTER OVARY CELL RETROVIRUS-LIKE C PARTICLES.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 32620,
	"type": 2167324,
	"label": "CHINESE HAMSTER OVARY CELL RETROVIRUS-LIKE C PARTICLES.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32620,
	"target": 6795,
	"type": 2167324,
	"label": "CHINESE HAMSTER OVARY CELL RETROVIRUS-LIKE C PARTICLES.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 2167324,
	"label": "CHINESE HAMSTER OVARY CELL RETROVIRUS-LIKE C PARTICLES.",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 2188536,
	"label": "USE OF LUNG SURFACTANTS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROM PRIOR TO THE BIRTH.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38184,
	"target": 32700,
	"type": 2190010,
	"label": "A PROCESS FOR THE DETERMINATION OF INTERLEUKINS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 2190010,
	"label": "A PROCESS FOR THE DETERMINATION OF INTERLEUKINS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56836,
	"target": 32700,
	"type": 2190010,
	"label": "A PROCESS FOR THE DETERMINATION OF INTERLEUKINS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 32700,
	"target": 6795,
	"type": 2190010,
	"label": "A PROCESS FOR THE DETERMINATION OF INTERLEUKINS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 2190010,
	"label": "A PROCESS FOR THE DETERMINATION OF INTERLEUKINS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 2215641,
	"label": "GAMMA INTERFERON-INTERLEUKIN-2 SYNERGISTIC COMPOSITIONS AND PROCESSES THEREFOR",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 2215641,
	"label": "GAMMA INTERFERON-INTERLEUKIN-2 SYNERGISTIC COMPOSITIONS AND PROCESSES THEREFOR",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 2215641,
	"label": "GAMMA INTERFERON-INTERLEUKIN-2 SYNERGISTIC COMPOSITIONS AND PROCESSES THEREFOR",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 2219625,
	"label": "PURIFIED IMMUNOGLOBULIN G MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS IFN-YPSILON AND PROCESS FOR ISOLATION OF SUCH MONOCLONAL ANTIBODY",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 2240766,
	"label": "New peptide aldehyde and boronic acid derivatives are proteinase inhibitors useful for treatment of viral infections, especially hepatitis",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 30951,
	"target": 30950,
	"type": 2243836,
	"label": "Process for manufacture of chiral succinic acid derivatives of formula",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2244125,
	"label": "VERFAHREN ZUR SUBTRAKTIVEN HYBRIDISIERUNG UND DIFFERENZIELLEN ANALYSE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 2247697,
	"label": "Alpha-cetoamides for treating viral infections especially hepatitis C, hepatitis G and human GB",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 2257435,
	"label": "TFIIB transcription factor from Candida albicans and methods of screening for inhibitors of Candida albicans growth",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 2257435,
	"label": "TFIIB transcription factor from Candida albicans and methods of screening for inhibitors of Candida albicans growth",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 2257435,
	"label": "TFIIB transcription factor from Candida albicans and methods of screening for inhibitors of Candida albicans growth",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2257435,
	"label": "TFIIB transcription factor from Candida albicans and methods of screening for inhibitors of Candida albicans growth",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 2257435,
	"label": "TFIIB transcription factor from Candida albicans and methods of screening for inhibitors of Candida albicans growth",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2257437,
	"label": "CANDIDA ALBICANS TATA-BINDING PROTEIN, NUCLEIC ACID AND ASSAYS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 2257437,
	"label": "CANDIDA ALBICANS TATA-BINDING PROTEIN, NUCLEIC ACID AND ASSAYS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 2257437,
	"label": "CANDIDA ALBICANS TATA-BINDING PROTEIN, NUCLEIC ACID AND ASSAYS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 2257437,
	"label": "CANDIDA ALBICANS TATA-BINDING PROTEIN, NUCLEIC ACID AND ASSAYS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 2257437,
	"label": "CANDIDA ALBICANS TATA-BINDING PROTEIN, NUCLEIC ACID AND ASSAYS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 2258897,
	"label": "PROMOTER OF HUMAN P27KIP1 GENE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 2258897,
	"label": "PROMOTER OF HUMAN P27KIP1 GENE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 2258897,
	"label": "PROMOTER OF HUMAN P27KIP1 GENE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2263239,
	"label": "NUCLEIC ACID ENCODING  i(M. TUBERCULOSIS) ALGU PROTEIN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 2271555,
	"label": "IFI206, A NOVEL INTERFERON-INDUCED POLYPEPTIDE, AND NUCLEIC ACIDS ENCODING THE SAME",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 2271555,
	"label": "IFI206, A NOVEL INTERFERON-INDUCED POLYPEPTIDE, AND NUCLEIC ACIDS ENCODING THE SAME",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2271555,
	"label": "IFI206, A NOVEL INTERFERON-INDUCED POLYPEPTIDE, AND NUCLEIC ACIDS ENCODING THE SAME",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 2279560,
	"label": "Production of inactive mutants or mutants with a low activity of an alkaline phosphatase and their expression in yeast",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 2279560,
	"label": "Production of inactive mutants or mutants with a low activity of an alkaline phosphatase and their expression in yeast",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 2279560,
	"label": "Production of inactive mutants or mutants with a low activity of an alkaline phosphatase and their expression in yeast",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 2280343,
	"label": "<i>STAPHYLOCOCCAL</i> GTPASE <i>OBG</i>CLEOTIDE SEQUENCE ENCODING <i>STAPHYLOCOCCAL</i> GTP-BINDING PROTEIN",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 2280343,
	"label": "<i>STAPHYLOCOCCAL</i> GTPASE <i>OBG</i>CLEOTIDE SEQUENCE ENCODING <i>STAPHYLOCOCCAL</i> GTP-BINDING PROTEIN",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 2280343,
	"label": "<i>STAPHYLOCOCCAL</i> GTPASE <i>OBG</i>CLEOTIDE SEQUENCE ENCODING <i>STAPHYLOCOCCAL</i> GTP-BINDING PROTEIN",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37859,
	"target": 6795,
	"type": 2280343,
	"label": "<i>STAPHYLOCOCCAL</i> GTPASE <i>OBG</i>CLEOTIDE SEQUENCE ENCODING <i>STAPHYLOCOCCAL</i> GTP-BINDING PROTEIN",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 2280343,
	"label": "<i>STAPHYLOCOCCAL</i> GTPASE <i>OBG</i>CLEOTIDE SEQUENCE ENCODING <i>STAPHYLOCOCCAL</i> GTP-BINDING PROTEIN",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2285316,
	"label": "METODO PARA LA PRODUCCION DE UNA TRANSCRIPTASA INVERSA AMV HETERODIMERICA ACTIVA, EN CELULAS PROCARIOTAS.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 2285316,
	"label": "METODO PARA LA PRODUCCION DE UNA TRANSCRIPTASA INVERSA AMV HETERODIMERICA ACTIVA, EN CELULAS PROCARIOTAS.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38237,
	"target": 37864,
	"type": 2285316,
	"label": "METODO PARA LA PRODUCCION DE UNA TRANSCRIPTASA INVERSA AMV HETERODIMERICA ACTIVA, EN CELULAS PROCARIOTAS.",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 2289406,
	"label": "HUMAN ERYTHROCYTE DIFFERENTIATION RELATED FACTOR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 2289406,
	"label": "HUMAN ERYTHROCYTE DIFFERENTIATION RELATED FACTOR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 2289406,
	"label": "HUMAN ERYTHROCYTE DIFFERENTIATION RELATED FACTOR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 2289406,
	"label": "HUMAN ERYTHROCYTE DIFFERENTIATION RELATED FACTOR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 2289406,
	"label": "HUMAN ERYTHROCYTE DIFFERENTIATION RELATED FACTOR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 2300662,
	"label": "VARIABLE REGION FUSION PEPTIDES THAT FORM EFFECTOR COMPLEXES IN THE PRESENCE OF ANTIGEN",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 2307209,
	"label": "COMPOSITIONS FOR DNA TRANSFECTION",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 2307209,
	"label": "COMPOSITIONS FOR DNA TRANSFECTION",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 2307209,
	"label": "COMPOSITIONS FOR DNA TRANSFECTION",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 2307689,
	"label": "REGULATED GENE EXPRESSION IN YEAST AND METHODS OF USE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2308907,
	"label": "METODO PARA PREPARAR ACIDOS NUCLEICOS PARA EL ANALISIS Y ESTUCHES UTILES PARA ELLO.",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32734,
	"type": 2310638,
	"label": "MUTATED HUMAN INSULIN RECEPTOR DNA",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32734,
	"target": 6795,
	"type": 2310638,
	"label": "MUTATED HUMAN INSULIN RECEPTOR DNA",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 2310638,
	"label": "MUTATED HUMAN INSULIN RECEPTOR DNA",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 2312520,
	"label": "AGONISTISCHE ANTIKÖRPER GEGEN DEN FLK2/FLT3-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 2312520,
	"label": "AGONISTISCHE ANTIKÖRPER GEGEN DEN FLK2/FLT3-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 2312520,
	"label": "AGONISTISCHE ANTIKÖRPER GEGEN DEN FLK2/FLT3-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 2312520,
	"label": "AGONISTISCHE ANTIKÖRPER GEGEN DEN FLK2/FLT3-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 2312520,
	"label": "AGONISTISCHE ANTIKÖRPER GEGEN DEN FLK2/FLT3-REZEPTOR UND DEREN VERWENDUNGEN",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 2322209,
	"label": "ANTI-IL-8 MONOCLONAL ANTIBODIES FOR TREATMENT OF INFLAMMATORY DISORDERS.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 7409,
	"type": 2322209,
	"label": "ANTI-IL-8 MONOCLONAL ANTIBODIES FOR TREATMENT OF INFLAMMATORY DISORDERS.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 2322209,
	"label": "ANTI-IL-8 MONOCLONAL ANTIBODIES FOR TREATMENT OF INFLAMMATORY DISORDERS.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 2324144,
	"label": "IFN-.GAMMA.RECEPTOR .BETA.-CHAIN AND DERIVATIVES THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56836,
	"target": 38181,
	"type": 2324144,
	"label": "IFN-.GAMMA.RECEPTOR .BETA.-CHAIN AND DERIVATIVES THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 56836,
	"target": 32788,
	"type": 2324144,
	"label": "IFN-.GAMMA.RECEPTOR .BETA.-CHAIN AND DERIVATIVES THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38067,
	"target": 6812,
	"type": 2332778,
	"label": "OCULAR GENE THERAPY",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 2333923,
	"label": "Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2336293,
	"label": "KUNITZ DOMAIN INHIBITOR PROTEINS DERIVED FROM ALZHEIMER'S AMYLOID 'beta'-PROTEIN PRECURSOR INHIBITOR.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 2336293,
	"label": "KUNITZ DOMAIN INHIBITOR PROTEINS DERIVED FROM ALZHEIMER'S AMYLOID 'beta'-PROTEIN PRECURSOR INHIBITOR.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 2336293,
	"label": "KUNITZ DOMAIN INHIBITOR PROTEINS DERIVED FROM ALZHEIMER'S AMYLOID 'beta'-PROTEIN PRECURSOR INHIBITOR.",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 2338730,
	"label": "SENSORY AND MOTOR NEURON DERIVED FACTOR (SMDF)    SENSORY AND MOTOR NEURON DERIVED FACTOR (SMDF)",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 2339821,
	"label": "PHARMACEUTICAL COMPOSITIONS CONTAINING ECOTIN AND HOMOLOGS THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 2339821,
	"label": "PHARMACEUTICAL COMPOSITIONS CONTAINING ECOTIN AND HOMOLOGS THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 2339821,
	"label": "PHARMACEUTICAL COMPOSITIONS CONTAINING ECOTIN AND HOMOLOGS THEREOF",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2340603,
	"label": "LIGHT EMISSION MODIFIER, AND USE THEREOF IN NUCLEIC ACID DETECTION, AMPLIFICATION, AND ANALYSIS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2341583,
	"label": "Associations of polymorphisms in the FRZB gene in obesity and osteoporosis",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56794,
	"target": 56765,
	"type": 2344009,
	"label": "HAND-HELD ANALYSIS DEVICE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 57358,
	"target": 56568,
	"type": 2345121,
	"label": "METHOD OF PROCESSING SET OF SPECTRUM, IN PARTICULAR, NMR SPECTRUM",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2345810,
	"label": "STABILIZATION OF LINEAR DOUBLE-STRANDED DNA IN THE PRESENCE OF EXONUCLEASES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 2348885,
	"label": "MASS SPECTROMETRY OF ANTIBODY CONJUGATES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 2348885,
	"label": "MASS SPECTROMETRY OF ANTIBODY CONJUGATES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 2348885,
	"label": "MASS SPECTROMETRY OF ANTIBODY CONJUGATES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 2348891,
	"label": "KNOCK-OUT ANIMAL FOR TAAR1 FUNCTION",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6427,
	"type": 2349638,
	"label": "REVERSIBLE HYDROPHOBIZATION OF ANTITUMOR DRUGS FOR ENHANCED FIRST-PASS DRUG UPTAKE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56765,
	"target": 37986,
	"type": 2351767,
	"label": "Method for detecting a mutation in a repetitive nucleic acid sequence",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 2355280,
	"label": "GLYT1 TRANSGENIC MOUSE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2355568,
	"label": "REAL TIME PCR ACCOMPANYING ADDITION OF PYROPHOSPHATASE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 2359633,
	"label": "DETECTION, IDENTIFICATION AND DIFFERENTIATION OF PROTEUS SPECIES USING THE SPACER REGION",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56765,
	"target": 38232,
	"type": 2361051,
	"label": "PROXIMAL MARKERS OF ARTERIAL THROMBOSIS AND INFLAMMATION FOR RISK STRATIFICATION OF CORONARY HEART DISEASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2363512,
	"label": "A METHOD TO REDUCE FALSE POSITIVE RESULTS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6841,
	"target": 6840,
	"type": 2378077,
	"label": "METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 56833,
	"target": 6841,
	"type": 2378077,
	"label": "METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 56833,
	"target": 6840,
	"type": 2378077,
	"label": "METHODS OF TREATMENT AND USES FOR CAMKII AND ITS INTERACTION WITH HDACS AND CALPAIN",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 56765,
	"type": 2409758,
	"label": "USE OF A MARKER COMBINATION COMPRISING OSTEOPONTIN AND CARCINOEMBRYONIC ANTIGEN IN THE ASSESSMENT OF COLORECTAL CANCER",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56765,
	"target": 38237,
	"type": 2409758,
	"label": "USE OF A MARKER COMBINATION COMPRISING OSTEOPONTIN AND CARCINOEMBRYONIC ANTIGEN IN THE ASSESSMENT OF COLORECTAL CANCER",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 2409758,
	"label": "USE OF A MARKER COMBINATION COMPRISING OSTEOPONTIN AND CARCINOEMBRYONIC ANTIGEN IN THE ASSESSMENT OF COLORECTAL CANCER",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2452393,
	"label": "Methods for determining sequence variants using ultra-deep sequencing",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 2452959,
	"label": "PURIFIED INTERLEUKIN-15/Fc FUSION PROTEIN AND PREPARATION THEREOF.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32698,
	"target": 7507,
	"type": 2452959,
	"label": "PURIFIED INTERLEUKIN-15/Fc FUSION PROTEIN AND PREPARATION THEREOF.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 2452959,
	"label": "PURIFIED INTERLEUKIN-15/Fc FUSION PROTEIN AND PREPARATION THEREOF.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 2453237,
	"label": "LINEAS CELULARES ESTABLES QUE EXPRESAN HERG.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56765,
	"target": 37899,
	"type": 2453237,
	"label": "LINEAS CELULARES ESTABLES QUE EXPRESAN HERG.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56765,
	"target": 37875,
	"type": 2453237,
	"label": "LINEAS CELULARES ESTABLES QUE EXPRESAN HERG.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 2454805,
	"label": "USE OF INORGANIC PYROPHOSPHATASE AS A MARKER FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2458562,
	"label": "Selective amplification of methylated nucleic acids",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6347,
	"target": 6299,
	"type": 2459557,
	"label": "ABCA1 ELEVATING COMPOUNDS",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2461444,
	"label": "NUCLEIC ACID ISOLATION USING POLIDOCANOL AND DERIVATIVES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2462571,
	"label": "TEMPERATURE SENSOR ELEMENT FOR MONITORING HEATING AND COOLING",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2463650,
	"label": "MULTIPLEXED SOLID-PHASE NUCLEIC ACID AMPLIFICATION ASSAY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56833,
	"target": 38237,
	"type": 2466861,
	"label": "ASSAYS FOR MEASURING PHOSPHATE MODIFICATION ENZYME ACTIVITY",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 2467368,
	"label": "PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 2467368,
	"label": "PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 31939,
	"target": 7424,
	"type": 2467368,
	"label": "PURINE DERIVATIVES AS A1 ADENOSINE RECEPTOR ANTAGONISTS",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 31912,
	"type": 2468051,
	"label": "SAQUINAVIR DERIVATIVES USEFUL IN IMMUNOASSAY",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 2469768,
	"label": "METHODS AND COMPOSITIONS FOR DETECTING BACILLUS ANTHRACIS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 2469768,
	"label": "METHODS AND COMPOSITIONS FOR DETECTING BACILLUS ANTHRACIS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 2469768,
	"label": "METHODS AND COMPOSITIONS FOR DETECTING BACILLUS ANTHRACIS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37988,
	"target": 37864,
	"type": 2469768,
	"label": "METHODS AND COMPOSITIONS FOR DETECTING BACILLUS ANTHRACIS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37988,
	"target": 37862,
	"type": 2469768,
	"label": "METHODS AND COMPOSITIONS FOR DETECTING BACILLUS ANTHRACIS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32769,
	"type": 2470769,
	"label": "ANTICUERPOS CONTRA LA 25-HIDROXIVITAMINA D.",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 2475368,
	"label": "AN ANTIBODY WHICH RECOGNIZES PHOSPHORYLATED POLYPEPTIDES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 2475667,
	"label": "ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 2477481,
	"label": "METHOD FOR PRODUCING ANTI-IDIOTYPIC ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 32777,
	"type": 2477481,
	"label": "METHOD FOR PRODUCING ANTI-IDIOTYPIC ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 2477481,
	"label": "METHOD FOR PRODUCING ANTI-IDIOTYPIC ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56765,
	"target": 37875,
	"type": 2477556,
	"label": "TRANSGENIC ALZHEIMER'S MOUSE MODEL VECTORS AND USES THEREOF",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 38065,
	"type": 2478598,
	"label": "Method for determining genotoxicity",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 2479409,
	"label": "NOVEL TARGETS FOR OBESITY FROM FAT TISSUE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 2482400,
	"label": "Methods for producing recombinant histidine-tagged inosine nonophosphate dehydrogenase polypeptides",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 2482400,
	"label": "Methods for producing recombinant histidine-tagged inosine nonophosphate dehydrogenase polypeptides",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 2482400,
	"label": "Methods for producing recombinant histidine-tagged inosine nonophosphate dehydrogenase polypeptides",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 2482400,
	"label": "Methods for producing recombinant histidine-tagged inosine nonophosphate dehydrogenase polypeptides",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 2482400,
	"label": "Methods for producing recombinant histidine-tagged inosine nonophosphate dehydrogenase polypeptides",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 2483288,
	"label": "GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND NUCLEIC ACID",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 2483533,
	"label": "B-CELL LYMPHOMA SPECIFIC ANTIGEN FOR USE IN DIAGNOSIS AND TREATMENT OF B-CELL MALIGNANCIES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 2483533,
	"label": "B-CELL LYMPHOMA SPECIFIC ANTIGEN FOR USE IN DIAGNOSIS AND TREATMENT OF B-CELL MALIGNANCIES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 32772,
	"type": 2483533,
	"label": "B-CELL LYMPHOMA SPECIFIC ANTIGEN FOR USE IN DIAGNOSIS AND TREATMENT OF B-CELL MALIGNANCIES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 32771,
	"type": 2483533,
	"label": "B-CELL LYMPHOMA SPECIFIC ANTIGEN FOR USE IN DIAGNOSIS AND TREATMENT OF B-CELL MALIGNANCIES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 32772,
	"type": 2483533,
	"label": "B-CELL LYMPHOMA SPECIFIC ANTIGEN FOR USE IN DIAGNOSIS AND TREATMENT OF B-CELL MALIGNANCIES",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 2485565,
	"label": "ENZYMATIC ASSAY OF HIV PROTEASE INHIBITORS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56833,
	"target": 38232,
	"type": 2485565,
	"label": "ENZYMATIC ASSAY OF HIV PROTEASE INHIBITORS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56833,
	"target": 37986,
	"type": 2485565,
	"label": "ENZYMATIC ASSAY OF HIV PROTEASE INHIBITORS",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 2485885,
	"label": "FIZZ1 FOR METABOLISM REGULATION",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 2486259,
	"label": "Gene transcription assay method",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 2487594,
	"label": "REKOMBINANTE DESOXYRIBONUCLEASE I AUS RINDER- PANKREAS MIT HOHER SPEZIFISCHER AKTIVITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2487594,
	"label": "REKOMBINANTE DESOXYRIBONUCLEASE I AUS RINDER- PANKREAS MIT HOHER SPEZIFISCHER AKTIVITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 37859,
	"type": 2487594,
	"label": "REKOMBINANTE DESOXYRIBONUCLEASE I AUS RINDER- PANKREAS MIT HOHER SPEZIFISCHER AKTIVITÄT",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56833,
	"target": 37986,
	"type": 2488545,
	"label": "CONJUGATE OF TISSUE NON-SPECIFIC ALKALINE PHOSPHATASE AND DEXTRAN, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 32754,
	"type": 2488637,
	"label": "PRC17: AN AMPLIFIED CANCER GENE",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32754,
	"target": 6795,
	"type": 2488637,
	"label": "PRC17: AN AMPLIFIED CANCER GENE",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 56834,
	"target": 6795,
	"type": 2488637,
	"label": "PRC17: AN AMPLIFIED CANCER GENE",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 6371,
	"target": 6279,
	"type": 2488930,
	"label": "HUMAN GROWTH HORMONE ANTAGONISTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 2490359,
	"label": "PHAGE DISPLAYED PDZ DOMAIN LIGANDS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 7508,
	"type": 2490359,
	"label": "PHAGE DISPLAYED PDZ DOMAIN LIGANDS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 2490359,
	"label": "PHAGE DISPLAYED PDZ DOMAIN LIGANDS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 2490609,
	"label": "SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 2490609,
	"label": "SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 38042,
	"type": 2490609,
	"label": "SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 2490609,
	"label": "SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 2490609,
	"label": "SELECTION OF CELLS EXPRESSING HETEROMERIC POLYPEPTIDES.",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 2491154,
	"label": "ANTICUERPOS PARA LA DETECCION DE EFAVIRENZ.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 6909,
	"type": 2491154,
	"label": "ANTICUERPOS PARA LA DETECCION DE EFAVIRENZ.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56836,
	"target": 6909,
	"type": 2491154,
	"label": "ANTICUERPOS PARA LA DETECCION DE EFAVIRENZ.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 2493498,
	"label": "Methods for the treatment of renal cell carcinoma",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 2493498,
	"label": "Methods for the treatment of renal cell carcinoma",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 2493498,
	"label": "Methods for the treatment of renal cell carcinoma",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56765,
	"target": 38232,
	"type": 2495306,
	"label": "Use of hepicidin as marker of chronic inflammatory disease, useful particularly for differential diagnosis between inflammatory and non-inflammatory chronic diseases",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 2496121,
	"label": "FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 2496121,
	"label": "FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 2496121,
	"label": "FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 2496121,
	"label": "FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37864,
	"target": 6854,
	"type": 2496121,
	"label": "FCE FUSION PROTEINS FOR TREATMENT OF ALLERGY AND ASTHMA.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 2496633,
	"label": "NUEVO FORMATO DE DETECCION PARA LAS REACCIONES EN CADENA DE LA POLIMERASA EN TIEMPO REAL DE INICIO EN CALIENTE.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 2498279,
	"label": "METHODS FOR ISOLATING NUCLEIC ACIDS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 2498284,
	"label": "CARBOXYPEPTIDASE B EXPRESSED BY RECOMBINATION, AND PURIFICATION OF THE SAME",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7487,
	"type": 2498827,
	"label": "USES OF OPG LIGAND TO MODULATE IMMUNE RESPONSES.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 2498995,
	"label": "METHODS OF CULTURING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 2498995,
	"label": "METHODS OF CULTURING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 2498995,
	"label": "METHODS OF CULTURING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 2499327,
	"label": "PEGYLIERTES UND DIGLYKOSYLIERTES ERYTHROPOIETIN",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 3009207,
	"label": "Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 3009207,
	"label": "Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 3009207,
	"label": "Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 3009207,
	"label": "Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 3009207,
	"label": "Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 3024298,
	"label": "PROCESS FOR THE PREPARATION OF AN ANTISERUM SPECIFIC TO HUMAN CARCINOEMBRYONIC ANTIGEN",
	"group": "Roche",
	"time": 9999,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 3024298,
	"label": "PROCESS FOR THE PREPARATION OF AN ANTISERUM SPECIFIC TO HUMAN CARCINOEMBRYONIC ANTIGEN",
	"group": "Roche",
	"time": 9999,
	"strength": 1
}, {
	"source": 56834,
	"target": 6962,
	"type": 3024298,
	"label": "PROCESS FOR THE PREPARATION OF AN ANTISERUM SPECIFIC TO HUMAN CARCINOEMBRYONIC ANTIGEN",
	"group": "Roche",
	"time": 9999,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 3032866,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 3032866,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 3032866,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 3032866,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 3032866,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 3041105,
	"label": "ANTICORPO MONOCLONAL ISOLADO, ANTICORPOS HUMANIZADO E QUIMÉRICO DO ANTICORPO MONOCLONAL ISOLADO, LINHA DE CÉLULA HIBRIDOMA ISOLADA, MÉTODO PARA INICIAR A CITOTOXIDEZ INDUZIDA POR ANTICORPO DE CÉLULAS CANCEROSAS EM UMA  AMOSTRA DE TECIDO SELECIONADA DE UM TUMOR HUMANO, CDMAB DO ANTICORPO MONOCLONAL ISOLADO OU SEU CDMAB E USOS DE UM ANTICORPO MONOCLONAL OU SEU CDMAB, SOZINHO OU EM CONJUÇÃO COM PELO MENOS UM AGENTE QUIMIOTERAPÊUTICO, E COMPOSIÇÃO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 3041105,
	"label": "ANTICORPO MONOCLONAL ISOLADO, ANTICORPOS HUMANIZADO E QUIMÉRICO DO ANTICORPO MONOCLONAL ISOLADO, LINHA DE CÉLULA HIBRIDOMA ISOLADA, MÉTODO PARA INICIAR A CITOTOXIDEZ INDUZIDA POR ANTICORPO DE CÉLULAS CANCEROSAS EM UMA  AMOSTRA DE TECIDO SELECIONADA DE UM TUMOR HUMANO, CDMAB DO ANTICORPO MONOCLONAL ISOLADO OU SEU CDMAB E USOS DE UM ANTICORPO MONOCLONAL OU SEU CDMAB, SOZINHO OU EM CONJUÇÃO COM PELO MENOS UM AGENTE QUIMIOTERAPÊUTICO, E COMPOSIÇÃO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 3041105,
	"label": "ANTICORPO MONOCLONAL ISOLADO, ANTICORPOS HUMANIZADO E QUIMÉRICO DO ANTICORPO MONOCLONAL ISOLADO, LINHA DE CÉLULA HIBRIDOMA ISOLADA, MÉTODO PARA INICIAR A CITOTOXIDEZ INDUZIDA POR ANTICORPO DE CÉLULAS CANCEROSAS EM UMA  AMOSTRA DE TECIDO SELECIONADA DE UM TUMOR HUMANO, CDMAB DO ANTICORPO MONOCLONAL ISOLADO OU SEU CDMAB E USOS DE UM ANTICORPO MONOCLONAL OU SEU CDMAB, SOZINHO OU EM CONJUÇÃO COM PELO MENOS UM AGENTE QUIMIOTERAPÊUTICO, E COMPOSIÇÃO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 3041105,
	"label": "ANTICORPO MONOCLONAL ISOLADO, ANTICORPOS HUMANIZADO E QUIMÉRICO DO ANTICORPO MONOCLONAL ISOLADO, LINHA DE CÉLULA HIBRIDOMA ISOLADA, MÉTODO PARA INICIAR A CITOTOXIDEZ INDUZIDA POR ANTICORPO DE CÉLULAS CANCEROSAS EM UMA  AMOSTRA DE TECIDO SELECIONADA DE UM TUMOR HUMANO, CDMAB DO ANTICORPO MONOCLONAL ISOLADO OU SEU CDMAB E USOS DE UM ANTICORPO MONOCLONAL OU SEU CDMAB, SOZINHO OU EM CONJUÇÃO COM PELO MENOS UM AGENTE QUIMIOTERAPÊUTICO, E COMPOSIÇÃO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 3041105,
	"label": "ANTICORPO MONOCLONAL ISOLADO, ANTICORPOS HUMANIZADO E QUIMÉRICO DO ANTICORPO MONOCLONAL ISOLADO, LINHA DE CÉLULA HIBRIDOMA ISOLADA, MÉTODO PARA INICIAR A CITOTOXIDEZ INDUZIDA POR ANTICORPO DE CÉLULAS CANCEROSAS EM UMA  AMOSTRA DE TECIDO SELECIONADA DE UM TUMOR HUMANO, CDMAB DO ANTICORPO MONOCLONAL ISOLADO OU SEU CDMAB E USOS DE UM ANTICORPO MONOCLONAL OU SEU CDMAB, SOZINHO OU EM CONJUÇÃO COM PELO MENOS UM AGENTE QUIMIOTERAPÊUTICO, E COMPOSIÇÃO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 3041106,
	"label": "Cancerose sykdomsmodifiserende antistoffer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 3041106,
	"label": "Cancerose sykdomsmodifiserende antistoffer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 3041106,
	"label": "Cancerose sykdomsmodifiserende antistoffer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 3041106,
	"label": "Cancerose sykdomsmodifiserende antistoffer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 3041106,
	"label": "Cancerose sykdomsmodifiserende antistoffer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 3041107,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES 180706-01",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 3041107,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES 180706-01",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 6962,
	"type": 3041107,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES 180706-01",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32754,
	"target": 6854,
	"type": 3053320,
	"label": "PROCESS FOR THE PRODUCTION OF CARCINOEMBRYONIC ANTIGEN",
	"group": "Roche",
	"time": 9999,
	"strength": 1
}, {
	"source": 27540,
	"target": 6957,
	"type": 3305087,
	"label": "PROSECCO PER FABBRICARE RADICAFARMA CEUTICI D ACIDO MERCAPTOCARBOSSILI CO AD SUO DIAGNOSTICO E RELATIVI PRODOTTI",
	"group": "Roche",
	"time": 1974,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 3315846,
	"label": "COMPOSES DERIVES DU CHOLECALCIFEROL, COMPOSITION PHARMACEUTIQUE ANTITUMORALE ET UTILISATION DESDITS COMPOSES DANS LA PREPARATION DE CETTE COMPOSITION PHARMACEUTIQUE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 3315846,
	"label": "COMPOSES DERIVES DU CHOLECALCIFEROL, COMPOSITION PHARMACEUTIQUE ANTITUMORALE ET UTILISATION DESDITS COMPOSES DANS LA PREPARATION DE CETTE COMPOSITION PHARMACEUTIQUE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 3315846,
	"label": "COMPOSES DERIVES DU CHOLECALCIFEROL, COMPOSITION PHARMACEUTIQUE ANTITUMORALE ET UTILISATION DESDITS COMPOSES DANS LA PREPARATION DE CETTE COMPOSITION PHARMACEUTIQUE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7507,
	"target": 6469,
	"type": 3323237,
	"label": "NOUVEAUX COMPOSES TETRACYCLIQUES, LEUR PREPARATION ET LES PREPARATIONS PHARMACEUTIQUES LES CONTENANT",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 32440,
	"target": 7507,
	"type": 3323237,
	"label": "NOUVEAUX COMPOSES TETRACYCLIQUES, LEUR PREPARATION ET LES PREPARATIONS PHARMACEUTIQUES LES CONTENANT",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 32440,
	"target": 6469,
	"type": 3323237,
	"label": "NOUVEAUX COMPOSES TETRACYCLIQUES, LEUR PREPARATION ET LES PREPARATIONS PHARMACEUTIQUES LES CONTENANT",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 3360552,
	"label": "New DNA associated with Alstrom syndrome, useful for diagnosis and identification of carriers, also related polypeptides, antibodies and transgenic animals",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 3360552,
	"label": "New DNA associated with Alstrom syndrome, useful for diagnosis and identification of carriers, also related polypeptides, antibodies and transgenic animals",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 3360552,
	"label": "New DNA associated with Alstrom syndrome, useful for diagnosis and identification of carriers, also related polypeptides, antibodies and transgenic animals",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 56833,
	"target": 37986,
	"type": 3360647,
	"label": "Test for inhibitors of heparanase, useful for treatment of e.g. cancer and inflammatory disease, using immobilized, labeled heparanase substrate",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 6484,
	"type": 3360673,
	"label": "Inhibiting expression of target gene, useful e.g. for treating cancer, by infecting cells with sequences encoding sense and antisense RNA homologous with the target",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 3388073,
	"label": "FREMGANGSMAADE TIL FREMSTILLING AF 2-KETO-L-GULONSYRE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 3392657,
	"label": "Thermostable or thermoactive DNA polymerase molecules with attenuated 3'-5' exonuclease activity",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 3392657,
	"label": "Thermostable or thermoactive DNA polymerase molecules with attenuated 3'-5' exonuclease activity",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 3392657,
	"label": "Thermostable or thermoactive DNA polymerase molecules with attenuated 3'-5' exonuclease activity",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6673,
	"target": 6229,
	"type": 3414409,
	"label": "Injectable composition of paclitaxel",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31499,
	"target": 6673,
	"type": 3414409,
	"label": "Injectable composition of paclitaxel",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31499,
	"target": 6229,
	"type": 3414409,
	"label": "Injectable composition of paclitaxel",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 7450,
	"type": 3537977,
	"label": "OSTEOPROTEGERINA/RECEPTORES DE FACTORES DE NECROSIS DE TUMORES",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7450,
	"target": 6483,
	"type": 3537977,
	"label": "OSTEOPROTEGERINA/RECEPTORES DE FACTORES DE NECROSIS DE TUMORES",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7508,
	"target": 6483,
	"type": 3537977,
	"label": "OSTEOPROTEGERINA/RECEPTORES DE FACTORES DE NECROSIS DE TUMORES",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 7508,
	"type": 3537977,
	"label": "OSTEOPROTEGERINA/RECEPTORES DE FACTORES DE NECROSIS DE TUMORES",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 7450,
	"type": 3537977,
	"label": "OSTEOPROTEGERINA/RECEPTORES DE FACTORES DE NECROSIS DE TUMORES",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 3592435,
	"label": "PROCESS FOR THE PREPARATION OF HEXACYCLIC CAMPTOTHECIN DERIVATIVES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32004,
	"target": 7507,
	"type": 3592435,
	"label": "PROCESS FOR THE PREPARATION OF HEXACYCLIC CAMPTOTHECIN DERIVATIVES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32004,
	"target": 6376,
	"type": 3592435,
	"label": "PROCESS FOR THE PREPARATION OF HEXACYCLIC CAMPTOTHECIN DERIVATIVES",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 3756286,
	"label": "Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 3756286,
	"label": "Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 3756286,
	"label": "Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 3756286,
	"label": "Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 3756286,
	"label": "Adjuvans-terapi ved anvendelse af anti-glypican 3 antistoffer",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 3769749,
	"label": "ED-71 preparation",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 6429,
	"target": 2138,
	"type": 3926659,
	"label": "Verfahren zur Vitaminierung von Nahrungs- und Futtermitteln",
	"group": "Roche",
	"time": 1963,
	"strength": 1
}, {
	"source": 6909,
	"target": 6795,
	"type": 3946429,
	"label": "NOUVEAUX DERIVES DE PENICILLOYL-POLYPEPTIDES, LEUR PREPARATION ET LEUR APPLICATION EN TANT QUE MEDICAMENT",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 7487,
	"target": 6795,
	"type": 3948125,
	"label": "DERIVES PEPTIDIQUES ET PROCEDE POUR LEUR PREPARATION",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 32254,
	"target": 6795,
	"type": 3966032,
	"label": "Phosphorylated nonapeptides, processes for the preparation thereof and pharmaceutical compositions containing them",
	"group": "Roche",
	"time": 1978,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 3975017,
	"label": "ANTIGNEI DEL CARCINOMA MAMMARIO E RELATIVO METODO PER ACCERTARNE LA PRESENZA NEL FLASMA SANGUIGNO O NEL SIERO",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 4036861,
	"label": "VERFAHREN ZUR HERSTELLUNG VON THYMOSIN (ALPHA)(PFEIL ABWAERTS)1(PFEIL ABWAERTS)",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 4093332,
	"label": "LIGANDS DE KIT SOLUBLES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 4093332,
	"label": "LIGANDS DE KIT SOLUBLES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 4093332,
	"label": "LIGANDS DE KIT SOLUBLES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 4093332,
	"label": "LIGANDS DE KIT SOLUBLES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 4093332,
	"label": "LIGANDS DE KIT SOLUBLES.",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 56834,
	"target": 37988,
	"type": 4142655,
	"label": "Nukleotid-Sequenzen, die selektiv exprimiert sind in pre-B-Zellen und Sonden zu diesem Zweck.",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32620,
	"target": 6854,
	"type": 4146594,
	"label": "SYNTHETIC PEPTIDE AND IMMUNOGENIC COMPOSITION",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 4180188,
	"label": "COMPOSES DERIVES DU CHOLECALCIFEROL ET LEUR PROCEDE DE PREPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION DESDITS COMPOSES DANS LA PREPARATION DE CETTE COMPOSITION",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 4180188,
	"label": "COMPOSES DERIVES DU CHOLECALCIFEROL ET LEUR PROCEDE DE PREPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION DESDITS COMPOSES DANS LA PREPARATION DE CETTE COMPOSITION",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 4180188,
	"label": "COMPOSES DERIVES DU CHOLECALCIFEROL ET LEUR PROCEDE DE PREPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION DESDITS COMPOSES DANS LA PREPARATION DE CETTE COMPOSITION",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 30485,
	"target": 7508,
	"type": 4180188,
	"label": "COMPOSES DERIVES DU CHOLECALCIFEROL ET LEUR PROCEDE DE PREPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION DESDITS COMPOSES DANS LA PREPARATION DE CETTE COMPOSITION",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 4180188,
	"label": "COMPOSES DERIVES DU CHOLECALCIFEROL ET LEUR PROCEDE DE PREPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION DESDITS COMPOSES DANS LA PREPARATION DE CETTE COMPOSITION",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38181,
	"target": 38164,
	"type": 4216147,
	"label": "Verfahren zur Herstellung von linearen DNA Fragmenten für die in vitro Expression von Proteinen",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 4216147,
	"label": "Verfahren zur Herstellung von linearen DNA Fragmenten für die in vitro Expression von Proteinen",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 4216147,
	"label": "Verfahren zur Herstellung von linearen DNA Fragmenten für die in vitro Expression von Proteinen",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37996,
	"type": 4326295,
	"label": "PREPARATION OF HUMAN IGF AND EGF VIA RECOMBINANT DNA TECHNOLOGY",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 4341408,
	"label": "METHODE ET MATERIAUX IMMUNOLOGIQUES POUR LE DOSAGE DE LA DIHYDROPYRIMIDINE DESHYDROGENASE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 56833,
	"target": 37899,
	"type": 4341408,
	"label": "METHODE ET MATERIAUX IMMUNOLOGIQUES POUR LE DOSAGE DE LA DIHYDROPYRIMIDINE DESHYDROGENASE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 4341408,
	"label": "METHODE ET MATERIAUX IMMUNOLOGIQUES POUR LE DOSAGE DE LA DIHYDROPYRIMIDINE DESHYDROGENASE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 4391882,
	"label": "Verbessertes Transkriptionsverfahren",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 4454154,
	"label": "VARIANTEN DES WACHSTUMSFAKTORS DER VASKULÄREN ENDOTHELZELLEN, IHRE VERWENDUNG SOWIE METHODEN FÜR IHRE HERSTELLUNG",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 4468289,
	"label": "Selective photoinducted flavin-dependent cleavage of RNA at G-U base pairs and kits therefor",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 4521140,
	"label": "MONOKLONALT ANTISTOF MED AFFINITET FOR HUMANT INTERLEUKIN-2",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 4521140,
	"label": "MONOKLONALT ANTISTOF MED AFFINITET FOR HUMANT INTERLEUKIN-2",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 56836,
	"target": 32788,
	"type": 4521140,
	"label": "MONOKLONALT ANTISTOF MED AFFINITET FOR HUMANT INTERLEUKIN-2",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32700,
	"target": 32698,
	"type": 4523751,
	"label": "Process for purifying recombinant human interleukin-2.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 4523751,
	"label": "Process for purifying recombinant human interleukin-2.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32700,
	"target": 32694,
	"type": 4523751,
	"label": "Process for purifying recombinant human interleukin-2.",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 31571,
	"target": 30485,
	"type": 4533373,
	"label": "PROCEDIMIENTO PARA LA PREPARACION DE DERIVADOS DE 2-OXO- O  2-HIDROXI-3-(ALCOXIMETIL)-4-(3-ALCOXI-4,4-DIMETIL-1-OCTENIL)-5-METILCICLOPENTANO",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 4609728,
	"label": "UN METODO PARA DETERMINAR LA CONCENTRACION DE ANTIGENO CARCINOEMBRIONICO EN UNA MUESTRA DE SUERO O PLASMA HUMANO.",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 4674131,
	"label": "DETERMINATION OF hTERT mRNA EXPRESSION",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38237,
	"target": 38164,
	"type": 4685361,
	"label": "COMPOSITION FOR HOT START NUCLEIC ACID AMPLIFICATION AND METHOD FOR HOT START NUCLEIC ACID AMPLIFICATION",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 4685361,
	"label": "COMPOSITION FOR HOT START NUCLEIC ACID AMPLIFICATION AND METHOD FOR HOT START NUCLEIC ACID AMPLIFICATION",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 4685361,
	"label": "COMPOSITION FOR HOT START NUCLEIC ACID AMPLIFICATION AND METHOD FOR HOT START NUCLEIC ACID AMPLIFICATION",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 4689795,
	"label": "REMEDIES FOR TUMOR IN HEMATOPOIETIC ORGANS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 6816,
	"target": 6812,
	"type": 4689795,
	"label": "REMEDIES FOR TUMOR IN HEMATOPOIETIC ORGANS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 4689795,
	"label": "REMEDIES FOR TUMOR IN HEMATOPOIETIC ORGANS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7508,
	"target": 6816,
	"type": 4689795,
	"label": "REMEDIES FOR TUMOR IN HEMATOPOIETIC ORGANS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 4689795,
	"label": "REMEDIES FOR TUMOR IN HEMATOPOIETIC ORGANS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 32527,
	"type": 4691642,
	"label": "Protein purification method",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 4691642,
	"label": "Protein purification method",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 32527,
	"type": 4691642,
	"label": "Protein purification method",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7425,
	"target": 7422,
	"type": 4704945,
	"label": "Novel gene and protein encoded by the gene",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 4704945,
	"label": "Novel gene and protein encoded by the gene",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 4704945,
	"label": "Novel gene and protein encoded by the gene",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 4707301,
	"label": "Mutant B-type DNA polymerases exhibiting improved performance in PCR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 4707301,
	"label": "Mutant B-type DNA polymerases exhibiting improved performance in PCR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 4707301,
	"label": "Mutant B-type DNA polymerases exhibiting improved performance in PCR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 4707301,
	"label": "Mutant B-type DNA polymerases exhibiting improved performance in PCR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 4707301,
	"label": "Mutant B-type DNA polymerases exhibiting improved performance in PCR",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6471,
	"target": 6469,
	"type": 4713915,
	"label": "Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 4718606,
	"label": "Verfahren zur rekombinanten Herstellung von Ribonukleoproteinen",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 4718606,
	"label": "Verfahren zur rekombinanten Herstellung von Ribonukleoproteinen",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 4718606,
	"label": "Verfahren zur rekombinanten Herstellung von Ribonukleoproteinen",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 4720640,
	"label": "NOVEL TUMOR MARKER FOR LUNG CANCER",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 6962,
	"target": 6854,
	"type": 4720640,
	"label": "NOVEL TUMOR MARKER FOR LUNG CANCER",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 6962,
	"target": 6795,
	"type": 4720640,
	"label": "NOVEL TUMOR MARKER FOR LUNG CANCER",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 4720640,
	"label": "NOVEL TUMOR MARKER FOR LUNG CANCER",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 4720640,
	"label": "NOVEL TUMOR MARKER FOR LUNG CANCER",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 4724639,
	"label": "VERWENDUNG VON REGULATORISCHEN SEQUENZEN ZUR SPEZIFISCHEN, TRANSIENTEN EXPRESSION IN NEURONAL DETERMINIERTEN ZELLEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 4727417,
	"label": "CXCR3 ANTAGONISTS",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 4727483,
	"label": "Modified antibodies against cd22 and utilization thereof",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 32754,
	"type": 4727777,
	"label": "BEI KREBS ÜBEREXPRIMIERTES GEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 4727777,
	"label": "BEI KREBS ÜBEREXPRIMIERTES GEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 32754,
	"type": 4727777,
	"label": "BEI KREBS ÜBEREXPRIMIERTES GEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32754,
	"target": 6795,
	"type": 4727777,
	"label": "BEI KREBS ÜBEREXPRIMIERTES GEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 6795,
	"type": 4727777,
	"label": "BEI KREBS ÜBEREXPRIMIERTES GEN",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 4727789,
	"label": "SUGAR CHAIN-MODIFIED ANTI-HM1.24 ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37996,
	"type": 4727789,
	"label": "SUGAR CHAIN-MODIFIED ANTI-HM1.24 ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37996,
	"target": 32779,
	"type": 4727789,
	"label": "SUGAR CHAIN-MODIFIED ANTI-HM1.24 ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37996,
	"target": 32771,
	"type": 4727789,
	"label": "SUGAR CHAIN-MODIFIED ANTI-HM1.24 ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 4727789,
	"label": "SUGAR CHAIN-MODIFIED ANTI-HM1.24 ANTIBODY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 4730287,
	"label": "Therapeutic Agent And Diagnostic Agent For Cholangiocarcinoma",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 4730287,
	"label": "Therapeutic Agent And Diagnostic Agent For Cholangiocarcinoma",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 4730287,
	"label": "Therapeutic Agent And Diagnostic Agent For Cholangiocarcinoma",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 4732612,
	"label": "Cell Death-Inducing Agents",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 4732612,
	"label": "Cell Death-Inducing Agents",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 4732612,
	"label": "Cell Death-Inducing Agents",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 4732612,
	"label": "Cell Death-Inducing Agents",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 4732612,
	"label": "Cell Death-Inducing Agents",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 4734033,
	"label": "TRANSPORTADOR DE FUCOSA.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38181,
	"target": 37988,
	"type": 4734033,
	"label": "TRANSPORTADOR DE FUCOSA.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37988,
	"type": 4734033,
	"label": "TRANSPORTADOR DE FUCOSA.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 4736983,
	"label": "Deimmunized binding molecules to CD3",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 4736983,
	"label": "Deimmunized binding molecules to CD3",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 4736983,
	"label": "Deimmunized binding molecules to CD3",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 4740114,
	"label": "VERFAHREN ZUM SCREENING DER LEICHTEN KETTE EINES ANTIKÖRPERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 4740114,
	"label": "VERFAHREN ZUM SCREENING DER LEICHTEN KETTE EINES ANTIKÖRPERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 4740114,
	"label": "VERFAHREN ZUM SCREENING DER LEICHTEN KETTE EINES ANTIKÖRPERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 4740114,
	"label": "VERFAHREN ZUM SCREENING DER LEICHTEN KETTE EINES ANTIKÖRPERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 4740114,
	"label": "VERFAHREN ZUM SCREENING DER LEICHTEN KETTE EINES ANTIKÖRPERS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6854,
	"target": 6812,
	"type": 4741582,
	"label": "Methods and compositions for the treatment of meconium aspiration syndrome",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38232,
	"target": 37862,
	"type": 4749992,
	"label": "CRYSTAL STRUCTURE OF DPP-IV AND ITS USE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 4749992,
	"label": "CRYSTAL STRUCTURE OF DPP-IV AND ITS USE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38232,
	"target": 7507,
	"type": 4749992,
	"label": "CRYSTAL STRUCTURE OF DPP-IV AND ITS USE",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 4752497,
	"label": "Methods for measuring activity of glutamine:fructose 6-phosphate amidotransferase and activity of inhibitors thereof",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7511,
	"target": 7359,
	"type": 4764311,
	"label": "SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 7511,
	"type": 4764311,
	"label": "SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 7359,
	"type": 4764311,
	"label": "SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 4764361,
	"label": "Methods of generating and using antibody-producing cells",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32771,
	"target": 6483,
	"type": 4764361,
	"label": "Methods of generating and using antibody-producing cells",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 6483,
	"type": 4764361,
	"label": "Methods of generating and using antibody-producing cells",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 4765868,
	"label": "NONHUMAN ANIMALS FOR ANTIBODY PRODUCTION, AND METHODS AND SYSTEMS FOR PRODUCING ANTIBODIES USING SUCH ANIMALS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 38065,
	"type": 4765868,
	"label": "NONHUMAN ANIMALS FOR ANTIBODY PRODUCTION, AND METHODS AND SYSTEMS FOR PRODUCING ANTIBODIES USING SUCH ANIMALS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 4765868,
	"label": "NONHUMAN ANIMALS FOR ANTIBODY PRODUCTION, AND METHODS AND SYSTEMS FOR PRODUCING ANTIBODIES USING SUCH ANIMALS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7425,
	"target": 7422,
	"type": 4768874,
	"label": "NOVEL IMIDAZOLIDINE DERIVATIVES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 4768874,
	"label": "NOVEL IMIDAZOLIDINE DERIVATIVES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 4768874,
	"label": "NOVEL IMIDAZOLIDINE DERIVATIVES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 4774206,
	"label": "Pharmaceutical agents for treating HCV infections",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 56765,
	"type": 4776461,
	"label": "METHOD FOR DISTINGUISHING AML-SPECIFIC FLT3 LENGTH MUTATIONS FROM TKD MUTATIONS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 4776960,
	"label": "Doppel-transgenisches, nicht-humanes Säugertiermodell für die Alzheimer Krankheit",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 4777393,
	"label": "Method of producing an antibody using a cell in which the function of fucose transporter is inhibited",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56765,
	"target": 38065,
	"type": 4778311,
	"label": "SGRF GENETICALLY MODIFIED NONHUMAN ANIMAL",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 4779858,
	"label": "Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors",
	"group": "Gilead",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 4779858,
	"label": "Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors",
	"group": "Gilead",
	"time": 2002,
	"strength": 1
}, {
	"source": 56834,
	"target": 6962,
	"type": 4779858,
	"label": "Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors",
	"group": "Gilead",
	"time": 2002,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 4780051,
	"label": "Biomarkers and expression profiles for toxicology",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37900,
	"target": 37878,
	"type": 4780941,
	"label": "ANTICUERPOS PARA IDENTIFICACION Y/O AISLAMIENTO DE AL MENOS UNA POBLACION CELULAR QUE SE SELECCIONA DEL GRUPO QUE COMPRENDE CELULAS TRONCALES HEMATOPOYETICAS, C. TRONCALES NEURONALES, C. PRECURSORAS NEURONALES, CELULAS TRONCALES MESENQUIMATOSAS Y C. PRECURSORAS MESENQUIMATOSAS.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37878,
	"target": 32770,
	"type": 4780941,
	"label": "ANTICUERPOS PARA IDENTIFICACION Y/O AISLAMIENTO DE AL MENOS UNA POBLACION CELULAR QUE SE SELECCIONA DEL GRUPO QUE COMPRENDE CELULAS TRONCALES HEMATOPOYETICAS, C. TRONCALES NEURONALES, C. PRECURSORAS NEURONALES, CELULAS TRONCALES MESENQUIMATOSAS Y C. PRECURSORAS MESENQUIMATOSAS.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 4780941,
	"label": "ANTICUERPOS PARA IDENTIFICACION Y/O AISLAMIENTO DE AL MENOS UNA POBLACION CELULAR QUE SE SELECCIONA DEL GRUPO QUE COMPRENDE CELULAS TRONCALES HEMATOPOYETICAS, C. TRONCALES NEURONALES, C. PRECURSORAS NEURONALES, CELULAS TRONCALES MESENQUIMATOSAS Y C. PRECURSORAS MESENQUIMATOSAS.",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 4782261,
	"label": "MENSCHLICHEN GEWEBEFAKTOR PRODUZIERENDES NICHTMENSCHLICHES KNOCK-IN -TIER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7511,
	"target": 6795,
	"type": 4782617,
	"label": "METHOD OF STABILIZING PROTEIN SOLUTIONS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 7511,
	"type": 4782617,
	"label": "METHOD OF STABILIZING PROTEIN SOLUTIONS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 4782617,
	"label": "METHOD OF STABILIZING PROTEIN SOLUTIONS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 56804,
	"type": 4783379,
	"label": "HUMAN IMMUNODEFICIENCY VIRUS ENTRY INHIBITOR ASSAY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32527,
	"target": 6795,
	"type": 4785663,
	"label": "PROCEDIMIENTO Y SISTEMAS PARA LA RECUPERACION DE PEPTIDOS.",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 4791830,
	"label": "IMPROVED LABELING REAGENT",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7487,
	"type": 4792946,
	"label": "sc(Fv)2 SITE-DIRECTED MUTANT",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 4808605,
	"label": "Pyrazolopyridine and pyrrolopyridine multikinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 4808605,
	"label": "Pyrazolopyridine and pyrrolopyridine multikinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 4808605,
	"label": "Pyrazolopyridine and pyrrolopyridine multikinase inhibitors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6229,
	"target": 6215,
	"type": 4808711,
	"label": "NOVEL ANTICANCER CONCOMITANT DRUG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6478,
	"target": 6376,
	"type": 4808711,
	"label": "NOVEL ANTICANCER CONCOMITANT DRUG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6376,
	"target": 6229,
	"type": 4808711,
	"label": "NOVEL ANTICANCER CONCOMITANT DRUG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6376,
	"target": 6215,
	"type": 4808711,
	"label": "NOVEL ANTICANCER CONCOMITANT DRUG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6478,
	"target": 6229,
	"type": 4808711,
	"label": "NOVEL ANTICANCER CONCOMITANT DRUG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32769,
	"target": 32689,
	"type": 4821784,
	"label": "Microbial expression of type 1 transforming growth factor, polypeptide analogs thereof and hybrid EGF/TGF polypeptides.",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38042,
	"target": 32769,
	"type": 4821784,
	"label": "Microbial expression of type 1 transforming growth factor, polypeptide analogs thereof and hybrid EGF/TGF polypeptides.",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38042,
	"target": 32689,
	"type": 4821784,
	"label": "Microbial expression of type 1 transforming growth factor, polypeptide analogs thereof and hybrid EGF/TGF polypeptides.",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 32694,
	"target": 6816,
	"type": 4826487,
	"label": "MANUFACTURE OF PURIFIED BIOLOGICALLY ACTIVE MONOMERIC INTERFERON",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 4829989,
	"label": "Methods and materials for development of parvovirus vaccine.",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 4830594,
	"label": "CSF (COLONY SENSITIVE FACTOR) INHIBITORY SUBSTANCE",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32696,
	"target": 7508,
	"type": 4830594,
	"label": "CSF (COLONY SENSITIVE FACTOR) INHIBITORY SUBSTANCE",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 32696,
	"target": 6795,
	"type": 4830594,
	"label": "CSF (COLONY SENSITIVE FACTOR) INHIBITORY SUBSTANCE",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 4830757,
	"label": "Rabies immunogenic polypeptides and vaccine using them, DNA sequences, expression vectors, recombinant cells, and cultures therefor, and processes for their production.",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 4832247,
	"label": "THE MANUFACTURE AND EXPRESSION OF GENES FOR CALCITONIN AND POLYPEPTIDE ANALOGS THEREOF.",
	"group": "Amgen",
	"time": 1983,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 4833111,
	"label": "Microbial expression of insulin-like growth factor.",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 4833111,
	"label": "Microbial expression of insulin-like growth factor.",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 4833111,
	"label": "Microbial expression of insulin-like growth factor.",
	"group": "Amgen",
	"time": 1984,
	"strength": 1
}, {
	"source": 32694,
	"target": 6816,
	"type": 4834832,
	"label": "PHARMACEUTICAL COMPOSITION FOR INTERFERON APPLICATION",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 32440,
	"target": 7507,
	"type": 4835107,
	"label": "PROCESS FOR OPTICALLY ACTIVE ANTHRACYCLINE GLYCOSIDES, THE NOVEL 4-DEOXY-ACLACINOMYCINS A AND B AND PHARMACEUTICAL PREPARATIONS",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 4836412,
	"label": "PLASMID VECTORS FOR EUKARYOTIC CELLS AND METHOD FOR SELECTING TRANSFECTED EUKARYOTIC CELLS",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 4836412,
	"label": "PLASMID VECTORS FOR EUKARYOTIC CELLS AND METHOD FOR SELECTING TRANSFECTED EUKARYOTIC CELLS",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 4836412,
	"label": "PLASMID VECTORS FOR EUKARYOTIC CELLS AND METHOD FOR SELECTING TRANSFECTED EUKARYOTIC CELLS",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 4838118,
	"label": "HUMAN LEUKOCYTE INTERFERONS, PROCESS FOR THEIR MICROBIAL PRODUCTION, INTERMEDIATES THEREFOR AND COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 4838118,
	"label": "HUMAN LEUKOCYTE INTERFERONS, PROCESS FOR THEIR MICROBIAL PRODUCTION, INTERMEDIATES THEREFOR AND COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 32694,
	"target": 7507,
	"type": 4838118,
	"label": "HUMAN LEUKOCYTE INTERFERONS, PROCESS FOR THEIR MICROBIAL PRODUCTION, INTERMEDIATES THEREFOR AND COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 4838118,
	"label": "HUMAN LEUKOCYTE INTERFERONS, PROCESS FOR THEIR MICROBIAL PRODUCTION, INTERMEDIATES THEREFOR AND COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 4838118,
	"label": "HUMAN LEUKOCYTE INTERFERONS, PROCESS FOR THEIR MICROBIAL PRODUCTION, INTERMEDIATES THEREFOR AND COMPOSITIONS CONTAINING THEM",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 4845473,
	"label": "DESACETYLTHYMOSIN ALPHA 1, ITS PROCESS OF PREPARATION AND ITS USE",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 4848523,
	"label": "Novel Pharmaceuticals That Use Anti-HLA Antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 4848523,
	"label": "Novel Pharmaceuticals That Use Anti-HLA Antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 4848523,
	"label": "Novel Pharmaceuticals That Use Anti-HLA Antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37988,
	"target": 6795,
	"type": 4856283,
	"label": "METHOD OF DETECTING MYCOPLASMA",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 4858270,
	"label": "HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 37988,
	"type": 4858612,
	"label": "Method for the preparation of nucleic acids from whole blood and its application in the diagnosis of TSE using real-time PCR",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 4860864,
	"label": "Anti-cancer agent comprising protein C inhibitor",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 4860864,
	"label": "Anti-cancer agent comprising protein C inhibitor",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7509,
	"target": 6795,
	"type": 4860864,
	"label": "Anti-cancer agent comprising protein C inhibitor",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 4865562,
	"label": "Labeling reagent",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 4871317,
	"label": "INTERLEUKIN-6 INHIBITORS",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 4882708,
	"label": "SECRETIVE GENE MANIFESTATION INDICATOR GENE PRODUCT",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32772,
	"target": 32754,
	"type": 4883763,
	"label": "Antibodies for transforming ras protein",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56836,
	"target": 32772,
	"type": 4883763,
	"label": "Antibodies for transforming ras protein",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56836,
	"target": 32754,
	"type": 4883763,
	"label": "Antibodies for transforming ras protein",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 4891460,
	"label": "ISOFORMS OF SOLUBLE IMMUNE RESPONSE SUPPRESSOR.",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 4911410,
	"label": "SPECIFIC PHOSPHOLIPASE D OF GLYCOCYLPHOSPHATIDYL INOSITOL",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 4923217,
	"label": "RECOMBINANT SIGMA NS PROTEIN",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 4926118,
	"label": "Chimaeric CD4-immunoglobulin polypeptides.",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 4928970,
	"label": "STABLE PROTEINS, METHODS FOR THEIR CONSTRUCTION, PLASMIDS AND OTHER DNA ENCODING THEM, CELL CULTURES HARBORING SUCH PLASMIDS",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 4941109,
	"label": "Stabilisierte flüssige Mischungen für die Markierung von Nukleinsäuren",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 4963623,
	"label": "NEUE RECOMBINANTE VIREN, DEREN VERWENDUNG UND DEREN HERSTELLUNG",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 4963623,
	"label": "NEUE RECOMBINANTE VIREN, DEREN VERWENDUNG UND DEREN HERSTELLUNG",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 4963623,
	"label": "NEUE RECOMBINANTE VIREN, DEREN VERWENDUNG UND DEREN HERSTELLUNG",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 4970135,
	"label": "Beta-8 integrin subunit antibodies",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 4976734,
	"label": "Polynucleotides encoding proteins mediating switch recombination",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 4976734,
	"label": "Polynucleotides encoding proteins mediating switch recombination",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 4976734,
	"label": "Polynucleotides encoding proteins mediating switch recombination",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37859,
	"target": 6795,
	"type": 4976734,
	"label": "Polynucleotides encoding proteins mediating switch recombination",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 4976734,
	"label": "Polynucleotides encoding proteins mediating switch recombination",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 4977027,
	"label": "Procedure and kit for the cloning of fragments",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 4986216,
	"label": "THE HOMEOBOX TRANSCRIPTION FACTOR BSX AND USES THEREOF FOR TREATING DISEASES, IN PARTICULAR OBESITY",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6812,
	"target": 6483,
	"type": 4986216,
	"label": "THE HOMEOBOX TRANSCRIPTION FACTOR BSX AND USES THEREOF FOR TREATING DISEASES, IN PARTICULAR OBESITY",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 6812,
	"type": 4986216,
	"label": "THE HOMEOBOX TRANSCRIPTION FACTOR BSX AND USES THEREOF FOR TREATING DISEASES, IN PARTICULAR OBESITY",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38065,
	"target": 6812,
	"type": 4986216,
	"label": "THE HOMEOBOX TRANSCRIPTION FACTOR BSX AND USES THEREOF FOR TREATING DISEASES, IN PARTICULAR OBESITY",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 6483,
	"type": 4986216,
	"label": "THE HOMEOBOX TRANSCRIPTION FACTOR BSX AND USES THEREOF FOR TREATING DISEASES, IN PARTICULAR OBESITY",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 37988,
	"type": 4986327,
	"label": "ANTICUERPO ESPECIFICO PARA EL RECEPTOR CCR5; ACIDO NUCLEICO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA TRATAR ENFERMEDADES INMUNOSUPRESORAS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37988,
	"target": 32770,
	"type": 4986327,
	"label": "ANTICUERPO ESPECIFICO PARA EL RECEPTOR CCR5; ACIDO NUCLEICO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA TRATAR ENFERMEDADES INMUNOSUPRESORAS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 4986327,
	"label": "ANTICUERPO ESPECIFICO PARA EL RECEPTOR CCR5; ACIDO NUCLEICO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA TRATAR ENFERMEDADES INMUNOSUPRESORAS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 4986327,
	"label": "ANTICUERPO ESPECIFICO PARA EL RECEPTOR CCR5; ACIDO NUCLEICO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA TRATAR ENFERMEDADES INMUNOSUPRESORAS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37988,
	"target": 7510,
	"type": 4986327,
	"label": "ANTICUERPO ESPECIFICO PARA EL RECEPTOR CCR5; ACIDO NUCLEICO QUE LO CODIFICA; METODO DE PRODUCCION; COMPOSICION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA TRATAR ENFERMEDADES INMUNOSUPRESORAS.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 30606,
	"target": 7507,
	"type": 4988401,
	"label": "TRICYCLIC FUSED INDOLE DERIVATIVES AND THEIR USE AS AURORA KINASE INHIBITORS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 4989122,
	"label": "HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 4989122,
	"label": "HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 6303,
	"type": 4989122,
	"label": "HETEROCYCLYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 4989638,
	"label": "COMBINED TREATMENT WITH AN N4-(SUBSTITUTED-OXYCARBONYL)-5'-DEOXY-5-FLUOROCYTIDINE DERIVATIVE AND AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 4992954,
	"label": "ANTI-IDIOTYPE CONJUGATE AND ITS USE AS A STANDARD IN AN IMMUNASSAY.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 56804,
	"type": 4997345,
	"label": "USE OF PROTEIN MASP AS A MARKER FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 4998665,
	"label": "MATRIX METALLOPROTEINASES INHIBITORS FOR THE STIMULATION AND PROTECTION OF BONE MARROW STEM CELLS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 4998841,
	"label": "PYRROLINE-5-CARBOXYLATE REDUCTASE AS A MARKER FOR COLORECTAL CONCER",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 4998842,
	"label": "USE OF PROTEIN PROC AS A MARKER FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 4998980,
	"label": "USE OF MICROSOMAL DIPEPTIDASE AS A MARKER FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 5000994,
	"label": "Measurement of nicotinamde N-methyl transferase in diagnosis of lung cancer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 5000994,
	"label": "Measurement of nicotinamde N-methyl transferase in diagnosis of lung cancer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 5000994,
	"label": "Measurement of nicotinamde N-methyl transferase in diagnosis of lung cancer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 5003703,
	"label": "USO DE UN ANTICUERPO ANTI-VEGF (FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR) PARA EL TRATAMIENTO DE UN PACIENTE QUE PADECE UNA RECAIDA DE CANCER HER2 POSITIVO DURANTE O DESPUES DEL TRATAMIENTO CON UN ANTICUERPO ANTI-HER2.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 5003703,
	"label": "USO DE UN ANTICUERPO ANTI-VEGF (FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR) PARA EL TRATAMIENTO DE UN PACIENTE QUE PADECE UNA RECAIDA DE CANCER HER2 POSITIVO DURANTE O DESPUES DEL TRATAMIENTO CON UN ANTICUERPO ANTI-HER2.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 6854,
	"type": 5003703,
	"label": "USO DE UN ANTICUERPO ANTI-VEGF (FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR) PARA EL TRATAMIENTO DE UN PACIENTE QUE PADECE UNA RECAIDA DE CANCER HER2 POSITIVO DURANTE O DESPUES DEL TRATAMIENTO CON UN ANTICUERPO ANTI-HER2.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32771,
	"target": 7509,
	"type": 5003703,
	"label": "USO DE UN ANTICUERPO ANTI-VEGF (FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR) PARA EL TRATAMIENTO DE UN PACIENTE QUE PADECE UNA RECAIDA DE CANCER HER2 POSITIVO DURANTE O DESPUES DEL TRATAMIENTO CON UN ANTICUERPO ANTI-HER2.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 5003703,
	"label": "USO DE UN ANTICUERPO ANTI-VEGF (FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR) PARA EL TRATAMIENTO DE UN PACIENTE QUE PADECE UNA RECAIDA DE CANCER HER2 POSITIVO DURANTE O DESPUES DEL TRATAMIENTO CON UN ANTICUERPO ANTI-HER2.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 5003704,
	"label": "TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 5004975,
	"label": "Método para la producción de factor-I de crecimiento similar a la insulina",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 5005085,
	"label": "Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 5005085,
	"label": "Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 5005085,
	"label": "Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 5005175,
	"label": "TERAPIA TUMORAL CON UNA COMBINACION DE ANTICUERPOS ANTI-HER2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32772,
	"target": 7509,
	"type": 5005175,
	"label": "TERAPIA TUMORAL CON UNA COMBINACION DE ANTICUERPOS ANTI-HER2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 5005175,
	"label": "TERAPIA TUMORAL CON UNA COMBINACION DE ANTICUERPOS ANTI-HER2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 5005176,
	"label": "Detection of antibodies raised against therapeutic antibodies",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 5006368,
	"label": "Production of extracellular microbial protein, particularly esterolytic enzymes, in heterologous bacteria transformed with appropriate nucleic acid and secretory apparatus",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6816,
	"target": 6795,
	"type": 5006802,
	"label": "HIDROGELES BIODEGRADABLES TERMOSENSIBLES/SENSIBLES AL PH PARA LA LIBERACION SOSTENIDA DE AGENTES BIOLOGICAMENTE ACTIVOS.",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7450,
	"target": 7424,
	"type": 5007849,
	"label": "Acylguanidine derivatives, useful for prevention and treatment of e.g. restenosis, arteriosclerosis, nephropathias, are victronectin receptor antagonists, cellular adhesion inhibitors, and inhibitors of osteoclast bone resorption",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 5016482,
	"label": "Recombinant microbial 3-hydroxybutyrate dehydrogenase a process for its production and the use thereof",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 5020429,
	"label": "Vector for positive selection, based on the cap gene, the pCAPs vector and its applications",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 5020429,
	"label": "Vector for positive selection, based on the cap gene, the pCAPs vector and its applications",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 5020429,
	"label": "Vector for positive selection, based on the cap gene, the pCAPs vector and its applications",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 5027247,
	"label": "T-cells specific for kidney carcinoma",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32770,
	"target": 32735,
	"type": 5027247,
	"label": "T-cells specific for kidney carcinoma",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 5027247,
	"label": "T-cells specific for kidney carcinoma",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 5027247,
	"label": "T-cells specific for kidney carcinoma",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 5027247,
	"label": "T-cells specific for kidney carcinoma",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 5028049,
	"label": "ANTIBODY AGAINST HEPATITIS TYPE G VIRUS AND ITS USE FOR DIAGNOSTIC DETECTION OF HGV AND AS THERAPEUTIC AGENT THEREFOR",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 5028049,
	"label": "ANTIBODY AGAINST HEPATITIS TYPE G VIRUS AND ITS USE FOR DIAGNOSTIC DETECTION OF HGV AND AS THERAPEUTIC AGENT THEREFOR",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 5028049,
	"label": "ANTIBODY AGAINST HEPATITIS TYPE G VIRUS AND ITS USE FOR DIAGNOSTIC DETECTION OF HGV AND AS THERAPEUTIC AGENT THEREFOR",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 5028768,
	"label": "MUTANTES RECOMBINANTES INACTIVOS DE LA PARTE CENRAL DE LA ESTREPTAVIDINA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 5028768,
	"label": "MUTANTES RECOMBINANTES INACTIVOS DE LA PARTE CENRAL DE LA ESTREPTAVIDINA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 5028768,
	"label": "MUTANTES RECOMBINANTES INACTIVOS DE LA PARTE CENRAL DE LA ESTREPTAVIDINA.",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 5088021,
	"label": "PEDIATRIC CAPECITABINE-CONTAINING TABLETS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7425,
	"target": 7424,
	"type": 5088116,
	"label": "ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7424,
	"target": 7409,
	"type": 5088116,
	"label": "ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7425,
	"target": 7409,
	"type": 5088116,
	"label": "ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 5088116,
	"label": "ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 5088116,
	"label": "ARYL PYRIDYL SULFONAMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 5088279,
	"label": "PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 5088279,
	"label": "PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 39999,
	"target": 7507,
	"type": 5088279,
	"label": "PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6367,
	"target": 6301,
	"type": 5090518,
	"label": "COMPUESTOS 1H-PIRAZOLO[3,4-C]PIRIDAZINILO, 1H-PIRAZOLO[3,4-B]PIRIDINILO, 1H-PIRAZOLO[3,4-C]PIRIDINILO E INDAZOLILO, INHIBIDORES NO NUCLEOSIDOS DE TRANSCRIPTASA INVERSA; COMPOSICION FARMACEUTICA QUE LOS CONTIENE; Y SU USO EN EL TRATAMIENTO Y/O PREVENC",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 5090518,
	"label": "COMPUESTOS 1H-PIRAZOLO[3,4-C]PIRIDAZINILO, 1H-PIRAZOLO[3,4-B]PIRIDINILO, 1H-PIRAZOLO[3,4-C]PIRIDINILO E INDAZOLILO, INHIBIDORES NO NUCLEOSIDOS DE TRANSCRIPTASA INVERSA; COMPOSICION FARMACEUTICA QUE LOS CONTIENE; Y SU USO EN EL TRATAMIENTO Y/O PREVENC",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 5090518,
	"label": "COMPUESTOS 1H-PIRAZOLO[3,4-C]PIRIDAZINILO, 1H-PIRAZOLO[3,4-B]PIRIDINILO, 1H-PIRAZOLO[3,4-C]PIRIDINILO E INDAZOLILO, INHIBIDORES NO NUCLEOSIDOS DE TRANSCRIPTASA INVERSA; COMPOSICION FARMACEUTICA QUE LOS CONTIENE; Y SU USO EN EL TRATAMIENTO Y/O PREVENC",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6301,
	"target": 6279,
	"type": 5091370,
	"label": "DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 5091370,
	"label": "DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 5091370,
	"label": "DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 5091370,
	"label": "DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 5091370,
	"label": "DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 5092964,
	"label": "NUEVOS DERIVADOS DEL ACIDO 4-AMINO-3-(AZOLIL-FENOXIMETIL)-TIENO[3,2-C]PIRIDIN-7-CARBOXILICO.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 5093413,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDO-PIRIDONA, INHIBIDORES DE LAS PROTEINA QUINASAS; COMPOSICION FARMACEUTICA; Y USO PARA EL TRATAMIENTO DE ENFERMEDADES TALES COMO ARTRITIS, SINDROME DE COLON IRRITABLE, SINDROME DISNEICO AGUDO DEL ADULTO, EPOC Y PARA EL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 5093413,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDO-PIRIDONA, INHIBIDORES DE LAS PROTEINA QUINASAS; COMPOSICION FARMACEUTICA; Y USO PARA EL TRATAMIENTO DE ENFERMEDADES TALES COMO ARTRITIS, SINDROME DE COLON IRRITABLE, SINDROME DISNEICO AGUDO DEL ADULTO, EPOC Y PARA EL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 5093413,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDO-PIRIDONA, INHIBIDORES DE LAS PROTEINA QUINASAS; COMPOSICION FARMACEUTICA; Y USO PARA EL TRATAMIENTO DE ENFERMEDADES TALES COMO ARTRITIS, SINDROME DE COLON IRRITABLE, SINDROME DISNEICO AGUDO DEL ADULTO, EPOC Y PARA EL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 5093413,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDO-PIRIDONA, INHIBIDORES DE LAS PROTEINA QUINASAS; COMPOSICION FARMACEUTICA; Y USO PARA EL TRATAMIENTO DE ENFERMEDADES TALES COMO ARTRITIS, SINDROME DE COLON IRRITABLE, SINDROME DISNEICO AGUDO DEL ADULTO, EPOC Y PARA EL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 5093413,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDO-PIRIDONA, INHIBIDORES DE LAS PROTEINA QUINASAS; COMPOSICION FARMACEUTICA; Y USO PARA EL TRATAMIENTO DE ENFERMEDADES TALES COMO ARTRITIS, SINDROME DE COLON IRRITABLE, SINDROME DISNEICO AGUDO DEL ADULTO, EPOC Y PARA EL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6292,
	"target": 6290,
	"type": 5094750,
	"label": "HETARILANILINAS COMO MODULADORES DE BETA-AMILOIDE.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6272,
	"target": 6213,
	"type": 5095280,
	"label": "COMPUESTOS DERIVADOS DE 2-[3-(3-CIANOFENOXI)(FENOXI O FENILSULFANIL)]-N-FENIL ACETAMIDA, INHIBIDORES DE LA TRANSCRIPTASA INVERSA DEL VIH; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; Y SU USO PARA TRATAR U",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 30950,
	"target": 30201,
	"type": 5095280,
	"label": "COMPUESTOS DERIVADOS DE 2-[3-(3-CIANOFENOXI)(FENOXI O FENILSULFANIL)]-N-FENIL ACETAMIDA, INHIBIDORES DE LA TRANSCRIPTASA INVERSA DEL VIH; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; Y SU USO PARA TRATAR U",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 30201,
	"target": 6272,
	"type": 5095280,
	"label": "COMPUESTOS DERIVADOS DE 2-[3-(3-CIANOFENOXI)(FENOXI O FENILSULFANIL)]-N-FENIL ACETAMIDA, INHIBIDORES DE LA TRANSCRIPTASA INVERSA DEL VIH; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; Y SU USO PARA TRATAR U",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 30201,
	"target": 6213,
	"type": 5095280,
	"label": "COMPUESTOS DERIVADOS DE 2-[3-(3-CIANOFENOXI)(FENOXI O FENILSULFANIL)]-N-FENIL ACETAMIDA, INHIBIDORES DE LA TRANSCRIPTASA INVERSA DEL VIH; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; Y SU USO PARA TRATAR U",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 30950,
	"target": 6272,
	"type": 5095280,
	"label": "COMPUESTOS DERIVADOS DE 2-[3-(3-CIANOFENOXI)(FENOXI O FENILSULFANIL)]-N-FENIL ACETAMIDA, INHIBIDORES DE LA TRANSCRIPTASA INVERSA DEL VIH; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; Y SU USO PARA TRATAR U",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6263,
	"type": 5095721,
	"label": "DERIVADOS DE 3,3-ESPIROINDOLINONA COMO AGENTES ANTAGONISTAS DE MDM2",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31965,
	"target": 7507,
	"type": 5095721,
	"label": "DERIVADOS DE 3,3-ESPIROINDOLINONA COMO AGENTES ANTAGONISTAS DE MDM2",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31965,
	"target": 6263,
	"type": 5095721,
	"label": "DERIVADOS DE 3,3-ESPIROINDOLINONA COMO AGENTES ANTAGONISTAS DE MDM2",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6303,
	"target": 6263,
	"type": 5095924,
	"label": "Derivados de espiroindolinona como inhibidores de MDM2-p53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6382,
	"target": 6303,
	"type": 5095924,
	"label": "Derivados de espiroindolinona como inhibidores de MDM2-p53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6382,
	"target": 6263,
	"type": 5095924,
	"label": "Derivados de espiroindolinona como inhibidores de MDM2-p53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 5095924,
	"label": "Derivados de espiroindolinona como inhibidores de MDM2-p53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 5095924,
	"label": "Derivados de espiroindolinona como inhibidores de MDM2-p53",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 30904,
	"target": 7359,
	"type": 5096269,
	"label": "COMPUESTOS DERIVADOS DE PIRAZOLES, ACTIVADORES DE GLUCOQUINASA; PROCESO DE PREPARACION DE DICHOS COMPUESTOS; COMPOSICION FARMACEUTICA QUE COMPRENDE DICHOS COMPUESTOS; Y USO PARA EL TRATAMIENTO DE ENFERMEDADES Y/O TRASTORNOS METABOLICOS, TAL COMO DIAB",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 5096784,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDIN-AMINA, MODULADORES DE JNK; PROCESO DE PREPARACION; COMPOSICIONES FARMACEUTICAS; Y USO PARA EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ASMA, DIABETES TIPO II, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON Y APOPLEJIA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 5096784,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDIN-AMINA, MODULADORES DE JNK; PROCESO DE PREPARACION; COMPOSICIONES FARMACEUTICAS; Y USO PARA EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ASMA, DIABETES TIPO II, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON Y APOPLEJIA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 5096784,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDIN-AMINA, MODULADORES DE JNK; PROCESO DE PREPARACION; COMPOSICIONES FARMACEUTICAS; Y USO PARA EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ASMA, DIABETES TIPO II, ENFERMEDAD DE ALZHEIMER, ENFERMEDAD DE PARKINSON Y APOPLEJIA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 5097444,
	"label": "Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6371,
	"target": 6366,
	"type": 5097780,
	"label": "COMPUESTOS DERIVADOS DE PIPERIDINAS SUSTITUIDAS; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; Y SU USO PARA TRATAR UNA INFECCION VIH.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 5098132,
	"label": "Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6352,
	"type": 5098132,
	"label": "Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 6352,
	"type": 5098132,
	"label": "Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 5098752,
	"label": "Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7425,
	"target": 7423,
	"type": 5098754,
	"label": "NOVEL USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7425,
	"type": 5098754,
	"label": "NOVEL USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7423,
	"type": 5098754,
	"label": "NOVEL USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 5101046,
	"label": "COMPUESTOS DERIVADOS DE BENZOTIAZOL, MODULADORES DE QUINASA; COMPOSICION FARMACEUTICA QUE LOS CONTIENE; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR LA QUINASA C-JUN-N-TERMINAL, TALES COMO TRASTORNOS AUTOINMUNES, INFLAMATORIOS, METABOLICO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6371,
	"target": 6280,
	"type": 5101046,
	"label": "COMPUESTOS DERIVADOS DE BENZOTIAZOL, MODULADORES DE QUINASA; COMPOSICION FARMACEUTICA QUE LOS CONTIENE; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR LA QUINASA C-JUN-N-TERMINAL, TALES COMO TRASTORNOS AUTOINMUNES, INFLAMATORIOS, METABOLICO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 5101046,
	"label": "COMPUESTOS DERIVADOS DE BENZOTIAZOL, MODULADORES DE QUINASA; COMPOSICION FARMACEUTICA QUE LOS CONTIENE; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR LA QUINASA C-JUN-N-TERMINAL, TALES COMO TRASTORNOS AUTOINMUNES, INFLAMATORIOS, METABOLICO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 6371,
	"type": 5101046,
	"label": "COMPUESTOS DERIVADOS DE BENZOTIAZOL, MODULADORES DE QUINASA; COMPOSICION FARMACEUTICA QUE LOS CONTIENE; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR LA QUINASA C-JUN-N-TERMINAL, TALES COMO TRASTORNOS AUTOINMUNES, INFLAMATORIOS, METABOLICO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6280,
	"type": 5101046,
	"label": "COMPUESTOS DERIVADOS DE BENZOTIAZOL, MODULADORES DE QUINASA; COMPOSICION FARMACEUTICA QUE LOS CONTIENE; Y SU USO PARA EL TRATAMIENTO DE UN TRASTORNO MEDIADO POR LA QUINASA C-JUN-N-TERMINAL, TALES COMO TRASTORNOS AUTOINMUNES, INFLAMATORIOS, METABOLICO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7359,
	"target": 6371,
	"type": 5101142,
	"label": "PYRIDINE- AND QUINOLINE-PYRIMIDINE-DERIVATIVES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6371,
	"target": 6263,
	"type": 5101905,
	"label": "COMPUESTOS DERIVADOS DE OCTAHIDRO-PIRROLO[3,4-C]PIRROL; COMPOSICION FARMACEUTICA QUE LA COMPRENDE; Y USO DEL COMPUESTO EN EL TRATAMIENTO DEL VIH, SIDA O ARC.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 5103123,
	"label": "USE OF TIMP-1 AS A MARKER FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 5103151,
	"label": "Antibody directed to G protein coupled receptors (GPCR)",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7360,
	"target": 6371,
	"type": 5119531,
	"label": "compostos, processo para a sua manufatura,composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, método para o tratamento ou prevenção de obesidade, de diabetes do tipo ii, e uso dos compostos na manufatura de medicamentos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 6892,
	"type": 5179180,
	"label": "Envelope protein of acquired immune deficiency syndrome virus",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32281,
	"target": 32254,
	"type": 5484847,
	"label": "Procédé pour la préparation des éthers-sels et d'amides de l'acide orthophosphorique",
	"group": "Roche",
	"time": 1945,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 5841719,
	"label": "2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 5841719,
	"label": "2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 6371,
	"type": 5841719,
	"label": "2-MORPHOLIN-4-YL-PYRIMIDINES AS PI3K INHIBITORS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 5849019,
	"label": "Substituted thieno- and furano- fused pyrimidines as PI3K inhibitors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 5942675,
	"label": "MOLECULA DE ADHESION AL ANTIGENO (AMB) QUE SE ADHIEREN A EGFR; CELULA HUESPED Y VECTOR QUE COMPRENDE DICHA ABM; METODO PARA PRODUCIR UNA ABM; COMPOSICION QUE COMPRENDE LA ABM; USO DE ABM PARA TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 5942675,
	"label": "MOLECULA DE ADHESION AL ANTIGENO (AMB) QUE SE ADHIEREN A EGFR; CELULA HUESPED Y VECTOR QUE COMPRENDE DICHA ABM; METODO PARA PRODUCIR UNA ABM; COMPOSICION QUE COMPRENDE LA ABM; USO DE ABM PARA TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 5942675,
	"label": "MOLECULA DE ADHESION AL ANTIGENO (AMB) QUE SE ADHIEREN A EGFR; CELULA HUESPED Y VECTOR QUE COMPRENDE DICHA ABM; METODO PARA PRODUCIR UNA ABM; COMPOSICION QUE COMPRENDE LA ABM; USO DE ABM PARA TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 5942675,
	"label": "MOLECULA DE ADHESION AL ANTIGENO (AMB) QUE SE ADHIEREN A EGFR; CELULA HUESPED Y VECTOR QUE COMPRENDE DICHA ABM; METODO PARA PRODUCIR UNA ABM; COMPOSICION QUE COMPRENDE LA ABM; USO DE ABM PARA TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 5942675,
	"label": "MOLECULA DE ADHESION AL ANTIGENO (AMB) QUE SE ADHIEREN A EGFR; CELULA HUESPED Y VECTOR QUE COMPRENDE DICHA ABM; METODO PARA PRODUCIR UNA ABM; COMPOSICION QUE COMPRENDE LA ABM; USO DE ABM PARA TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 5957648,
	"label": "ANTIBODIES AGAINST TYPE 2 TUMOR NECROSIS FACTOR RECEPTOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 5957648,
	"label": "ANTIBODIES AGAINST TYPE 2 TUMOR NECROSIS FACTOR RECEPTOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37904,
	"target": 32779,
	"type": 5957648,
	"label": "ANTIBODIES AGAINST TYPE 2 TUMOR NECROSIS FACTOR RECEPTOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 5957648,
	"label": "ANTIBODIES AGAINST TYPE 2 TUMOR NECROSIS FACTOR RECEPTOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 5957648,
	"label": "ANTIBODIES AGAINST TYPE 2 TUMOR NECROSIS FACTOR RECEPTOR",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 5960997,
	"label": "NOVEL 9,10-SECOANDROSTANE BASED COMPOUND",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38065,
	"target": 32694,
	"type": 5963476,
	"label": "TSG GENE-KNOCKOUT ANIMAL",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7360,
	"target": 6429,
	"type": 5964664,
	"label": "MEDICINE FOR TREATING HYPERCALCEMIA",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 5970570,
	"label": "Vitamin D3-responsive sequences located 5'-upstream of the p27/kip 1 gene and methods of screening for pharmaceutical agents using the sequences",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37988,
	"target": 37899,
	"type": 5970570,
	"label": "Vitamin D3-responsive sequences located 5'-upstream of the p27/kip 1 gene and methods of screening for pharmaceutical agents using the sequences",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37988,
	"target": 37859,
	"type": 5970570,
	"label": "Vitamin D3-responsive sequences located 5'-upstream of the p27/kip 1 gene and methods of screening for pharmaceutical agents using the sequences",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7507,
	"target": 6431,
	"type": 5970570,
	"label": "Vitamin D3-responsive sequences located 5'-upstream of the p27/kip 1 gene and methods of screening for pharmaceutical agents using the sequences",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 5970570,
	"label": "Vitamin D3-responsive sequences located 5'-upstream of the p27/kip 1 gene and methods of screening for pharmaceutical agents using the sequences",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 5970666,
	"label": "GFP expression vector localized in mitochondria",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56765,
	"target": 38065,
	"type": 5970666,
	"label": "GFP expression vector localized in mitochondria",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 56765,
	"target": 37899,
	"type": 5970666,
	"label": "GFP expression vector localized in mitochondria",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 5971543,
	"label": "ANTITUMOR AGENT",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37960,
	"target": 6795,
	"type": 5973449,
	"label": "PROTEIN HAVING PGE2 SYNTHASE ACTIVITY AND USE THEREOF",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 5975119,
	"label": "NR10 SPLICING VARIANTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 5975119,
	"label": "NR10 SPLICING VARIANTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 5975119,
	"label": "NR10 SPLICING VARIANTS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 7424,
	"target": 6795,
	"type": 5975120,
	"label": "METHOD OF GENE TRANSFER VIA VASCULAR SYSTEM OR URETER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32478,
	"target": 7424,
	"type": 5975120,
	"label": "METHOD OF GENE TRANSFER VIA VASCULAR SYSTEM OR URETER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32478,
	"target": 6795,
	"type": 5975120,
	"label": "METHOD OF GENE TRANSFER VIA VASCULAR SYSTEM OR URETER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 5975716,
	"label": "3-Methyl-20-epi-vitamin D derivatives",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 5980465,
	"label": "ANGIOGENESIS INHIBITORS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32769,
	"target": 7509,
	"type": 5980465,
	"label": "ANGIOGENESIS INHIBITORS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32769,
	"target": 7507,
	"type": 5980465,
	"label": "ANGIOGENESIS INHIBITORS",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38065,
	"target": 32734,
	"type": 5981033,
	"label": "VITAMIN D RECEPTOR-DEFICIENT CELL LINE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32734,
	"target": 6795,
	"type": 5981033,
	"label": "VITAMIN D RECEPTOR-DEFICIENT CELL LINE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38065,
	"target": 6795,
	"type": 5981033,
	"label": "VITAMIN D RECEPTOR-DEFICIENT CELL LINE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 5981227,
	"label": "CARCINOSTATIC AGENT CONTAINING NOVEL PLATINUM COMPLEX AS ACTIVE COMPONENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 5981230,
	"label": "CARCINOSTATIC AGENT CONTAINING NOVEL PLATINUM COMPLEX AS ACTIVE COMPONENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 5981231,
	"label": "CARCINOSTATIC AGENT CONTAINING PLATINUM COMPLEX AS ACTIVE COMPONENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 6816,
	"type": 5991326,
	"label": "COMPOSITION CONTAINING INTERFERON AND VITAMIND DERIVATIVE ANTUMOR THERAPY",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 6006514,
	"label": "Mouse with defective endotheline-1 gene function",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 6006545,
	"label": "THERAPEUTIC AGENT FOR RENAL CARCINOMA COMPRISING ANTISENSE OLIGONUCLEOTIDE DERIVATIVE CORRESPONDING TO HUMAN INTERLEUKIN-6 RECEPTOR",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 6006545,
	"label": "THERAPEUTIC AGENT FOR RENAL CARCINOMA COMPRISING ANTISENSE OLIGONUCLEOTIDE DERIVATIVE CORRESPONDING TO HUMAN INTERLEUKIN-6 RECEPTOR",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37988,
	"target": 32698,
	"type": 6006545,
	"label": "THERAPEUTIC AGENT FOR RENAL CARCINOMA COMPRISING ANTISENSE OLIGONUCLEOTIDE DERIVATIVE CORRESPONDING TO HUMAN INTERLEUKIN-6 RECEPTOR",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32698,
	"target": 7424,
	"type": 6006545,
	"label": "THERAPEUTIC AGENT FOR RENAL CARCINOMA COMPRISING ANTISENSE OLIGONUCLEOTIDE DERIVATIVE CORRESPONDING TO HUMAN INTERLEUKIN-6 RECEPTOR",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 7424,
	"type": 6006545,
	"label": "THERAPEUTIC AGENT FOR RENAL CARCINOMA COMPRISING ANTISENSE OLIGONUCLEOTIDE DERIVATIVE CORRESPONDING TO HUMAN INTERLEUKIN-6 RECEPTOR",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7425,
	"target": 7360,
	"type": 6009016,
	"label": "CONSERVATIVE TREATMENT AGENT FOR RENAL INSUFFICIENCY",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 6019739,
	"label": "PHYLACTIC",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32696,
	"target": 32694,
	"type": 6019739,
	"label": "PHYLACTIC",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 6019739,
	"label": "PHYLACTIC",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 6019739,
	"label": "PHYLACTIC",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32696,
	"type": 6019739,
	"label": "PHYLACTIC",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 7510,
	"target": 6429,
	"type": 6028611,
	"label": "DRUG CONTAINING 9,10-SECOPREGNATRIENE DERIVATIVE AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 6028612,
	"label": "DRUG CONTAINING 9,10-SECO-5,7,10(19)-PREGNATRIENE DERIVATIVE AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 6028612,
	"label": "DRUG CONTAINING 9,10-SECO-5,7,10(19)-PREGNATRIENE DERIVATIVE AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 6028612,
	"label": "DRUG CONTAINING 9,10-SECO-5,7,10(19)-PREGNATRIENE DERIVATIVE AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 6033083,
	"label": "SYNOSTOSIS PROMOTOR",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7425,
	"target": 6429,
	"type": 6040489,
	"label": "REMEDY FOR NEPHRITIS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 6054999,
	"label": "ANTIULCER AGENT",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 6058924,
	"label": "STABLE GRANULOCYTE COLONY STIMULATING FACTOR-CONTAINING PREPARATION",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 6065678,
	"label": "ANTI-MALIGNANT TUMOR AGENT AND KIT FOR TREATING MALIGNANT TUMOR",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 6065678,
	"label": "ANTI-MALIGNANT TUMOR AGENT AND KIT FOR TREATING MALIGNANT TUMOR",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 32697,
	"type": 6065678,
	"label": "ANTI-MALIGNANT TUMOR AGENT AND KIT FOR TREATING MALIGNANT TUMOR",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 6065678,
	"label": "ANTI-MALIGNANT TUMOR AGENT AND KIT FOR TREATING MALIGNANT TUMOR",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32697,
	"target": 7507,
	"type": 6065678,
	"label": "ANTI-MALIGNANT TUMOR AGENT AND KIT FOR TREATING MALIGNANT TUMOR",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 6071959,
	"label": "DRUG CONTAINING 20-OXAVITAMIN D3 AS AN ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7425,
	"target": 6429,
	"type": 6074264,
	"label": "DRUG CONTAINING NOVEL VITAMIN D3 DERIVATIVE AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 6080292,
	"label": "POLY(ADP-RIBOSE) SYNTHASE ACTIVITY DEFICIENT MOUSE EMBRYONIC STEM CELL LINE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7507,
	"target": 6566,
	"type": 6080886,
	"label": "MICROTUBULE-BINDING PROTEIN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 6080886,
	"label": "MICROTUBULE-BINDING PROTEIN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 6080886,
	"label": "MICROTUBULE-BINDING PROTEIN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 6566,
	"type": 6080886,
	"label": "MICROTUBULE-BINDING PROTEIN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 6080886,
	"label": "MICROTUBULE-BINDING PROTEIN",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7511,
	"target": 7510,
	"type": 6085532,
	"label": "1BETA-HYDROXYVITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7510,
	"target": 7450,
	"type": 6085532,
	"label": "1BETA-HYDROXYVITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7511,
	"target": 7450,
	"type": 6085532,
	"label": "1BETA-HYDROXYVITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 6085532,
	"label": "1BETA-HYDROXYVITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7510,
	"target": 6429,
	"type": 6085532,
	"label": "1BETA-HYDROXYVITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 6093442,
	"label": "LEUKEMIA REMEDY",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 7508,
	"target": 6816,
	"type": 6096028,
	"label": "Method for the treatment of chronic myelogenous leukemia",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37878,
	"target": 37875,
	"type": 6097355,
	"label": "ERYTHROPOIETIN-DEPENDENT HUMAN CELL LINE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 6097355,
	"label": "ERYTHROPOIETIN-DEPENDENT HUMAN CELL LINE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37878,
	"target": 6795,
	"type": 6097355,
	"label": "ERYTHROPOIETIN-DEPENDENT HUMAN CELL LINE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37904,
	"target": 37899,
	"type": 6104897,
	"label": "ANTI-HUMAN SCAVENGER RECEPTOR ANTIBODY",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 6104897,
	"label": "ANTI-HUMAN SCAVENGER RECEPTOR ANTIBODY",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 6104897,
	"label": "ANTI-HUMAN SCAVENGER RECEPTOR ANTIBODY",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 6104897,
	"label": "ANTI-HUMAN SCAVENGER RECEPTOR ANTIBODY",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 6104897,
	"label": "ANTI-HUMAN SCAVENGER RECEPTOR ANTIBODY",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 6795,
	"target": 6539,
	"type": 6107469,
	"label": "ANTICANCER AGENT",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 6107469,
	"label": "ANTICANCER AGENT",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 6107469,
	"label": "ANTICANCER AGENT",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 6111004,
	"label": "REMEDY FOR PSORIASIS",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 38184,
	"target": 37875,
	"type": 6118959,
	"label": "MONOCLONAL ANTIBODY, METHOD FOR ITS MANUFACTURE AND ITS USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 6118959,
	"label": "MONOCLONAL ANTIBODY, METHOD FOR ITS MANUFACTURE AND ITS USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 56836,
	"target": 37875,
	"type": 6118959,
	"label": "MONOCLONAL ANTIBODY, METHOD FOR ITS MANUFACTURE AND ITS USE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 6121235,
	"label": "24-OXO-22-OXAVITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 6134836,
	"label": "VITAMIN D DERIVATIVE CONTAINING SUBSTITUENT GROUP AT 2BETA-POSITION",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 6134836,
	"label": "VITAMIN D DERIVATIVE CONTAINING SUBSTITUENT GROUP AT 2BETA-POSITION",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 6134836,
	"label": "VITAMIN D DERIVATIVE CONTAINING SUBSTITUENT GROUP AT 2BETA-POSITION",
	"group": "Roche",
	"time": 1992,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 6186980,
	"label": "GENE INVOLVED IN DIFFERENTIATION MAINTENANCE OF SMOOTH MUSCLE CELL",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 6186980,
	"label": "GENE INVOLVED IN DIFFERENTIATION MAINTENANCE OF SMOOTH MUSCLE CELL",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 6795,
	"target": 6483,
	"type": 6186980,
	"label": "GENE INVOLVED IN DIFFERENTIATION MAINTENANCE OF SMOOTH MUSCLE CELL",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 6186980,
	"label": "GENE INVOLVED IN DIFFERENTIATION MAINTENANCE OF SMOOTH MUSCLE CELL",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 6186980,
	"label": "GENE INVOLVED IN DIFFERENTIATION MAINTENANCE OF SMOOTH MUSCLE CELL",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 6191910,
	"label": "2-SUBSTITUTED VITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 6193895,
	"label": "Methods of Screening for Modified Antibodies With Agonistic Activities",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 6193895,
	"label": "Methods of Screening for Modified Antibodies With Agonistic Activities",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 6193895,
	"label": "Methods of Screening for Modified Antibodies With Agonistic Activities",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 6197202,
	"label": "CHIMERIC RECEPTORS AND METHOD OF SCREENING LIGANDS OR INHIBITORS FOR THE RECEPTORS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 6197202,
	"label": "CHIMERIC RECEPTORS AND METHOD OF SCREENING LIGANDS OR INHIBITORS FOR THE RECEPTORS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 6197202,
	"label": "CHIMERIC RECEPTORS AND METHOD OF SCREENING LIGANDS OR INHIBITORS FOR THE RECEPTORS",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 6202088,
	"label": "EMBRYONIC STEM CELL STRAIN DEFECTIVE IN POLY(ADP-RIBOSE)GLYCOHYDROLASE ACTIVITY",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 7450,
	"target": 6567,
	"type": 6238504,
	"label": "PREVENTIVE AND REMEDY FOR BONE DISEASE",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 6239612,
	"label": "REMEDY FOR THROMBOPENIA",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7358,
	"target": 6471,
	"type": 6248911,
	"label": "PREVENTIVE AND REMEDY FOR HEPATITIS C VIRUS INFECTION",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 6252120,
	"label": "Gen transportador de taurina",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 6252120,
	"label": "Gen transportador de taurina",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 6252120,
	"label": "Gen transportador de taurina",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6484,
	"target": 6419,
	"type": 6253218,
	"label": "THERAPEUTIC AND PREVENTIVE AGENT FOR HCV",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 6253218,
	"label": "THERAPEUTIC AND PREVENTIVE AGENT FOR HCV",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7358,
	"target": 6484,
	"type": 6253218,
	"label": "THERAPEUTIC AND PREVENTIVE AGENT FOR HCV",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7358,
	"target": 6419,
	"type": 6253218,
	"label": "THERAPEUTIC AND PREVENTIVE AGENT FOR HCV",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6484,
	"type": 6253218,
	"label": "THERAPEUTIC AND PREVENTIVE AGENT FOR HCV",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6292,
	"type": 6254813,
	"label": "&alpha;-amino acid derivatives and medicaments containing the same as an active ingredient",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 6258434,
	"label": "AGENTES INDUCTORES DE MUERTE CELULAR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 6258434,
	"label": "AGENTES INDUCTORES DE MUERTE CELULAR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 6258434,
	"label": "AGENTES INDUCTORES DE MUERTE CELULAR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 6258434,
	"label": "AGENTES INDUCTORES DE MUERTE CELULAR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 6258434,
	"label": "AGENTES INDUCTORES DE MUERTE CELULAR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 6259681,
	"label": "BMP antibodies and methods of treating kidney disease using the same",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 7424,
	"type": 6259681,
	"label": "BMP antibodies and methods of treating kidney disease using the same",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 7424,
	"type": 6259681,
	"label": "BMP antibodies and methods of treating kidney disease using the same",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 6260755,
	"label": "PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING HCV INFECTION",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 6260755,
	"label": "PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING HCV INFECTION",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 6260755,
	"label": "PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING HCV INFECTION",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7497,
	"type": 6261185,
	"label": "SUBSTANCE FOR USE IN TREATMENT OR PREVENTION OF HCV INFECTION",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7497,
	"target": 6483,
	"type": 6261185,
	"label": "SUBSTANCE FOR USE IN TREATMENT OR PREVENTION OF HCV INFECTION",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 6261185,
	"label": "SUBSTANCE FOR USE IN TREATMENT OR PREVENTION OF HCV INFECTION",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 6264766,
	"label": "COMPUESTOS DERIVADOS DE PIRIMIDINA, INHIBIDORES DE PI3K; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHO COMPUESTO; Y USO DEL COMPUESTO EN ENFERMEDADES PROLIFERATIVAS COMO CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 6267367,
	"label": "Method for preparing fusion protein",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 6267367,
	"label": "Method for preparing fusion protein",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 6267367,
	"label": "Method for preparing fusion protein",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 6267367,
	"label": "Method for preparing fusion protein",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 6267367,
	"label": "Method for preparing fusion protein",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 6267441,
	"label": "PROPHYLACTIC AND/OR THERAPEUTIC AGENTS FOR PERIPHERAL NEUROPATHY",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 6268000,
	"label": "METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 6268000,
	"label": "METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 6268000,
	"label": "METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 6268000,
	"label": "METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 6268000,
	"label": "METHODS FOR CONTROLLING BLOOD PHARMACOKINETICS OF ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 6268010,
	"label": "METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 6268010,
	"label": "METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 6268010,
	"label": "METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 6268010,
	"label": "METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 6268010,
	"label": "METHODS OF MODIFYING ANTIBODIES FOR PURIFICATION OF BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 6276029,
	"label": "CANCER-ASSOCIATED ANTIGEN ANALOG PEPTIDE AND UTILIZATION OF THE SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37889,
	"type": 6276029,
	"label": "CANCER-ASSOCIATED ANTIGEN ANALOG PEPTIDE AND UTILIZATION OF THE SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37889,
	"target": 37862,
	"type": 6276029,
	"label": "CANCER-ASSOCIATED ANTIGEN ANALOG PEPTIDE AND UTILIZATION OF THE SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37889,
	"target": 37859,
	"type": 6276029,
	"label": "CANCER-ASSOCIATED ANTIGEN ANALOG PEPTIDE AND UTILIZATION OF THE SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 6276029,
	"label": "CANCER-ASSOCIATED ANTIGEN ANALOG PEPTIDE AND UTILIZATION OF THE SAME",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 6276925,
	"label": "METHOD FOR PRODUCTION OF ANTIBODY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 6276925,
	"label": "METHOD FOR PRODUCTION OF ANTIBODY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 6276925,
	"label": "METHOD FOR PRODUCTION OF ANTIBODY",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 6305018,
	"label": "COMPUESTOS MACROCICLICOS DERIVADOS DE 6-ARIL-4-MERCAPTO-[1.3.5]TRIAZINA/[1.3]PIRIMIDIN-2-AMINA; COMPOSICION FARMACEUTICA, UTILES EN EL TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7358,
	"target": 6382,
	"type": 6305018,
	"label": "COMPUESTOS MACROCICLICOS DERIVADOS DE 6-ARIL-4-MERCAPTO-[1.3.5]TRIAZINA/[1.3]PIRIMIDIN-2-AMINA; COMPOSICION FARMACEUTICA, UTILES EN EL TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 6305018,
	"label": "COMPUESTOS MACROCICLICOS DERIVADOS DE 6-ARIL-4-MERCAPTO-[1.3.5]TRIAZINA/[1.3]PIRIMIDIN-2-AMINA; COMPOSICION FARMACEUTICA, UTILES EN EL TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 32698,
	"type": 6307674,
	"label": "Agents for suppressing chronic rejection reaction",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32698,
	"target": 6854,
	"type": 6307674,
	"label": "Agents for suppressing chronic rejection reaction",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 6307674,
	"label": "Agents for suppressing chronic rejection reaction",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 6320030,
	"label": "THERAPEUTIC AGENT FOR INFLAMMATORY MYOPATHY CONTAINING IL-6 ANTAGONIST AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 6380259,
	"label": "Novel metalloprotease containing a thrombospondin domain (MPTS protein) is useful to treat aggrecan associated disease including rheumatoid arthritis and osteoarthritis",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 32769,
	"type": 6489443,
	"label": "ANTIBODIES SPECIFIC FOR HUMAN GALANIN, AND USES THEREOF",
	"group": "Amgen",
	"time": 2004,
	"strength": 1
}, {
	"source": 6347,
	"target": 6345,
	"type": 6489501,
	"label": "NEW ANTI-SICKLING AGENTS: SELECTION METHODS AND EFFECTIVE COMPOUNDS",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32754,
	"target": 32734,
	"type": 6502944,
	"label": "G protein-coupled receptors",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37864,
	"target": 32754,
	"type": 6502944,
	"label": "G protein-coupled receptors",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 37864,
	"target": 32734,
	"type": 6502944,
	"label": "G protein-coupled receptors",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32734,
	"target": 6795,
	"type": 6502944,
	"label": "G protein-coupled receptors",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 32754,
	"target": 6795,
	"type": 6502944,
	"label": "G protein-coupled receptors",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 6503851,
	"label": "Methods of regulating cytokine receptor signaling",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 6503851,
	"label": "Methods of regulating cytokine receptor signaling",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 6503851,
	"label": "Methods of regulating cytokine receptor signaling",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 56834,
	"target": 32478,
	"type": 6506634,
	"label": "DIAGNOSIS AND TREATMENT OF CANCER USING MAMMALIAN PELLINO POLYPEPTIDES AND POLYNUCLEOTIDES",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 37904,
	"target": 37899,
	"type": 6527949,
	"label": "MIT DER ZELLTEILUNGSFURCHE ASSOZIIERTE TYROSINPHOSPHORYLIERTE PROTEINE (PSTPIPS)",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 6527949,
	"label": "MIT DER ZELLTEILUNGSFURCHE ASSOZIIERTE TYROSINPHOSPHORYLIERTE PROTEINE (PSTPIPS)",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 6527949,
	"label": "MIT DER ZELLTEILUNGSFURCHE ASSOZIIERTE TYROSINPHOSPHORYLIERTE PROTEINE (PSTPIPS)",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 6541304,
	"label": "Antibody formulation",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 6542540,
	"label": "Treatment of cancer using anti-Apo-2 antibodies",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 6546611,
	"label": "DETECTION OF    BORDETELLA",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 32769,
	"type": 6555921,
	"label": "Methods and compositions for immunologically modulating growth hormone receptor activity",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32769,
	"target": 6854,
	"type": 6555921,
	"label": "Methods and compositions for immunologically modulating growth hormone receptor activity",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 6555921,
	"label": "Methods and compositions for immunologically modulating growth hormone receptor activity",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 6561260,
	"label": "Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 6561260,
	"label": "Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37904,
	"target": 32772,
	"type": 6561260,
	"label": "Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 6561260,
	"label": "Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 56833,
	"target": 37904,
	"type": 6561260,
	"label": "Isolated nucleic acids, vectors and host cells encoding ErbB3 antibodies",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 6563360,
	"label": "Bevacizumab tel que présent dans le produit AVASTIN approuvé par l'AEEM, comprenant les différentes formes et modifications post-traductionnelles du Bevacizumab qui y est présent, ainsi que les variantes immunologiques et immunochimiques de ceux-ci (AVASTIN).",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 6563360,
	"label": "Bevacizumab tel que présent dans le produit AVASTIN approuvé par l'AEEM, comprenant les différentes formes et modifications post-traductionnelles du Bevacizumab qui y est présent, ainsi que les variantes immunologiques et immunochimiques de ceux-ci (AVASTIN).",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38181,
	"target": 32779,
	"type": 6563360,
	"label": "Bevacizumab tel que présent dans le produit AVASTIN approuvé par l'AEEM, comprenant les différentes formes et modifications post-traductionnelles du Bevacizumab qui y est présent, ainsi que les variantes immunologiques et immunochimiques de ceux-ci (AVASTIN).",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 6563360,
	"label": "Bevacizumab tel que présent dans le produit AVASTIN approuvé par l'AEEM, comprenant les différentes formes et modifications post-traductionnelles du Bevacizumab qui y est présent, ainsi que les variantes immunologiques et immunochimiques de ceux-ci (AVASTIN).",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 6563360,
	"label": "Bevacizumab tel que présent dans le produit AVASTIN approuvé par l'AEEM, comprenant les différentes formes et modifications post-traductionnelles du Bevacizumab qui y est présent, ainsi que les variantes immunologiques et immunochimiques de ceux-ci (AVASTIN).",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 6564613,
	"label": "Monoclonal antibodies to type I interferon receptor",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 6564742,
	"label": "STANNIOCALCIN-1, VARIANT OR ANTAGONISTS THEREOF FOR SELECTIVE MODULATION OF VASCULARIZATION",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 6812,
	"type": 6564742,
	"label": "STANNIOCALCIN-1, VARIANT OR ANTAGONISTS THEREOF FOR SELECTIVE MODULATION OF VASCULARIZATION",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 6564742,
	"label": "STANNIOCALCIN-1, VARIANT OR ANTAGONISTS THEREOF FOR SELECTIVE MODULATION OF VASCULARIZATION",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 6573724,
	"label": "NOVEL PLATELET AGGREGATION INHIBITORS FROM THE LEECH",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37996,
	"target": 6795,
	"type": 6587786,
	"label": "PURIFICATION OF INSULIN-LIKE GROWTH FACTOR",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 6598461,
	"label": "Non-human animal exhibiting bone metastasis of tumor cells",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 7509,
	"type": 6598461,
	"label": "Non-human animal exhibiting bone metastasis of tumor cells",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38065,
	"target": 7509,
	"type": 6598461,
	"label": "Non-human animal exhibiting bone metastasis of tumor cells",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 6601234,
	"label": "Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 6601234,
	"label": "Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 6601234,
	"label": "Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 6601438,
	"label": "ErbB4 receptor-specific neuregulin related ligands and uses therefor",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 6613501,
	"label": "Variable domain library and uses",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32772,
	"type": 6613501,
	"label": "Variable domain library and uses",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 6613501,
	"label": "Variable domain library and uses",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56804,
	"target": 38184,
	"type": 6613501,
	"label": "Variable domain library and uses",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56804,
	"target": 32772,
	"type": 6613501,
	"label": "Variable domain library and uses",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 6616355,
	"label": "Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agent",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 32777,
	"type": 6616355,
	"label": "Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agent",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 6616355,
	"label": "Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agent",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32777,
	"target": 7510,
	"type": 6616355,
	"label": "Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agent",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37993,
	"target": 7510,
	"type": 6616355,
	"label": "Therapeutic compositions comprising anti-IGE antibodies and immunosuppressive agent",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 6623464,
	"label": "DOMÄNEN DER KONSTANTEN REGION VON IMMUNOGLOBULINEN MIT VERBESSERTER STABILITÄT",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 7510,
	"type": 6623464,
	"label": "DOMÄNEN DER KONSTANTEN REGION VON IMMUNOGLOBULINEN MIT VERBESSERTER STABILITÄT",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 6623464,
	"label": "DOMÄNEN DER KONSTANTEN REGION VON IMMUNOGLOBULINEN MIT VERBESSERTER STABILITÄT",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 6623691,
	"label": "ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 6623691,
	"label": "ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 6623691,
	"label": "ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 6623691,
	"label": "ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 6623691,
	"label": "ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 6637048,
	"label": "Composition and method for treating inflammatory diseases",
	"group": "Amgen",
	"time": 1998,
	"strength": 1
}, {
	"source": 30815,
	"target": 30814,
	"type": 6649937,
	"label": "Octahydroisoquinoline derivatives",
	"group": "Roche",
	"time": 1950,
	"strength": 1
}, {
	"source": 7510,
	"target": 6429,
	"type": 6661405,
	"label": "Method for inhibiting the lowering of immunological function and agent therefor",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 7510,
	"target": 6429,
	"type": 6661407,
	"label": "Method for suppressing abnormal rise in immunological function and agent useful therefor",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 6676481,
	"label": "UNA COMPOSICION QUE COMPRENDE UN RECEPTOR OB VARIANTE 12.1, UNA MOLECULA DE ACIDO NUCLEICO QUE CODIFICA DICHO RECEPTOR LIGADO OPERATIVAMENTE A UN PROMOTOR, UN VECTOR DE EXPRESION, UNA CELULA HUESPED, UN RECEPTOR OB QUIMERICO FUSIONADO A UNA INMUNOLOGLUBINA Y ANTICUERPO AGONISTA MONOCLONAL QUE SE LIG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 6676481,
	"label": "UNA COMPOSICION QUE COMPRENDE UN RECEPTOR OB VARIANTE 12.1, UNA MOLECULA DE ACIDO NUCLEICO QUE CODIFICA DICHO RECEPTOR LIGADO OPERATIVAMENTE A UN PROMOTOR, UN VECTOR DE EXPRESION, UNA CELULA HUESPED, UN RECEPTOR OB QUIMERICO FUSIONADO A UNA INMUNOLOGLUBINA Y ANTICUERPO AGONISTA MONOCLONAL QUE SE LIG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 6676481,
	"label": "UNA COMPOSICION QUE COMPRENDE UN RECEPTOR OB VARIANTE 12.1, UNA MOLECULA DE ACIDO NUCLEICO QUE CODIFICA DICHO RECEPTOR LIGADO OPERATIVAMENTE A UN PROMOTOR, UN VECTOR DE EXPRESION, UNA CELULA HUESPED, UN RECEPTOR OB QUIMERICO FUSIONADO A UNA INMUNOLOGLUBINA Y ANTICUERPO AGONISTA MONOCLONAL QUE SE LIG",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 6687313,
	"label": "Diagnosis and treatment of hepatic disorders",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 56765,
	"type": 6687322,
	"label": "Analytical method",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 6732633,
	"label": "Conjugado, composição, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método para produzir um polipeptìdeo e polipeptìdeo.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 6732633,
	"label": "Conjugado, composição, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método para produzir um polipeptìdeo e polipeptìdeo.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 6732633,
	"label": "Conjugado, composição, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método para produzir um polipeptìdeo e polipeptìdeo.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 6732633,
	"label": "Conjugado, composição, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método para produzir um polipeptìdeo e polipeptìdeo.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32779,
	"target": 7510,
	"type": 6732633,
	"label": "Conjugado, composição, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método para produzir um polipeptìdeo e polipeptìdeo.",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37988,
	"target": 6795,
	"type": 6738676,
	"label": "INHIBITION OF GENE FUNCTION BY DELIVERY OF POLYNUCLEOTIDE-BASED GENE EXPRESSION INHIBITORS TO MAMMALIAN CELLS IN VIVO",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 6760318,
	"label": "Method of treating infectious diseases with granulocyte colony-stimulating factor",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 30171,
	"target": 6795,
	"type": 6879746,
	"label": "Arylsulfonanilide derivatives",
	"group": "Amgen",
	"time": 1999,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 6889329,
	"label": "Method of treating leukemia or leukemoid diseases",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 6889329,
	"label": "Method of treating leukemia or leukemoid diseases",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 6889329,
	"label": "Method of treating leukemia or leukemoid diseases",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 30815,
	"target": 30814,
	"type": 6889714,
	"label": "SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES",
	"group": "Roche",
	"time": 1967,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 6901893,
	"label": "HUMAN NEURTURIN RECEPTOR- a (NTNR a ) POLYPEPTIDES, ANTIBODIES TO NTNR a AND COMPOSITION COMPRISING THE SAME",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 6901893,
	"label": "HUMAN NEURTURIN RECEPTOR- a (NTNR a ) POLYPEPTIDES, ANTIBODIES TO NTNR a AND COMPOSITION COMPRISING THE SAME",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 6901893,
	"label": "HUMAN NEURTURIN RECEPTOR- a (NTNR a ) POLYPEPTIDES, ANTIBODIES TO NTNR a AND COMPOSITION COMPRISING THE SAME",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 6907830,
	"label": "Methods and compositions for modulating prostasin",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 6907830,
	"label": "Methods and compositions for modulating prostasin",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 6907830,
	"label": "Methods and compositions for modulating prostasin",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 30815,
	"target": 30814,
	"type": 6930447,
	"label": "4-HYDROXY-ISOQUINOLINES AND PROCESSES FOR THEIR PREPARATION",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 32022,
	"target": 30815,
	"type": 6930447,
	"label": "4-HYDROXY-ISOQUINOLINES AND PROCESSES FOR THEIR PREPARATION",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 32022,
	"target": 30814,
	"type": 6930447,
	"label": "4-HYDROXY-ISOQUINOLINES AND PROCESSES FOR THEIR PREPARATION",
	"group": "Roche",
	"time": 1971,
	"strength": 1
}, {
	"source": 30815,
	"target": 30814,
	"type": 6948676,
	"label": "4-PHENYL ISOQUINOLINES AND PROCESS FOR PREPARING SAME",
	"group": "Roche",
	"time": 1970,
	"strength": 1
}, {
	"source": 32506,
	"target": 6427,
	"type": 6958242,
	"label": "6-HALO-4-OXA-3-ANDROSTANE, VERFAHREN ZU DEREN HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL, SOWIE 3,5-SECO-A-NOR-  ANDROSTAN-5-OL-3-CARBONSAEURE-VERBINDUNGEN ALS ZWISCHENPRODUKTE",
	"group": "Roche",
	"time": 1968,
	"strength": 1
}, {
	"source": 56834,
	"target": 37897,
	"type": 7008285,
	"label": "Animal model of ligand activated HER2 expressing tumors",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 7054337,
	"label": "Method for selectively blocking hemoglobin RNA amplification",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7068908,
	"label": "CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7068908,
	"label": "CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7068908,
	"label": "CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY",
	"group": "Gilead",
	"time": 2006,
	"strength": 1
}, {
	"source": 56765,
	"target": 6812,
	"type": 7071057,
	"label": "Receptor ligands and methods of modulating receptors",
	"group": "Amgen",
	"time": 2003,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 7082364,
	"label": "Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu uso",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7082364,
	"label": "Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu uso",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 56836,
	"target": 7507,
	"type": 7082364,
	"label": "Método para identificação de antìgeno, método para a produção de um composto, método para a inibição de proliferação de células, método para o tratamento de câncer, composição e seu uso",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38071,
	"target": 37988,
	"type": 7087191,
	"label": "VECTORS FOR INDUCIBLE EXPRESSION OF HAIRPIN RNA AND USE THEREOF",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37988,
	"target": 37875,
	"type": 7087191,
	"label": "VECTORS FOR INDUCIBLE EXPRESSION OF HAIRPIN RNA AND USE THEREOF",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38071,
	"target": 37875,
	"type": 7087191,
	"label": "VECTORS FOR INDUCIBLE EXPRESSION OF HAIRPIN RNA AND USE THEREOF",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7087310,
	"label": "anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32004,
	"target": 31912,
	"type": 7109405,
	"label": "6,7,8,9-TETRAHYDRO-7A,11A-ETHANOOXYINDOLO(1,2-H)(1,7)NAPHTHYRIDIN-10(11H)-ONES",
	"group": "Roche",
	"time": 1973,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7119054,
	"label": "HUMAN MONOCLONAL ANTIBODIES THAT BIND TO VERY LATE ANTIGEN-1 FOR THE TREATMENT OF INFLAMMATION AND OTHER DISORDERS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 7119054,
	"label": "HUMAN MONOCLONAL ANTIBODIES THAT BIND TO VERY LATE ANTIGEN-1 FOR THE TREATMENT OF INFLAMMATION AND OTHER DISORDERS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 7119054,
	"label": "HUMAN MONOCLONAL ANTIBODIES THAT BIND TO VERY LATE ANTIGEN-1 FOR THE TREATMENT OF INFLAMMATION AND OTHER DISORDERS",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 7137084,
	"label": "Method of Producing Pan-Specific Antibodies",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7145944,
	"label": "Method of Treatment Using Humanized Anti-CD11a Antibodies",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 7217667,
	"label": "Anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 7217667,
	"label": "Anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 37875,
	"type": 7217667,
	"label": "Anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37875,
	"target": 32770,
	"type": 7217667,
	"label": "Anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7217667,
	"label": "Anti-ErbB2 antibodies",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 7241996,
	"label": "Method of diagnosing the presence of a tumor in a mammal by assessing CDO expression levels",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7245596,
	"label": "POTENT T CELL MODULATING MOLECULES",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 7245596,
	"label": "POTENT T CELL MODULATING MOLECULES",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 32771,
	"target": 6795,
	"type": 7245596,
	"label": "POTENT T CELL MODULATING MOLECULES",
	"group": "Amgen",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 7263937,
	"label": "Human E3&alpha; ubiquitin ligase family",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56833,
	"target": 38184,
	"type": 7263937,
	"label": "Human E3&alpha; ubiquitin ligase family",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56833,
	"target": 37864,
	"type": 7263937,
	"label": "Human E3&alpha; ubiquitin ligase family",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 7264440,
	"label": "Methods and compositions comprising glycoprotein glycoforms",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 7264440,
	"label": "Methods and compositions comprising glycoprotein glycoforms",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 7264440,
	"label": "Methods and compositions comprising glycoprotein glycoforms",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 7275420,
	"label": "Methods and compositions for galactosylated glycoproteins",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 7275420,
	"label": "Methods and compositions for galactosylated glycoproteins",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 7275420,
	"label": "Methods and compositions for galactosylated glycoproteins",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 31965,
	"target": 31912,
	"type": 7284969,
	"label": "FUSED CYCLIC COMPOUNDS AS INTEGRASE INHIBITORS",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7284969,
	"label": "FUSED CYCLIC COMPOUNDS AS INTEGRASE INHIBITORS",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 31965,
	"target": 6301,
	"type": 7284969,
	"label": "FUSED CYCLIC COMPOUNDS AS INTEGRASE INHIBITORS",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 6376,
	"target": 6367,
	"type": 7298100,
	"label": "Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7298772,
	"label": "CARBOXYLIC ACID SALT OF 2,6-DIAMINOPURINE PHOSPHONAMIDE DERIVATIVE, METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES AND TREATING BLOOD NEOPLASMS, KIT, STERILE AQUEOUS SOLUTION AND COMPOSITION",
	"group": "Gilead",
	"time": 2007,
	"strength": 1
}, {
	"source": 6478,
	"target": 6376,
	"type": 7303124,
	"label": "composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 7303124,
	"label": "composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7303124,
	"label": "composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 7309697,
	"label": "OB protein-polymer chimeras",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 7309788,
	"label": "Refolding of recombinant proteins",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7487,
	"target": 6403,
	"type": 7319387,
	"label": "PYRIDAZINONE COMPOUNDS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37875,
	"target": 7487,
	"type": 7319387,
	"label": "PYRIDAZINONE COMPOUNDS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37875,
	"target": 6403,
	"type": 7319387,
	"label": "PYRIDAZINONE COMPOUNDS",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 7322953,
	"label": "BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 31081,
	"type": 7322953,
	"label": "BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7360,
	"target": 6376,
	"type": 7322953,
	"label": "BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7322953,
	"label": "BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31081,
	"target": 7507,
	"type": 7322953,
	"label": "BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37900,
	"type": 7334569,
	"label": "Anti-VEGF antibodies",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 7334569,
	"label": "Anti-VEGF antibodies",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56836,
	"target": 37900,
	"type": 7334569,
	"label": "Anti-VEGF antibodies",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 7355515,
	"label": "Anticuerpos multiespecíficos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32777,
	"target": 32772,
	"type": 7355515,
	"label": "Anticuerpos multiespecíficos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 7355515,
	"label": "Anticuerpos multiespecíficos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 7355515,
	"label": "Anticuerpos multiespecíficos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32772,
	"target": 6854,
	"type": 7355515,
	"label": "Anticuerpos multiespecíficos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6376,
	"target": 6367,
	"type": 7364863,
	"label": "compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6367,
	"target": 6298,
	"type": 7364863,
	"label": "compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6376,
	"target": 6298,
	"type": 7364863,
	"label": "compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7364863,
	"label": "compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 7364863,
	"label": "compostos, composiÇço farmacÊutica, mÉtodo para inibir, o crescimento celular anormal ou tratar uma disfunÇço hiperproliferativa, mÉtodo para tratar uma doenÇa inflamatària e mÉtodo para tratar uma doenÇa autoimune",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 7371317,
	"label": "Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7371317,
	"label": "Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 7371317,
	"label": "Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7360,
	"target": 6840,
	"type": 7378735,
	"label": "COMPOSITIONS COMPRISING MODIFIED LCAT AND USE THEREOF FOR TREATING ATHEROSCLEROSIS",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 7378888,
	"label": "Compuestos de piridona sustituidos con alquino y métodos de uso",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 7378888,
	"label": "Compuestos de piridona sustituidos con alquino y métodos de uso",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7378888,
	"label": "Compuestos de piridona sustituidos con alquino y métodos de uso",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7382688,
	"label": "Epoxicetonas peptídicas para la inhibición del proteosoma",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 7383330,
	"label": "Stable isotonic lyophilized protein formulations, such as anti-IgE and anti-HER2 antibody formulations, wherein protein concentration is 2-40 times greater than protein concentration before lyophilization",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7409,
	"target": 6854,
	"type": 7383330,
	"label": "Stable isotonic lyophilized protein formulations, such as anti-IgE and anti-HER2 antibody formulations, wherein protein concentration is 2-40 times greater than protein concentration before lyophilization",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 7383330,
	"label": "Stable isotonic lyophilized protein formulations, such as anti-IgE and anti-HER2 antibody formulations, wherein protein concentration is 2-40 times greater than protein concentration before lyophilization",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 6301,
	"target": 6263,
	"type": 7390991,
	"label": "COMPUESTOS DERIVADOS DE PIRROLO[3,2-C]PIRIDINA; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO DE UN TRASTORNO HIPERPROLIFERATIVO O UNA ENFERMEDAD INFLAMATORIA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7390991,
	"label": "COMPUESTOS DERIVADOS DE PIRROLO[3,2-C]PIRIDINA; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO DE UN TRASTORNO HIPERPROLIFERATIVO O UNA ENFERMEDAD INFLAMATORIA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6263,
	"type": 7390991,
	"label": "COMPUESTOS DERIVADOS DE PIRROLO[3,2-C]PIRIDINA; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO DE UN TRASTORNO HIPERPROLIFERATIVO O UNA ENFERMEDAD INFLAMATORIA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7390991,
	"label": "COMPUESTOS DERIVADOS DE PIRROLO[3,2-C]PIRIDINA; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO DE UN TRASTORNO HIPERPROLIFERATIVO O UNA ENFERMEDAD INFLAMATORIA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7390991,
	"label": "COMPUESTOS DERIVADOS DE PIRROLO[3,2-C]PIRIDINA; COMPOSICION FARMACEUTICA; Y USO EN EL TRATAMIENTO DE UN TRASTORNO HIPERPROLIFERATIVO O UNA ENFERMEDAD INFLAMATORIA.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7392256,
	"label": "COMPUESTOS DERIVADOS DE HETEROCICLOS SUSTITUIDOS CON MORFOLINA, INHIBIDORES DE LA ACTIVIDAD PI3 QUINASA; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; KIT FARMACEUTICO; Y SU USO PARA EL TRATAMIENTO PROFILACTICO O TERAPEUTICO DEL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7392256,
	"label": "COMPUESTOS DERIVADOS DE HETEROCICLOS SUSTITUIDOS CON MORFOLINA, INHIBIDORES DE LA ACTIVIDAD PI3 QUINASA; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; KIT FARMACEUTICO; Y SU USO PARA EL TRATAMIENTO PROFILACTICO O TERAPEUTICO DEL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 6376,
	"type": 7392256,
	"label": "COMPUESTOS DERIVADOS DE HETEROCICLOS SUSTITUIDOS CON MORFOLINA, INHIBIDORES DE LA ACTIVIDAD PI3 QUINASA; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; KIT FARMACEUTICO; Y SU USO PARA EL TRATAMIENTO PROFILACTICO O TERAPEUTICO DEL CANCER.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6484,
	"type": 7394138,
	"label": "USO DE UN ANTAGONISTA DE LA PROTEINA PIK3R3 PARA INHIBIR EL CRECIMIENTO DE UN GLIOMA QUE EXPRESA DICHA PROTEINA; Y METODO PARA DIAGNOSTICAR LA PRESENCIA DE UN GLIOMA EN UN MAMIFERO.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7394138,
	"label": "USO DE UN ANTAGONISTA DE LA PROTEINA PIK3R3 PARA INHIBIR EL CRECIMIENTO DE UN GLIOMA QUE EXPRESA DICHA PROTEINA; Y METODO PARA DIAGNOSTICAR LA PRESENCIA DE UN GLIOMA EN UN MAMIFERO.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 6484,
	"type": 7394138,
	"label": "USO DE UN ANTAGONISTA DE LA PROTEINA PIK3R3 PARA INHIBIR EL CRECIMIENTO DE UN GLIOMA QUE EXPRESA DICHA PROTEINA; Y METODO PARA DIAGNOSTICAR LA PRESENCIA DE UN GLIOMA EN UN MAMIFERO.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 7510,
	"type": 7412491,
	"label": "anticorpos murino,anticorpo quimÉrico, domÍnios variÁveis de um anticorpo humanizado, anticorpos anti-fator d humanizado, polipeptÍdeos, anticorpo humanizado, fragmento de anticorpo, Ácidos nuclÉico isolados, vetores , linhagem celular, composiÇço, uso, mÉtodo para produÇço de um anticorpo anti-fator d humanizado ou fragmentos destes e anticorpos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37893,
	"target": 6795,
	"type": 7433052,
	"label": "Uses of Wnt polypeptides",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7440864,
	"label": "IMIDAZO- UND TRIAZOLOPYRIDINVERBINDUNGEN UND VERFAHREN ZU DEREN ANWENDUNG",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 7447229,
	"label": "Antibodies Directed to Angiopoietin-like Protein 4 and Uses Thereof",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 37875,
	"target": 7509,
	"type": 7448820,
	"label": "ALTERED BR-3 BINDING POLYPEPTIDES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 7448883,
	"label": "PROTEINA DE UNION A ANTIGENO QUE SE UNE AL RECEPTOR DE GLUCAGON HUMANO; ACIDO NUCLEICO QUE LA CODIFICA; METODO DE PRODUCCION; COMPOSICION FARMACEUTICA QUE LA COMPRENDE; Y SU USO PARA TRATAR O PREVENIR LA DIABETES TIPO 2.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 7448883,
	"label": "PROTEINA DE UNION A ANTIGENO QUE SE UNE AL RECEPTOR DE GLUCAGON HUMANO; ACIDO NUCLEICO QUE LA CODIFICA; METODO DE PRODUCCION; COMPOSICION FARMACEUTICA QUE LA COMPRENDE; Y SU USO PARA TRATAR O PREVENIR LA DIABETES TIPO 2.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7448883,
	"label": "PROTEINA DE UNION A ANTIGENO QUE SE UNE AL RECEPTOR DE GLUCAGON HUMANO; ACIDO NUCLEICO QUE LA CODIFICA; METODO DE PRODUCCION; COMPOSICION FARMACEUTICA QUE LA COMPRENDE; Y SU USO PARA TRATAR O PREVENIR LA DIABETES TIPO 2.",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 6367,
	"target": 6301,
	"type": 7449982,
	"label": "composto, composiÇço farmacÊutica, e, mÉtodos para tratar cÂncer, para reduzir o tamanho do tumor, para tratar distérbios mediados por hgf, e para reduzir a metÁstase em um tumor em um paciente",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 7449982,
	"label": "composto, composiÇço farmacÊutica, e, mÉtodos para tratar cÂncer, para reduzir o tamanho do tumor, para tratar distérbios mediados por hgf, e para reduzir a metÁstase em um tumor em um paciente",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7449982,
	"label": "composto, composiÇço farmacÊutica, e, mÉtodos para tratar cÂncer, para reduzir o tamanho do tumor, para tratar distérbios mediados por hgf, e para reduzir a metÁstase em um tumor em um paciente",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7449982,
	"label": "composto, composiÇço farmacÊutica, e, mÉtodos para tratar cÂncer, para reduzir o tamanho do tumor, para tratar distérbios mediados por hgf, e para reduzir a metÁstase em um tumor em um paciente",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 7449982,
	"label": "composto, composiÇço farmacÊutica, e, mÉtodos para tratar cÂncer, para reduzir o tamanho do tumor, para tratar distérbios mediados por hgf, e para reduzir a metÁstase em um tumor em um paciente",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 6302,
	"type": 7450294,
	"label": "Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 6371,
	"type": 7451292,
	"label": "DI-AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 6913,
	"target": 6795,
	"type": 7457268,
	"label": "TREATMENT OF VARIOLA VIRAL INFECTIONS USING A TISSUE FACTOR INHIBITOR",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32788,
	"target": 32769,
	"type": 7463379,
	"label": "GLP-1 COMPOUND/GLUCAGON ANTIBODY COMPOSITIONS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 7463379,
	"label": "GLP-1 COMPOUND/GLUCAGON ANTIBODY COMPOSITIONS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32769,
	"type": 7463379,
	"label": "GLP-1 COMPOUND/GLUCAGON ANTIBODY COMPOSITIONS.",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 7477173,
	"label": "ANTICUERPO ANTILINFOTOXINA ALFA (LT-ALFA); COMPOSICION CON EL ANTICUERPO; HIBRIDOMA PTA-7538; ACIDO NUCLEICO CODIFICANTE DEL ANTICUERPO; VECTOR Y CELULA HUESPED QUE COMPRENDEN EL ACIDO NUCLEICO; METODO PARA INHIBIR LA PROLIFERACION CELULAR ACTIVADA P",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 7477920,
	"label": "METHODS AND COMPOSITIONS RELATING TO ZPA POLYPEPTIDES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6795,
	"target": 6417,
	"type": 7478888,
	"label": "mÉtodos para tratar neoplasma e mÉtodos para tratar neoplasma de plasmàcitos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 7478888,
	"label": "mÉtodos para tratar neoplasma e mÉtodos para tratar neoplasma de plasmàcitos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6417,
	"type": 7478888,
	"label": "mÉtodos para tratar neoplasma e mÉtodos para tratar neoplasma de plasmàcitos",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6838,
	"target": 6795,
	"type": 7479702,
	"label": "Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6957,
	"target": 6838,
	"type": 7479702,
	"label": "Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6957,
	"target": 6795,
	"type": 7479702,
	"label": "Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6795,
	"target": 6483,
	"type": 7479702,
	"label": "Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6838,
	"target": 6483,
	"type": 7479702,
	"label": "Compositions and methods for the diagnosis and treatment of bladder and urinary tract tumors",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 7479767,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 7479767,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 6483,
	"type": 7479767,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 7480186,
	"label": "GENETIC VARIATIONS (IN THE PHOSPHATIDYLINOSITOL 3-KINASE REGULATORY SUBUNIT 1 PIK3R1 PROTEIN) ASSOCIATED WITH TUMORS AND METHOD OF TESTING FOR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 32754,
	"type": 7480186,
	"label": "GENETIC VARIATIONS (IN THE PHOSPHATIDYLINOSITOL 3-KINASE REGULATORY SUBUNIT 1 PIK3R1 PROTEIN) ASSOCIATED WITH TUMORS AND METHOD OF TESTING FOR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 39999,
	"target": 32754,
	"type": 7480186,
	"label": "GENETIC VARIATIONS (IN THE PHOSPHATIDYLINOSITOL 3-KINASE REGULATORY SUBUNIT 1 PIK3R1 PROTEIN) ASSOCIATED WITH TUMORS AND METHOD OF TESTING FOR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32754,
	"target": 7507,
	"type": 7480186,
	"label": "GENETIC VARIATIONS (IN THE PHOSPHATIDYLINOSITOL 3-KINASE REGULATORY SUBUNIT 1 PIK3R1 PROTEIN) ASSOCIATED WITH TUMORS AND METHOD OF TESTING FOR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 7480186,
	"label": "GENETIC VARIATIONS (IN THE PHOSPHATIDYLINOSITOL 3-KINASE REGULATORY SUBUNIT 1 PIK3R1 PROTEIN) ASSOCIATED WITH TUMORS AND METHOD OF TESTING FOR",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 7480809,
	"label": "ANTAGONISTA DE WNT QUE COMPRENDE UN COMPONENTE DEL DOMINIO FRIZZLED Y UN DOMINIO FC; SECUENCIA DE ACIDOS NUCLEICOS QUE LO CODIFICA; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR TRASTORNOS DE PROLIFERACION CELULAR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 7480809,
	"label": "ANTAGONISTA DE WNT QUE COMPRENDE UN COMPONENTE DEL DOMINIO FRIZZLED Y UN DOMINIO FC; SECUENCIA DE ACIDOS NUCLEICOS QUE LO CODIFICA; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR TRASTORNOS DE PROLIFERACION CELULAR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 7480809,
	"label": "ANTAGONISTA DE WNT QUE COMPRENDE UN COMPONENTE DEL DOMINIO FRIZZLED Y UN DOMINIO FC; SECUENCIA DE ACIDOS NUCLEICOS QUE LO CODIFICA; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR TRASTORNOS DE PROLIFERACION CELULAR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 7480809,
	"label": "ANTAGONISTA DE WNT QUE COMPRENDE UN COMPONENTE DEL DOMINIO FRIZZLED Y UN DOMINIO FC; SECUENCIA DE ACIDOS NUCLEICOS QUE LO CODIFICA; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR TRASTORNOS DE PROLIFERACION CELULAR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 7507,
	"type": 7480809,
	"label": "ANTAGONISTA DE WNT QUE COMPRENDE UN COMPONENTE DEL DOMINIO FRIZZLED Y UN DOMINIO FC; SECUENCIA DE ACIDOS NUCLEICOS QUE LO CODIFICA; COMPOSICION QUE LO COMPRENDE; Y SU USO PARA TRATAR TRASTORNOS DE PROLIFERACION CELULAR.",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 7480973,
	"label": "ANTICUERPO ANTI-STEAP-1; POLINUCLEOTIDO QUE CODIFICA EL ANTICUERPO; VECTOR Y CELULA QUE COMPRENDEN EL POLINUCLEOTIDO; METODOS PARA FABRICAR Y DETECTAR EL ANTICUERPO; INMUNOCONJUGADO DEL ANTICUERPO CON UN AGENTE CITOTOXICO; COMPOSICION CON EL INMUNOCO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7480973,
	"label": "ANTICUERPO ANTI-STEAP-1; POLINUCLEOTIDO QUE CODIFICA EL ANTICUERPO; VECTOR Y CELULA QUE COMPRENDEN EL POLINUCLEOTIDO; METODOS PARA FABRICAR Y DETECTAR EL ANTICUERPO; INMUNOCONJUGADO DEL ANTICUERPO CON UN AGENTE CITOTOXICO; COMPOSICION CON EL INMUNOCO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 7480973,
	"label": "ANTICUERPO ANTI-STEAP-1; POLINUCLEOTIDO QUE CODIFICA EL ANTICUERPO; VECTOR Y CELULA QUE COMPRENDEN EL POLINUCLEOTIDO; METODOS PARA FABRICAR Y DETECTAR EL ANTICUERPO; INMUNOCONJUGADO DEL ANTICUERPO CON UN AGENTE CITOTOXICO; COMPOSICION CON EL INMUNOCO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 7480973,
	"label": "ANTICUERPO ANTI-STEAP-1; POLINUCLEOTIDO QUE CODIFICA EL ANTICUERPO; VECTOR Y CELULA QUE COMPRENDEN EL POLINUCLEOTIDO; METODOS PARA FABRICAR Y DETECTAR EL ANTICUERPO; INMUNOCONJUGADO DEL ANTICUERPO CON UN AGENTE CITOTOXICO; COMPOSICION CON EL INMUNOCO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7480973,
	"label": "ANTICUERPO ANTI-STEAP-1; POLINUCLEOTIDO QUE CODIFICA EL ANTICUERPO; VECTOR Y CELULA QUE COMPRENDEN EL POLINUCLEOTIDO; METODOS PARA FABRICAR Y DETECTAR EL ANTICUERPO; INMUNOCONJUGADO DEL ANTICUERPO CON UN AGENTE CITOTOXICO; COMPOSICION CON EL INMUNOCO",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 37878,
	"type": 7481442,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 7481442,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37878,
	"target": 7507,
	"type": 7481442,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 7481442,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37878,
	"target": 6483,
	"type": 7481442,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7481478,
	"label": "ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 7510,
	"type": 7481478,
	"label": "ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 7481478,
	"label": "ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 6483,
	"type": 7481540,
	"label": "METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 7481906,
	"label": "AURORA KINASE MODULATORS AND METHOD OF USE.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7481906,
	"label": "AURORA KINASE MODULATORS AND METHOD OF USE.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6366,
	"type": 7481906,
	"label": "AURORA KINASE MODULATORS AND METHOD OF USE.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7360,
	"target": 6376,
	"type": 7481976,
	"label": "3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 7481976,
	"label": "3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7481976,
	"label": "3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 6376,
	"target": 6367,
	"type": 7482785,
	"label": "QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 6367,
	"target": 6302,
	"type": 7482785,
	"label": "QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 6376,
	"target": 6302,
	"type": 7482785,
	"label": "QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7482785,
	"label": "QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 7482785,
	"label": "QUINOLONES AND AZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7482927,
	"label": "PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 7482935,
	"label": "Potent, stable and non-immunosuppressive anti-CD4 antibodies",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 7483451,
	"label": "METHODS OF PROTEIN PURIFICATION",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 7483451,
	"label": "METHODS OF PROTEIN PURIFICATION",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7483451,
	"label": "METHODS OF PROTEIN PURIFICATION",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7483764,
	"label": "COMPOUNDS FOR ENZYME INHIBITION",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 7483764,
	"label": "COMPOUNDS FOR ENZYME INHIBITION",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 7483764,
	"label": "COMPOUNDS FOR ENZYME INHIBITION",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 7486102,
	"label": "POLIPEPTIDO QUE SE UNE ESPECIFICAMENTE A UN DOMINIO PDZ DE LA PROTEINA HTRA1; POLINUCLEOTIDO QUE LO CODIFICA; METODO DE PRODUCCION; ANTICUERPO QUE SE UNE A EL; Y SU USO PARA TRATAR PATOLOGIAS RELACIONADAS CON LA PROTEINA HTRA1.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31056,
	"target": 7507,
	"type": 7486806,
	"label": "Compuestos de arilsulfonamida",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 7488833,
	"label": "ANTAGONISTAS CRIg",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7497,
	"type": 7488833,
	"label": "ANTAGONISTAS CRIg",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 7497,
	"type": 7488833,
	"label": "ANTAGONISTAS CRIg",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7489042,
	"label": "anticorpos isolados, polipeptÍdeos imunoglobulinas, anticorpo hepsina, molÉcula de Ácido nuclÉico, cÉlula hospedeira, linhagem celular, mÉtodos para produzir o anticorpo, para diagnosticar a presenÇa de hepsina, tratar uma doenÇa, para monitorar a doenÇa residual, para detectar o estado da doenÇa, para diagnosticar uma disfunÇço, composiÇço, arranjo ou chip de proteÍna e kit",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 7489042,
	"label": "anticorpos isolados, polipeptÍdeos imunoglobulinas, anticorpo hepsina, molÉcula de Ácido nuclÉico, cÉlula hospedeira, linhagem celular, mÉtodos para produzir o anticorpo, para diagnosticar a presenÇa de hepsina, tratar uma doenÇa, para monitorar a doenÇa residual, para detectar o estado da doenÇa, para diagnosticar uma disfunÇço, composiÇço, arranjo ou chip de proteÍna e kit",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 7489042,
	"label": "anticorpos isolados, polipeptÍdeos imunoglobulinas, anticorpo hepsina, molÉcula de Ácido nuclÉico, cÉlula hospedeira, linhagem celular, mÉtodos para produzir o anticorpo, para diagnosticar a presenÇa de hepsina, tratar uma doenÇa, para monitorar a doenÇa residual, para detectar o estado da doenÇa, para diagnosticar uma disfunÇço, composiÇço, arranjo ou chip de proteÍna e kit",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7489042,
	"label": "anticorpos isolados, polipeptÍdeos imunoglobulinas, anticorpo hepsina, molÉcula de Ácido nuclÉico, cÉlula hospedeira, linhagem celular, mÉtodos para produzir o anticorpo, para diagnosticar a presenÇa de hepsina, tratar uma doenÇa, para monitorar a doenÇa residual, para detectar o estado da doenÇa, para diagnosticar uma disfunÇço, composiÇço, arranjo ou chip de proteÍna e kit",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 7489042,
	"label": "anticorpos isolados, polipeptÍdeos imunoglobulinas, anticorpo hepsina, molÉcula de Ácido nuclÉico, cÉlula hospedeira, linhagem celular, mÉtodos para produzir o anticorpo, para diagnosticar a presenÇa de hepsina, tratar uma doenÇa, para monitorar a doenÇa residual, para detectar o estado da doenÇa, para diagnosticar uma disfunÇço, composiÇço, arranjo ou chip de proteÍna e kit",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 7489044,
	"label": "Methods for identifying a candidate inhibitor substance that inhibits hepsin activation of pro-urokinase type plasminogen activator",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38232,
	"target": 7507,
	"type": 7489044,
	"label": "Methods for identifying a candidate inhibitor substance that inhibits hepsin activation of pro-urokinase type plasminogen activator",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38232,
	"target": 6795,
	"type": 7489044,
	"label": "Methods for identifying a candidate inhibitor substance that inhibits hepsin activation of pro-urokinase type plasminogen activator",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7490358,
	"label": "COMPUESTOS DERIVADOS DE HETEROCICLOS SUSTITUIDOS CON MORFOLINA, INHIBIDORES DE LA ACTIVIDAD DE PI3 QUINASA; COMPOSICION FARMACEUTICA QUE COMPRENDE A DICHOS COMPUESTOS; KIT FARMACEUTICO; Y SU USO EN EL TRATAMIENTO PROFILACTICO O TERAPEUTICO DEL CANCER",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7490493,
	"label": "ANTICUERPO ANTI-MUC16 DISENADO CON CISTEINA; CONJUGADO QUE LO COMPRENDE; METODO DE PRODUCCION; FORMULACION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA TRATAR EL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7490493,
	"label": "ANTICUERPO ANTI-MUC16 DISENADO CON CISTEINA; CONJUGADO QUE LO COMPRENDE; METODO DE PRODUCCION; FORMULACION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA TRATAR EL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 7490493,
	"label": "ANTICUERPO ANTI-MUC16 DISENADO CON CISTEINA; CONJUGADO QUE LO COMPRENDE; METODO DE PRODUCCION; FORMULACION FARMACEUTICA QUE LO COMPRENDE; Y SU USO PARA TRATAR EL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7422,
	"target": 6812,
	"type": 7493321,
	"label": "NOTCH RECEPTOR AGONISTS AND USES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 7422,
	"type": 7493321,
	"label": "NOTCH RECEPTOR AGONISTS AND USES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 6812,
	"type": 7493321,
	"label": "NOTCH RECEPTOR AGONISTS AND USES",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38232,
	"target": 37947,
	"type": 7494692,
	"label": "CRYSTAL STRUCTURE OF HEPATOCYTE GROWTH FACTOR ACTIVATOR COMPLEXED WITH KUNITZ DOMAIN INHIBITOR",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 7505393,
	"label": "COMPUESTOS DERIVADOS DE HETEROCICLOS NITROGENADOS, INHIBIDORES DE LAS PROTEINAS DE APOPTOSIS; Y USO EN EL TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31197,
	"target": 7507,
	"type": 7505393,
	"label": "COMPUESTOS DERIVADOS DE HETEROCICLOS NITROGENADOS, INHIBIDORES DE LAS PROTEINAS DE APOPTOSIS; Y USO EN EL TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31197,
	"target": 6290,
	"type": 7505393,
	"label": "COMPUESTOS DERIVADOS DE HETEROCICLOS NITROGENADOS, INHIBIDORES DE LAS PROTEINAS DE APOPTOSIS; Y USO EN EL TRATAMIENTO DEL CANCER.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6539,
	"target": 6478,
	"type": 7508055,
	"label": "COMBINACIONES DE COMPUESTOS INHIBIDORES DE FOSFOINOSITIDA 3-QUINASA Y AGENTES QUIMIOTERAPEUTICOS Y LOS METODOS DE USO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 7508055,
	"label": "COMBINACIONES DE COMPUESTOS INHIBIDORES DE FOSFOINOSITIDA 3-QUINASA Y AGENTES QUIMIOTERAPEUTICOS Y LOS METODOS DE USO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 7508055,
	"label": "COMBINACIONES DE COMPUESTOS INHIBIDORES DE FOSFOINOSITIDA 3-QUINASA Y AGENTES QUIMIOTERAPEUTICOS Y LOS METODOS DE USO",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38065,
	"target": 7409,
	"type": 7510985,
	"label": "Antigen binding proteins capable of binding thymic stromal lymphopoietin",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7512267,
	"label": "INHIBICION DE ANGIOGENESIS MEDIANTE ANTAGONISTAS O ANTICUERPOS BV8",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7513432,
	"label": "Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7513432,
	"label": "Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 6376,
	"type": 7513432,
	"label": "Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 7513471,
	"label": "INHIBIDORES DE QUINASAS SIMIL POLO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32478,
	"target": 6484,
	"type": 7514048,
	"label": "NUCLEIC ACIDS HYBRIDIZABLE TO MICRO RNA AND PRECURSORS THEREOF",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7515938,
	"label": "DERIVADOS DE PIRIMIDINA COMO INHIBIDORES DE LA FOSFATIDILINOSITOL-3-KINASA.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6816,
	"target": 6403,
	"type": 7522633,
	"label": "1-METHYL-BENZO[1,2,4]THIADIAZINE, 1-OXIDE DERIVATIVES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 7523094,
	"label": "PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7523094,
	"label": "PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 38065,
	"type": 7523094,
	"label": "PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 7523094,
	"label": "PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 7523094,
	"label": "PROTEIN EXPRESSION FROM MULTIPLE NUCLEIC ACIDS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 7527489,
	"label": "Piridazinas anilladas para el tratamiento de tumores dirigidos por señalización Hedgehog inapropiada",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7527489,
	"label": "Piridazinas anilladas para el tratamiento de tumores dirigidos por señalización Hedgehog inapropiada",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 7527489,
	"label": "Piridazinas anilladas para el tratamiento de tumores dirigidos por señalización Hedgehog inapropiada",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 7528138,
	"label": "2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONE ANALOGS FOR THE INHIBITION OF BETA-SECRETASE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 7535436,
	"label": "Thienopyrimidiene derivatives as PI3k inhibitors",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7360,
	"target": 6376,
	"type": 7535436,
	"label": "Thienopyrimidiene derivatives as PI3k inhibitors",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7535436,
	"label": "Thienopyrimidiene derivatives as PI3k inhibitors",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32788,
	"target": 32771,
	"type": 7537446,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7537446,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7537446,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 7537446,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 7537446,
	"label": "CANCEROUS DISEASE MODIFYING ANTIBODIES.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6295,
	"type": 7538018,
	"label": "PYRAZOLE INHIBITORS OF WNT SIGNALING",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 7538877,
	"label": "CELL CULTURE METHOD USING AMINO ACID-ENRICHED MEDIUM",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 7538877,
	"label": "CELL CULTURE METHOD USING AMINO ACID-ENRICHED MEDIUM",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7538877,
	"label": "CELL CULTURE METHOD USING AMINO ACID-ENRICHED MEDIUM",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 7538877,
	"label": "CELL CULTURE METHOD USING AMINO ACID-ENRICHED MEDIUM",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 7538877,
	"label": "CELL CULTURE METHOD USING AMINO ACID-ENRICHED MEDIUM",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7541532,
	"label": "HOMOGENEOUS ANTIBODY POPULATIONS.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 7541532,
	"label": "HOMOGENEOUS ANTIBODY POPULATIONS.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7541532,
	"label": "HOMOGENEOUS ANTIBODY POPULATIONS.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37904,
	"target": 32771,
	"type": 7542728,
	"label": "NLRR-1 ANTAGONISTS AND USES THEREOF",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7542728,
	"label": "NLRR-1 ANTAGONISTS AND USES THEREOF",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37904,
	"target": 7507,
	"type": 7542728,
	"label": "NLRR-1 ANTAGONISTS AND USES THEREOF",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6376,
	"target": 6302,
	"type": 7543477,
	"label": "CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7543477,
	"label": "CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 7543477,
	"label": "CONDENSED PIPERIDINE DERIVATIVES USEFUL AS VANILLOID RECEPTOR LIGANDS",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7544301,
	"label": "TERAPIA DE COMBINACION DE UN ANTICUERPO ANTI-CD20 DE TIPO II CON UN AGENTE ACTIVO ANTI-BCL-2",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7509,
	"type": 7544301,
	"label": "TERAPIA DE COMBINACION DE UN ANTICUERPO ANTI-CD20 DE TIPO II CON UN AGENTE ACTIVO ANTI-BCL-2",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7544301,
	"label": "TERAPIA DE COMBINACION DE UN ANTICUERPO ANTI-CD20 DE TIPO II CON UN AGENTE ACTIVO ANTI-BCL-2",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 7544883,
	"label": "INHIBIDORES DE EPOXI CETONA PROTEASA PEPTIDICOS CRISTALINOS Y LÐA SINTESIS DE CETO-EPOXIDOS AMINOACIDICOS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7409,
	"target": 6290,
	"type": 7546867,
	"label": "INHALED AZTREONAM LYSINE FOR THE TREATMENT OF DEFICITS IN HEALTH-RELATED QUALITY-OF LIFE IN LUNG DISEASES.",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 7553810,
	"label": "ANTICUERPOS ANTI-IGE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 32777,
	"type": 7553810,
	"label": "ANTICUERPOS ANTI-IGE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 7553810,
	"label": "ANTICUERPOS ANTI-IGE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 6892,
	"target": 6812,
	"type": 7554444,
	"label": "METHODS OF USE OF GAMMA INHIBITOR COMPOUNDS FOR THE ATTENUATION OF PAIN.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 7562576,
	"label": "MARKER PANEL FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38237,
	"target": 38232,
	"type": 7562576,
	"label": "MARKER PANEL FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56833,
	"target": 38237,
	"type": 7562576,
	"label": "MARKER PANEL FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 7562576,
	"label": "MARKER PANEL FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56833,
	"target": 38232,
	"type": 7562576,
	"label": "MARKER PANEL FOR COLORECTAL CANCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38237,
	"target": 37986,
	"type": 7562594,
	"label": "PREDICTION OF GENOTOXICITY",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 7562596,
	"label": "NOVEL RUBELLA E1 ENVELOPE PROTEIN VARIANTS AND THEIR USE IN THE DETECTION OF ANTI-RUBELLA ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 7562596,
	"label": "NOVEL RUBELLA E1 ENVELOPE PROTEIN VARIANTS AND THEIR USE IN THE DETECTION OF ANTI-RUBELLA ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 7562596,
	"label": "NOVEL RUBELLA E1 ENVELOPE PROTEIN VARIANTS AND THEIR USE IN THE DETECTION OF ANTI-RUBELLA ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7562628,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 7562628,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 7562628,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7562629,
	"label": "ANTICUERPOS BIVALENTES BIOESPECIFICOS EN DONDE EN UNA CADENA LIGERA Y UNA CADENA PESADA, LOS DOMINIOS VARIABLES VL Y VH ESTAN REEPLAZADOS EL UNO POR EL OTRO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 7562629,
	"label": "ANTICUERPOS BIVALENTES BIOESPECIFICOS EN DONDE EN UNA CADENA LIGERA Y UNA CADENA PESADA, LOS DOMINIOS VARIABLES VL Y VH ESTAN REEPLAZADOS EL UNO POR EL OTRO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 7562629,
	"label": "ANTICUERPOS BIVALENTES BIOESPECIFICOS EN DONDE EN UNA CADENA LIGERA Y UNA CADENA PESADA, LOS DOMINIOS VARIABLES VL Y VH ESTAN REEPLAZADOS EL UNO POR EL OTRO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7562630,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS, EN DONDE LOS DOMINIOS CONSTANTES CL Y CH1 EN UNA CADENA LIGERA Y EN UNA CADENA PESADA ESTAN REEMPLAZADOS EL UNO POR EL OTRO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 7562630,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS, EN DONDE LOS DOMINIOS CONSTANTES CL Y CH1 EN UNA CADENA LIGERA Y EN UNA CADENA PESADA ESTAN REEMPLAZADOS EL UNO POR EL OTRO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 7562630,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS, EN DONDE LOS DOMINIOS CONSTANTES CL Y CH1 EN UNA CADENA LIGERA Y EN UNA CADENA PESADA ESTAN REEMPLAZADOS EL UNO POR EL OTRO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 7562630,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS, EN DONDE LOS DOMINIOS CONSTANTES CL Y CH1 EN UNA CADENA LIGERA Y EN UNA CADENA PESADA ESTAN REEMPLAZADOS EL UNO POR EL OTRO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 7562630,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS, EN DONDE LOS DOMINIOS CONSTANTES CL Y CH1 EN UNA CADENA LIGERA Y EN UNA CADENA PESADA ESTAN REEMPLAZADOS EL UNO POR EL OTRO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6299,
	"target": 6290,
	"type": 7563111,
	"label": "p27 PROTEIN INDUCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6371,
	"target": 6299,
	"type": 7563111,
	"label": "p27 PROTEIN INDUCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6371,
	"target": 6290,
	"type": 7563111,
	"label": "p27 PROTEIN INDUCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7563111,
	"label": "p27 PROTEIN INDUCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6299,
	"type": 7563111,
	"label": "p27 PROTEIN INDUCER",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 6321,
	"type": 7563468,
	"label": "NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 29830,
	"target": 7508,
	"type": 7563468,
	"label": "NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 29830,
	"target": 6321,
	"type": 7563468,
	"label": "NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7563859,
	"label": "Methods of treatment using IL-18 receptor antigen binding proteins",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7358,
	"type": 7563859,
	"label": "Methods of treatment using IL-18 receptor antigen binding proteins",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 7358,
	"type": 7563859,
	"label": "Methods of treatment using IL-18 receptor antigen binding proteins",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 7564798,
	"label": "SPIROINDOLINONE DERIVATIVES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7568429,
	"label": "PYRAZOLO-PYRIDINONE DERIVATIVES AND METHODS OF USE",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7569182,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 7569182,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 7569182,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 7569182,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 7569182,
	"label": "ANTICUERPOS BIVALENTES BIESPECIFICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56740,
	"target": 38232,
	"type": 7569186,
	"label": "STABILITY TESTING OF ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37947,
	"type": 7569204,
	"label": "Insulin-degrading enzyme crystals",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 7569204,
	"label": "Insulin-degrading enzyme crystals",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38232,
	"target": 37947,
	"type": 7569204,
	"label": "Insulin-degrading enzyme crystals",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7570821,
	"label": "Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 7570821,
	"label": "Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7570821,
	"label": "Novel antibodies which bind alpha5beta1 (fibronectin receptor) and uses thereof",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 7571885,
	"label": "Anti-amyloid antibodies and uses thereof",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7571888,
	"label": "Imidazopyridazine inhibitors of PI3 kinase for cancer treatment",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 7571888,
	"label": "Imidazopyridazine inhibitors of PI3 kinase for cancer treatment",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 6367,
	"type": 7571888,
	"label": "Imidazopyridazine inhibitors of PI3 kinase for cancer treatment",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7508,
	"type": 7571888,
	"label": "Imidazopyridazine inhibitors of PI3 kinase for cancer treatment",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7571888,
	"label": "Imidazopyridazine inhibitors of PI3 kinase for cancer treatment",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 7572015,
	"label": "Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37862,
	"target": 32779,
	"type": 7572015,
	"label": "Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 7572015,
	"label": "Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 7572015,
	"label": "Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37862,
	"target": 6795,
	"type": 7572015,
	"label": "Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7450,
	"target": 6795,
	"type": 7572733,
	"label": "SCREENING METHODS USING G-PROTEIN COUPLED RECEPTORS AND RELATED COMPOSITIONS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 39999,
	"target": 7450,
	"type": 7572733,
	"label": "SCREENING METHODS USING G-PROTEIN COUPLED RECEPTORS AND RELATED COMPOSITIONS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 39999,
	"target": 6795,
	"type": 7572733,
	"label": "SCREENING METHODS USING G-PROTEIN COUPLED RECEPTORS AND RELATED COMPOSITIONS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 7572930,
	"label": "PIRIMIDIL CICLOPENTANOS HIDROXILADOS EN FORMA DE INHIBIDORES DE AKT PROTEINA QUINASA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 7572935,
	"label": "PIRIMIDIL CICLOPENTANOS HIDROXILADOS EN FORMA DE INHIBIDORES DE AKT PROTEINA QUINASA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 7572937,
	"label": "PLEXIND1 AGONISTS AND THEIR USE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 7572938,
	"label": "5H-Ciclopenta[d]pirimidinas como inhibidores de proteínas cinasas AKT",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 7573034,
	"label": "METHODS FOR INHIBITING ANGIOGENESIS USING EGFL8 ANTAGONISTS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38065,
	"target": 7507,
	"type": 7573034,
	"label": "METHODS FOR INHIBITING ANGIOGENESIS USING EGFL8 ANTAGONISTS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38065,
	"target": 6854,
	"type": 7573034,
	"label": "METHODS FOR INHIBITING ANGIOGENESIS USING EGFL8 ANTAGONISTS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7409,
	"target": 7358,
	"type": 7576231,
	"label": "USO DE UN ANTAGONISTA DE LA PROTEINA BETA-KLOTHO (KLB) PARA TRATAR TRASTORNOS ASOCIADOS A LA EXPRESION O ACTIVIDAD DE KLB.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 7576231,
	"label": "USO DE UN ANTAGONISTA DE LA PROTEINA BETA-KLOTHO (KLB) PARA TRATAR TRASTORNOS ASOCIADOS A LA EXPRESION O ACTIVIDAD DE KLB.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 7576231,
	"label": "USO DE UN ANTAGONISTA DE LA PROTEINA BETA-KLOTHO (KLB) PARA TRATAR TRASTORNOS ASOCIADOS A LA EXPRESION O ACTIVIDAD DE KLB.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7358,
	"target": 6812,
	"type": 7576231,
	"label": "USO DE UN ANTAGONISTA DE LA PROTEINA BETA-KLOTHO (KLB) PARA TRATAR TRASTORNOS ASOCIADOS A LA EXPRESION O ACTIVIDAD DE KLB.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7409,
	"target": 6812,
	"type": 7576231,
	"label": "USO DE UN ANTAGONISTA DE LA PROTEINA BETA-KLOTHO (KLB) PARA TRATAR TRASTORNOS ASOCIADOS A LA EXPRESION O ACTIVIDAD DE KLB.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 7578131,
	"label": "QUADRUPLE TRANSGENIC NON-HUMAN ANIMAL",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7578131,
	"label": "QUADRUPLE TRANSGENIC NON-HUMAN ANIMAL",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 7578131,
	"label": "QUADRUPLE TRANSGENIC NON-HUMAN ANIMAL",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7580517,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 7580517,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7580517,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7580517,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 7580517,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7580518,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7580518,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7580518,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7580518,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 7580518,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 7580519,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7580519,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 7580519,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 7580519,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7580519,
	"label": "An anti-cancer cytotoxic monoclonal antibody.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 7584307,
	"label": "Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7584307,
	"label": "Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7584307,
	"label": "Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6539,
	"type": 7584307,
	"label": "Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 7584307,
	"label": "Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 7586754,
	"label": "A3 ADENOSINE RECEPTOR ANTAGONISTS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 7586807,
	"label": "ANTICUERPOS ANTI-TENB2 PRODUCIDOS POR INGENIERIA DE CISTEINA Y CONJUGADOS DE FARMACO Y ANTICUERPO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7586807,
	"label": "ANTICUERPOS ANTI-TENB2 PRODUCIDOS POR INGENIERIA DE CISTEINA Y CONJUGADOS DE FARMACO Y ANTICUERPO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7586807,
	"label": "ANTICUERPOS ANTI-TENB2 PRODUCIDOS POR INGENIERIA DE CISTEINA Y CONJUGADOS DE FARMACO Y ANTICUERPO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6367,
	"target": 6301,
	"type": 7587802,
	"label": "COMPUESTOS HETEROCICLICOS ANTIVIRICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 7587802,
	"label": "COMPUESTOS HETEROCICLICOS ANTIVIRICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7587802,
	"label": "COMPUESTOS HETEROCICLICOS ANTIVIRICOS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56765,
	"target": 38164,
	"type": 7588116,
	"label": "High-risk human papillomavirus detection",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 7592008,
	"label": "CXCR3 ANTAGONISTS",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 7592008,
	"label": "CXCR3 ANTAGONISTS",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7592008,
	"label": "CXCR3 ANTAGONISTS",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 56836,
	"target": 32770,
	"type": 7592072,
	"label": "FERROPORTIN ANTIBODIES AND METHODS OF USE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7592072,
	"label": "FERROPORTIN ANTIBODIES AND METHODS OF USE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 56836,
	"target": 7507,
	"type": 7592072,
	"label": "FERROPORTIN ANTIBODIES AND METHODS OF USE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 7592120,
	"label": "COMPOSICIONES QUE COMPRENDEN ANTICUERPO QUE SE FIJA AL DOMINIO II DE HER2 Y SUS VARIANTES ACIDAS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 7592120,
	"label": "COMPOSICIONES QUE COMPRENDEN ANTICUERPO QUE SE FIJA AL DOMINIO II DE HER2 Y SUS VARIANTES ACIDAS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7592120,
	"label": "COMPOSICIONES QUE COMPRENDEN ANTICUERPO QUE SE FIJA AL DOMINIO II DE HER2 Y SUS VARIANTES ACIDAS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 7592120,
	"label": "COMPOSICIONES QUE COMPRENDEN ANTICUERPO QUE SE FIJA AL DOMINIO II DE HER2 Y SUS VARIANTES ACIDAS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7425,
	"type": 7592120,
	"label": "COMPOSICIONES QUE COMPRENDEN ANTICUERPO QUE SE FIJA AL DOMINIO II DE HER2 Y SUS VARIANTES ACIDAS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7592194,
	"label": "PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 7592521,
	"label": "AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 7592521,
	"label": "AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 7592521,
	"label": "AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56836,
	"target": 32779,
	"type": 7592521,
	"label": "AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 7592521,
	"label": "AN ANTI-CANCER CYTOTOXIC MONOCLONAL ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 7594440,
	"label": "ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 32772,
	"type": 7594440,
	"label": "ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37993,
	"target": 32772,
	"type": 7594440,
	"label": "ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 7594440,
	"label": "ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 7594440,
	"label": "ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7596532,
	"label": "Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7596532,
	"label": "Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7596532,
	"label": "Imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives for the treatment of inflammatory diseases",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 7598699,
	"label": "MEDIACION DE CITOTOXICIDAD DE CELULAS QUE EVIDENCIAN LA EXPRESION SUPERFICIAL DE CD9",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7598699,
	"label": "MEDIACION DE CITOTOXICIDAD DE CELULAS QUE EVIDENCIAN LA EXPRESION SUPERFICIAL DE CD9",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 7598699,
	"label": "MEDIACION DE CITOTOXICIDAD DE CELULAS QUE EVIDENCIAN LA EXPRESION SUPERFICIAL DE CD9",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6272,
	"type": 7599010,
	"label": "SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 30951,
	"target": 7507,
	"type": 7599010,
	"label": "SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 30951,
	"target": 6272,
	"type": 7599010,
	"label": "SUBSTITUTED HYDANTOINS AS MEK KINASE INHIBITORS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7599771,
	"label": "8-ANILINOIMIDAZOPYRIDINE UND IHRE VERWENDUNG ALS ANTIKREBSMITTEL UND/ODER ENTZÜNDUNGSHEMMENDE MITTEL",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7599771,
	"label": "8-ANILINOIMIDAZOPYRIDINE UND IHRE VERWENDUNG ALS ANTIKREBSMITTEL UND/ODER ENTZÜNDUNGSHEMMENDE MITTEL",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7599771,
	"label": "8-ANILINOIMIDAZOPYRIDINE UND IHRE VERWENDUNG ALS ANTIKREBSMITTEL UND/ODER ENTZÜNDUNGSHEMMENDE MITTEL",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 7409,
	"type": 7603277,
	"label": "DOSING METHODS FOR TREATING DISEASE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7604261,
	"label": "USO DE UN INHIBIDOR DE LA GAMMA-SECRETASA PARA TRATAMIENTO DEL CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 7604261,
	"label": "USO DE UN INHIBIDOR DE LA GAMMA-SECRETASA PARA TRATAMIENTO DEL CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7509,
	"target": 6478,
	"type": 7604261,
	"label": "USO DE UN INHIBIDOR DE LA GAMMA-SECRETASA PARA TRATAMIENTO DEL CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7497,
	"target": 6478,
	"type": 7604338,
	"label": "NUCLEOSIDOS 2' , 4' -SUSTITUIDOS COMO AGENTES ANTIVIRALES",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7606738,
	"label": "DERIVADOS ESPIROINDOLINONA COMO AGENTES ANTICANCEROSOS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 7606738,
	"label": "DERIVADOS ESPIROINDOLINONA COMO AGENTES ANTICANCEROSOS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 6303,
	"type": 7606738,
	"label": "DERIVADOS ESPIROINDOLINONA COMO AGENTES ANTICANCEROSOS.",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7606765,
	"label": "Azaindolizinas y procedimientos de uso",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7606765,
	"label": "Azaindolizinas y procedimientos de uso",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7606765,
	"label": "Azaindolizinas y procedimientos de uso",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7409,
	"target": 6280,
	"type": 7608425,
	"label": "TRIAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND /OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 7610076,
	"label": "PIRROLOPIRAZINAS COMO INHIBIDORES DE QUINASAS.",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6390,
	"type": 7610384,
	"label": "BENZOMORPHOLINE DERIVATIVES AND METHODS OF USE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 7614116,
	"label": "Mutant DNA polymerases with improved pyrophosphorolysis activated polymerization (PAP) ability",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 7614116,
	"label": "Mutant DNA polymerases with improved pyrophosphorolysis activated polymerization (PAP) ability",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 7614116,
	"label": "Mutant DNA polymerases with improved pyrophosphorolysis activated polymerization (PAP) ability",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7614116,
	"label": "Mutant DNA polymerases with improved pyrophosphorolysis activated polymerization (PAP) ability",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 7614116,
	"label": "Mutant DNA polymerases with improved pyrophosphorolysis activated polymerization (PAP) ability",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7616293,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING TUMOR PROGRESSION.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6489,
	"type": 7616293,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING TUMOR PROGRESSION.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 7616293,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING TUMOR PROGRESSION.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7616293,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING TUMOR PROGRESSION.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7616293,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING TUMOR PROGRESSION.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 7616509,
	"label": "METHOD OF PRODUCING HETEROGENEOUS PROTEIN.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 7616509,
	"label": "METHOD OF PRODUCING HETEROGENEOUS PROTEIN.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 7616509,
	"label": "METHOD OF PRODUCING HETEROGENEOUS PROTEIN.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 7616509,
	"label": "METHOD OF PRODUCING HETEROGENEOUS PROTEIN.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 7616509,
	"label": "METHOD OF PRODUCING HETEROGENEOUS PROTEIN.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6957,
	"type": 7618523,
	"label": "VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIS THERAPY",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 7618523,
	"label": "VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIS THERAPY",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 6957,
	"type": 7618523,
	"label": "VEGF POLYMORPHISMS AND ANTI-ANGIOGENESIS THERAPY",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 7618984,
	"label": "Purine derivatives useful as PI3 kinase inhibitors",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 7618984,
	"label": "Purine derivatives useful as PI3 kinase inhibitors",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31939,
	"target": 7360,
	"type": 7618984,
	"label": "Purine derivatives useful as PI3 kinase inhibitors",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7626554,
	"label": "COMPOSICIONES Y METODOS DE USO DE LA QUINASA -1 SIMILAR AL RECEPTOR DE LA ACTIVINA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 7626554,
	"label": "COMPOSICIONES Y METODOS DE USO DE LA QUINASA -1 SIMILAR AL RECEPTOR DE LA ACTIVINA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 6812,
	"type": 7626554,
	"label": "COMPOSICIONES Y METODOS DE USO DE LA QUINASA -1 SIMILAR AL RECEPTOR DE LA ACTIVINA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 7628578,
	"label": "Nuevos derivados de bencimidazol y su empleo como agonsitas del FXR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7487,
	"target": 6812,
	"type": 7628580,
	"label": "Compositions and methods for treatment of microbial disorders",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32698,
	"target": 7487,
	"type": 7628580,
	"label": "Compositions and methods for treatment of microbial disorders",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32698,
	"target": 6812,
	"type": 7628580,
	"label": "Compositions and methods for treatment of microbial disorders",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7629020,
	"label": "REGION CONSTANTE DE ANTICUERPO MUTANTE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 7629020,
	"label": "REGION CONSTANTE DE ANTICUERPO MUTANTE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 7629020,
	"label": "REGION CONSTANTE DE ANTICUERPO MUTANTE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 7629020,
	"label": "REGION CONSTANTE DE ANTICUERPO MUTANTE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 7629020,
	"label": "REGION CONSTANTE DE ANTICUERPO MUTANTE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 7629028,
	"label": "METODOS PARA MODIFICAR EL PUNTO ISOELECTRICO DE ANTICUERPOS MEDIANTE LA SUSTITUCION DE AMINOACIDOS EN LA REGION DE DETERMINACION DE LA COMPLEMENTARIEDAD (CDR)",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 7629028,
	"label": "METODOS PARA MODIFICAR EL PUNTO ISOELECTRICO DE ANTICUERPOS MEDIANTE LA SUSTITUCION DE AMINOACIDOS EN LA REGION DE DETERMINACION DE LA COMPLEMENTARIEDAD (CDR)",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 7629028,
	"label": "METODOS PARA MODIFICAR EL PUNTO ISOELECTRICO DE ANTICUERPOS MEDIANTE LA SUSTITUCION DE AMINOACIDOS EN LA REGION DE DETERMINACION DE LA COMPLEMENTARIEDAD (CDR)",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7629028,
	"label": "METODOS PARA MODIFICAR EL PUNTO ISOELECTRICO DE ANTICUERPOS MEDIANTE LA SUSTITUCION DE AMINOACIDOS EN LA REGION DE DETERMINACION DE LA COMPLEMENTARIEDAD (CDR)",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 7629028,
	"label": "METODOS PARA MODIFICAR EL PUNTO ISOELECTRICO DE ANTICUERPOS MEDIANTE LA SUSTITUCION DE AMINOACIDOS EN LA REGION DE DETERMINACION DE LA COMPLEMENTARIEDAD (CDR)",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7424,
	"target": 7409,
	"type": 7629532,
	"label": "WISE BINDING ANTIBODIES AND EPITOPES",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 7424,
	"type": 7629532,
	"label": "WISE BINDING ANTIBODIES AND EPITOPES",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 32779,
	"target": 7409,
	"type": 7629532,
	"label": "WISE BINDING ANTIBODIES AND EPITOPES",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7631240,
	"label": "TERAPIA DE COMBINACION DE UN ANTICUERPO ANTI-CD20 DE TIPO II CON UN INHIBIDOR DE PROTEASOMA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 7631474,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7631474,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 7631474,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 7631474,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 7631474,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 7632312,
	"label": "Detection of PCR products in gel electrophoresis",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 7632670,
	"label": "ANTI-BST2 ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 7632670,
	"label": "ANTI-BST2 ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 7632670,
	"label": "ANTI-BST2 ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 32771,
	"type": 7632670,
	"label": "ANTI-BST2 ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 7632670,
	"label": "ANTI-BST2 ANTIBODY.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37878,
	"target": 32770,
	"type": 7633930,
	"label": "Antibodies with enhanced ADCC function",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7635646,
	"label": "ANTIBODY PREPARATION",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7636820,
	"label": "Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 7636820,
	"label": "Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 7636820,
	"label": "Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6371,
	"target": 6303,
	"type": 7637327,
	"label": "Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use",
	"group": "Amgen",
	"time": 2008,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7639217,
	"label": "METHODS AND ASSAYS FOR CAPTURE OF NUCLEIC ACIDS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 39999,
	"target": 38164,
	"type": 7639217,
	"label": "METHODS AND ASSAYS FOR CAPTURE OF NUCLEIC ACIDS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 7639217,
	"label": "METHODS AND ASSAYS FOR CAPTURE OF NUCLEIC ACIDS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6489,
	"type": 7639974,
	"label": "GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 7639974,
	"label": "GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 7639974,
	"label": "GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 6489,
	"type": 7639974,
	"label": "GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7639974,
	"label": "GENETIC VARIATIONS ASSOCIATED WITH DRUG RESISTANCE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 7641481,
	"label": "Stabilized protein compositions",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7642051,
	"label": "COMPUESTOS FUSIONADOS DE PIRIDINA, PIRIMIDINA Y TRIAZINA COMO INHIBIDORES DEL CICLO CELULAR",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 7643469,
	"label": "Phthalazinone derivatives for ibhibiting the activity of the enzyme poly (ADP-ribose)polymerase-1 (PARP-1)",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6471,
	"type": 7643938,
	"label": "USE OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATING NON-HODGKIN' S LYMPHOMAS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7643938,
	"label": "USE OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATING NON-HODGKIN' S LYMPHOMAS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 6471,
	"type": 7643938,
	"label": "USE OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN COMBINATION WITH CYCLOPHOSPHAMIDE, VINCRISTINE AND DOXORUBICINE FOR TREATING NON-HODGKIN' S LYMPHOMAS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 31042,
	"type": 7647669,
	"label": "GEM-DISUBSTITUIERTE UND SPIROCYCLISCHE AMINOPYRIDINE/PYRIMIDINE ALS ZELLCYCLUS- INHIBITOREN",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31042,
	"target": 6376,
	"type": 7647669,
	"label": "GEM-DISUBSTITUIERTE UND SPIROCYCLISCHE AMINOPYRIDINE/PYRIMIDINE ALS ZELLCYCLUS- INHIBITOREN",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7647669,
	"label": "GEM-DISUBSTITUIERTE UND SPIROCYCLISCHE AMINOPYRIDINE/PYRIMIDINE ALS ZELLCYCLUS- INHIBITOREN",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 7647673,
	"label": "NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7647698,
	"label": "ANTI-NR10 ANTIBODIES AND UTILIZATION OF THE SAME",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 7647698,
	"label": "ANTI-NR10 ANTIBODIES AND UTILIZATION OF THE SAME",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 7647698,
	"label": "ANTI-NR10 ANTIBODIES AND UTILIZATION OF THE SAME",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7437,
	"target": 6812,
	"type": 7647790,
	"label": "Method for treating pruritus comprising administering an NR10 antagonist",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7437,
	"type": 7647790,
	"label": "Method for treating pruritus comprising administering an NR10 antagonist",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 7647790,
	"label": "Method for treating pruritus comprising administering an NR10 antagonist",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7648834,
	"label": "Moduladores de la aurora cinasa y método de uso",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6382,
	"target": 6376,
	"type": 7648834,
	"label": "Moduladores de la aurora cinasa y método de uso",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6376,
	"target": 6367,
	"type": 7648834,
	"label": "Moduladores de la aurora cinasa y método de uso",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6382,
	"target": 6367,
	"type": 7648834,
	"label": "Moduladores de la aurora cinasa y método de uso",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6367,
	"target": 6301,
	"type": 7648834,
	"label": "Moduladores de la aurora cinasa y método de uso",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 7652323,
	"label": "Polynucleotides encoding humanized anti-factor D antibodies",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37900,
	"target": 37899,
	"type": 7652965,
	"label": "MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37900,
	"type": 7652965,
	"label": "MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 7652965,
	"label": "MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32772,
	"type": 7652965,
	"label": "MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37900,
	"target": 32772,
	"type": 7652965,
	"label": "MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 7654903,
	"label": "TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 7360,
	"target": 6301,
	"type": 7654903,
	"label": "TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7654903,
	"label": "TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7654903,
	"label": "TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 7654903,
	"label": "TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS.",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 6390,
	"target": 6301,
	"type": 7656426,
	"label": "INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6390,
	"type": 7656426,
	"label": "INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7656426,
	"label": "INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 7656709,
	"label": "PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7360,
	"target": 6382,
	"type": 7656709,
	"label": "PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 7656709,
	"label": "PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 6292,
	"target": 6290,
	"type": 7656715,
	"label": "Aminothiazoles as FBPase inhibitors for diabetes",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6390,
	"target": 6347,
	"type": 7657258,
	"label": "Inhibidores de la replicación del virus de la inmunodeficiencia humana",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 6376,
	"type": 7660030,
	"label": "THERAPY OF RITUXIMAB-REFRACTORY RHEUMATOID ARTHRITIS PATIENTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31965,
	"target": 6376,
	"type": 7665121,
	"label": "GPR119 RECEPTOR AGONISTS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 7665122,
	"label": "A PHARMACEUTICAL FORMULATION COMPRISING AN ANTIBODY AGAINST OX40L, USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32769,
	"target": 7507,
	"type": 7666440,
	"label": "ANTI-HEPCIDIN ANTIBODIES AND METHODS OF USE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 56833,
	"target": 56765,
	"type": 7666566,
	"label": "Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7669769,
	"label": "Pyrimidinyl pyridone inhibitors of kinases",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7669769,
	"label": "Pyrimidinyl pyridone inhibitors of kinases",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7669769,
	"label": "Pyrimidinyl pyridone inhibitors of kinases",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 7673519,
	"label": "Afucosylated antibodies against CCR5 and their use for the treatment of inflammatory conditions",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7673519,
	"label": "Afucosylated antibodies against CCR5 and their use for the treatment of inflammatory conditions",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7673519,
	"label": "Afucosylated antibodies against CCR5 and their use for the treatment of inflammatory conditions",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7674111,
	"label": "Inhibition of urokinase-type plasminogen activator (uPA) activity",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7508,
	"type": 7674111,
	"label": "Inhibition of urokinase-type plasminogen activator (uPA) activity",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7674111,
	"label": "Inhibition of urokinase-type plasminogen activator (uPA) activity",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7675245,
	"label": "CELL FOR USE IN THE PRODUCTION OF EXOGENOUS PROTEIN, AND PRODUCTION PROCESS USING THE CELL.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 7675245,
	"label": "CELL FOR USE IN THE PRODUCTION OF EXOGENOUS PROTEIN, AND PRODUCTION PROCESS USING THE CELL.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 7675245,
	"label": "CELL FOR USE IN THE PRODUCTION OF EXOGENOUS PROTEIN, AND PRODUCTION PROCESS USING THE CELL.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 7675245,
	"label": "CELL FOR USE IN THE PRODUCTION OF EXOGENOUS PROTEIN, AND PRODUCTION PROCESS USING THE CELL.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 7675245,
	"label": "CELL FOR USE IN THE PRODUCTION OF EXOGENOUS PROTEIN, AND PRODUCTION PROCESS USING THE CELL.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6371,
	"target": 6303,
	"type": 7676255,
	"label": "Heterocyclic antiviral compounds",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7678418,
	"label": "RIBONUCLEOTIDE TAG NUCLEIC ACID DETECTION",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7682523,
	"label": "INHIBITORS OF GM-CSF AND IL-17 FOR THERAPY.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 6301,
	"target": 6279,
	"type": 7685206,
	"label": "DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7479,
	"target": 6301,
	"type": 7685206,
	"label": "DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7479,
	"target": 6279,
	"type": 7685206,
	"label": "DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7479,
	"type": 7685206,
	"label": "DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7685206,
	"label": "DERIVADOS DE IMIDAZOLIDINONA COMO INHIBIDORES DE 11b-HSD1",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 7685305,
	"label": "COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING ASTHMA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 6812,
	"type": 7685305,
	"label": "COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING ASTHMA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 7685305,
	"label": "COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING ASTHMA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6410,
	"target": 6229,
	"type": 7687364,
	"label": "COMBINACIONES DE UN CONJUGADO ANTICUERPO-FARMACO ANTI-HER2 Y AGENTES QUIMIOTERAPEUTICOS Y LOS METODOS DE USO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 7687364,
	"label": "COMBINACIONES DE UN CONJUGADO ANTICUERPO-FARMACO ANTI-HER2 Y AGENTES QUIMIOTERAPEUTICOS Y LOS METODOS DE USO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 7687364,
	"label": "COMBINACIONES DE UN CONJUGADO ANTICUERPO-FARMACO ANTI-HER2 Y AGENTES QUIMIOTERAPEUTICOS Y LOS METODOS DE USO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6292,
	"target": 6281,
	"type": 7690787,
	"label": "BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6292,
	"type": 7690787,
	"label": "BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6281,
	"type": 7690787,
	"label": "BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7692850,
	"label": "System and method for improved processing of nucleic acids for production of sequencable libraries",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 39999,
	"target": 38164,
	"type": 7692850,
	"label": "System and method for improved processing of nucleic acids for production of sequencable libraries",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 7692850,
	"label": "System and method for improved processing of nucleic acids for production of sequencable libraries",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37947,
	"target": 37899,
	"type": 7694424,
	"label": "Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 6957,
	"type": 7694424,
	"label": "Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37947,
	"target": 6957,
	"type": 7694424,
	"label": "Neutralizing proprotein convertase subtilisin kexin type 9 ( PCSK9) variants and uses thereof",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7695287,
	"label": "INHIBITORS OF CELL PROLIFERATION AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6198,
	"type": 7695287,
	"label": "INHIBITORS OF CELL PROLIFERATION AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 6198,
	"type": 7695287,
	"label": "INHIBITORS OF CELL PROLIFERATION AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 30171,
	"target": 7508,
	"type": 7695287,
	"label": "INHIBITORS OF CELL PROLIFERATION AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 30171,
	"target": 7507,
	"type": 7695287,
	"label": "INHIBITORS OF CELL PROLIFERATION AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38065,
	"target": 37993,
	"type": 7695388,
	"label": "ANTICUERPOS DIRIGIDOS A ANGIOPOIETINA 1 Y ANGIOPOIETINA 2 Y USOS DE LOS MISMOS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 7695388,
	"label": "ANTICUERPOS DIRIGIDOS A ANGIOPOIETINA 1 Y ANGIOPOIETINA 2 Y USOS DE LOS MISMOS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38065,
	"target": 32788,
	"type": 7695388,
	"label": "ANTICUERPOS DIRIGIDOS A ANGIOPOIETINA 1 Y ANGIOPOIETINA 2 Y USOS DE LOS MISMOS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 7695388,
	"label": "ANTICUERPOS DIRIGIDOS A ANGIOPOIETINA 1 Y ANGIOPOIETINA 2 Y USOS DE LOS MISMOS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 7695388,
	"label": "ANTICUERPOS DIRIGIDOS A ANGIOPOIETINA 1 Y ANGIOPOIETINA 2 Y USOS DE LOS MISMOS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 7695538,
	"label": "COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7695538,
	"label": "COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 7695538,
	"label": "COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7695538,
	"label": "COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7695538,
	"label": "COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 7696595,
	"label": "Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7424,
	"target": 6301,
	"type": 7696595,
	"label": "Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7696595,
	"label": "Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7696595,
	"label": "Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7424,
	"type": 7696595,
	"label": "Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7696596,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7696596,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7696596,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 7696597,
	"label": "DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7424,
	"target": 6301,
	"type": 7696597,
	"label": "DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7696597,
	"label": "DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7696597,
	"label": "DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7424,
	"type": 7696597,
	"label": "DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7697613,
	"label": "DERIVADOS DE FENILAMINO COMO MODULADORES DE BETA-AMILOIDE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32291,
	"target": 7507,
	"type": 7699454,
	"label": "Phosphonate derivatives featuring a fused heterocycling ring such as purine for treating cancer and other cellular proliferation diseases",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 30821,
	"type": 7700569,
	"label": "PROCESS FOR THE PREPARATION OF PYRIDO [2,1-A] ISOQUINOLINE DERIVATIVES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7701531,
	"label": "Nucleic acid amplification in the presence of modified randomers",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 7707745,
	"label": "ANTI-HEDGEHOG ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7707745,
	"label": "ANTI-HEDGEHOG ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7707745,
	"label": "ANTI-HEDGEHOG ANTIBODIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6367,
	"target": 6301,
	"type": 7708839,
	"label": "NUEVOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA E IMIDAZO[1,2-b]-PIRIDAZINA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 7708839,
	"label": "NUEVOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA E IMIDAZO[1,2-b]-PIRIDAZINA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7708839,
	"label": "NUEVOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA E IMIDAZO[1,2-b]-PIRIDAZINA",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7708896,
	"label": "2 -MORPHOLINOPYRIMIDINES AND THEIR USE AS PI3 KINASE INHIBITORS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 6854,
	"target": 6229,
	"type": 7709168,
	"label": "TREATMENT OF METASTIC BREAST CANCER BY A COMBINATION OF TWO ANTI-HER2 ANTIBODIES AND A TAXENE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 7709168,
	"label": "TREATMENT OF METASTIC BREAST CANCER BY A COMBINATION OF TWO ANTI-HER2 ANTIBODIES AND A TAXENE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 7709168,
	"label": "TREATMENT OF METASTIC BREAST CANCER BY A COMBINATION OF TWO ANTI-HER2 ANTIBODIES AND A TAXENE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 7709168,
	"label": "TREATMENT OF METASTIC BREAST CANCER BY A COMBINATION OF TWO ANTI-HER2 ANTIBODIES AND A TAXENE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32772,
	"target": 6854,
	"type": 7709168,
	"label": "TREATMENT OF METASTIC BREAST CANCER BY A COMBINATION OF TWO ANTI-HER2 ANTIBODIES AND A TAXENE",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7710511,
	"label": "6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7508,
	"type": 7710511,
	"label": "6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7710511,
	"label": "6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7409,
	"target": 6185,
	"type": 7711425,
	"label": "SUBSTITUTED AMINOTETRALINES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 6812,
	"type": 7711502,
	"label": "VARIANTES DE CRIg MADURAS POR AFINIDAD",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 7712724,
	"label": "USE OF PHARMACEUTICAL COMPOSITIONS COMPRISING A CASPASE INHIBITOR FOR TREATING INTERSTITIAL LUNG DISEASES",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7716717,
	"label": "System and method for detection of HIV tropism variants",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 7719791,
	"label": "PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 7719798,
	"label": "IMIDAZOLYLPYRIMIDINE COMPOUNDS AS HDAC AND / OR CDK INHIBITORS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7360,
	"target": 6382,
	"type": 7719798,
	"label": "IMIDAZOLYLPYRIMIDINE COMPOUNDS AS HDAC AND / OR CDK INHIBITORS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7360,
	"target": 6371,
	"type": 7719798,
	"label": "IMIDAZOLYLPYRIMIDINE COMPOUNDS AS HDAC AND / OR CDK INHIBITORS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 7720840,
	"label": "USE OF GDNF AND GDNF RECEPTOR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 7720840,
	"label": "USE OF GDNF AND GDNF RECEPTOR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 7720840,
	"label": "USE OF GDNF AND GDNF RECEPTOR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 7720840,
	"label": "USE OF GDNF AND GDNF RECEPTOR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 7720840,
	"label": "USE OF GDNF AND GDNF RECEPTOR",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7508,
	"type": 7721329,
	"label": "S1P1 receptor agonists and use thereof",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 6301,
	"type": 7721329,
	"label": "S1P1 receptor agonists and use thereof",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 6301,
	"type": 7721329,
	"label": "S1P1 receptor agonists and use thereof",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32022,
	"target": 6371,
	"type": 7721342,
	"label": "ALKYNYL ALCOHOLS AS KINASE INHIBITORS.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7726617,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 7726617,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7726617,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 7726617,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 7726617,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7726618,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7726618,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 7726618,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 7726618,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7726618,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7487,
	"type": 7730090,
	"label": "RESPONSES TO IMMUNIZATIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH A CD20 ANTIBODY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7487,
	"target": 6854,
	"type": 7730090,
	"label": "RESPONSES TO IMMUNIZATIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH A CD20 ANTIBODY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 6854,
	"type": 7730090,
	"label": "RESPONSES TO IMMUNIZATIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH A CD20 ANTIBODY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 7730293,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 7730293,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 7730293,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7730293,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 7730293,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 38232,
	"type": 7730474,
	"label": "ASC como marcador del cáncer de pulmón",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7737945,
	"label": "Cancerous Disease Modifying Antibodies",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6957,
	"type": 7737945,
	"label": "Cancerous Disease Modifying Antibodies",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 6957,
	"type": 7737945,
	"label": "Cancerous Disease Modifying Antibodies",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 7737945,
	"label": "Cancerous Disease Modifying Antibodies",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 7737945,
	"label": "Cancerous Disease Modifying Antibodies",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 7743400,
	"label": "High concentration antibody-containing liquid formulation",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 7743949,
	"label": "Uses of FGF21 polypeptides comprising two or more mutations",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7409,
	"target": 6427,
	"type": 7745985,
	"label": "Corticosteroid linked beta-agonist compounds for use in therapy",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37878,
	"type": 7748197,
	"label": "NOVEL METHOD OF PREPARING SPECIMEN HAVING EXCELLENT ABILITIES TO MAINTAIN TISSUE MORPHOLOGY AND MAINTAIN NUCLEIC ACID QUALITIES",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 38181,
	"target": 37960,
	"type": 7750833,
	"label": "SLPA AS A TOOL FOR RECOMBINANT PROTEIN AND ENZYME TECHNOLOGY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37960,
	"target": 32788,
	"type": 7750833,
	"label": "SLPA AS A TOOL FOR RECOMBINANT PROTEIN AND ENZYME TECHNOLOGY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 7750833,
	"label": "SLPA AS A TOOL FOR RECOMBINANT PROTEIN AND ENZYME TECHNOLOGY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 6854,
	"type": 7750833,
	"label": "SLPA AS A TOOL FOR RECOMBINANT PROTEIN AND ENZYME TECHNOLOGY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37960,
	"target": 6854,
	"type": 7750833,
	"label": "SLPA AS A TOOL FOR RECOMBINANT PROTEIN AND ENZYME TECHNOLOGY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6816,
	"target": 6376,
	"type": 7751827,
	"label": "2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6816,
	"type": 7751827,
	"label": "2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7751827,
	"label": "2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 32437,
	"target": 7507,
	"type": 7751840,
	"label": "CONJUGADOS DERIVADOS DE ANTRACICLINA, PROCESO PARA SU PREPARACION Y SU USO COMO COMPUESTOS ANTITUMORALES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 7751841,
	"label": "FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7409,
	"target": 6371,
	"type": 7751841,
	"label": "FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7751841,
	"label": "FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7751841,
	"label": "FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 7751841,
	"label": "FUSED HETEROCYCLYC INHIBITORS OF HISTONE DEACETYLASE AND/OR CYCLIN-DEPENDENT KINASES",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7754542,
	"label": "4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6213,
	"target": 6166,
	"type": 7756634,
	"label": "METHODS OF TREATING HYPERACIDIC DISORDERS.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6213,
	"type": 7756634,
	"label": "METHODS OF TREATING HYPERACIDIC DISORDERS.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6166,
	"type": 7756634,
	"label": "METHODS OF TREATING HYPERACIDIC DISORDERS.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 30201,
	"target": 6213,
	"type": 7759850,
	"label": "POLYMORPHS OF ACYL SULFONAMIDES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 30630,
	"target": 7507,
	"type": 7762326,
	"label": "Derivados de isoindolona como inhibidores de la quinasa MEK y métodos de utilización",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7762327,
	"label": "HETEROCICLOS BICICLICOS SUSTITUIDOS Y METODOS DE USO",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7762327,
	"label": "HETEROCICLOS BICICLICOS SUSTITUIDOS Y METODOS DE USO",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7762327,
	"label": "HETEROCICLOS BICICLICOS SUSTITUIDOS Y METODOS DE USO",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7765160,
	"label": "Proofreading primer extension",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7766914,
	"label": "AURORA KINASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7766914,
	"label": "AURORA KINASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 7766914,
	"label": "AURORA KINASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6229,
	"target": 6215,
	"type": 7774562,
	"label": "DOSAGE REGIMEN COMPRISING AP02L/TRAIL, ANTI-VEGF / ANTI-CD20 AND CHEMOTHERAPY TO TREAT NSCLC OR NON-HODGKIN'S LYMPHOMA, RESPECTIVELY",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6812,
	"target": 6229,
	"type": 7774562,
	"label": "DOSAGE REGIMEN COMPRISING AP02L/TRAIL, ANTI-VEGF / ANTI-CD20 AND CHEMOTHERAPY TO TREAT NSCLC OR NON-HODGKIN'S LYMPHOMA, RESPECTIVELY",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6812,
	"target": 6215,
	"type": 7774562,
	"label": "DOSAGE REGIMEN COMPRISING AP02L/TRAIL, ANTI-VEGF / ANTI-CD20 AND CHEMOTHERAPY TO TREAT NSCLC OR NON-HODGKIN'S LYMPHOMA, RESPECTIVELY",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 6812,
	"type": 7774562,
	"label": "DOSAGE REGIMEN COMPRISING AP02L/TRAIL, ANTI-VEGF / ANTI-CD20 AND CHEMOTHERAPY TO TREAT NSCLC OR NON-HODGKIN'S LYMPHOMA, RESPECTIVELY",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 6229,
	"type": 7774562,
	"label": "DOSAGE REGIMEN COMPRISING AP02L/TRAIL, ANTI-VEGF / ANTI-CD20 AND CHEMOTHERAPY TO TREAT NSCLC OR NON-HODGKIN'S LYMPHOMA, RESPECTIVELY",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7776616,
	"label": "SYSTEMS AND METHODS FOR STEP DISCONTINUITY REMOVAL IN REAL-TIME PCR FLUORESCENCE DATA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31307,
	"target": 30904,
	"type": 7777474,
	"label": "HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7777476,
	"label": "NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES.",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6550,
	"type": 7777704,
	"label": "HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7778021,
	"label": "Dicarbazoles y procedimientos de uso",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7778021,
	"label": "Dicarbazoles y procedimientos de uso",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 6376,
	"type": 7778021,
	"label": "Dicarbazoles y procedimientos de uso",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6302,
	"target": 6301,
	"type": 7778022,
	"label": "METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 7778022,
	"label": "METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7778022,
	"label": "METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7778023,
	"label": "SUBSTITUTED PYRROLES AND METHODS OF USE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7778232,
	"label": "CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE HISTONE DEACETYLASE INHIBITOR COMPOUNDS.",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6366,
	"target": 6360,
	"type": 7779184,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 7779184,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6360,
	"type": 7779184,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7779184,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6366,
	"type": 7779184,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7780522,
	"label": "FUSION PROTEIN COMPOSED OF LIGAND BONDED PROTEIN AND STABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 7780522,
	"label": "FUSION PROTEIN COMPOSED OF LIGAND BONDED PROTEIN AND STABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 7780522,
	"label": "FUSION PROTEIN COMPOSED OF LIGAND BONDED PROTEIN AND STABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 7780522,
	"label": "FUSION PROTEIN COMPOSED OF LIGAND BONDED PROTEIN AND STABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 7780522,
	"label": "FUSION PROTEIN COMPOSED OF LIGAND BONDED PROTEIN AND STABLE PLASMA PROTEIN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 7781525,
	"label": "COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7782224,
	"label": "Lysis and reverse transcription for MRNA quantification",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7784045,
	"label": "HETEROCICLOS COMO INHIBIDORES DE PROTEINAS CINASAS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6301,
	"target": 6280,
	"type": 7784045,
	"label": "HETEROCICLOS COMO INHIBIDORES DE PROTEINAS CINASAS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 7784045,
	"label": "HETEROCICLOS COMO INHIBIDORES DE PROTEINAS CINASAS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 6376,
	"target": 6280,
	"type": 7784045,
	"label": "HETEROCICLOS COMO INHIBIDORES DE PROTEINAS CINASAS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 7784045,
	"label": "HETEROCICLOS COMO INHIBIDORES DE PROTEINAS CINASAS.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7786791,
	"label": "MOLÉCULE DE LIAISON À L'ANTIGÈNE CAPABLE DE SE LIER À DEUX MOLÉCULES D'ANTIGÈNE OU PLUS DE MANIÈRE RÉPÉTÉE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37878,
	"target": 37875,
	"type": 7787649,
	"label": "SMALL SCALE SHAKER FLASK CULTIVATION",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7789980,
	"label": "CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXC D3, IGF-1RXCD3 OR FAPALPHA XCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 7789980,
	"label": "CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXC D3, IGF-1RXCD3 OR FAPALPHA XCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 7789980,
	"label": "CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXC D3, IGF-1RXCD3 OR FAPALPHA XCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7789980,
	"label": "CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXC D3, IGF-1RXCD3 OR FAPALPHA XCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 38181,
	"target": 32771,
	"type": 7789980,
	"label": "CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXC D3, IGF-1RXCD3 OR FAPALPHA XCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7789981,
	"label": "CROSS-SPECIES-SPECIFIC (HUMAN AND PRIMATE) BISPECIFIC SINGLE CHAIN ANTIBODY THAT BINDS BOTH CD3 (EPSILON) EPITOPE AND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA)",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 7789981,
	"label": "CROSS-SPECIES-SPECIFIC (HUMAN AND PRIMATE) BISPECIFIC SINGLE CHAIN ANTIBODY THAT BINDS BOTH CD3 (EPSILON) EPITOPE AND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA)",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7789981,
	"label": "CROSS-SPECIES-SPECIFIC (HUMAN AND PRIMATE) BISPECIFIC SINGLE CHAIN ANTIBODY THAT BINDS BOTH CD3 (EPSILON) EPITOPE AND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA)",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7789981,
	"label": "CROSS-SPECIES-SPECIFIC (HUMAN AND PRIMATE) BISPECIFIC SINGLE CHAIN ANTIBODY THAT BINDS BOTH CD3 (EPSILON) EPITOPE AND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA)",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7789981,
	"label": "CROSS-SPECIES-SPECIFIC (HUMAN AND PRIMATE) BISPECIFIC SINGLE CHAIN ANTIBODY THAT BINDS BOTH CD3 (EPSILON) EPITOPE AND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PMSA)",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7789982,
	"label": "CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 7409,
	"type": 7790891,
	"label": "PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7508,
	"type": 7790891,
	"label": "PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 7790891,
	"label": "PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 7791344,
	"label": "ANTICUERPOS QUE MODIFICAN ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 7791344,
	"label": "ANTICUERPOS QUE MODIFICAN ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56836,
	"target": 32771,
	"type": 7791344,
	"label": "ANTICUERPOS QUE MODIFICAN ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7791344,
	"label": "ANTICUERPOS QUE MODIFICAN ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7791344,
	"label": "ANTICUERPOS QUE MODIFICAN ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 7791681,
	"label": "CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 7791681,
	"label": "CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 7791681,
	"label": "CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37864,
	"target": 7510,
	"type": 7791681,
	"label": "CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 7791681,
	"label": "CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32478,
	"type": 7792934,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TGF-BETA RECEPTOR GENES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32478,
	"target": 6489,
	"type": 7792934,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TGF-BETA RECEPTOR GENES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 6489,
	"type": 7792934,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TGF-BETA RECEPTOR GENES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7796302,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-EGFR / ANTI-IGF-1R",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 7796302,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-EGFR / ANTI-IGF-1R",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 7796302,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-EGFR / ANTI-IGF-1R",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7796302,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-EGFR / ANTI-IGF-1R",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 7796302,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-EGFR / ANTI-IGF-1R",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 30972,
	"target": 7360,
	"type": 7797336,
	"label": "NEW BENZIMIDAZOLE DERIVATIVES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7799696,
	"label": "PYRIMIDINYL PYRIDONE INHIBITORS OF JNK",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6371,
	"target": 6366,
	"type": 7802740,
	"label": "AURORA KINASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7802740,
	"label": "AURORA KINASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 7802740,
	"label": "AURORA KINASE MODULATORS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7802883,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 7802883,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7802883,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 7802883,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7802883,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7802884,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37900,
	"target": 32771,
	"type": 7802884,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 7802884,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 7802884,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37900,
	"target": 7507,
	"type": 7802884,
	"label": "ANTICUERPOS MODIFICADORES DE ENFERMEDADES CANCEROSAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 7804870,
	"label": "GENETIC POLYMORPHISMS IN AGE-RELATED MACULAR DEGENERATION",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 7804890,
	"label": "Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 7804890,
	"label": "Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7804890,
	"label": "Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 7804890,
	"label": "Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7508,
	"type": 7804890,
	"label": "Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7380,
	"target": 6407,
	"type": 7804924,
	"label": "ARYCYCLOHEXYLETHERS DE DIHYDROTETRAZABENZOAZULENES POUR EMPLOI EN TANT QU'ANTAGONISTES DU RECEPTEUR V1A DE LA VASOPRESSINE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7806110,
	"label": "Pyrrolopyrazinyl urea kinase inhibitors",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 7806131,
	"label": "SCREENING ASSAYS FOR THE IDENTIFICATION OF BACE2 INHIBITORS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6281,
	"target": 6229,
	"type": 7806140,
	"label": "NOVEL COMBINED ADMINISTRATION",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 7360,
	"type": 7807023,
	"label": "FGF21 MUTANTS AND USES THEREOF",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 7807893,
	"label": "VARIANT HEDGEHOG-INTERACTING PROTEIN (HHIP1) AND METHODS AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 7807893,
	"label": "VARIANT HEDGEHOG-INTERACTING PROTEIN (HHIP1) AND METHODS AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 7807893,
	"label": "VARIANT HEDGEHOG-INTERACTING PROTEIN (HHIP1) AND METHODS AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 7807893,
	"label": "VARIANT HEDGEHOG-INTERACTING PROTEIN (HHIP1) AND METHODS AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 7807893,
	"label": "VARIANT HEDGEHOG-INTERACTING PROTEIN (HHIP1) AND METHODS AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7808131,
	"label": "Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7508,
	"type": 7808131,
	"label": "Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7808131,
	"label": "Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 7808131,
	"label": "Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 6962,
	"type": 7808131,
	"label": "Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7425,
	"target": 6407,
	"type": 7810901,
	"label": "Alkylcyclohexylethers of dihydrotetraazabenzoazulene derivatives,the method for making the same and the use thereof",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 7813027,
	"label": "ACIDES NAPHTYLACÉTIQUES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 30251,
	"target": 7510,
	"type": 7813027,
	"label": "ACIDES NAPHTYLACÉTIQUES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 30251,
	"target": 7409,
	"type": 7813027,
	"label": "ACIDES NAPHTYLACÉTIQUES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 7814278,
	"label": "COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DE GENES DEL FACTOR VII",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 7814278,
	"label": "COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DE GENES DEL FACTOR VII",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37988,
	"target": 37899,
	"type": 7814278,
	"label": "COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DE GENES DEL FACTOR VII",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 6483,
	"type": 7814278,
	"label": "COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DE GENES DEL FACTOR VII",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 6483,
	"type": 7814278,
	"label": "COMPOSICIONES Y METODOS PARA INHIBIR LA EXPRESION DE GENES DEL FACTOR VII",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 7821207,
	"label": "ANTI-UNC5B ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7821207,
	"label": "ANTI-UNC5B ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 7821207,
	"label": "ANTI-UNC5B ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 7508,
	"type": 7822583,
	"label": "usos de um antagonista de neuropilin-2, anticorpos antinrp2b, anticorpos anti-nrp2a, composiÇço, composiÇço farmacÊutica e antagonista nrp2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7822583,
	"label": "usos de um antagonista de neuropilin-2, anticorpos antinrp2b, anticorpos anti-nrp2a, composiÇço, composiÇço farmacÊutica e antagonista nrp2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7822583,
	"label": "usos de um antagonista de neuropilin-2, anticorpos antinrp2b, anticorpos anti-nrp2a, composiÇço, composiÇço farmacÊutica e antagonista nrp2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7822583,
	"label": "usos de um antagonista de neuropilin-2, anticorpos antinrp2b, anticorpos anti-nrp2a, composiÇço, composiÇço farmacÊutica e antagonista nrp2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7509,
	"type": 7822583,
	"label": "usos de um antagonista de neuropilin-2, anticorpos antinrp2b, anticorpos anti-nrp2a, composiÇço, composiÇço farmacÊutica e antagonista nrp2",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7359,
	"type": 7822616,
	"label": "Neuroinvasion inhibitor",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7822616,
	"label": "Neuroinvasion inhibitor",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7359,
	"type": 7822616,
	"label": "Neuroinvasion inhibitor",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6403,
	"target": 6398,
	"type": 7824041,
	"label": "COMPUESTOS DE 1,1-DIÓXIDO DE [1,2,4,]TIADIAZINA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 7824457,
	"label": "TREATMENT METHOD.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7824457,
	"label": "TREATMENT METHOD.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 7824457,
	"label": "TREATMENT METHOD.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 7824477,
	"label": "DETERMINATION OF IMMUNOGLOBULIN ENCODING NUCLEID ACID",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 6812,
	"type": 7826360,
	"label": "IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 7826360,
	"label": "IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 7826360,
	"label": "IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF.",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7833529,
	"label": "Allele-specific amplification",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 7833529,
	"label": "Allele-specific amplification",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 7833529,
	"label": "Allele-specific amplification",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 7834804,
	"label": "3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 7835459,
	"label": "BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR AND HUMAN ANGIOPOIETIN-2",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 7835459,
	"label": "BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR AND HUMAN ANGIOPOIETIN-2",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 7835459,
	"label": "BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR AND HUMAN ANGIOPOIETIN-2",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 7836343,
	"label": "ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 7836343,
	"label": "ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 7836343,
	"label": "ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7836343,
	"label": "ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 7836343,
	"label": "ANTI-NOTCH2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7837465,
	"label": "CALCIUM RECEPTOR MODULATING AGENTS",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 7837467,
	"label": "Aza- and Diaza-Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31081,
	"target": 6360,
	"type": 7839232,
	"label": "2 -OXOQUINOXALIN BLOCKERS OF THE LATE SODIUM CHANNEL",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7839783,
	"label": "COMBINATION THERAPY COMPRISING A C-MET ANTAGONIST AND A VEGF ANTAGONIST",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7840253,
	"label": "CAPILLARY",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32022,
	"target": 31995,
	"type": 7841207,
	"label": "ESPIRO-5,6-DIHIDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENOS COMO ANTAGONISTAS DE LA V1a",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6407,
	"target": 6281,
	"type": 7841207,
	"label": "ESPIRO-5,6-DIHIDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENOS COMO ANTAGONISTAS DE LA V1a",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31995,
	"target": 6407,
	"type": 7841207,
	"label": "ESPIRO-5,6-DIHIDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENOS COMO ANTAGONISTAS DE LA V1a",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32022,
	"target": 6407,
	"type": 7841207,
	"label": "ESPIRO-5,6-DIHIDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENOS COMO ANTAGONISTAS DE LA V1a",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31995,
	"target": 6281,
	"type": 7841207,
	"label": "ESPIRO-5,6-DIHIDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENOS COMO ANTAGONISTAS DE LA V1a",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38184,
	"target": 32772,
	"type": 7842225,
	"label": "IMMUNOGLOBULIN VARIANTS AND USES THEREOF.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 7842225,
	"label": "IMMUNOGLOBULIN VARIANTS AND USES THEREOF.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 7842225,
	"label": "IMMUNOGLOBULIN VARIANTS AND USES THEREOF.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 7845744,
	"label": "NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7847301,
	"label": "IMPROVED METHOD FOR THE PREVENTION OF CARRYOVER CONTAMINATION IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31846,
	"target": 7510,
	"type": 7848216,
	"label": "Inhibitors of Bruton's tyrosine kinase",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6382,
	"type": 7848405,
	"label": "1, 3, 5 -TRIAZ INE DERIVATIVES USEFUL IN THE TREATMENT OF CHRONIC PAIN DISORDERS",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 56836,
	"target": 32770,
	"type": 7849683,
	"label": "ANTIBODIES AGAINST HUMAN EPO RECEPTOR",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 6854,
	"type": 7849757,
	"label": "FORMULACION FARMACEUTICA DE UN ANTICUERPO CONTRA P-SELECTINA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 7849757,
	"label": "FORMULACION FARMACEUTICA DE UN ANTICUERPO CONTRA P-SELECTINA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 7849757,
	"label": "FORMULACION FARMACEUTICA DE UN ANTICUERPO CONTRA P-SELECTINA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7851425,
	"label": "TRISPECIFIC HEXAVALENT ANTIBODIES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 6913,
	"type": 7851427,
	"label": "MULTIVALENT ANTIBODIES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6795,
	"target": 6483,
	"type": 7859081,
	"label": "COMPOSITIONS AND METHODS FOR THE PREVENTION OF OXIDATIVE DEGRADATION OF PROTEINS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7859463,
	"label": "ANTICUERPOS PARA CCR2",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 7859463,
	"label": "ANTICUERPOS PARA CCR2",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7487,
	"type": 7859463,
	"label": "ANTICUERPOS PARA CCR2",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37900,
	"target": 32770,
	"type": 7859463,
	"label": "ANTICUERPOS PARA CCR2",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 7859463,
	"label": "ANTICUERPOS PARA CCR2",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7487,
	"target": 6367,
	"type": 7859517,
	"label": "Compuestos de piridazino-piridinona para el tratamiento de enfermedades mediadas por proteína cinasa",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7487,
	"type": 7859517,
	"label": "Compuestos de piridazino-piridinona para el tratamiento de enfermedades mediadas por proteína cinasa",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 7859517,
	"label": "Compuestos de piridazino-piridinona para el tratamiento de enfermedades mediadas por proteína cinasa",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 7859519,
	"label": "Diagnostics and Treatments for VEGF-Independent Tumors",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 7859521,
	"label": "MULTISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 7859521,
	"label": "MULTISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7859521,
	"label": "MULTISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 7859521,
	"label": "MULTISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32772,
	"type": 7859521,
	"label": "MULTISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 7861815,
	"label": "Polyanion for improved nucleic acid amplification",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37988,
	"type": 7861815,
	"label": "Polyanion for improved nucleic acid amplification",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7861815,
	"label": "Polyanion for improved nucleic acid amplification",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 7862103,
	"label": "Methods of Treating Autoimmune Diseases Using CD4 Antibodies",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 7862181,
	"label": "ANTIBODIES AGAINST HUMAN EPO RECEPTOR",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 7862181,
	"label": "ANTIBODIES AGAINST HUMAN EPO RECEPTOR",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 7862181,
	"label": "ANTIBODIES AGAINST HUMAN EPO RECEPTOR",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 7862181,
	"label": "ANTIBODIES AGAINST HUMAN EPO RECEPTOR",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 7862181,
	"label": "ANTIBODIES AGAINST HUMAN EPO RECEPTOR",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 7867836,
	"label": "FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 30171,
	"target": 7507,
	"type": 7869804,
	"label": "TOLUIDINE SULFONAMIDES AND THEIR USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 7872854,
	"label": "SPIROINDOLINONE DERIVATIVE PRODRUGS.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 7875353,
	"label": "METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 7875470,
	"label": "HEPATITIS C VIRUS COMBINATION THERAPY.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 6816,
	"type": 7875470,
	"label": "HEPATITIS C VIRUS COMBINATION THERAPY.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 6816,
	"type": 7875470,
	"label": "HEPATITIS C VIRUS COMBINATION THERAPY.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 7875540,
	"label": "ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID &amp;beta; PEPTIDE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 7875540,
	"label": "ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID &amp;beta; PEPTIDE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56836,
	"target": 32777,
	"type": 7875540,
	"label": "ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID &amp;beta; PEPTIDE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 7876943,
	"label": "CRYSTAL STRUCTURES OF NEUROPILIN FRAGMENTS AND NEUROPILIN-ANTIBODY COMPLEXES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7876943,
	"label": "CRYSTAL STRUCTURES OF NEUROPILIN FRAGMENTS AND NEUROPILIN-ANTIBODY COMPLEXES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 7876943,
	"label": "CRYSTAL STRUCTURES OF NEUROPILIN FRAGMENTS AND NEUROPILIN-ANTIBODY COMPLEXES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7878971,
	"label": "Nucleic acid amplification with allele-specific suppression of sequence variants",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 7879810,
	"label": "ANTICUERPOS CONTRA LA ANGIOPOYETINA 2 HUMANA (DIVISIONAL EXP. 2011-0321)",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7879810,
	"label": "ANTICUERPOS CONTRA LA ANGIOPOYETINA 2 HUMANA (DIVISIONAL EXP. 2011-0321)",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 7879810,
	"label": "ANTICUERPOS CONTRA LA ANGIOPOYETINA 2 HUMANA (DIVISIONAL EXP. 2011-0321)",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7879810,
	"label": "ANTICUERPOS CONTRA LA ANGIOPOYETINA 2 HUMANA (DIVISIONAL EXP. 2011-0321)",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 7879810,
	"label": "ANTICUERPOS CONTRA LA ANGIOPOYETINA 2 HUMANA (DIVISIONAL EXP. 2011-0321)",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7883052,
	"label": "DERIVADOS DE PTERIDINONA Y PIRIMIDINODIAZEPINONA Y COMPOSICIONES FARMACÉUTICAS QUE MODULAN EN FORMA SELECTIVA LOS RECEPTORES TIPO TOLL, MÉTODOS Y USOS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 7883158,
	"label": "COMPRIMIDOS DE CAPECITABINA DE DISGREGACION RAPIDA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 30990,
	"target": 6382,
	"type": 7883161,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 7883399,
	"label": "METHODS FOR INHIBITING OCULAR ANGIOGENESIS.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7884710,
	"label": "CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 7884710,
	"label": "CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 6382,
	"type": 7884710,
	"label": "CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6382,
	"target": 6279,
	"type": 7884714,
	"label": "AMIDE DERIVATIVES AS BTK INHIBITORS IN THE TREATMENT OF ALLERGIC, AUTOIMMUNE AND INFLAMMATORY DISORDERS AS WELL AS CANCER",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7888234,
	"label": "Triazolopyridine JAK Inhibitor Compounds and Methods",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7888234,
	"label": "Triazolopyridine JAK Inhibitor Compounds and Methods",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7888234,
	"label": "Triazolopyridine JAK Inhibitor Compounds and Methods",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7888237,
	"label": "TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7888237,
	"label": "TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7888237,
	"label": "TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 7889163,
	"label": "USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERAPY FOR TREATING BREAST CANCER.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6478,
	"target": 6229,
	"type": 7889163,
	"label": "USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERAPY FOR TREATING BREAST CANCER.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 7889163,
	"label": "USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERAPY FOR TREATING BREAST CANCER.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7509,
	"target": 6478,
	"type": 7889163,
	"label": "USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERAPY FOR TREATING BREAST CANCER.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 7889163,
	"label": "USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERAPY FOR TREATING BREAST CANCER.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 7892544,
	"label": "METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 7487,
	"type": 7892544,
	"label": "METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7487,
	"type": 7892544,
	"label": "METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 7892544,
	"label": "METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 7892544,
	"label": "METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO TREAT INFECTION RESULTING FROM T-CELL DYSFUNCTION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 7893556,
	"label": "Pharmaceutical composition",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 32734,
	"type": 7895555,
	"label": "PROTEINES DE LIAISON AU RECEPTEUR CGRP HUMAIN",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 7895555,
	"label": "PROTEINES DE LIAISON AU RECEPTEUR CGRP HUMAIN",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 7895555,
	"label": "PROTEINES DE LIAISON AU RECEPTEUR CGRP HUMAIN",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37862,
	"target": 32734,
	"type": 7895555,
	"label": "PROTEINES DE LIAISON AU RECEPTEUR CGRP HUMAIN",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 7895555,
	"label": "PROTEINES DE LIAISON AU RECEPTEUR CGRP HUMAIN",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7897160,
	"label": "DRIED COMPOSITION OF REACTIVE COMPOUND WITH STABILIZED POLYMERASE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7898092,
	"label": "Humanized anti-cmet antagonists",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 7898092,
	"label": "Humanized anti-cmet antagonists",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 7898092,
	"label": "Humanized anti-cmet antagonists",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 7898092,
	"label": "Humanized anti-cmet antagonists",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 7898092,
	"label": "Humanized anti-cmet antagonists",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 7898775,
	"label": "METHODS AND SYSTEMS FOR ENRICHMENT OF TARGET GENOMIC SEQUENCES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 7898775,
	"label": "METHODS AND SYSTEMS FOR ENRICHMENT OF TARGET GENOMIC SEQUENCES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 39999,
	"target": 32478,
	"type": 7898775,
	"label": "METHODS AND SYSTEMS FOR ENRICHMENT OF TARGET GENOMIC SEQUENCES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 7898945,
	"label": "INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 7898945,
	"label": "INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 7898945,
	"label": "INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 6371,
	"target": 6301,
	"type": 7899056,
	"label": "Imidazo [1, 2 -a] pyridines as jnk modulators",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 7899056,
	"label": "Imidazo [1, 2 -a] pyridines as jnk modulators",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 7899056,
	"label": "Imidazo [1, 2 -a] pyridines as jnk modulators",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7360,
	"target": 6371,
	"type": 7902952,
	"label": "PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7907220,
	"label": "MINIATURIZED, HIGH-THROUGHPUT NUCLEIC ACID ANALYSIS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 39999,
	"target": 38164,
	"type": 7907220,
	"label": "MINIATURIZED, HIGH-THROUGHPUT NUCLEIC ACID ANALYSIS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 7907220,
	"label": "MINIATURIZED, HIGH-THROUGHPUT NUCLEIC ACID ANALYSIS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 38164,
	"type": 7907803,
	"label": "METHOD FOR OBTAINING IMMUNOGLOBULIN ENCODING NUCLEIC ACID",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 7907803,
	"label": "METHOD FOR OBTAINING IMMUNOGLOBULIN ENCODING NUCLEIC ACID",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 7907803,
	"label": "METHOD FOR OBTAINING IMMUNOGLOBULIN ENCODING NUCLEIC ACID",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 7908268,
	"label": "3, 3' -SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6816,
	"target": 6478,
	"type": 7912428,
	"label": "COMBINAISON D'UN INHIBITEUR NUCLEOSIDIQUE DE POLYMERASE AVEC UN INHIBITEUR MACROCYCLIQUE DE PROTEASE ET SON UTILISATION DANS LE TRAITEMENT DE L'HEPATITE C, DE LA FIBROSE HEPATIQUE ET D'UNE ALTERATION DE LA FONCTION HEPATIQUE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 7912428,
	"label": "COMBINAISON D'UN INHIBITEUR NUCLEOSIDIQUE DE POLYMERASE AVEC UN INHIBITEUR MACROCYCLIQUE DE PROTEASE ET SON UTILISATION DANS LE TRAITEMENT DE L'HEPATITE C, DE LA FIBROSE HEPATIQUE ET D'UNE ALTERATION DE LA FONCTION HEPATIQUE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7358,
	"target": 6478,
	"type": 7912428,
	"label": "COMBINAISON D'UN INHIBITEUR NUCLEOSIDIQUE DE POLYMERASE AVEC UN INHIBITEUR MACROCYCLIQUE DE PROTEASE ET SON UTILISATION DANS LE TRAITEMENT DE L'HEPATITE C, DE LA FIBROSE HEPATIQUE ET D'UNE ALTERATION DE LA FONCTION HEPATIQUE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32734,
	"type": 7918398,
	"label": "VARIANTS OF ACTIVIN IIB RECEPTOR POLYPEPTIDES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32734,
	"target": 7507,
	"type": 7918398,
	"label": "VARIANTS OF ACTIVIN IIB RECEPTOR POLYPEPTIDES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 7918398,
	"label": "VARIANTS OF ACTIVIN IIB RECEPTOR POLYPEPTIDES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 7918869,
	"label": "Spiroindolinone pyridine derivatives",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 7920157,
	"label": "Inhibitors of Apoptosis (IAP) for treating cancer",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 7924502,
	"label": "Pyrimidine compounds, compositions and methods of use",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7924502,
	"label": "Pyrimidine compounds, compositions and methods of use",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 7924502,
	"label": "Pyrimidine compounds, compositions and methods of use",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 7926634,
	"label": "ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 7926634,
	"label": "ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 7926634,
	"label": "ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 7926634,
	"label": "ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 32772,
	"type": 7926634,
	"label": "ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7425,
	"target": 7409,
	"type": 7929629,
	"label": "AZAINDOLE P2X3 AND P2X2/3 MODULATORS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 7930670,
	"label": "Compuestos inhibidores de PI3K de tipo pirazolopiridina y sus procedimientos de uso",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 7930670,
	"label": "Compuestos inhibidores de PI3K de tipo pirazolopiridina y sus procedimientos de uso",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7511,
	"target": 6301,
	"type": 7930670,
	"label": "Compuestos inhibidores de PI3K de tipo pirazolopiridina y sus procedimientos de uso",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7511,
	"type": 7930670,
	"label": "Compuestos inhibidores de PI3K de tipo pirazolopiridina y sus procedimientos de uso",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 7930670,
	"label": "Compuestos inhibidores de PI3K de tipo pirazolopiridina y sus procedimientos de uso",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 7930781,
	"label": "THIAZOLYL-BENZIMIDAZOLES",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8018657,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-HER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 8018657,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-HER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8018657,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-HER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 8018657,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-HER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32772,
	"type": 8018657,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-HER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8020476,
	"label": "Novel anti-&agr;5&bgr;1 antibodies and uses thereof",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8020476,
	"label": "Novel anti-&agr;5&bgr;1 antibodies and uses thereof",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 8020476,
	"label": "Novel anti-&agr;5&bgr;1 antibodies and uses thereof",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 6489,
	"type": 8021333,
	"label": "USE OF IL-27 ANTAGONISTS TO TREAT LUPUS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 8021546,
	"label": "METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8023167,
	"label": "Improved Interleukin-6 receptor antibody molecule",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8023167,
	"label": "Improved Interleukin-6 receptor antibody molecule",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 8023167,
	"label": "Improved Interleukin-6 receptor antibody molecule",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 8023167,
	"label": "Improved Interleukin-6 receptor antibody molecule",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8023167,
	"label": "Improved Interleukin-6 receptor antibody molecule",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8024004,
	"label": "ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37904,
	"type": 8024004,
	"label": "ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37904,
	"target": 32788,
	"type": 8024004,
	"label": "ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 8024004,
	"label": "ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 8024004,
	"label": "ANTI-FCRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8024020,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-ERBB-3/ANTI-C-MET",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 8024020,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-ERBB-3/ANTI-C-MET",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8024020,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-ERBB-3/ANTI-C-MET",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 8024020,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-ERBB-3/ANTI-C-MET",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32772,
	"type": 8024020,
	"label": "ANTICUERPOS BIESPECÍFICOS ANTI-ERBB-3/ANTI-C-MET",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8024021,
	"label": "Combination therapy of an afucosylated antibody and one or more of the cytokines selected from human GM-CSF, human M-CSF and/or human IL-3",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 8024021,
	"label": "Combination therapy of an afucosylated antibody and one or more of the cytokines selected from human GM-CSF, human M-CSF and/or human IL-3",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7509,
	"target": 6795,
	"type": 8024021,
	"label": "Combination therapy of an afucosylated antibody and one or more of the cytokines selected from human GM-CSF, human M-CSF and/or human IL-3",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8024084,
	"label": "TRIVALENT, BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 8024084,
	"label": "TRIVALENT, BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8024084,
	"label": "TRIVALENT, BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8024084,
	"label": "TRIVALENT, BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 8024084,
	"label": "TRIVALENT, BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7425,
	"target": 7422,
	"type": 8024634,
	"label": "3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 8024634,
	"label": "3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7422,
	"type": 8024634,
	"label": "3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7422,
	"target": 6303,
	"type": 8024634,
	"label": "3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7425,
	"target": 6303,
	"type": 8024634,
	"label": "3,3'-SPIROINDOLINONE DERIVATIVES AND THEIR USE FOR CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6816,
	"target": 6403,
	"type": 8026977,
	"label": "A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 32004,
	"type": 8027900,
	"label": "TREATMENT OF CANCER WITH A HUMANIZED ANTI-EGFR IGG1 ANTIBODY AND IRINOTECAN.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32004,
	"target": 7507,
	"type": 8027900,
	"label": "TREATMENT OF CANCER WITH A HUMANIZED ANTI-EGFR IGG1 ANTIBODY AND IRINOTECAN.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8027900,
	"label": "TREATMENT OF CANCER WITH A HUMANIZED ANTI-EGFR IGG1 ANTIBODY AND IRINOTECAN.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 8028427,
	"label": "BISPECIFIC ANTI-ERBB-1/ANTI-C-MET ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8028427,
	"label": "BISPECIFIC ANTI-ERBB-1/ANTI-C-MET ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8028427,
	"label": "BISPECIFIC ANTI-ERBB-1/ANTI-C-MET ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 8028427,
	"label": "BISPECIFIC ANTI-ERBB-1/ANTI-C-MET ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 8028427,
	"label": "BISPECIFIC ANTI-ERBB-1/ANTI-C-MET ANTIBODIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8028428,
	"label": "ANTICUERPOS MULTIESPECIFICOS QUE COMPRENDEN ANTICUERPOS DE LONGITUD COMPLETA Y FRAGMENTOS FAB DE CADENA SENCILLA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 8028428,
	"label": "ANTICUERPOS MULTIESPECIFICOS QUE COMPRENDEN ANTICUERPOS DE LONGITUD COMPLETA Y FRAGMENTOS FAB DE CADENA SENCILLA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 8028428,
	"label": "ANTICUERPOS MULTIESPECIFICOS QUE COMPRENDEN ANTICUERPOS DE LONGITUD COMPLETA Y FRAGMENTOS FAB DE CADENA SENCILLA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8028428,
	"label": "ANTICUERPOS MULTIESPECIFICOS QUE COMPRENDEN ANTICUERPOS DE LONGITUD COMPLETA Y FRAGMENTOS FAB DE CADENA SENCILLA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38042,
	"target": 32779,
	"type": 8028428,
	"label": "ANTICUERPOS MULTIESPECIFICOS QUE COMPRENDEN ANTICUERPOS DE LONGITUD COMPLETA Y FRAGMENTOS FAB DE CADENA SENCILLA",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8028488,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 6376,
	"target": 6367,
	"type": 8028488,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8028488,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7508,
	"target": 6376,
	"type": 8028488,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 8028488,
	"label": "INHIBITORS OF PI3 KINASE.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8029700,
	"label": "ANTICUERPOS CONTRA LA PROTEÍNA TWEAK HUMANA Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8029700,
	"label": "ANTICUERPOS CONTRA LA PROTEÍNA TWEAK HUMANA Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8029700,
	"label": "ANTICUERPOS CONTRA LA PROTEÍNA TWEAK HUMANA Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8029700,
	"label": "ANTICUERPOS CONTRA LA PROTEÍNA TWEAK HUMANA Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 8029700,
	"label": "ANTICUERPOS CONTRA LA PROTEÍNA TWEAK HUMANA Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6172,
	"target": 6166,
	"type": 8036001,
	"label": "SELECTIVE INHIBITION OF HISTONE DEACETYLASES 1 AND 2 AS A TREATMENT FOR CARDIAC HYPERTROPHY",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 6816,
	"target": 6403,
	"type": 8037385,
	"label": "5,6-dihydro-1H-pyridin-2-one compounds",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 8037423,
	"label": "METHOD OF TREATMENT",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 8037423,
	"label": "METHOD OF TREATMENT",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7425,
	"target": 6812,
	"type": 8037423,
	"label": "METHOD OF TREATMENT",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7425,
	"target": 6795,
	"type": 8037423,
	"label": "METHOD OF TREATMENT",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 8037423,
	"label": "METHOD OF TREATMENT",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8056813,
	"label": "COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8056813,
	"label": "COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 8056813,
	"label": "COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8056813,
	"label": "COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8056813,
	"label": "COMPOSITIONS AND METHODS FOR REGULATING CELL OSMOLARITY.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8067308,
	"label": "ANTICUERPO ANTAGONISTA ESPECIFICO PARA EL HETERODIMERO DE ALFA-4-BETA-7",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 6478,
	"target": 6471,
	"type": 8067388,
	"label": "COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6471,
	"target": 6376,
	"type": 8067388,
	"label": "COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6478,
	"target": 6376,
	"type": 8067388,
	"label": "COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 8067388,
	"label": "COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6471,
	"type": 8067388,
	"label": "COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6962,
	"target": 6961,
	"type": 8101378,
	"label": "Methods and compositions for protein labelling",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6961,
	"target": 6957,
	"type": 8101378,
	"label": "Methods and compositions for protein labelling",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6962,
	"target": 6957,
	"type": 8101378,
	"label": "Methods and compositions for protein labelling",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32694,
	"target": 6962,
	"type": 8101378,
	"label": "Methods and compositions for protein labelling",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32694,
	"target": 6961,
	"type": 8101378,
	"label": "Methods and compositions for protein labelling",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37881,
	"type": 8130972,
	"label": "HYPER IGE ANIMAL MODEL WITH ENHANCED IMMUNOGLOBULIN HEAVY CHAIN CLASS SWITCHING TO C&amp;epsi;",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 8130972,
	"label": "HYPER IGE ANIMAL MODEL WITH ENHANCED IMMUNOGLOBULIN HEAVY CHAIN CLASS SWITCHING TO C&amp;epsi;",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38065,
	"target": 37881,
	"type": 8130972,
	"label": "HYPER IGE ANIMAL MODEL WITH ENHANCED IMMUNOGLOBULIN HEAVY CHAIN CLASS SWITCHING TO C&amp;epsi;",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 8154068,
	"label": "Modulators for her2 signaling in her2 expressing patients with gastric cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8154068,
	"label": "Modulators for her2 signaling in her2 expressing patients with gastric cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 8154068,
	"label": "Modulators for her2 signaling in her2 expressing patients with gastric cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 8154575,
	"label": "Use of DPPIV/Seprase as a marker for cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38237,
	"target": 38232,
	"type": 8154575,
	"label": "Use of DPPIV/Seprase as a marker for cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56833,
	"target": 38237,
	"type": 8154575,
	"label": "Use of DPPIV/Seprase as a marker for cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 38237,
	"type": 8154575,
	"label": "Use of DPPIV/Seprase as a marker for cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56833,
	"target": 38232,
	"type": 8154575,
	"label": "Use of DPPIV/Seprase as a marker for cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 8154934,
	"label": "BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 8155928,
	"label": "HETEROARYL COMPOUNDS AS PIKK INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 8155928,
	"label": "HETEROARYL COMPOUNDS AS PIKK INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8155928,
	"label": "HETEROARYL COMPOUNDS AS PIKK INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8155928,
	"label": "HETEROARYL COMPOUNDS AS PIKK INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6382,
	"type": 8155928,
	"label": "HETEROARYL COMPOUNDS AS PIKK INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 6489,
	"target": 6483,
	"type": 8158446,
	"label": "Oligoribonucleotide or Peptide Nucleic Acid Capable of Inhibiting Activity of Hepatitis C Virus",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6447,
	"type": 8158458,
	"label": "1-(2h)-isoquinolone derivative",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6390,
	"type": 8159533,
	"label": "IMIDAZOPYRAZINE SYK INHIBITORS",
	"group": "Gilead",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 39999,
	"type": 8159538,
	"label": "Secernin-1 as a marker for cancer",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8159539,
	"label": "ANTICUERPOS TRIESPECIFICOS O TETRAESPECIFICOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8159539,
	"label": "ANTICUERPOS TRIESPECIFICOS O TETRAESPECIFICOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8159539,
	"label": "ANTICUERPOS TRIESPECIFICOS O TETRAESPECIFICOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8159539,
	"label": "ANTICUERPOS TRIESPECIFICOS O TETRAESPECIFICOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 8159539,
	"label": "ANTICUERPOS TRIESPECIFICOS O TETRAESPECIFICOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32003,
	"target": 6302,
	"type": 8160385,
	"label": "NOVEL ISOQUINOLINE DERIVATIVES.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8161527,
	"label": "6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8164518,
	"label": "BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6376,
	"target": 6166,
	"type": 8168867,
	"label": "BIOMARKERS FOR IGF-1R INHIBITOR THERAPY",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8168867,
	"label": "BIOMARKERS FOR IGF-1R INHIBITOR THERAPY",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6166,
	"type": 8168867,
	"label": "BIOMARKERS FOR IGF-1R INHIBITOR THERAPY",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 8168867,
	"label": "BIOMARKERS FOR IGF-1R INHIBITOR THERAPY",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8168867,
	"label": "BIOMARKERS FOR IGF-1R INHIBITOR THERAPY",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6229,
	"target": 6164,
	"type": 8170750,
	"label": "VESICLE PREPARATION",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6795,
	"target": 6484,
	"type": 8172426,
	"label": "MODULATION OF AXON DEGENERATION.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 8172907,
	"label": "PEPTIDE-CONTAINING CULTURE MEDIUM FOR CULTURING ANIMAL CELL",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 8172907,
	"label": "PEPTIDE-CONTAINING CULTURE MEDIUM FOR CULTURING ANIMAL CELL",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38181,
	"target": 37878,
	"type": 8172907,
	"label": "PEPTIDE-CONTAINING CULTURE MEDIUM FOR CULTURING ANIMAL CELL",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8173292,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIONES FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 6939,
	"target": 6854,
	"type": 8173292,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIONES FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6939,
	"type": 8173292,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIONES FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 6939,
	"type": 8173292,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIONES FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 8173292,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIONES FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8173294,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIOENS FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 8173294,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIOENS FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7508,
	"target": 6854,
	"type": 8173294,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIOENS FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 8173294,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIOENS FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8173294,
	"label": "METODO Y FORMULACION PARA REDUCIR LA AGREGACION DE UNA MACROMOLECULA BAJO CONDICIOENS FISIOLOGICAS",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7360,
	"target": 6303,
	"type": 8173629,
	"label": "AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8175369,
	"label": "COMPUESTOS DE PIRAZOLOPIRIMIDINA COMO INHIBIDORES DE JAK Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8176692,
	"label": "MÉTODOS DE TRATAMIENTO PARA TUMORES SÓLIDOS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8176692,
	"label": "MÉTODOS DE TRATAMIENTO PARA TUMORES SÓLIDOS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 8176692,
	"label": "MÉTODOS DE TRATAMIENTO PARA TUMORES SÓLIDOS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31939,
	"target": 7510,
	"type": 8176692,
	"label": "MÉTODOS DE TRATAMIENTO PARA TUMORES SÓLIDOS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 8176692,
	"label": "MÉTODOS DE TRATAMIENTO PARA TUMORES SÓLIDOS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8180866,
	"label": "HUMANIZED ANTI-EGFL7 ANTIBODY AND METHOD FOR USING THE SAME",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 8180866,
	"label": "HUMANIZED ANTI-EGFL7 ANTIBODY AND METHOD FOR USING THE SAME",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 8180866,
	"label": "HUMANIZED ANTI-EGFL7 ANTIBODY AND METHOD FOR USING THE SAME",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6290,
	"target": 6263,
	"type": 8181318,
	"label": "Methods for improving pharmacokinetics",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 8181369,
	"label": "METHODS FOR ASSESSING RESPONSIVENESS OF B-CELL LYMPHOMA TO TREATMENT WITH ANTI-CD40 ANTIBODIES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 8181650,
	"label": "FRAGMENTATION RESISTANT IgG1 Fc-CONJUGATES",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 6802,
	"target": 6539,
	"type": 8188121,
	"label": "TERAPIA DE COMBINACIÓN CON PÉPTIDOS EPOXICETONAS PEPTÍDICAS",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6802,
	"type": 8188121,
	"label": "TERAPIA DE COMBINACIÓN CON PÉPTIDOS EPOXICETONAS PEPTÍDICAS",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 8188121,
	"label": "TERAPIA DE COMBINACIÓN CON PÉPTIDOS EPOXICETONAS PEPTÍDICAS",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8188263,
	"label": "ADJUVANT CANCER THERAPY",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 8191498,
	"label": "FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56833,
	"target": 39999,
	"type": 8191498,
	"label": "FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 39999,
	"type": 8191498,
	"label": "FLAP ENDONUCLEASE-1 AS A MARKER FOR CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8192566,
	"label": "A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8193461,
	"label": "COMPUESTOS HETEROCICLICOS COMO INHBIDORES DE BCL-2 Y BCL-XL",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8194051,
	"label": "HETEROCYCLIC COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31939,
	"target": 31912,
	"type": 8194888,
	"label": "4H - PYRIDO [ 1, 2 - A] PYRIMIDIN - 4 - ONE DERIVATIVES AS PI3 K INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 8194888,
	"label": "4H - PYRIDO [ 1, 2 - A] PYRIMIDIN - 4 - ONE DERIVATIVES AS PI3 K INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31939,
	"target": 6371,
	"type": 8194888,
	"label": "4H - PYRIDO [ 1, 2 - A] PYRIMIDIN - 4 - ONE DERIVATIVES AS PI3 K INHIBITORS.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31995,
	"target": 31912,
	"type": 8194889,
	"label": "HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3 K ACTIVITY.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6390,
	"type": 8194889,
	"label": "HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3 K ACTIVITY.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31995,
	"target": 6390,
	"type": 8194889,
	"label": "HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3 K ACTIVITY.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8195657,
	"label": "GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 8199864,
	"label": "DESIGN OF STABLE AND AGGREGATION FREE ANTIBODY FC MOLECULES THROUGH CH3 DOMAIN INTERFACE ENGINEERING",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 8199864,
	"label": "DESIGN OF STABLE AND AGGREGATION FREE ANTIBODY FC MOLECULES THROUGH CH3 DOMAIN INTERFACE ENGINEERING",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 8199864,
	"label": "DESIGN OF STABLE AND AGGREGATION FREE ANTIBODY FC MOLECULES THROUGH CH3 DOMAIN INTERFACE ENGINEERING",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8200132,
	"label": "métodos para o tratamento de leucemia mielóide aguda",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 7508,
	"type": 8200132,
	"label": "métodos para o tratamento de leucemia mielóide aguda",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8200132,
	"label": "métodos para o tratamento de leucemia mielóide aguda",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 8200132,
	"label": "métodos para o tratamento de leucemia mielóide aguda",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 7509,
	"type": 8200132,
	"label": "métodos para o tratamento de leucemia mielóide aguda",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8201579,
	"label": "IMAGERIE DE VASCULARISATION DE TUMEUR IN VIVO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 8202857,
	"label": "POLYCYCLIC DERIVATIVES OF PYRIDINE AND THEIR USE IN THE TREATMENT OF (INTER ALIA) RHEUMATOID ARTHRITIS AND SIMILAR DISEASES.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7511,
	"target": 7510,
	"type": 8202860,
	"label": "DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DEMYELINATING DISEASES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 8202860,
	"label": "DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DEMYELINATING DISEASES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 8202860,
	"label": "DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DEMYELINATING DISEASES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 8202875,
	"label": "DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 8202875,
	"label": "DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8202875,
	"label": "DIAGNOSTIC METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8203019,
	"label": "PROCESS FOR PRODUCING HETEROLOGOUS POLYPEPTIDE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8203019,
	"label": "PROCESS FOR PRODUCING HETEROLOGOUS POLYPEPTIDE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 8203019,
	"label": "PROCESS FOR PRODUCING HETEROLOGOUS POLYPEPTIDE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8203019,
	"label": "PROCESS FOR PRODUCING HETEROLOGOUS POLYPEPTIDE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8203019,
	"label": "PROCESS FOR PRODUCING HETEROLOGOUS POLYPEPTIDE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6281,
	"target": 6272,
	"type": 8207773,
	"label": "Heterocyclic antiviral compounds",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8208565,
	"label": "PROTEINAS BIESPECIFICAS TETRAVALENTES DE UNION A ANTIGENO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 8208565,
	"label": "PROTEINAS BIESPECIFICAS TETRAVALENTES DE UNION A ANTIGENO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8208565,
	"label": "PROTEINAS BIESPECIFICAS TETRAVALENTES DE UNION A ANTIGENO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 8208565,
	"label": "PROTEINAS BIESPECIFICAS TETRAVALENTES DE UNION A ANTIGENO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 8208565,
	"label": "PROTEINAS BIESPECIFICAS TETRAVALENTES DE UNION A ANTIGENO",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 8212546,
	"label": "ATROPISOMERS OF 2-PURINYL-3-TOLYL-QUINAZOLINONE DERIVATIVES AND METHODS OF USE",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8212920,
	"label": "PROTEINAS BIESPECIFICAS DE UNION A ANTIGENOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 8212920,
	"label": "PROTEINAS BIESPECIFICAS DE UNION A ANTIGENOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 8212920,
	"label": "PROTEINAS BIESPECIFICAS DE UNION A ANTIGENOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8212920,
	"label": "PROTEINAS BIESPECIFICAS DE UNION A ANTIGENOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 8212920,
	"label": "PROTEINAS BIESPECIFICAS DE UNION A ANTIGENOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 8213542,
	"label": "USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 7464,
	"type": 8213542,
	"label": "USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 7464,
	"type": 8213542,
	"label": "USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32694,
	"type": 8216516,
	"label": "HEPARIN AFFINITY ERYTHROPOIETIN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 8216516,
	"label": "HEPARIN AFFINITY ERYTHROPOIETIN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 8216516,
	"label": "HEPARIN AFFINITY ERYTHROPOIETIN",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 38065,
	"target": 32770,
	"type": 8218664,
	"label": "ANTIBODIES AGAINST HUMAN CCN1 AND USES THEREOF.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8218664,
	"label": "ANTIBODIES AGAINST HUMAN CCN1 AND USES THEREOF.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38065,
	"target": 7507,
	"type": 8218664,
	"label": "ANTIBODIES AGAINST HUMAN CCN1 AND USES THEREOF.",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 8219652,
	"label": "ANTICORPS ANTI-FGFR3 ET PROCÉDÉS D'UTILISATION DE CEUX-CI",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 8219652,
	"label": "ANTICORPS ANTI-FGFR3 ET PROCÉDÉS D'UTILISATION DE CEUX-CI",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 8219652,
	"label": "ANTICORPS ANTI-FGFR3 ET PROCÉDÉS D'UTILISATION DE CEUX-CI",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8219652,
	"label": "ANTICORPS ANTI-FGFR3 ET PROCÉDÉS D'UTILISATION DE CEUX-CI",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 8219652,
	"label": "ANTICORPS ANTI-FGFR3 ET PROCÉDÉS D'UTILISATION DE CEUX-CI",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8220531,
	"label": "COMPOSICIONES QUE INCLUYEN COMPUESTOS QUE CONTIENEN LA {3-[5-(4-CLORO-FENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DIFLUOR-FENIL}-AMIDA DEL ÁCIDO PROPANO-1-SULFÓNICO Y MÉTODOS PARA FABRICAR ESTAS COMPOSICIONES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8220531,
	"label": "COMPOSICIONES QUE INCLUYEN COMPUESTOS QUE CONTIENEN LA {3-[5-(4-CLORO-FENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DIFLUOR-FENIL}-AMIDA DEL ÁCIDO PROPANO-1-SULFÓNICO Y MÉTODOS PARA FABRICAR ESTAS COMPOSICIONES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 6301,
	"type": 8220531,
	"label": "COMPOSICIONES QUE INCLUYEN COMPUESTOS QUE CONTIENEN LA {3-[5-(4-CLORO-FENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DIFLUOR-FENIL}-AMIDA DEL ÁCIDO PROPANO-1-SULFÓNICO Y MÉTODOS PARA FABRICAR ESTAS COMPOSICIONES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7508,
	"type": 8220531,
	"label": "COMPOSICIONES QUE INCLUYEN COMPUESTOS QUE CONTIENEN LA {3-[5-(4-CLORO-FENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DIFLUOR-FENIL}-AMIDA DEL ÁCIDO PROPANO-1-SULFÓNICO Y MÉTODOS PARA FABRICAR ESTAS COMPOSICIONES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8220531,
	"label": "COMPOSICIONES QUE INCLUYEN COMPUESTOS QUE CONTIENEN LA {3-[5-(4-CLORO-FENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DIFLUOR-FENIL}-AMIDA DEL ÁCIDO PROPANO-1-SULFÓNICO Y MÉTODOS PARA FABRICAR ESTAS COMPOSICIONES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8220535,
	"label": "ANTICORPS ET IMMUNOCONJUGUÉS ANTI-FCRH5 ET PROCÉDÉS D'UTILISATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37904,
	"type": 8220535,
	"label": "ANTICORPS ET IMMUNOCONJUGUÉS ANTI-FCRH5 ET PROCÉDÉS D'UTILISATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37904,
	"target": 32788,
	"type": 8220535,
	"label": "ANTICORPS ET IMMUNOCONJUGUÉS ANTI-FCRH5 ET PROCÉDÉS D'UTILISATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 8220535,
	"label": "ANTICORPS ET IMMUNOCONJUGUÉS ANTI-FCRH5 ET PROCÉDÉS D'UTILISATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 8220535,
	"label": "ANTICORPS ET IMMUNOCONJUGUÉS ANTI-FCRH5 ET PROCÉDÉS D'UTILISATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8223496,
	"label": "Format of probes to detect nucleic acid differences",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 8223496,
	"label": "Format of probes to detect nucleic acid differences",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 8223496,
	"label": "Format of probes to detect nucleic acid differences",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 8223976,
	"label": "Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 8223976,
	"label": "Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 8223976,
	"label": "Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 32771,
	"type": 8223976,
	"label": "Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 32771,
	"type": 8223976,
	"label": "Antibodies to Carcinoembryonic Antigen (CEA), Methods of Making Same, and Uses Thereof",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 32772,
	"type": 8224122,
	"label": "OPTIMIZING THE PRODUCTION OF ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8224156,
	"label": "PROCESS FOR THE MANUFACTURE OF INTERMEDIATES FOR PREPARING PHARMACEUTICALLY ACTIVE COMPOUNDS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8224817,
	"label": "THÉRAPIE ANTI-ANGIOGENÈSE POUR LE TRAITEMENT D'UN CANCER DU SEIN PRÉCÉDEMMENT TRAITÉ",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 8224817,
	"label": "THÉRAPIE ANTI-ANGIOGENÈSE POUR LE TRAITEMENT D'UN CANCER DU SEIN PRÉCÉDEMMENT TRAITÉ",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7425,
	"type": 8224817,
	"label": "THÉRAPIE ANTI-ANGIOGENÈSE POUR LE TRAITEMENT D'UN CANCER DU SEIN PRÉCÉDEMMENT TRAITÉ",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32694,
	"type": 8225851,
	"label": "INMUNOCONJUGADOS DIRIGIDOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 8226328,
	"label": "PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 8226328,
	"label": "PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37878,
	"type": 8226328,
	"label": "PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8226511,
	"label": "POLYTHÉRAPIE À BASE D'UN ANTICORPS AFUCOSYLÉ ANTI-CD20 ET DE BENDAMUSTINE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8226511,
	"label": "POLYTHÉRAPIE À BASE D'UN ANTICORPS AFUCOSYLÉ ANTI-CD20 ET DE BENDAMUSTINE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 8226511,
	"label": "POLYTHÉRAPIE À BASE D'UN ANTICORPS AFUCOSYLÉ ANTI-CD20 ET DE BENDAMUSTINE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 8226921,
	"label": "RESPONSIVENESS TO ANGIOGENESIS INHIBITORS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8226921,
	"label": "RESPONSIVENESS TO ANGIOGENESIS INHIBITORS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 6816,
	"type": 8226921,
	"label": "RESPONSIVENESS TO ANGIOGENESIS INHIBITORS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8226934,
	"label": "TERAPIA COMBINATORIA DE UN ANTICUERPO ANTI-CD20 AFUCOSILADO CON FLUDARABINA Y/O MITOXANTRONA",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 8227856,
	"label": "METHOD AND DEVICE FOR MULTIPLE FEED CULTIVATION",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8228989,
	"label": "ANTIBODIES WITH ENHANCED ADCC FUNCTIONS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 8230913,
	"label": "VELOCITY FACTOR",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8236798,
	"label": "Fructosyl amino acid oxidase",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8236798,
	"label": "Fructosyl amino acid oxidase",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 8236798,
	"label": "Fructosyl amino acid oxidase",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 7360,
	"type": 8237920,
	"label": "A1 ADENOSINE RECEPTOR AGONIST POLYMORPHS",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 39999,
	"target": 7507,
	"type": 8238315,
	"label": "BIOLOGICAL MARKERS FOR MONITORING PATIENT RESPONSE TO VEGF ANTAGONISTS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8241595,
	"label": "N-4(-((3-(2-AMINO-4 PYRIMIDINYL)-2-PYRIDINYL)OXY)PHÉNYL)-4-(4-MÉTHYL-2- THIÉNYL)-1-PHTALAZINAMINE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UN CANCER RÉSISTANT AUX AGENTS ANTIMITOTIQUES",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 6371,
	"target": 6366,
	"type": 8241595,
	"label": "N-4(-((3-(2-AMINO-4 PYRIMIDINYL)-2-PYRIDINYL)OXY)PHÉNYL)-4-(4-MÉTHYL-2- THIÉNYL)-1-PHTALAZINAMINE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UN CANCER RÉSISTANT AUX AGENTS ANTIMITOTIQUES",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8241595,
	"label": "N-4(-((3-(2-AMINO-4 PYRIMIDINYL)-2-PYRIDINYL)OXY)PHÉNYL)-4-(4-MÉTHYL-2- THIÉNYL)-1-PHTALAZINAMINE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UN CANCER RÉSISTANT AUX AGENTS ANTIMITOTIQUES",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 6371,
	"type": 8241595,
	"label": "N-4(-((3-(2-AMINO-4 PYRIMIDINYL)-2-PYRIDINYL)OXY)PHÉNYL)-4-(4-MÉTHYL-2- THIÉNYL)-1-PHTALAZINAMINE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UN CANCER RÉSISTANT AUX AGENTS ANTIMITOTIQUES",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6366,
	"type": 8241595,
	"label": "N-4(-((3-(2-AMINO-4 PYRIMIDINYL)-2-PYRIDINYL)OXY)PHÉNYL)-4-(4-MÉTHYL-2- THIÉNYL)-1-PHTALAZINAMINE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UN CANCER RÉSISTANT AUX AGENTS ANTIMITOTIQUES",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8243063,
	"label": "MACROCYCLIC INHIBITORS OF JAK.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32004,
	"target": 7510,
	"type": 8243063,
	"label": "MACROCYCLIC INHIBITORS OF JAK.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32004,
	"target": 7507,
	"type": 8243063,
	"label": "MACROCYCLIC INHIBITORS OF JAK.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8243076,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING AN EPCAMXCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 8243076,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING AN EPCAMXCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8243076,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING AN EPCAMXCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8243076,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING AN EPCAMXCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 8243076,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING AN EPCAMXCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 8243536,
	"label": "MULTISTEP FINAL FILTRATION",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8244450,
	"label": "ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 8244450,
	"label": "ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 8244450,
	"label": "ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 8244450,
	"label": "ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 7509,
	"type": 8244450,
	"label": "ANTI-VEGF-C ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6292,
	"type": 8245136,
	"label": "COMPOSÉS DE BENZOXÉPINE INHIBITEURS DE PI3K ET LEURS PROCÉDÉS D'UTILISATION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7511,
	"target": 7507,
	"type": 8247970,
	"label": "INHIBITORS OF JAK.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6281,
	"target": 6279,
	"type": 8249607,
	"label": "BENZOXAZEPIN PI3K-INHIBITORFORBINDELSER OG DERES ANVENDELSE I BEHANDLINGEN AF CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6281,
	"type": 8249607,
	"label": "BENZOXAZEPIN PI3K-INHIBITORFORBINDELSER OG DERES ANVENDELSE I BEHANDLINGEN AF CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 8249607,
	"label": "BENZOXAZEPIN PI3K-INHIBITORFORBINDELSER OG DERES ANVENDELSE I BEHANDLINGEN AF CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56740,
	"target": 38232,
	"type": 8249611,
	"label": "A-FUCOSYLATION DETECTION IN ANTIBODIES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 8250743,
	"label": "METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER AGENT",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7358,
	"type": 8254751,
	"label": "Dihydropyrido[4,3-b]pyrazine-3-ones as modulators of toll-like receptors",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8256104,
	"label": "BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 8256104,
	"label": "BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8256104,
	"label": "BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8256104,
	"label": "BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 8256104,
	"label": "BISPECIFIC DEATH RECEPTOR AGONISTIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8257437,
	"label": "ANTICUERPOS ANTI-CDCP1 HUMANIZADOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 8257437,
	"label": "ANTICUERPOS ANTI-CDCP1 HUMANIZADOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 8257437,
	"label": "ANTICUERPOS ANTI-CDCP1 HUMANIZADOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 8257437,
	"label": "ANTICUERPOS ANTI-CDCP1 HUMANIZADOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 8257437,
	"label": "ANTICUERPOS ANTI-CDCP1 HUMANIZADOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8257949,
	"label": "ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8257949,
	"label": "ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8257949,
	"label": "ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 32772,
	"type": 8257949,
	"label": "ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 8257949,
	"label": "ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 8257967,
	"label": "4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8257967,
	"label": "4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6290,
	"type": 8257967,
	"label": "4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 8262765,
	"label": "ANTIBODY CONSTANT REGION VARIANT",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 8262765,
	"label": "ANTIBODY CONSTANT REGION VARIANT",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 8262765,
	"label": "ANTIBODY CONSTANT REGION VARIANT",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 8262766,
	"label": "ANTIBODY CONSTANT REGION VARIANT",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 8265770,
	"label": "SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 8265770,
	"label": "SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 6795,
	"type": 8265770,
	"label": "SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3.",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 6398,
	"target": 6301,
	"type": 8268490,
	"label": "FUSED TRIAZOLE AMINES AS P2X7 MODULATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7409,
	"target": 6398,
	"type": 8268490,
	"label": "FUSED TRIAZOLE AMINES AS P2X7 MODULATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7409,
	"target": 6301,
	"type": 8268490,
	"label": "FUSED TRIAZOLE AMINES AS P2X7 MODULATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 8268490,
	"label": "FUSED TRIAZOLE AMINES AS P2X7 MODULATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6398,
	"type": 8268490,
	"label": "FUSED TRIAZOLE AMINES AS P2X7 MODULATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6539,
	"target": 6478,
	"type": 8268599,
	"label": "METHODS AND COMPOSITIONS FOR DIAGNOSTICS USE IN CANCER PATIENTS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 8268599,
	"label": "METHODS AND COMPOSITIONS FOR DIAGNOSTICS USE IN CANCER PATIENTS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 8268599,
	"label": "METHODS AND COMPOSITIONS FOR DIAGNOSTICS USE IN CANCER PATIENTS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6382,
	"target": 6376,
	"type": 8269827,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 8269827,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8269827,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8269828,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 8269828,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7424,
	"type": 8269828,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7424,
	"target": 6376,
	"type": 8269828,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8269828,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 8269830,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6371,
	"target": 6301,
	"type": 8269832,
	"label": "1H-PYRAZOLO [ 3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 8269832,
	"label": "1H-PYRAZOLO [ 3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7424,
	"target": 6371,
	"type": 8269832,
	"label": "1H-PYRAZOLO [ 3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7424,
	"target": 6301,
	"type": 8269832,
	"label": "1H-PYRAZOLO [ 3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8269832,
	"label": "1H-PYRAZOLO [ 3, 4-B] PYRIDINE COMPOUNDS FOR INHIBITING RAF KINASE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 8271989,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7424,
	"target": 6376,
	"type": 8271989,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8271989,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 8273381,
	"label": "ANTICUERPOS ANTI IL-17F Y METODOS DE USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 6417,
	"type": 8274158,
	"label": "GENE EXPRESSION MARKERS FOR CROHN'S DISEASE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7409,
	"target": 7360,
	"type": 8275542,
	"label": "DIHYDROPYRIMIDONE AMIDES AS P2X7 MODULATORS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 8276030,
	"label": "BETA CELL MARKER ANTIBODY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37878,
	"target": 32770,
	"type": 8276030,
	"label": "BETA CELL MARKER ANTIBODY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8276030,
	"label": "BETA CELL MARKER ANTIBODY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 8276081,
	"label": "TREATMENT OF LIVER DISORDERS WITH PI3K INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 8276081,
	"label": "TREATMENT OF LIVER DISORDERS WITH PI3K INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 7358,
	"type": 8276081,
	"label": "TREATMENT OF LIVER DISORDERS WITH PI3K INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8276480,
	"label": "Set of oligonucleotide probes as well as methods and uses thereto",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56804,
	"target": 38164,
	"type": 8276480,
	"label": "Set of oligonucleotide probes as well as methods and uses thereto",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56804,
	"target": 37986,
	"type": 8276480,
	"label": "Set of oligonucleotide probes as well as methods and uses thereto",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8278721,
	"label": "INHIBITORS OF JNK.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7509,
	"type": 8279795,
	"label": "INHIBITION OF TUMOR METASTASIS USING BV8- OR G-CSF-ANTAGONISTS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6376,
	"target": 6367,
	"type": 8282024,
	"label": "COMPUESTOS HETEROCÍCLICOS FUSIONADOS COMO MODULADORES DE CANALES IÓNICOS, METODO DE TRATAMIENTO Y COMPOSICIONES QUE LOS CONTIENEN",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 6367,
	"target": 6301,
	"type": 8282024,
	"label": "COMPUESTOS HETEROCÍCLICOS FUSIONADOS COMO MODULADORES DE CANALES IÓNICOS, METODO DE TRATAMIENTO Y COMPOSICIONES QUE LOS CONTIENEN",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 8282024,
	"label": "COMPUESTOS HETEROCÍCLICOS FUSIONADOS COMO MODULADORES DE CANALES IÓNICOS, METODO DE TRATAMIENTO Y COMPOSICIONES QUE LOS CONTIENEN",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 8282024,
	"label": "COMPUESTOS HETEROCÍCLICOS FUSIONADOS COMO MODULADORES DE CANALES IÓNICOS, METODO DE TRATAMIENTO Y COMPOSICIONES QUE LOS CONTIENEN",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 8282024,
	"label": "COMPUESTOS HETEROCÍCLICOS FUSIONADOS COMO MODULADORES DE CANALES IÓNICOS, METODO DE TRATAMIENTO Y COMPOSICIONES QUE LOS CONTIENEN",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 6371,
	"type": 8282544,
	"label": "INHIBIDORES DE QUINASA QUE REGULAN LA SEÑAL DE APOPTOSIS COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y UN MÉTODO DE TRATAMIENTO",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 8282544,
	"label": "INHIBIDORES DE QUINASA QUE REGULAN LA SEÑAL DE APOPTOSIS COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y UN MÉTODO DE TRATAMIENTO",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 8282544,
	"label": "INHIBIDORES DE QUINASA QUE REGULAN LA SEÑAL DE APOPTOSIS COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y UN MÉTODO DE TRATAMIENTO",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8287908,
	"label": "Combination treatments",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6539,
	"target": 6229,
	"type": 8287908,
	"label": "Combination treatments",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 8287908,
	"label": "Combination treatments",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 8287908,
	"label": "Combination treatments",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8287908,
	"label": "Combination treatments",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8295535,
	"label": "PROTEÍNAS DE UNIÓN AL ANTÍGENO DE LA IL-23 HUMANA",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 8295535,
	"label": "PROTEÍNAS DE UNIÓN AL ANTÍGENO DE LA IL-23 HUMANA",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 8295535,
	"label": "PROTEÍNAS DE UNIÓN AL ANTÍGENO DE LA IL-23 HUMANA",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37862,
	"target": 7510,
	"type": 8295535,
	"label": "PROTEÍNAS DE UNIÓN AL ANTÍGENO DE LA IL-23 HUMANA",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 7510,
	"type": 8295535,
	"label": "PROTEÍNAS DE UNIÓN AL ANTÍGENO DE LA IL-23 HUMANA",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 8296687,
	"label": "ACTIVIN RECEPTOR-LIKE KINASE-1 ANTAGONIST AND VEGFR3 ANTAGONIST COMBINATIONS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8296687,
	"label": "ACTIVIN RECEPTOR-LIKE KINASE-1 ANTAGONIST AND VEGFR3 ANTAGONIST COMBINATIONS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 8296687,
	"label": "ACTIVIN RECEPTOR-LIKE KINASE-1 ANTAGONIST AND VEGFR3 ANTAGONIST COMBINATIONS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8299000,
	"label": "ANTICUERPO ANTI-AXL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6471,
	"type": 8299000,
	"label": "ANTICUERPO ANTI-AXL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8299000,
	"label": "ANTICUERPO ANTI-AXL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 8299000,
	"label": "ANTICUERPO ANTI-AXL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 6471,
	"type": 8299000,
	"label": "ANTICUERPO ANTI-AXL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 8302037,
	"label": "BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE II COMPOSITIONS AND METHODS OF USE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8302047,
	"label": "ACTIVIN RECEPTOR TYPE IIB COMPOSITIONS AND METHODS OF USE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 39999,
	"target": 32788,
	"type": 8303636,
	"label": "CALIBRATION REAGENT AND USES THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 8303931,
	"label": "GLYCOSYLATED REPEAT-MOTIF-MOLECULE CONJUGATES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 8303931,
	"label": "GLYCOSYLATED REPEAT-MOTIF-MOLECULE CONJUGATES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 32772,
	"type": 8303931,
	"label": "GLYCOSYLATED REPEAT-MOTIF-MOLECULE CONJUGATES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 8303931,
	"label": "GLYCOSYLATED REPEAT-MOTIF-MOLECULE CONJUGATES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 8303931,
	"label": "GLYCOSYLATED REPEAT-MOTIF-MOLECULE CONJUGATES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8303960,
	"label": "N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 8303960,
	"label": "N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 6376,
	"type": 8303960,
	"label": "N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8303962,
	"label": "N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 7508,
	"type": 8303962,
	"label": "N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 8303962,
	"label": "N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8305831,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KIF10 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 7508,
	"type": 8305831,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KIF10 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8305831,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KIF10 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6489,
	"type": 8305831,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KIF10 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 6489,
	"type": 8305831,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KIF10 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 7509,
	"type": 8307466,
	"label": "ANTICUERPOS QUE SE UNEN PREFERENCIALMENTE AL DOMINIO 4 EXTRACELULAR DE CSF 1R HUMANO Y USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8307466,
	"label": "ANTICUERPOS QUE SE UNEN PREFERENCIALMENTE AL DOMINIO 4 EXTRACELULAR DE CSF 1R HUMANO Y USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8307466,
	"label": "ANTICUERPOS QUE SE UNEN PREFERENCIALMENTE AL DOMINIO 4 EXTRACELULAR DE CSF 1R HUMANO Y USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 8307466,
	"label": "ANTICUERPOS QUE SE UNEN PREFERENCIALMENTE AL DOMINIO 4 EXTRACELULAR DE CSF 1R HUMANO Y USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7509,
	"type": 8307466,
	"label": "ANTICUERPOS QUE SE UNEN PREFERENCIALMENTE AL DOMINIO 4 EXTRACELULAR DE CSF 1R HUMANO Y USO DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8310367,
	"label": "OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 8311961,
	"label": "1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 8313126,
	"label": "AGENT FOR PREVENTING FOREARM BONE FRACTURE, WHICH COMPRISES ELDECALCITOL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 8313126,
	"label": "AGENT FOR PREVENTING FOREARM BONE FRACTURE, WHICH COMPRISES ELDECALCITOL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 8313126,
	"label": "AGENT FOR PREVENTING FOREARM BONE FRACTURE, WHICH COMPRISES ELDECALCITOL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 8313127,
	"label": "AGENT FOR PREVENTING NON-TRAUMATIC VERTEBRAL FRACTURE IN SEVERE OSTEOPOROSIS PATIENTS, WHICH COMPRISES ELDECALCITOL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7450,
	"target": 6431,
	"type": 8313127,
	"label": "AGENT FOR PREVENTING NON-TRAUMATIC VERTEBRAL FRACTURE IN SEVERE OSTEOPOROSIS PATIENTS, WHICH COMPRISES ELDECALCITOL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 8313127,
	"label": "AGENT FOR PREVENTING NON-TRAUMATIC VERTEBRAL FRACTURE IN SEVERE OSTEOPOROSIS PATIENTS, WHICH COMPRISES ELDECALCITOL",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8314602,
	"label": "DERIVADOS DE PIRAZOLOPIRIMIDINA COMO INHIBIDORES DE JAK QUINASAS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7360,
	"target": 6301,
	"type": 8315351,
	"label": "AZAINDOLE GLUCOKINASE ACTIVATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 8315351,
	"label": "AZAINDOLE GLUCOKINASE ACTIVATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8315351,
	"label": "AZAINDOLE GLUCOKINASE ACTIVATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 8316396,
	"label": "Ethynyl compounds useful for treatment of CNS disorders",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8317335,
	"label": "Allele-Specific Amplification of Nucleic Acids",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8317420,
	"label": "Novel antibody formulation",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 31056,
	"type": 8317602,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8317602,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31056,
	"target": 7507,
	"type": 8317602,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8317602,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31056,
	"target": 6376,
	"type": 8317602,
	"label": "RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8320721,
	"label": "COMPUESTOS TETRACÍCLICOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8325495,
	"label": "ANTICUERPOS ANTI-HER3 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 8325495,
	"label": "ANTICUERPOS ANTI-HER3 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37859,
	"target": 32772,
	"type": 8325495,
	"label": "ANTICUERPOS ANTI-HER3 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37859,
	"target": 32770,
	"type": 8325495,
	"label": "ANTICUERPOS ANTI-HER3 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32772,
	"type": 8325495,
	"label": "ANTICUERPOS ANTI-HER3 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 8325496,
	"label": "SEQUENCE DEPENDENT AGGREGATION.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8325496,
	"label": "SEQUENCE DEPENDENT AGGREGATION.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8325496,
	"label": "SEQUENCE DEPENDENT AGGREGATION.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 8325496,
	"label": "SEQUENCE DEPENDENT AGGREGATION.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 8325496,
	"label": "SEQUENCE DEPENDENT AGGREGATION.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 8326202,
	"label": "Preferential amplification of mRNA over DNA using chemically modified primers",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8327623,
	"label": "ANTIBODIES FOR TREATING AND DIAGNOSING TUMORS EXPRESSING SLC34A2 (TAT211 = SEQID2 ).",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 8327623,
	"label": "ANTIBODIES FOR TREATING AND DIAGNOSING TUMORS EXPRESSING SLC34A2 (TAT211 = SEQID2 ).",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8327623,
	"label": "ANTIBODIES FOR TREATING AND DIAGNOSING TUMORS EXPRESSING SLC34A2 (TAT211 = SEQID2 ).",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 8327623,
	"label": "ANTIBODIES FOR TREATING AND DIAGNOSING TUMORS EXPRESSING SLC34A2 (TAT211 = SEQID2 ).",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 8327623,
	"label": "ANTIBODIES FOR TREATING AND DIAGNOSING TUMORS EXPRESSING SLC34A2 (TAT211 = SEQID2 ).",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6303,
	"target": 6301,
	"type": 8328252,
	"label": "COMPUESTOS DE ESPIROPIPERIDINA Y USO FARMACEUTICO DE LOS MISMOS PARA EL TRATAMIENTO DE DIABETES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6290,
	"target": 6263,
	"type": 8328366,
	"label": "ESPIROINDOLINONA-PIRROLIDINAS CON ACTIVIDAD SOBRE MDM2",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6371,
	"target": 6290,
	"type": 8328366,
	"label": "ESPIROINDOLINONA-PIRROLIDINAS CON ACTIVIDAD SOBRE MDM2",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6371,
	"target": 6263,
	"type": 8328366,
	"label": "ESPIROINDOLINONA-PIRROLIDINAS CON ACTIVIDAD SOBRE MDM2",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8328366,
	"label": "ESPIROINDOLINONA-PIRROLIDINAS CON ACTIVIDAD SOBRE MDM2",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 8328366,
	"label": "ESPIROINDOLINONA-PIRROLIDINAS CON ACTIVIDAD SOBRE MDM2",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6371,
	"target": 6272,
	"type": 8330735,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6816,
	"target": 6371,
	"type": 8330735,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6816,
	"target": 6272,
	"type": 8330735,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 8330800,
	"label": "PROTEÍNAS DE ENLACE QUE SE ENLAZAN A FGFR1c HUMANO, B(BETA)-KLOTHO HUMANO Y A AMBOS FGFR1c HUMANO Y B(BETA)-KLOTHO HUMANO",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 8330800,
	"label": "PROTEÍNAS DE ENLACE QUE SE ENLAZAN A FGFR1c HUMANO, B(BETA)-KLOTHO HUMANO Y A AMBOS FGFR1c HUMANO Y B(BETA)-KLOTHO HUMANO",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 6795,
	"type": 8330800,
	"label": "PROTEÍNAS DE ENLACE QUE SE ENLAZAN A FGFR1c HUMANO, B(BETA)-KLOTHO HUMANO Y A AMBOS FGFR1c HUMANO Y B(BETA)-KLOTHO HUMANO",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8340701,
	"label": "Multiwell plate and lid",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 8342444,
	"label": "MATERIALES Y MÉTODOS PARA EL TRATAMIENTO O PREVENCIÓN DE ENFERMEDADES ASOCIADAS AL HER-3",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8342444,
	"label": "MATERIALES Y MÉTODOS PARA EL TRATAMIENTO O PREVENCIÓN DE ENFERMEDADES ASOCIADAS AL HER-3",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8342444,
	"label": "MATERIALES Y MÉTODOS PARA EL TRATAMIENTO O PREVENCIÓN DE ENFERMEDADES ASOCIADAS AL HER-3",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8342444,
	"label": "MATERIALES Y MÉTODOS PARA EL TRATAMIENTO O PREVENCIÓN DE ENFERMEDADES ASOCIADAS AL HER-3",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 8342444,
	"label": "MATERIALES Y MÉTODOS PARA EL TRATAMIENTO O PREVENCIÓN DE ENFERMEDADES ASOCIADAS AL HER-3",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8343221,
	"label": "PROTEINAS DE ENLACE DE ANTIGENOS ANTI-ORAI 1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 8343221,
	"label": "PROTEINAS DE ENLACE DE ANTIGENOS ANTI-ORAI 1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8343221,
	"label": "PROTEINAS DE ENLACE DE ANTIGENOS ANTI-ORAI 1 Y USOS DE LAS MISMAS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8343246,
	"label": "PROTÉINES DE LIAISON À ANTIGÈNE HUMAIN QUI SE LIENT À BÊTA-KLOTHO, AUX RÉCEPTEURS DE FGF ET AUX COMPLEXES DE CEUX-CI",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 56836,
	"target": 37993,
	"type": 8343834,
	"label": "MARKER PROTEIN FOR TYPE-2 DIABETES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6333,
	"type": 8344135,
	"label": "SULTAM DERIVATIVES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7360,
	"target": 6303,
	"type": 8344145,
	"label": "AZACYCLIC SPIRO DERIVATIVES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 31081,
	"type": 8348765,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6360,
	"type": 8348765,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 31081,
	"target": 7507,
	"type": 8348765,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8348765,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 31081,
	"target": 6360,
	"type": 8348765,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7511,
	"target": 7510,
	"type": 8349034,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 6489,
	"type": 8349034,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7511,
	"target": 6489,
	"type": 8349034,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32478,
	"type": 8349034,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32478,
	"target": 7511,
	"type": 8349034,
	"label": "COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8350107,
	"label": "METHODS OF TREATING METASTATIC BREAST CANCER WITH TRASTUZUMAB-MCC-DM1",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8350135,
	"label": "METHOD FOR THE DETECTION OF A RNA MOLECULE, KIT AND USE RELATED THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37878,
	"type": 8351341,
	"label": "NON-CROSS-REACTIVE ANTI IgG ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37878,
	"target": 32777,
	"type": 8351341,
	"label": "NON-CROSS-REACTIVE ANTI IgG ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32777,
	"type": 8351341,
	"label": "NON-CROSS-REACTIVE ANTI IgG ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 8351959,
	"label": "METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8351959,
	"label": "METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 32770,
	"type": 8351959,
	"label": "METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8351966,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32779,
	"type": 8351966,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 7508,
	"type": 8351966,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 8351966,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7508,
	"type": 8351966,
	"label": "DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 8352680,
	"label": "MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 8352680,
	"label": "MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 8352680,
	"label": "MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8353455,
	"label": "DERIVADOS DE IMIDAZOPIRIDINA O IMIDAZOPIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 10A",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8353455,
	"label": "DERIVADOS DE IMIDAZOPIRIDINA O IMIDAZOPIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 10A",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8353455,
	"label": "DERIVADOS DE IMIDAZOPIRIDINA O IMIDAZOPIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 10A",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 8353456,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6816,
	"target": 6376,
	"type": 8353456,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6816,
	"target": 6301,
	"type": 8353456,
	"label": "HETEROCYCLIC ANTIVIRAL COMPOUNDS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 8354702,
	"label": "TRATAMIENTO DE CÁNCER DE ANTAGONISTAS NOTCH 1 RESISTENTES UTILIZANDO ANTAGONISTAS NOTCH3",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 8354702,
	"label": "TRATAMIENTO DE CÁNCER DE ANTAGONISTAS NOTCH 1 RESISTENTES UTILIZANDO ANTAGONISTAS NOTCH3",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7508,
	"type": 8354702,
	"label": "TRATAMIENTO DE CÁNCER DE ANTAGONISTAS NOTCH 1 RESISTENTES UTILIZANDO ANTAGONISTAS NOTCH3",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8355237,
	"label": "Use of IL-17 Receptor A antigen binding proteins",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8358250,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF MACROPHAGE-STIMULATING PROTEIN.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8358250,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF MACROPHAGE-STIMULATING PROTEIN.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38232,
	"target": 37862,
	"type": 8358250,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF MACROPHAGE-STIMULATING PROTEIN.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38232,
	"target": 37859,
	"type": 8358250,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF MACROPHAGE-STIMULATING PROTEIN.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37859,
	"target": 7508,
	"type": 8358250,
	"label": "METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF MACROPHAGE-STIMULATING PROTEIN.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8358471,
	"label": "Anti-hepsin antibodies and methods using same",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8358471,
	"label": "Anti-hepsin antibodies and methods using same",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8358471,
	"label": "Anti-hepsin antibodies and methods using same",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8358471,
	"label": "Anti-hepsin antibodies and methods using same",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 8358471,
	"label": "Anti-hepsin antibodies and methods using same",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6476,
	"target": 6382,
	"type": 8358584,
	"label": "ANALOGOS DE CARBA-NUCLEOSIDOS SUSTITUIDOS CON 2'-FLUORO PARA TRATAMIENTO ANTIVIRAL",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8359190,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 8359190,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8359190,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 8359190,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8359190,
	"label": "METHOD FOR PRODUCING A CELL CAPABLE OF HIGH-YIELD PRODUCTION OF HETEROPROTEINS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8361518,
	"label": "COMBINAISONS D'UN INHIBITEUR DE PI3K ET D'UN INHIBITEUR DE MEK",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6550,
	"type": 8361518,
	"label": "COMBINAISONS D'UN INHIBITEUR DE PI3K ET D'UN INHIBITEUR DE MEK",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 6550,
	"type": 8361518,
	"label": "COMBINAISONS D'UN INHIBITEUR DE PI3K ET D'UN INHIBITEUR DE MEK",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8364377,
	"label": "PHARMACEUTICAL COMPOSITION FOR MAINTENANCE THERAPY WHICH CONTAINS ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS-I AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6301,
	"target": 6281,
	"type": 8368891,
	"label": "GAMMA SECRETASE MODULATERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6390,
	"target": 6301,
	"type": 8368891,
	"label": "GAMMA SECRETASE MODULATERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6390,
	"target": 6281,
	"type": 8368891,
	"label": "GAMMA SECRETASE MODULATERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6390,
	"type": 8368891,
	"label": "GAMMA SECRETASE MODULATERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8368891,
	"label": "GAMMA SECRETASE MODULATERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37897,
	"target": 37889,
	"type": 8368919,
	"label": "3D ADCC NK FACS assay",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 37897,
	"type": 8368919,
	"label": "3D ADCC NK FACS assay",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 37889,
	"type": 8368919,
	"label": "3D ADCC NK FACS assay",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8369758,
	"label": "AMINOPYRAZOLE DERIVATIVE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37988,
	"target": 6489,
	"type": 8369924,
	"label": "COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8370269,
	"label": "PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8370269,
	"label": "PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 8370269,
	"label": "PYRIDO[3,2-D]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6303,
	"target": 6263,
	"type": 8373291,
	"label": "SUBSTITUTED SPIROINDOLINONES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 8373291,
	"label": "SUBSTITUTED SPIROINDOLINONES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6263,
	"type": 8373291,
	"label": "SUBSTITUTED SPIROINDOLINONES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 8377087,
	"label": "EXPRESSION VECTOR.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8377087,
	"label": "EXPRESSION VECTOR.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 38065,
	"type": 8377087,
	"label": "EXPRESSION VECTOR.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 8377087,
	"label": "EXPRESSION VECTOR.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 8377087,
	"label": "EXPRESSION VECTOR.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 8378163,
	"label": "Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37897,
	"target": 7507,
	"type": 8378163,
	"label": "Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37897,
	"target": 6962,
	"type": 8378163,
	"label": "Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56740,
	"target": 38232,
	"type": 8379929,
	"label": "METHOD FOR THE DETERMINATION OF SEQUENCE VARIANTS OF POLYPEPTIDES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6489,
	"target": 6483,
	"type": 8380128,
	"label": "THERAPEUTIC METHODS AND COMPOSITIONS",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6489,
	"type": 8380128,
	"label": "THERAPEUTIC METHODS AND COMPOSITIONS",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 8380128,
	"label": "THERAPEUTIC METHODS AND COMPOSITIONS",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 8380128,
	"label": "THERAPEUTIC METHODS AND COMPOSITIONS",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 37875,
	"target": 6489,
	"type": 8380128,
	"label": "THERAPEUTIC METHODS AND COMPOSITIONS",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8381927,
	"label": "ANTICORPS MONOCLONAL ANTI-CD44 DESTINÉ À ÊTRE UTILISÉ POUR TRAITER LE CARCINOME À CELLULES SQUAMEUSES DE LA TÊTE ET DU COU",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 8381927,
	"label": "ANTICORPS MONOCLONAL ANTI-CD44 DESTINÉ À ÊTRE UTILISÉ POUR TRAITER LE CARCINOME À CELLULES SQUAMEUSES DE LA TÊTE ET DU COU",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 8381927,
	"label": "ANTICORPS MONOCLONAL ANTI-CD44 DESTINÉ À ÊTRE UTILISÉ POUR TRAITER LE CARCINOME À CELLULES SQUAMEUSES DE LA TÊTE ET DU COU",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 8381927,
	"label": "ANTICORPS MONOCLONAL ANTI-CD44 DESTINÉ À ÊTRE UTILISÉ POUR TRAITER LE CARCINOME À CELLULES SQUAMEUSES DE LA TÊTE ET DU COU",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8381927,
	"label": "ANTICORPS MONOCLONAL ANTI-CD44 DESTINÉ À ÊTRE UTILISÉ POUR TRAITER LE CARCINOME À CELLULES SQUAMEUSES DE LA TÊTE ET DU COU",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 8383388,
	"label": "TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8383388,
	"label": "TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 8383388,
	"label": "TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6821,
	"target": 6812,
	"type": 8384721,
	"label": "ANALOGUE DU PEPTIDE D'OXYNTOMODULINE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 8389367,
	"label": "METHODS FOR MODULATING A PDGF-AA MEDIATED BIOLOGICAL RESPONSE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8389367,
	"label": "METHODS FOR MODULATING A PDGF-AA MEDIATED BIOLOGICAL RESPONSE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 6812,
	"type": 8389367,
	"label": "METHODS FOR MODULATING A PDGF-AA MEDIATED BIOLOGICAL RESPONSE",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7360,
	"target": 6371,
	"type": 8391721,
	"label": "4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 8391724,
	"label": "TUMOR TISSUE BASED BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8391724,
	"label": "TUMOR TISSUE BASED BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8391724,
	"label": "TUMOR TISSUE BASED BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 7424,
	"type": 8393206,
	"label": "AGENTES Y EPÍTOPOS ENLAZADOS A WISE",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 6816,
	"target": 6476,
	"type": 8393642,
	"label": "Antiviral nucleosides",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 8394352,
	"label": "Compositions and Methods for Inhibiting Expression of IKK2 Genes",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7409,
	"target": 6489,
	"type": 8394352,
	"label": "Compositions and Methods for Inhibiting Expression of IKK2 Genes",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7510,
	"target": 6489,
	"type": 8394352,
	"label": "Compositions and Methods for Inhibiting Expression of IKK2 Genes",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 7510,
	"type": 8394352,
	"label": "Compositions and Methods for Inhibiting Expression of IKK2 Genes",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 7409,
	"type": 8394352,
	"label": "Compositions and Methods for Inhibiting Expression of IKK2 Genes",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8399464,
	"label": "HETEROCYCLIC COMPOUNDS AND THEIR USES.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8402579,
	"label": "IMIDAZOPYRIDINES SYK INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 8402579,
	"label": "IMIDAZOPYRIDINES SYK INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7409,
	"type": 8402579,
	"label": "IMIDAZOPYRIDINES SYK INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7409,
	"target": 6301,
	"type": 8402579,
	"label": "IMIDAZOPYRIDINES SYK INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8402579,
	"label": "IMIDAZOPYRIDINES SYK INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8402768,
	"label": "FRAGMENTS OF THE PA SUBUNIT OF RNA DEPENDENT RNA POLYMERASE FROM PANDEMIC INFLUENZA VIRUS A 2009 H1N1, AND THEIR USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 32612,
	"type": 8402768,
	"label": "FRAGMENTS OF THE PA SUBUNIT OF RNA DEPENDENT RNA POLYMERASE FROM PANDEMIC INFLUENZA VIRUS A 2009 H1N1, AND THEIR USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32612,
	"type": 8402768,
	"label": "FRAGMENTS OF THE PA SUBUNIT OF RNA DEPENDENT RNA POLYMERASE FROM PANDEMIC INFLUENZA VIRUS A 2009 H1N1, AND THEIR USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7425,
	"target": 6407,
	"type": 8404345,
	"label": "ARYL - /HETEROARYL - CYCLOHEXENYL - TETRAAZABENZO [E] AZULENES AS VASOPRESSIN ANTAGONISTS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7497,
	"target": 7358,
	"type": 8405039,
	"label": "INHIBITEURS PEPTIQUES CYCLIQUES DE LA REPLICATION DU VIRUS DE L'HÉPATITE C",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7479,
	"target": 6483,
	"type": 8407646,
	"label": "METHODS AND COMPOSITIONS FOR TREATMENT OF OCULAR FIBROSIS",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8409978,
	"label": "MODIFIED ANTIBODY CONSTANT REGIONS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8409980,
	"label": "ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8409980,
	"label": "ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 8409980,
	"label": "ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8409980,
	"label": "ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 8409980,
	"label": "ANTIBODY CAPABLE OF RECOGNIZING HLA CLASS I",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 8412433,
	"label": "COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8412433,
	"label": "COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8412433,
	"label": "COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8412433,
	"label": "COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 8412433,
	"label": "COILED COIL AND/OR TETHER CONTAINING PROTEIN COMPLEXES AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8415765,
	"label": "BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8415765,
	"label": "BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 8415765,
	"label": "BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 8415765,
	"label": "BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 8415765,
	"label": "BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8415766,
	"label": "BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8415766,
	"label": "BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 32779,
	"type": 8415766,
	"label": "BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 8415766,
	"label": "BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8415766,
	"label": "BISPECIFIC ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7431,
	"target": 6407,
	"type": 8415783,
	"label": "ARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6371,
	"target": 6301,
	"type": 8417197,
	"label": "IMIDAZOPYRIDINE AND PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 8417197,
	"label": "IMIDAZOPYRIDINE AND PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8417197,
	"label": "IMIDAZOPYRIDINE AND PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8417630,
	"label": "CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 8417630,
	"label": "CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8417630,
	"label": "CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 8417630,
	"label": "CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 8417630,
	"label": "CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7360,
	"target": 6303,
	"type": 8419831,
	"label": "AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8422687,
	"label": "DETERGENT FREE POLYMERASES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 8424223,
	"label": "ANTI-LRP6 ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37859,
	"target": 32770,
	"type": 8424223,
	"label": "ANTI-LRP6 ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8424223,
	"label": "ANTI-LRP6 ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8424223,
	"label": "ANTI-LRP6 ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 8424223,
	"label": "ANTI-LRP6 ANTIBODIES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8426884,
	"label": "Pyrrolopyrazine kinase inhibitors",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8426886,
	"label": "DÉRIVÉS DE N-(IMIDAZOPYRIMIDIN-7-YL)HÉTÉROARYLAMIDE ET LEUR UTILISATION COMME INHIBITEURS DE PDE10A)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6229,
	"target": 6215,
	"type": 8428342,
	"label": "THÉRAPIE ANTI-ANGIOGÉNIQUE POUR LE TRAITEMENT DU CANCER DES OVAIRES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 8428342,
	"label": "THÉRAPIE ANTI-ANGIOGÉNIQUE POUR LE TRAITEMENT DU CANCER DES OVAIRES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6215,
	"type": 8428342,
	"label": "THÉRAPIE ANTI-ANGIOGÉNIQUE POUR LE TRAITEMENT DU CANCER DES OVAIRES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8429100,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8429100,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8429100,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8429100,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8429100,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7509,
	"type": 8429101,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8429101,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8429101,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8429101,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8429101,
	"label": "ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8429291,
	"label": "DETERMINING SENSITIVITY OF CELLS TO B-RAF INHIBITOR TREATMENT BY DETECTING KRAS MUTATION AND RTK EXPRESSION LEVELS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 8429557,
	"label": "ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8430431,
	"label": "COMPOSITIONS ET METHODES POUR LE DIAGNOSTIC ET LE TRAITEMENT D'UNE TUMEUR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 8430431,
	"label": "COMPOSITIONS ET METHODES POUR LE DIAGNOSTIC ET LE TRAITEMENT D'UNE TUMEUR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 8430431,
	"label": "COMPOSITIONS ET METHODES POUR LE DIAGNOSTIC ET LE TRAITEMENT D'UNE TUMEUR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8430431,
	"label": "COMPOSITIONS ET METHODES POUR LE DIAGNOSTIC ET LE TRAITEMENT D'UNE TUMEUR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 8430431,
	"label": "COMPOSITIONS ET METHODES POUR LE DIAGNOSTIC ET LE TRAITEMENT D'UNE TUMEUR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 8431233,
	"label": "NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING CANCER.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38042,
	"target": 7507,
	"type": 8431233,
	"label": "NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING CANCER.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38042,
	"target": 6483,
	"type": 8431233,
	"label": "NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING CANCER.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8438932,
	"label": "ANTI-BV8 ANTIBODIES AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 7509,
	"type": 8438932,
	"label": "ANTI-BV8 ANTIBODIES AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 8438932,
	"label": "ANTI-BV8 ANTIBODIES AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8440551,
	"label": "Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 6816,
	"target": 6302,
	"type": 8441833,
	"label": "ANTIVIRAL COMPOUNDS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 7497,
	"target": 6816,
	"type": 8445221,
	"label": "METHODS OF TREATING HBV AND HCV INFECTION",
	"group": "Gilead",
	"time": 2010,
	"strength": 1
}, {
	"source": 6795,
	"target": 6489,
	"type": 8450168,
	"label": "COMBINATION THERAPY AND METHOD FOR ASSESSING RESISTANCE TO TREATMENT.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 8450168,
	"label": "COMBINATION THERAPY AND METHOD FOR ASSESSING RESISTANCE TO TREATMENT.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6489,
	"type": 8450168,
	"label": "COMBINATION THERAPY AND METHOD FOR ASSESSING RESISTANCE TO TREATMENT.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8450168,
	"label": "COMBINATION THERAPY AND METHOD FOR ASSESSING RESISTANCE TO TREATMENT.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 6795,
	"type": 8450168,
	"label": "COMBINATION THERAPY AND METHOD FOR ASSESSING RESISTANCE TO TREATMENT.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8451092,
	"label": "PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 8451092,
	"label": "PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7409,
	"type": 8451092,
	"label": "PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56836,
	"target": 56834,
	"type": 8451645,
	"label": "ANTI-C-MPL ANTIBODIES",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 8451645,
	"label": "ANTI-C-MPL ANTIBODIES",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8451645,
	"label": "ANTI-C-MPL ANTIBODIES",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 8451645,
	"label": "ANTI-C-MPL ANTIBODIES",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 8451645,
	"label": "ANTI-C-MPL ANTIBODIES",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32003,
	"target": 31995,
	"type": 8452052,
	"label": "COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31995,
	"target": 6279,
	"type": 8452052,
	"label": "COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32003,
	"target": 6279,
	"type": 8452052,
	"label": "COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37988,
	"target": 6816,
	"type": 8455820,
	"label": "SINGLE NUCLEOTIDE POLYMORPHISMS THAT PREDICT HCV TREATMENT OUTCOMES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 8458469,
	"label": "DIAGNOSTIC METHOD FOR THE DETECTION OF CELLS EX VIVO.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6957,
	"target": 6403,
	"type": 8462109,
	"label": "Deuterated 5,6-dihydro-1H-pyridin-2-one compounds",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 8464844,
	"label": "ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32788,
	"type": 8464844,
	"label": "ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 8464844,
	"label": "ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 56833,
	"target": 37993,
	"type": 8464844,
	"label": "ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 56833,
	"target": 32788,
	"type": 8464844,
	"label": "ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 8467107,
	"label": "COMPOSITIONS AND METHODS USEFUL FOR REDUCING THE VISCOSITY OF PROTEIN-CONTAINING FORMULATIONS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8468989,
	"label": "PRODUCTION OF HETEROMULTIMERIC PROTEINS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 8468989,
	"label": "PRODUCTION OF HETEROMULTIMERIC PROTEINS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8468989,
	"label": "PRODUCTION OF HETEROMULTIMERIC PROTEINS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 8468989,
	"label": "PRODUCTION OF HETEROMULTIMERIC PROTEINS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32771,
	"type": 8468989,
	"label": "PRODUCTION OF HETEROMULTIMERIC PROTEINS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7409,
	"target": 6341,
	"type": 8470033,
	"label": "?ANÁLOGOS DE QUINOLINA BI?FUNCIONALES, SU USO EN LA MANUFACTURA DE MEDICAMENTOS,COMPOSICIONES QUE LOS COMPRENDEN Y PROCESOS DE PREPARACION?.",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6371,
	"target": 6302,
	"type": 8470034,
	"label": "ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 39999,
	"target": 38164,
	"type": 8471572,
	"label": "CLONAL PRE-AMPLIFICATION IN EMULSION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 8472173,
	"label": "ANTICUERPOS ESPECIFICAMENTE LIGANTES DEL TSLPR HUMANO Y METODOS DE UTILIZACION DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 8472173,
	"label": "ANTICUERPOS ESPECIFICAMENTE LIGANTES DEL TSLPR HUMANO Y METODOS DE UTILIZACION DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 8472173,
	"label": "ANTICUERPOS ESPECIFICAMENTE LIGANTES DEL TSLPR HUMANO Y METODOS DE UTILIZACION DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 8472173,
	"label": "ANTICUERPOS ESPECIFICAMENTE LIGANTES DEL TSLPR HUMANO Y METODOS DE UTILIZACION DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8472173,
	"label": "ANTICUERPOS ESPECIFICAMENTE LIGANTES DEL TSLPR HUMANO Y METODOS DE UTILIZACION DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8472918,
	"label": "CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 7511,
	"type": 8472981,
	"label": "GENE EXPRESSION MARKERS FOR PREDICTING RESPONSE TO INTERLEUKIN-6 RECEPTOR-INHIBITING MONOCLONAL ANTIBODY DRUG TREATMENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8473098,
	"label": "METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED PATIENTS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6376,
	"target": 6367,
	"type": 8475616,
	"label": "HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6816,
	"target": 6376,
	"type": 8475616,
	"label": "HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6816,
	"target": 6367,
	"type": 8475616,
	"label": "HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 8475616,
	"label": "HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 7358,
	"target": 6376,
	"type": 8475616,
	"label": "HETEROCYCLIC FLAVIVIRIDAE VIRUS INHIBITORS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 7360,
	"target": 6303,
	"type": 8480841,
	"label": "NEW AZACYCLIC COMPOUNDS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 8480853,
	"label": "PYRAZOLO [1, 5A] PYRIMIDINE AND THIENO [3, 2B] PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 6466,
	"type": 8480970,
	"label": "COMPOSITIONS AND METHODS CONTAINING ALKYLGYCOSIDES FOR STABILIZING PROTEIN- CONTAINING FORMULATIONS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8483358,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8483362,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 8483363,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37988,
	"type": 8483363,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8483363,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8483364,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8483365,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8483366,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8483367,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8483369,
	"label": "DNA POLYMERASES WITH INCREASED 3'-MISMATCH DISCRIMINATION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6290,
	"target": 6263,
	"type": 8483770,
	"label": "3-OXO-3,9-DIHYDRO-1H-CHROMENO[2,3-C]PYRROLES AS GLUCOKINASE ACTIVATORS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6302,
	"target": 6301,
	"type": 8483778,
	"label": "QUINOLIZIDINE AND INDOLIZIDINE DERIVATIVES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 8483778,
	"label": "QUINOLIZIDINE AND INDOLIZIDINE DERIVATIVES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8483778,
	"label": "QUINOLIZIDINE AND INDOLIZIDINE DERIVATIVES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37897,
	"type": 8484122,
	"label": "METHOD FOR SEARCHING AND SCREENING FOR TARGET OF ANTI-CANCER AGENT USING NON-HUMAN ANIMAL MODEL HAVING NOG ESTABLISHED CANCER CELL LINE TRANSPLANTED THEREIN",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8484152,
	"label": "POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8484152,
	"label": "POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 8484152,
	"label": "POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8484152,
	"label": "POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8484152,
	"label": "POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 8484778,
	"label": "3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 8486054,
	"label": "COMPUESTOS PYRAZOLO[1,5-A]PIRIMIDINAS PARA TRATAMIENTO ANTIVIRAL DEL VIRUS SINCICIAL RESPIRATORIO HUMANO, SUS COMPOSICIONES Y MÉTODOS DE PRODUCCIÓN.",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6263,
	"type": 8486149,
	"label": "N-SUBSTITUTED PYRROLIDINES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8486149,
	"label": "N-SUBSTITUTED PYRROLIDINES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6263,
	"type": 8486149,
	"label": "N-SUBSTITUTED PYRROLIDINES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 8487482,
	"label": "DERIVADOS HETEROCICLICOS DE DIHIDRO-PIRIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA EL TRATAMIENTO DE LA INFECCION POR VHC",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8487778,
	"label": "SCNN1A/TNFRSF1A FUSION PROTEINS IN CANCER",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 8490744,
	"label": "NOVEL TETRAHYDROQUINOLINE DERIVATIVES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8490744,
	"label": "NOVEL TETRAHYDROQUINOLINE DERIVATIVES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 8490744,
	"label": "NOVEL TETRAHYDROQUINOLINE DERIVATIVES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6290,
	"target": 6281,
	"type": 8495512,
	"label": "UN RÉGIMEN DE DOSIFICACIÓN, MÉTODOS PARA TRATAR EL VIRUS DE LA HEPATITIS C, COMPOSICIÓN FARMACÉUTICA, COMPUESTA, COMPUESTOS ANTI-HCV Y KIT",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6301,
	"target": 6290,
	"type": 8495512,
	"label": "UN RÉGIMEN DE DOSIFICACIÓN, MÉTODOS PARA TRATAR EL VIRUS DE LA HEPATITIS C, COMPOSICIÓN FARMACÉUTICA, COMPUESTA, COMPUESTOS ANTI-HCV Y KIT",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6301,
	"target": 6281,
	"type": 8495512,
	"label": "UN RÉGIMEN DE DOSIFICACIÓN, MÉTODOS PARA TRATAR EL VIRUS DE LA HEPATITIS C, COMPOSICIÓN FARMACÉUTICA, COMPUESTA, COMPUESTOS ANTI-HCV Y KIT",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8495512,
	"label": "UN RÉGIMEN DE DOSIFICACIÓN, MÉTODOS PARA TRATAR EL VIRUS DE LA HEPATITIS C, COMPOSICIÓN FARMACÉUTICA, COMPUESTA, COMPUESTOS ANTI-HCV Y KIT",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6290,
	"type": 8495512,
	"label": "UN RÉGIMEN DE DOSIFICACIÓN, MÉTODOS PARA TRATAR EL VIRUS DE LA HEPATITIS C, COMPOSICIÓN FARMACÉUTICA, COMPUESTA, COMPUESTOS ANTI-HCV Y KIT",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8496992,
	"label": "MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 8496992,
	"label": "MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 8496992,
	"label": "MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8496992,
	"label": "MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 8496992,
	"label": "MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32772,
	"type": 8498465,
	"label": "PREDICTING RESPONSE TO A HER INHIBITOR",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6360,
	"type": 8498963,
	"label": "COMPOSÉS DE PYRIDONE ET D'AZA-PYRIDONE ET LEURS PROCÉDÉS D'UTILISATION",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37897,
	"type": 8501324,
	"label": "ENHANCED DEATH RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37897,
	"target": 32770,
	"type": 8501324,
	"label": "ENHANCED DEATH RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8501324,
	"label": "ENHANCED DEATH RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8501324,
	"label": "ENHANCED DEATH RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37897,
	"target": 7507,
	"type": 8501324,
	"label": "ENHANCED DEATH RECEPTOR AGONISTS.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8505457,
	"label": "MONOMERIC ANTIBODY FC.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8505457,
	"label": "MONOMERIC ANTIBODY FC.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 8505457,
	"label": "MONOMERIC ANTIBODY FC.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8505457,
	"label": "MONOMERIC ANTIBODY FC.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8505457,
	"label": "MONOMERIC ANTIBODY FC.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 56765,
	"target": 38184,
	"type": 8507307,
	"label": "Single B-cell cultivation method and specific antibody production",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8508034,
	"label": "TARGETED BINDING AGENTS AGAINST B7-H1.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8508034,
	"label": "TARGETED BINDING AGENTS AGAINST B7-H1.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 8508034,
	"label": "TARGETED BINDING AGENTS AGAINST B7-H1.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8508034,
	"label": "TARGETED BINDING AGENTS AGAINST B7-H1.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 8508034,
	"label": "TARGETED BINDING AGENTS AGAINST B7-H1.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7409,
	"target": 6301,
	"type": 8508770,
	"label": "?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7409,
	"type": 8508770,
	"label": "?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8508770,
	"label": "?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 8509396,
	"label": "Composiciones y métodos para el diagnóstico y tratamiento de tumores",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 37864,
	"type": 8509396,
	"label": "Composiciones y métodos para el diagnóstico y tratamiento de tumores",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 8509396,
	"label": "Composiciones y métodos para el diagnóstico y tratamiento de tumores",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8509396,
	"label": "Composiciones y métodos para el diagnóstico y tratamiento de tumores",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 8509396,
	"label": "Composiciones y métodos para el diagnóstico y tratamiento de tumores",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7360,
	"target": 6819,
	"type": 8514619,
	"label": "CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 7360,
	"type": 8514619,
	"label": "CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 6819,
	"type": 8514619,
	"label": "CHIMERIC FIBROBLAST GROWTH FACTORS WITH ALTERED RECEPTOR SPECIFICITY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 8517406,
	"label": "METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 8517844,
	"label": "METHOD FOR THE SELECTION OF A LONG-TERM PRODUCING CELL.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37988,
	"type": 8517844,
	"label": "METHOD FOR THE SELECTION OF A LONG-TERM PRODUCING CELL.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 8517844,
	"label": "METHOD FOR THE SELECTION OF A LONG-TERM PRODUCING CELL.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8518515,
	"label": "COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6299,
	"type": 8518515,
	"label": "COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 6299,
	"type": 8518515,
	"label": "COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8519243,
	"label": "Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7425,
	"target": 7380,
	"type": 8519247,
	"label": "HETÉROARYL-CYCLOHEXYL-TÉTRAAZABENZO[E)AZULÈNES COMME ANTAGONISTES DES RÉCEPTEURS DE LA VASOPRESSINE V1A",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7380,
	"target": 6407,
	"type": 8519247,
	"label": "HETÉROARYL-CYCLOHEXYL-TÉTRAAZABENZO[E)AZULÈNES COMME ANTAGONISTES DES RÉCEPTEURS DE LA VASOPRESSINE V1A",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7425,
	"target": 6407,
	"type": 8519247,
	"label": "HETÉROARYL-CYCLOHEXYL-TÉTRAAZABENZO[E)AZULÈNES COMME ANTAGONISTES DES RÉCEPTEURS DE LA VASOPRESSINE V1A",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7358,
	"target": 6407,
	"type": 8521330,
	"label": "HETEROBIARYL-CYCLOHEXYL-TETRAAZABENZO[E]AZULENES.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 31912,
	"type": 8525499,
	"label": "DERIVADOS DE BENCIMIDAZOL E IMIDAZO[1,2-A]PIRIDINA, COMPOSICION FARMACEUTICA QUE LOS CONTIENE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR DISFUNCION DE PI3Kd",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 8525499,
	"label": "DERIVADOS DE BENCIMIDAZOL E IMIDAZO[1,2-A]PIRIDINA, COMPOSICION FARMACEUTICA QUE LOS CONTIENE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR DISFUNCION DE PI3Kd",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31939,
	"target": 6371,
	"type": 8525499,
	"label": "DERIVADOS DE BENCIMIDAZOL E IMIDAZO[1,2-A]PIRIDINA, COMPOSICION FARMACEUTICA QUE LOS CONTIENE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR DISFUNCION DE PI3Kd",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8526771,
	"label": "Novel T7 RNA polymerase variants with enhanced thermostability",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8526771,
	"label": "Novel T7 RNA polymerase variants with enhanced thermostability",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 8526771,
	"label": "Novel T7 RNA polymerase variants with enhanced thermostability",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8526771,
	"label": "Novel T7 RNA polymerase variants with enhanced thermostability",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37899,
	"type": 8526771,
	"label": "Novel T7 RNA polymerase variants with enhanced thermostability",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6371,
	"target": 6263,
	"type": 8527251,
	"label": "SPIROINDOLINONE PYRROLIDINES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 8528125,
	"label": "THROMBOPOIETIC COMPOUNDS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 8528125,
	"label": "THROMBOPOIETIC COMPOUNDS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 8528125,
	"label": "THROMBOPOIETIC COMPOUNDS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 37864,
	"target": 32788,
	"type": 8528125,
	"label": "THROMBOPOIETIC COMPOUNDS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 8528125,
	"label": "THROMBOPOIETIC COMPOUNDS",
	"group": "Amgen",
	"time": 2010,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 8529304,
	"label": "BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37875,
	"target": 6812,
	"type": 8529304,
	"label": "BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 6812,
	"type": 8529304,
	"label": "BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8529306,
	"label": "HUMAN FGF RECEPTOR AND .BETA.-KLOTHO BINDING PROTEINS",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 8529306,
	"label": "HUMAN FGF RECEPTOR AND .BETA.-KLOTHO BINDING PROTEINS",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8529306,
	"label": "HUMAN FGF RECEPTOR AND .BETA.-KLOTHO BINDING PROTEINS",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 8529392,
	"label": "FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56833,
	"target": 7507,
	"type": 8529392,
	"label": "FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8529392,
	"label": "FOX03A AS PREDICTIVE BIOMARKER FOR PI3K/AKT KINASE PATHWAY INHIBITOR EFFICACY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8532631,
	"label": "ACTIVATABLE BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 8532631,
	"label": "ACTIVATABLE BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8532631,
	"label": "ACTIVATABLE BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8532631,
	"label": "ACTIVATABLE BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 8532631,
	"label": "ACTIVATABLE BISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8532633,
	"label": "ANTICUERPOS CONTRA IL-18R1 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 7409,
	"type": 8532633,
	"label": "ANTICUERPOS CONTRA IL-18R1 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8532633,
	"label": "ANTICUERPOS CONTRA IL-18R1 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8532633,
	"label": "ANTICUERPOS CONTRA IL-18R1 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8532633,
	"label": "ANTICUERPOS CONTRA IL-18R1 Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 8532636,
	"label": "PROKARYOTIC EXPRESSION CONSTRUCT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 8532636,
	"label": "PROKARYOTIC EXPRESSION CONSTRUCT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 8532636,
	"label": "PROKARYOTIC EXPRESSION CONSTRUCT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 8532636,
	"label": "PROKARYOTIC EXPRESSION CONSTRUCT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 8532636,
	"label": "PROKARYOTIC EXPRESSION CONSTRUCT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8532644,
	"label": "RECOMBINANT FC-FUSION PROTEIN OF THE FIFTH FIBRONECTIN TYPE III DOMAIN OF DCC.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8532644,
	"label": "RECOMBINANT FC-FUSION PROTEIN OF THE FIFTH FIBRONECTIN TYPE III DOMAIN OF DCC.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 8532644,
	"label": "RECOMBINANT FC-FUSION PROTEIN OF THE FIFTH FIBRONECTIN TYPE III DOMAIN OF DCC.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 8532644,
	"label": "RECOMBINANT FC-FUSION PROTEIN OF THE FIFTH FIBRONECTIN TYPE III DOMAIN OF DCC.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 37862,
	"type": 8532644,
	"label": "RECOMBINANT FC-FUSION PROTEIN OF THE FIFTH FIBRONECTIN TYPE III DOMAIN OF DCC.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 8534462,
	"label": "ALKALINE FEED",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8535363,
	"label": "CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) BIOMARKERS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 8535363,
	"label": "CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) BIOMARKERS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 7508,
	"type": 8535363,
	"label": "CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) BIOMARKERS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37900,
	"target": 37899,
	"type": 8535384,
	"label": "ANTI-HUMAN IGG1 ANTIBODY.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 32777,
	"type": 8535384,
	"label": "ANTI-HUMAN IGG1 ANTIBODY.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37900,
	"target": 32777,
	"type": 8535384,
	"label": "ANTI-HUMAN IGG1 ANTIBODY.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56836,
	"target": 37900,
	"type": 8535384,
	"label": "ANTI-HUMAN IGG1 ANTIBODY.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 8535384,
	"label": "ANTI-HUMAN IGG1 ANTIBODY.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8536488,
	"label": "ANTIBODY CONSTANT REGION VARIANT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 8536488,
	"label": "ANTIBODY CONSTANT REGION VARIANT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 7510,
	"type": 8536488,
	"label": "ANTIBODY CONSTANT REGION VARIANT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7511,
	"target": 6854,
	"type": 8537336,
	"label": "ANTIBODIES TO IL-1.BETA. AND IL-18, FOR TREATMENT OF DISEASE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 8538362,
	"label": "Dipeptides to enhance yield and viability from cell cultures",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 8538380,
	"label": "Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 8538380,
	"label": "Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56836,
	"target": 37986,
	"type": 8538380,
	"label": "Anticuerpos peptídicos beta amiloide anti-n3p glu y usos de los mismos",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8538724,
	"label": "ANTI-ICAM3 ANTIBODY AND USE THEREOF",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8538724,
	"label": "ANTI-ICAM3 ANTIBODY AND USE THEREOF",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 8538724,
	"label": "ANTI-ICAM3 ANTIBODY AND USE THEREOF",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8538724,
	"label": "ANTI-ICAM3 ANTIBODY AND USE THEREOF",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 7508,
	"type": 8538724,
	"label": "ANTI-ICAM3 ANTIBODY AND USE THEREOF",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8538857,
	"label": "USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7422,
	"target": 6962,
	"type": 8538857,
	"label": "USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32772,
	"type": 8538857,
	"label": "USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8538857,
	"label": "USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7422,
	"type": 8538857,
	"label": "USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8539013,
	"label": "A method to identify a patient with an increased likelihood of responding to an anti-cancer therapy",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32004,
	"target": 32003,
	"type": 8540375,
	"label": "Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 6301,
	"target": 6299,
	"type": 8540375,
	"label": "Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32003,
	"target": 6301,
	"type": 8540375,
	"label": "Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32004,
	"target": 6301,
	"type": 8540375,
	"label": "Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32003,
	"target": 6299,
	"type": 8540375,
	"label": "Derivatives of 1H-isoindol-3-amine, 1H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as Beta-secretase Inhibitors",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8540998,
	"label": "TERAPIA DE COMBINACION, PRODUCTO FARMACEUTICO, KIT Y USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8541017,
	"label": "TERAPIA DE COMBINACION DE UN ANTICUERPO ANTI-CD20 AFUCOSILADO CON UN ANTICUERPO ANTI-VEGF",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 8541017,
	"label": "TERAPIA DE COMBINACION DE UN ANTICUERPO ANTI-CD20 AFUCOSILADO CON UN ANTICUERPO ANTI-VEGF",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8541017,
	"label": "TERAPIA DE COMBINACION DE UN ANTICUERPO ANTI-CD20 AFUCOSILADO CON UN ANTICUERPO ANTI-VEGF",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8542575,
	"label": "CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS)",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 6566,
	"type": 8542575,
	"label": "CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS)",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 6566,
	"type": 8542575,
	"label": "CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS)",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6539,
	"target": 6478,
	"type": 8543473,
	"label": "NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 8543473,
	"label": "NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 8543473,
	"label": "NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37947,
	"target": 7509,
	"type": 8544109,
	"label": "Methods and compositions for modulating hepatocyte growth factor activator",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38042,
	"target": 6795,
	"type": 8545476,
	"label": "METHOD FOR PRODUCING A TETRANECTIN-APOLIPOPROTEIN A-I PARTICLE, THE LIPID PARTICLE OBTAINED THEREWITH AND ITS USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 8545596,
	"label": "Antibodies That Bind Myostatin, Compositions And Methods",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 8547043,
	"label": "BISPECIFIC ANTIBODIES COMPRISING A DISULFIDE STABILIZED - FV FRAGMENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 8547043,
	"label": "BISPECIFIC ANTIBODIES COMPRISING A DISULFIDE STABILIZED - FV FRAGMENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8547043,
	"label": "BISPECIFIC ANTIBODIES COMPRISING A DISULFIDE STABILIZED - FV FRAGMENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 8547043,
	"label": "BISPECIFIC ANTIBODIES COMPRISING A DISULFIDE STABILIZED - FV FRAGMENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32772,
	"type": 8547043,
	"label": "BISPECIFIC ANTIBODIES COMPRISING A DISULFIDE STABILIZED - FV FRAGMENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 8548932,
	"label": "METHODS FOR NUCLEIC ACID CAPTURE AND SEQUENCING",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 8550186,
	"label": "SUBSTITUTED HEXAHYDROPYRROLO [1, 2 - C] IMIDAZOLONES USEFUL AS MDM2 INHIBITORS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8552944,
	"label": "Generic Buffer For Amplification",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8553283,
	"label": "ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37862,
	"target": 32771,
	"type": 8553283,
	"label": "ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37864,
	"target": 32771,
	"type": 8553283,
	"label": "ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 8553283,
	"label": "ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 8553283,
	"label": "ANTI-TENASCIN-C A2 ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31570,
	"target": 6382,
	"type": 8553361,
	"label": "PROCÉDÉS ET COMPOSÉS POUR TRAITER DES INFECTIONS À VIRUS PARAMYXOVIRIDAE",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 7360,
	"target": 6303,
	"type": 8555513,
	"label": "DERIVADOS DE 2,8-DIAZA-ESPIRO[4,5]DECAN-1-ONA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN, PROCESO PARA PREPARARLOS Y USO DE LOS MISMOS PARA TRATAR DIABETES, OBESIDAD, DISLIPEMIA Y SINDROME METABOLICO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8556239,
	"label": "GENERIC PCR",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8556380,
	"label": "ANTI-MHC ANTIBODY ANTI-VIRAL CYTOKINE FUSION PROTEIN.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 8556380,
	"label": "ANTI-MHC ANTIBODY ANTI-VIRAL CYTOKINE FUSION PROTEIN.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 8556380,
	"label": "ANTI-MHC ANTIBODY ANTI-VIRAL CYTOKINE FUSION PROTEIN.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8556380,
	"label": "ANTI-MHC ANTIBODY ANTI-VIRAL CYTOKINE FUSION PROTEIN.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 8556380,
	"label": "ANTI-MHC ANTIBODY ANTI-VIRAL CYTOKINE FUSION PROTEIN.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 8559535,
	"label": "HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8559535,
	"label": "HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 8559535,
	"label": "HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 6281,
	"type": 8559543,
	"label": "APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 37988,
	"target": 6489,
	"type": 8560064,
	"label": "SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8567667,
	"label": "Antibodies that Bind to Lysyl Oxidase-Like 2 (LOXL2) and Methods of Use Therefor",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 56833,
	"target": 7509,
	"type": 8567667,
	"label": "Antibodies that Bind to Lysyl Oxidase-Like 2 (LOXL2) and Methods of Use Therefor",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 56833,
	"target": 7507,
	"type": 8567667,
	"label": "Antibodies that Bind to Lysyl Oxidase-Like 2 (LOXL2) and Methods of Use Therefor",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6301,
	"target": 6263,
	"type": 8571318,
	"label": "SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 8571318,
	"label": "SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6376,
	"target": 6263,
	"type": 8571318,
	"label": "SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8571318,
	"label": "SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8571318,
	"label": "SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56833,
	"target": 38237,
	"type": 8572138,
	"label": "METHOD FOR THE IDENTIFICATION OF CATECHOL O-METHYLTRANSFERASE MODULATORS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 8572452,
	"label": "ANTICUERPOS ANTI-FAP (PROTEINA DE ACTIVACION FIBROBLASTICA) Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 8572452,
	"label": "ANTICUERPOS ANTI-FAP (PROTEINA DE ACTIVACION FIBROBLASTICA) Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 8572452,
	"label": "ANTICUERPOS ANTI-FAP (PROTEINA DE ACTIVACION FIBROBLASTICA) Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 8573115,
	"label": "NOVEL FED-BATCH CULTURE METHOD",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8573686,
	"label": "TERAPIA DE COMBINACION PARA EL TRATAMIENTO DEL CANCER, PRODUCTO FARMACEUTICO, EQUIPO, KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 8581634,
	"label": "CARRIER IMMUNOGLOBULINS AND USES THEREOF.",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 37864,
	"target": 32770,
	"type": 8581634,
	"label": "CARRIER IMMUNOGLOBULINS AND USES THEREOF.",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 8581634,
	"label": "CARRIER IMMUNOGLOBULINS AND USES THEREOF.",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8584671,
	"label": "COMPUESTOS Y COMPOSICIONES NOVEDOSOS PARA LA INHIBICION DE NAMPT",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8584671,
	"label": "COMPUESTOS Y COMPOSICIONES NOVEDOSOS PARA LA INHIBICION DE NAMPT",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8584671,
	"label": "COMPUESTOS Y COMPOSICIONES NOVEDOSOS PARA LA INHIBICION DE NAMPT",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8588388,
	"label": "4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6371,
	"target": 6301,
	"type": 8590166,
	"label": "Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8590166,
	"label": "Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8590166,
	"label": "Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8590166,
	"label": "Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 8590166,
	"label": "Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRK",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56833,
	"target": 38232,
	"type": 8590839,
	"label": "METHOD FOR MONITORING CATHEPSIN S INHIBITION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37988,
	"target": 37875,
	"type": 8590844,
	"label": "COMPOSICIONES Y METODOS PARA LA INHIBICION DE LA EXPRESION DE LOS GENES RRM2",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37875,
	"target": 32478,
	"type": 8590844,
	"label": "COMPOSICIONES Y METODOS PARA LA INHIBICION DE LA EXPRESION DE LOS GENES RRM2",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37988,
	"target": 32478,
	"type": 8590844,
	"label": "COMPOSICIONES Y METODOS PARA LA INHIBICION DE LA EXPRESION DE LOS GENES RRM2",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32478,
	"target": 7507,
	"type": 8590844,
	"label": "COMPOSICIONES Y METODOS PARA LA INHIBICION DE LA EXPRESION DE LOS GENES RRM2",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 8590844,
	"label": "COMPOSICIONES Y METODOS PARA LA INHIBICION DE LA EXPRESION DE LOS GENES RRM2",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38042,
	"target": 37986,
	"type": 8592823,
	"label": "SERPIN-FINGER FUSION POLYPEPTIDE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 8592823,
	"label": "SERPIN-FINGER FUSION POLYPEPTIDE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 8592823,
	"label": "SERPIN-FINGER FUSION POLYPEPTIDE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 8595346,
	"label": "METHOD FOR CELL LYSIS AND PCR WITHIN THE SAME REACTION CHAMBER",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 8595530,
	"label": "Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 6816,
	"target": 6476,
	"type": 8596173,
	"label": "USO DE ANALOGOS DE CARBA-NUCLEOSIDOS-2-FLUOR SUSTITUIDOS PARA PREPARAR MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIONES POR VIRUS DE LA INFLUENZA, Y COMPUESTOS RELACIONADOS",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8598025,
	"label": "ANTICUERPOS CONTRA LA TWEAK HUMANA Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37862,
	"target": 7507,
	"type": 8598025,
	"label": "ANTICUERPOS CONTRA LA TWEAK HUMANA Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 8598025,
	"label": "ANTICUERPOS CONTRA LA TWEAK HUMANA Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 8602307,
	"label": "ANTI-PlGF ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 8602307,
	"label": "ANTI-PlGF ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 8602307,
	"label": "ANTI-PlGF ANTIBODIES AND METHODS USING SAME",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8602726,
	"label": "FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS.",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 8605933,
	"label": "HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7424,
	"target": 6341,
	"type": 8605934,
	"label": "QUINOLINES AS P13K INHIBITORS.",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 8611882,
	"label": "BIOMARKERS AND METHODS OF TREATMENT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8611882,
	"label": "BIOMARKERS AND METHODS OF TREATMENT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 8611882,
	"label": "BIOMARKERS AND METHODS OF TREATMENT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8613292,
	"label": "ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8613292,
	"label": "ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 8613292,
	"label": "ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8613292,
	"label": "ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 8613292,
	"label": "ANTI-NEUROPILIN ANTIBODIES AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7450,
	"target": 6795,
	"type": 8615763,
	"label": "PARATHYROID HORMONE ANALOGS AND USES THEREOF.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31995,
	"target": 31912,
	"type": 8622045,
	"label": "TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6478,
	"target": 6263,
	"type": 8622055,
	"label": "PHARMACEUTICAL COMPOSITIONS FOR TREATING HCV INFECTIONS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37893,
	"type": 8622876,
	"label": "SCREENING METHOD FOR SUBSTANCE HAVING HEMOCYTE MATURATION ACCELERATION ACTION",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8623392,
	"label": "PYRROLIDINE DERIVATIVES USED AS CATHEPSIN INHIBITORS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8623848,
	"label": "Pyrimidine compounds that inhibit anaplastic lymphoma kinase",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8623848,
	"label": "Pyrimidine compounds that inhibit anaplastic lymphoma kinase",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 8623848,
	"label": "Pyrimidine compounds that inhibit anaplastic lymphoma kinase",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 6821,
	"target": 6795,
	"type": 8623861,
	"label": "GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7360,
	"target": 6821,
	"type": 8623861,
	"label": "GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 8623861,
	"label": "GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 8624759,
	"label": "TREATMENT METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 7425,
	"type": 8624759,
	"label": "TREATMENT METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7425,
	"type": 8624759,
	"label": "TREATMENT METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7425,
	"target": 6229,
	"type": 8624759,
	"label": "TREATMENT METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 8624759,
	"label": "TREATMENT METHODS.",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 8625187,
	"label": "MURINE MODEL OF INFLAMMATION WITH IL33 N-TERMINAL DOMAIN DELETION.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6489,
	"target": 6376,
	"type": 8625633,
	"label": "METHODS OF TREATING TUMORS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6489,
	"type": 8625633,
	"label": "METHODS OF TREATING TUMORS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8625633,
	"label": "METHODS OF TREATING TUMORS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 7511,
	"type": 8627677,
	"label": "Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 32478,
	"type": 8631587,
	"label": "CONJUGATE BETWEEN A THIOPHILIC SOLID PHASE AND AN OLIGONUCLEOTIDE COMPRISING A THIOOXONUCLEOTIDE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31056,
	"target": 7507,
	"type": 8631783,
	"label": "IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 31056,
	"type": 8631783,
	"label": "IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8631783,
	"label": "IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 8637673,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8637673,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 8637673,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8637673,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 8637673,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8640628,
	"label": "ANTICUERPOS CD20 CON FUNCION DEL EFECTOR Y AFINIDAD DE ENLACE AL RECEPTOR FC MEJORADAS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8640628,
	"label": "ANTICUERPOS CD20 CON FUNCION DEL EFECTOR Y AFINIDAD DE ENLACE AL RECEPTOR FC MEJORADAS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8640628,
	"label": "ANTICUERPOS CD20 CON FUNCION DEL EFECTOR Y AFINIDAD DE ENLACE AL RECEPTOR FC MEJORADAS",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8642864,
	"label": "MEDIOS Y MÉTODO PARA EL TRATAMIENTO DEL LINFOMA DIFUSO DE CÉLULAS B GRANDES (DLBCL)",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8642864,
	"label": "MEDIOS Y MÉTODO PARA EL TRATAMIENTO DEL LINFOMA DIFUSO DE CÉLULAS B GRANDES (DLBCL)",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 8642864,
	"label": "MEDIOS Y MÉTODO PARA EL TRATAMIENTO DEL LINFOMA DIFUSO DE CÉLULAS B GRANDES (DLBCL)",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 37988,
	"target": 37986,
	"type": 8643829,
	"label": "PREDICTING PROGRESSION TO ADVANCED AGE-RELATED MACULAR DEGENERATION USING A POLYGENIC SCORE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 60265,
	"target": 37988,
	"type": 8643829,
	"label": "PREDICTING PROGRESSION TO ADVANCED AGE-RELATED MACULAR DEGENERATION USING A POLYGENIC SCORE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 60265,
	"target": 37986,
	"type": 8643829,
	"label": "PREDICTING PROGRESSION TO ADVANCED AGE-RELATED MACULAR DEGENERATION USING A POLYGENIC SCORE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56836,
	"target": 56833,
	"type": 8643848,
	"label": "UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56833,
	"target": 37993,
	"type": 8643848,
	"label": "UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 56836,
	"target": 37993,
	"type": 8643848,
	"label": "UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8644308,
	"label": "COMPUESTOS DE TRIAZOLOPIRIMIDINA COMO INHIBIDORES DE PDE10A, UN PROCESO PARA SU OBTENCION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES DEL SNC",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8644308,
	"label": "COMPUESTOS DE TRIAZOLOPIRIMIDINA COMO INHIBIDORES DE PDE10A, UN PROCESO PARA SU OBTENCION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES DEL SNC",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8644308,
	"label": "COMPUESTOS DE TRIAZOLOPIRIMIDINA COMO INHIBIDORES DE PDE10A, UN PROCESO PARA SU OBTENCION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES DEL SNC",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 6376,
	"type": 8647585,
	"label": "SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 8648024,
	"label": "5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS.",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 7359,
	"type": 8649330,
	"label": "THERAPEUTIC AGENTS FOR PANCREATIC CANCER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7359,
	"target": 6478,
	"type": 8649330,
	"label": "THERAPEUTIC AGENTS FOR PANCREATIC CANCER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 8649330,
	"label": "THERAPEUTIC AGENTS FOR PANCREATIC CANCER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8649330,
	"label": "THERAPEUTIC AGENTS FOR PANCREATIC CANCER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7359,
	"type": 8649330,
	"label": "THERAPEUTIC AGENTS FOR PANCREATIC CANCER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 8649333,
	"label": "ANTITUMOR T CELL RESPONSE ENHANCER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8649333,
	"label": "ANTITUMOR T CELL RESPONSE ENHANCER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 6478,
	"type": 8649333,
	"label": "ANTITUMOR T CELL RESPONSE ENHANCER",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 8649765,
	"label": "PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8651066,
	"label": "DECREASING LACTATE LEVEL AND INCREASING POLYPEPTIDE PRODUCTION BY DOWNREGULATING THE EXPRESSION OF LACTATE DEHYDROGENASE AND PYRUVATE DEHYDROGENASE KINASE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 37899,
	"type": 8651066,
	"label": "DECREASING LACTATE LEVEL AND INCREASING POLYPEPTIDE PRODUCTION BY DOWNREGULATING THE EXPRESSION OF LACTATE DEHYDROGENASE AND PYRUVATE DEHYDROGENASE KINASE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 37864,
	"type": 8651066,
	"label": "DECREASING LACTATE LEVEL AND INCREASING POLYPEPTIDE PRODUCTION BY DOWNREGULATING THE EXPRESSION OF LACTATE DEHYDROGENASE AND PYRUVATE DEHYDROGENASE KINASE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 8654075,
	"label": "anticorpos de cadeia simples biespecìficos e composição farmacêutica compreendendo os mesmos",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 6816,
	"target": 6301,
	"type": 8676967,
	"label": "TERAPIA DE COMBINACION QUE COMPRENDE {3-[5-(4-CLOROFENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DI-FLUOR-FENIL}-AMIDA DEL ACIDO PROPANO-1-SULFONICO Y UN INTERFERON PARA EL USO EN EL TRATAMIENTO DEL CANCER Y KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 8676967,
	"label": "TERAPIA DE COMBINACION QUE COMPRENDE {3-[5-(4-CLOROFENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DI-FLUOR-FENIL}-AMIDA DEL ACIDO PROPANO-1-SULFONICO Y UN INTERFERON PARA EL USO EN EL TRATAMIENTO DEL CANCER Y KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8676967,
	"label": "TERAPIA DE COMBINACION QUE COMPRENDE {3-[5-(4-CLOROFENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DI-FLUOR-FENIL}-AMIDA DEL ACIDO PROPANO-1-SULFONICO Y UN INTERFERON PARA EL USO EN EL TRATAMIENTO DEL CANCER Y KIT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8676985,
	"label": "COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A MDM2 INHIBITOR.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 8677127,
	"label": "Alaninyl maytansinol antibody conjugates",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 8677127,
	"label": "Alaninyl maytansinol antibody conjugates",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 6854,
	"type": 8677127,
	"label": "Alaninyl maytansinol antibody conjugates",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8745412,
	"label": "OXAZOLO [5, 4 -B] PYRIDIN- 5 -YL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32003,
	"target": 31995,
	"type": 8747568,
	"label": "Spiro-Amino-Imidazolone and Spiro-Amino-Dihydro-Pyrimidinone Compounds as Beta-Secretase Modulators and Methods of Use",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 8766039,
	"label": "AGTR1 AS A MARKER FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 8766039,
	"label": "AGTR1 AS A MARKER FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 6229,
	"type": 8766039,
	"label": "AGTR1 AS A MARKER FOR BEVACIZUMAB COMBINATION THERAPIES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31995,
	"target": 6280,
	"type": 8770778,
	"label": "1,2,3-triazole-imidazole compounds",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8770793,
	"label": "QUINOLINE DERIVATIVES AS PIK3 INHIBITORS.",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8770793,
	"label": "QUINOLINE DERIVATIVES AS PIK3 INHIBITORS.",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 6371,
	"type": 8770793,
	"label": "QUINOLINE DERIVATIVES AS PIK3 INHIBITORS.",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 7424,
	"target": 6229,
	"type": 8780198,
	"label": "NEW BIARYL AMIDE DERIVATIVES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 8780377,
	"label": "TREATMENT OF HER2-POSITIVE CANCER WITH PACLITAXEL AND TRASTUZUMAB-MCC-DM1",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 8780750,
	"label": "A PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7360,
	"target": 6909,
	"type": 8780750,
	"label": "A PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6909,
	"type": 8780750,
	"label": "A PHARMACEUTICAL COMPOSITION OF A COMPLEX OF AN ANTI-DIG ANTIBODY AND DIGOXIGENIN THAT IS CONJUGATED TO A PEPTIDE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8792829,
	"label": "ANTICORPS ANTI-RÉCEPTEUR DE LA BARRIÈRE HÉMATO-ENCÉPHALIQUE À FAIBLE AFFINITÉ ET LEURS UTILISATIONS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8793106,
	"label": "ANTICUERPOS ANTI-AXL (RECEPTOR DE TIROSINA QUINASAS) Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 8793106,
	"label": "ANTICUERPOS ANTI-AXL (RECEPTOR DE TIROSINA QUINASAS) Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 8793106,
	"label": "ANTICUERPOS ANTI-AXL (RECEPTOR DE TIROSINA QUINASAS) Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 8793106,
	"label": "ANTICUERPOS ANTI-AXL (RECEPTOR DE TIROSINA QUINASAS) Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32771,
	"target": 7510,
	"type": 8793106,
	"label": "ANTICUERPOS ANTI-AXL (RECEPTOR DE TIROSINA QUINASAS) Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 8814106,
	"label": "POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32772,
	"target": 7507,
	"type": 8814106,
	"label": "POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 8814106,
	"label": "POLYPEPTIDE-POLYNUCLEOTIDE-COMPLEX AND ITS USE IN TARGETED EFFECTOR MOIETY DELIVERY",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 8892651,
	"label": "VARIANTES DE Fc Y METODOS PARA SU PRODUCCION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 8892651,
	"label": "VARIANTES DE Fc Y METODOS PARA SU PRODUCCION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 8892651,
	"label": "VARIANTES DE Fc Y METODOS PARA SU PRODUCCION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 8894020,
	"label": "ANTICUERPOS CONTRA EL IL33R HUMANO Y USOS DE LOS MISMOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8898237,
	"label": "SUBSTITUTED HETEROARYL 2', 3', 7', 7A' - TETRAHYDROSPIRO-[PYRROLE-3, 6' - PYRROLO [1, 2-C] IMIDAZOLE] - 1', 2 (1H, 5'H) -DIONES AS ANTICANCER AGENTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8898249,
	"label": "ANTICUERPOS DEL ANTIGENO CARCINOEMBRIONARIO HUMANO (CEA)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8898249,
	"label": "ANTICUERPOS DEL ANTIGENO CARCINOEMBRIONARIO HUMANO (CEA)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 8898249,
	"label": "ANTICUERPOS DEL ANTIGENO CARCINOEMBRIONARIO HUMANO (CEA)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8898249,
	"label": "ANTICUERPOS DEL ANTIGENO CARCINOEMBRIONARIO HUMANO (CEA)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 8898249,
	"label": "ANTICUERPOS DEL ANTIGENO CARCINOEMBRIONARIO HUMANO (CEA)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6489,
	"target": 6483,
	"type": 8898857,
	"label": "THERAPEUTIC AGENT FOR HEPATITIS C CONTAINING RRM2 ANTAGONIST AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 6489,
	"type": 8898857,
	"label": "THERAPEUTIC AGENT FOR HEPATITIS C CONTAINING RRM2 ANTAGONIST AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 6483,
	"type": 8898857,
	"label": "THERAPEUTIC AGENT FOR HEPATITIS C CONTAINING RRM2 ANTAGONIST AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8899696,
	"label": "ANTICORPS CONTRE LA METALLOPROTEINASE DE MATRICE 9",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8899696,
	"label": "ANTICORPS CONTRE LA METALLOPROTEINASE DE MATRICE 9",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 8899696,
	"label": "ANTICORPS CONTRE LA METALLOPROTEINASE DE MATRICE 9",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 8899696,
	"label": "ANTICORPS CONTRE LA METALLOPROTEINASE DE MATRICE 9",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 8899696,
	"label": "ANTICORPS CONTRE LA METALLOPROTEINASE DE MATRICE 9",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 38065,
	"target": 37993,
	"type": 8903234,
	"label": "PROTEINAS DE UNION A ANTIGENO",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 7507,
	"type": 8903234,
	"label": "PROTEINAS DE UNION A ANTIGENO",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 7507,
	"type": 8903234,
	"label": "PROTEINAS DE UNION A ANTIGENO",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 8903235,
	"label": "PROTEINAS MONOVALENTES QUE SE UNEN A ANTIGENOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 8903235,
	"label": "PROTEINAS MONOVALENTES QUE SE UNEN A ANTIGENOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 8903235,
	"label": "PROTEINAS MONOVALENTES QUE SE UNEN A ANTIGENOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 8903235,
	"label": "PROTEINAS MONOVALENTES QUE SE UNEN A ANTIGENOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 8903235,
	"label": "PROTEINAS MONOVALENTES QUE SE UNEN A ANTIGENOS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6301,
	"target": 6281,
	"type": 8903526,
	"label": "DERIVADOS DE PIPERIDINA PUENTEADA",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8903526,
	"label": "DERIVADOS DE PIPERIDINA PUENTEADA",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6281,
	"type": 8903526,
	"label": "DERIVADOS DE PIPERIDINA PUENTEADA",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8904848,
	"label": "INMUNOTERAPIA MEJORADA, COMPOSICION FARMACEUTICA, KIT",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 7510,
	"type": 8904848,
	"label": "INMUNOTERAPIA MEJORADA, COMPOSICION FARMACEUTICA, KIT",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 8904848,
	"label": "INMUNOTERAPIA MEJORADA, COMPOSICION FARMACEUTICA, KIT",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 6854,
	"type": 8909493,
	"label": "SAFE AND FUNCTIONAL HUMANIZED ANTI BETA-AMYLOID ANTIBODY.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 8909861,
	"label": "BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8909861,
	"label": "BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8909861,
	"label": "BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8913456,
	"label": "COMPUESTOS TRICICLICOS INHIBIDORES DE LA PI3K Y COMPOSICIONES FARMACEUTICAS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 8915282,
	"label": "ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 32771,
	"type": 8915282,
	"label": "ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8915282,
	"label": "ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 37899,
	"type": 8915282,
	"label": "ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 8915282,
	"label": "ANTI-MESOTHELIN ANTIBODIES AND IMMUNOCONJUGATES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8918052,
	"label": "NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32700,
	"target": 32698,
	"type": 8920232,
	"label": "Polipéptidos interleuquina-2 mutantes",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32788,
	"target": 32779,
	"type": 8920232,
	"label": "Polipéptidos interleuquina-2 mutantes",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32700,
	"type": 8920232,
	"label": "Polipéptidos interleuquina-2 mutantes",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32698,
	"type": 8920232,
	"label": "Polipéptidos interleuquina-2 mutantes",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32788,
	"target": 32700,
	"type": 8920232,
	"label": "Polipéptidos interleuquina-2 mutantes",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38065,
	"target": 37904,
	"type": 8924832,
	"label": "Nav1.7 knockout mice and uses thereof",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 6489,
	"target": 6341,
	"type": 8927210,
	"label": "AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6489,
	"type": 8927210,
	"label": "AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6341,
	"type": 8927210,
	"label": "AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 8927215,
	"label": "ANTI-PCSK9 ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 8927215,
	"label": "ANTI-PCSK9 ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 8927215,
	"label": "ANTI-PCSK9 ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7360,
	"target": 7358,
	"type": 8930342,
	"label": "SEC-HYDROXYCYCLOHEXYL DERIVATIVES AS HSL INHIBITORS FOR THE TREATMENT DIABETES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 8931526,
	"label": "ANTIBODY FC VARIANTS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 8936362,
	"label": "BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 7360,
	"type": 8936362,
	"label": "BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 7360,
	"type": 8936362,
	"label": "BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37878,
	"target": 37875,
	"type": 8937783,
	"label": "MEDIO DE CULTIVO CELULAR PARA EXPOSICION UVC Y METODOS RELACIONADOS CON EL MISMO",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 31995,
	"target": 7360,
	"type": 8937969,
	"label": "NEW AZASPIRODECANONE COMPOUNDS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7511,
	"target": 6816,
	"type": 8939026,
	"label": "ANTIVIRAL COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8939321,
	"label": "SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8939321,
	"label": "SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 8939321,
	"label": "SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6816,
	"target": 6478,
	"type": 8940812,
	"label": "SELECTION OF HCV TREATMENT",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 8944976,
	"label": "IMIDAZO PYRAZINES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8944976,
	"label": "IMIDAZO PYRAZINES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7508,
	"target": 6371,
	"type": 8944976,
	"label": "IMIDAZO PYRAZINES.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6382,
	"target": 6371,
	"type": 8944993,
	"label": "6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 8944993,
	"label": "6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 8944993,
	"label": "6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 37875,
	"type": 8952916,
	"label": "DOMAIN INSERTION IMMUNOGLOBULIN",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 37875,
	"target": 6854,
	"type": 8952916,
	"label": "DOMAIN INSERTION IMMUNOGLOBULIN",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 8952916,
	"label": "DOMAIN INSERTION IMMUNOGLOBULIN",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 6279,
	"target": 6263,
	"type": 8953652,
	"label": "METODOS PARA TRATAR VIRUS DE HEPATITIS C (HCV), COMPOSICION",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6301,
	"target": 6290,
	"type": 8953783,
	"label": "INHIBITORS OF CYTOCHROME P450",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8953783,
	"label": "INHIBITORS OF CYTOCHROME P450",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6290,
	"type": 8953783,
	"label": "INHIBITORS OF CYTOCHROME P450",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 31995,
	"target": 31912,
	"type": 8956010,
	"label": "BICYCLIC COMPOUNDS AS PIM INHIBITORS.",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 31042,
	"type": 8956556,
	"label": "AMINOPIRIDINAS/PIRIMIDINAS ESPIROCICLICAS Y GEM-DISUSTITUIDAS COMO INHIBIDORES DEL CICLO CELULAR.",
	"group": "Amgen",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 8956977,
	"label": "PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8956977,
	"label": "PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 8956977,
	"label": "PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 8956979,
	"label": "1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 8956979,
	"label": "1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6302,
	"type": 8956979,
	"label": "1,6- AND 1,8-NAPHTHYRIDINES USEFUL AS DYRK1 INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 8956981,
	"label": "PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31317,
	"target": 6299,
	"type": 8960106,
	"label": "BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 8970168,
	"label": "A METHOD FOR CULTURING MAMMALIAN CELLS TO IMPROVE RECOMBINANT PROTEIN PRODUCTION",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 6816,
	"target": 6398,
	"type": 8971140,
	"label": "BRIDGED POLYCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7511,
	"target": 6816,
	"type": 8971140,
	"label": "BRIDGED POLYCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7511,
	"target": 6398,
	"type": 8971140,
	"label": "BRIDGED POLYCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7358,
	"type": 8971161,
	"label": "METHODS OF TREATING LIVER CONDITIONS USING NOTCH2 ANTAGONISTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6229,
	"target": 6215,
	"type": 8975696,
	"label": "Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 6410,
	"target": 6229,
	"type": 8975696,
	"label": "Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 6410,
	"target": 6215,
	"type": 8975696,
	"label": "Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 8975696,
	"label": "Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 8975696,
	"label": "Combination of motesanib, a taxane and a platinum-containing anti-cancer drug for use in the treatment of non-small cell lung cancer in a population subset",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6366,
	"type": 8976231,
	"label": "Inhibitors of Bruton's Tyrosine Kinase",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6812,
	"type": 8979711,
	"label": "VASCULAR DISRUPTION AGENTS AND USES THEREOF",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6295,
	"type": 8981182,
	"label": "Azole compounds as Pim inhibitors",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7409,
	"target": 6376,
	"type": 8981450,
	"label": "COMPOSICIONES Y METODOS PARA TRATAR LA HIPERTENSION PULMONAR",
	"group": "Gilead",
	"time": 2011,
	"strength": 1
}, {
	"source": 6301,
	"target": 6263,
	"type": 8982513,
	"label": "NEW HEXAHYDROCYCLOPENTAPYRROLONE, HEXAHYDROPYRROLOPYRROLONE, OCTAHYDROPYRROLOPYRIDINONE AND OCTAHYDROPYRIDINONE COMPOUNDS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7360,
	"target": 6301,
	"type": 8982513,
	"label": "NEW HEXAHYDROCYCLOPENTAPYRROLONE, HEXAHYDROPYRROLOPYRROLONE, OCTAHYDROPYRROLOPYRIDINONE AND OCTAHYDROPYRIDINONE COMPOUNDS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7360,
	"target": 6263,
	"type": 8982513,
	"label": "NEW HEXAHYDROCYCLOPENTAPYRROLONE, HEXAHYDROPYRROLOPYRROLONE, OCTAHYDROPYRROLOPYRIDINONE AND OCTAHYDROPYRIDINONE COMPOUNDS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 8982513,
	"label": "NEW HEXAHYDROCYCLOPENTAPYRROLONE, HEXAHYDROPYRROLOPYRROLONE, OCTAHYDROPYRROLOPYRIDINONE AND OCTAHYDROPYRIDINONE COMPOUNDS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 8982513,
	"label": "NEW HEXAHYDROCYCLOPENTAPYRROLONE, HEXAHYDROPYRROLOPYRROLONE, OCTAHYDROPYRROLOPYRIDINONE AND OCTAHYDROPYRIDINONE COMPOUNDS.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6279,
	"target": 6263,
	"type": 8983624,
	"label": "NEW HEXAHYDROPYRROLOIMIDAZOLONE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8988439,
	"label": "REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 8988439,
	"label": "REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 8988439,
	"label": "REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 8988439,
	"label": "REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 32779,
	"type": 8988439,
	"label": "REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 8995970,
	"label": "PROTEÍNAS HUMANAS DE UNIÓN AL ANTÍGENO QUE SE UNEN A UN COMPLEJO QUE COMPRENDE (beta)-KLOTHO y UN RECEPTOR PARA FGF",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 32779,
	"type": 8995970,
	"label": "PROTEÍNAS HUMANAS DE UNIÓN AL ANTÍGENO QUE SE UNEN A UN COMPLEJO QUE COMPRENDE (beta)-KLOTHO y UN RECEPTOR PARA FGF",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 32770,
	"type": 8995970,
	"label": "PROTEÍNAS HUMANAS DE UNIÓN AL ANTÍGENO QUE SE UNEN A UN COMPLEJO QUE COMPRENDE (beta)-KLOTHO y UN RECEPTOR PARA FGF",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7360,
	"type": 8995970,
	"label": "PROTEÍNAS HUMANAS DE UNIÓN AL ANTÍGENO QUE SE UNEN A UN COMPLEJO QUE COMPRENDE (beta)-KLOTHO y UN RECEPTOR PARA FGF",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 7360,
	"type": 8995970,
	"label": "PROTEÍNAS HUMANAS DE UNIÓN AL ANTÍGENO QUE SE UNEN A UN COMPLEJO QUE COMPRENDE (beta)-KLOTHO y UN RECEPTOR PARA FGF",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 8997023,
	"label": "ANTIBODY BINDING TO ABCA1 POLYPEPTIDE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 8998695,
	"label": "AGENTE TERAPEUTICO QUE INDUCE CITOTOXICIDAD",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 8998695,
	"label": "AGENTE TERAPEUTICO QUE INDUCE CITOTOXICIDAD",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 8998695,
	"label": "AGENTE TERAPEUTICO QUE INDUCE CITOTOXICIDAD",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 8998695,
	"label": "AGENTE TERAPEUTICO QUE INDUCE CITOTOXICIDAD",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37859,
	"target": 32779,
	"type": 8998695,
	"label": "AGENTE TERAPEUTICO QUE INDUCE CITOTOXICIDAD",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37878,
	"target": 32770,
	"type": 9006312,
	"label": "Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 56833,
	"type": 9006472,
	"label": "LYSYL OXIDASE-LIKE 2 ASSAY AND METHODS OF USE THEREOF",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 9011615,
	"label": "AGONISTAS DE FGFR1 Y SUS MÈTODOS DE USO",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 9011615,
	"label": "AGONISTAS DE FGFR1 Y SUS MÈTODOS DE USO",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 9011615,
	"label": "AGONISTAS DE FGFR1 Y SUS MÈTODOS DE USO",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 7360,
	"type": 9011615,
	"label": "AGONISTAS DE FGFR1 Y SUS MÈTODOS DE USO",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37862,
	"target": 7360,
	"type": 9011615,
	"label": "AGONISTAS DE FGFR1 Y SUS MÈTODOS DE USO",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6539,
	"target": 6478,
	"type": 9011776,
	"label": "METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6478,
	"target": 6376,
	"type": 9011776,
	"label": "METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6539,
	"target": 6376,
	"type": 9011776,
	"label": "METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6539,
	"type": 9011776,
	"label": "METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 9011776,
	"label": "METHODS OF TREATING MESOTHELIOMA WITH A PI3K INHIBITOR COMPOUND",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 9012376,
	"label": "MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 9012376,
	"label": "MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 9012376,
	"label": "MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 9012376,
	"label": "MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 9012376,
	"label": "MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37900,
	"target": 37899,
	"type": 9013627,
	"label": "DIALYSIS FERMENTER-BIOREACTOR WITH DIALYSIS DEVICE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 9013627,
	"label": "DIALYSIS FERMENTER-BIOREACTOR WITH DIALYSIS DEVICE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37900,
	"target": 37878,
	"type": 9013627,
	"label": "DIALYSIS FERMENTER-BIOREACTOR WITH DIALYSIS DEVICE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7508,
	"type": 9017989,
	"label": "TRIAZOLOPYRIDINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 6301,
	"type": 9017989,
	"label": "TRIAZOLOPYRIDINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 6301,
	"type": 9017989,
	"label": "TRIAZOLOPYRIDINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 9017989,
	"label": "TRIAZOLOPYRIDINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7508,
	"type": 9017989,
	"label": "TRIAZOLOPYRIDINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 9018978,
	"label": "Novel antigen binding proteins",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6957,
	"type": 9018978,
	"label": "Novel antigen binding proteins",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 9018978,
	"label": "Novel antigen binding proteins",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 9018978,
	"label": "Novel antigen binding proteins",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9018978,
	"label": "Novel antigen binding proteins",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37875,
	"target": 7507,
	"type": 9028443,
	"label": "Cancer stem cell mass and process for production thereof",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38065,
	"target": 6812,
	"type": 9030666,
	"label": "Potent and selective inhibitors of Nav1.3 and Nav1.7",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 9031665,
	"label": "COMPOSICIONES DE ANTICUERPO ANTI COMPLEJO I DE HCMV Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 9031665,
	"label": "COMPOSICIONES DE ANTICUERPO ANTI COMPLEJO I DE HCMV Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37859,
	"type": 9031665,
	"label": "COMPOSICIONES DE ANTICUERPO ANTI COMPLEJO I DE HCMV Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 9031665,
	"label": "COMPOSICIONES DE ANTICUERPO ANTI COMPLEJO I DE HCMV Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38181,
	"target": 37862,
	"type": 9031665,
	"label": "COMPOSICIONES DE ANTICUERPO ANTI COMPLEJO I DE HCMV Y METODOS DE USO",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 9034300,
	"label": "TERAPIAS COMBINADAS PARA MALIGNIDADES HEMATOLOGICAS",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 9034300,
	"label": "TERAPIAS COMBINADAS PARA MALIGNIDADES HEMATOLOGICAS",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 6854,
	"type": 9034300,
	"label": "TERAPIAS COMBINADAS PARA MALIGNIDADES HEMATOLOGICAS",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 9036145,
	"label": "INHIBIDORES TRICICLICOS FUSIONADOS DOBLES DE LAS CDK 4/6 Y DE LA FLT3",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 9036145,
	"label": "INHIBIDORES TRICICLICOS FUSIONADOS DOBLES DE LAS CDK 4/6 Y DE LA FLT3",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 6376,
	"type": 9036145,
	"label": "INHIBIDORES TRICICLICOS FUSIONADOS DOBLES DE LAS CDK 4/6 Y DE LA FLT3",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 31572,
	"target": 7508,
	"type": 9036145,
	"label": "INHIBIDORES TRICICLICOS FUSIONADOS DOBLES DE LAS CDK 4/6 Y DE LA FLT3",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 31572,
	"target": 7507,
	"type": 9036145,
	"label": "INHIBIDORES TRICICLICOS FUSIONADOS DOBLES DE LAS CDK 4/6 Y DE LA FLT3",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 9040331,
	"label": "METHOD AND CONSTRUCTS FOR THE PH DEPENDENT PASSAGE OF THE BLOOD-BRAIN-BARRIER",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 9040332,
	"label": "MICROWAVES FOR IMMUNOHISTOCHEMICAL ANALYSIS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38164,
	"target": 37986,
	"type": 9045073,
	"label": "DNA POLYMERASES WITH IMPROVED ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 39999,
	"type": 9045675,
	"label": "PREDICTING RESPONSE TO ANTI-CD20 THERAPY IN DLBCL PATIENTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 9047994,
	"label": "Predictive biomarker of survival in the treatment of renal cell carcinoma",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 9047994,
	"label": "Predictive biomarker of survival in the treatment of renal cell carcinoma",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 6795,
	"type": 9047994,
	"label": "Predictive biomarker of survival in the treatment of renal cell carcinoma",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37897,
	"target": 32770,
	"type": 9049871,
	"label": "Anti-c-met antibody formulations",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9049871,
	"label": "Anti-c-met antibody formulations",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37897,
	"target": 7507,
	"type": 9049871,
	"label": "Anti-c-met antibody formulations",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 9052881,
	"label": "DOSIFICACION PARA TRATAMIENTO CON ANTICUERPOS ANTI-DOMINIO 7 DE TIPO DE FACTOR DE CRECIMIENTO EPIDERMICO (ANTI-EGFL7)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7508,
	"type": 9052881,
	"label": "DOSIFICACION PARA TRATAMIENTO CON ANTICUERPOS ANTI-DOMINIO 7 DE TIPO DE FACTOR DE CRECIMIENTO EPIDERMICO (ANTI-EGFL7)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 9052881,
	"label": "DOSIFICACION PARA TRATAMIENTO CON ANTICUERPOS ANTI-DOMINIO 7 DE TIPO DE FACTOR DE CRECIMIENTO EPIDERMICO (ANTI-EGFL7)",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 9053283,
	"label": "Mammalian cell culture",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 9059605,
	"label": "PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9059605,
	"label": "PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 6301,
	"type": 9059605,
	"label": "PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 9059605,
	"label": "PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9059605,
	"label": "PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 9059609,
	"label": "INDAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 32698,
	"type": 9061798,
	"label": "IL-17 RECEPTOR A IS REQUIRED FOR IL-17C BIOLOGY",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32478,
	"target": 6854,
	"type": 9068580,
	"label": "BIOLOGICAL MARKERS AND METHODS FOR PREDICTING RESPONSE TO B-CELL ANTAGONISTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6371,
	"target": 6290,
	"type": 9080636,
	"label": "BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31851,
	"target": 6371,
	"type": 9080636,
	"label": "BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31851,
	"target": 6290,
	"type": 9080636,
	"label": "BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9080648,
	"label": "TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31939,
	"target": 7497,
	"type": 9081711,
	"label": "HEMIFUMARATO DE TENOFOVIR ALAFENAMIDA, SUS COMPOSICIONES,  MÉTODO DE PREPARACIÓN, MÉTODOS PARA TRATAR INFECCIONES VIRALES Y SU USO PARA PREPARAR MEDI CAMENTOS",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 9087415,
	"label": "Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6376,
	"target": 6298,
	"type": 9087415,
	"label": "Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 9087415,
	"label": "Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6298,
	"type": 9087415,
	"label": "Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9087415,
	"label": "Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6280,
	"type": 9088513,
	"label": "PDE10 MODULATORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 9091697,
	"label": "THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 9091697,
	"label": "THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 9091697,
	"label": "THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 9091697,
	"label": "THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 9091697,
	"label": "THERAPEUTIC ANTIGEN-BINDING MOLECULE WITH A FcRn-BINDING DOMAIN THAT PROMOTES ANTIGEN CLEARANCE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 9092282,
	"label": "FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 9092282,
	"label": "FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 9092282,
	"label": "FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 9092282,
	"label": "FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37859,
	"target": 32779,
	"type": 9092282,
	"label": "FC-FREE ANTIBODIES COMPRISING TWO FAB FRAGMENTS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 9092283,
	"label": "BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9092283,
	"label": "BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 9092283,
	"label": "BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 9092284,
	"label": "BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 9092284,
	"label": "BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 9092284,
	"label": "BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 32771,
	"type": 9092284,
	"label": "BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 32779,
	"type": 9092284,
	"label": "BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 9092518,
	"label": "Serine/threonine kinase inhibitors",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 9094067,
	"label": "BISPECIFIC ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 9094067,
	"label": "BISPECIFIC ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 9094067,
	"label": "BISPECIFIC ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37993,
	"type": 9094067,
	"label": "BISPECIFIC ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 9094067,
	"label": "BISPECIFIC ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7511,
	"target": 7487,
	"type": 9094330,
	"label": "PYRROLOPYRAZINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9095411,
	"label": "ANTI-MCSP ANTIBODIES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 9095412,
	"label": "BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9095412,
	"label": "BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 9095412,
	"label": "BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9097804,
	"label": "MEDICINE CONTAINING FOUR-RING COMPOUND",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 9100537,
	"label": "METHOD FOR IMPROVING PHYSICAL PROPERTIES OF ANTIBODY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6821,
	"type": 9103348,
	"label": "AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37988,
	"target": 7507,
	"type": 9103348,
	"label": "AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37988,
	"target": 6821,
	"type": 9103348,
	"label": "AUTOPHAGY INDUCER AND INHIBITOR COMBINATION THERAPY FOR THE TREATMENT OF NEOPLASMS",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 9108044,
	"label": "ANIMAL CELL CULTURING METHOD.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37899,
	"target": 37878,
	"type": 9108044,
	"label": "ANIMAL CELL CULTURING METHOD.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 9108044,
	"label": "ANIMAL CELL CULTURING METHOD.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 9108044,
	"label": "ANIMAL CELL CULTURING METHOD.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 37878,
	"type": 9108044,
	"label": "ANIMAL CELL CULTURING METHOD.",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 6301,
	"type": 9108226,
	"label": "FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 9108226,
	"label": "FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9108226,
	"label": "FUSED TRICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF JANUS KINASES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 9108231,
	"label": "TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 9108231,
	"label": "TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 6302,
	"type": 9108231,
	"label": "TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 9108231,
	"label": "TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9108231,
	"label": "TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 32698,
	"type": 9108566,
	"label": "METHOD FOR SEPARATION OF MONOMERIC POLYPEPTIDES FROM AGGREGATED POLYPEPTIDES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 9117683,
	"label": "IMIDAZOPYRIDAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7508,
	"type": 9117683,
	"label": "IMIDAZOPYRIDAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 9117683,
	"label": "IMIDAZOPYRIDAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 9117683,
	"label": "IMIDAZOPYRIDAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7508,
	"target": 6367,
	"type": 9117683,
	"label": "IMIDAZOPYRIDAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7479,
	"target": 6376,
	"type": 9122419,
	"label": "[1, 2, 3] TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32772,
	"target": 32771,
	"type": 9123315,
	"label": "USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 9123315,
	"label": "USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7509,
	"type": 9123315,
	"label": "USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32772,
	"target": 7509,
	"type": 9123315,
	"label": "USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9123315,
	"label": "USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6367,
	"target": 6301,
	"type": 9127527,
	"label": "BICYCLIC PIPERAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6367,
	"type": 9127527,
	"label": "BICYCLIC PIPERAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9127527,
	"label": "BICYCLIC PIPERAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9127527,
	"label": "BICYCLIC PIPERAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 9127527,
	"label": "BICYCLIC PIPERAZINE COMPOUNDS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 6366,
	"type": 9127635,
	"label": "8-FLUOROPHTHALAZIN-1 (2H) - ONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 9127638,
	"label": "HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7510,
	"type": 9127638,
	"label": "HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9127638,
	"label": "HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 9130384,
	"label": "TREATMENT OF PHARMACOLOGICAL-INDUCED HYPOCHLORHYDRIA",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6854,
	"target": 6371,
	"type": 9134278,
	"label": "SCD1 ANTAGONISTS FOR TREATING CANCER",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 9143018,
	"label": "RECOMBINANT POLYPEPTIDE PRODUCTION METHOD",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 9143018,
	"label": "RECOMBINANT POLYPEPTIDE PRODUCTION METHOD",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 9143018,
	"label": "RECOMBINANT POLYPEPTIDE PRODUCTION METHOD",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37859,
	"type": 9143018,
	"label": "RECOMBINANT POLYPEPTIDE PRODUCTION METHOD",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 9143018,
	"label": "RECOMBINANT POLYPEPTIDE PRODUCTION METHOD",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 9146168,
	"label": "PROTEINAS DE UNIÓN AL ANTÍGENO CD27L",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 9146168,
	"label": "PROTEINAS DE UNIÓN AL ANTÍGENO CD27L",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7510,
	"type": 9146168,
	"label": "PROTEINAS DE UNIÓN AL ANTÍGENO CD27L",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9146168,
	"label": "PROTEINAS DE UNIÓN AL ANTÍGENO CD27L",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 7510,
	"type": 9146168,
	"label": "PROTEINAS DE UNIÓN AL ANTÍGENO CD27L",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 6854,
	"target": 6301,
	"type": 9151195,
	"label": "COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56833,
	"target": 6854,
	"type": 9151195,
	"label": "COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56833,
	"target": 6301,
	"type": 9151195,
	"label": "COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6299,
	"type": 9153376,
	"label": "Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 9153376,
	"label": "Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31042,
	"target": 6299,
	"type": 9153376,
	"label": "Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31042,
	"target": 7507,
	"type": 9153383,
	"label": "COMBINATIONS OF AKT AND MEK INHIBITOR COMPOUNDS, AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 32770,
	"type": 9155938,
	"label": "IN VIVO ADCC MODEL",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7425,
	"target": 7424,
	"type": 9155979,
	"label": "AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 9161904,
	"label": "Purification of anti-c-met antibodies",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9162308,
	"label": "FORMAS SOLIDAS DE {3-[5-(4-CLORO-FENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DIFLUOR-FENIL}-AMIDA DEL ACIDO PROPANO-1-SULFONICO",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9162308,
	"label": "FORMAS SOLIDAS DE {3-[5-(4-CLORO-FENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DIFLUOR-FENIL}-AMIDA DEL ACIDO PROPANO-1-SULFONICO",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9162308,
	"label": "FORMAS SOLIDAS DE {3-[5-(4-CLORO-FENIL)-1H-PIRROLO[2,3-B]PIRIDINA-3-CARBONIL]-2,4-DIFLUOR-FENIL}-AMIDA DEL ACIDO PROPANO-1-SULFONICO",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6279,
	"type": 9164297,
	"label": "BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9164297,
	"label": "BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6279,
	"type": 9164297,
	"label": "BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6371,
	"target": 6301,
	"type": 9167287,
	"label": "PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY FOR HIGH MELTING HYDROPHOBIC COMPOUND",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 9167287,
	"label": "PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY FOR HIGH MELTING HYDROPHOBIC COMPOUND",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9167287,
	"label": "PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY FOR HIGH MELTING HYDROPHOBIC COMPOUND",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6382,
	"type": 9168430,
	"label": "CYCLOALKYL DERIVATIVES AS INHIBITORS OF BONE RESPORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 9170543,
	"label": "METHODS OF TREATING EPIDERMAL GROWTH FACTOR DELETION MUTANT VIII RELATED DISORDERS",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9170543,
	"label": "METHODS OF TREATING EPIDERMAL GROWTH FACTOR DELETION MUTANT VIII RELATED DISORDERS",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9170543,
	"label": "METHODS OF TREATING EPIDERMAL GROWTH FACTOR DELETION MUTANT VIII RELATED DISORDERS",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6367,
	"type": 9170613,
	"label": "INHIBITORS OF BRUTON'S TYROSINE KINASE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9181614,
	"label": "IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7424,
	"type": 9181634,
	"label": "NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7409,
	"target": 6390,
	"type": 9188869,
	"label": "BENZOXAZINE DERIVATIVES AS CRAC MODULATORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 9190527,
	"label": "COMBINATION THERAPY USING ANTI - CD20 ANTIBODY AND HUMAN IL-15",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 9193885,
	"label": "PROCESS FOR ANTIBODY G1 GLYCOFORM PRODUCTION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7424,
	"target": 7358,
	"type": 9195010,
	"label": "INHIBIDOR DE LA QUINASA QUE REGULA LA SEÑAL DE LA APOPTOSIS",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 9197981,
	"label": "STABLE PROTEIN-CONTAINING PREPARATION CONTAINING ARGININAMIDE OR ANALOGOUS COMPOUND THEREOF",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 9202509,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37862,
	"type": 9202509,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37859,
	"type": 9202509,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37859,
	"target": 32779,
	"type": 9202509,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 32779,
	"type": 9202509,
	"label": "ANTI-POLYUBIQUITIN ANTIBODIES AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 9203084,
	"label": "ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37875,
	"target": 32527,
	"type": 9206237,
	"label": "FLOCCULATION METHOD",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32478,
	"target": 7507,
	"type": 9206286,
	"label": "INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING LFA-1",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 9206306,
	"label": "BISPECIFIC ANTIBODY MOLECULES WITH ANTIGEN-TRANSFECTED T-CELLS AND THEIR USE IN MEDICINE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 6489,
	"type": 9206582,
	"label": "Anti-LRP5 antibodies and methods of use",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32772,
	"target": 6913,
	"type": 9216850,
	"label": "ARTICLES OF MANUFACTURE AND METHODS FOR CO-ADMINISTRATION OF ANTIBODIES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 9219035,
	"label": "Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 9219045,
	"label": "PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL INFECTIONS AND DISORDERS",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7424,
	"type": 9221378,
	"label": "USE OF ANTI-CD83 AGONIST ANTIBODIES FOR TREATING AUTOIMMUNE DISEASES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 9222057,
	"label": "Heterodimerized polypeptide",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 9222057,
	"label": "Heterodimerized polypeptide",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 9222057,
	"label": "Heterodimerized polypeptide",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 9224727,
	"label": "2 -AMINO- PYRIDO [3, 2 -D] PYRIMIDINE DERIVATIVES AS HCV INHIBITORS",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 9233818,
	"label": "PCSK9-BINDING POLYPEPTIDES AND METHODS OF USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6390,
	"target": 6376,
	"type": 9237488,
	"label": "PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 9246038,
	"label": "SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6272,
	"type": 9246039,
	"label": "OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9246411,
	"label": "PYRAZOLOPYRIDINES FOR TREATMENT OF PARKINSONS DISEASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6360,
	"type": 9247644,
	"label": "SULFAMIDE SODIUM CHANNEL INHIBITORS",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9248219,
	"label": "COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6229,
	"type": 9248265,
	"label": "Combination therapy for the treatment of ovarian cancer",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6360,
	"type": 9250186,
	"label": "HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9250238,
	"label": "COMBINATION THERAPY (VEMRUFENIB AND A MDM2 INHIBITOR) FOR THE TREATMENT PROLIFERATIVE DISORDERS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 9255533,
	"label": "CANCER STEM CELL ISOLATION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9255533,
	"label": "CANCER STEM CELL ISOLATION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 9255533,
	"label": "CANCER STEM CELL ISOLATION",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9256672,
	"label": "AMIDAS COMO INHIBIDORES DE PIM",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 6376,
	"target": 6371,
	"type": 9264149,
	"label": "2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 9264149,
	"label": "2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 9264149,
	"label": "2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9264149,
	"label": "2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 9264149,
	"label": "2, 4-DIAMINE-PYRIMIDINE DERIVATIVE AS SERINE/THREONINE KINASE INHIBITORS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9268617,
	"label": "4-AZAINDOLE INHIBITORS OF CRAC",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9268624,
	"label": "7-AZAINDOLE INHIBITORS OF CRAC",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 32771,
	"type": 9269832,
	"label": "COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32769,
	"type": 9270164,
	"label": "FULL LENGTH ANTIBODY DISPLAY SYSTEM FOR EUKARYOTIC CELLS AND ITS USE",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 37986,
	"type": 9270165,
	"label": "EXPRESSION VECTOR ORGANIZATION, NOVEL PRODUCTION CELL GENERATION METHODS AND THEIR USE FOR THE RECOMBINANT PRODUCTION OF POLYPEPTIDES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 9276599,
	"label": "NOVEL ANTI-DDR1 ANTIBODY HAVING ANTI-TUMOR ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 9276599,
	"label": "NOVEL ANTI-DDR1 ANTIBODY HAVING ANTI-TUMOR ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 9276599,
	"label": "NOVEL ANTI-DDR1 ANTIBODY HAVING ANTI-TUMOR ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 9276599,
	"label": "NOVEL ANTI-DDR1 ANTIBODY HAVING ANTI-TUMOR ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 9276599,
	"label": "NOVEL ANTI-DDR1 ANTIBODY HAVING ANTI-TUMOR ACTIVITY",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9285165,
	"label": "Triazolopyridine compounds",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9285165,
	"label": "Triazolopyridine compounds",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9285165,
	"label": "Triazolopyridine compounds",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 37988,
	"type": 9289394,
	"label": "Monovalent antigen binding proteins",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37988,
	"target": 32770,
	"type": 9289394,
	"label": "Monovalent antigen binding proteins",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 9289394,
	"label": "Monovalent antigen binding proteins",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9289394,
	"label": "Monovalent antigen binding proteins",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37988,
	"target": 7507,
	"type": 9289394,
	"label": "Monovalent antigen binding proteins",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9289395,
	"label": "Novel immunoconjugates",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 9289396,
	"label": "CEA antibodies",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7424,
	"target": 6371,
	"type": 9292254,
	"label": "New biaryl amide derivatives",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31912,
	"target": 6371,
	"type": 9295878,
	"label": "PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 9299818,
	"label": "ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 9299818,
	"label": "ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37862,
	"type": 9299818,
	"label": "ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 9299818,
	"label": "ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 9299818,
	"label": "ANTIGEN-BINDING MOLECULE HAVING REGULATED CONJUGATION BETWEEN HEAVY-CHAIN AND LIGHT-CHAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6795,
	"target": 6301,
	"type": 9302410,
	"label": "Therapeutic combinations and methods of treating melanoma",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 9302410,
	"label": "Therapeutic combinations and methods of treating melanoma",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9302410,
	"label": "Therapeutic combinations and methods of treating melanoma",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6164,
	"type": 9305236,
	"label": "SELECTIVE INHIBITORS OF UNDIFFERENTIATED CELLS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6371,
	"type": 9305549,
	"label": "Use of AMG 900 for the Treatment of Cancer",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 31939,
	"target": 7507,
	"type": 9307935,
	"label": "COMPOSITIONS AND METHODS OF TREATING A PROLIFERATIVE DISEASE WITH A QUINAZOLINONE DERIVATIVE",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 6854,
	"target": 6410,
	"type": 9310364,
	"label": "MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3 KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 9315169,
	"label": "Autoimmune Antibodies",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 9315177,
	"label": "PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 9315177,
	"label": "PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9315177,
	"label": "PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9315177,
	"label": "PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 9315177,
	"label": "PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 9318206,
	"label": "METHODS FOR IMPROVING SAFETY OF BLOOD-BRAIN BARRIER TRANSPORT",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 6280,
	"type": 9320659,
	"label": "N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6281,
	"target": 6280,
	"type": 9320660,
	"label": "N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 6281,
	"type": 9320660,
	"label": "N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7510,
	"target": 6280,
	"type": 9320660,
	"label": "N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6816,
	"target": 6279,
	"type": 9321893,
	"label": "ANTIVIRAL COMPOUNDS INHIBITORS OF HCV NS5B",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 38065,
	"target": 32788,
	"type": 9323094,
	"label": "Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 7507,
	"type": 9323094,
	"label": "Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38065,
	"target": 7507,
	"type": 9323094,
	"label": "Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 9326178,
	"label": "PYRROLOPYRIMIDONE AND PYRROLOPYRIDONE INHIBITORS OF TANKYRASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9326178,
	"label": "PYRROLOPYRIMIDONE AND PYRROLOPYRIDONE INHIBITORS OF TANKYRASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 9326178,
	"label": "PYRROLOPYRIMIDONE AND PYRROLOPYRIDONE INHIBITORS OF TANKYRASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 9336081,
	"label": "ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 9336081,
	"label": "ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 6962,
	"type": 9336081,
	"label": "ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 31851,
	"type": 9339082,
	"label": "?COMPUESTOS PARA EL TRATAMIENTO DEL HIV, COMPOSICIONES,MÉTODOS DE PREPARACIÓN, INTERMEDIARIOS Y MÉTODOS TERAPÉUTICOS?.",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 6376,
	"target": 6360,
	"type": 9341385,
	"label": "PYRROLIDINO HETEROCYCLES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6360,
	"target": 6281,
	"type": 9341385,
	"label": "PYRROLIDINO HETEROCYCLES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6376,
	"target": 6281,
	"type": 9341385,
	"label": "PYRROLIDINO HETEROCYCLES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6280,
	"type": 9341388,
	"label": "TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 31056,
	"type": 9341414,
	"label": "AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31056,
	"target": 6376,
	"type": 9341414,
	"label": "AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6376,
	"type": 9341414,
	"label": "AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32772,
	"target": 32770,
	"type": 9345755,
	"label": "MULTISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32772,
	"type": 9345755,
	"label": "MULTISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 9345755,
	"label": "MULTISPECIFIC ANTIBODIES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6301,
	"target": 6292,
	"type": 9345774,
	"label": "7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 9345774,
	"label": "7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6376,
	"target": 6292,
	"type": 9345774,
	"label": "7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6376,
	"target": 6301,
	"type": 9345775,
	"label": "7-OXO-4,7 -DIHYDRO- PYRAZOLO [1, 5 -A] PYRIMIDINE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 9350476,
	"label": "BISPECIFIC ANTIBODIES AGAINST HUMAN TWEAK AND HUMAN IL17 AND USES THEREOF",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 32770,
	"type": 9351131,
	"label": "ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6962,
	"type": 9351131,
	"label": "ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9351131,
	"label": "ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9351131,
	"label": "ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 6962,
	"type": 9351131,
	"label": "ANTI-LGR5 ANTIBODIES AND IMMUNOCONJUGATES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 9352523,
	"label": "NOVEL QUINOXALINE INHIBITORS OF PI3K",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 9354694,
	"label": "Ion concentration-dependent binding molecule library",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 7511,
	"type": 9354694,
	"label": "Ion concentration-dependent binding molecule library",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 7511,
	"type": 9354694,
	"label": "Ion concentration-dependent binding molecule library",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 9359414,
	"label": "ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 9359414,
	"label": "ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 9359414,
	"label": "ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 9359414,
	"label": "ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32770,
	"type": 9359414,
	"label": "ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 9359429,
	"label": "ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 9359429,
	"label": "ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 9359429,
	"label": "ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 9365635,
	"label": "Novel heterocyclic derivatives and their uses",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 6376,
	"target": 6302,
	"type": 9365635,
	"label": "Novel heterocyclic derivatives and their uses",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6376,
	"type": 9365635,
	"label": "Novel heterocyclic derivatives and their uses",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7510,
	"target": 6376,
	"type": 9365635,
	"label": "Novel heterocyclic derivatives and their uses",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6302,
	"type": 9365635,
	"label": "Novel heterocyclic derivatives and their uses",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 9368365,
	"label": "ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SACCHARIDE CHAIN RECEPTOR-BINDING DOMAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 9368365,
	"label": "ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SACCHARIDE CHAIN RECEPTOR-BINDING DOMAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 9368365,
	"label": "ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SACCHARIDE CHAIN RECEPTOR-BINDING DOMAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 6854,
	"type": 9368365,
	"label": "ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SACCHARIDE CHAIN RECEPTOR-BINDING DOMAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 6854,
	"type": 9368365,
	"label": "ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SACCHARIDE CHAIN RECEPTOR-BINDING DOMAIN",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6476,
	"type": 9375767,
	"label": "IMMUNOCONJUGATES COMPRISING ANTI - CD79B ANTIBODIES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6290,
	"type": 9376591,
	"label": "Inhibitors of IAP",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 38065,
	"type": 9377557,
	"label": "EXPRESSION AND SECRETION SYSTEM",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38184,
	"target": 6854,
	"type": 9380261,
	"label": "GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 6376,
	"target": 6371,
	"type": 9384257,
	"label": "INHIBITORS OF HEPATITIS C VIRUS",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 9385041,
	"label": "COMBINATION THERAPY OF INHIBITORS FOR IGF1 R AND PI3K",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6476,
	"type": 9385607,
	"label": "IMMUNOCONJUGATES COMPRISING ANTI-CD22 ANTIBODIES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6382,
	"target": 6376,
	"type": 9388402,
	"label": "METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION WITHOUT COMPANION DIAGNOSIS",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 9389870,
	"label": "ANTIBODIES TO MATRIX METALLOPROTEINASE 9",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 37947,
	"target": 7507,
	"type": 9389870,
	"label": "ANTIBODIES TO MATRIX METALLOPROTEINASE 9",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 37947,
	"target": 6854,
	"type": 9389870,
	"label": "ANTIBODIES TO MATRIX METALLOPROTEINASE 9",
	"group": "Gilead",
	"time": 2012,
	"strength": 1
}, {
	"source": 38232,
	"target": 7507,
	"type": 9400975,
	"label": "ENGINEERED CONFORMATIONALLY-STABILIZED PROTEINS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7507,
	"target": 6301,
	"type": 9401624,
	"label": "AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9401624,
	"label": "AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 6301,
	"type": 9401624,
	"label": "AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9401625,
	"label": "PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7450,
	"target": 6298,
	"type": 9401626,
	"label": "AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7509,
	"target": 7508,
	"type": 9401627,
	"label": "AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 9401627,
	"label": "AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 9401627,
	"label": "AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6303,
	"type": 9401627,
	"label": "AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7508,
	"target": 6303,
	"type": 9401627,
	"label": "AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31939,
	"target": 7508,
	"type": 9403600,
	"label": "POLIMORFOS DE (S)?2?(1?(9H?PURIN?6?ILAMINO)PROPIL)?5?FLUOR?3?FENILQUINAZOLIN?4(3H)?ONA, COMPOSICIÓN Y MÉTODO DE PREPARACIÓN",
	"group": "Gilead",
	"time": 2013,
	"strength": 1
}, {
	"source": 7450,
	"target": 7424,
	"type": 9407830,
	"label": "MODIFIED FC REGION OF ANTIBODY",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6382,
	"target": 6376,
	"type": 9412358,
	"label": "Compounds for treating spinal muscular atrophy",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31042,
	"target": 6382,
	"type": 9412358,
	"label": "Compounds for treating spinal muscular atrophy",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31042,
	"target": 6376,
	"type": 9412358,
	"label": "Compounds for treating spinal muscular atrophy",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 32770,
	"type": 9412381,
	"label": "METHODS OF TREATING FGFR3 RELATED CONDITIONS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9419288,
	"label": "Bispecific T cell activating antigen binding molecules",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 9424277,
	"label": "HUMAN BTNL3 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 9438320,
	"label": "PROTEÍNAS DE UNIÓN ANTI-MESOTELINA",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9438320,
	"label": "PROTEÍNAS DE UNIÓN ANTI-MESOTELINA",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 7507,
	"type": 9438320,
	"label": "PROTEÍNAS DE UNIÓN ANTI-MESOTELINA",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 31851,
	"type": 9438374,
	"label": "ARYL SULTAM DERIVATIVES AS RORc MODULATORS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 31851,
	"type": 9439373,
	"label": "ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31851,
	"target": 7507,
	"type": 9439373,
	"label": "ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9439373,
	"label": "ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 9440507,
	"label": "BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 56834,
	"target": 6550,
	"type": 9442120,
	"label": "BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6290,
	"target": 6263,
	"type": 9443761,
	"label": "COMBINATION OF THERAPEUTIC AGENTS FOR TREATING HCV INFECTION",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6478,
	"target": 6403,
	"type": 9443761,
	"label": "COMBINATION OF THERAPEUTIC AGENTS FOR TREATING HCV INFECTION",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6403,
	"target": 6290,
	"type": 9443761,
	"label": "COMBINATION OF THERAPEUTIC AGENTS FOR TREATING HCV INFECTION",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6403,
	"target": 6263,
	"type": 9443761,
	"label": "COMBINATION OF THERAPEUTIC AGENTS FOR TREATING HCV INFECTION",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6478,
	"target": 6290,
	"type": 9443761,
	"label": "COMBINATION OF THERAPEUTIC AGENTS FOR TREATING HCV INFECTION",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6816,
	"target": 6281,
	"type": 9443824,
	"label": "TRIAZOLE COMPOUNDS AS ANTIVIRALS",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 9444049,
	"label": "Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37986,
	"type": 9444049,
	"label": "Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 9444049,
	"label": "Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37986,
	"target": 37859,
	"type": 9444049,
	"label": "Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 9444049,
	"label": "Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 39999,
	"target": 37986,
	"type": 9444060,
	"label": "Peptide-compound cyclization method",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 9447043,
	"label": "5-AZAINDAZOLE COMPOUNDS AND METHODS OF USE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 31995,
	"target": 6376,
	"type": 9450709,
	"label": "Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 9459384,
	"label": "QUINAZOLINEDIONE DERIVATIVE",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37993,
	"target": 37988,
	"type": 9490595,
	"label": "PROTEÍNAS DE UNIÓN A ANTÍGENO DIRIGIDAS CONTRA EL RECEPTOR ST2",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 38065,
	"target": 37993,
	"type": 9490595,
	"label": "PROTEÍNAS DE UNIÓN A ANTÍGENO DIRIGIDAS CONTRA EL RECEPTOR ST2",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 38065,
	"target": 37988,
	"type": 9490595,
	"label": "PROTEÍNAS DE UNIÓN A ANTÍGENO DIRIGIDAS CONTRA EL RECEPTOR ST2",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 37988,
	"target": 32770,
	"type": 9490595,
	"label": "PROTEÍNAS DE UNIÓN A ANTÍGENO DIRIGIDAS CONTRA EL RECEPTOR ST2",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 9490595,
	"label": "PROTEÍNAS DE UNIÓN A ANTÍGENO DIRIGIDAS CONTRA EL RECEPTOR ST2",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 9491723,
	"label": "Novel azetidine derivatives",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 9504209,
	"label": "Anti-MCSP antibodies",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 9539261,
	"label": "ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 9539261,
	"label": "ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 9539261,
	"label": "ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 6838,
	"target": 6795,
	"type": 9579555,
	"label": "Procédé pour la préparation d'un composé de thrombokinase",
	"group": "Roche",
	"time": 1947,
	"strength": 1
}, {
	"source": 37947,
	"target": 6838,
	"type": 9579555,
	"label": "Procédé pour la préparation d'un composé de thrombokinase",
	"group": "Roche",
	"time": 1947,
	"strength": 1
}, {
	"source": 37947,
	"target": 6795,
	"type": 9579555,
	"label": "Procédé pour la préparation d'un composé de thrombokinase",
	"group": "Roche",
	"time": 1947,
	"strength": 1
}, {
	"source": 7507,
	"target": 6478,
	"type": 9595484,
	"label": "THERAPEUTIC COMPOSITION CONTAINING AT LEAST DIFLOMOTECAN ANDCAPECITABIN E",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 30820,
	"target": 30816,
	"type": 10645394,
	"label": "Novel isoquinoline derivatives and salts thereof and a process for the manufacture of same",
	"group": "Roche",
	"time": 1959,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 10819649,
	"label": "VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS FOR USE AS MEDICAMENTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 10819649,
	"label": "VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS FOR USE AS MEDICAMENTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 10819649,
	"label": "VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS FOR USE AS MEDICAMENTS IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 30821,
	"target": 30814,
	"type": 10831448,
	"label": "1-benzyl-5, 6, 7, 8-tetrahydroisoquinoline and derivatives thereof",
	"group": "Roche",
	"time": 1950,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 10926174,
	"label": "Combination therapy using a TNF binding protein for treating TNF-mediated diseases",
	"group": "Amgen",
	"time": 2001,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 10926336,
	"label": "Antibodies to death receptor 4 (DR4) and uses thereof",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37993,
	"target": 37904,
	"type": 10926336,
	"label": "Antibodies to death receptor 4 (DR4) and uses thereof",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37904,
	"target": 32779,
	"type": 10926336,
	"label": "Antibodies to death receptor 4 (DR4) and uses thereof",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 10926336,
	"label": "Antibodies to death receptor 4 (DR4) and uses thereof",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 10926336,
	"label": "Antibodies to death receptor 4 (DR4) and uses thereof",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 10926485,
	"label": "Diagnosis and treatment of hepatic disorders",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 10926485,
	"label": "Diagnosis and treatment of hepatic disorders",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56836,
	"target": 37904,
	"type": 10926485,
	"label": "Diagnosis and treatment of hepatic disorders",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 56836,
	"target": 32770,
	"type": 10926485,
	"label": "Diagnosis and treatment of hepatic disorders",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 10926485,
	"label": "Diagnosis and treatment of hepatic disorders",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38164,
	"target": 32478,
	"type": 10926818,
	"label": "2'fluoropyrimidine anti-calf intestinal phosphate nucleic acid ligands",
	"group": "Gilead",
	"time": 2005,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 10926973,
	"label": "Antibody variants with higher binding affinity compared to parent antibodies",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 10927218,
	"label": "APO-2 ligand",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 37899,
	"type": 10927218,
	"label": "APO-2 ligand",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 37862,
	"type": 10927218,
	"label": "APO-2 ligand",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37862,
	"target": 32770,
	"type": 10927218,
	"label": "APO-2 ligand",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 10927218,
	"label": "APO-2 ligand",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 10927298,
	"label": "Methods for enhancing the efficacy of cancer therapy",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 10927371,
	"label": "Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 37864,
	"type": 10927371,
	"label": "Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38042,
	"target": 37862,
	"type": 10927371,
	"label": "Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 10927495,
	"label": "Uses of agonists and antagonists to modulate activity of TNF-related molecules",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 6854,
	"target": 6795,
	"type": 10927495,
	"label": "Uses of agonists and antagonists to modulate activity of TNF-related molecules",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6854,
	"type": 10927495,
	"label": "Uses of agonists and antagonists to modulate activity of TNF-related molecules",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7510,
	"target": 6854,
	"type": 10927495,
	"label": "Uses of agonists and antagonists to modulate activity of TNF-related molecules",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 10927495,
	"label": "Uses of agonists and antagonists to modulate activity of TNF-related molecules",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 32788,
	"type": 10927650,
	"label": "Tumor Endothelial Marker 7Alpha Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 10976444,
	"label": "Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 37875,
	"type": 10979837,
	"label": "Polypeptide production in animal cell culture",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 11001623,
	"label": "VERFAHREN UND VERBINDUNGEN ZUR VERLÄNGERUNG DER HALBWERTZEITEN BEI DER AUSSCHEIDUNG VON BIOWIRKSAMEN VERBINDUNGEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32779,
	"target": 6795,
	"type": 11001623,
	"label": "VERFAHREN UND VERBINDUNGEN ZUR VERLÄNGERUNG DER HALBWERTZEITEN BEI DER AUSSCHEIDUNG VON BIOWIRKSAMEN VERBINDUNGEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 11001623,
	"label": "VERFAHREN UND VERBINDUNGEN ZUR VERLÄNGERUNG DER HALBWERTZEITEN BEI DER AUSSCHEIDUNG VON BIOWIRKSAMEN VERBINDUNGEN",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 11001902,
	"label": "Vitamin D derivative with substituent at the 2 beta -position",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32735,
	"target": 32698,
	"type": 11009707,
	"label": "Method for treating or preventing gastrointestinal disease with epithelium-derived T-cell factor",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38004,
	"target": 37900,
	"type": 11009707,
	"label": "Method for treating or preventing gastrointestinal disease with epithelium-derived T-cell factor",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37900,
	"target": 32735,
	"type": 11009707,
	"label": "Method for treating or preventing gastrointestinal disease with epithelium-derived T-cell factor",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 37900,
	"target": 32698,
	"type": 11009707,
	"label": "Method for treating or preventing gastrointestinal disease with epithelium-derived T-cell factor",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 38004,
	"target": 32735,
	"type": 11009707,
	"label": "Method for treating or preventing gastrointestinal disease with epithelium-derived T-cell factor",
	"group": "Amgen",
	"time": 1996,
	"strength": 1
}, {
	"source": 56833,
	"target": 6795,
	"type": 11013342,
	"label": "Antibodies to human carboxypeptidase B and methods of use thereof",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38065,
	"target": 6854,
	"type": 11017891,
	"label": "Method for evaluating and modifying biological activity",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 11028460,
	"label": "Altered polypeptides with increased half-life",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 11035504,
	"label": "FÜR DIE GAMMA-UNTEREINHEIT DES REZEPTORS MIT HOHER AFFINITÄT FÜR IMMUNGLOBULIN E KODIERENDE CDNAS",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38065,
	"target": 37864,
	"type": 11037402,
	"label": "High throughput knockout constructs in yeast by homologous recombination",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 38181,
	"target": 32694,
	"type": 11048029,
	"label": "Control of norleucine incorporation into recombinant proteins",
	"group": "Amgen",
	"time": 1994,
	"strength": 1
}, {
	"source": 6854,
	"target": 6816,
	"type": 11054050,
	"label": "Use of tumor necrosis factor (TNF) as an adjuvant",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 37875,
	"target": 6795,
	"type": 11079667,
	"label": "Mammalian cell culture process",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 11133867,
	"label": "APO-2L receptor agonist and CPT-11 synergism",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 11133867,
	"label": "APO-2L receptor agonist and CPT-11 synergism",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 11133867,
	"label": "APO-2L receptor agonist and CPT-11 synergism",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 37988,
	"target": 37864,
	"type": 11160267,
	"label": "Osteoprotegerin binding proteins and receptors",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 37864,
	"target": 6812,
	"type": 11160267,
	"label": "Osteoprotegerin binding proteins and receptors",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 37988,
	"target": 6812,
	"type": 11160267,
	"label": "Osteoprotegerin binding proteins and receptors",
	"group": "Amgen",
	"time": 2013,
	"strength": 1
}, {
	"source": 38181,
	"target": 6795,
	"type": 11161000,
	"label": "Novel Compositions and Methods for the Treatment of Psoriasis",
	"group": "Roche",
	"time": 2013,
	"strength": 1
}, {
	"source": 7507,
	"target": 6483,
	"type": 11161622,
	"label": "Compositions and methods comprising an EGFL7 antagonist for modulating vascular development",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32788,
	"target": 32770,
	"type": 11164224,
	"label": "Rankl antibody-PTH/PTHrP chimeric molecules",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7450,
	"type": 11164224,
	"label": "Rankl antibody-PTH/PTHrP chimeric molecules",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 7450,
	"type": 11164224,
	"label": "Rankl antibody-PTH/PTHrP chimeric molecules",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 38184,
	"target": 32694,
	"type": 11443508,
	"label": "ANTITISSUE FACTOR ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 32694,
	"target": 7507,
	"type": 11443508,
	"label": "ANTITISSUE FACTOR ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 11443508,
	"label": "ANTITISSUE FACTOR ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2000,
	"strength": 1
}, {
	"source": 7425,
	"target": 6241,
	"type": 11904546,
	"label": "PROPHYLACTIC AND TREATING AGENT FOR MAMMITIS IN DOMESTIC ANIMALS AND ITS APPLICATION",
	"group": "Roche",
	"time": 1979,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 11912862,
	"label": "11HYDROXYVITAMIN D3",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 7424,
	"target": 6795,
	"type": 11989322,
	"label": "THERAPEUTIC AGENT FOR RENAL INSUFFICIENCY",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 7424,
	"type": 11989322,
	"label": "THERAPEUTIC AGENT FOR RENAL INSUFFICIENCY",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 11989322,
	"label": "THERAPEUTIC AGENT FOR RENAL INSUFFICIENCY",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 12037747,
	"label": "DNA SEQUENCE, POLYPEPTIDE EXHIBITING HEMATOPOIETIC BIOLOGICAL ACTIVITY, USE THEREOF AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37899,
	"type": 12037747,
	"label": "DNA SEQUENCE, POLYPEPTIDE EXHIBITING HEMATOPOIETIC BIOLOGICAL ACTIVITY, USE THEREOF AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 12037747,
	"label": "DNA SEQUENCE, POLYPEPTIDE EXHIBITING HEMATOPOIETIC BIOLOGICAL ACTIVITY, USE THEREOF AND PHARMACEUTICAL COMPOSITIONS",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 12386260,
	"label": "8ALPHA-HYDROXYVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 12482966,
	"label": "NEW VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 30485,
	"target": 6431,
	"type": 12482966,
	"label": "NEW VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 12482966,
	"label": "NEW VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 12792950,
	"label": "Reconstructed hyman antibody against human interleukin-8",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38042,
	"target": 37993,
	"type": 12792950,
	"label": "Reconstructed hyman antibody against human interleukin-8",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37993,
	"target": 37864,
	"type": 12792950,
	"label": "Reconstructed hyman antibody against human interleukin-8",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 12792950,
	"label": "Reconstructed hyman antibody against human interleukin-8",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 38042,
	"type": 12792950,
	"label": "Reconstructed hyman antibody against human interleukin-8",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 12919800,
	"label": "NOVEL VITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 6909,
	"target": 6429,
	"type": 13016051,
	"label": "VITAMIN D DERIVATIVE CONTAINING SUBSTITUENT GROUP AT SECOND POSITION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7450,
	"target": 6909,
	"type": 13016051,
	"label": "VITAMIN D DERIVATIVE CONTAINING SUBSTITUENT GROUP AT SECOND POSITION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7450,
	"target": 6429,
	"type": 13016051,
	"label": "VITAMIN D DERIVATIVE CONTAINING SUBSTITUENT GROUP AT SECOND POSITION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 30485,
	"target": 7450,
	"type": 13016051,
	"label": "VITAMIN D DERIVATIVE CONTAINING SUBSTITUENT GROUP AT SECOND POSITION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 30485,
	"target": 6909,
	"type": 13016051,
	"label": "VITAMIN D DERIVATIVE CONTAINING SUBSTITUENT GROUP AT SECOND POSITION",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 13028295,
	"label": "20-OXA-21-NORBITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 13028295,
	"label": "20-OXA-21-NORBITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 13028295,
	"label": "20-OXA-21-NORBITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 13523044,
	"label": "20-OXO OR 20-SUBSTITUTED OXIMINOVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 13523044,
	"label": "20-OXO OR 20-SUBSTITUTED OXIMINOVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 13523044,
	"label": "20-OXO OR 20-SUBSTITUTED OXIMINOVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 13850228,
	"label": "A VITAMIN D DERIVATIVE WITH SUBSTITUENT AT THE 2.BETA.-POSITION",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32698,
	"target": 32694,
	"type": 13961820,
	"label": "BSF2 ANTAGONIST",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 13961820,
	"label": "BSF2 ANTAGONIST",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32694,
	"target": 7507,
	"type": 13961820,
	"label": "BSF2 ANTAGONIST",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32698,
	"target": 7507,
	"type": 13961820,
	"label": "BSF2 ANTAGONIST",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 13961820,
	"label": "BSF2 ANTAGONIST",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 14530944,
	"label": "IL-6 AUTOCRINE-PROLIFERATIVE HUMAN MYELOMA CELLS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6565,
	"type": 14530944,
	"label": "IL-6 AUTOCRINE-PROLIFERATIVE HUMAN MYELOMA CELLS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 14530944,
	"label": "IL-6 AUTOCRINE-PROLIFERATIVE HUMAN MYELOMA CELLS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 14530944,
	"label": "IL-6 AUTOCRINE-PROLIFERATIVE HUMAN MYELOMA CELLS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37899,
	"target": 6565,
	"type": 14530944,
	"label": "IL-6 AUTOCRINE-PROLIFERATIVE HUMAN MYELOMA CELLS",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 14785025,
	"label": "Immunosuppressive agents",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 15326863,
	"label": "INHIBITION OF TUMOR METASTASIS BY ANTI NEUROPILIN 2 ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38004,
	"target": 37986,
	"type": 15698014,
	"label": "PRODUCTION OF HUMAN 1L-6 RECEPTOR",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 15698014,
	"label": "PRODUCTION OF HUMAN 1L-6 RECEPTOR",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38004,
	"target": 37899,
	"type": 15698014,
	"label": "PRODUCTION OF HUMAN 1L-6 RECEPTOR",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37899,
	"target": 32698,
	"type": 15698014,
	"label": "PRODUCTION OF HUMAN 1L-6 RECEPTOR",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 15698014,
	"label": "PRODUCTION OF HUMAN 1L-6 RECEPTOR",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 38181,
	"target": 38042,
	"type": 15850183,
	"label": "Enhanced solubility of recombinant proteins using Uracil DNA glycosylase inhibitor",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7509,
	"target": 7450,
	"type": 16011679,
	"label": "Thiazole derivatives",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 16269088,
	"label": "METHOD FOR ANTIBODY STABILIZATION",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37864,
	"target": 7511,
	"type": 16452370,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7509,
	"target": 7479,
	"type": 16477526,
	"label": "FRAGMENT OF NEUROPILIN AND CRYSTAL STRUCTURE OF NEUROPILIN-ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7509,
	"type": 16477526,
	"label": "FRAGMENT OF NEUROPILIN AND CRYSTAL STRUCTURE OF NEUROPILIN-ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7479,
	"type": 16477526,
	"label": "FRAGMENT OF NEUROPILIN AND CRYSTAL STRUCTURE OF NEUROPILIN-ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37993,
	"target": 37899,
	"type": 16545749,
	"label": "Antibody chimeric chain chimeric antibody against human tissue factor, humanized antibody chain, humanized antibody, DNA, expression vector, host, preparation process and therapeutical agent",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 16545749,
	"label": "Antibody chimeric chain chimeric antibody against human tissue factor, humanized antibody chain, humanized antibody, DNA, expression vector, host, preparation process and therapeutical agent",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 16545749,
	"label": "Antibody chimeric chain chimeric antibody against human tissue factor, humanized antibody chain, humanized antibody, DNA, expression vector, host, preparation process and therapeutical agent",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 7360,
	"target": 7358,
	"type": 16636888,
	"label": "REMEDY FOR COPPER METABOLISM DISORDER",
	"group": "Roche",
	"time": 1979,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 16745854,
	"label": "CANCER METASTASIS SUPPRESSING AGENT",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 16745854,
	"label": "CANCER METASTASIS SUPPRESSING AGENT",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7509,
	"target": 6795,
	"type": 16745854,
	"label": "CANCER METASTASIS SUPPRESSING AGENT",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7409,
	"target": 6795,
	"type": 16809021,
	"label": "HUMANIZED ANTI-beta7 ANTAGONIST AND USE THEREOF",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 56834,
	"target": 6484,
	"type": 16959552,
	"label": "COP1 MOLECULES AND USES THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 31912,
	"target": 7360,
	"type": 17475104,
	"label": "3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 37864,
	"target": 37862,
	"type": 17853159,
	"label": "IL-6 RECEPTOR DERIVATIVE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37862,
	"target": 37859,
	"type": 17853159,
	"label": "IL-6 RECEPTOR DERIVATIVE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37864,
	"target": 37859,
	"type": 17853159,
	"label": "IL-6 RECEPTOR DERIVATIVE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 17853159,
	"label": "IL-6 RECEPTOR DERIVATIVE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37899,
	"target": 37862,
	"type": 17853159,
	"label": "IL-6 RECEPTOR DERIVATIVE",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 18148079,
	"label": "Monoclonal antibody inducing apoptosis",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 18148079,
	"label": "Monoclonal antibody inducing apoptosis",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 18148079,
	"label": "Monoclonal antibody inducing apoptosis",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 18148079,
	"label": "Monoclonal antibody inducing apoptosis",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37904,
	"target": 7508,
	"type": 18148079,
	"label": "Monoclonal antibody inducing apoptosis",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 6909,
	"target": 6429,
	"type": 18251318,
	"label": "NOVEL VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 30485,
	"target": 6909,
	"type": 18251318,
	"label": "NOVEL VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 18251318,
	"label": "NOVEL VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 7375,
	"target": 6185,
	"type": 18363738,
	"label": "AGENT FOR TREATING HASHIMOTO STRUMITIS",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 18507712,
	"label": "Injectable aqueous emulsions of fat soluble vitamins",
	"group": "Roche",
	"time": 1965,
	"strength": 1
}, {
	"source": 32779,
	"target": 32777,
	"type": 19122367,
	"label": "CDR-repaired antibodies",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 19122367,
	"label": "CDR-repaired antibodies",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32779,
	"target": 32770,
	"type": 19122367,
	"label": "CDR-repaired antibodies",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7409,
	"target": 6841,
	"type": 19603184,
	"label": "HUMAN DNASE I VARIANTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 7409,
	"type": 19603184,
	"label": "HUMAN DNASE I VARIANTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 37986,
	"target": 6841,
	"type": 19603184,
	"label": "HUMAN DNASE I VARIANTS",
	"group": "Roche",
	"time": 2008,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 19615697,
	"label": "INHIBICION DE METASTASIS DE TUMOR POR ANTICUERPOS ANTI NEUROPILINA 2",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 19846032,
	"label": "BLOOD SERUM CALCIUM-DECREASING FACTOR DERIVED FROM RAT PANCREAS AND METHOD FOR PURIFYING THE SAME",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 19883327,
	"label": "PREPARATION OF VITAMIN D DERIVATIVES",
	"group": "Roche",
	"time": 1977,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 19959557,
	"label": "NOVEL VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 32777,
	"target": 32770,
	"type": 20067121,
	"label": "BISPECIFIC MOLECULES CROSS-LINKING ITIM AND ITAM FOR THERAPY OF ALLERGIES",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 20282170,
	"label": "Medicament against cachexia",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 7507,
	"type": 20282170,
	"label": "Medicament against cachexia",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 20282170,
	"label": "Medicament against cachexia",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 20440824,
	"label": "NOVEL DNA",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37986,
	"target": 32697,
	"type": 20440824,
	"label": "NOVEL DNA",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 20440824,
	"label": "NOVEL DNA",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 20800930,
	"label": "Truncated soluble tumor necrosis factor type-I and type-II receptors",
	"group": "Amgen",
	"time": 1997,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 20816686,
	"label": "Purified and isolated polypeptide, use thereof, DNA sequence for its expression and pharmaceutical composition",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37864,
	"target": 32697,
	"type": 20816686,
	"label": "Purified and isolated polypeptide, use thereof, DNA sequence for its expression and pharmaceutical composition",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 32697,
	"type": 20816686,
	"label": "Purified and isolated polypeptide, use thereof, DNA sequence for its expression and pharmaceutical composition",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 32697,
	"target": 6795,
	"type": 20816686,
	"label": "Purified and isolated polypeptide, use thereof, DNA sequence for its expression and pharmaceutical composition",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 20816686,
	"label": "Purified and isolated polypeptide, use thereof, DNA sequence for its expression and pharmaceutical composition",
	"group": "Amgen",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 21037014,
	"label": "GENE FOR INFLAMMATORY CYTOKINE-INDUCING FACTOR",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 21570190,
	"label": "NEW CARCINOSTATIC AGENT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7507,
	"target": 6213,
	"type": 21570190,
	"label": "NEW CARCINOSTATIC AGENT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 7508,
	"target": 6213,
	"type": 21570190,
	"label": "NEW CARCINOSTATIC AGENT",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 21614816,
	"label": "COMPOSITION AND METHOD FOR INHIBITING GROWTH OF TUMOROUS CELL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 21614816,
	"label": "COMPOSITION AND METHOD FOR INHIBITING GROWTH OF TUMOROUS CELL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 21614816,
	"label": "COMPOSITION AND METHOD FOR INHIBITING GROWTH OF TUMOROUS CELL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37864,
	"target": 32779,
	"type": 21614816,
	"label": "COMPOSITION AND METHOD FOR INHIBITING GROWTH OF TUMOROUS CELL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 21614816,
	"label": "COMPOSITION AND METHOD FOR INHIBITING GROWTH OF TUMOROUS CELL",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 37897,
	"target": 37878,
	"type": 22124776,
	"label": "METHOD FOR SCREENING TUMOR-WORSENING FACTOR AND TUMOR WORSENING-INHIBITING COMPOUND",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37878,
	"target": 7507,
	"type": 22124776,
	"label": "METHOD FOR SCREENING TUMOR-WORSENING FACTOR AND TUMOR WORSENING-INHIBITING COMPOUND",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37897,
	"target": 7507,
	"type": 22124776,
	"label": "METHOD FOR SCREENING TUMOR-WORSENING FACTOR AND TUMOR WORSENING-INHIBITING COMPOUND",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 22329594,
	"label": "APO-2 ligand variants and uses thereof",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 22329594,
	"label": "APO-2 ligand variants and uses thereof",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 22329594,
	"label": "APO-2 ligand variants and uses thereof",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 22582722,
	"label": "NOVEL VITAMIN D DERIVATIVE AND ITS PREPARATION",
	"group": "Roche",
	"time": 1978,
	"strength": 1
}, {
	"source": 6466,
	"target": 6462,
	"type": 22635554,
	"label": "AGENT FOR REMOVING BIOLOGICAL FILM",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 6466,
	"target": 6133,
	"type": 22642353,
	"label": "STABLE LIQUID MEDICINE CONTAINING AZULENE DERIVATIVE AND ITS PRODUCTION",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 23305978,
	"label": "Method for predicting and/or preventing preterm labor",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32788,
	"target": 32694,
	"type": 23691235,
	"label": "MODIFIED ERITHROPOIETIN",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 23691235,
	"label": "MODIFIED ERITHROPOIETIN",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 32788,
	"target": 6795,
	"type": 23691235,
	"label": "MODIFIED ERITHROPOIETIN",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 37986,
	"target": 37960,
	"type": 23703012,
	"label": "PROTEIN BINDING TO TOPOISOMERASE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 32770,
	"type": 23712775,
	"label": "MEDICINE CONTAINING APOPTOSIS-INDUCING MONOCLONAL ANTIBODY AS ACTIVE COMPONENT",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 23712775,
	"label": "MEDICINE CONTAINING APOPTOSIS-INDUCING MONOCLONAL ANTIBODY AS ACTIVE COMPONENT",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37899,
	"target": 7508,
	"type": 23712775,
	"label": "MEDICINE CONTAINING APOPTOSIS-INDUCING MONOCLONAL ANTIBODY AS ACTIVE COMPONENT",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 32738,
	"type": 23927570,
	"label": "Specific binding agents to hepatocyte growth factor",
	"group": "Amgen",
	"time": 2011,
	"strength": 1
}, {
	"source": 32689,
	"target": 6795,
	"type": 23984721,
	"label": "Transforming Growth Factor-Beta-Related Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2006,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 24555316,
	"label": "O-substituted hydroxy coumarone derivatives functioning as antitumor and anti-metastasis agents",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6241,
	"type": 24555316,
	"label": "O-substituted hydroxy coumarone derivatives functioning as antitumor and anti-metastasis agents",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7509,
	"target": 6241,
	"type": 24555316,
	"label": "O-substituted hydroxy coumarone derivatives functioning as antitumor and anti-metastasis agents",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38042,
	"target": 32770,
	"type": 24999525,
	"label": "APO-2 receptor",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 24999525,
	"label": "APO-2 receptor",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 38042,
	"target": 6812,
	"type": 24999525,
	"label": "APO-2 receptor",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32698,
	"target": 6795,
	"type": 25233262,
	"label": "REMEDY FOR DISEASE RELATED TO SENSITIZED T CELL",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 31912,
	"target": 31081,
	"type": 25484007,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7507,
	"target": 6360,
	"type": 25484007,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 31081,
	"target": 7507,
	"type": 25484007,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 25484007,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 31081,
	"target": 6360,
	"type": 25484007,
	"label": "BICYCLIC NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS FOR USE AS STEAROYL COA DESATURASE INHIBITORS",
	"group": "Gilead",
	"time": 2008,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 25532849,
	"label": "Peptide epoxyketones for proteasome inhibition",
	"group": "Amgen",
	"time": 2012,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 25747416,
	"label": "NOVEL TRANS-VITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 25843951,
	"label": "MYELOMA MEDICINE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 37899,
	"target": 37864,
	"type": 25869465,
	"label": "GENE EXHIBITING DISEASE TYPE-SPECIFIC CHANGE IN EXPRESSION IN VARIOUS TYPES OF CANCER, AND UTILIZATION THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 25869465,
	"label": "GENE EXHIBITING DISEASE TYPE-SPECIFIC CHANGE IN EXPRESSION IN VARIOUS TYPES OF CANCER, AND UTILIZATION THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 25869465,
	"label": "GENE EXHIBITING DISEASE TYPE-SPECIFIC CHANGE IN EXPRESSION IN VARIOUS TYPES OF CANCER, AND UTILIZATION THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 7507,
	"type": 25869465,
	"label": "GENE EXHIBITING DISEASE TYPE-SPECIFIC CHANGE IN EXPRESSION IN VARIOUS TYPES OF CANCER, AND UTILIZATION THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 25869465,
	"label": "GENE EXHIBITING DISEASE TYPE-SPECIFIC CHANGE IN EXPRESSION IN VARIOUS TYPES OF CANCER, AND UTILIZATION THEREOF",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 28540,
	"target": 28157,
	"type": 25989531,
	"label": "2-phenylindene derivatives and process for the manufacture of same",
	"group": "Roche",
	"time": 1944,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 26078123,
	"label": "INHIBITION OF TUMOR METASTASIS BY ANTI NEUROPILIN 2 (Nrp2) ANTIBODIES",
	"group": "Roche",
	"time": 2007,
	"strength": 1
}, {
	"source": 6812,
	"target": 6795,
	"type": 26367563,
	"label": "ANTITUMOR AGENT",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37899,
	"target": 37875,
	"type": 26374622,
	"label": "IL-6 RECEPTOR DERIVATIVE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 26374622,
	"label": "IL-6 RECEPTOR DERIVATIVE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37986,
	"target": 37875,
	"type": 26374622,
	"label": "IL-6 RECEPTOR DERIVATIVE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32788,
	"target": 32771,
	"type": 26420512,
	"label": "INTERLEUKIN-22 POLYPEPTIDE, NUCLEIC ACID FOR CODING THE SAME, AND MEDICAL TREATMENT METHOD OF PANCREAS DISEASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38004,
	"target": 37986,
	"type": 26420512,
	"label": "INTERLEUKIN-22 POLYPEPTIDE, NUCLEIC ACID FOR CODING THE SAME, AND MEDICAL TREATMENT METHOD OF PANCREAS DISEASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32788,
	"type": 26420512,
	"label": "INTERLEUKIN-22 POLYPEPTIDE, NUCLEIC ACID FOR CODING THE SAME, AND MEDICAL TREATMENT METHOD OF PANCREAS DISEASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 32771,
	"type": 26420512,
	"label": "INTERLEUKIN-22 POLYPEPTIDE, NUCLEIC ACID FOR CODING THE SAME, AND MEDICAL TREATMENT METHOD OF PANCREAS DISEASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 38004,
	"target": 32788,
	"type": 26420512,
	"label": "INTERLEUKIN-22 POLYPEPTIDE, NUCLEIC ACID FOR CODING THE SAME, AND MEDICAL TREATMENT METHOD OF PANCREAS DISEASE",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 26620610,
	"label": "CRYSTAL STRUCTURE OF NEUROPILIN FRAGMENT AND NEUROPILIN-ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7508,
	"type": 26620610,
	"label": "CRYSTAL STRUCTURE OF NEUROPILIN FRAGMENT AND NEUROPILIN-ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 26620610,
	"label": "CRYSTAL STRUCTURE OF NEUROPILIN FRAGMENT AND NEUROPILIN-ANTIBODY COMPLEX",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 26795146,
	"label": "5,6-EPOXIDIZED TRANS-VITAMIN D3",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 26952190,
	"label": "IMMORTALIZED HUMAN MESANGIAL CELL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37899,
	"target": 7424,
	"type": 26952190,
	"label": "IMMORTALIZED HUMAN MESANGIAL CELL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 37986,
	"target": 7424,
	"type": 26952190,
	"label": "IMMORTALIZED HUMAN MESANGIAL CELL",
	"group": "Roche",
	"time": 2006,
	"strength": 1
}, {
	"source": 32004,
	"target": 31851,
	"type": 27519328,
	"label": "water soluble camptothecin derivates",
	"group": "Gilead",
	"time": 1993,
	"strength": 1
}, {
	"source": 32612,
	"target": 6795,
	"type": 27593890,
	"label": "Conjugated ligands for the stimulation of blood cell proliferation by effecting dimerization of the receptor for stem cell factor",
	"group": "Amgen",
	"time": 2000,
	"strength": 1
}, {
	"source": 7509,
	"target": 7487,
	"type": 27759680,
	"label": "Thiazole derivatives",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7487,
	"target": 7450,
	"type": 27759680,
	"label": "Thiazole derivatives",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7509,
	"target": 7450,
	"type": 27759680,
	"label": "Thiazole derivatives",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 27886100,
	"label": "NOVEL PLATINUM COMPLEX",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 56834,
	"target": 32788,
	"type": 27940332,
	"label": "COMPOSITION FOR DIAGNOSIS OF PROSTATE DISEASE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 32788,
	"target": 6854,
	"type": 27940332,
	"label": "COMPOSITION FOR DIAGNOSIS OF PROSTATE DISEASE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 27940332,
	"label": "COMPOSITION FOR DIAGNOSIS OF PROSTATE DISEASE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 28120160,
	"label": "Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7509,
	"target": 7507,
	"type": 28196800,
	"label": "ANTI VEGF-D ANTIBODY, AND USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 7509,
	"type": 28196800,
	"label": "ANTI VEGF-D ANTIBODY, AND USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 28196800,
	"label": "ANTI VEGF-D ANTIBODY, AND USE THEREOF",
	"group": "Roche",
	"time": 2010,
	"strength": 1
}, {
	"source": 38232,
	"target": 37986,
	"type": 28216281,
	"label": "METHOD FOR SCREENING BONE MASS INCREASING AGENT",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 28504183,
	"label": "24,24-DIFULORO-25-HYDROXYVITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 7510,
	"target": 7507,
	"type": 28575511,
	"label": "N-TERMINAL MODIFIED G-CSF AND CONSENSUS INF PREFERABLY MODIFIED BY ATTACHMENT OF A WATER SOLUBLE POLYMER EG PEG",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 28575511,
	"label": "N-TERMINAL MODIFIED G-CSF AND CONSENSUS INF PREFERABLY MODIFIED BY ATTACHMENT OF A WATER SOLUBLE POLYMER EG PEG",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 7510,
	"target": 6795,
	"type": 28575511,
	"label": "N-TERMINAL MODIFIED G-CSF AND CONSENSUS INF PREFERABLY MODIFIED BY ATTACHMENT OF A WATER SOLUBLE POLYMER EG PEG",
	"group": "Amgen",
	"time": 1995,
	"strength": 1
}, {
	"source": 38042,
	"target": 6812,
	"type": 29325191,
	"label": "Recombinant proteins",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 29340504,
	"label": "PURIFICATION OF RECOMBINANT INTERLEUKIN-2",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 7360,
	"target": 6795,
	"type": 29488514,
	"label": "GROWTH PROMOTING COMPOSITION FOR ANIMAL",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 29576352,
	"label": "19-SUBSTITUTED VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1988,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 29895753,
	"label": "Conjugate of hedgehog protein exhibiting increased activity, process of its preparation and its therapeutical application",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 29978273,
	"label": "1* 255DIHYDROXYVITAMIN",
	"group": "Roche",
	"time": 1978,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 30098869,
	"label": "23,25,26-TRIHYDROXYVITAMIN D3",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 37986,
	"target": 6795,
	"type": 30509998,
	"label": "THERAPEUTIC AGENT FOR DISEASE OF BRAIN AND NERVE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 30524977,
	"label": "ANTITUMOR AGENT",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 7507,
	"target": 6795,
	"type": 30524977,
	"label": "ANTITUMOR AGENT",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 7508,
	"target": 6795,
	"type": 30524977,
	"label": "ANTITUMOR AGENT",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 30659593,
	"label": "NOVEL 22-OXAVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 30485,
	"target": 7507,
	"type": 30659593,
	"label": "NOVEL 22-OXAVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 30659593,
	"label": "NOVEL 22-OXAVITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1989,
	"strength": 1
}, {
	"source": 30485,
	"target": 27540,
	"type": 31196637,
	"label": "NEW SYNTHETIC METHOD OF VITAMIN D COMPOUNDS",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 31221921,
	"label": "COMBINED USE OF ANTI-CD47 ANTIBODY AND INTEGRIN LIGAND",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38232,
	"target": 37947,
	"type": 31569396,
	"label": "TISSUE PLASMINOGEN ACTIVATOR HAVING ZYMOGENIC OR FIBRIN SPECIFIC PROPERTIES",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 31640895,
	"label": "CELL OF SCAVENGER RECEPTOR-PRODUCING ANIMAL",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7507,
	"target": 6484,
	"type": 31979606,
	"label": "METHODS OF USING CDK8 ANTAGONISTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 7507,
	"type": 31979606,
	"label": "METHODS OF USING CDK8 ANTAGONISTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 56834,
	"target": 6484,
	"type": 31979606,
	"label": "METHODS OF USING CDK8 ANTAGONISTS",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 37904,
	"target": 32770,
	"type": 32014635,
	"label": "Human interleudin-1 receptor accessory Protein",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 32770,
	"target": 6812,
	"type": 32014635,
	"label": "Human interleudin-1 receptor accessory Protein",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 37904,
	"target": 6812,
	"type": 32014635,
	"label": "Human interleudin-1 receptor accessory Protein",
	"group": "Roche",
	"time": 1996,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 32118548,
	"label": "NOVEL PLATINUM COMPLEX",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 32180005,
	"label": "GENE ENCODING BRAIN SPECIFIC TYROSINE KINASE",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 32609580,
	"label": "METHODS FOR PRODUCING ANTIBODY",
	"group": "Roche",
	"time": 2003,
	"strength": 1
}, {
	"source": 38184,
	"target": 37904,
	"type": 32649009,
	"label": "ANTIBODY TO MURINE INTERLEUKIN-6 RECEPTOR AND ITS USE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 32649009,
	"label": "ANTIBODY TO MURINE INTERLEUKIN-6 RECEPTOR AND ITS USE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 56836,
	"target": 37904,
	"type": 32649009,
	"label": "ANTIBODY TO MURINE INTERLEUKIN-6 RECEPTOR AND ITS USE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 37904,
	"target": 7510,
	"type": 32649009,
	"label": "ANTIBODY TO MURINE INTERLEUKIN-6 RECEPTOR AND ITS USE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 7510,
	"type": 32649009,
	"label": "ANTIBODY TO MURINE INTERLEUKIN-6 RECEPTOR AND ITS USE",
	"group": "Roche",
	"time": 1991,
	"strength": 1
}, {
	"source": 38184,
	"target": 37875,
	"type": 32719236,
	"label": "METHOD FOR MEASURING ANTI-HUMAN LIVER SPECIFIC ANTIGEN-ANTIBODY QUANTITY USING ANTI-IDIOTYPE ANTIBODY AND APPLICATION THEREOF TO DIAGNOSIS OF HEPATIC DISEASE",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37875,
	"target": 32788,
	"type": 32719236,
	"label": "METHOD FOR MEASURING ANTI-HUMAN LIVER SPECIFIC ANTIGEN-ANTIBODY QUANTITY USING ANTI-IDIOTYPE ANTIBODY AND APPLICATION THEREOF TO DIAGNOSIS OF HEPATIC DISEASE",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38184,
	"target": 32788,
	"type": 32719236,
	"label": "METHOD FOR MEASURING ANTI-HUMAN LIVER SPECIFIC ANTIGEN-ANTIBODY QUANTITY USING ANTI-IDIOTYPE ANTIBODY AND APPLICATION THEREOF TO DIAGNOSIS OF HEPATIC DISEASE",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 32810205,
	"label": "ADDITIVE FOR ANIMAL CELL CULTURE MEDIUM AND METHOD FOR PRODUCING PROTEIN USING THE SAME",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37878,
	"type": 32810554,
	"label": "METHOD FOR EFFICIENTLY PRODUCING ANIMAL INDIVIDUAL FROM SOMATIC CELL",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37864,
	"target": 6795,
	"type": 33061876,
	"label": "Homogeneous, recombinant immune interferon fragments",
	"group": "Roche",
	"time": 1987,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 33326487,
	"label": "HYDANTOCIDIN DERIVATIVE",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 32612,
	"target": 6854,
	"type": 33447917,
	"label": "Microbial expression of human influenza hemagglutinin proteins",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 6471,
	"target": 6469,
	"type": 33733126,
	"label": "DRUG FOR CONSTIPATION",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 32437,
	"target": 6471,
	"type": 33733126,
	"label": "DRUG FOR CONSTIPATION",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 32437,
	"target": 6469,
	"type": 33733126,
	"label": "DRUG FOR CONSTIPATION",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 33892466,
	"label": "CANCER CELL PROLIFERATION INHIBITOR CONTAINING ANTI-CDCP1 ANTIBODY",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37899,
	"target": 7507,
	"type": 33892466,
	"label": "CANCER CELL PROLIFERATION INHIBITOR CONTAINING ANTI-CDCP1 ANTIBODY",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 7507,
	"type": 33892466,
	"label": "CANCER CELL PROLIFERATION INHIBITOR CONTAINING ANTI-CDCP1 ANTIBODY",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 34317575,
	"label": "EPOXIDIZED PREVITAMIN D3",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 34936354,
	"label": "COMPOUND HAVING ADSS INHIBITORY EFFECT",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38237,
	"target": 6483,
	"type": 34948134,
	"label": "ANTICANCER AGENT CONTAINING CDC7L1 KINASE INHIBITOR",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 31571,
	"target": 30485,
	"type": 35058729,
	"label": "Process for the preparation of 24,24-difluoro-1 alpha ,25-dihydroxy vitamin D3 and intermediates obtained therefrom",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 38181,
	"target": 32788,
	"type": 35145109,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 32788,
	"target": 6812,
	"type": 35145109,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38181,
	"target": 6812,
	"type": 35145109,
	"label": "Compositions and methods for the treatment of immune related diseases",
	"group": "Roche",
	"time": 2012,
	"strength": 1
}, {
	"source": 38042,
	"target": 32788,
	"type": 35275300,
	"label": "Multimeric cytomegalovirus antigen useful as an immunoassay reagent, and which comprises at least two p52 peptide sequences",
	"group": "Roche",
	"time": 1999,
	"strength": 1
}, {
	"source": 56834,
	"target": 56804,
	"type": 35969558,
	"label": "METHOD FOR QUANTIFYING PROSTATE SPECIFIC ANTIGEN AND ALPHA1-ANTITRYPSIN COMPOSITE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 56804,
	"target": 6854,
	"type": 35969558,
	"label": "METHOD FOR QUANTIFYING PROSTATE SPECIFIC ANTIGEN AND ALPHA1-ANTITRYPSIN COMPOSITE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 56834,
	"target": 6854,
	"type": 35969558,
	"label": "METHOD FOR QUANTIFYING PROSTATE SPECIFIC ANTIGEN AND ALPHA1-ANTITRYPSIN COMPOSITE",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32788,
	"target": 32694,
	"type": 35987518,
	"label": "ANTITUMOR AGENT",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32694,
	"target": 6862,
	"type": 35987518,
	"label": "ANTITUMOR AGENT",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 32788,
	"target": 6862,
	"type": 35987518,
	"label": "ANTITUMOR AGENT",
	"group": "Roche",
	"time": 1985,
	"strength": 1
}, {
	"source": 6301,
	"target": 6298,
	"type": 35997451,
	"label": "INDOLE DERIVATIVE AND MONO- OR DI-AZIDOINDOLE DERIVATIVE HAVING AMINO BAND",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 36402914,
	"label": "NOVEL VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1984,
	"strength": 1
}, {
	"source": 37986,
	"target": 37899,
	"type": 36552077,
	"label": "METHOD FOR INDUCING FORMATION OF HETEROTROPIC BONE AND/OR MARROW IN LIVER",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 38181,
	"type": 36804623,
	"label": "Cystine-Knot Polypeptides: Cloaked-2 Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 7424,
	"type": 36804623,
	"label": "Cystine-Knot Polypeptides: Cloaked-2 Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38181,
	"target": 37859,
	"type": 36804623,
	"label": "Cystine-Knot Polypeptides: Cloaked-2 Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37859,
	"type": 36804623,
	"label": "Cystine-Knot Polypeptides: Cloaked-2 Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 37859,
	"target": 7507,
	"type": 36804623,
	"label": "Cystine-Knot Polypeptides: Cloaked-2 Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 36990882,
	"label": "7,8-EPOXIDIZED VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 32770,
	"target": 7507,
	"type": 37264724,
	"label": "INHIBICION DE METASTASIS DE TUMOR POR ANTICUERPOS ANTI NEUROPILINA",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 31056,
	"target": 7360,
	"type": 37435525,
	"label": "1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 30606,
	"target": 6795,
	"type": 37447369,
	"label": "TURUNAN-TURUNAN PIROL BARU",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 56804,
	"target": 6854,
	"type": 37482272,
	"label": "QUANTITATIVE DETERMINATION OF ANTIGENIC SUBSTANCES AND REAGENT KIT FOR THE SAME",
	"group": "Roche",
	"time": 1976,
	"strength": 1
}, {
	"source": 6431,
	"target": 6429,
	"type": 37574206,
	"label": "STABLE ACTIVATED VITAMIN D3 PREPARATION",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7360,
	"target": 6431,
	"type": 37574206,
	"label": "STABLE ACTIVATED VITAMIN D3 PREPARATION",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7360,
	"target": 6429,
	"type": 37574206,
	"label": "STABLE ACTIVATED VITAMIN D3 PREPARATION",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 37583863,
	"label": "PRODUCTION OF RECOMBINANT MOUSE IL-6 RECEPTOR",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 37986,
	"target": 32698,
	"type": 37583863,
	"label": "PRODUCTION OF RECOMBINANT MOUSE IL-6 RECEPTOR",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 38181,
	"target": 32698,
	"type": 37583863,
	"label": "PRODUCTION OF RECOMBINANT MOUSE IL-6 RECEPTOR",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 7508,
	"target": 7507,
	"type": 38080498,
	"label": "CANCER ELIMINATING AGENT",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 38080498,
	"label": "CANCER ELIMINATING AGENT",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 7508,
	"target": 6429,
	"type": 38080498,
	"label": "CANCER ELIMINATING AGENT",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 7426,
	"target": 7425,
	"type": 38134465,
	"label": "SUCRALFATE-CONTAINING PHARMACEUTICAL COMPOSITION FOR LOCAL ADMINISTRATION",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 38415733,
	"label": "Composto processo para sua preparação composição farmacêutica e utilização",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 6410,
	"type": 38581819,
	"label": "PRODUCTION OF PLATINUM COMPLEX",
	"group": "Roche",
	"time": 1986,
	"strength": 1
}, {
	"source": 38184,
	"target": 37900,
	"type": 38844594,
	"label": "NEW COMPOSITION AND METHODS FOR THERAPY OF IMMNUNE-ASSOCIATED DISEASES WITH IMMUNITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 37900,
	"target": 7510,
	"type": 38844594,
	"label": "NEW COMPOSITION AND METHODS FOR THERAPY OF IMMNUNE-ASSOCIATED DISEASES WITH IMMUNITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 38184,
	"target": 7510,
	"type": 38844594,
	"label": "NEW COMPOSITION AND METHODS FOR THERAPY OF IMMNUNE-ASSOCIATED DISEASES WITH IMMUNITY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31912,
	"target": 7507,
	"type": 39206720,
	"label": "AUXILIARY AGENT FOR LIGHT-IRRADIATION THERAPY",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32738,
	"target": 6795,
	"type": 39338154,
	"label": "Oligonucleotide primers for HLA class I B locus DNA typing",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37993,
	"target": 37900,
	"type": 39424916,
	"label": "Anti-DLL4 antibodies and methods using same",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37900,
	"target": 32771,
	"type": 39424916,
	"label": "Anti-DLL4 antibodies and methods using same",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 39424916,
	"label": "Anti-DLL4 antibodies and methods using same",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 32771,
	"target": 7507,
	"type": 39424916,
	"label": "Anti-DLL4 antibodies and methods using same",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 37900,
	"target": 7507,
	"type": 39424916,
	"label": "Anti-DLL4 antibodies and methods using same",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 39638279,
	"label": "NOVEL VITAMIN D DERIVATIVE",
	"group": "Roche",
	"time": 1980,
	"strength": 1
}, {
	"source": 30951,
	"target": 6909,
	"type": 39679603,
	"label": "NOVEL HAPTEN ANTIGEN AND ITS PREPARATION",
	"group": "Roche",
	"time": 1979,
	"strength": 1
}, {
	"source": 7507,
	"target": 6185,
	"type": 39755943,
	"label": "ANTITUMOR AGENT COMPRISING N-STYRYLPHENYLAMINOBENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT",
	"group": "Roche",
	"time": 2001,
	"strength": 1
}, {
	"source": 31081,
	"target": 31056,
	"type": 39937035,
	"label": "HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6360,
	"type": 39937035,
	"label": "HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31056,
	"target": 7507,
	"type": 39937035,
	"label": "HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31081,
	"target": 7507,
	"type": 39937035,
	"label": "HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 31056,
	"target": 6360,
	"type": 39937035,
	"label": "HETEROCYCLIC SULFONAMIDES AS RAF INHIBITORS",
	"group": "Roche",
	"time": 2011,
	"strength": 1
}, {
	"source": 7507,
	"target": 6429,
	"type": 40197384,
	"label": "5,6-EPOXIDIZED VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1982,
	"strength": 1
}, {
	"source": 37986,
	"target": 7507,
	"type": 40293471,
	"label": "ANTICANCER ACTIVITY ENHANCER FOR ANTICANCER AGENT CONTAINING ANTI-MRP1 ANTIBODY",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 37986,
	"target": 37878,
	"type": 40293474,
	"label": "METHOD FOR SELECTING CULTURED CELL STRAIN INFLUENCED BY CHARACTER OF CLINICAL SPECIMEN, AND METHOD FOR SELECTING GENE SPECIFIC TO DISEASE FROM WHICH CLINICAL SPECIMEN IS DERIVED",
	"group": "Roche",
	"time": 2002,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 40406595,
	"label": "Altered polypeptides with increased half-life",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37993,
	"target": 32770,
	"type": 40406595,
	"label": "Altered polypeptides with increased half-life",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 32770,
	"type": 40406595,
	"label": "Altered polypeptides with increased half-life",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 40406595,
	"label": "Altered polypeptides with increased half-life",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 37993,
	"target": 6795,
	"type": 40406595,
	"label": "Altered polypeptides with increased half-life",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 40839130,
	"label": "MONOCLONAL ANTIBODY AGAINST HBs ANTIGEN OF HEPATITIS B VIRUS, GENE AND PEPTIDE RELATING THERETO, METHOD FOR ASSAYING HEPATITIS B VIRUS, METHOD FOR DIAGNOSIS OF HEPATITIS B AND METHOD FOR TREATMENT OF HEPATITIS B",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 37986,
	"target": 32779,
	"type": 40839130,
	"label": "MONOCLONAL ANTIBODY AGAINST HBs ANTIGEN OF HEPATITIS B VIRUS, GENE AND PEPTIDE RELATING THERETO, METHOD FOR ASSAYING HEPATITIS B VIRUS, METHOD FOR DIAGNOSIS OF HEPATITIS B AND METHOD FOR TREATMENT OF HEPATITIS B",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 40839130,
	"label": "MONOCLONAL ANTIBODY AGAINST HBs ANTIGEN OF HEPATITIS B VIRUS, GENE AND PEPTIDE RELATING THERETO, METHOD FOR ASSAYING HEPATITIS B VIRUS, METHOD FOR DIAGNOSIS OF HEPATITIS B AND METHOD FOR TREATMENT OF HEPATITIS B",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 38184,
	"type": 40839130,
	"label": "MONOCLONAL ANTIBODY AGAINST HBs ANTIGEN OF HEPATITIS B VIRUS, GENE AND PEPTIDE RELATING THERETO, METHOD FOR ASSAYING HEPATITIS B VIRUS, METHOD FOR DIAGNOSIS OF HEPATITIS B AND METHOD FOR TREATMENT OF HEPATITIS B",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 56834,
	"target": 37986,
	"type": 40839130,
	"label": "MONOCLONAL ANTIBODY AGAINST HBs ANTIGEN OF HEPATITIS B VIRUS, GENE AND PEPTIDE RELATING THERETO, METHOD FOR ASSAYING HEPATITIS B VIRUS, METHOD FOR DIAGNOSIS OF HEPATITIS B AND METHOD FOR TREATMENT OF HEPATITIS B",
	"group": "Roche",
	"time": 2005,
	"strength": 1
}, {
	"source": 32779,
	"target": 32771,
	"type": 41115104,
	"label": "Pharmaceutical preparation for lymphatic tumors, antibody, chimeric antibody and modified antibody",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 37993,
	"type": 41115104,
	"label": "Pharmaceutical preparation for lymphatic tumors, antibody, chimeric antibody and modified antibody",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 32779,
	"type": 41115104,
	"label": "Pharmaceutical preparation for lymphatic tumors, antibody, chimeric antibody and modified antibody",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 37993,
	"target": 32771,
	"type": 41115104,
	"label": "Pharmaceutical preparation for lymphatic tumors, antibody, chimeric antibody and modified antibody",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 38184,
	"target": 32779,
	"type": 41115104,
	"label": "Pharmaceutical preparation for lymphatic tumors, antibody, chimeric antibody and modified antibody",
	"group": "Roche",
	"time": 1998,
	"strength": 1
}, {
	"source": 7358,
	"target": 6795,
	"type": 41210255,
	"label": "INTERLEUKIN-6 CONTAINING TREATING AGENT FOR AUTOIMMUNE LIVER DISEASE AND SALIVARY GLAND DISEASE",
	"group": "Roche",
	"time": 1993,
	"strength": 1
}, {
	"source": 6601,
	"target": 6586,
	"type": 41815943,
	"label": "LIQUID MEDICINE FOR INTERNAL USE",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 42288826,
	"label": "6,19-ETHYLENEVITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1983,
	"strength": 1
}, {
	"source": 7360,
	"target": 6241,
	"type": 42303621,
	"label": "ORALLY ADMINISTERING COMPOSITION FOR VETERINARY PURPOSES",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 42437811,
	"label": "ISOLATION AND PRODUCTION OF CATALYTIC ANTIBODY USING PHAGE TECHNOLOGY",
	"group": "Roche",
	"time": 2004,
	"strength": 1
}, {
	"source": 31571,
	"target": 30485,
	"type": 42804420,
	"label": "19-SUBSTITUTED VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 30485,
	"target": 6429,
	"type": 42804420,
	"label": "19-SUBSTITUTED VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 31571,
	"target": 6429,
	"type": 42804420,
	"label": "19-SUBSTITUTED VITAMIN D3 DERIVATIVE",
	"group": "Roche",
	"time": 1981,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 43215166,
	"label": "IL-17 Receptor Like Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37986,
	"type": 43215166,
	"label": "IL-17 Receptor Like Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37864,
	"type": 43215166,
	"label": "IL-17 Receptor Like Molecules and Uses Thereof",
	"group": "Amgen",
	"time": 2007,
	"strength": 1
}, {
	"source": 38184,
	"target": 37899,
	"type": 43398752,
	"label": "MOUSE MONOCLONAL ANTIBODY MAB710F AND PRODUCTION THEREOF",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56836,
	"target": 38184,
	"type": 43398752,
	"label": "MOUSE MONOCLONAL ANTIBODY MAB710F AND PRODUCTION THEREOF",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 56836,
	"target": 37899,
	"type": 43398752,
	"label": "MOUSE MONOCLONAL ANTIBODY MAB710F AND PRODUCTION THEREOF",
	"group": "Roche",
	"time": 1990,
	"strength": 1
}, {
	"source": 32770,
	"target": 6795,
	"type": 43609550,
	"label": "Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor",
	"group": "Roche",
	"time": 1995,
	"strength": 1
}, {
	"source": 7507,
	"target": 7358,
	"type": 43665595,
	"label": "BENZOFURAN DERIVATIVE HAVING ANTI-HEPATITIS C VIRUS EFFECT",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7358,
	"target": 6816,
	"type": 43665595,
	"label": "BENZOFURAN DERIVATIVE HAVING ANTI-HEPATITIS C VIRUS EFFECT",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7507,
	"target": 6816,
	"type": 43665595,
	"label": "BENZOFURAN DERIVATIVE HAVING ANTI-HEPATITIS C VIRUS EFFECT",
	"group": "Roche",
	"time": 2009,
	"strength": 1
}, {
	"source": 7360,
	"target": 6601,
	"type": 43971190,
	"label": "CHINESE HERBAL ORAL ADMINISTRATION SOLUTION",
	"group": "Roche",
	"time": 1997,
	"strength": 1
}, {
	"source": 32697,
	"target": 32696,
	"type": 44411790,
	"label": "GRANULAR COLONY STIUMULATING FACTOR DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32696,
	"target": 32694,
	"type": 44411790,
	"label": "GRANULAR COLONY STIUMULATING FACTOR DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32697,
	"target": 32694,
	"type": 44411790,
	"label": "GRANULAR COLONY STIUMULATING FACTOR DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32694,
	"target": 6795,
	"type": 44411790,
	"label": "GRANULAR COLONY STIUMULATING FACTOR DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 32696,
	"target": 6795,
	"type": 44411790,
	"label": "GRANULAR COLONY STIUMULATING FACTOR DERIVATIVE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37986,
	"target": 37864,
	"type": 44497469,
	"label": "PRODUCTION OF NEW POLYPEPETIDE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37986,
	"type": 44497469,
	"label": "PRODUCTION OF NEW POLYPEPETIDE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 38181,
	"target": 37864,
	"type": 44497469,
	"label": "PRODUCTION OF NEW POLYPEPETIDE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, {
	"source": 37864,
	"target": 32697,
	"type": 44497469,
	"label": "PRODUCTION OF NEW POLYPEPETIDE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}, 
{
	"source": 37986,
	"target": 32697,
	"type": 44497469,
	"label": "PRODUCTION OF NEW POLYPEPETIDE",
	"group": "Roche",
	"time": 1994,
	"strength": 1
}]
